SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

Ministério da Saúde
Secretaria Executiva
Departamento de Logística em Saúde
Coordenação-Geral de Aquisições de Insumos Estratégicos para Saúde
Coordenação de Licitações e Análise de Mercado de Insumos Estratégicos para Saúde
Divisão de Análise das Aquisições de Insumos Estratégicos para Saúde

CONTRATO Nº 29/2021

Processo nº 25000.175250/2020-85

CONTRATO QUE ENTRE SI
CELEBRAM A UNIÃO, POR
INTERMÉDIO DO DEPARTAMENTO
DE LOGÍSTICA EM SAÚDE DA
SECRETARIA EXECUTIVA | DO
MINISTÉRIO DA SAÚDE E A BHARAT
BIOTECH LIMITED INTERNATIONAL,
REPRESENTADA PELA EMPRESA
PRECISA COMERCIALIZAÇÃO DE
MEDICAMENTOS LTDA.

A UNIÃO por intermédio do Departamento de Logísca em Saúde da Secretaria Execuva do Ministério
da Saúde, inscrita no CNPJ sob o nº 00.394.544/0008-51, com sede em Brasília — DF, neste ato
representada por seu Diretor, Sr. ROBERTO FERREIRA DIAS, portador da Carteira de Idendade RG
nº 152.991.800, expedida pela SSP/PR, e inscrito no CPF sob o nº 086.758.087-98, em conformidade
com a Portaria nº 262, de 08/01/2019, publicada no Diário Oficial da União n.º 6, de 09/01/2019,
doravante denominada CONTRATANTE, e de outro lado a empresa BHARAT BIOTECH LIMITED
INTERNATIONAL, representanda pela empresa PRECISA COMERCIALIZAÇÃO DE
MEDICAMENTOS LTDA, CNPJ: 03.394.819/0005-00, com sede na Avenida Portugal nº 1100, Rua 5,
Parte A-14-B, Itaqui, Itapevi/SP, CEP: 06.696-060, doravante denominada CONTRATADA, neste ato
representada por EMANUELA BATISTA DE SOUZA MEDRADES, portadora da Carteira de
Idendade RG nº 354.357.591, expedida pela SSP/SP, e inscrita no CPF nº 330.976.208-42, de acordo
com o constante no Processo Eletrônico nº 25000.175250/2020-85, em observância às disposições da
Lei nº 8.666, de 21 de junho de 1993 e da Medida Provisória nº 1.026, de 6 de janeiro de 2021,
resolvem celebrar o presente Termo de Contrato, por meio da Dispensa de Licitação nº 10/2021, com
fundamento no Artigo 2º, inciso I, da Medida Provisória nº 1.026/2021 e mediante as cláusulas e
condições a seguir enunciadas:

https://sei.saude gov. br/sei/docum ento. consulta. externa. php?id...o. acesso, externo=0 &infra. hash=4f9bc60208643dbff37917bods189boa Página 1 de 1
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

1. CLÁUSULA PRIMEIRA - DO OBJETO

11. O objeto do presente Termo de Contrato é a aquisição de VACINA, COVID-19
(CORONAVÍRUS, SARS-COV-2), INJETÁVEL (Covaxin/BBV152), conforme especificações
estabelecidas no Termo de Referência e na proposta final, as quais integram este instrumento,
independente de transcrição.

 

 

 

 

 

 

 

 

 

12. Discriminação do objeto:
Descrição do Item Unidade : Valor
Item (Objeto) CATMAT | ge Medida | Quantidade | nitário
VACINA, COVID-19
(CORONAVÍRUS, SARS-COV-
1 2), INJETÁVEL BR0475096 Doses 20.000.000 US$ 15,00
(Covaxin/BBV152)
13. A CONTRATANTE terá o direito de exclusividade/preferência na aquisição de doses da

VACINA, COVID-19 (CORONAVÍRUS, SARS-COV-2), INJETÁVEL (Covaxin/BBV152),
produzidas ou importadas pela Contratada em todo o território nacional, enquanto durar a pandemina.

14. A CONTRATANTE poderá autorizar em caráter excepcional a comercialização pela
Contratada de doses da VACINA, COVID-19 (CORONAVÍRUS, SARS-COV-2), INJETÁVEL
(Covaxin/BBV152), devendo, para tanto, ser notificada formalmente sobre a intenção de venda com
antecedência mínima de 20 (vinte) dias da data prevista para contratação junto a outro ente, sobre a
intenção de venda, com a devida justificativa.

15. A CONTRATANTE deverá se manifestar sobre a autorização de comercialização/venda
no prazo máximo de 05 (cinco) dias a contar da data do protocolo da notificação formal.

 

 

 

 

 

 

 

 

 

 

 

 

 

2. CLÁUSULA SEGUNDA - DA FORMA DE FORNECIMENTO
21. Cronograma de entrega:
VACINA, COVID-19 (CORONAYVÍRUS, SARS-COV-2), INJETAVEL
QUANTITATIVO | PRAZO MÁXIMO DE ENTREGA

PARCELA |“ (nosEs) (ATÉ)

1º 4.000.000 20 dias após a assinatura do Contrato

2 4.000.000 30 dias após a assinatura do Contrato

3º 4.000.000 45 dias após a assinatura do Contrato

4 4.000.000 60 dias após a assinatura do Contrato

5º 4.000.000 70 dias após a assinatura do Contrato

TOTAL 20.000.000

22. A CONTRATANTE poderá anuir com a alteração do cronograma, desde que verificada a

ausência de culpa da CONTRATADA em possível atraso injustificado.

23. Havendo necessidade de prorrogação ou antecipação no cronograma, ou do quantitativo
da respectiva parcela de entrega, caberá à CONTRATADA encaminhar ofício com embasamento
técnico e justificativas, incumbindo à CONTRATANTE se manifestar quanto ao impacto da alteração e
o aceite ou não da nova proposta, de acordo com o interesse da Administração.

https://sei.saude gov. br/sei/docum ento. consulta. externa. php?id...o. acesso, externo=0 &infra. hash=4f9bc60208643dbff37917bods18oboa Página 2 de 1
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

24. Os ofícios de prorrogação dos cronogramas, ou de alteração dos quantitativos das
parcelas, somente serão apreciados se encaminhados com antecedência mínima de 30 (trinta) dias da
data prevista para a entrega de cada parcela, ressalvados os casos fortuitos ou de força maior.

25. O quantitativo final do lote a ser entregue deverá ser confirmado por oficio ao Ministério
da Saúde com a antecedência mínima de dois dias úteis antes da data de entrega, sem prejuízo ao
exposto do item anterior.

3. CLÁUSULA TERCEIRA - DA VIGÊNCIA

31. O prazo de vigência deste Termo de Contrato inicia-se na data de sua assinatura e
vigorará por 12 (doze) meses, prorrogáveis, nos termos do artigo 57, 81º, da Lei nº 8.666 de 1993.

4. CLÁUSULA QUARTA - DO PREÇO

41. O valor total do presente Termo de Contrato é de US$ 300.000.000,00 (trezentos milhões
de dólares americanos), que convertidos na hipótese de US$ 1,00 para R$ 5,38 perfaz o valor total
estimado de R$ 1.614.000.000,00 (um bilhão, seiscentos e quatorze milhões de reais).

42. No valor acima estão incluídas todas as despesas ordinárias diretas e indiretas
decorrentes da execução contratual, inclusive tributos e/ou impostos, encargos sociais, trabalhistas,
previdenciários, fiscais e comerciais incidentes, taxa de administração, frete, seguro e outros
necessários ao cumprimento integral do objeto da contratação.

5. CLÁUSULA QUINTA - DA DOTAÇÃO ORÇAMENTÁRIA

51. As despesas decorrentes desta contratação estão programadas em dotação orçamentária
própria, prevista no orçamento da União, para o exercício de 2021, na classificação abaixo:

Gestão/Unidade: 00001/250005

Fonte: Decreto nº 10.595 de 07/01/2021.
Programa de Trabalho: 10.122.5018.21C0.6500
Elemento de Despesas: 33.90.30.

52. No exercício seguinte, se for o caso, as despesas correrão à conta dos recursos próprios
para atender às despesas da mesma natureza, cuja alocação será feita no início de cada exercício
financeiro, recursos já destacados e aprovados por Medida Provisória no exercício de 2020.

6. CLÁUSULA SEXTA - DO PAGAMENTO

61. O pagamento só será feito uma vez concluída a análise e a eventual aprovação integral
pela Anvisa, para uso emergencial e temporário e/ou registro definitivo.

62. O pagamento à CONTRATADA, que apresentar proposta de preço em moeda
estrangeira, será realizado no prazo máximo de até 30 (trinta) dias, contados a partir da apresentação
dos documentos que comprovem a efetiva entrega do objeto contratado (AWB, Invoice, Packing-list)
na Coordenação de Execução Orçamentária e Financeira — CEOF, que providenciará a autorização do

https://sei.saude gov. br/sei/docum ento. consulta. externa. php?id...o. acesso, externo=0 &infra. hash=4f9bc60208643dbff37917bods1Bsboa Página 3 de 1
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

responsável pelo Departamento de Logística em Saúde - DLOG, de acordo com as normas internas em
vigor.

621. No caso de entregas efetuadas antes da aprovação integral pela Anvisa, para uso
emergencial e temporário e/ou registro definitivo, o prazo de que trata o subitem anterior somente será
iniciado após, cumulativamente, serem efetivadas tanto a aprovação em questão, em qualquer
modalidade, quanto a entrega do objeto a ser pago.

63. Para cada parcela liquidada, será pago pela CONTRATANTE à Instituição Financeira,
responsável pela realização da operação de contratação cambial, comissão bancária sobre o valor da
operação a ser realizada.

64. A CONTRATADA brasileira que apresentar proposta de preço em moeda estrangeira terá
o pagamento efetuado em moeda brasileira à taxa de câmbio vigente, PTAX, fornecida pelo Banco
Central do Brasil (www.bcb.gov.br) no dia útil imediatamente anterior à data do efetivo pagamento.
Para tal, se fará necessária a apresentação de uma nova Nota Fiscal Complementar contemplando a
diferença decorrente da variação cambial a maior. Na hipótese de o câmbio estar a menor, será
necessária a glosa do valor.

65. Os pagamentos decorrentes de despesas cujos valores não ultrapassem o limite de que
trata o inciso II do art. 24 da Lei 8.666, de 1993, deverão ser efetuados no prazo de até 5 (cinco) dias
úteis, contados da data da apresentação da Nota Fiscal, nos termos do art. 5º, $ 3º, da Lei nº 8.666, de
1993,

6.6. Considera-se ocorrido o recebimento da nota fiscal ou fatura no momento em que o
órgão contratante atestar a execução do objeto do contrato.

67. A Nota Fiscal ou Fatura deverá ser obrigatoriamente acompanhada da comprovação da
regularidade fiscal, constatada por meio de consulta on-line ao SICAF ou, na impossibilidade de acesso
ao referido Sistema, mediante consulta aos sítios eletrônicos oficiais ou à documentação mencionada no
art. 29 da Lei nº 8.666, de 1993.

6.8. Constatando-se, junto ao SICAF, a situação de irregularidade do fornecedor contratado,
deverão ser tomadas as providências previstas no art. 31 da Instrução Normativa nº 3, de 26 de abril de
2018.

69. Havendo erro na apresentação da Nota Fiscal ou dos documentos pertinentes à
contratação, ou, ainda, circunstância que impeça a liquidação da despesa, como, por exemplo,
obrigação financeira pendente, decorrente de penalidade imposta ou inadimplência, o pagamento ficará
sobrestado até que a Contratada providencie as medidas saneadoras. Nesta hipótese, o prazo para
pagamento iniciar-se-á após a comprovação da regularização da situação, não acarretando qualquer
ônus para a Contratante.

6.10. Será considerada data do pagamento o dia em que constar como emitida a ordem
bancária para pagamento.

611. Antes de cada pagamento à contratada, será realizada consulta ao SICAF para verificar a
manutenção das condições de habilitação exigidas no TR.

612. Constatando-se, junto ao SICAF, a situação de irregularidade da contratada, será
providenciada sua notificação, por escrito, para que, no prazo de 5 (cinco) dias úteis, regularize sua
situação ou, no mesmo prazo, apresente sua defesa. O prazo poderá ser prorrogado uma vez, por igual
período, a critério da contratante.

613. Previamente à emissão de nota de empenho e a cada pagamento, a Administração deverá
realizar consulta ao SICAF para identificar possível suspensão temporária de participação em licitação,
no âmbito do órgão ou entidade, proibição de contratar com o Poder Público, bem como ocorrências

https://sei.saude gov. br/sei/docum ento. consulta. externa. php?id...o. acesso, externo=0 &infra. hash=4f9bc60208643dbff37917bods18sboa Página 4 de 1
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

impeditivas indiretas, observado o disposto no art. 29, da Instrução Normativa nº 3, de 26 de abril de
2018.

64. Não havendo regularização ou sendo a defesa considerada improcedente, a contratante
deverá comunicar aos órgãos responsáveis pela fiscalização da regularidade fiscal quanto à
inadimplência da contratada, bem como quanto à existência de pagamento a ser efetuado, para que
sejam acionados os meios pertinentes e necessários para garantir o recebimento de seus créditos.

615. Persistindo a irregularidade, a contratante deverá adotar as medidas necessárias à

rescisão contratual nos autos do processo administrativo correspondente, assegurada à contratada a
ampla defesa.

6.16. Havendo a efetiva execução do objeto, os pagamentos serão realizados normalmente, até
que se decida pela rescisão do contrato, caso a contratada não regularize sua situação junto ao SICAF.

617. Será rescindido o contrato em execução com a contratada inadimplente no SICAF, salvo
por motivo de economicidade, segurança nacional ou outro de interesse público de alta relevância,
devidamente justificado, em qualquer caso, pela máxima autoridade da contratante.

618. Quando do pagamento, será efetuada a retenção tributária prevista na legislação
aplicável.
619. A Contratada regularmente optante pelo Simples Nacional, nos termos da Lei

Complementar nº 123, de 2006, não sofrerá a retenção tributária quanto aos impostos e contribuições
abrangidos por aquele regime. No entanto, o pagamento ficará condicionado à apresentação de
comprovação, por meio de documento oficial, de que faz jus ao tratamento tributário favorecido
previsto na referida Lei Complementar.

6.20. Nos casos de eventuais atrasos de pagamento, desde que a Contratada não tenha
concorrido, de alguma forma, para tanto, fica convencionado que a taxa de compensação financeira
devida pela Contratante, entre a data do vencimento e o efetivo adimplemento da parcela, é calculada
mediante a aplicação da seguinte fórmula:

EM =IxNx VP, sendo:
EM = Encargos moratórios;

N = Número de dias entre a data prevista para o pagamento e a do efetivo pagamento;
VP = Valor da parcela a ser paga.

= Índice de compensação financeira = 0,00016438, assim apurado:

 

 

 

 

 

 

1 = 0,00016438
I=(Tx) I= (SiS00 ) TX = Percentual da taxa anual = 6%
7. CLÁUSULA SÉTIMA - DA GARANTIA DE EXECUÇÃO
74. A CONTRATADA, no prazo de 10 dias após a assinatura do Termo de Contrato ou

aceite do instrumento equivalente, prestará garantia no valor de US$ 15.000.000,00 (quinze milhões de
dólares americanos), que convertidos na hipótese de US$ 1,00 para R$ 5,38 perfaz o valor total
estimado de R$ 80.700.000,00 (oitenta milhões e setecentos mil reais) correspondente a 5% do valor
do Contrato, que será liberada de acordo com as condições previstas no Termo de Referência, conforme
disposto no art. 56 da Lei nº 8.666, de 1993, desde que cumpridas as obrigações contratuais.

72. Caberá ao contratado optar por uma das seguintes modalidades de garantia:

https://sei.saude gov. br/sei/docum ento. consulta. externa. php?id...o. acesso, externo=0 &infra. hash=4f9bc60208643dbff37917bods1Bsboa Página 5 de 1
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

7241. Caução em dinheiro ou em títulos da dívida pública, devendo estes ter sido emitidos sob
a forma escritural, mediante registro em sistema centralizado de liquidação e de custódia autorizado
pelo Banco Central do Brasil e avaliados pelos seus valores econômicos, conforme definido pelo
Ministério da Fazenda;

722. Seguro-garantia;
723. Fiança bancária.
73. A garantia em dinheiro deverá ser efetuada em favor da Contratante, na Caixa

Econômica Federal, com correção monetária, em favor do contratante.

74. No caso de alteração do valor do contrato, ou prorrogação de sua vigência, a garantia
deverá ser readequada ou renovada nas mesmas condições.

75. Se o valor da garantia for utilizado total ou parcialmente em pagamento de qualquer
obrigação, a Contratada obriga-se a fazer a respectiva reposição no prazo máximo de 10 dias úteis,
contados da data em que for notificada.

76. A Contratante executará a garantia na forma prevista na legislação que rege a matéria.

77. A garantia prestada pelo contratado será liberada ou restituída após a execução do
contrato e, quando em dinheiro, atualizada monetariamente. (artigo 56, $4º da Lei nº 8666/93).

8. CLÁUSULA OITAVA - DO REAJUSTE

81. As regras acerca do reajuste do valor contratual são as estabelecidas no Termo de
Referência.

9. CLÁUSULA NONA - DAS ALTERAÇÕES

941. Eventuais alterações contratuais reger-se-ão pela disciplina do art. 65 da Lei nº 8.666, de
1993.

92. A CONTRATADA é obrigada a aceitar, nas mesmas condições contratuais, os

acréscimos ou supressões que se fizerem necessários, até o limite de 50% (cinquenta por cento) do
valor inicial atualizado do contrato, conforme o art. 9º da MP 1.026 de 2021.

10. CLÁUSULA DÉCIMA - CRITÉRIO DE ACEITAÇÃO DO OBJETO, ENTREGA
E RECEBIMENTO

10.1. OS CRITÉRIOS DE ACEITAÇÃO DO OBJETO são aqueles previstos no Termo de
Referência.

10.2. DO LOCAL DE ENTREGA:

10.21. As entregas das parcelas deverão ser realizadas de forma centralizada no Almoxarifado

do Ministério da Saúde em São Paulo no endereço abaixo:
a) Produtos FÁRMACO (Medicamentos/Vacinas/insumos relacionados):

b) Endereço: Rua Jamil João Zarif, nº 684, Jardim Santa Vicência, UNIDADES 11 A
17 e 18º Guarulhos — SP

https://sei.saude gov. br/sei/docum ento. consulta. externa. php?id...o. acesso, externo=0 &infra. hash=4f9bc60208643dbff37917bods18sboa Página 6 de 1
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

c) CEP: 07.143-000.
d) E-mail para agendamento: c glog.agendamentoOWsaude. gov.br

10.2.2. A Contratada deverá agendar cada entrega, entrando em contato com a área responsável
através do telefone: (61) 3315-7770 ou (61) 3315.3582.

10.3. DO RECEBIMENTO DO OBJETO:

10.31. Nos termos do art. 73, inciso II, alíneas a e b da lei nº 8.666/93, os imunobiológicos,

objeto desta aquisição, serão recebidos da seguinte forma:

10.3.2. Os bens serão recebidos provisoriamente no prazo de 1 dia, pelo(a) responsável pelo
acompanhamento e fiscalização do contrato, para efeito de posterior verificação de sua conformidade
com as especificações constantes neste Termo de Referência e na proposta.

10.3.3. Os bens poderão ser rejeitados, no todo ou em parte, quando em desacordo com as
especificações constantes neste Termo de Referência e na proposta, devendo ser substituídos no prazo
de 15 dias, a contar da notificação da contratada, às suas custas, sem prejuízo da aplicação das
penalidades.

10.3.4. Os bens serão recebidos definitivamente no prazo de 15 dias, contados do recebimento
provisório, após a verificação da qualidade pelo INCQS e quantidade do material e consequente
aceitação mediante termo circunstanciado.

10.3.5. Na hipótese de a verificação a que se refere o subitem anterior não ser procedida dentro
do prazo fixado, reputar-se-á como realizada, consumando-se o recebimento definitivo no dia do
esgotamento do prazo.

10.3.6. O recebimento provisório ou definitivo do objeto não exclui a responsabilidade da
contratada pelos prejuízos resultantes da incorreta execução do contrato.

Mo CLÁUSULA DÉCIMA PRIMEIRA - DO CONTROLE E DA FISCALIZAÇÃO
(CRITÉRIO DE MEDIÇÃO)
1a. Nos termos do art. 67 Lei nº 8.666, de 1993, será designado representante para

acompanhar e fiscalizar a entrega dos bens, anotando em registro próprio todas as ocorrências
relacionadas com a execução e determinando o que for necessário à regularização de falhas ou defeitos
observados.

11.2. O recebimento de material de valor superior a R$ 176.000,00 (cento e setenta e seis mil
reais) será confiado a uma comissão de, no mínimo, 3 (três) membros, designados pela autoridade
competente.

11.3. A CONTRATANTE indicará um fiscal de contrato ou comissão, que será responsável
pelo acompanhamento e fiscalização da execução, conforme Portaria GM nº 78/2006 e Circular
MS/SE/GAB nº 40, emitida pelo Gabinete da Secretaria Executiva, assim como artigos. 67 e 73 da Lei
nº 8.666/1993. 9.3.

11.4. O Fiscal/comissão do contrato deverá manter permanente vigilância sobre as obrigações
da CONTRATADA, definidas nos dispositivos contratuais e condições do Termo de Referência e,
fundamentalmente, quanto à inarredável observância aos princípios e preceitos consubstanciados na Lei
nº 8.666/93, com suas alterações.

11.5. A fiscalização de que trata este item não exclui nem reduz a responsabilidade da
Contratada, inclusive perante terceiros, por qualquer irregularidade, ainda que resultante de

https://sei.saude gov. br/sei/docum ento. consulta. externa. php?id...o. acesso, externo=0 &infra. hash=4f9bc60208643dbff37917bods189boa Página 7 de
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

imperfeições técnicas ou vícios redibitórios, e, na ocorrência desta, não implica em corresponsabilidade
da Administração ou de seus agentes e prepostos, de conformidade com o art. 70 da Lei nº 8.666, de
1993.

11.6. O representante da Administração anotará em registro próprio todas as ocorrências
relacionadas com a execução do contrato, indicando dia, mês e ano, bem como o nome dos funcionários
eventualmente envolvidos, determinando o que for necessário à regularização das falhas ou defeitos
observados e encaminhando os apontamentos à autoridade competente para as providências cabíveis.

12. CLÁUSULA DÉCIMA SEGUNDA - DAS OBRIGAÇÕES DA CONTRATANTE E
DA CONTRATADA
121. As obrigações da CONTRATANTE e da CONTRATADA são aquelas previstas no

Termo de Referência.

13. CLÁUSULA DÉCIMA TERCEIRA - DAS SANÇÕES ADMINISTRATIVAS

131. As sanções referentes à execução do contrato são aquelas previstas no Termo de
Referência.

14. CLÁUSULA DÉCIMA QUARTA - DA SUSPENSÃO

141. Caso a Anvisa suspenda a produção e o uso da vacina, automaticamente ficarão

suspensas a execução e as obrigações previstas no presente instrumento.

15. CLÁUSULA DÉCIMA QUINTA - DA RESCISÃO
151. O presente Termo de Contrato poderá ser rescindido:
1511. Por ato unilateral e escrito da Administração, nas situações previstas nos incisos I a XIL e

XVII do art. 78 da Lei nº 8.666, de 1993, e com as consequências indicadas no art. 80 da mesma Lei,
sem prejuízo da aplicação das sanções previstas no Termo de Referência, anexo ao Edital;

15.1.2. Amigavelmente, nos termos do art. 79, inciso II, da Lei nº 8.666, de 1993;

151.3. Caso a Contratada não consiga a autorização para uso emergencial junto à Anvisa, nesta
hipótese, sem qualquer ônus para a Contratante, não sendo devido, sequer, o pagamento pelas parcelas
eventualmente entregues;

15.1.4. Caso, após a autorização para uso emergencial e antes da completa execução do contrato,
a ANVISA não registre o produto e/ou revogue a autorização para uso emergencial, nessa hipótese, sem
ônus para a Contratante em relação às doses ainda não entregues. Quanto às doses já entregues e não
administradas, a Contratante será ressarcida pelo valor pago.

151.5. Por perda da autorização regulatória expedida pela ANVISA;

15.1.6. Pela falta de eficácia da vacina contra variantes que se tornem prevalentes em território
nacional, em grau tal que impeça de atingir a efetiva imunidade de rebanho por vacinação na população
brasileira

15.2. Os casos de rescisão contratual serão formalmente motivados, assegurando-se à

https://sei.saude gov. br/sei/docum ento. consulta. externa. php?id...o. acesso, externo=0 &infra. hash=4f9bc60208643dbff37917bods18sboa Página 8 de 1
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

CONTRATADA o direito à prévia e ampla defesa.

15.3. A CONTRATADA reconhece os direitos da CONTRATANTE em caso de rescisão
administrativa prevista no art. 77 da Lei nº 8.666, de 1993.

15.4. O termo de rescisão será precedido de Relatório indicativo dos seguintes aspectos,
conforme o caso :

1541. Balanço dos eventos contratuais já cumpridos ou parcialmente cumpridos;

15.42. Relação dos pagamentos já efetuados e ainda devidos;

15.43. Indenizações e multas.

16. CLÁUSULA DÉCIMA SEXTA - DAS VEDAÇÕES E PERMISSÕES

16.1. É vedado à CONTRATADA interromper a execução do contrato sob alegação de

inadimplemento por parte da CONTRATANTE, salvo nos casos previstos em lei.

16.2. É permitido à CONTRATADA caucionar ou utilizar este Termo de Contrato para
qualquer operação financeira, nos termos e de acordo com os procedimentos previstos na Instrução
Normativa SEGES/ME nº 53, de 8 de julho de 2020.

16.3. A cessão de crédito, a ser feita mediante celebração de termo aditivo, dependerá de
comprovação da regularidade fiscal e trabalhista da cessionária, bem como da certificação de que a
cessionária não se encontra impedida de licitar e contratar com o Poder Público, conforme a legislação
em vigor, nos termos do Parecer JL-01, de 18 de maio de 2020.

16.4. A crédito a ser pago à cessionária é exatamente aquele que seria destinado à cedente
(contratada) pela execução do objeto contratual, com o desconto de eventuais multas, glosas e prejuízos
causados à Administração, sem prejuízo da utilização de institutos tais como os da conta vinculada e do
pagamento direto previstos na IN SEGES/ME nº 5, de 2017, caso aplicáveis.

17. CLÁUSULA DÉCIMA SÉTIMA - DOS CASOS OMISSOS

171. Os casos omissos serão decididos pela CONTRATANTE, segundo as disposições
contidas na Medida Provisória nº 1.026 de 2021; na Lei nº 8.666 de 1993, na Lei nº 10.520 de 2002 e
demais normas federais de licitações e contratos administrativos e, subsidiariamente, segundo as
disposições contidas na Lei nº 8.078, de 1990 - Código de Defesa do Consumidor - e normas e
princípios gerais dos contratos.

18. . CLÁUSULA DÉCIMA OITAVA - DA APROVAÇÃO DA DISPENSA DE
LICITAÇÃO
18.1. A lavratura do presente Contrato referente à Dispensa de Licitação nº 10/2021, com

base no artigo 2º, inciso I, da Medida Provisória nº 1.026, de 6 de janeiro de 2021, foi publicada no
Diário Oficial - Edição Extra em 19/02/2021, conforme determinado pelo caput do artigo 26 da Lei
8.666/93.

18.2. Incumbirá à CONTRATANTE, no prazo de cinco dias úteis contados da assinatura deste
instrumento, providenciar a disponibilização, em sítio oficial específico na rede mundial de
computadores (internet), do ato de autorização da contratação direta, bem como as disposições da
Medida Provisória nº 1.026, de 6 de janeiro de 2021, observados, no que couber, os requisitos previstos

https://sei.saude gov. br/sei/docum ento. consulta. externa. php?id...o. acesso, externo=0 &infra hash=4f9bc60208643dbff37917bods1Bsboa Página 9 de 1
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

no 8 3º do art. 8º da Leinº 12.527, de 18 de novembro de 2011.

183. O presente Termo de Contrato se vincula ao Termo de Referência da Contratante e à
proposta da Contratada.

19. CLÁUSULA DÉCIMA NONA - ALTERAÇÃO SUBJETIVA

19.1. É admissível a fusão, cisão ou incorporação da contratada com/em outra pessoa jurídica,
desde que sejam observados pela nova pessoa jurídica todos os requisitos de habilitação exigidos na
contratação; sejam mantidas as demais cláusulas e condições do contrato; não haja prejuízo à execução
do objeto pactuado e haja a anuência expressa da Administração à continuidade do contrato.

20. CLÁUSULA VIGÉSIMA - DA SUBCONTRATAÇÃO

20.1. Não será admitida a subcontratação do objeto do Contrato.

21. CLÁUSULA VIGÉSIMA PRIMEIRA - DO FORO

21.1. É eleito o Foro da Judiciária do Distrito Federal - Justiça Federal para dirimir os litigios

que decorrerem da execução deste Termo de Contrato que não possam ser compostos pela conciliação,
conforme art. 55, 82º da Lei nº 8.666/93.

E, para firmeza e prova de assim haverem, entre si, ajustado e acordado, após ter sido lido juntamente
com seu(s) anexo(s), o presente Contrato é assinado eletronicamente pelas partes.

22. TESTEMUNHAS

Marcelo Batista Costa
CPF: 052.126.897-40
Departamento de Logística em Saúde - DLOG/SE

Túlio Belchior Mano da Silveira
CPF: 189.185.558-14

Precisa Comercialização de Medicamentos Ltda.

 

»s |) Documento assinado eletronicamente por TÚLIO BELCHIOR MANO DA SILVEIRA,

seil B Usuário Externo, em 25/02/2021, às 14:28, conforme horário oficial de Brasília, com

assinatura fundamento no art. 6º, $ 1º, do Decreto nº 8.539, de 8 de outubro de 2015; e art. 8º, da Portaria
nº 900 de 31 de Março de 2017.

os) Documento assinado eletronicamente por Emanuela Batista de Souza Medrades, Usuário
seil B Externo, em 25/02/2021, às 14:31, conforme horário oficial de Brasília, com fundamento no art.

assinatura 6º, 8 1º, do Decreto nº 8.539, de 8 de outubro de 2015; e art. 8º, da Portaria nº 900 de 31 de
eletrônica
Março de 2017.

 

 

 

https://sei.saude gov. br/sei/docum ento. consulta, externa. php?id.... acesso. externo=0&infra hash=4f9bc60 208643dbff37917bods189bo4 Página 10 de 11
SEI/MS - 0019155275 - Contrato 29/02/2021 16:27

 

—

( qr Documento assinado eletronicamente por Roberto Ferreira Dias, Diretor(a) do Departamento

seil 8 de Logística, em 25/02/2021, às 16:28, conforme horário oficial de Brasília, com fundamento no
l apsinaturo art. 6º, 8 1º, do Decreto nº 8.539, de 8 de outubro de 2015; e art. 8º, da Portaria nº 900 de 31 de
Março de 2017.

 

 

 

—

( o Documento assinado eletronicamente por Marcelo Batista Costa, Coordenador(a)-Geral de
seil B Aquisições de Insumos Estratégicos para Saúde substituto(a), em 25/02/2021, às 16:22,
assinatura conforme horário oficial de Brasília, com fundamento no art. 6º, $ 1º, do Decreto nº 8.539, de 8

de outubro de 2015; e art. 8º, da Portaria nº 900 de 31 de Março de 2017.

 

 

A autenticidade deste documento pode ser conferida no site

http://sei saude gov.br/sei/controlador externo php?

Fx acao=documento conferir&id orgao acesso externo=0, informando o código verificador
0019155275 e o código CRC 1CAO07D3B.

E

   
    

 

 

 

Referência: Processo nº 25000.175250/2020-85 SEI nº 0019155275

Divisão de Análise das Aquisições de Insumos Estratégicos para Saúde - DIVAN
Esplanada dos Ministérios, Bloco G - Bairro Zona Cívico-A dministrativa, Brasília/DF, CEP 70058-900
Site - saude.gov.br

https://sei.saude gov. br/sei/docum ento. consulta, externa. php?id.... acesso. externo=0&infra hash=4f9bc60 208643dbff37917bods189bo4 Página 11 de
 

Ministério da Saúde
Secretaria Executiva
Departamento de Logística em Saúde

OFÍCIO Nº 62/2021/DLOG/SE/MS
Brasília, 22 de março de 2021.

Ao Senhor

ANTONIO BARRA TORRES

Diretor-Presidente da Agência Nacional de Vigilância Sanitária- GADIP
SIA, Trecho 5, Área Especial 57, Lote 200, Bloco A/B, 1º Andar
CEP.: 71205-050

Telefones: (61) 3462-4342

Email: gabinete .presidencia Ganvisa.gov.br

Assunto: Solicitação de autorização para importação em caráter
Excepcional de 20.000.000 (vinte milhões) de doses da Vacina COVAXIN

Senhor Diretor Presidente,

1. Considerando Decreto Legislativo na 06 de 20 de março de 2020 que
ratifica o Reconhecimento, para os fins do art. 65 da Lei Complementar nº 101,
de 4 de maio de 2000, a ocorrência do estado de calamidade pública, nos
termos da solicitação do Presidente da República encaminhada por meio da
Mensagem nº 93, de 18 de março de 2020;

2. Considerando trata-se de processo de aquisição celebrado entre este
Ministério da Saúde (MS) e a empresa BHARAT BIOTECH LIMITED
INTERNATIONAL, representada pela empresa PRECISA COMERCIALIZAÇÃO DE
MEDICAMENTOS LTDA, CNPJ: 03,394.819/0005-00, com sede na Avenida
Portugal nº 1100, Rua 5, Parte A-14-B, Itaqui, Itapevi/SP, CEP: 06.696-060,
pelo instrumentado Contrato 29/2021 para aquisição de 20.000.000 (vinte
milhões) de doses da Vacina COVAXIN/BBV152 divididos em 05 (cinco) parcelas
de 4.000.000 (quatro milhões) cada.

3. Considerando que o fabricante BHARANT BIOTECH
INTERNATIONAL LIMITED (BBIL) localizado na Genome Valley, Shameerpt,
Hyderabad, Telangana, Índia, não possui registro sanitário junto a Agência
Nacional de Vigilância Sanitária (ANVISA);

4. Considerando o disposto nos Art. 4º e 5a da Resolução da Diretoria
Colegiada (RDC) na 476, de 10 de março de 2021 que:

“Estabelece os procedimentos e requisitos para submissão de pedido de
autorização excepcional e temporária para importação e distribuição de
medicamentos e vacinas contra Covidi9 para o enfrentamento da
emergência de saúde pública de importância nacional decorrente do surto do
novo coronavírus (SARS-CoV-2), nos termos da Lei nº 14.124, de 10 de
março de 2021”. e
5. Considerando tratar-se de insumo essencial para o enfrentamento da
Pandemia de SARS-COV-2, este Departamento de Logística (DLOG/SE-MS), vem
por meio deste, mui respeitosamente, solicitar a Vossa Senhoria autorização
para esta importação EM CARATER EXCEPCIONAL das 20.000.000 (vinte
milhões) de doses, objeto do contrato em questão, afim de seja dada a devida
continuidade deste processo.

6.
Atenciosamente,

ROBERTO FERREIRA DIAS
Diretor do Departamento de Logística em Saúde

 

 

Documento assinado eletronicamente por Roberto Ferreira Dias,
seil; Diretor(a) do Departamento de Logística, em 22/03/2021, às 15:07,
sell [5 | conforme horário oficial de Brasília, com fundamento no art. 6º, 8 1º, do

eletrônica Decreto nº 8.539, de 8 de outubro de 2015; e art. 8º, da Portaria nº 900 de
31 de Março de 2017.

 

A autenticidade deste documento pode ser conferida no site
http://sei.saude.gov.br/sei/controlador externo.php?

* acao=documento conferir&id orgao acesso externo=0, informando o
4 código verificador 0019668812 e o código CRC 40F915B2.

 

 

 

Referência: Processo nº 25000.043170/2021-42 SEI nº 0019668812

Departamento de Logística em Saúde - DLOG
Esplanada dos Ministérios, Bloco G - Bairro Zona Cívico-Administrativa, Brasília/DF, CEP 70058-900
Site - saude.gov.br
 

F. No. BIO/MA/20/000103
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

FDA Bhawan, Kotla Road,
New Delhi- 110002
Dated: 11/3/20%

To Ê

M/s Bharat Biotech International Ltd.,

Genome Valley, Shameerpet,

Hyderabad, India -500078.

Subject- Permission to manufacture of Whole-virion Inactivated SARS-CoV-2 Vaccine
(BBV152) for restricted use in emergency situation in Form CT-23 as per the provisions of
New Drugs and Clinical Trials Rules, 2019 under Drugs & Cosmetics Act, 1940 - regarding.

Reference:

1. Permission granted by this Directorate in Form CT-23 vide no. MF/BIO/21/000002dated
03.01.2021.

2. Your letter nos. BBIL/RA/21/173, 177, 187 dated 06.03.2021, 08.03.2021 & 10.03.2021
submitted to this office vide email dated 06.03.2021, 08.03.2021 & 10.03.2021.

Sir,

This is with reference to the permission granted by this Directorate in Form CT-23
vide no. MF/BIO/21/000002 dated 03.01.2021 to manufacture Whole-virion Inactivated
SARS-CoV-2 Vaccine (BBV152) for restricted use in emergency situation in public interest
use in as an abundant precaution, in clinical trial mode with various conditions.

In this regard, the interim safety and efficacy data of phase III clinical trial of Whole
Virion, Inactivated Corona Virus Vaccine (BBV152) in the country submitted to this office
was reviewed in consultation with SEC (COVID-19) committee on 08.03.2021 & 10.03.2021
respectively, wherein after detailed deliberation the committee recommended for omission
of the condition of the use of the vaccine in clinical trial mode. However, the vaccine should
be continued to be used under restricted use in emergency situation condition. Further, the
ongoing phase III clinical trial should be continued as per the approved protocol. The firm
should update the prescribing information and factsheet accordingly (under restricted use in
emergency situation condition). All other conditions of the marketing authorisation shall
continue to remain the same.

Accordingly, based on the recommendations of SEC, the condition “This permission
is for restricted use in emergency situation in public interest use in as an abundant
precaution, in clinical trial mode” as mentioned in the said permission is amended to read
as “This permission is for restricted use in emergency situation in public interest”. However,
you are required to continue ongoing Phase III clinical trial as per approved clinical trial
protocol & submit revised summary of product characteristics (SmPC), Fissenticia
Information (Pl) and Factsheet.

Yours faithfully,
Vac :
ae
(Dr. V. G. Somani)

Drugs Controller General (India)
Central Licensing Authority

Pagelof2
 

Copy to:

ds Tre Deputy Drugs Controller (India), CDSCO Zonal office, CDSCO Bhavan, Beside T.B.
& Demonstration Centre, S.R. Nagar, Hyderabad - 500038, India.

2. The Drugs Controller Telangana, Directorate of Drug Control Administration, Drug Control
Bhavan, Vengal Rao Nagar, Hyderabad-500 038, India.

Page Z0f2
 

File No: BIO/MA/20/000103

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)
FDA Bhawan, Kotla Road,
New Delhi- 110002.

Dated: GIiiz034
To,

Mis Bharat Biotech International Ltd.,
Genome Valley, Shameerpet,
Hyderabad, India -500 078.

Subject: Request for amend the Form CT-23 for permission to manufacture Whole Virion,
Inactivated Corona Virus Vaccine (BBV 152) for sale and distribution — regarding

References:
1. Your letter vide no. BBIL/RA/20/006 dated 05.01.2021 submitted to this office vide
diary no. 120 dated 06.01.2021.
2. Permission granted by this Directorate in Form CT-23 vide no. MF/BIO/21/000002
dated 03.01.2021.

SirlMadam,

With reference to the subject cited above and based on the submission of
information/documents to this office, the name of product code of Whole Virion, Inactivated
Corona Virus Vaccine mentioned in the cover letter and permission is hereby amended to
read as “BBV152” instead of BBV152C or BBV152B respectively.

Further, as per the license issued in Form 28D, 2.5ml, 5ml & 140 ml vial
presentations, are also permitted subject to condition mentioned in permission, license &
communication in this regard including the provisions of New Drugs and & Clinical trials
Rules, 2019 under Drugs and Cosmetics Act, 1940.

Yours faithfully,

vos

(Dr. V. G. Somani)
Drugs Controller General (India)

Copy to:
1. The Deputy Drugs Controller (India), CDSCO Zonal office, CDSCO Bhavan, Beside
T.B. & Demonstration Centre, S.R. Nagar, Hyderabad - 500038, India
2. The Director, CDL, Kasauli, HP
File No. BIO/MA/20/000103

 

 

Teias
From:
The Drugs Controller General, India
Directorate General of Health Services
FDA Bhawan, Kotla Road,
New Delhi- 110002, India.
Dated: 03-JAN-2021
To

M/s Bharat Biotech International Ltd.,
Genome Valley, Shameerpet,
Hyderabad, India -500 078.

Subject: Application for permission to manufacture of Whole-virion Inactivated SARS-CoV-2
Vaccine (BBV152C) for restricted use in emergency situation in Form CT-23 as per the provisions
of New Drugs and Clinical Trials Rules, 2019 under Drugs & Cosmetics Act, 1940- regarding.

Reference: SUGAM application no. BIO/CT21/FF/2020/22922 dated 07-Dec-2020.

Sir,

Please find enclosed herewith permission no. MF/BIO/21/000002 dated 03-Jan-2021 in
Form CT-23 to manufacture of Whole-virion Inactivated SARS-CoV-2-Vaccine (BBV152C) for
restricted use in emergency situation in public interest as an abundant precaution, in clinical trial
mode as per the provisions of New Drugs and Clinical: Trial Rules, 2019 under Drugs &
Cosmetics Act, 1940.

Yours faithfully,
VENUGOPAL no
GIRDHARILAL
SOMANI
(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licensing Authority

 

Copy to:

1. The Deputy Drugs Controller (India), CDSCO Zonal office, CDSCO Bhavan, Beside T.B. &
Demonstration Centre, S.R. Nagar, Hyderabad - 500038, India.

2. The Drugs Controller Telangana, Directorate of Drug Control Administration, Drug Control
Bhavan, Vengal Rao Nagar, Hyderabad-500 038, India.
F. No.: BIO/MA/20/000103

Permission no.: MF/BIO/21/000002 dated 03-JAN-2021

FORM CT-23
(See rules 81, 82, 83 and 84)

PERMISSION TO MANUFACTURE PHARMACEUTICAL FORMULATION OF NEW DRUG
FOR SALE OR FOR DISTRIBUTION

The Central Licensing Authority hereby grant permission to M/s Bharat Biotech International
Limited, Sy. No. 230, 231 & 235, Genome Valley, Shameerpet Mandal, Medchal-Malkajgiri District,
Telangana State- 500078. Telephone No.: nil, Fax: nil, E-Mail:draQDbharatbiotech.com, Telephone
No.: nil, Fax: nil, E-MailidraQObharatbiotech.com to manufacture for sale of pharmaceutical
formulation manufactured by a manufacturer specified below.

2. Details of manufacturer and its manufacturing site under this license:

 

s.
No

Name and address of
manufacturer (full name and
address with telephone and e-
mail address of manufacturer).

Name and address of manufacturing site (full
name and address with telephone and e-mail
address of manufacturing site).

 

 

Bharat Biotech Intemational
Limited, Sy. No. 230, 231 & 235,
Genome Valley, Shameerpet
Mandal, Medchal-Malkajgiri

District, Telangana State- 500078.
Telephone No.: nil, Fax: nil, E-
Mail:dra(Dbharatbiotech.com

 

Bharat Biotech International Limited, Sy. No. 230,
231 & 235, Genome Valley, Shameerpet Mandal,
Medchal-Malkajgiri District, Telangana State- 500078.

 

 

 

 

Telephone No.: nil, Fax: nil, E-
Mail:draQDbharatbiotech.com .
Component Manufacturing facility
Drug substance | e Facility PS2, Building S
Drug Product [e Building A, Facility PA1

 

 

 

 

3. Details of pharmaceutical formulation:

 

Name of the New
drug to be
manufactured:

Whole Virion Inactivated Corona Virus Vaccine, [BBV152B]

 

Dosage form:

Suspension for injection
Presentation: single dose glass vial (0.5ml)
Route of Administration: Intramuscular

 

Composition:

Each dose of 0.5ml contains:

 

 

 

 

 

 

 

 

Active Ingredients Quantity
Whole Virion, Inactivated Corona Virus antigen 6 mcg
(Strain: NIV-2020-770)

Inactive Ingredients Quantity
Aluminium Hydroxide gel equivalent to Alt++ 250 meg
TLR 7/8 Agonist 15 meg
2-Phenoxyethanol (2PE) L.P. 2.5 mg
Phosphate Buffered Saline q.s. to 0.5 mL

 

 

 

* Produced in Vero cells.

 

For active immunization against Corona Virus Disease (COVID-19) for

 

 

storage condition:

 

Indication:
age 218 years when administered in two doses interval of day O & day
28.

Shelf life with 6 months when stored at 2 to 8 ºC.

 

Page lof2

 
F. No.: BIO/MA/20/000103
Permission no.: MF/BIO/21/000002 dated 03-JAN-2021

4. This is subject to the conditions prescribed in Chapter X of the New Drugs and Clinical Trials

Rules, 2019 under the Drugs and Cosmetics Act, 1940.
5. This permission is for restricted use in emergency situation in public interest as an abundant

precaution, in clinical trial mode.

6. The fim should provide the protocol for rolling out for the restricted use of the vaccine in
emergency situation.

7. The firm should provide the updated prescribing information/ Package Insert and Summary
of Product Characteristics (SmPC) for Whole Virion Inactivated Corona Virus Vaccine
(BBV152B) and also disseminate the necessary information, instructions and educational
materials through their website.

8. The firm should submit updated safety, efficacy & immunogenicity data from the ongoing
Phase |, II & III clinical trials till the completion of trials as per requirement of New Drugs &
Clinical Trials, 2019.

9. The firm should submit'safety data including the data on AEFI and AESI, with due analysis,
every 15 days for the first two months & monthly thereafter and also as per requirement of
New Drugs & Clinical Trials, 2019.

10. The firm should submit Risk management plan.

11.The firm should submit ongoing stability of commercial scale batches (real time and
accelerated) of drug substance & drug product.

12.The permission is subject to condition of satisfactory evaluation & lot release by CDL,
Kasauli. Further, each batch/lot of Whole Virion Inactivated Corona Virus Vaccine,
(BBV152B) shall be released from Central Drugs Laboratory, Kasauli.

VENUGOPAL
GIRDHARILA
LSOMANI

 

(Dr. V. G. Somani)

Place: New Delhi Drugs Controller General (India)
Date: 03-Jan-2021 Central Licensing Authority
Dr. V. G. SOMANI

 

Drugs Controller General (India)

- General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, .T.O.
New Delhi-110002

 

Page 2 of2
w PRECISA

Medicamentos
DECLARAÇÃO

Ateste de adoção das estratégias de monitoramento e cumprimento das diretrizes de
Farmacovigilância nos termos da RDC/ANVISA 476, de 10 de março de 2021
artigo 12 inciso Ille Anexo

A PRECISA - COMERCIALIZACAO DE MEDICAMENTOS LTDA,, pessoa
jurídica de direito privado, com endereço na Avenida Portugal, n.º 1100, Rua 5, parte
A-14, Bairro Itaqui, Cidade de Itapevi, Estado de São Paulo, CEP 06696-060, CNPJ
03.394.819/0005-00, neste ato representada por Emanuela Batista de Souza
Medrades, brasileira, farmacêutica, portador do RG 35.435.759-1- SSP-SP e CPF
330.976.208-42, considerando o disposto na Resolução de Diretoria Colegiada - RDC
nº 476, de 10 de março de 2021, considerando o disposto na Resolução de Diretoria
Colegiada - RDC nº 476, de 10 de março de 2021, o importador, na pessoa de
PRECISA - COMERCIALIZACAO DE MEDICAMENTOS LTDA, CPF/CNPJ
03.392.918/0005-00, DECLARA cumprir o disposto nas normas sanitárias vigentes
para a importação e distribuição de medicamentos e vacinas para Covid-19. O
importador declara que realiza todos os procedimentos necessários e possui
capacidade técnica e administrativa para garantir a qualidade, segurança e eficácia
do medicamento ou vacina para Covid-19 objeto da importação, bem como adotará
as estratégias de monitoramento e cumprirá as diretrizes de farmacovigilância
estabelecidas pela Anvisa. O importador, na pessoa de PRECISA -
COMERCIALIZACAO DE MEDICAMENTOS LTDA, se responsabiliza pela
veracidade e fidedignidade das informações aqui prestadas e declara que está ciente
de que é responsável pela qualidade, segurança e eficácia do medicamento ou vacina
para Covid-19, bem como assegura que este está adequado aos fins a que se destina
e cumpre os requisitos legais e sanitários. Declaro estar ciente que o descumprimento
das disposições contidas nesta Resolução e nas demais vinculadas constitui infração
sanitária, nos termos da Lei nº 6437, de 20 de agosto de 1977, sem prejuízo das
responsabilidades civil, administrativa e penal cabíveis.

Por ser expressão da verdade, firmamos a presente para que surta os seus
efeitos legais.

Brasília/DF, 17 de março de 2021.

EMANUELA BATISTA DE SOUZA | Assinado de forma digital por EMANUELA
BATISTA DE SOUZA MEDRADES:33097620842.

MEDRADES:33097620842 Dados: 2021.03.17 17:38:27 -0300'

EMANUELA BATISTA DE SOUZA MEDRADES
CPF 330.976.208-42
Representante Legal/Técnica

      
 
   

Office: Av. Tamboré, 267, 28º andar - Barueri— SP | Pharma: Av. Portugal, 1100 - Itapevi - SP
Phone: +55 11 3080-5140 | www.precisamedicamentos.com.br

Declaração Atest 125000.043170/2021-42 / pg. 20
Investigator s Brochure BBV 152

   

COVID-19 WHOLE VIRION
INACTIVATED
CORONAVIRUS VACCINE
BBV152

 

INVESTIGATOR"S
BROCHURE FOR PHASE 3
CLINICAL TRIAL

Version 4.0 Effective Date 08 Mar 2021

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 10f 72
Investigator's Brochure BBV 152

Disclosure Statement

This document contains information that is confidential and proprietary to Bharat Biotech International Ltd
(BBIL). This information is being provided to you solely for the purpose of evaluation and/or conducting a
clinical trial for BBIL. You may disclose the contents of this document only to study personnel under your
supervision and/or to your Institutional Review Board/ Independent Ethics Committee who need to know the
contents for this purpose and who have been advised on the confidential nature of the document.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 2 0f 72
Investigator's Brochure BBV 152

DECLARATION BY RESPONSIBLE SPONSOR REPRESENTATIVE(S)

This Investigator Brochure version É 4.0 with effective from 08 Mar 2021 is authored by:

+ fue 08.03.2021

Date

This Investigator Brochure was critically and scientifically reviewed. and has been
approved by me.

ode, [e 08.03.2021

Dr. V. Krishna Mohan Date
Whole-Time Director

Bharat Biotech International Ltd

Genome Valley

Hyderabad 500078

kmohanBbharatbiotech.com

Tel: +91 40 2348 0567

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 3 of 72
Investigator's Brochure BBV 152

LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

2-PE 2-Phenoxyethanol

AGMK African Green Monkey Kidney

ATCC American type culture Collection

BBIL Bharat Biotech Intemational Limited

BRM Bacterial Reverse Mutation

BSC Biosafety Cabinet

BP British Pharmacopoiea

CoA Certificate of Analysis

CPCSEA Committee for the Purpose of Control and Supervision on
Experimental Animals

CPE Cytopathic Effect

cvs Control Virus Sample

DCG(I) Drugs Controller General(India)

DMSO Dimethyl Sulphoxide

DNA Deoxyribonucleic Acid

DMEM Dulbecco”s Modified Eagle's Medium

DSMB Data Safety Monitoring Board

EDTA Ethylenediamine Tetra Acetic Acid

ELISA Enzyme Linked Immunosorbent Assay

EoPC End of Production Culture

EP European Pharmacopoeia

IHS In-House Specification

IP Indian Pharmacopoiea

FBS Fetal Bovine Serum

GCP Good Clinical Practices

GMP Good Manufacturing Practices

HIV Human Immunodeficiency Virus

HTLV Human T-lymphotropic virus

IAEC Institutional Animal Ethics Committee

IBSC Institutional Biosafety Committee

ICH International Council for Harmonization

IM Intramuscular

IPA Isopropyl Alcohol

IPQC In-Process Quality Control

IRB Institutional Review Board

LAF Laminar Air Flow

MCB Master Cell Bank

MCHC Mean Corpuscular Hemoglobin Concentration

MCV Mean Corpuscular Volume

MEM Minimum Essential Medium,Eagle

MOI Multiplicity of Infection

MTD Mean Time to Death

MTD Maximum Tolerated Dose

MVB Master Virus Bank

NA Not Applicable

NGS Next Generation Sequencing

NLT Not Less Than

NMT Not More Than

NOAEL No Observed Adverse Effect Level

NOC No Objection Certificate

NRA National Regulatory Authority

NsP Non-Structural Protein

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 40f 72
Investigator's Brochure BBV 152

oD
OECD
PBS
PCR
PERT

Optical Density

Organization for Economic Co-operation and Development
Phosphate Buffered Saline

Polymerase Chain Reaction

Product Enhanced Reverse Transcriptase

Quality Assurance

Quality Control Department

Quantitative Product Enhanced Reverse Transcriptase
Research and Development

Repeat Dose Toxicity

Ribonucleic Acid

Reverse Transcription-Polymerase Chain Reaction
Single Human Dose

50% Cell Culture Infectious Dose

Technical Report Series

United States Pharmacopoeia

Working Cell Bank

Water for Injection

World Health Organization

Working Virus Bank

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 5 of 72
Investigator's Brochure BBV 152

Table of Contents

1 INTRODUCTION....

11 CORONAVIRUS
1.2 STRUCTURE...
1.3 GENETIC DIVERSIT

2 | CORONAVIRUS INFECTION

21 TRANSMISSION ....
2.2 CLINICAL SYMPTOMS
2.3 DISEASE BURDEN
2.4 DIAGNOSIS ..
24.1 Molecular test
24.2 Serology
24.3 Laboratory examinations
244 Imaging..
2441 Chest X-ray examinatio
2442 Chest computed tomography.
2443 Lung ultrasound

2.5 TREATMENT ..

3  COVID 19 VACCINE DEVELOPMENT ....

3.1 RATIONALE....
3.2 HISTORY AND CURRENT STATUS...
3.3 CHALLENGES IN NEW VACCINE DEVELOPMENT
3.4 TARGET PRODUCT PROFILE

4 | CORONAVIRUS VACCINE PRODUCT DEVELOPMENT AT BHARAT BIOTECH...

41 SUMMARY ...
42 VERO-CELL SUBSTRATE
42.1 MASTER CELL BANK (MCB) PREPARATION
42.2 MASTER CELL BANKCHARACTERIZATIO!
42.3 MANUFACTURER'S WORKING CELL BANK (MWCB) PREPARATION..
42.4 MANUFACTURER'S WORKING CELL BANK CHARACTERIZATION ..
42.5 CHARACTERIZATION OF END OF PRODUCTION CELLS (EOPC) ...

5 — CORONAVIRUS VACCINE STRAIN....

5.1 CELL SUBSTRATE....
5.2 SYSTEM OF SEED/MASTER/WORKING BANKS...
5.2.1 Master Cell Bank Establishment and Characterization:
5.2.2  Manufacturer's Working Cell Bank Establishment and Characterizatio:
5.3 DESCRIPTION, HISTORY AND CHARACTERIZATION & SEED LOT SYSTEM FOR VERO CELLS
5.3.1 Embryonated eggs and other cells substrates:
5.3.2 Master Seed and Working Seed of Virus Banks
5.3.2.1 Virus Strain....
5.322 Virus Seed Lot Systei

54 PREPARATION OF MASTER VIRUS BANK (MVB)
5.5 CHARACTERIZATION OF MVB ...
5.6 PREPARATION OF WORKING VIRUS BANK (WVB)....
5.7 (CHARACTERIZATION OF WORKING VIRUS BANK (WVB)

6 — CORONAVIRUS BANKS.

6.1 VIRUS SEED LOT SYSTEM...
6.2 PREPARATION OF P3 MASTER SEED VIRUS
6.3 CHARACTERIZATION OFP3 MASTER SEED VIRUS
6.4 CHARACTERIZATION OFMVB.....

6411 WHOLE GENOME SEQUENCING BY NGS PLATFORM

6.4.1.2 MVB CHARACTERIZATION AS PER WHO TRS96:
6.5 PREPARATION OF WORKING VIRUS BANK (WVB
6.6 CHARACTERIZATION OF WVB ....

 

 

 

 

 

 
 
  
 
 
  
  
 
  

 

 

 

 
 

 

 

 

 
 
 
  

 

 

 

 
   
  
 
  
 
 
 
 
 
  

 

 

 

 
 
  
   

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 60f 72
Investigator's Brochure BBV 152

6.6.1 WHOLE GENOME SEQUENCING BY NGS PLATFORM
6.6.2 WVB CHARACTERIZATION AS PER TRS963

7 CORONAVIRUS VACCINE PRODUCTION...

71 VACCINE BULK ....
7.2 LOT RELEASE SPECIFICATIONS
7.3 VACCINESTABILITY ..

7.3.1 BULKSTABLITY

7.3.2 FINISHED PRODUCTSTABILIT
7.4 FORMULATION DEVELOPMENT .

74.1 Scope:.

74.2 Type of Formulations executed is given below:

8 ANALYTICAL METHODS ESTABLISHMENT......

8.1 TESTS FOR VIRUS QUANTITATION....
8.1.1 MEDIAN TISSUE CULTURE INFECTIOUS DOSE (CCID50)
8.1.2 Safety AND IMMUNOGENICITY TESTING OF THE CANDIDATE VACCINE,

8121 INSTITUTIONAL ANIMAL ETHICS COMMITTEE (IAEC) APPROVAL

8.2 GLP PRE-CLINICAL TOXICITY STUDIES
8.2.1 8.2.1 GLP STATEMENT
8.2.2 ANIMAL MODELS

8.3 PRE-CLINICAL STUDIES:
8.3.1 Safety and immunogenicity in Mice, Rats, and Rabbi
8.3.2 Immunogenicity and protective efficacy in the Syrian hamster:
8.3.3 Immunogenicity and protective efficacy in rhesus macaques
8.3.4 Overall Conclusion of the Preclinical studi

9 CLINICAL DEVELOPMENT PATHWAY.

 
 

 

 

 

 

 

 

 

 

 

   
 
 
 
  
 
 
 
    
   
 
 
 
  
   
 
   
 
  
 
 
  
 
 
  
  
 

9.1 STUDY DESIGN AND PARTICIPANTS 49
9.1.1 Study Vaccine.... 50
9.1.2 Study Procedure: 50
9.1.3 Blinding. 50
9.14 Safety As 51
9.1.5 | Immunogeni 51

9.2 RESULTS 51
9.2.1 Safety 51
9.2.2 Immune responses 53

10 PRELIMINARY REPORT OF THE PHA:

10.1 STUDY DESIGN AND PARTICIPANTS
10.2 STUDY VACCINE
10.3 | STUDY PROCEDURES.
10.4 — BLINDING....
10.5 SAFETY ASSESSMENT:
10.6 — IMMUNOGENICITY ASSESSMENT:
10.7 RESULTS.
10.8 SAFETY
10.9 — IMMUNE RESPONSE!
10.10 CONCLUSION:...

1 INVESTIGATIONAL VACCINE (INV)

11.1 RATIONALE FOR PHASE 3 DOSE SELECTION:
11.2 COMPOSITION OF STUDY VACCINE
11.3 PLACEBO COMPOSITION...

11.4 DOSAGE FORM AND ROUTE OF ADMINISTRATION .
11.5 VACCINE STORAGE
11.6 HANDLING OF STUDY VACCINE AND PLACEB:
11.7 STUDY DESIGN AND SUBJECT SELECTION.
11.8 BLINDING....

2 CLINICAL TRIAL

 

 

 

 
 
 

 

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 7 0f 72
Investigator's Brochure BBV 152

11.9 METHOD OF ADMINISTRATION
11.10 PRECAUTIONS FOR HANDLING VACCINE SUPPLIES
11.11 WARNING...
11.12EFFICACY ASSESSMENT.
11.13 SAFETY

11.13.1 SERIOUS ADVERSE EVENTS .
11.14 INTERIM PHASE 3 RESULTS: ...

12 RESTRICTED USE OF COVAXIN UNDER CLINICAL TRIAL MODE .....

 

 
  
 
 
 
 

 

12.1.1 Vaccination Procedure: .
12.1.2 Adverse Events and SAEs Collection Procedure:
12.1.3 CONCLUSIONS..

13 NEUTRALIZATION OF UK-VARIANT VUI-202012/01 WITH COVAXIN VACCINATED HUMAN
SERUM..... 0 69

14 REFERENCES

 

 

 

 

 

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 8 0f 72
Investigator's Brochure BBV 152

1 INTRODUCTION
1.1 CORONAVIRUS

In December 2019, a novel coronavirus (CoV) started causing illness and death in Wuhan
province of China (1). The International Committee on Taxonomy of Viruses (ICTV) named
the new virus as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) because
of its phylogenetically close relationship with SARS-CoV and the disease was named
Coronavirus disease 2019 (COVID-19) by World Health Organization (WHO) (2,3). The
WHO declared COVID-19 as global pandemic on March 11, 2020 as the number of
confirmed cases increased outside China to 13-fold with increasing number of countries
affected with the virus to three-fold(4). The number of confirmed cases and mortality keeps
on increasing every day and at present (ar Sep 2020), there are about 30 million confirmed
cases and 900,000 deaths reported worldwide (WHO) (5).

The first case of laboratory confirmed SARS-Cov-2 was detected on 1*December 2019 in
Wuhan, China. The initial outbreak reported to occur in the Seafood market in Huanan
involving about 41 people. An epidemiological alert was issued on 31º December 2019 to
shut down the market on 1º“January 2020. The infection then spread many cities and
provinces of China. The first exported case from china was detected in Thailand on
13"January 2020 and simultaneously, the disease spread rapidly across many other countries
involving 205 countries (6). As of 12º Sep 2020, about 30 million confirmed cases and
900,000 deaths have been reported worldwide involving 216 countries, territories or areas
(5).The initial mortality rates for patients in the hospital were estimated to be 11%-15%, but
more recent data were 2%-3%. The mortality rate also varies from country to country, co-
morbid conditions, isolation practice of the country (6). As of March og" 2021, the total
number confirmed cases of COVID-19 cases and death in India are 11,229,398 and 157,853
deaths, respectively as per the Official data of Govt. of India official data and the first
COVID-19 case in Brazil was reported on Feb 26, 2020, in the city of São Paulo, and as of 2
Feb 2021, approximately 224,504 deaths and 9,204,731 Cases have been reported (7).

1.2 STRUCTURE

Coronavirus is a spherical or pleomorphic enveloped particle containing single-stranded
(positive-sense) RNA associated with a nucleoprotein within a capsid comprised of matrix
protein. The envelope bears club-shaped glycoprotein projections. Some coronaviruses also
contain a hem agglutinin-esterase protein (HE) [8].

Coronaviruses possess the largest genomes (26.4-31.7 kb) among all known RNA viruses,
with G + C contents varying from 32% to 43%. Variable numbers of small ORFs are present
between the various conserved genes (ORFlab, spike, envelope, membrane and
nucleocapsid) and, downstream to the nucleocapsid gene in different coronavirus lineages.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 9 of 72
Investigator's Brochure BBV 152

The viral genome contains distinctive features, including a unique N-terminal fragment
within the spike protein. Genes for the major structural proteins in all coronaviruses occur in
the 5'-3' order as S, E, M, and N [9].

The structureof SARS-CoV-2 consists of the following: a spike protein (S),
hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein
(E) a nucleoclapid protein (N) and RNA as seen in the figure below. [10]

 

 

| spike(s18s2)

      
 

Nucleocapsid (N)

Membrane (M)

Envelope (8) R, Angiotensin Converting

SSRNA
(+ sense, -30kbinlength)

SARS-CoV-2 STRUCTURE
Source: https:/Avww.ncbi.nIm.nih.gov/books/NBK554776/figure/article-52171
EEE a

 

 

 

 

ECO

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 100f72
Investigator s Brochure BBV 152

Figure 1: Electron Microscope image of SARS-CoV-2 Structure of BBIL Clarified virus
from EM Facility, National Institute of Virology, Pune

Spike protein (S) is heavily glycosylated, utilizes an N-terminal signal sequence to gain
access to the ER and mediate attachment to host receptors. It is the largest structure and
makes the distinct spikes on the surface of the virus. S protein is cleaved by cellular furin-like
protease [11] into two separate polypeptides S1 and S2.

Nucleocapsid protein (N) binds to RNA in vitro and is heavily phosphorylated. N proteins
binds the viral genome in a bead on a string type conformation. This protein likely helps
tether the viral genome to replicase-transcriptase complex (RTC), and subsequently package
the encapsulated genome into viral particles.

Membrane protein (M) is the most abundant structural protein. It does not contain signal
sequence and exists as a dimer in the virion. It may have two different conformations to
enable it to promote membrane curvature as well as bind to nucleocapsid.

Envelope protein (E) is found in small quantities in within the virus. It is most likely a
transmembrane protein and with ion channel activity. The protein facilitates assembly and
release of the virus and has other functions such as ion channel activity. It is not necessary for
viral replication but it is for pathogenesis.

RNA is the genome of the SARS-CoV-2 virus and contains positive-sense, single-stranded
RNA.

Receptor-binding domain (RBD): Receptor recognition by coronaviruses is the first and
essential step for infecting host cells. Coronavirus entry into host cells is mediated by the
transmembrane S glycoprotein that forms homotrimers protruding from the viral surface [12].
S glycoprotein comprises two functional subunits responsible for binding to the host cell
receptor (S1 subunit) and fusion of the viral and cellular membranes (S2 subunit). The distal
S1 subunit comprises the receptor-binding domain (RBD) and contributes to stabilization of
the prefusion state of the membrane-anchored S2 subunit that contains the fusion machinery
[13]. The receptor binding motif (RBM) in RBD is responsible for direct binding to ACE2
and its binding affinity may directly affect the virus infectivity and transmissibility [14].

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 11 0f72
Investigator s Brochure BBV 152

SARS-CoV-2

 

Figure 2: Receptor Binding Domain

[Source: Omotuyi, O.; Nash, O.; Ajiboye, B.; Metibemu, D.; Oyinloye, B.; Ojo, A.; Okaiyeto, K. The
Disruption of SARS-CoV-2 RBD/ACE-2 Complex by Ubrogepant Is Mediated by Interface Hydration.
Preprints 2020, 2020030466 (doi: 10.20944/preprints202003.0466.v1][15].

Coronavirus entry into susceptible cells is a complex process that requires the concerted
action of receptor-binding and proteolytic processing of the S protein to promote virus-cell
fusion. As the coronavirus S glycoprotein is surface-exposed and mediates entry into host
cells, it is the main target of neutralizing antibodies (Abs) upon infection and the focus of
therapeutic and vaccine design.

1.3 GENETIC DIVERSITY

Nucleotide substitution has been proposed to be one of the most important mechanisms of
viral evolution in nature. The rapid spread of SARS-CoV-2 raises intriguing questions such
as whether its evolution is driven by mutations. To assess the genetic variation, Tung Phan
reported that eighty-six complete or near-complete genomes of SARS- CoV-2 were collected
from GISAID [https:/Avww .gisaid. org/]. These SARS-CoV-2 strains were detected in
infected patients ftom China (50), USA (11), Australia (5), Japan (5), France (4), Singapore
(3), England (2), Taiwan (2), South Korea (1), Belgium (1), Germany (1), and Vietnam (1).
The pair-wise nucleotide sequence alignment was performed by ClustalX2, and the sequence
of the strain China/WHU01/2020/EPI ISL 406716 was used as a reference genome. Like
other beta-coronaviruses, the genome of SARS-CoV-2 has a long ORFlab polyprotein at the
5' end, followed by four major structural proteins, including the spike surface glycoprotein,
small envelope protein, matrix protein, and nucleocapsid protein. The genetic analysis
discovered three deletions in the genomes of SARSCoV-2 from Japan (Aichi), USA

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 120f 72
Investigator s Brochure BBV 152

(Wisconsin), and Australia (Victoria). Two deletions (three nucleotides and twenty-four
nucleotides) were in the ORFlab polyprotein, and one deletion (ten nucleotides) was in the 3"
end of the genome. The nucleotide sequence alignment also revealed ninety-three mutations
over the entire genomes of SARS-CoV-2. Forty-two missense mutations were identified in all
the major non-structural and structural proteins, except the envelope protein. Twenty-nine
missense mutations were in the ORFlab polyprotein, eight in the spike surface glycoprotein,
one in the matrix protein, and four in the nucleocapsid protein. Of note, three mutations
(D354, Y364, and F367) located in the spike surface glycoprotein receptor-binding domain.
The spike surface glycoprotein plays an essential role in binding to receptors on the host cell
and determines host tropism. It is also the major target of neutralizing antibodies. Mutations
in the spike surface glycoprotein might induce its conformational changes, which probably
led to the changing antigenicity. To date, a study on localization of amino acids involved in
conformational changes of the SARS-CoV-2 spike surface glycoprotein structure is not
available. The identification of these amino acids is of significance and should be
investigated by further studies. [12].

2 CORONAVIRUS INFECTION
2.1 TRANSMISSION

The human-to-human transmissions occur via droplets and contact. The RO currently is
estimated by the WHO as 1.4-2.5. RO describes about how many secondary cases that is
expected to be produced from one primary infection in a susceptible population. For example,
the median RO for seasonal flu is reported as 1.28 with interquartile range of 1.19-1.37),
whereas for measles it is reported as 12-18. As RO value can be affected based on the local
factors such as disease susceptibility, case detection rate and infection control measures, it
should be calculated from population specific data taking local variability factors into
consideration. Therefore, RO value of COVID-19 may be changed in future when additional
information on the disease become available [13].

2.2 CLINICAL SYMPTOMS

Signs and symptoms of coronavirus disease 2019 (COVID-19) may appear two to 14 days
after exposure. This time after exposure and before having symptoms is called the incubation
period. Common signs and symptoms can include:

e Fever
e Cough
e — Tiredness
Other symptoms can include:

*  Shortness of breath or difficulty breathing
e Muscle aches

e Chills

e Sorethroat

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 130f72
Investigator s Brochure BBV 152

e | Loss oftaste or smell

e  Headache

e Chestpain
This list is not all inclusive. Other less common symptoms have been reported, such as rash,
nausea, vomiting and diarrhea. Children have similar symptoms to adults and generally have
mild illness.

The severity of COVID-19 symptoms can range from very mild to severe. Some people may
have only a few symptoms, and some people may have no symptoms at all. People who are
older or who have existing chronic medical conditions, such as heart disease, lung disease,
diabetes, severe obesity, chronic kidney or liver disease, or who have compromised immune
systems may be at higher risk of serious illness. This is similar to what is seen with other
respiratory illnesses, such as influenza.

Some people may experience worsened symptoms, such as worsened shortness of breath and
pneumonia, about a week after symptoms start.

 

2.3 DISEASE BURDEN

In India, the first three SARS-CoV-2 cases were reported from Kerala during January 27-31,
2020. Later during March 2020, cases were also reported from a group of Italian tourists
(n=15) and their contacts in New Delhi, India. Simultaneously, cases were reported in Agra,
Uttar Pradesh, which was the outcome of close contact of an infected Delhi-based individual
who returned from Italy. Subsequently, SARS-CoV-2 cases were reported from all over the
country. As of Sep 12 2020, the total number confirmed cases of COVID-19 cases and death
in India are - 5 million, and 77,000 deaths, respectively as per the Official data of Govt. of
India official data [7].

2.4 DIAGNOSIS

2.4.1 MOLECULAR TEST

The WHO recommends collecting specimens from both the upper respiratory tract (naso- and
oropharyngeal samples) and lower respiratory tract such as expectorated sputum,
endotracheal aspirate, or bronchoalveolar lavage. The collection of BAL samples should only
be performed in mechanically ventilated patients as lower respiratory tract samples seem to
remain positive for a more extended period. The samples require storage at four degrees
celsius. In the laboratory, amplification of the genetic material extracted from the saliva or
mucus sample is through a reverse polymerase chain reaction (RT-PCR), which involves the
synthesis of a double-stranded DNA molecule from an RNA mold. Once the genetic material
is sufficient, the search is for those portions of the genetic code of the CoV that are
conserved. The probes used are based on the initial gene sequence released by the Shanghai
Public Health Clinical Center & School of Public Health, Fudan University, Shanghai, China
on Virological.org, and subsequent confirmatory evaluation by additional labs. If the test
result is positive, it is recommended that the test is repeated for verification. In patients with

  
 

 

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 14 0f 72
Investigator s Brochure BBV 152

confirmed COVID-19 diagnosis, the laboratory evaluation should be repeated to evaluate
for viral clearance prior to being released from observation. The availability of testing will
vatry based on which country a person lives in with increasing availability occurring nearly
daily.

2.4.2 SEROLOGY

Despite the numerous antibody tests designed, to date serologic diagnosis has limitations in
both specificity and sensitivity. Again, results from different tests vary. A CDC research on a
test developed by the US Vaccine Research Center at the National Institutes of Health is
ongoing. Of note, this test seems to have specificity higher than 99% with a sensitivity of
96%. Nevertheless, further research is needed for elucidating several aspects of the matter.

Inparticular:
e If IgG antibodies will provide immunity from future SARS-CoV-2 infection.
* On the protective titer of antibodies.
e On the duration of the protection.

Serologic, however, can have an important role in broad-based surveillance.

2.4.3 LABORATORY EXAMINATIONS
Concerning laboratory examinations:

e In the early stage of the disease, a normal or decreased total white blood cell count
(WBC) and a decreased lymphocyte count can be demonstrated. Interestingly,
lymphopenia appears to be a negative prognostic factor.

e Increased values of liver enzymes, lactate dehydrogenase (LDH), muscle enzymes,
and C-reactive protein can be detected.

* Unless a bacterial overlap, a normal procalcitonin value is found.

e The elevated neutrophil-to-lymphocyte ratio (NLR), derived NLR ratio (d-NLR)
[neutrophil count divided by the result of WBC count minus neutrophil count], and
platelet-to-lymphocyte ratio, can be the expression of the inflammatory
storm.[23] The correction of these indices is an expression of a favourable trend.

e Increased D-dimer.

e In critical patients, D-dimer valueis increased, blood lymphocytes decreased
persistently, and laboratory alterations of multiorgan imbalance (high amylase,
coagulation disorders, etc.) are found.

2.4.4 IMAGING

2.4.4.1 CHEST X-RAY EXAMINATION

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 15 0f72
Investigator s Brochure BBV 152

Since the disease manifests itself as pneumonia, radiological imaging has a fundamental role
in the diagnostic process, management, and follow-up. Standard radiographic examination
(X-ray) of the chest has a low sensitivity in identifying early lung changes and in the initial
stages of the disease. At this stage, it can be completely negative. In the more advanced
stages of infection, the chest X-ray examination generally shows bilateral multifocal alveolar
opacities, which tend to confluence up to the complete opacity of the lung. Pleural effusion
can be associated.

   

2.44.2 CHEST COMPUTED TOMOGRAPHY
Given the high sensitivity of the method, chest computed tomography (CT), in particular

high-resolution CT (HRCT), is the method of choice in the study of COVID-19 pneumonia,
even in the initial stages. Several non-specific HRCT findings and patterns can be found.
Most of these findings may also be observed in other lung infections, such as Influenza A
(HIN1), CMV, SARS, MERS, streptococcus, and Chlamydia, Mycoplasma. The most
common findings are multifocal bilateral "ground or ground glass" (GG) areas associated
with consolidation areas with patchy distribution, mainly peripheral/subpleural and with
greater involvement of the posterior regions and lower lobes. The "crazy paving” pattern can
be also observed. This latter finding is characterized by the presence of GG areas with
superimposed interlobular septal thickening and intralobular septal thickening. It is a non-
specific finding that can be detected in different conditions. Other findings are the “reversed
halo sign” which is a focal area of GG delimited by a peripheral ring with consolidation, and
the finding of cavitations, calcifications, Iymphadenopathies, and pleural effusion.

2.4.4.3 LUNG ULTRASOUND

Ultrasound approach can allow evaluating the evolution of the disease, from a focal
interstitial pattern up to "white lung”" with evidence often of sub-pleural consolidations. Tt
should be performed within the first 24 hours in the suspect and every 24/48 hours and can be
useful for patient follow-up, choice of the setting of mechanical ventilation, and for
indication of prone positioning. The main sonographic features are:

e Pleural lines often thickened, irregular, and discontinuous until it almost appears
discontinuous; subpleural lesions can be seen as small patchy consolidations or
nodules.

* B lines. They are often motionless, coalescent, and cascade and can flow up to the
square of "White lung”.

e Thickenings. They are most evident in the posterior and bilateral fields especially in
the lower fields; the dynamic air bronchogram within the consolidation is a
manifestation of disease evolution.

e Perilesional pleural effusion

In summary, during the course of the disease, it is possible to identify the first phase
with focal areas of fixed B lines, a phase of numerical increase of the lines B up to the white

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 160f 72
Investigator s Brochure BBV 152

lung with small subpleural thickenings, and further progress until evidence of posterior
consolidations.

2.5 TREATMENT

There is no specific antiviral treatment recommended for COVID-19, and no vaccine is
currently available. The treatment is symptomatic, and oxygen therapy represents the first
step for addressing respiratory impairment. Non-invasive and invasive mechanical ventilation
may be necessary in cases of respiratory failure refractory to oxygen therapy.

The clinical management of COVID-19 should be based on the stage and type of syndrome
associated with disease at the time of presentation. Mild illness can be managed with
conventional symptomatic treatment. Patients with severe illness may require immediate
supplementary oxygen therapy. At present, there are no approved drugs with proven efficacy
available for the treatment of COVID-19. Some of drugs approved drugs for other diseases
are currently used worldwide for the treatment of the patients. The drugs/therapy currently
used are either re-purposed or tried as experimental therapy for the treatment of COVID-19
[13,16]. These are:

1) Anti-malarial drugs: Hydroxychloroquine, Chloroquine

2) Anti-retroviral drugs: Lopinavir/Ritonavir (Protease inhibitors)
3) Anti-viral drugs: Remdesivir (nucleoside analogue), Favipiravir
4) Corticosteroids: Methylprednisolone

5) Monoclonal antibodies: Tocilizumab

6) Intravenous immunoglobulin (IVIG)

7) Convalescent plasma transfusion

 

Remdesivir has been authorized in US under Emergency Use Authorization for the
management of adult and pediatric patients for whom use of an IV agent is clinically
appropriate and who are under the care or consultation of a licensed clinician skilled in the
diagnosis and management of patients with potentially life-threatening illness. Favipiravir has
been approved for restricted emergency use in India.

Although none of the vaccines are approved for the prevention of COVID-19, many vaccine
candidates are under development throughout the world.

3 COVID 19 VACCINE DEVELOPMENT

3.1 RATIONALE

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is accelerating
globally leading to an increase in morbidity and mortality. The high-risk group includes the
health care workers (HCW) (physicians and paramedical staff), working amid SARS-CoV-2
infected patients, all other people including household contacts of COVID-19 confirmed
patients, people currently residing or working in COVID-19 hotspots/outbreak areas where
there is a high risk of transmission of SARS-CoV-2 infection and especially the elderly
people (age >60 Years). Though SARS-CoV-2 infection may cause mild symptoms in many,
nearly 14% develop a severe disease that requires hospitalization and oxygen support, and

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 17 0f72
Investigator's Brochure BBV 152

5% require admission to an intensive care unit. In severe cases, COVID-19 can be
complicated by acute respiratory distress syndrome, sepsis, septic shock, and multiorgan
failure with an estimated case fatality of 3.4%.

The COVID-19 pandemic is rapidly worsening in all parts of the world, overwhelming health
systems. There is a serious threat to a densely populated country like India. Also, reports
from all over the world demonstrate that the disease takes a severe course in elderly people
and people with co-morbid conditions leading to higher mortality rates. Thus, there is an
urgent need to ensure the safety and health of existing people living in COVID-19 affected
areas where there is a high risk of disease transmission and find strategies to prevent the
SARS-CoV-2 infection among such populations.

 

To date, no specific antiviral drug has been approved for COVID-19 although remdesivir has
been given Emergency Use Authorization approval by USFDA, and Favipiravir has been
used under restricted emergency use in India. Hence, there is a necessity to develop a vaccine
to prevent SARS-CoV-2 infection. Various types of COVID-19 vaccines, such as DNA,
RNA based formulations, recombinant subunit vaccines containing the viral protein (Spike)
epitopes, vector-based formulations (eg: Adenovirus, Measles, Rabies,) and traditional
inactivated vaccines are under development 10,11,12,13. Two Chinese based vaccine
manufacturing company (Sinovac Biotech Ltd., and China National Pharmaceutical Group
Co., Ltd. (Sinopharm)) have developed inactivated vaccine formulation against the SARS-
CoV-2 virus and proved its safety and immunogenicity in animals such as mice, rats, and
non-primate mammal, rhesus macaque monkeys [17,18]. The phase 1/2 (Sinopharm) and
Phase 2 (Sinovac Biotech Ltd.) results have been published and the inactivated vaccine have
demonstrated safety and immunogenicity in healthy adults [19,20]. Currently, the phase 3
clinical trials for these two inactivated vaccines are ongoing.

3.2 HISTORY AND CURRENT STATUS

The potential vaccine target could be whole cell antigen (WCA), spike protein (S protein)
(The Full-Length S Protein, RBD, NTD, S1 subunit, FP), nucleocapsid protein (N Protein),
membrane protein (M Protein) or envelope protein (E protein). The potential vaccine
candidates for covid-19 can be categorized into various types such as whole-cell killed and
live-attenuated vaccines, subunit vaccines, mRNA vaccines, DNA vaccine, live vector
vaccines, synthetic peptide or epitope vaccine.

As of 10” Aug 2020, about 139 vaccine candidates are in preclinical evaluation stage and 28
candidate vaccines in clinical evaluation stage. (The COVID-19 vaccine development
landscape, WHO).

3.3 CHALLENGES IN NEW VACCINE DEVELOPMENT

New vaccine development is challenging as usually the reference reagents like antibodies,

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 18 0f 72
Investigator s Brochure BBV 152

reference vaccine for testing and virus strain suitable for vaccine development are not
available. Hence fundamental work is required to qualify any virus strain to be used as a
vaccine strain. Extensive validation is required to qualify primary in-house reference
reagents. However, the most challenging aspect of a new vaccine development is the
derivation and rationalization of vaccine doses for clinical testing. The use of different
platform technologies renders comparison of protective correlates induced by the different
candidate vaccines difficult to 2 .

In the case of COVIDI9 vaccine development at Bharat Biotech there were additional
challenges. The vaccine project was initiated at the time when very little or no information
was available on virus pathogenesis, genetic diversity, transmission, diagnosis, serological
correlates for protection or animal models to test the vaccine concepts. From vaccine point of
view, there was no information on whether the virus can be cultured in vitro in cell substrates
and if yes, which cell substrates are best suitable, mechanism of adaptation to cells, potential
virus titers and the feasibility to manufacture the vaccine product for human administration,
as the published information at that time pertained to passaging the virus in mouse brain
which is not suitable for vaccine production. The extent of R&D work done on this vaccine
has now led to the development of a very promising candidate vaccine being advanced into
clinical development.

3.4 TARGET PRODUCT PROFILE

Table 1: Develop and license vaccine for reactive use in outbreak settings (Outbreak)
and/or with long-term protection for administration to those at high ongoing risk of
COVID-19 (LT)

 

 

BBV 152 Vaccine | Preferred Critical or Minimal
characteristics
Indication for use Outbreak: Outbreak:

For active immunization of
at-risk persons in the area of
an on-going outbreak for the
prevention of infection of
SARS-CoV-2; to be used in
conjunction with | other
control measures to curtail or
end an outbreak.

Long Term (LT

For active immunization of
at-risk persons to prevent
COVID-19

For active immunization of
at-risk persons in the area of
an on-going outbreak for the
prevention of COVID-19; to
be used in conjunction with
other control measures to
curtail or end an outbreak
Long Term (LT):

For active immunization of
at-risk persons to prevent
COVID-19

 

 

Contraindication

 

None

 

Some contraindications (e.g.,

immunocompromised) may

 

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL

Page 19 0f72

 
 

 

be acceptable

 

Target population

All ages!. Suitable for
administration to pregnant
and lactating women.

Adults, including elderly

 

Safety/Reactogenicity

Safety and reactogenicity
sufficient to provide a highly
favourable benefit/risk

profile in the context of
observed vaccine efficacy;
with only mild, transient
adverse events related to
vaccination and no serious
AEs.

Outbreak:
Safety and reactogenicity
whereby vaccine benefits

outweigh safety risks?

Long Term (LT):

Safety and reactogenicity
sufficient to provide a highly
favourable benefit/risk

profile in the context of
observed vaccine efficacy;
with only mild, transient
adverse events related to
vaccination.

 

Measures of Efficacy

At least 70% efficacy (on
population basis, with
consistent results in the
elderly”. Endpoint may be
assessed vs. disease, severe
disease, and/or
shedding/transmission.
Outbreak:

Rapid onset of protection
(less than 2 weeks).

Long Term (LT):

Rapid onset of protection is
less important.

Clear demonstration | of
efficacy (on population basis)
ideally with -50% point
estimate. Endpoint may be
assessed vs. disease, severe
disease, and/or
shedding/transmission”.

 

Dose regimen

Outbreak:

Two-dose primary series”.
Long Term (LT):

Lower frequency (yearly or
less) of booster doses is

Outbreak:
No more than
regimen*.
Long Term (LT):

Booster doses permitted

two dose

 

 

 

preferred.

Durability of protection Confers protection for at | Confers protection for at
least 1 year. least 6 months”.

Route of Administration Outbreak: Any route of administration

 

Any route of administration
is acceptable, if vaccine is
safe and effective.

 

is acceptable, if vaccine is
safe and effective

 

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL

Page 20 0f 72

 
Investigator s Brochure BBV 152

 

Long Term (LT):

Any route of administration
is acceptable.

 

 

 

 

Product Stability and | Higher storage temperatures | Outbreak:
Storage and higher thermostability | Storage at 2ºC 8ºC or
will greatly enhance vaccine | higher;
distribution and availability,
and are thus strongly
preferred. Long Term (LT):
Storage at 2º€ 8ºC or
higher;
Co-administration with | Outbreak: Stand-alone product
other vaccines Stand-alone product.
Long Term (LT):
potential for
coadministration with other
vaccines (e.g, flu, polio,
measles, pneumococcal)
preferred
Presentation Outbreak: Multi- or mono- dose

 

Multi-dose presentation is
preferred for ease of use in
campaigns.
Long Term (LT):
Mono-dose or
presentations are acceptable
Maximum parenteral dose
volume: 0.5 mL

Multi-dose presentations
should be formulated,
managed and discarded in
compliance with WHO's
multi-dose vial policy.

multidose

 

presentations are acceptable.
Maximum parenteral dose

volume: 1 mL Multi-dose
presentations should be
formulated, managed and
discarded in compliance with
WHO's multi-idose  vial
policy.

 

1LRecognize that herd immunity (and transmission blocking) will depend on broad immunization, likel;

including children.

2 Benefit/risk may depend on age, other factors. Benefit/risk assessment should take potential for enhanced

disease into account.

3 The lower confidence limit of the efficacy estimate could be lower

 

alf regulatory authorization is provided with incomplete clinical efficacy data, effectiveness data are to be

generated during use

5 Note strong preference for single-dose, but do not desire to discourage development of2-dose vaccines if that

is what is feasible

snote cholera is 2 dose, and many 2 dose vaccines confer partial protection after a single dose. For two-dose

vacci protection after single d: ould be ed
7 This might not be demonstrated in initial clinical studies, but could be supported by follow-on studies, animal

data, etc

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL

Page 21 0f72

 
Investigator's Brochure BBV 152

4 CORONAVIRUS VACCINE PRODUCT DEVELOPMENT AT BHARAT
BIOTECH

41 SUMMARY

The aim was to manufacture a safe COVID-19 vaccine based on the whole-virion inactivated
vaccine under BSL3 facility for human clinical trial. This vaccine was based on vero cell
manufacturing platform, manufactured and characterized at Bioreliance USA. The safety is
well established. This vaccine used the same platform used for vaccines, such as Rabies,
Rotavirus, Chikungunya, Zika, Japanese Encephalitis, Inactivated Polio vaccines.

The coronavirus vaccine BBVI52 is whole virion inactivated vaccine developed in
collaboration with Indian Council of Medical Research and National Institute of Virology,

Pune.
devátage e

Advantage Bharat Biotech !
GMP MCB of Vero cells prepared and validated at BioReliance, USA!

* Same cell banks used in commercial production of Rotavirus, JE, !
Rabies vaccines '

*  Chikungunya, & Zika vaccines (Clinical development) 1
1

1

1

 

      
 
  
    

iema CER
CER

[Rae ç

 

 

GMP production established

   
   

 

|
[NT
EUA

Figure 3: Summary of Vaccine product Development
4.2 VERO-CELL SUBSTRATE

 

 

 

4.2.1 MASTER CELL BANK (MCB) PREPARATION

Vero Cell MCB was prepared and characterized by BioReliance for BBIL. The preparation
of MCB was initiated by BioReliance with 2 cryovials of Vero MCB (P/N: 5.41075L/N:
3006- 103388.) at passage 48 (equivalent to passage*130 of ATCC CCL-81). Vero Cells
were seeded in 2 x 225 cm? flasks. Cells were serially passaged three more times up to the

stage of 109 x 225 cm? flasks. Cells were harvested from all the 105 flasks and cryo
preservation medium containing 90% FBS and 10% DMSO was added to the pooled cell
suspension. The cell suspension was distributed in 1.0 mL aliquots into sterile cryo vials

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 220f 72
Investigator's Brochure BBV 152

labelled as under:

Vero MCB, P-11

P/N: BHAMCI.FP, L/N: 3006-104986
10/07/03 1 mL Vial &

BioReliance. Stored: Lig. N2

The running passage level of notional P$l1 is P$133 as per the records of BioReliance.
The Vero Cell MCB was completely characterized at BioReliance.

4.2.2 MASTER CELL BANKCHARACTERIZATION

a) Sterility test in accordance with 21CFR, USP 26 AND EP. Result was satisfactory.

b) Test for Bacteriostatic/Fungistatic activity of a test article using direct inoculation
method. Result was satisfactory.

c) Test for the presence of Agar cultivable and Non-Agar cultivable Mycoplasma.
Results: Test was negative.

d) Cell culture identification and characterization. Results: Isoenzyme analysis is
consistent with cells of Cercopithecus monkey origin.

e) Test for the presence of inapparent viruses in suckling mice, adult mice and
embryonated hen's eggs. Results: No evidence of contamination with adventitious
agents.

£) In vitro assay for the presence of viral contaminants. Results: Adventitious viral
contaminants were not detected.

g) PCR assay for the detection of Simian Virus 40 in biological samples.
Results: Negative for SV40 DNA

h) PCR assay for the detection of Simian Retrovirus in biological samples. Results:
Negative for SRV sequence

i) Transmission electron microscopic evaluation of cultured cells. Results: Negative
for virus like particles and other microbial agents.

5) Product Enhanced Revert Transcriptase (PERT) assay for the detection of Retrovirus
in biological samples. Results: Negative for RT activity.

k) Cytogenetic analysis for the characterization of cell lines. Results: Identity
confirmed as African Green Monkey Cells.

 

 

4.2.3 MANUFACTURERS WORKING CELL BANK (MWCB) PREPARATION

One cryovial was taken from the Vero MCB P/N: (BioReliance) P$133 and seeded into
1xT- 150 flask (P$134). At the time of revival, cell count of the re-suspended cells was
found to be 5.6x 10º cells and viability was found to be 56%. Cells were serially passaged
further up to P$138 for expansion in order to obtain 144 x T-150 flasks. Cells were
trypsinised, harvested and made into a cell suspension. To the cell suspension,
cryopreservation medium (90% FBS+10% DMSO) was added. Cell suspension was

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 23 0f 72
Investigator's Brochure BBV 152

aliquoted in 1.2 mL aliquots into sterile cryovials.

4.2.4 MANUFACTURER'S WORKING CELL BANK CHARACTERIZATION

MWCB cryovials were tested for sterility and mycoplasma at BBIL. Samples were sent to
BioReliance for characterization.

a) Sterility test in accordance with 21 CFR, USP 27 AND EP for final product;
Results: Satisfactory

b) Test for the presence of Agar-cultivable and Non-Agar Cultivable Mycoplasmas in
accordance with EP and USFDA; Results: Negative

c) Cell culture identification and characterization; Results: Isoenzyme analysis
consistent with cells of Cercopithecus monkey origin.

d) Cytogenetic analysis for the characterization of cell lines; Results: Identified as
African Green Monkey Kidney (AGMK) Cells

4.2.5 CHARACTERIZATION OF END OF PRODUCTION CELLS (EOPC)

a) Evaluation of tumor formation in nude athymic mice following subcutaneous
injection of cell suspension; Results: Non-tumorigenic.

b) 28 Day in vitro assay for the detection of viral contaminants in 3 detector cell
lines; Results: Negative for the presence of viral contaminants.

5 CORONAVIRUS VACCINE STRAIN
GENERAL DESCRIPTION AND HISTORY OF STARTING MATERIAL
5.1 CELL SUBSTRATE

The origin of Vero Cells is from ATCC. Vero Cell CCL-81(Lot No. F-11497) was procured
by Bio Reliance Corporation (BRC) from ATCC and Master Cell Bank was prepared by
(BRC). The part number of the Vero Cell batch is BHAMCI.FP and the Lot Number is 3006-
104986.

5.2 SYSTEM OF SEED/MASTER/WORKING BANKS

5.2.1 MASTER CELL BANK ESTABLISHMENT AND CHARACTERIZATION:

Bharat Biotech engaged BioReliance Corporation, Rockville, MD, USA, in 2005 to prepare
and characterize Vero Cell Master Cell Bank for the production of viral vaccines. The origin
of Vero Cell line used by BioReliance Corporation, for the preparation of Vero Master Cell
Bank for Bharat Biotech was Vero ATCCE.CCL-81TM. Vero Cell line was developed in
1962 by Y. Yasumura and Y. Kawakita at the Chiba University in Chiba, Japan from the
kidneys of a normal Cercopithecus aethiops monkey and was given to National Institutes of

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 24 0f 72
Investigator s Brochure BBV 152

Allergy and Infectious Diseases (NIAID) in the USA in 1964 and NIAID, in turn, provided
the cell line to the American Type Culture Collection (ATCC) in 1966.

Bio Reliance received Vero Cells from ATCC with a passage number 122 and prepared MCB
with a passage number at 133. It was numbered as Vero MCB P/N: BHAMCI.FP, L/N:
3006-104986. The MCB was fully characterized by BioReliance, the tests and results of
which are given Table: 2.

Table — 2: Various tests performed for characterization of MCB and the results

 

 

 

 

 

 

 

 

 

 

 

 

 

S. No Test performed Observation/Result
Sterility Test in Accordance with
1. 21CFR, USP 26 and/ or European Satisfactory
Pharmacopeia (EP) for final product
Test for Bacteriostatic / Fungistatic
2. Activity of a test article using direct Satisfactory
inoculation method
Test for the presence of Agar cultivable .
3. . Negative
and Non-Agar cultivable Mycoplasma
Cell culture identification and Isoenzyme analysis consistent with
4. e - io
characterization cells of Cercopithecus Monkey origin
Test for the Pres f inapparant
É ê o e Tesenes O tmêpP aram No evidence of contamination with
5. viruses in suckling mice, adult mice and ..
; adventitious agents
embryonated hen's eggs
6 In vitro assay for the presence of Viral Adventitious viral contaminants were
. contaminants not detected
Polymerase chain Reaction assay for the
7. detection of Simian Virus 40 (SV40) in Negative for SV40 DNA
Biological samples
Polymerase chain Reaction assay for the
8. detection of Simian Retrovirus (SRV) in Negative for SRV Sequence
Biological samples
9 Transmission Electron Microscopic Negative for Virus-Like Particles and
. evaluation of cultured cells other microbial agents
Product Enhanced Reverse Transcriptase Negative RT activity at a sensitivity of
. atIVi activity at a sensitivity
10. PERT) Assay for the detect f
(PERT) Assay for the detection o 2x10/ RT Units/4.0ul of test article
Retrovirus in Biological samples
Cyt tic Analysis for th
11. Ylogenetlo Anatysis for fe Identified as African Green Monkey

 

characterization of cell lines

 

 

The tests done by BioReliance on End of Production Culture (EOPC), Vero-CCL81 EOPC

 

 

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL

Page 25 0f 72

 
Investigator s Brochure BBV 152

Table — 3: Tests performed and the results

 

 

 

 

S. No Test Performed Results
í Evaluation of Tumor formation in nude (NU/NU) athymic | Not considered to be
mice following subcutaneous injection of cell suspension Tumorigenic
2 28 Day In vitro Assay for the Detection of Viral Negative

 

Contaminants-3 Detector cell lines

 

 

Each MCB cryovial contains approximately 10” cells/1.0mL. These cells are stored at -130ºC
or below in the cell bank storage area in Building 'C' and are controlled, monitored and issued

by OA.

5.2.2 MANUFACTURER'S
CHARACTERIZATION:

WORKING

CELL BANK

ESTABLISHMENT

AND

The MWCB was characterized by BBIL as per Specification no. SMS003

Table -4: Various tests performed for the characterization of MWCB and the results

 

 

 

 

 

 

 

 

 

 

 

S.No Test Performed Specification Results
. Should show 222 bp band after PCR 222 bp band
1 Identity amplification in Gel Analysis for bserved
AGMK species observe
No Growth observed
2 Sterility No Growth should be observed | JO SWIM ODSEIve
(Sterile)
3 Mycoplasma Should be Negative for Mycoplasma Negative for .
Mycoplasma species
4 Adventitious agents Should be Free from Adventitious Free from
(in-vivo and in-vitro) Agents Adventitious Agents
. Should be Free from Free from
5 Haemadsorption . . Haemadsorbing
Haemadsorbing viruses .
viruses
Cells are healthy and
6 Growth characteristics | Cells should be healthy and growing eis are ca vam
growing
90% to 110% recovery should be
7 Homogeneity test observed from initial cell count in 98.94%
each cryovials
8 Cell Viability NLT 80% 98.7%
É ,
9 Cell count NLT 5 x 10º cells/ cryovial 5:21 x 10 cells)
cryovial

 

 

 

 

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL

Page 260f 72

 

 
Investigator's Brochure BBV 152

Flow chart of Vero MWCB Preparation:
Stage 1: Vials of MCB, Pf 133

Stage 2: Revival (1xT-25 flask), P& 134
Stage 3: Cell Expansion I(1 x T-175 cm? flask), Pé 135
Stage 4: Cell Expansion II (4x T-175 cm? flask), Pg 136
Stage 5: Cell q” NI (Ix CS10), P$ 137

Stage 6: Cell Expansion IV (6 x CS10), P4 138

I

Cryo-preserved, Pé 138

5.3 DESCRIPTION, HISTORY AND CHARACTERIZATION & SEED LOT
SYSTEM FOR VERO CELLS

5.3.1 EMBRYONATED EGGS AND OTHER CELLS SUBSTRATES:
Not Applicable.

5.3.2 MASTER SEED AND WORKING SEED OF VIRUS BANKS
5.3.2.1 VIRUS STRAIN

A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated with
human to human transmission and extreme human sickness has been as of late announced
from the city of Wuhan in China. The nucleocapsid protein (N-protein) and spike protein (S-
protein) are encoded by all coronaviruses, including the coronavirus (SARS-CoV-2, COVID-
19) that was first detected in Wuhan City, China, in December 2019.

5.3.2.2 VIRUS SEED LOT SYSTEM

The seed virus (Strain NIV 2020-770) were transferred from ICMR —National Institute of
Virology to Bharat Biotech. This strain was the first successful virus isolation from the nasal
and throat swabs of person with a travel history from Italy. The seed virus received from the
NIV was adapted and amplified to produce MASTER VIRUS BANK (MVB). WORKING

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 27 0f 72
Investigator s Brochure BBV 152

VIRUS BANK (WVB) was prepared from MVB and characterized. WVB is being used for
the production.

5.4 PREPARATION OF MASTER VIRUS BANK (MVB)
SARS-COV-2 Master Virus Bank preparation flow chart

Receive Vero MWCB

y

Revival of MWCB
Media change
Cell Expqnsion 1
Celi Expansion 2

Celi Expansion 3

y

Receive SARS-COV-2 Virus Seed

k

Thaw the cryovial(s) and dilute in Media

Add the virus eta into2 x CS 40

y

Incubate at 36+1ºC for 1 hrs+10 mins

k

Top up with Media and incubate at 36+1ºC for 3-4 days

Harvest Collection and Clarification
Aliquot and Store at -70+5ºC

5.5 CHARACTERIZATION OF MVB

Characterization of MVB was done and the following QC tests certified the MVB for
production of vaccine lots.

Table -5: Various tests performed for the characterization of MVB and the results

 

 

 

 

 

 

 

S.No TEST SPECIFICATION
1 Identity (By In-vitro method) Virus titration by qgPCR serve as an identity test
2 Sterility No Growth should be observed
3 Mycoplasma Should be negative for mycoplasma
4 | Virus titration (in vitro) NLT 10º CCIDso'mL

 

 

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 28 0f 72

 
 

Investigator s Brochure BBV 152

 

 

 

 

5 | Virus Titration by gPCR NLT 10º” Copies per mL

6 Adventitious agents (In-vitro) Should be free from Adventitious agents

7 Haemadsorption Should be free from Haemadsorption agents

8 Virus identity by NGS method | | 95% sequence should match with published
Sequence

 

 

 

 

5.6 PREPARATION OF WORKING VIRUS BANK (WVB)

Working Virus Bank (WVB) was prepared from the well characterized MVB.
The working virus banks were prepared as follows:

Receive Vero MWCB

y

Revival of MWCB

Media change

y

Cell Expansion 1
Celi Expansion 2
Celi Expansion 3

Celi Expansion 4

y

Receive Covid 19 Virus Seed

Thaw the cryovial(s) and dilute in Media

y

Add the virus seed into3 x CS 40

Incubate at 36+1ºC for 1 hrs+10 mins

y

Top up with Media and incubate at 36+1*C for 3-4 days

Harvest Collection and Clarification

Aliquot and Store at -70+5ºC

5.7 CHARACTERIZATION OF WORKING VIRUS BANK (WVB)

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 29 0f 72
Investigator s Brochure BBV 152

Characterization of WVB was done and the following QC tests certified the MVB for
production of vaccine lots.

Table -6: Various test performed for the characterization of WVB with specification

 

 

 

 

 

 

 

 

 

 

 

 

S.No TEST SPECIFICATION
1 Identity (By In-vitro method) Virus titration by qgPCR serve as an identity test
2 Sterility No Growth should be observed
3 Mycoplasma Should be negative for mycoplasma
4 | Virus titration (in vitro) NLT 10º” CCIDso/mL
5 | Virus Titration by gPCR NLT 10º” Copies per mL
6 Adventitious agents (In-vitro) Should be free from Adventitious agents
7 Haemadsorption Should be free from Haemadsorption agents
8 Virus identity by NGS method | | 95% sequence should match with published
sequence

 

6 CORONAVIRUS BANKS
6.1 VIRUS SEED LOT SYSTEM

A virus seed lot system was established to provide traceability to the virus stocks used in the
production of vaccine lots.

6.2 PREPARATION OF P3 MASTER SEED VIRUS

Coronavirus Seed Virus as described earlier was used for the preparation of P3 Master
Seed. The seed virus was aged twice in C6/36 Ae. albopictus cells and plaque purified
twice from Vero cells to obtain *Coronavirus Master Seed which was advanced into
preparation of GMP Master Virus Banks. The virus titer in the P3 Master Seed is 107º
CCIDS5O / mL.

 

6.3 CHARACTERIZATION OF P3 MASTER SEED VIRUS
The Corona P3 Master Seed Virus was extensively tested for mycoplasma, sterility, virus

titer, whole genome sequencing by Next Generation Sequencing (NGS) platform before
advancing to the preparation of GMP Master Virus Banks.

6.4 CHARACTERIZATION OF MVB

6.4.1.1 WHOLE GENOME SEQUENCING BY NGS PLATFORM

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 30 0f 72

 
Investigator s Brochure BBV 152

The genomic RNA isolated from the pre-seed was sequenced using NGS platform at
Genotypic Technologies, Bangalore. The sequence confirmed the identity of the MR 766
strain of Coronavirus.

6.4.1.2 MVB CHARACTERIZATION AS PER WHO TRS963

Table 7: QC Specification No. SMS 034

 

 

 

 

 

 

 

 

 

S.No. Tests Specifications Results
95% Sequence should match with
L Virus identity by sequencing (NGS published sequence Under Test
Method)
2. Virus — identity by In-Vitro Method | Virus titration by qPCR serve as an Complies
Identity test
3. Sterility by direct inoculation method No growth should be observed Sterile
4. Mycoplasma by PCR method Should be free from mycoplasma Negative for
mycoplasma
5. Virus titration (In-Vitro) NLT 106.00 CCID50/ml 106.25 CCID50/ml
6. Virus titration by qPCR NLT 106.00 Copies per mL 107.25 Copies per mL]
7. Adventitious agents (In-vitro) Should be free from adventitious Under Test
agents
8. Haemadsorption Should be free om imemadsorbing Under Test

 

 

 

 

 

6.5 PREPARATION OF WORKING VIRUS BANK (WVB)

Working Virus Bank (WVB) was prepared from the well characterized MVB under GMP
conditions.

6.6 CHARACTERIZATION OF WVB
6.6.1 WHOLE GENOME SEQUENCING BY NGS PLATFORM

The genomic RNA isolated from the WVB was sequenced by NGS platform using Illumina
NextSeg500. The nucleotide sequence confirmed the identity of coronavirus.

6.6.2 WVB CHARACTERIZATION AS PER TRS963

Table 8: QC Specification No. SMS 034

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 31 0f72
Investigator s Brochure BBV 152

 

 

 

 

method

S.No Test Specification Results
Virus identity by sequencing .
l (NGS Method) 95% Sequence should match with | Under Test
Virus identity by In-Vitro | Virus titration by qPCR serve as an a
2. Method Identity test Complies
3 Sterilityby direct inoculation No growth should be observed Sterile

 

4 | Mycoplasma by PCR method

Should be free from mycoplasma

Negative for

 

 

 

 

 

 

 

viruses

 

mycoplasma
5 Virus titration (In-Vitro) NLT 106.00 CCID50/ml 106.88
teus tiram ! ' CCID50/ml
6. Virus titration by qPCR NLT 106.00 Copies permL | 197:44 Copies
per mL
7. | Adventitious agents (In-vitro) Should be free from adventitious Under Test
agents
8. Haemadsorption Should be free from haemadsorbing Under Test

 

7. CORONAVIRUS VACCINE PRODUCTION

7.1  VACCINE BULK

GMP production of vaccine bulk was standardized at 80 L pilot scale. The flow chart
below describes the steps involved in the bioprocess related to production of purified
inactivated bulk of coronavirus vaccine. All the steps in production comply with the In-
Process Quality Control (IPQC) parameters established for GMP production of vaccine
bulk. In-process steps for quality checking of the vaccine bulk were developed at different
stages of the bioprocess to ensure consistency and to prevent any inadvertent introduction

of contamination from extraneous agents.

PROCESS FLOW CHART: drug substance

Dispensing of Raw Materials

v

Washing and sterilization of Consumables

Sterilization of glassware

v

Solution preparation (pH)

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL

Page 32 0f 72

 
Investigator's Brochure BBV 152

Filtration

y

Revival of Vero cell ftom WVCB (Cell count)

+

Fluid change (Sterility from spent medium)

Vero cell expansion —1 (Cell count and sample from spent medium)

Vero cell expansion —2 (Cell count and sample from spent medium)

Vero cell expansion —3 (Cell count and sample from spent medium)

MOI calculation Infection (sample from spent medium)

v

Inactivation of SARS-COV-2 viral harvest after addition A buffer

Purification of inactivated virus by Column Chromatography

+

Concentration and Buffer exchange of SARS-COV-2 by using TFF
v

Sterile filtration of SARS-COV-2

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 33 0f 72
Investigator's Brochure BBV 152

 

 

Dispensing

Preparaion of Solutions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fo * F +
Pregaratonor IN NaOH Preparmiónor | | Preparation of Preparation of
solufion EN HO solution | IM NasHPO, solution IM NeH;PO, solutioa |
: E— z -
il vi Am il 2u mi
Preparaion of | Filter with 0.2pu filter Filter with 0.2 filter
PBS (IN NeOH/N HO
pH7.4:03) |
: -
+ Alumimium Hpdroxide gel Purificd ibactivated bulk of
E tio dispensing Corona virus antigem

 

 

 

Preparation of 2PE
with PBS

 

 

 

 

Filter with: 0,2p Alter

 
     

 

 

Addition of Aluminium
Hydtoxide gel to the PES and sé

the content Lómin. At B470 REM

Addition of Purified inactivased bulk of corona
Virus Antigen and tir ihe contem 20 + Sin. Ar

 

Formuintion
Container

 

  

 

 

 

 

  

Makeup the volume with
PES

    
 

 

>,
Final Bi

- Description
. Identification

pH

Alininm Content
Serility

Protein adsorpeion
. 2-Phenoxyeihanol
content

Fases

 
  

 

 

80H) RPM

 

 

 

 

 

 

 

 

 

 

al Endlotnato

 

 

 

    

1 JAN -
Prepared By: DD No Checked By
pés ade E

 

 

 

 

   

 

After addition of PES+2PE, check the pH Finished Produet.:
(IM Na; HPOs/ IM NaH;PO, pH 7.450.2 ) | 1. Description
E 2. Identification
Stir the Formalated bulk for 30 5 minutes at am
OS URERE 4 Extrnetable volume
o 5. Aluminium content
MH —— | 6 Residual Bovine
| Filling and Stogpering Serum Albunnia
content
RS 7 Stesility
Sealing & Bacterial Eadoiaxins
3. 2-Phenoxyeihanol
= content
Visual inspectioa of filled viuls =» | IO Residual cellular
F DNA contem
Storage at2 -89C coldioom 11. Protein adsorptiom
test
12 Total protein
contem
13.Osmolality

 

 

  

E

E q |
Approved By: Beça?

UNCONTROLÍED COPY

 

ap

  
       
  

 

 

 

 

Í

Figure 4: Manufacturing flow chart for Whole-virion Inactivated Coronavirus vaccine (BBV-

152)

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL Page 34 0f 72
Investigator s Brochure BBV 152

7.2 LOT RELEASE SPECIFICATIONS

The table lists the in-house specifications and the proposed limits of the constituents and
extraneous matter in the Coronavirus vaccine product. The limits were defined after
performing tests for consistency from R&D pilot scale batches of the vaccine. The GMP
pilot scale batches of the product described in this document comply with the following
specifications and the limits.

Table 9: Lot Release Specifications

 

 

 

 

 

 

 

 

 

 

 

 

 

 

S.No Tests Performed Acceptance criteria
Final lot
1. co White, translucent liquid free from
Description .
particulate matter
ee The ratio of OD of test sample to OD of
2. Identification .
negative control should not be less than 2
3. pH For Information Only
4. Extractable Volume NLT 0.50 mL
5. Aluminium Content NLT 0.19 mg/SHD and NMT 0.29
mg/SHD
Residual Bovine S Albumi
6. estdua! Bovine Serum Albumin NMT 50 ng per Single Human Dose
content
7. Sterility No growth should be observed (Sterile)
. . Less than 25 international Units (TU) per
8. Bacterial Endotoxins
asterta! indotoxins single human dose (SHD)
Go g G%
9. 2-Phenoxyethanol content NLT 85.0% and NMT 115.0 % of the
stated label claim
10. Residual Cellular DNA Content NMT 10 ng per Single Human Dose
G% stg ai g
H Protein adsorption Test NLT 75% of the stated claim of total
protein

 

 

 

7.3 VACCINESTABILITY

7.3.1 BULKSTABILITY

Thestabilitytestingofthebulkmaterialthatisstoredaftermanufacture,butpriortoformulation

was studied. Stability testing has been planned for batches for which manufacture and
storage are representative of the manufacturing scale of production. Hence, the qualities of
the batches of vaccine bulk placed into the stability program are a representative of the
quality of the material used in preclinical toxicology and to be used in clinical studies.
During manufacture of the inactivated, purified Coronavirus bulk no specific intermediate

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 35 0f 72

 
Investigator's Brochure BBV 152

that can potentially alter the stability of the final purified bulk substance was identified.
The protocols used for stability indicating profile of purified, inactivated Coronavirus bulk
provides methods to detect changes in the purity and sterility of the product. Bulk
substance batches for Phase I trial are planned to keep under stability programme at real
time temperature. .

7.3.2 FINISHED PRODUCTSTABILITY

Stability testing has been done on batches of the formulated material that have been
derived from the same vaccine bulk which was entered into the stability testing program.
Stability testing specifications of the pilot scale batches and storage conditions can be
considered as representative of the manufacturing scale of operations. Hence the quality of
the batches of vaccine product placed into the stability program is a representative of the
quality of the material used earlier in Pre-Clinical toxicology studies and of the quality of
the material to be made at manufacturing scale. The samples will be stored at 5+3ºC for
real time stability and at 25+2ºCfor accelerated stability in an upright position and hence
there was no interaction of the drug substance with the closure. The clinical batches
manufactured under GMP will be kept for stability testing program and the studies are
ongoing. At the accelerated storage condition of 25+ 2ºC five time points, including the
initial and final time points at 0, 1, 3 and 6 months would be carried out.

The stability of the vaccine product is planned to study under stress conditions with
temperature stress of 37ºC for 07 days. Good thermal stability of the product was observed
up to 37ºC during the above time period. This study helps us to understand the effect of
minor or major excursions in temperature on the vaccine. From the results of the stability
testing of the vaccine product from pilot scale batches, real time storage condition of
543ºC Will be confirmed with proposed shelf life of at least two years.

7.4 FORMULATION DEVELOPMENT

This product development report is limited for “Whole Virion, Inactivated Coronavirus
Vaccine (BBV 152)” for intended use to prevent the Coronavirus infection.

7.4.1 SCOPE:

The scope of this report is applicable to development of “Whole Virion, Inactivated Corona
Virus Vaccine (BBV152)” which is intended for prevention of Coronavirus infection,
wherein Algel is used as an adjuvant while the Whole Virion Inactivated Corona Virus
protein is used as an antigen, based on extensive literature survey 2 concentration of antigens
ie 3 and 6 mcg/single human dose in as 0.5mL presentation were used.

7.4.2 TYPE OF FORMULATIONS EXECUTED IS GIVEN BELOW:

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 36 0f 72
Investigator's Brochure BBV 152

1. 152A: 3ug of protein concentration /SHD with 0.25 mg/ml Algel2 (AI*)

concentration

2. 152B: 6ug of protein concentration /SHD with 0.25 mg/ml Algel2 (AI)
concentration

3. 152C: 6ug of protein concentration/SHD with 0.25mg/ ml Algell (AI**)
concentration

Three different formulations were carried out with varying concentration of the antigen as
well as the Algel and in one formulation no Algel was added. In all the above
formulations, 10mM PBS and 2Phenoxyethanol concentration 5mg/mL were common.

In brief the formulation was carried out using calculated quantity of sterile phosphate
buffer, addition of the required quantity of the bulk protein, adjuvant, and 2-
Phenoxyethanol 5mg/mL concentration and mixing for 60 minutes.

The formulations were tested for protein adsorption and it confirms that based on the
above results it was concluded that the percentage of protein adsorption was meeting the
criteria of over 75% binding of the protein to the gel.

8 ANALYTICAL METHODS ESTABLISHMENT
8.1 TESTS FOR VIRUS QUANTITATION
8.1.1 MEDIAN TISSUE CULTURE INFECTIOUS DOSE (CCIDso)

Tissue culture infectious dose is the amount of a virus which causes CPE in 50% of cell
cultures and is expressed as CCID50/ml. This assay is performed to determine the
infectious titer of coronavirus that causes CPE over a period of 5 days while the cells in
culture remain viable. Briefly, standardized numbers of Vero cells are seeded in growth
medium 24 hrs before the assay in 96-well flat bottom tissue culture plates and the plates
were incubated overnight in 37ºC incubator with 5% CO2.When the cells are 90-95%
confluent, coronavirus vaccine was seeded at 10- fold serial dilutions (log dilutions) of the

 

virus in serum free medium and incubated for 60 min at 37ºC with 5% CO2. Equal volume
of growth medium was added in the control wells. After incubation, the virus containing
medium was discarded and 200 ul of growth medium was added to each well and the
plates were incubated in a37ºC incubator with 5% CO2 for 5 days. Signs of CPE were
monitored in each well using inverted microscope at the end of the incubation period. The
number of CPE positive and negative wells was recorded and CCIDS50 titer was calculated
using Reed and Muench method.

Calculation:

Proportionate Distance (PD) = (% CPE at dilution above 50%) — (50%
(% CPE at dilution above 50%) — (% CPE at dilution

below 50%)

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 37 0f 72
Investigator's Brochure BBV 152

10 10g total dilution above 50% - (PD x log DF)
CCIDS50 /ml

50% end point titer

*DF = Dilution factor

8.1.2 SarerY AND IMMUNOGENICITY TESTING OF THE CANDIDATE
VACCINE

8.1.2.1 INSTITUTIONAL ANIMAL ETHICS COMMITTEE (IAEC) APPROVAL

All the animal studies were performed after obtaining permission from the Institutional
Animal Ethics Committee (IAEC). The functioning of Bharat Biotech's IAEC is overseen
by the Committee for the Purpose of Control and Supervision of Experiments on Animals
(CPCSEA). CPCSEA is a statutory body constituted under the Prevention of Cruelty to
Animals Act, 1960, Govt. of India.

8.2 GLP PRE-CLINICAL TOXICITYSTUDIES
8.2.1 8.2.1 GLPSTATEMENT

The non-clinical (or pre-clinical) toxicity studies to assess the safety of the candidate
Coronavirus vaccine 'BBV 152º were performed in compliance with the norms of Good
Laboratory Practice (GLP). The studies were carried out at RCC Laboratories India Pvt.
Ltd Hyderabad, which is a OECD certified GLP laboratory. All the studies were
conducted with the approval of the Institutional Biosafety Committee (IBSC) and the
Institutional Animal Ethics Committee (IAEC) of the RCC Laboratories India Pvt. Ltd.

The pre-clinical studies complied with the following guidelines:

e Schedule Y (Amended version of 2005) of the Drugs and Cosmetics Act 1940 and
Rules 1945 of the Government of India.

e ICH harmonized tripartite guidelines: Non-Clinical Safety studies for the conduct
of Human Clinical Trials for Pharmaceuticals, 16 July 1997.

e WHO Guidelines on Nonclinical Evaluation of Vaccines, Adopted by the 64th
meeting of the WHO Expert Committee on Biological Standardization, 21-25
November 2013.

e Amex 2 Guidelines on the nonclinical evaluation of vaccine adjuvants and
adjuvanted vaccines. WHO Expert Committee on Biological Standardization
Sixty-fourth report, TRS 987 Annex 2.

e CPCSEA Guidelines for Laboratory Animal Facility, India Journal of
Pharmacology, 2003; 35: 257-274.

e OECD Guidelines for the Testing of Chemicals, Section 4, Health Effects, 1998

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 38 0f 72
Investigator's Brochure BBV 152

8.2.2 ANIMAL MODELS

Human intended adjuvanted vaccine was tested for potency in 2 small animal models (Mice,
and Rabbits) as per regulatory requirement. Animals were housed in Bharat Biotech, animal
facility, after taking appropriate Institutional Animal Ethics Committee (IAEC) approvals.
End point investigation (Histopathology, Biochemistry & Hematology) was carried out CRO
(RCC Laboratories).

a. Mice: Balb/C (inbred) mice were be used for immunogenicity study. Swiss
Albino (Outbred) mice were used for Repeated Dose toxicity.

b. *Rabbits: New England White Rabbits were tested for Safety. However, we
collected blood to evaluate the antigen specific antibody titer elicited by the
Inactivated SARS-CoV-2 vaccine.

c. *Rats: Wistar Rats were used to conduct repeated dose toxicity study for
adjuvanted vaccine.

d. Hamster: Syrian Hamster was conducted also be used to test protective efficacy
and immunogenicity of inactivated vaccine at NIV, Pune.

e. Non-Human Primates: Challenge studies were conducted to test protective
efficacy and immunogenicity of BBV152 in Rhesus Macaques at NIV, Pune.

8.3 PRE-CLINICAL STUDIES:
8.3.1 SAFETY AND IMMUNOGENICITY IN MICE, RATS, AND RABBITS:

Study objective:
To evaluate the safety and immunogenicity of a whole-virion inactivated SARS-

COV-2 vaccine (BBV 152), adjuvanted with aluminium hydroxide gel (Algel), or anovel
TLR7/8 agonist adsorbed Algel.

Study design:

We used a well-characterized SARS-CoV-2 strain and anestablished vero cell
platform to produce large-scale GMP grade highly purified inactivated antigen,
BBV152. Product development and manufacturing were carried out in a BSL-3 facility.
Immunogenicity was determined at two antigen concentrations (3ug and 6ug), with
two different adjutants in mice, rats, and rabbits.

Three animal models were used to evaluate the immunogenicity and safety of the three
inactivated whole virion vaccine formulations (BBVI52 A, B&C).

a) Mice: Balb/C or Swiss Albino mice (6-8week old) were vaccinated via an
intraperitoneal or intramuscular route with either 1/1088 or 1/20tBof full human single

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 39 0f 72
Investigator's Brochure BBV 152

dose (BBV152 A, Bor C) of inactivated vaccine with or without adjuvant on day 0, 7
& 14 days (nt+1 (one extra dose compared to the intended human regimen doses). A
formulation with 9ug was also tested.

b) Rats: Wistar Rats (6-8weeks old) were vaccinated intramuscularly with 9ugof
inactivated whole-virion vaccine with Algel-1 or Algel-2 on days 0, 7 & 14 days (n+1
doses).

c) Rabbits: Zealand white rabbits (3-4 months old) were vaccinated via an

intramuscular route with full Human intended single dose (BBV152 A, Bor C; n+1
doses). The animals were observed up to 14 days, post third dose.

All studies were conducted with an equal number of males and females unless otherwise
specified. The control group was injected with saline. Animals were bled from the retro-
orbital plexus; 2hoursbefore each immunization on 0, 7, 14 & 21 days, and serum was
separated and stored at -20ºC until further use.

Pooled and individual sera from vaccinated mice and rabbits were used to test the antigen-
specific antibody binding titer and antibody isotyping profile by Enzyme-Linked
Immunosorbent Assay (ELISA). Pooled or Individual sera from all vaccinated species (mice,
rabbits & rats) were used to test neutralization antibody titer by Plaque Reduction
Neutralization Test (PRNT90) or Micro Neutralization Test (MNT50).

BBV152 vaccine candidates were formulated with two alum adjuvants: Algel
(aluminium hydroxidegel) and Algel-IMDG, animidazoquinoline class molecule
(TLR7/TLR8 agonist abbreviated as IMDG) adsorbed on aluminium hydroxide gel.
The agonist molecule for Algel-IMDG was licensed from ViroVax LLC, USA. Three
vaccine formulations were prepared with 3ug and 6ug with Algel-IMDG (BBV152A
and BBV152B, respectively) and 6ug with Algel (BBV152C).

Results:

Both the adjuvanted vaccines (with Algel and Algel-IMDG), Antigen and Adjuvant alone did
not reveal any treatment-related findings, except local reactions when administered through
the human intended route (intramuscular) on days 0, 7, and 14 (n+1) with full Human single
dose (HSD) or higher than HSD in rodents and non-rodents, thereby establishing the vaccine
safety. All the three inactivated whole virion SARS-CoV-2 vaccine candidates showed 100%
seroconversion with high titers of antigen binding and neutralizing antibody responses. The
adjuvanted formulation, BBV152B, when immunized in Balb/C mice, showed 10 times
higher dose sparing effect compared to antigen alone (Figure 5 & 6). These formulations also
induced immunity that is biased towards Thl mediated response, as demonstrated by the ratio
between IgG2a and IgG1 (greater than 1) (Figure 7). Additionally, secretion of anti-viral
cytokines such as IL-2, IL-4, IL-6, IL-10, IL-17, TNF-o, IFN-y was observed on days 7 and
14 (7 days after the 1º& 2º“ dose) of vaccination with Algel-IMDG adjuvanted formulations.
A combination of high neutralizing antibody titers elicited against inactivated antigen alone

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 40 0f 72
Investigator's Brochure BBV 152

and the presence intact spike protein on the surface of the virus confirms that the antigen is in
the right confirmation and can itself may act as a Thl inducer with its surface glycoproteins,
intracellular viral proteins. The study publication is available as pre-print at bioRxiv

(doi: https://doi.org/10.1101/2020.09.09.285445) [21].

5 19%

E mc ]

 

  

 

= 319 49 + Agel = eu Ag 4 Algo!
= Qua Ag + Agel = ag Ag + AlgolimDO
= GUGA + NGSLIMDG — Sug Ag + Aga IMDG
D F

    

Me higher

  

Ra: E E E gs
8 E
el = Su A + AL IMDS at gal?

= Guy Aq + AlgoliMDG

Figure 5: BBV152 Vaccines Induces High Virus-specific Antibody Response in
Mice

 

  

 

 

A B
10º
10º
Doy7 Day 14 Doy21
= 69 Ag 4 Algo = 39.49 4 AgOLIMDO = 419 Ag + AlgoLIMDG
c
Deyo Dey7 Day 14 Dey21
= 6u9 Ag + Algel = 3ug Ag + Algel-IMDG
= 6Hg Ag + Algo IMDG = HCS

 

 

Figure 6: BBV152 Induces Robust Neutralizing Antibody Response in Rabbits

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 41 0f72
Investigator's Brochure BBV 152

 

 

A B p=013] P=018
20
15 E
É 5 5
É Es
o Bs
É
1962071961 (19620/1963)/1961
Spike Specific (51) antibody Isotypes
= 6u9Ag+Algel mm 9 AIgoLIMDG = 6ug AlgolAMDG
c
Eos Eos É os
á É 06 É 06
Boto) E É
é É o4 É o4
É 05) ms — T É É E
E Ho: Boo =
E oo É co HH 8 oo!
o Ls ss E É sp
E EM E AS EE a
' nó CE on
8º 8 a a 8 a
RO 1 as
o o seo? o”

1000:

Eytobinos (pg/ml)

 

n2 né 6 WRG Info ILHA 110 e
cttino leves Crtno tres
=D0 =D? mou noz upa mõo nor mb moi noz
E
8oo
E 600:
ER
&
É 20

 

Adjuvant Concentration (ug/ml)

 

mur $Hg Ag + Algei (BBV 152C]
o Agel 3ug Ag + Algel-IMDG (BBV 1524)
É gotamno emo Ag + Agel ADS tuUv 1520)

 

no

 

Figure 7: BBV152 Induces A Robust Virus-specific T Cell Response.
Conclusion:

BBV152 vaccine formulations generated significantly high antigen-binding and
neutralizing antibody titers, at both concentrations, in all three species with excellent
safety profiles. The inactivated vaccine formulation containing TLRY7/8 agonist
adjuvant-induced Th1 biased antibody responses with elevated IgG2a/IgG1 ratio and
increased levels of SARS-CoV-2 specific IRFN-y + CD4 T lymphocyte response.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 42 0f 72

 
Investigator's Brochure BBV 152

8.3.2  IMMUNOGENICITY AND PROTECTIVE EFFICACY IN THE SYRIAN HAMSTERS

Study objective:
To assess the immunogenicity and protective efficacy of an inactivated SARS-CoV-2 vaccine
(BBV152) in hamsters.

Study design:

Two different antigen concentrations (3 ug and 6 ug) and 2 adjuvants namely Algel 1 (Alum)
and Algel 2 (TLR 7/8 (imidazoquinoline) agonist adsorbed alum) in combinations were used
for the study. The vaccine formulations evaluated in the study were 6 ug antigen with Algell,
3 ug with Algel 2, and 6 ug with Algel 2. Accordingly, the animals were divided into 4
groups (9 animals/per groups):

1. Placebo -PBS

2. 6ugantigen with Algell
3. 3ug with Algel 2

4. 6ug with Algel 2

Immunization of hamsters

Animals of each group were immunized with 0.1 ml of PBS/vaccine formulations
intramuscularly in the left hind leg under isoflurane anaesthesia 0, 14, and 35 days. Post
immunization hamsters were observed daily for clinical signs and injection site reaction.
Rectal temperature was monitored every 24 hours for 3 days post-immunization and weekly
thereafter. Body weight was measured every alternate day for the first week and weekly
thereafter. The hamsters were bled on day 12, 21, and 48 post-immunization to check for
antibody response.

Challenge study in hamsters

For optimization, of the intranasal virus challenge dose, SARS-CoV-2 dilutions ranging from
10 !5 TCID50 /0.1ml to 10 *º TCIDSO /ml were inoculated in 5 groups of 6 Syrian hamsters
each in containment facility.

The immunized hamsters were challenged with 0.1 ml of 10 *º TCID50 SARS-CoV-2 virus
intranasally on the eighth-week post-immunization (day 50) in the containment facility of
ICMR-National Institute of Virology, Pune under isoflurane anaesthesia.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 43 0f 72
Investigator s Brochure BBV 152

 

 

 

H Jg de * ae px y tó

— > Necropsy  Necropsy Necropsy
r ) n=3/ n=3/ n=3/
( ose Virus
mares Dose Regimen IstDose 2ndDose  3rdDose challenge group group group

Hamsters n=9/group

  

 

1.Placebo- PBS o “da NM, 35 s 7 SN ds
2.6ug+Algel1 Day 24 Day 24 Day 4 CADEIA DPI 4
3.3ug+Algel2 ,

4cug+Algel2 | o 12 E

 

Collection of blood, throat swab,
nasal wash, and tissue specimens

|

Collection of blood specimens

 

 

 

Figure 8: Experiment summary of the workflow Syrian Hamster study

Results
Three dose vaccination regimes with three formulations of BBV 152 induced significant titres

of SARS-CoV-2 specific IgG and neutralizing antibodies (Figure 9). The formulation with
imidazoquinoline adsorbed on alum adjuvant remarkably generated a quick and robust
immune response. Th1 biased immune response was demonstrated by the detection of IgG2
antibodies. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any
histopathological changes in the lungs. The protection of the hamsters was evident by the
rapid clearance of the virus from lower respiratory tract, reduced virus load in upper
respiratory tract, absence of lung pathology and robust humoral immune response. The study
publication is available as pre-print at Research Square (DOI:10.21203/1s.3.1s-76768/v1)

[22].

 

 

s
a

Optical density at 480 nm
é
:
a
ementa
Optical denaly at 450 nm
a
cm
O
ea
4
aa
em
“+
ted

  

 

    

Ea E eecçe E
ao Y E age T
5 2 A “a 3 7 15
Days (limmunisation prasey pr
c we D los E tgG2
= s
E £
E. 1. E .n-
ãs E 5 TT
dº 1 - És E
&: -. 82
gs Ê
o

 

 

Pta

 

 

 

pos
Eua+Alnol 4
Sug+Aigei 2
EuotAlgei 2

Pas
eugealger
usa espe 2
esgvalgei 2

 

Figure 9: Humoral response in vaccinated animals

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 4 0f72

 
Investigator's Brochure BBV 152

Conclusion: These findings confirm the immunogenic potential of BBV152 and further
protection of hamsters challenged with SARS-CoV-2.

8.3.3 IMMUNOGENICITY AND PROTECTIVE EFFICACY IN RHESUS MACAQUES

Study objective:
To assess the immunogenicity and protective efficacy of an inactivated SARS-CoV-2 vaccine
(BBV152) in rhesus macaques.

Study design:

Twenty macaques were divided into four groups of five animals each. One group was
administered a placebo while three groups were immunized with three different vaccine
candidates at O and 14 days. The groups were:

1. Group I: Placebo -PBS

2. Group IH: 6 ug + Adjuvant A
3. Group II: 3 ug + Adjuvant B
4. Group IV: 6 ug + Adjuvant B

All the macaques were challenged with SARS-CoV-2 fourteen days after the second dose.

 

First Second |
Dose Dose | Necropsy
í í y ,
y NU ng
à N

— b

) E | 280ay > ADI O [ape > | sDeL IDR)
/ V V V V

 

 

 

 

Two-Dose Vaccination Regimen Virus Collection of blood, nasal swab, throatswab, rectal swab, bronchoalvcolar
e Groupil) (Placebo: Phosphate challenge lavage fluid, urine, stool specimens and acquisition of chestX-rays.

buffer saline)

 

+ Group-ll (6ug+ AdjuvantA)

* Groupelll (Sug+AdjuvantB) |

« Group-IV (6ug + Adjuvant-B)
—

 

 

Figure 10: Experiment summary of the workflow of NHP study

Results

The protective response was observed with increasing SARS-CoV-2 specific IgG and
neutralizing antibody titers from 3rd-week post-immunization. Weight loss, pyrexia and
worsening of SpO2 at room air, lethargy, reduced food and water intake, reduced self-
grooming was observed in placebo group and persisted till 7 DPI whereas these features
resolved in the other group II and IV. Viral clearance was observed from bronchoalveolar

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 45 0f 72
Investigator s Brochure BBV 152

lavage fluid, nasal swab, throat swab, and lung tissues at 7 days post-infection in the
vaccinated groups. No evidence of pneumonia was observed by histopathological
examination in vaccinated groups, unlike the placebo group which showed features of
interstitial pneumonia and localization of viral antigen in the alveolar epithelium and
macrophages by immunohistochemistry. The study publication is available as pre-print at
Research Square (DOI:10.21203/rs.3.1s-65715/v 1) [23].

 

B IgG
eres * toretdpreaia
dvds Soretdjoaçd

 

Igl tro

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Optical Demaity at 4400m

 

Naceinatica Vaceination

  

 

E

so0o:

aco:
E qm
z
É mo

1000:

é E E

o 12 1» Bs =”
Vacfatica — Vadéitiom pri

 

 

Figure 11: Humoral response in vaccinated animal

Conclusion:
The study demonstrates that a two-dose vaccination regimen induced a significant immune
response and provided effective protection in animals challenged with SARS-CoV-2.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 46 0f 72
Investigator s Brochure BBV 152

Table 10: Overview of the pre-clinical studie:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Route of Dosing . Key Test Item
Study Type Test System | Testltem | agministration| Regimen| — Unit dose result
Antigen,
Adjuvante
Wistar Rats vaccines, |  Intramuscular
Adjuvants
— ! 1/10º or 1/20% of
Swiss Adjuvanted human equivalent
Albino vaccines & | (e | dose. (3ug and
? vaccinos & | Intramuscular Gue with Algel.
Mice ! - Day & & | IMDGGBBVIS2
Antigen, A and BBVIS2B,
Repeated dose Adjuvan respectively), and/AlI the Test Items
o te 6ug with Algel
toxicity BALB/c Mice | vaccines, | - Intraperitoncal (BBVI520)) have been
studies andjuva demonstrated to
nes be safe from a
Toxicology
New Zealand | adjuvan perspective.
White Rabbits ted Intramuscular
Vaccines
Mutagenicity assay
(Bacterial Reverse Salmonella Algel- - - -
Mutation) typhimurium | IMDG
Maximum Swiss albino
Algel-
Tolerated mice & Wistar | IMDG Intramuscular Day0  |2O9ug Algel and
. 20ug IMDG
Dose studies Rats
BBVIS2 an
inactivated vaceine
:4| “induced potent
3ug and Gug with ced |
fa ti
Immunogenicity and . [BBV-IS2A,B, (BBVISZA and | ma biased immune
protective efficacy | Syrian hamsters | and placebo) Intramuscular | Day 0 & 14) BBVISD.  lresponse was clicited
respectively), and
6ug with Algel | pUBBVIS
(BBVI52C)) 2 protect
Syrian hamsters from
SARS-Cov-2
pneumonia.
À two-dose
vaccination regimen
3ug and Gug with Jusing 3ug dose of the
Algel-IMDG | vaccine candidate
Immunogenicity and o (BBVISZA and | with adjuvant B
protoctivo efficacy | Rhesusmacaques PEV. a pu intramuscular | Day 0 & 14)  BBVIS2B, | | induce a significant
+ respectively), and fimmune response and
6ug with Algel | provide effective
(BBVI520) — |protection in animais
challenged vith
SARS-Cov2.
Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 47 0f 72
Investigator's Brochure BBV 152

8.3.4. OVERALL CONCLUSION OF THE PRECLINICAL STUDIES:

Based on the above pre-clinical study results, it was concluded that all formulations shown to
be safe, immunogenic, in both mice, rats& rabbits. The vaccine candidates showed good
immune response and protective efficacy in Syrian hamsters and Rhesus macaques. Hence, it
can be concluded that the vaccine candidate manufactured was safe and effective.

9 CLINICAL DEVELOPMENT PATHWAY

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are accelerating
globally leading to an increase in morbidity and mortality. In view of the prevailing covid-19
pandemic, the clinical trial has been designed in a seamless manner (phase1/2) compared to
conventional approach. The sample size has been deliberately kept large to assess the
immune responses from the vaccine ensuring a high degree of power.

The Clinical study was designed as a adaptive, Seamless Phase 1, Followed by Phase 2.

The safety, reactogenicity, tolerability, and immunogenicity was evaluated through Four arms
(BBV152-A, BBV152-B, BBV152-C and Placebo) in Phase I and Based on the Phasel results two
arms (BBV152-A and BBV152-B) were selected for Phase II.

WholeVirion, Inactivated SARS-CoV-2 Vaccine (BBV152) has proven to be safe and well-
tolerated in the Phase II study. The vaccine containing 6 ug of whole virion plus adjuvant
was selected for Phase 3.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 48 0f 72
Investigator's Brochure BBV 152

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Phase-i
k

( First | [3ug+ Algel-IMDG Gug+ Algel- IMDG Gug+ Algel Algel only

dose (BBVI52A) (BBVI152 B) (BBVI52 C) (Placebo)
| Day 0) (N=100) (N=100) (N=100) (N=75)

v y y

pesa 3ug+ AlgeLIMDG Gug+ Algel-IMDG 6ug+ Algel Algel only
Day 14 (BBVI52 A) (BBVI52 B) (BBVI52 C) (Placebo)

 

 

 

 

 

Interim analysis was done on day 28 post-second dose and two Algel-IMDG formulations
(BBVISZA & BBV152B) has been selected for phase - 2

 

+

 

Phase-2

 

 

 

+ a

 

 

 

E 3ng+ Algel-IMDG
| aa ge (BBVI52 A)
ay (N=190)
(Soma ne
a (BBVI52 A)

 

 

 

 

6ug+ Algel-IMDG
(BBVIS2 B)
(N=190)

 

 

 

6ug+ Alge-IMDG
(BBVI52 B)

 

 

 

 

Interim analysis was done on day 42 post-second dose and Algel-IMDG formulations

(BBV152B) has been selected for phase - 3

 

 

+

 

Phase-3

 

 

 

[a

 

 

6ug+ Algel-

(BBVI52 B)

IMDG

 

(N=12,900)

 

Figure 12: COVAXIN Clinical Trial Pathway

Preliminary Report of the Phase 1 Clinical Trial

 

Placebo
(N=12,900)

 

 

 

We conducted a double-blind, multicentre, randomized, controlled phase 1 trial to evaluate
the safety, reactogenicity, tolerability, and immunogenicity of three different formulations of
BBV-152 (BBV-152A, BBV-152B, and BBV-152C) in healthy male and nonpregnant female

volunteers.

9.1 STUDY DESIGN AND PARTICIPANTS

Healthy individuals aged 18-55 years were taken into study. All the individuals were
screened for eligibility based on the health status, including medical history, laboratory
findings, vital signs, and physical examination and enrolled after getting signed and dated

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL

Page 49 0f 72

 
Investigator's Brochure BBV 152

written informed consent (audio/video consent for vulnerable participants). Participants who
tested positive for Covid-19 at the screening by either nucleic acid test or serology were
excluded from the trial. Details of inclusion and exclusion criteria can be found on
www.clinicaltrials.gov: NCT04471519.

Participants were assigned a computer-generated randomization number (IWRS). After
meeting eligibility, participants were randomized equally to receive three vaccine groups
(BBV 1524, BBV 152B, BBV 152C) and a control group of aluminum hydroxide (alum)
adjuvant only. A two-dose intramuscular regimen was adopted, 14 days apart at dose
strength.

The trial was conducted across 11 sites in India. The trial was approved by the Central
Licensing Authority (India), respective Ethics Committees, and was conducted in compliance
with all International and local Ethical guidelines.

9.1.1 STUDY VACCINE
BBV152 (manufactured by Bharat Biotech) is a whole virion B-propiolactone-inactivated

SARS-COV-2 vaccine. The candidates were formulated with two adjuvants: Algel (alum)
and Algel-IMDG, an imidazoquinoline class molecule (TLR7/TLR$ agonist abbreviated as
IMDG) adsorbed onto Algel. The agonist molecule for Algel-IMDG was licensed from
ViroVax LLC, USA. Three vaccine formulations were prepared with 3ug and 6ug with
Algel-IMDG (BBV152A and BBV152B, respectively) and 6ug with Algel (BBV152C). The
placebo group contained only sterile phosphate-buffered solution and Algel adjuvant. The
vaccine was provided as a sterile liquid for injection through the intramuscular route at a
volume of 0.5mL/dose, as a two-dose regimen, 14 days apart.

9.1.2 STUDY PROCEDURES
Two doses of BBV 152 vaccine were administered at a volume of 0.5mL/dose injection

intramuscularly (deltoid muscle) at days O and 14. The follow-up visits were scheduled on
days 7, 28, 42, 104, and 194 days. The study was performed in a dose-escalation manner
wherein after completing vaccination in the first 50 participants with BBV 152A (the lowest
antigen concentration) and placebo, the participants were followed up for seven days and
safety was assessed by an independent Data Safety Monitoring Board (DSMB). Based on the
DSMB recommendation, the trial was allowed to continue by the remaining participants'
enrollment across all groups.

9.1.3 BLINDING
The appearance, color, viscosity across all treatment, and control formulations were identical.

Treatment groups were blinded against participants, investigators, study coordinators, study-
related personnel, and the sponsor (excluding an unblinded CRO, tasked with the dispatch of
vaccine vials and generation of master randomization code). Blinding was maintained using
the randomization code.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 50 0f 72
Investigator s Brochure BBV 152

9.1.4 SAFETY ASSESSMENTS
The primary safety outcome was the number and percentage of participants with solicited

local and systemic reactogenicity within -two hours, -7 days, -14 days, and 28 days after
vaccination. Participants recorded local and systemic reactions using a diary card for seven
days after each vaccination. No formal instructions on the use of analgesics were given to
participants before or after vaccination. Laboratory values (serum chemistry and hematology)
were compared between the pre-vaccination (day 0) and the post-vaccination (day 28) visits.

9.1.5  IMMUNOGENICITY ASSESSMENTS

Binding antibody (IgG) responses against RBD, S, and N proteins of SARS-CoV-2, were
assessed by enzyme-linked immunosorbent assay (ELISA) and expressed as Geometric Mean
Titers (GMTs). Neutralizing antibody titers (NAbs) were assessed by wild type virus
neutralization assays: micro-neutralization assay (MNTso) across the entire cohort.
Seroconversion (SCR) rates were defined as titers remaining >4-fold above baseline. All
serum samples were analyzed in a blinded manner at Bharat Biotech and NIV.

 

9.2 RESULTS

Among the 555 screened between July 13º and July 29th, 2020, 375 participants were
randomized. Among the three treatment arms, 100 each were randomized into the BBV152-
A, -B, and C groups, respectively, and 75 were randomized into the control arm.

9.2.1 SAFETY

After the first and second vaccination, all AEs were mild or moderate in severity and resolved
transiently. Pain at the injection site was the most common local adverse event reported. The
other adverse events reported were fever, headache, fatigue, body pain, cold, cough, nausea,
vomiting, and dizziness. The distribution of local and systemic AEs was equal amongst all
groups, and is mentioned in the below table. A total of 7 AEs was reported within 2 hours
after Dose 1 (3 ug with Algel-IMDG: 0; 6 ug with Algel-IMDG: 2, 6 ug with Algel: 1,
Control arm: 4) The AEs were pain at injection site, swelling of arm, headache, giddiness,
feeling hungry. No immediate AEs were reported after Dose 2.

One serious adverse event was reported in the BBV152 C arm. The participant was found
positive for SARS-CoV-2 (by RT-PCR) 9 days after screening and 5 days following the
administration of vaccine. The participant was hospitalized, and recovered after treatment.
Based on the causality assessment, the serious adverse event was not related to the vaccine.

Table 11: Adverse events reported in Phase 1 study

 

 

 

 

 

 

 

 

 

3 ug with 6 ug with 6 ug with
Adverse Events Agel IMDG AlgebIMDG Algel Cons m
N=100 N=100 N=100 o
0-7 Days
Local reactions
Pain at injection site

 

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 51 0f72

 
 

Mild

4(49%; 1.1 — 9.9)

4(4%; 1.1 — 9.9)

1(19%; 0.0-5.5)

U39%; 0.3-9.3)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Moderate 1(1%; 0.0-5.5) 1(1%; 0.0-5.5) 0 0
Swelling
Mild 0 0 0 1(1%; 0.0-7.2)
Moderate 0 0 0 0
Systemic reactions
Fever
Mild 0 1(1%; 0.0-5.5) 1(1%; 0.0-5.5) 0
Moderate 0 1(1%; 0.0-5.5) 2 (2%; 0.2-7.0) 0
Body ache
Fatigue.
Mild 1(1%; 0.0-5.4) 0 0 0
Moderate 22%; 0.2-7.0) 33%; 0.6-8.5) 0 0
Headache
Mild 1(1%; 0.03-5.5) | 22%; 0.2-7.0) 0 5(7%; 2.2-14.9)
Moderate 0 33%; 0.6-8.5) U2%; 0.2-7.0) 0
Nausea or vomiting
Mild 1(1%; 0.03-5.5) | 22%: 0.2-7.0) | 2(2%:0.2-7.0) | 243%; 0.3-9.3)
Moderate 0 0 0 0
0-14 Days
Local reactions
Pain at injection site
Mild 2(2%; 0.2-7.0) | 1(1%; 0.03-5.5) | 1(1%; 0.0-5.5) 0
Moderate 0 0 0 0
Swelling
Mild 0 0 0 0
Moderate 0 0 0 0
Systemic reactions
Fever
Mild 2 1 1 0
Moderate 0 0 0 0
Body ache
Mild 0 0 0 0
Moderate 1(1%; 0.0-5.5) 0 0 0
Fatigue
Mild 1(1%; 0.03-5.4) 0 3(3%:0.6-8.5) 0
Moderate 1 0 0 0
Headache
Mild 0 0 0 0
Moderate 0 0 0 0
Nausea or vomiting
Mild 0 0 0 0
Moderate 0 0 0 0

 

 

 

 

 

Data are n (%; 95% CI). The safety set includes all participants who received one dose of the
vaccine (n=375). Dose 1 events are from days 0-7 and dose 2 events are days 14-21. The
grading scale for most adverse events was based on the US Food and Drug Administration

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL

Page 520f 72

 
Investigator s Brochure BBV 152

(FDA) guidance document for toxicity grading scale for healthy adult and adolescent
volunteers enrolled in preventive vaccine clinical trials. For adverse events where grading
was not mentioned in the FDA guidance document, we have used the common terminology
criteria for adverse events grading. There were no severe adverse events.

9.2.2  IMMUNE RESPONSES

Neutralizing Antibody Titers

Since all recruited participants were screened for IgM and IgG antibodies to SARS-CoV-2,
no participants had detectable NAbs at baseline (analyzed by MNTs59). The proportion of
participants that demonstrated seroconversion (after Day 28) was 87.88%, 91.92%, and
82.8% in the BBV152.-A, -B, and -C, groups, respectively. Post second dose GMTs (Day 28)
among the three vaccine arms were 61.7, 66.4, and 48 in the BBV152 -A, -B, and -C groups,
respectively. Responses in BBV152 -A and -B were noticeably higher than BBV152C, albeit
not statistically significant. Anti-spike glycoprotein IgG antibodies secretion was seen on day
104 post vaccination, which shows the long-lasting T-cell memory response generated by
BBV152. Similar results of long-term immunity were reported in convalescent patients who
previously had COVID-19. Presently, memory B-cell responses from BBV152 are currently
being evaluated [24, 25].

Table 12: Neutralizing titers and Seroconversion rates in different treatment groups

 

 

 

 

 

 

 

Day O Day 14 Day 28
Groups
GMT GMT n(SC%) GMT n(SC%)
(95% CI) (95% CI) (95% CI) (95% CD) | (95% CD
87
Treatment A 6.21 9.14 10 (10.1%) 61.70 (87.88%)
N=99 (5.92,6.52) (8.05, 10.40) | (4.16, 16.04) | (49.50, 76.90) | (81.45,
9431)
91
Treatment B 6.01 11.20 21(21.21%) 66.4 (91.92%)
N=99 (5.81, 6.23) (9.56, 13.00) | (13.16, 29.27) | (53.40, 82.40) | (86.55,
97.29)
7
Treatment C 5.95 9.45 7 (7.53%) 48.00 (82.8%)
(N=93) (5.80, 6.10) (8.20, 10.90) | (2.16, 12.89) | (37.70, 61.10) | (75.12,
90.47)
Treatment D 6.13 6.07 7.20 E eo
(N=73) (5.84, 6.43) (5.86, 6.28) - (6.39, 8.11) e)

 

 

 

 

 

 

 

9.3 CONCLUSION:

Based on the interim results of the Phase 1 clinical trial, the BBV-152 B formulation
(6ug + adjuvant B (Alum + imidazoquinoline)) produced better immune response
compared to BBV-152A and C although the difference was not statistically different.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 53 0f 72
Investigator's Brochure BBV 152

In conclusion, Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) has been proven
to be safe and well tolerated, and immunogenic in the Phase 1 study.

COVAXIN Phase I clinical study publication and Supplementary data is enclosed as
Annexure 1

10 PRELIMINARY REPORT OF THE PHASE 2 CLINICAL TRIAL

We conducted a double-blind, randomized, multicentre phase 2 trial to evaluate the
immunogenicity and safety of BBV-152 in healthy adults and adolescents.

10.1 STUDY DESIGN AND PARTICIPANTS

Healthy individuals aged 12-65 years were taken into study. All the individuals were
screened for eligibility based on the health status, including medical history, laboratory
findings, vital signs, and physical examination and enrolled after getting signed and dated
written informed consent (audio/video consent for vulnerable participants). Participants who
tested positive for Covid-19 at the screening by either nucleic acid test or serology were
excluded from the trial. Details of inclusion and exclusion criteria can be found on
www.clinicaltrials.gov: NCT04471519.

Participants were assigned a computer-generated randomization number (IWRS). After
meeting eligibility, participants were randomized equally to receive two groups BBV152 and
a control group of aluminum hydroxide (alum) adjuvant only. A two-dose intramuscular
regimen was adopted, 28 days apart.

The trial was conducted across 9 sites in India. The trial was approved by the Central
Licensing Authority (India), respective Ethics Committees, and was conducted in compliance
with all International and local Ethical guidelines.

10.2 STUDY VACCINE
BBV152 (manufactured by Bharat Biotech) is a whole virion B-propiolactone-inactivated

SARS-COV-2 vaccine. The vaccine candidate is formulated with Algel-IMDG, an
imidazoquinoline class molecule (TLR7/TLR$8 agonist abbreviated as IMDG) adsorbed onto
Algel. The agonist molecule for Algel-IMDG was licensed from ViroVax LLC, USA. The
vaccine was provided as a sterile liquid for injection through the intramuscular route at a
volume of 0.5mL/dose, as a two-dose regimen, 28 days apart.

10.3 STUDY PROCEDURES
Two doses of BBV 152 vaccine were administered at a volume of 0.5mL/dose injection

intramuscularly (deltoid muscle) at days O and 28. The follow-up visits were scheduled on
days 42, 56, 118, and 208 days.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 54 0f 72
Investigator s Brochure BBV 152

10.4 BLINDING
The appearance, color, viscosity across all treatment, and control formulations were identical.

Treatment groups were blinded against participants, investigators, study coordinators, study-
related personnel, and the sponsor (excluding an unblinded CRO, tasked with the dispatch of
vaccine vials and generation of master randomization code). Blinding was maintained using
the randomization code.

10.5 SAFETY ASSESSMENTS
The primary safety outcome was the number and percentage of participants with solicited

local and systemic reactogenicity within -two hours, 7 days (days 0-7 and days 28-35) post
vaccination. All the events are to be recorded in a memory aid containing fields for symptom
onset, severity, time to resolution, and concomitant medications, and participants were
instructed to complete the form daily. The form was collected during the next visit to the site.
Routine telephone calls were scheduled following the first 7 days after each vaccination.
Laboratory values (serum chemistry and hematology) were compared between the pre-
vaccination (day 0) and the post-vaccination (day 28) visits.

10.6 IMMUNOGENICITY ASSESSMENTS

Anti-IgG responses against the spike (S1) glycoprotein, receptor-binding domain (RBD), and
nucleocapsid protein of SARS-CoV-2 were assessed by ELISA (Syngene, Bangalore, India),
and are expressed as geometric mean titres (GMTs). Wild-type virus neutralising antibody
titres in serum samples were analysed with a microneutralisation assay (MNTS50) and a
plaque-reduction neutralisation test (PRNTS50) at Bharat Biotech in a masked manner. MNT50
and PRNTSO were developed in-house. Seroconversion was defined as a post-vaccination
titre at least four-fold higher than the pre-vaccination titre. To ensure the validity of our
assay, an arbitrary number of serum samples (n=40) were selected at random and tested by
PRNTS50 at National Institute of Virology.

10.7 RESULTS
Among the 921 screened between September 7” and September 11º, 2020, 380 participants

were randomized. Among the two treatment arms, 190 each were randomized into the
BBV152-A, and B groups, respectively.

10.8 SAFETY

After the first and second vaccination, all AEs were mild or moderate in severity and resolved
transiently. Pain at the injection site, followed by headache, fatigue and fever were the most
common adverse event reported. No severe or life-threatening solicited adverse events were
reported. No significant difference in safety was observed between these two groups. No
serious adverse events were reported in this study.

Table 13: Adverse events reported in Phase 2

 

Dose 1 Dose 2

 

 

3 ug with 6 ug with 3ug with 6 ug with

Adyerse Events AlgelIMDG | Alge-IMDG | Algel-IMDG | Alge-IMDG

 

 

 

 

 

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 55 0f 72

 
 

 

[o N=190 | N=190 |  N=190 [|  N=190

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Local reactions

Pain at injection site

Mild 5(3%) 6(3%) 4%) 4(2%)
Moderate 1(1%) 0 0 1(1%)
Redness at injection site

Mild 1(1%) 11%) 0 0
Moderate 0 0 0 0

Itching

Mild 1(1%) 11%) 0 2(1%)
Moderate 0 0 0 0
Stiffness in upper arm

Mild 1(1%) 0 0 0
Moderate 0 0 0 0
Weakness injection arm

Mild 0 0 1(1%) 0
Moderate 0 0 0 0
Systemic reactions

Body ache

Mild 0 2(1%) 11%) 2(1%)
Moderate 0 11%) 0 0
Fever

Mild 2 (1%) 5(3%) 5(3%) 4 (2%)
Moderate 1(1%) 3(2%) 0 0
Headache

Mild 21%) 1(1%) 1(1%) 2(1%)
Moderate 0 0 0 11%)
Malaise

Mild 4 (2%) 1(1%) 3 (2%) 0
Moderate 0 0 0 0
Weakness

Mild 0 0 1(1%) 2(1%)
Moderate 0 1(1%) 0 0
Rashes

Mild 0 0 1(1%) 0
Moderate 0 0 0 0

 

 

 

 

 

Data are n (%). The safety analysis set includes all participants who received one dose of the
vaccine (n=380). The number of participants who had a solicited adverse event after
receiving dose 1 (days 0-7) and dose 2 (days 28-35) is shown.

10.9 IMMUNE RESPONSES

Neutralizing Antibody Titers

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 56 0f 72

 
Investigator's Brochure BBV 152

Since all recruited participants were screened for IgM and IgG antibodies to SARS-CoV-2,
no participants had detectable NAbs at baseline (analyzed by MNT'so). Seroconversion based
on PRNT50 at day 56 was reported in 170 (92-9% [95% CI 88:2-96-2] of 184 participants in
the 3 ug with Algel-IMDG group and 174 (98:3% [95-1-99-6]) of 177 participants in the 6
ug with Algel-IMDG group. GMTs (MNTS50) at day 56 were 92:5 (95% CI 77:7-110:2) in
the 3 ug with Algel-IMDG group and 160-1 (135-8-188-8) in the 6 ug with Algel-IMDG
group. Seroconversion based on MNTSO at day 56 was reported in 161 (88-0% [95% CI
82-4-92:3]) of 184 participants in the 3 ug with Algel-IMDG group and 171 (96-6% [92-8-
98-81) of 177 participants in the 6 ug with Algel-IMDG group. The 3 ug with Algel-IMDG
and 6 ug with Algel-IMDG formulations elicited T-cell responses that were biased to a Th1
phenotype at day 42. No significant difference in the proportion of participants who had a
solicited local and systemic adverse reaction in the 3 ug with Algel-IMDG group (37 [9-7%;
95% CI 6:9-13-2] of 380) and the 6 ug with Algel-IMDG group (39 [10-3%; 7:4-13-8] of
380) was observed between days 0-7 and days 28-35; no serious adverse events were
reported in the study. From the phase 1 trial, 3-month post-second-dose GMTs (MNT50)
were 39-9 (95% CI 32:0-49-9) in the 3ug with Algel-IMDG group, 69-5 (53:7-89-9) in the 6
ug with Algel-IMDG group, 53-3 (40-1-71-0) in the 6 ug with Algel group, and 20-7 (14:5-
29-5) in the Algel alone group.

10.10 CONCLUSION:

Based on the interim results of the Phase 2 clinical trial, the BBV-152 B formulation
produced better immune response compared to BBV-1524A.

In conclusion, Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) has been proven
to be safe and well tolerated, and immunogenic in the Phase 2 study.

COVAXIN Phase II clinical study publication and supplementary data is enclosed as
Annexure 2

11 INVESTIGATIONAL VACCINE (INV)

11.1 RATIONALE FOR PHASE 3 DOSE SELECTION:
e Two antigen concentrations (3ug and 6ug) with two different adjuvants were
studied in different animal models such as mice, rats, rabbits, Syrian
hamsters, and Rhesus macaques.

e All BBV152 vaccine formulations generated significantly high antigen-
binding and neutralizing antibody titers, at both concentrations, in the three-
animal species (mice, rats, and rabbits) with excellent safety profiles.

e Likewise, three dose vaccination regimens with three formulations of
BBVI152 induced significant titres of SARS-CoV-2 specific IgG and
neutralizing antibodies in the Syrian Hamster challenge study. The
formulation with imidazoquinoline adsorbed on alum adjuvant (BBV-152 A

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 57 0f 72
In gator s Brochure BBV 152

and B) remarkably generated a quick and robust immune response.

e In the Rhesus macaques challenge study, the protective response was
observed with increasing SARS-CoV-2 specific IgG and neutralizing
antibody titers from 3rd-week post-immunization. Based on the antibody
titres, viral loads in nasal, throat, and bronchoalveolar lavage swab,
respiratory tract, lungs, and extra-pulmonary organs, clinic-radiological
analyses, histopathological examinations, and immunohistochemistry
findings, the study demonstrated that a two-dose vaccination regimen
adjuvant B (Alum + imidazoquinoline) induced a significant immune
response and provided effective protection in animals challenged with SARS-
CovV-2.

e Based on the interim results of the Phase 1 clinical trial, the BBV-152B
formulation (6ug + adjuvant B (Alum + imidazoquinoline)) produced better
immune response compared to BBV-152 A and C.

 

e Based on the results of the mice, rat, and rabbit study, Syrian hamster and rhesus
macaques challenge study, and interim results of the Phase 1 clinical trial, the BBV-
152 B formulation (6ug + adjuvant B (Alum + imidazoquinoline)) was selected for
the Phase 3 Efficacy Study.

 

 

 

11.2 COMPOSITION OF STUDY VACCINE

Whole Virion Inactivated SARS-CoV-2 vaccine (BBV152-B) will be administered as an
intramuscular injection.

 

 

 

 

 

 

 

 

Active Ingredient Quantity
no . BBVI52B

Whole Virion, Inactivated Corona

Virus Antigen

(Strain: NIV-2020-770) 6ug

Inactive Ingredients

Aluminium Hydroxide Gel equivalent 250 meg

to AI

TLR7/8 Agonist 15 mcg

2-Phenoxyethanol (2PE) LP. 2.5mg

Phosphate Buffered Saline q.s. to 0.5 mL

 

 

 

 

11.3 PLACEBO COMPOSITION

The vaccine composition of the placebo per single human dose (SHD) of 0.5 ml is as follows:

 

 

 

Ingredient Quantity

 

 

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 58 0f 72
Investigator's Brochure BBV 152

 

 

 

Aluminium Hydroxide Gel equivalent 250 meg
to AI

2-Phenoxyethanol (2PE) LP. 2.5mg
Phosphate Buffered Saline q.s. to 0.5 mL

 

 

 

 

11.4 DOSAGE FORM AND ROUTE OF ADMINISTRATION

COVID-19 Vaccine (BBV152-B) is a liquid 0.5 mL Vero cell-derived inactivated vaccine
containing NLT 6ug and administered as a two-dose regimen intramuscularly (IM) 4 weeks
apart (Day O and Day 28).

11.5 VACCINE STORAGE

Inactivated Whole-virion inactivated vaccine 'BBV152 B” and the placebo vaccine should be
stored refrigerated at +2 to +8ºC. The vaccine consignment will be shipped with a
temperature logger. Any excursion in the temperature during storage below +2ºC or above
+8ºC for more than 24 hours should be notified to the Sponsor, and should wait for Sponsor
instructions for further action.

11.6 HANDLING OF STUDY VACCINE AND PLACEBO

The study vaccine and placebo will be stored at +2ºC to +8ºC at the study site. The required
number of test articles and placebo vials will be transported from the Sponsor's
manufacturing site in insulated vaccine vial containers containing cool packs. The vaccine
vial should be taken from the refrigerator only minutes before injection and the used vial with
remaining contents if any, should be immediately discarded.

11.7 STUDY DESIGN AND SUBJECT SELECTION

The study is conducted as Event-Driven, Phase3, Randomized, Double-blind, Placebo-
controlled, Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity, and Lot-to-
Lot consistency of BBV 152, a Whole-virion Inactivated SARS-CoV-2 Vaccine in Adults>18
Years of Age.

11.8 BLINDING

The control is identical to the vaccine. Sufficient measures will be taken to assure that
blinding of participants and evaluation staff is maintained. Study product assignments will be
accessible to the data coordinating center staff and others who are required to know this
information to ensure proper trial conduct. The DSMB members may also be unblinded to
treatment assignment as required to review vaccine safety and efficacy. Emergency
unblinding decisions are expected to be rare and justified only when that information is
needed for the future clinical management of that participant.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 59 0f72
Investigator's Brochure BBV 152

If in the opinion of the investigator, the event the health and safety of the participant will
benefit from knowing the treatment code, efforts will be made to contact the medical monitor
as long as patient safety is not at imminent risk. If the subject is at imminent risk, the
investigator should have the ability to unblind although should notify the Medical Monitor
(MM) and Sponsor as soon as possible thereafter.

11.9 METHOD OF ADMINISTRATION

The vials are taken from the refrigerator just before use and brought to ambient temperature.
The contents of the vials are mixed well before drawing with a needle. Sterile, disposable,
single use syringe and needle are to be used for injection. The vaccine is administered into
the deltoid muscle above arm pit and below acromion.

11.10 PRECAUTIONS FOR HANDLING VACCINE SUPPLIES

A vaccine inventory log shall be maintained at the site of storage. Vaccine shall be stored in a
refrigerator at +2ºC to +8ºC. The temperature should be monitored and recorded at regular
intervals. A temperature log shall be posted on the refrigerator. An effective power back up
shall be maintained to counter any power failures.

11.11 WARNING

e Do NOT allow access to any unauthorized person to the vaccine storage area. If
possible, keep the refrigerator locked.

e Do NOT store food or any eatables, chemicals, drugs or any material other than the
test articles in the refrigerator

e Once taken out of the refrigerator, the vaccine should be administered immediately or
discarded.

11.12 EFFICACY ASSESSMENT

Success will be defined by a two-sided 95% CI for vaccine efficacy (adjusted as
necessary for interim monitoring) with a lower bound > 30%. The International Coalition
of Medicines Regulatory Authorities noted that “a specific numeric value to be used for
the lower bound and vaccine efficacy point estimate was not agreed upon at this stage”.
It was also reflected that efficacy estimates crossing a certain pre-specified lower bound
for efficacy, due to factors such as epidemiological evolution of the pandemic, would not
preclude the possibility of a positive benefit-risk conclusion if there also were other data
supportive of efficacy.

K is anticipated that the 6-month COVID-19 attack rate in the control arm will be
approximately 1 percent. The trial is endpoint driven; the primary efficacy analysis is
triggered by the accrual of 130 primary endpoint events across the two arms, at which
point the results will be analyzed and reported. In the event overwhelming efficacy is
detected during the interim analysis, placebo participants may be provided with closeout
vaccinations.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 60 0f 72
Investigator s Brochure BBV 152

11.13 SAFETY

There are 25,800 participants were recruited in the study. It is decided to consider all
AEs reported till 11 am (IST) March 1, 2021 for first 8000 enrolled participants. All the
participants were followed up telephonically for 7 days after each dose of vaccination
and reported all the solicited AEs. Unsolicited AEs from all the participants were
reported throughout follow-up period (Till Day 42). A total of 655 adverse events were
reported and equally distributed in both vaccine and placebo groups. Among these 655
AEs 605 were mild, 34 were moderate and 16 were severe and the severity of the AEs is
similar in both the groups. All the AEs except 20 were resolved without seguelae.
Detailed AEs list is summarized in the Table 14.

TABLE 14: Adverse events reported in Phase III (Interim Analysis)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Treatment Arm
Description BBV152 Placebo Total
(N=4,061) (N=3,804) (N=7,865)
n(%) n(%) n(%)
No of Subject with at least one
adverse Event 335 (8.25) | 300(7.89) 635 (8.07)
No of Subjects with at least one Local Solicited AE
within 7 days after Day O Vaccination 99 (2.44) 94 (2.47) 193 (2.45)
(1 event not resolved)
No of Subjects with at least one Local Solicited AE
within 7 days after Day 28 Vaccination 55 (1.35) 39 (1.03) 94 (1.20)
(1 event not resolved)
No of Subjects with at least one Systemic Solicited
AE within 7 days after Day O Vaccination 94 (2.31) 55 (1.45) 149( 1.89)
(1 event not resolved)
No of subjects with at least one Systemic Solicited
AE within 7 days after Day 28 Vaccination 30 (0.74) 23( 0.60) 53 ( No 0.67)
(1 event not resolved)
No of subjects with at least one Unsolicited
adverse Events 50(1.23) 67(1.76) 117 (1.49)
|AIl Ongoing Adverse Events 9(0.22) 11(0.29) 20 (0.25)
Severity
Mild 317(781) | 288(7.57) 605 (7.69)
Moderate 17(0.42) 17(0.45) 34 (0.43)
Severe 9(0.22) 7(018) 16 (0.20)

 

 

11.13.1 SERIOUS ADVERSE EVENTS

Ali the participants (25800) were followed up for serious adverse events (SAEs) and 43 SAEs
were reported till date and among those cases 33 were resolved, 3 cases are ongoing and 7
deaths were reported. All the SAEs were not related to the vaccine and distributed equally
among the two treatment groups. Detailed description of the SAEs is given in the Table 15.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL

Page 61 0f 72
Investigator s Brochure BBV 152

TABLE 15: SAEs Line Listing of Phase III (Interim Analysis)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

s | Studysite Date of Date of Seriousness | Diagnosisot | Causality | Causality | Oytcome of
No | Sereening | qqministration | 9eurrence of | “Criteria the Event | Assessment | Assessment | o pyent
Number) SAE by PI by Sponsor
19-11-2020 Road traffic
(1º Dose) accident (RTA)- Recovered and
NIMS, (Vaccine/Place ros | Crush Injury left o. discharged
1 Hyderabad bo; Blinded) | 20112020 | Hospitalizaú foot and Unrclated | Ymrelated | from hospital
(32000107) 2º dose was Fracture neck of on 23"! Nov
not 23 and 2020.
administered 4metatarsal.
18-11-2020 Uncontrolled
(1º Dose) Type-2 Diabetes Recovered and
NIMS, (Vaccine/Place Hospitalizati mellitus with Unlikel discharged
2 Hyderabad bo; Blinded) 29-11-2020 Ospitalizati Diabetic nikey | Unrelated | from hospital
(32000073) 2º dose was om ketoacidosis and on 12º Dec
not dyselectrolytemi 2020
administered a.
20-11-2020 :
(1º Dose) Recovered and
PGIMS, (Vaccine/Place Hospitalizati Unrelated from hospital
3 Rohtak bo; Blinded) 05-12-2020 spltátiza COVID-S é Unrelated PO
(32100001) 2º dose was om 3 poe 2020
Dot condition
administered
28-11-2020
(18 Dose) ton E Recovered and
NIMS, (Vaccine/Piace Hospitalizati | breath, pedal Uniikel from hospital
4 Hyderabad bo; Blinded) 05-12-2020 spitaliza ath, peca Y | Uneiated | do sprta
BONO ia on edema and fever 6º Dec 2020 in
€ ) se vas ( days). stable
administered condition
25-11-2020
(Ds Pee
NIMS, (Vaccine/Piace Hospitalizati Unlikely from hospital
5 Hyderabad bo; Blinded) 07-12-2020 o COVID-I9 Unrelated à o
(32000272) 2º dose was on Hr jDec 2020
not a
administered condition
25-11-2020 :
(é De) Peer aê
NIMS, (Vaccine/Place Hospitalizati Uniike! from hospital
6 Hyderabad bo; Blinded) 10-12-2020 Ospitalizati COVID-I9 nhkely | Unrelated om hospita
(32000242) 2” dose was on 15 Dee 2020
not sab
administered condition
08-12-2020 :
Grant Medical (1º Dose) Reco vered and
College & JJ | (Vaccine/Place Hospitatizai | 6 ei from ha "8! tal
7 Hospital, bo; Blinded) 12-12-2020 sa izati Omocysteine | Tnrelated | Unrelated o sabio a
: a sta
(aredoiso) 2 dose vas condition on
administered 26º Dee 2020
07-12-2020
SRM Medical (1º Dose) Recovered and
College & | (Vaccine/Place Hospitalizai | Clinical emeric discharged
8 Hospital, bo; Blinded) 15-12-2020 spitaliza fever with Unrelated Unrelated | from hospital
Chennai 2º" dose was om dehydration. on 17º Dec
(32500018) not 2020
administered
People's Recovered and
College ot discharged
Medical Doses from hospital
Sciences & (Vacein /Place Left non- on 18º Dec
9 Rescarch bo; Blindeg) | 17122020 | Hospitalizai | functioning | Unrciaed | Unrelated | 2020 váth
Centre, 2 dose vas on hydronephrotie advice to
Bhopal, or vas Kidney follow up for
Madhya cri further
y idministered
Pradesh adminis treatment plan
(30900546)
Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 62 0f72

 
Investigator s Brochure BBV 152

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pooplos
College of
Medical Doses
Sojences de (Vaccine/Place
10 Conte bo: Blinded) 21-12-2020 Death Death Unrclated | Untelated Fatal
nte, 2º dose was
Bhopal, not
Madhya ot
Pradesh administered
(30900809)
26-122020
MGMCRI- (vatcinsPhco "Hollow viscus
n SBV, bo; Blinded) | 01-01-2020 | Hospitalizai | perforation with | reared | Unrelated | Recovered
Puducherry 2 dose vas on Acute Kidney
(30800390) ose vas Injury -? Cause”
administered
Pooplos
College of a
ea 10-12:2020 (1 ,
sima | Resavered anã
aecine/Place ulizati ischar
2 Research bo; Blindea) | 06012021 | Hospitalizai | | icrabscess | Unrclated | Unrelated
nte, 2º dose was en
Bhopal, not
Madhya ot
Pradesh administered
(30900578)
Vydchi a
Institute of sara CD ei2200 Recovered and
Nursing (Vaccine/Place (Date of o . - discharged
Sciences and cen ú - | Hospitalizati Left lung o from Hospital
13 S bo; Blinded) awareness of : Unrelated | Unrelated Sp
Research DE dose vao REOSOL on opacity-LRTI 0n23
Centre, o 201 December
Bangalore. adm ered ) 2020
(31100060) Í o
People's a
| 1or122020(1
College of Dose) . Recovered and
medical Vaccine/Place Left non- discharged
research center, | (Vaccine/Pla Hospitalizati | — functioning discharge
14 bo; Blinded) 07-01-2021 . Unrelated Unrelated from Hospital
Bhopal, o on hydronephrotic R
2” dose was : on 21*Jan
Madhya kidney
paia not 2021.
rades! administered
(30900546)
People's
College of a
e o 18-12:2020 (1 ,
Sciences & | (y Dl uv in both Recovered and
aecine/Place co | Injuryinbot ischarg:
15 Research bo; blindod) | 08012021 | Hospializali | mo towerlimbs | Unrelated | Untelated | from Hospital
Bhopal. 2" dose was (ankie) on 19º Feb
opal,
Madi not 2021.
Pradesh administered
(30901496)
People's
Collegeor | 16/12/2020 (1º
Medical Dose) o
Sciences & | (Vaccine/Place a ara
16 Rescarch dos Blindod) awareness ot | Hospitalizati | mauro cataract | Unrelated | Unrelated | from hospital
nt, se was | SAE:13/01/20 om on 1º Jan
Bhopal, not 21 021
Madhya administered :
Pradesh
(30901257)
People's
College of a CAD with
g 16/12/2020 (1 !
quledica Dose) 03/01/2021 hypatencion Recovered and
R - (Vaccine/Place (Date of enlizati nie discharged
escarch cine - | Hospitalizati |  Pneuminitis o A e
17 Cei bo; Blinded) awareness of Unrelated Unrelated from hospital
ntre, o: 5 on JACSITVD. She o
Bhopal 2” dose was SAE: al on6ºJan
pal, not 13/01/2021) was also 2021.
Madhya administered positive with
Pradesh É º COVID-I9.
(30901279)
ersion 4. ective Date ar age 63 0
V 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL P; 630f72

 
Investigator s Brochure BBV 152

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Peoples
Colege of 17/12/2020 (1º
ia Doo) Recovered and
ences RE | 14/01/2021 0º Eospitalizai Acute discharged
18 testa Dose) 15/01/2021 spitalizati | chojecysttis and | Unrelated | Unrelated | fromthe
ntre, : on tits o
opa (Vaecine/Place cholelithiasis. hospital on 22.
Mai bo; Blinded) -01-2021
Pradesh
(20901436)
People's
College of 14-12:2020 (1º
seios amd | ig DE q Recover and
dences md | LLOLZ02I( Hospital | Renal Cateut discharged
19 tescare dose) 18-01-2021 a with Unrelated | Unrelated | from the
Blogal (Vaccine/Place Hepatomegaly. hospital on 19-
Ma bo; Blinded) 012021
Pradesh
(30901004)
21-12-2020 (1º
Dose) 1601-2021
dona à | (VaceineiPiace (Date of
20 bo; Blinded) | awareness of Death Death Unrelated | Unrelated Fatal
(32001 o; '
143) 2º dose was | the SAE:2I-
not 01-2021)
administered
Jawaharlal 25-11-2020 (1º
Nehru Medical Dose) | ace
a |  collegeand | 212200 (0 | srenoss of Death Death Unrelated | Unrelated Fatal
Hospital, AMU, dose)
; : the SAE-
Aligarh (accineiPace | pc)
(81300207) | bo: Blindea)
SE | asno”
os Dose) 11-01-2021 Recovered and
Sciences and | (Vaccine/Place (Date of Hospitalizati | Atypical viral discharged
2 Research bo; Blinded) awareness of seo a pneumonia Unrelated | Unrelated from the
Centre. 2º dose was the SAE: 14- hospital on 15-
+ not 01-2021) 012021
Bangalore administered
(31100290) 5
People's
Collegeof
medical 18-12-2020 (1 Recovered and
seiences and Dose) | Generalised discharged
2 Research | 20012021(20 | o orogo | Hospitalizai | roay pain Unrelated | Unrelated from the
Boat q a om hospital on
Bhopal, accine/Place
Madhya bo; Blinded) 25-01-2021
Pradesh
(30901512)
FIZ
Dose)
ANMS, New | (Vaccine/Place a a
2a Delhi bo; Blinded) “Awareness: Death Death Unrelated | Untelated Fatal
(30100090) | Pidosewas | Jari
not
administered
GMERS | 28-12-2020 (17
Medical Dose) 0801-2021
Colegeand | (VaccineiPiace | — (Dateof
25 | Civil Hospital, | bo;Blinded) | awareness of Death Death Unlikely | Untikely Fatal
Sola, 2" dose was SAE: 27-01-
Abmedabad not 2021)
(81500928) | administered
People's
Collegeof a
medical 13-12-2020 (1 . Recovered and
! Dose) Right eye Co veres
sciences and | 19.01.2021 Hospitalizati | mature cataract discharged
26 Research 2"IDose) 01-02-2021 seo É ani d efe c Unrclated | Unrelated | from Hospital
centre, Bhopal, | |, DOS ye on 12º Feb
(Vaccine/Place pscudophakia
Madhya Dos Blindod 2021.
Pradesh ;
(30900901)
Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 64 0f 72

 
Investigator s Brochure BBV 152

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SRM Medical
College 28122020 (1º | 31012021
Hospital & Dose)
Research 25-01-2021 (Date of N
27 Centre, (Dose) awareness by Death Death Unrclated | Untelated Fatal
Kanchipuram,T | (Vaccine/Place | Sponsor: OI-
amil Nadu bo; Blinded) 02-2021)
(32500447)
SRM Medical
College 23-12-2021 (1º Recovered and
Hospital & Dose) discharged
Rescarch (Vaccine/Place a Hospitalizai Viral from the
28 Centre bo; Blinded) e o spltatiza pneumonia due Unrclated | Unrelated | hospitalon9º
Kanchipuram, | 2" dose was 2 0D1 . om to COVID-I9 Feb 202lin
Tamil Nadu not 2021) stable
(32500303) |  administered condition
People's
College of a
medical 12-12-2020 (1 Recovered and
sciences and Dose) o nua discharged
» Ra | 0901-2021 CH | 02022021 | Hospitaizai | Chronicoriis | urrejarea | Unetaed | Todo
Dose) on media 9
centre, Bhopal, hospital ont 8-
(Vaccine/Place
Madhya bo: Blinded) 02-2021
Pradesh ”
(30900770)
People's
College of a
medical 10:12:2020 (1 Recovered and
sciences and | 79 Po rá italizati conchial discharged
30 Rescarch TOA ( 02022021 | Hospitalizai | Bronchia Unrelated | Unrelated | from the
Dose) on asthma c
centre, Bhopal, hospital on 15-
M (Vaccine/Place
adhya bo; Blinded) 02-2021
Pradesh ”
(30900606)
Maharaja 27-12-2020 (1 Recovered and
Agrasen Super | ,,9 Po rá italizati ; discharged
a spociality 4 Doo 6 04022021 | Hospializai | covip.i Unrclated | Untelated | qomthe
Hospital, Iaipur | (yrocinePiace hospital on 04-
(32700845) bo: Blinded) 02-2021
Maharaja 27-12-2020 (1 Recovered and
Agrasen Super | ,,9 Po rá Hospitalizati discharged
32 speciality Dose) 6 04-02-2021 ospinizal | COVIDI9 Unreiated | Unrelated from the
Hospital, Iapur | (yrocinePiace hospital on 04-
(32700848) bo: Blinded) 02-2021
27-11-2020 (17 | 03022021 -
ANMS.N Dose) (Date of | Could be fere ed and
" SEW | 26-12-2020 (2º | awreness-06- | Hospitalizati mmune associated Under ischarg
33 Delhi Thrombocytope from the
Dose) 022021) on withthe | Evaluation c
(0100013) , nia Purpura. | hospital on 08-
(Vaccine/Place vaccine. 022021
bo: Blinded)
DirectoroF | 09-12-2020 (1% -
Public Health Dose) ara
wa | &Medicine | 060120210 | 0,00» | Hospitalizati | coympo | Unreiated | Unrelated | fromthe
study site, Dose) on c
e , hospital on 16-
Chennai (Vaccine/Place 022021
(31200001) bo; Blinded)
People's
College of a
medical | 97122020 Recovered and
seiences end | 95 02081 (ms Hospitalizati | Chronic otitis discharged
35 Rescarch x 12022021 oprtatiza MUS | Unrclated | Un related from the
Dose) on media c
centre, Bhopal, , hospital on 22-
(Vaccine/Place
Madhya bos Blindod) 02-2021
Pradesh ”
(30900391)
Prakash | 3012202001 Recovered and
Institute of Dose) Fever, discharged
36 Medical | 2601202100 | ,592202 | Hospitalizai | pongacheand | Unrelated | Unrelated | tromthe
Science & Dose) on “
c cough hospital on 14-
Research, (Vaccine/Place 022021
Sangli, bo; Blinded) o
Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIA Page 65 0f 72

 
Investigator s Brochure BBV 152

 

Maharashtra

 

 

 

 

 

 

 

 

 

 

 

(32900012)
02-12-2020 (1º -
ATIMS, New Dose) ars
Delhi 30-12-2020 (2º Hospitalizati Myocardial i from
3 | coroa Dose) 19022021 o intacto (MD | Unlikely | Unrelated from the
, hospital on O1-
(Vaccine/Place 32001
bo; Blinded)
22-12-2020 (1º Ongoing at the
NIMS Dose) 24022021 time of
a8 | tiydembaa | 190120210 (Date of Hospitalizai | covID19 Uniikely Under | submissionof
(32001185) Dose) avareness: 25- on Evaluation | the reportby
(Vaccine/Place | 02-2021) the
bo; Blinded) investigator
Sir Ganga Ram | 19-12-2020(1º | 2402-2021 Ongoing at the
Hospital Marg, Dose) (Date of time of
39 Rajinder 20-01-2021 (2! | awareness: 25- | Hospitalizati | Fever and body Under Under submission of
Nagar, New Dose) 022021) on ache Evaluation | Evaluation | the reportby
Delhi (Vaccine/Place the
(32300066) bo; Blinded) investigator
Aligamh 30 Do CO) 24022021 Recovered and
Muslim 31-12-2020 (2º (Date of Hospitalizati Epistaxis Under discharged
40 | University, Unrelated : from the
ligado Dose) on Evaluation | hospital 9027.
eu Vaccine/Place sao
(31300560) Ya lindo) 022021
People's
College of a
medical ra Gº | 01032021
sciences and 0 nd (Date of isa Acute o
4 Rescarch | 070 Das (2 | avareness: 03. | Hospitalizati | q acerbarion or | Unrelted | p Under | Ongoing
centre, Bhopal, o 03-2021) COPD E
Madhya (Vaccine/Place
Prado bo; Blinded)
(30900606)
26-12-2020 (1º :
AUMS, N Dose) 91-03-2021 aaa
+ New | 2301-2021 (24 (Date of Hospitalizati = . Under ischarg
“2 Delhi , Cholecystitis | Unlikely : from the
Dose) avareness: 05- on Evaluation “
(30100314) : hospital on 02-
(Vaccine/Place | 03-2021) OD
bo; Blinded) :
Vydehi
Institute of | 06-01-2021 (1º
Nursing Dose) 03-03-2021
Sciences and | 03-02-2021 (2%! (Date of Under Under
43 Rescarch Dose) Awareness:05- Death Death Evaluation | Evaluation Fatal
Centre, (Vaccine/Place | 03-2021)
Bangalore bo; Blinded)
(1100476)

 

 

 

 

 

 

 

11.14 INTERIM PHASE 3 RESULT;

 

The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including
2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of Phase 3
clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild,
moderate, or severe) COVID-19 with onset at least 14 days after the second study
vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline.

The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were
observed in the placebo group versus 7 cases observed in the BBV152 (COVAXINS)
group, resulting in a point estimate of vaccine efficacy of 80.6%.

 

Version 4.0 Effective Date 08 Mar 2021

CONFIDENTIAL

Page 66 0f 72

 
Investigator s Brochure BBV 152

The interim analysis included a preliminary review of the safety database, which showed
that severe, serious, and medically attended adverse events occurred at low levels and
were balanced between vaccine and placebo groups. The trial's conduct and monitoring
are as per Good Clinical Practice guidelines and have been outsourced to IQVIA.

Analysis from the National Institute of Virology indicates that vaccine-induced
antibodies can neutralize the UK variant strains and other heterologous strains, which has

been published in bioRxiv. https://doi.org/10.1101/2021.01.26.426986

 

Phase II efficacy interim report is enclosed as Annexure 3
12 RESTRICTED USE OF COVAXIN UNDER CLINICAL TRIAL MODE

Bharat Biotech International Limited (BBIL) in collaboration with Indian Council of
Medical Research (ICMR) has developed an inactivated whole virion COVID-19 vaccine,
COVAXINO. The COVAXING has been evaluated for safety, reactogenicity and
immunogenicity in phase 1 and 2 clinical trials and the trial reports were submitted to the
Central Drugs Standard Control Organization (CDSCO) India. COVAXINO has been
approved under emergency use authorization with permission number MF/BIO/21/000002,
dated 03.01.2021, F. No: BIO/MA/20/000103. This permission is given for restricted use
in emergency situation in public interest as an abundant precaution, in clinical trial mode,
where COVAXINO vaccine will be administered to the vaccine recipients and they will be
followed up for safety. COVAXINO (prepared under Good manufacturing practices, as
required under the Drugs and Cosmetics Act, 1940 and the NCDT Rules 2019) has been
approved by CDSCO for Restricted Use in Emergency situation in Public Interest as an
abundant precaution in Clinical Trial Mode, in India on 3rd January 2021.

12.1 IMPLEMENTATION PLAN - PROCEDURES
Bharat Biotech along with ICMR has taken approval for the Implementation Plan from
the Cental Ethic Committee of ICMR and and SEC committee of CDSCO.
Subsequently, BBIL has sent lakhs of hard copies of Fact Sheets, Informed Consent

forms and Information Leaflets to each designated vaccination sites across the country.

1. The Fact sheet in regional language was provided to the vaccine recipient before
vaccination and vaccine recipients were given time to read (in case of inability to read —
it was read out to him/her by vaccination staff) to understand it. Opportunity was given
to the vaccine recipients to ask clarifying questions to the vaccinator. Vaccinator has
used the information leaflet to answer the queries raised by the vaccine recipient.
Following questions and clarifications, the fact sheet was returned by the vaccine

recipients to the vaccinator.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 67 0f72
Investigator's Brochure BBV 152

2. If the vaccine recipient agrees to be vaccinated with COVAXINO, he/she has to sign
an informed consent form (ICF) (in case of inability to write, he/she has put a left thumb
impression on the ICF). Only after signing the informed consent, the vaccine recipients
were vaccinated with COVAXINO.

3. The informed consent is required at the time of first dose only. The separate consent

is not required for subsequent dose.

12.1.1 VACCINATION PROCEDURE:

Vaccine recipients were provided information in local language pertaining to the vaccine
administration with the help of a Fact Sheet containing details about COVAXINO. On day 01
(Visit 1) and day 28 (Visit 2) recipients were administered with the doses of the COVAXINO
via the intramuscular route. After Day 1 and Day 28 vaccination, Vaccine recipients were
given Adverse Event Form to record the adverse events and they were made to remain for at
least 30 minutes after vaccination for observation to record any adverse event.

12.1.2 ADVERSE EVENTS AND SAES COLLECTION PROCEDURE:

1. The designated staff has collated the consent forms obtained on the previous day for record
keeping. These were files with date of vaccination, session site specifications and planning
unit mentioned on it. A team, consisting of about 150 BBIL sales and marketing
employees and ICMR employees, was set-up at the regional level to telephonically contact
and enquire about the adverse events based on grouping of vaccine recipients as follows:

e Day 7 after dose 1 including symptoms related to Covid-19 and positive RT-PCR test
(if any)

e Day 28 after dose 1 including symptoms related to Covid-19 and positive RT-PCR
test (if any)

* Day 7 after dose 2 including symptoms related to Covid-19 and positive RT-PCR test
(if any)

* Day 28 after dose 2, including symptoms related to Covid-19 and positive RTPCR
test (if any)

2. The list of the vaccine recipients was generated on a daily basis with contact numbers.
3. Adverse events and serious adverse events following immunization (AEFI) informed
during the aforementioned contacts were recorded application against the respective

personnel identified of a vaccine recipient.

4. Grouping of the vaccine recipients in minor, severe and serious adverse event (as the case
may be) was done by District Immunization Officer (DIO) on a daily basis. For all

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 68 0f 72
Investigator s Brochure BBV 152

serious and severe cases, the Case Report Form (CRF) has been raised for further
investigation by District AEFI Committee.

5. In case of any serious adverse events linked to the COVAXINTM immunization
program, the details of the serious adverse events were recorded by the designated
Immunization officers or Health care workers of the vaccination site. BBIL has
coordinated through email/telephone/other means to coordinate with the Immunization
officers/Health care workers to get the required details of SAE. Upon receipt of these
details, submitted SAE report to DSMB, ICMR Central Ethics Committee
CDSCO/DCGI.

7. Drug regulators (Drugs Controller General of India, DCGI) has been provided with the
collated data for review and assessment on vaccine safety, on a monthly basis.

8. The end point and the final outcome of the aforementioned AEFI monitoring related to
COVAXIN was based on the recommendations made by the regulatory authority
(DCGD.

A toll-free number and an email, the details of which are in the fact sheet, were assigned
at BBIL to answer the queries of vaccine beneficiaries. Numerous queries via telephone
and emails were addressed on a daily basis. Causality of all SAEs was assessed by the
Immunization officer, BBIL, ICMR Central Ethics Committee.

12.1.3 CONCLUSIONS

The Restricted use of COVAXINO under clinical trial mode was initiated on 16th Jan
2021. Under this program, a total of more than 13 lakh beneficiaries have been
vaccinated with COVAXINO. Despite numerous attempts by BBIL and ICMR, data was
not shared in a timely manner by the site immunization officers. A total of 8149
beneficiaries have reported adverse events following immunization. No death cases were
reported in the restricted use of COVAXINQ under clinical trial mode. In conclusion, the
COVAXINO can be considered as a safe vaccine.

Restricted Use of COV AXINº under clinical trial mode report is as Annexure-4.

13 NEUTRALIZATION OF UK-VARIANT VUI-202012/01 WITH COVAXIN
VACCINATED HUMAN SERUM
National Institute of Virology (NIV), India was successfully isolated and characterized

the hCoV-19/India/20203522 SARS-CoV-2 (VOC) 202012/01 from UK retumees in
India with all signature mutations of the UK-variant.

The plaque reduction neutralization test (PRNTso) using sera collected from the 26
recipients of BBV152/COV AXINTM against hNCoV-19/India/20203522 (UK variant) and
hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 69 0f 72
Investigator's Brochure BBV 152

of the vaccinated individuals sera showed against UK-variant and the heterologous strain
with similar efficiency, dispel the uncertainty of possible neutralization escape.

Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum
Publication is enclosed as Annexure 5

14 REFERENCES

1.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
study. Lancet. 2020 28;395(10229):1054-62.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
binding. Lancet. 2020 22:395(10224):565-74.

Severe acute respiratory syndrome-related coronavirus: The species and its viruses — a
statement of the Coronavirus Study Group | bioRxiv [Internet]. [cited 2020 Apr 12].
Available from: https://www biorxiv.org/content/10.1101/2020.02.07.937862v1

Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020
19;91(1):157-60.

Coronavirus disease 2019 [Internet]. [cited 2020 Apr 12]. Available from:
https://www who .int/emergencies/diseases/novel-coronavirus-2019

Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: An overview. J] Chin Med
Assoc. 2020;83(3):217-20.

&IndiaFightsCorona COVID-19 [Internet]. MyGov.in. 2020 [cited 2020 Apr 12].
Available from: https://mygov.in/covid-19/

Lake MA. What we know so far: COVID-19 current clinical knowledge and research.
Clin Med (Lond). 2020;20(2):124-7.

Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, et al. Neutralization
of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum [Internet].
Microbiology; 2021 Jan [cited 2021 Feb 22]. Available from:
http://biorxiv.org/lookup/doi/10.1101/2021.01.26.426986

C.AM. de Haan, L. Kuo, P.S. Masters, H. Vennema, P.J.M. RottierCoronavirus particle

assembly: primary structure requirements of the membrane protein. J Virol, 72 (8)
(1998), pp. 6838-6850.

9. P.C.Y. Woo, Y. Huang, S.K.P. Lau, K.-Y. YuenCoronavirus genomics and bioinformatics

analysis Viruses, 2 (8) (2010), pp. 1804-1820.

10. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis.

Methods Mol Biol. 2015;1282:1-23. https://doi.org/10.1007/978-1-4939-2438-7 1

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 70 0f 72
Investigator's Brochure BBV 152

11. Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. SARS-CoV-2 Cell Entry
Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease
Inhibitor. Cell.S0092-8674(20)30229-4 Advance online publication.
https://doi.org/10.1016/j.cell.2020.02.052

12. Tortorici, M.A., and Veesler, D. (2019). Structural insights into coronavirus entry. Adv.
Virus Res. 105, 93-116.

13. Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., &Veesler, D.
(2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.

Celi, 181(0), 281-292.e6. https://doi.org/10.1016/j.cell.2020.02.058

14. Wan, Y., Shang, J., Graham, R., Baric, R.S. & Li, F. Receptor recognition by novel
coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS.
JV1.00127-00120 (2020).

15. Omotuyi, O.; Nash, O.; Ajiboye, B.; Metibemu, D.; Oyinloye, B.; Ojo, A.; Okaiyeto, K.
The Disruption of SARS-CoV-2 RBD/ACE-2 Complex by Ubrogepant Is Mediated by
Interface Hydration. Preprints 2020, 2020030466 (doi: 10.20944/preprints202003.0466.v1].
16. 12. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus
disease (COVID-19) outbreak. J Autoimmun. 2020 Feb 26:102433. doi:
10.1016/j.jaut.2020.102433. [Epub ahead of print]

17. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated
vaccine candidate for SARS-CoV-2. Science [Internet]. 2020 May 6 [cited 2020 Sep 27];
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202686/

18. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an
Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
Cell. 2020 Aug 6;182(3):713-721.e9.

19. Zhang Y-J, Zeng G, Pan H-X, Li C-G, Kan B, Hu Y-L, et al. Inmunogenicity and Safety
of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the
Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial. medRxiv. 2020
Aug 10;2020.07.31.20161216.

20. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity
Outcomes: Interim Analysis of 2 Randomized Clinical Trials [Internet]. [cited 2020 Sep 27].
Available from:
https://w ww unboundmedicine.com/medline/citation/32789505/Effect of an Inactivated Va
ccine Against SARS-CoV-

2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinic
al Trials.

21. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion
InactivatedSARS-CoV-2 Vaccine - BBV152 | bioRxiv [Internet]. [cited 2020 Sep 27].
Available from: https://www .biorxiv.org/content/10.1101/2020.09.09.285445v1.
22.Immunogenicity and protective efficacy of BBV152: a whole virion inactivated SARS
CoV-2 vaccine in the Syrian hamster model. 2020 Sep 16 [cited 2020 Sep 27]; Available
from: https://www.researchsquare.com/article/rs-76768/v1.

 

 

23.Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-
CoV-2 vaccine in rhesus macaques. 2020 Sep 10 [cited 2020 Sep 27]; Available from:
https://www researchsquare.com/article/rs-65715/v1.

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 71 0f 72
Investigator's Brochure BBV 152

24.Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and
immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind,
randomised, phase 1 trial. Lancet Infect Dis 2021 Jan; 2021. https://doi.org/10.1016/81473-
3099(20)30942-7

25.Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S et al. Safety and
immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results ftom a
double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-
blind, randomised phase 1 trial. . Lancet Infect Dis 2021 Mar; 2021.
https://doi.org/10.1016/81473-3099(21)00094-3.

26. Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, et al. Neutralization
of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum [Internet].
Microbiology; 2021 Jan [cited 2021 Feb 224. Available from:
http://biorxiv.org/lookup/doi/10.1101/2021.01.26.426986

 

Version 4.0 Effective Date 08 Mar 2021 CONFIDENTIAL Page 72 0f 72
ANNEAURE-l
Articles

 

Safety and immunogenicity of an inactivated SARS-CoV-2
vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, Sai Prasad, Siddharth Reddy, Vamshi Sarangi, Brunda Ganneru, Gajanan Sapkal,
Pragya Yadav, Priya Abraham, Samiran Panda, Nivedita Gupta, Prabhakar Reddy, Savita Verma, Sanjay Kumar Rai, ChandramaniSingh,
Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Venkat Rao, Randeep Guleria, Krishna Ella,
Balram Bhargava

Summary
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBVI52 is a whole-virion inactivated
SARS-CoV-2 vaccine formulated with a tolllike receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or

alum (Algel).

Methods We did a double-blind, multicentre, randomised, controlled phase 1 trial to assess the safety and
immunogenicity of BBV152 at 11 hospitals across India. Healthy adults aged 18-55 years who were deemed healthy by
the investigator were eligible. Individuals with positive SARS-CoV-2 nucleic acid and/or serology tests were excluded.
Participanis were randomly assigned to receive either one of three vaccine formuilations (3 pg with Algel-IMDG, 6 ng
with Algel-IMDG, or 6 pg with Algel) or an Algel only control vaccine group. Block randomisation was done with a
web response platform. Participants and investigators were masked to treatment group allocation. Two intramuscular
doses of vaccines were administered on day O (the day of randomisation) and day 14. Primary outcomes were solicited
local and systemic reactogenicity events at 2 h and 7 days after vaccination and throughout the full study duration,
including serious adverse events. Secondary outcome was seroconversion (at least four-fold increase from baseline)
based on wild-type virus neutralisation. Cell-mediated responses were evaluated by intracelular staining and ELISpot.
The trial is registered at ClinicalTrials.gov (NCT04471519).

Findings Between July 13 and 30, 2020, 827 participants were screened, of whom 375 were enrolled. Among the
enrolled participants, 100 each were randomly assigned to the three vaccine groups, and 75 were randomly assigned
to the control group (Algel only). After both doses, solicited local and systemic adverse reactions were reported by
17 (17%; 95% CI 10-5-26-1) participants in the 3 ng with AlgelIMDG group, 21 (21%; 13-8-30-5) in the 6 ng with
Algel.IMDG group, 14 (14%; 8-1-22.7) in the 6 pg with Algel group, and ten (10%; 6-9-23.6) in the Algel-only group.
The most common solicited adverse events were injection site pain (17 [5%] of 375 participants), headache (13 [3%),
fatigue (11 [3%]), fever (nine [2%], and nausea or vomiting (seven [2%). All solicited adverse events were mild
(43 [699] of 62) or moderate (19 [31%]) and were more frequent after the first dose. One serious adverse event of viral
pneumonitis was reported in the 6 pg with Algel group, unrelated to the vaccine. Seroconversion rates (%) were
87.9, 91.9, and 82.8 in the 3 pg with Algel-IMDG, 6 pg with Algel-IMDG, and 6 pg with Algel groups, respectively.
CD4' and CD8' Tecell responses were detected in a subset of 16 participants from both Algel-IMDG groups.

Interpretation BBV152 led to tolerable safety outcomes and enhanced immune responses. Both AlgelIMDG
formulations were selected for phase 2 immunogenicity trials. Further efficacy trials are warranted.

Funding Bharat Biotech International.
Copyright O 2021 Elsevier Ltd. All rights reserved.

Introduction molecule, which is a toll-like receptor (TLR) 7/8 agonist,

Spread of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infections has led to a global COVID-9
pandemic. Vaccines from multiple manufacturers will be
needed to address the global need for SARS-CoV-2
vaccines and thus far, 194 vaccine candidates are in
development.

A desirable characteristic for any COVID-19 vaccine
candidate is the ability to induce T-helper-1 cell (Th1)
responses? Whole-virion inactivated vaccines are usually
formulated with Alum, which does not have the ability to
induce cell-mediated responses.! An imidazoquinoline

has been used to stimulate cell-mediated responses
Algel-IMDG (an imidazoquinoline molecule chemisorbed
on alum [Algel]) has been designed to traffic vaccine
antigen directly to draining lymph nodes without
diffusing into the systemic circulation. BBVI52 is à
whole-virion inactivated SARS-CoV-2 vaccine adjuvanted
with Algel-IMDG.

Preclinical studies in mice, rats, and rabbits showed
appropriate safety profiles and humoral and cell.mediated
responses” Two live viral challenge protective efficacy
studies in hamsters and non-human primates were done.

wunwthelancet.com/infection Published online January 21, 2021. https:/[doi.org/10.1016/51473-3099(20)30942-7

0%

Cons

Lancet nfect Dis 2021

Published Online
Janvary21,2021
httpsjfdoiorg/10:1016/
S14733099(20)30942-7

See Online/Comment
httpsyfdoiorg/10:1016/
S1473-3099(20]30988-9
Bharat Biotech, Hyderabad,
India (R Ella MBBS,

KM Vadresu PhD,

HJogdand DVMM, 5 Prasad MSc,
S Reddy MSc V SarangiBSc,
BGanneru PhD, K Ella PhD);
Indian Council of Medical
Rescarch-National Institute of
Virology, Pune, India.

(G Sapkal PhD, P Yadav PhD,

P Abraham PhD); IndianCouncil
of Medical Research, New
Delhi, India (S Panda MO,
NGupta MD, B Bhargava MD);
Nizams Institute of Medical
Sciences, Hyderabad, India.

(P Reddy MD); Pandit Bhagwat
Dayal Sharma Post Graduate
Instituteof Medical Sciences,
Rohtak, India (5 Verma PhD);
AllIndia Institute of Medical
Sciences, New Delhi, India

(6 Kumar Rai MD, R Guleria MD);
All India Institute of Medical
Sciences, Patna, India

(CSingh MD); Redkar Hospital,
Dargalim, India

(SV Redkar MD); Gillurkar
Hospital, Nagpur, India

(CS Gillurkar MD); Prakhar
Hospital, Kanpur, India

(1 SKushwaha MD); SRM
Hospitaland Research Centre,
Kattankulathur, India

(S Mohapatra MD); Instituteof
Medical Sciences and SUM
Hospital, Bhubaneswar, India
(VRao MD)

Correspondenceto:
Dr Krishna Mohan Vadrevo,
Bharat Biotech, Genome Valley,
Hyderabad 500 078, India
kmohangbharathiotech.com

Forthe WHO COVID-19
dashboard see https;covidtS.
who.inty
Articles

 

See Online forappendix

Researchin context

Evidence before this study
We searched PubMed on Jan 15, 2020, for published research
artides using the search terms “SARS-CoV-2”, “COVID-19",
“vaccine”, and “clinical trial”, with no language or date
restrictions. We found several publications on COVID-19
vaccine clinical trials from mRNA, adenovirus, protein subunit,
and inactivated vaccines.

AsofJan 15, 2020, nine vaccines have received emergency use
authorisationto be administered to prevent COVID-19. Inactivated
vaccines have been approved for decades with well established
safety profiles. Immune responses from two other inactivated
vaccines have been reported; however, with few results oncell-
mediated responses. Bharat Biotech has developed a vero cell-
based whole-virion inactivated severe acute respiratory syndrome
coronavirus2 (SARS-CoV-2) vaccine (BBV152) formulated with
alum anda TLR7/8 agonist producing aT-helper-1 cellskewed
response. This vaccine candidate reported protectionintwo live
viral non-human primate and hamster challenge models.

In both studies, protection was evident by rapid clearance
of virus in the lower and upper respiratory tract, and
absence of lung pathology (after viral challenge) *º Here,
we report the interim findings from the randomised,
controlled, double-blind phase 1 trial on the safety
and immunogenicity of three different formulations of
BBV152 and one control group containing Algel (without
antigen). This phase 1 trial was done with the intention
of selecting two formulations for progression to the
phase 2 trial.

Methods

Study design and participants

This is a randomised, double-blind, multicentre, phase 1
trial to assess the safety, reactogenicity, tolerability, and
immunogenicity of the whole-virion inactivated SARS-
CoV.2 vaccine (BBVI52) in healthy adult volunteers, at
11 hospitals across nine states of India (appendix pp 5, 13).
Participants were aged 18-55 years and deemed healthy by
the investigator at the time of enrolment. At the screening
visit, participants were tested with both SARS-CoV-2
nucleic acid (TRUPCR SARS-CoV-2 RT-PCR; 3B BlackBio
Biotech, Bhopal, India) and serology (chemiluminescence
immunoassay; LIAISON SARS-CoV-2 S1/S2 IgG; Dia-
Sorin, Saluggia, Italy) tests (conducted at Dr Dangs Lab
[New Delhi, India) using commercially available assays;
appendix p 3). If found positive for any one test, they were
excluded from the trial. The median time between the
screening visit and vaccination visit was 4 days (range 3-6).
Other key exclusion criteria were an axillary temperature
of more than 37.0ºC and known allergy to any vaccine
component. Participants were screened for eligibility on
the basis of their health status, including their medical
history, laboratory findings (haematology, biochemistry,
and urine tests), vital signs, and physical examination

 

Added value of this study

We reportthe preliminary analyses for the safety and
immunogenicity ofthe vaccine candidate BBV152 in 375
vaccinated adults. All vaccine groups had similar reactogenicity
and serological outcomes to the control group. BBV152 led to
enhanced immune responses; the 3-gg and 6-1g Algel-IMDG
vaccines induced T-cell responses that were biased to T-helper-1
cells.

Implications of all the available evidence

Findings from other inactivated SARS-CoV-2 vaccine
candidates are corroborating. However, to the best of our
knowledge, ours is the only reported inactivated COVID-19
vaccine candidate inducing cell-mediated responses and
humoral neutralising responses. Both Algel-IMDG
formulations will be assessed in a phase 2

immunogenicity trial.

results, and were enrolled after providing signed and dated
informed consent forms. Full inclusion and exclusion
criteria are in the protocol.

The trial was approved by the National Regulatory
Authority (India) and the respective ethics committees
and was conducted in compliance with all International
Council for Harmonization Good Clinical Practice
guidelines.

Randomisation and masking
The master randomisation list was uploaded on the
interactive web response system, which contained
the randomisation number and intended allocation. The
depot manager uploaded the Kit code list and assigned the
kits to the sites that had the kit codes and the allocation
groups. At the site level, the system would set the rando-
misation number and the allotment of the kit without
displaying the true group allocation, and the system would
allocate the same treatment group for the second visit. For
the first 50 participants, a block size of five with ten blocks
was generated for the 3 pg with Algel-IMDG and control
groups ata ratio of 4:1. In the remaining participants, the
number of blocks was 20. For the first 15 blocks, a block
size of 16 was used to randomly assign participants
(3:5:5:3) to 3 pg with Algel.IMDG, 6 pg with Algel-IMDG,
6 pg with Algel, or Algel-only control. The next five blocks
were size 17, and used to randomly assign participants
(3:5:5:4) to 3 pg with Algel-IMDG, 6 pg with Algel-IMDG,
6 ug with Algel, or Algel.only control. An unmasked
contract research organisation, Sclin Soft Technologies,
generated the randomisation list for the study.
Participants, investigators, study coordinators, study-
related personnel, and the funder were masked to
treatment group allocation (excluding an unmasked
member of the contract research organisation, who was

 

www helancet.comyinfection. Published online January 21, 2021 https://doiorg/10-1016/51473-3099(20)30942-7
Articles

 

tasked with the dispatch and labelling of vaccine vials
and the generation of the master randomisation code).
Participants were assigned a computer-generated rando-
misation code that maintained masking. The masked
study nurse was responsible for vaccine preparation and
administration. Each vial contained a unique code that
ensured appropriate masking. The appearance, colour, and
viscosity were identical across all vaccine and control
formulations.

Procedures

The virus strain (NIV-2020:770) containing the Asp614GIy
mutation, isolated from a COVID-I9 patient and
sequenced at the Indian Council of Medical Research
National Institute of Virology, was provided to Bharat
Biotech.” Biosafety level 3 manufacturing facilities and a
well established Vero cell manufacturing platform (with
proven safety in other licensed live and inactivated
vaccines) were used for the rapid development of
BBV152."*

BBVIS2 (manufactured by Bharat Biotech) is a whole-
virion B-propiolactone-inactivated SARS-CoV-2 vaccine.
The NIV-2020-770 strain contains the Asp614Gly mutation,
which is characterised by aspartic acid to glycine shift at
the amino acid position 614 of the spike protein.”

The candidates were formulated with two adjuvants:
Algel (alum) and Algel-IMDG, an imidazoquinoline class
molecule (TLR7 and TLR$ agonist) adsorbed onto Algel.
After their eligibility was established, participants were
assigned to the four groups. The control group contained
only a sterile phosphate-buffered solution and Algel. Both
the vaccine and control were stored at 2-8'C.

The vaccine (BBV152) and the control were provided as a
sterile liquid that was injected intramusculary (deltoid
muscle) at a volume of0-5 mL/dose in a two-dose regimen
on day O (day of randomisation) and day 14. This accelerated
schedule was chosen given the context of the ongoing
pandemic. No onsite dose preparation was required. Each
glass vial contained a single dose of either vaccine or
control formulation that required no additional dilution
steps. No prophylactic medication (ibuprofen or aceta-
minophen) was prescribed either before or after
vaccination.

The follow-up visits were scheduled on days 7, 28, 42,
104, and 194 after vaccination. The study was done in a
dose-escalation manner after completing vaccination in
the first 50 participants with 3 pg with Algel-IMDG (the
lowest antigen concentration) and the control; these
participants were monitored for 7 days for safety. The
independent data safety monitoring board reviewed
masked safety data and decided whether the trial was
allowed to continue with enrolment of the remaining
participants into all groups.

Outcomes
The primary outcome was the number and proportion of
participants with solicited localand systemic reactogenicity

events at 2 h and 7 days after vaccination and throughout
the full study duration, including serious adverse
events. The secondary outcomes was immunogenicity, in
terms of geometric mean titres (GMTs) and four-fold
seroconversion rate of neutralising antibodies, from
baseline to days 14, 28, 42, 104, and 194.

Safety assessments

The unsolicited adverse events were recorded for 28 days
after vaccination. Laboratory values (serum chemistry,
haematology, and urine) were compared before vacci-
nation (day 0) and after vaccination (day 28).

Participants were observed for 2 h after vaccination to
assess reactogenicity. They were instructed to record
local and systemic reactions within 7 days (days 0-7 and
days 14-21) after vaccination using a diary card. The diary
card contained fields for symptom onset, severity, time to
resolution, concomitant medication, and was collected
during the next visit to the site. Routine telephone calls
were scheduled after the first7 days after each vaccination.

Solicited local adverse events were pain at the injection
site and swelling, and systemic adverse events, including
fever, fatigue or malaise, myalgia, body aches, headaches,
nausea or vomiting, anorexia, chills, generalised rash, and
diarrhoea. Al unsolicited adverse events were reported by
participants throughout the study. Adverse events were
graded according to the severity score (mild, moderate, or
severe) and whether they were related or not related to
the investigational vaccine, as detailed in the protocol
(appendix p 6).

Immunogenicity assessments
IgG responses against the spike (S1) glycoprotein,
receptor-binding domain, and nucleocapsid protein of
SARS-CoV.2 were assessed by an in-house-developed
ELISA and are expressed as GMTs. Neutralising antibody
titres were assessed by wild-type virus neutralisation
assays: a microneutralisation assay (MNT, and a plaque-
reduction neutralisation test (PRNT,), at Bharat Biotech.
These assays were based on the Asp614Cly strain
(appendix p 4). To establish interlaboratory comparability,
a subset of randomly selected serum samples (n=50) was
analysed by MNT, at the National Institute of Virology.
Additionally, three laboratory strains were used in vitro for
PRNT, at the National Institute of Virology: the BBVI52
strain NIV-2020-770 homologous, and two heterologous
strains from the O clade (nCoV-Q111 and nCoV-Q100).
Genomic analyses of strains were reported by Potdar and
colleagues.” Only the NIV-2020-770 strain contained the
Asp614Gly mutation.”

To compare vaccine-induced responses to natural
SARS-CoV-2 infections, 41 convalescent serum samples
(collected within 1-3 months after nucleic acid test-based
diagnosis) were tested by MNT, These serum samples
were collected from both selfreported symptomatic
(n=25) and asymptomatic (n=16) patients with COVID-A9
at Nizam's Institute of Medical Sciences (NIMS;

wunwthelancet.com/infection Published online January 21, 2021. https:/[doi.org/10.1016/51473-3099(20)30942-7
Articles

 

Hyderabad, India). The age of these participants was
23-62 years. For symptomatic patients, ascertainment
of severity grading and requirement of supplemental
oxygen was not obtainable. A participant who achieved
seroconversion was defined as having a post-vaccination
titre at least four-fold greater than their respective
pre-vaccination titre. Serum samples were analysed in a
masked manner at Bharat Biotech and the National
Institute of Virology.

Cell-mediated responses were assessed in a subset
of participants at one site (NIMS). The contract research
organisation generated a random code containing
randomisation numbers, which was provided to the staff
to identify participants. Blood (3-5 mL) was collected
from those participants who consented to the additional
volume on days O and 28. Peripheral blood mononuclear
cells were collected to assess IEN-y by ELISpot (13 in
vaccinated groups and six in the control group).
Intracellular cytokine staining was used to assess T-cell
responses in the remaining samples that contained an
adequate number of cells. To ensure equal distribution,
eight samples in each vaccine group were selected. These
assays were done at Indoor Biotechnologies (Bangalore,
India) and Bharat Biotech. All samples were analysed in

a masked manner The details of all assay methods are in
the appendix (p 5).

 

Using a two-sided 5% significance level, power was
calculated for several levels of the absolute difference
between seroconversion rates for vaccine formulations,
and we decided on the power to find a statistically
significant difference between rates if the true underlying
absolute difference was at least 20%. The allocation ratio
was 1:1:1 for three vaccine formulations and 4:1 for the
vaccine (all formulations combined) to placebo. The
placebo group was not included in the sample size
calculations. For a sample size of 90 for each formulation,
the power to find a statistically significant absolute
difference for a true underlying difference of 20% was at
least 80% if the lower seroconversion rate for two
formulations was at least 52%, which is lower than the
seroconversion rate we expected for an effective vaccine.
The sample size chosen was 100 per vaccine formulation,
to allow for loss of data because of withdrawals or loss to
follow-up. We did not incorporate an adjustment for
multiple comparisons, because this phase 1 study was
not a pivotal study for licensure, and we planned to

 

897 individuals assessed for eligibilty

 

 

522 excluded
70 RT-PCR positive
63 ELISA positive
4) 153 abnormallaboratonyvalues
16 outof study window
132 targetenrolment achieved
88 other”

 

 

 

y t

375 envolled

t +

 

100 randomk assigned to3 pg with 100randomiy assigned to 6 pg
AlgelIMDGand received with Algel-IMDG and received
frstdose (first 40 participants frstdose
assessed for safety before

progressianto other groups)

 

 

 

 

100 randomiyassigned to 6 pg 75assignedto controland received
with Algel and received frstdose (frstten participants
frstdose assessed for safety before

progressianto other groups)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Awithdrew consent Aprotocal deviation 3withdrew consent Awithdrew consent
[di [nd [| 1positiveforSARS-Cov-2] P
99received second dose | [ 99 received second dose | [ 96 received second dose | [ Prev seco se |

 

 

 

3 lostto folk 1 lostto follow

 

 

 

99 analysed forimmunogenicity
andsafety

99 analysed for immunogenicity
andsafety

 

 

 

 

73 analysed for immunogenicity
andsafety

93 analysed for immunogenicity
and safety

 

 

 

 

 

 

 

 

Figure 4: Trial profile

SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. “Unable to contactthe participant for vaccination or withdrawal of consent.

www thelancet.comyinfection. Published online January 21, 2021 https://doiorg/10-1016/51473-3099(20)30942-7
Articles

 

choose two vaccine formulations from the phase 1 study
for further assessment. Sample size estimation was done
using PASS 13 software, version 13.0.17.

Safety endpoints are described as frequencies (9%).
GMT with 959% CI are used for immunological endpoints.
For continuous variables (<20 observations), medians and
IQRs are reported. The exact binomial calculation was
used for the CI estimation of proportions. The Wilson's
test was used to test differences in proportions. CI
estimation for the GMT was based on the log, (titre) and
the assumption that the log, (titre) was normally
distributed. A comparison of GMTs was done with t tests
on the means of the log, (titre). Significance was set at
p<0-05 (two-sided). This preliminary report contains
results regarding immunogenicity (days 0-28) and safety
outcomes (days 0-42). Descriptive and inferential statistics
were assessed using SAS, version 9.2. The trial was
registered at ClinicalTrials.gov (NCTO4471519).

Role ofthe funding source
The funder of the study had no role in data collection,
data analysis, data interpretation, or writing of the report,
but was involved in study design. All authors had full
access to all the data in the study and had final
responsibility for the decision to submit for publication.

Results

Between July 13 and 30, 2020, 897 individuals were
screened and 375 were enrolled. Of the 522 initially
screened individuals who were excluded, 133 participants
were excluded because they were positive for SARS-CoV-2
by nucleic acid test or serology and 153 were excluded
because of abnormal laboratory values (figure 1). The
first 50 participants enrolled were monitored for 7 days
after vaccination, and on the basis of the independent
data safety monitoring board review of masked safety
data, the trial was allowed to continue with enrolment of
the remaining participants into all groups. Among the
enrolled participants, 100 each were randomly assigned
to the three vaccine groups, and 75 were randomly
assigned to the control group (Algel only). Demographic
characteristics of the participants were similar across
groups (table 1).

After dose 1, solicited local adverse reactions were
reported by five (5%; 95% CI 1:9-11.8) participants in
the 3 pg with Algel.IMDG group, five (5%; 1-9-11-8) in
the 6 pg with Alge IMDG group, one (1%; 0-05-6-2)
in the 6 pg with Algel group, and three (3%; 1.04-12.03),
in the Algel-only control group. Solicited systemic adverse
reactions were reported by five (5%; 1-9-11-8) participants
in the 3 pg with Algel-IMDG group, 14 (14%; 8-1-22..7) in
the 6 ug with Algel.IMDG group, eight (8%; 3-8-15.6)
in the 6 pg with Algel group, and seven (7%; 4.2-18-9) in
the Algel-only group (table 2; appendix p 14). The most
common solicited adverse events were injection site pain
(17 [596] of 375 participants), headache (13 [396]), fatigue
(L1 [396]), fever (nine [29%]), and nausea or vomiting (seven

[296]. All adverse events were mild or moderate in
severity and resolved within 24 h of onset. After both
doses, solicited local and systemic adverse reactions were
reported by 17 (17%; 95% CI 10-5-26-1) participants in
the 3 pg with Algel-IMDG group, 21 (21%; 13-8-30-5) in
the 6 ng with Algel.IMDG group, 14 (14%; 8.1-22.7)
in the 6 pg with Algel group, and ten (10%; 6-9-23.6) in
the Algelonly group. All adverse events were mild
(43 [69%] of 62) or moderate (19 [319%]) and were more
frequent after the first dose than the second. No
significant differences were observed between the
vaccinated and control groups.

44 unsolicited adverse events were reported by 24 (6%)
of 375 participants (appendix p 6). Biochemical, haemato-
logical, and urine parameters outside of the normal

 

 

 

 

BBVIS23hg BBVIS26pg BBVIS26 Hg Algelonty
withAlgel-  withAlgel  withAlgel  (n=75)
IMDG IMDG (n=100)
(n=100) (n=100)
Age, years
Median (IQR) 325 350 320 290
(25:0-40.0) (250400) (250400) (240380)
=18t0<25 29 (29%) 28(28%) 31614)  22(29%)
=26t0 40 «7 (474) ar(arm) 45(45m)  37(49%)
>40t0<55 24 (24%) 25(25%)  24(24%) 16 (21%)
Sex
Men 78 (8%) e(s)  7606%)  er(e1m)
Women 22 (22%) 18(18%) 24 (24%) 14 (19%)
Body-mass index”, kg/m? 248 (3.5) 258(42) 24967)  246(35)
Vitalsigns
Systolie blood pressure, mm Hg 1229(85)  1235(9) 216(83) 1236(85)
Diastolic blood pressure, mm Hg 794069) 793065) 79263)  794(64)
Pulse rate, beats per min 774(73) 781(82)  780(59)  783(76)
Respiratory rate, breaths per min 169 (23) 16726) — 11(26) 169(22)
Temperature, *C 366(04) 36506) 36504)  366(04)
Sites
AllIndia Institute of Medical Sciences, 3(3%) 6 (6%) 3 (8%) 4 (5%)
New Delhi
All India Institute of Medical Sciences, 25 (25%) 9(9%) o) 719%)
Patna
Gillukar Multispeciality Hospital 10 (10%) 14(14%) 19(19%)  2(16%)
Institute of Medical Sciences and SUM  4(4%) 5(5%) 9 (9%) 5 (7%)
Hospital
Jeevan Rekeha Hospital 1(1%) 1(1%) 2 (2%) o
Nizamis Institute of Medical Sciences 11 (11%) 14(14%) as (15%) 7(9%)
Pandit Bhagwiat Dayal Sharma Post 22 (22%) 10(10%)  a5(15%)  16(21%)
Graduate Institute of Medical Sciences
Prakhar Hospital 8 (8%) 10(10%) (11%)  10(13%)
Rana Hospital and Trauma Centre 1(134) 3 (34) 2 (23%) 2(8%)
Redkar Hospital 70%) 14(14%)  13(13%) 9 (12%)
SRM Hospital and Research Center 8 (8%) 14 (14%) 5 (5%) 3 (4%)
Data are (3%) or mean (SD) unless otherwise stated. The intention-to-treat population included al participants who
received atleastone dose. *Caleulation was based onthe bodyweight and height measured at the time of screening
No dataon race were collected; all participants were south Asian.
Table 1: Demographiccharacteristics of'the participants in the intention-to-treat population

 

wunwthelancet.com/infection Published online January 21, 2021. https:/[doi.org/10.1016/51473-3099(20)30942-7

 
Articles

 

 

 

 

 

 

Dose1 Dose2
3pgwithAlgel- — GugwithAlgel-  6ugwithAlgel  Algelonty 3pgwithAlgel- — GugwithAlgel- 6 ug withAlgel - Algelonty
IMDG (n=100)  IMDG (n=100)  (n=100) (n=75) IMDG (n=100)  IMDG (n=100)  (n=100) (n=75)
Local reactions
Painatinjectionsite
Mila 4(4%11-99) 4(461199) 1(10055) 2(3%0393) 2(2/0270)  1(1%00355) 1(1%0055) O
Moderate 1(1%;00-5:5)  1(100-55) O o o o o o
Swelling
Mila o o o 11%0072) O o o o
Moderate O o o o o o o o
Systemic reactions
Fever
Mila o 1(100-55) 1(10055) O 2(2%02-70)  1(1%0055) 1(1%0055) O
Moderate O 1(1%0055) 2(2%0270) O o o o o
Body ache
Mila o 1(1%00355) O o o o o o
Moderate O 1(100-55) 1(10055) O 1(1%00-55) O o o
Fatigue
Mild 1(1;00-54) O o o 1(1%003-54) O 3(3%06-85) 0
Moderate 2(24;0270) 3(3%06-85) O o 1(1%00-55) O o o
Headache
Mild 1(1%/0:0355) 2(2%02-70) O 5(7%/22-14:9) O o o o
Moderate O 3(3606-85) 2(240270) O o o o o
Nausea or vomiting
Mila 1(14;00355) 2(24/0270) 2(2/0270) 2(3%0393) O o o o
Moderate O o o o o o o o
Dataare n (9%; 95% C1) The safety set includes all participants who received one dose ofthe vaccine (n=375). Dose events are from days 0-7 and dose 2 events are
days14-21. Thegrading scale for most adverse events was based on the US Food and Drug Administration (FDA) quidance document for toxicity grading scale for healthy
adultand adolescent volunteers enrolled in preventive vaccine clinical trial. For adverse everis where grading was not mentioned inthe FDA guidance document, we have.
used the common terminology criteria for adverse events grading. There were no severe adverse events
Table 2: Solicited adverse events inthe safety set

 

 

ranges had no corroborating clinical manifestations
(appendix pp 7-9).

One serious adverse event was reported in the 6 ug
with Algel group. The participant was screened on
July 25 and vaccinated on July 30. 5 days later, the
participant reported fever and headache (initially
reported as a solicited adverse event), and on Aug 8
tested positive for SARS-CoV-2 (by a nucleic acid test).
The symptoms were initially mild in nature, with the
onset of relapsing fever requiring admission to hospital
on Aug 15. The participant had stable vital signs (except
body temperature) during their hospital stay and did
not require supplemental oxygen. The participant was
discharged on Aug 22 after a negative nucleic acid
test result. The event was not causally associated
with the vaccine. No other symptomatic SARS-CoV-2
infections were reported between days O and 75.
However, follow-up of routine SARS-CoV-2 nucleic
acid testing was not done on any scheduled or
illness visit.

IgG titres (GMTs) to all epitopes (spike protein,
receptorbinding domain, and nucleocapsid protein)
increased rapidly after the administration of both doses

(figure 24-C; appendix pp 3-4). Both 3 ug and 6 pg with
Algel-IMDG groups reported similar anti-spike, anti-
receptor binding, and anti-nucleoprotein IgG titres
(GMs), adding to the dose-sparing effect of the adjuvant.
Binding antibody titres to the whole-virion inactivated
antigen are shown in the appendix (p 15). The mean
isotyping ratios ([gG1/1gG4) were greater than 1 for all
vaccinated groups, which was indicative of a Th! bias
(figure 2D).

Seroconversion rates (after the second dose), based on
MNT, were 87-9% (95% CI 79-8-94-3) in the 3 ug with
Algel-IMDG group, 91-9% (84-6-96-0) in the 6 pg with
Algel IMDG group, and 82-8% (73-7-89-2) in the 6 ng
with Algel group (figure 34). Seroconversion (at day 28) in
the control group was reported in six (8% [3-6-17-2]) of
75 participants, suggestive of asymptomatic infection. The
post-second-dose GMTs (MNT) were 61-7 (49-5-76-9) in
the 3 ig with Algel-IMDG group, 6-4 (53-4-82.4) in the
6 ug with Algel-IMDG group, and 48-0 (37-7-61-1) in the
6 yg with Algel group. Responses in the Algel-IMDG
groups were not significantly different to the response in
the 6 pg with Algel group. The vaccine-induced responses
were similar to those observed in the convalescent

www helancet.comyinfection. Published online January 21, 2021 https://doiorg/10-1016/51473-3099(20)30942-7
Articles

 

serum collected from 41 patients who had recovered from
COVID-I9 (figure 3B). On these 41 patients, the
median titre of symptomatic patients (n=25; median 142.2
[[QR 56-6-350]) was significantly higher than that of the
asymptomatic patients (n=16; 22.6 [90-56 5]; appendix
p 16). Seroconversion rates analysed by PRNT, (after the
second dose) were 93-4% (95% C1 83.7-97.8) in the 3 pg
with Algel-IMDG group, 86-4% (75-1-93.2) in the 6 pg
with AlgeLIMDG group, and 866% (74:3-93.6) in the
6 ug with Algel group (figure 3).

MNT, wild-type neutralising antibody responses for a
subset of paired serum samples (n=50) were analysed at
the National Institute of Virology and Bharat Biotech (on
day 28, 2 weeks after the second vaccination in all groups).
Additionally, neutralising antibodies were analysed by
PRNT, at Bharat Biotech and the National Institute of
Virology. Similar results were obtained for MNT, and
PRNT, assays at both laboratories (appendix p 17).
Randomly selected serum samples from day 28 were
analysed by PRNT, at the National Institute of Virology
with homologous and heterologous strain assessments.
Neutralisation responses, regardless of the challenge
strain, were observed (figure 3D).

In a subset of randomly selected blood samples at one
site, IFN-y ELISpotresponses against SARS-CoV.2 peptides
peaked at about 100-120 spot-forming cells per million
peripheral blood mononuclear cells in all vaccinated groups
on day 28. Both the Algel-IMDG groups elicited CD3,
CD4, and CD8* T-cell responses that were reflected in the
IFN-y production, albeit in a small number of samples.
However, there was a minimal detection of less than 0-5%
of CD3:, CD4;, and CD8: Tecell responses in the 6 pg with
Algel group and the Algel only group (appendix p 16).

Discussion

We report the interim findings from the phase 1 clinical
trial of BBV152, a whole-virion inactivated SARS-CoV-2
vaccine. The vaccine was well tolerated in all dose groups
with no vaccine-related serious adverse events. Both
humoral and cell-mediated responses were observed in
the recipients of the Algel-IMDG-based vaccines.

The most common adverse event was pain at the
injection site, followed by headache, fatigue, and fever. The
overall incidence of solicited local and systemic adverse
events in this study was 14-21% in all vaccine-treated
groups, which is noticeably lower than the rates for other
SARS-CoV-2 vaccine platform candidates'* and similar
to the rates for other inactivated SARS-CoV-2 vaccine
candidates“= One serious adverse event (positive for
SARS-CoV-2 by a nucleic acid test) in an individual in the
6 ng with Algel group was not related to vaccination.
Because the event occurred in the 5 days after vaccination,
the development of a protective immune response was
not likely.

BBVI52 induced binding and neutralising antibody
responses that were similar to those induced by other
SARS-CoV-2 inactivated vaccine candidates.* Titres

 

 

 

 

 

A B
104 10
- 5 j Ê s
É aos ; Bs) 5 Ê
Ê E ã
E
ê o 5 ao
g . . . e a . . . .
É aos é e
& E
10” T T T T T T T 10" T T T T T
o 22 0 28 0 28 0 28 o 28 0 28 0 28 0 28
PEDAL EDU
SIS SPO ED SS SIS
Seo cs dd SC E
Ss e Ss
S S S S
sf ef of ef
Time since vaccination (days) Time since vaccination (days)
c D
= ot E
É 10) + .
E o 3 É
É ao 3 ã É .
g 3 &
2 E
É leo cc e z mem
2 o E
É aos Ê
É á ==
E vd , a T T r +
o 22 0 28 0 28 0 28 o Sr PS Da e
LA Sa So A
PD SENSE RE pe
ES CI DÃO é
So SC Er õ 8
Cs
SP
Time since vaccination (days) Treatment

 

Figure 2: SARS-CoV-2 IgG titres against anti
nucleocapsid IgG (C) and anti-spike protein I961/19G4 ratio (D)

 

 

ike protein (A), receptor-binding domain (B), and

ELISA results at baseline (day 0) and 2 weeks after the second vaccination (day 28). InA-C, error bars show 95% CIs.
The cutoff for detectable antibodies was 1/500. Some samples were positive for SARS-CoV-2 in the control group,
asevident bythe antibody titres on day 28. Endpoint titre dilution forday 28 sera sampleswasestablished with

baseline (day 0), interpolated fromthe absorbance of the corresponding day O sample.

Cutoff (mean+3 SD) for

day O vas caleulated considering the absorbance of allsera dilutions (1/500 to 1/32000) tested, except the lowest
dilution (1/500). ELISA titres (endpointtitres) on day 14 were not analysed. In D, the isotyping ratio was calculated

(ina randomiy selected subset) as 1961/1964; dots show-the individual datapoints and

horizontal bars show means.

with error bars for 95% CIs. Endpoint titre=the highest sera dilution at which the absorbancevias above the cutoff.
GMT=geometric mean titre. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2

from the Anti-spike IgG ELISA assay correlated positively
with live virus microneutralisation assay titres (R2=051).
We assessed an accelerated schedule (vaccination 2 weeks
apar!) and did not include a routine schedule (vaccination
4 weeks apart). It has been reported that a routine
schedule for another SARS-CoV-2 vaccine candidate
offers better immune responses, as is to be expected.”
The 4-week schedule for BBVI52 3 pg and 6 pg with
Algel-IMDG is being assessed in a phase 2 trial in
380 volunteers (NCT04471519). Here, we showed that all
vaccine formulations were Th1 skewed with IgG1/IgG4
ratios greater than 1. Furthermore, the Algel. IMDG
formulations were associated with an increase in the
frequency of CD4 INF+y T cells compared with the 6 pg

wuwthelancet.com/infection Published online January 21, 2021. https:/[doi.org/10.1016/51473-3099(20)30942-7

 
Articles

 

 

100-

ation

 

 

10! Corvalescent serum GMT 6231 (95%CI 4077-9522)

 

 

 

 

 

Time since vacciration (days)

 

EE &
dio é 5 5 5 $
Ei o É «
&ê É o =
Et o I Es ." . . so!
E É aos
2d ; ;
“ T T T T T T T 1 1 TY TT DT TT TI T
14 28 14 28 14 28 14 28 o 14 28 0 14 28 O 14 28 0 14 28 Human
—— 1 —— sv voe va vo convalescent
309 69 6ug Control 3u9 6ug 6ug Control serum (n=41)
AlgeAMDG  Alge-IMDG Algel (n=73) Algel-IMDG  AlgelAMDG Alopl (n=73)
(n99) (ro) (=) (mo9) (99) (me93)
Time since vaccination (days) Time since vaccination (days)
c D
100. ao o 39 Algel-IMDG (n=15) O 6 pg Algel(n=15)
E i & 6 pg Algel-IMDG (n=15) O Control (n=5)
És 10" Loo .
EE Ê
25 co E o
2 É
Ê “o PE o" ,
Ê Ei
É “20 10º.
o , 10º
o 28 o 28 o 28 o 28
0 ma o — vo o s—
319 619 6ngAlgel — Algelalone NIV-2020-770 nGov-qua nCov-quoo
AlgeHMDG  AlgeHMDG  (n=93) (n=73)
(n99)  (n=99)

SARS-Coy-2 homologous and heterologous strains.

 

 

Figure 3: SARS-CoV-2 wild-type MNT,, seroconversion rates (A) and GMT (B) and PRNT,,seroconversion rates (C) and medians (D)
Results atbaseline (day 0), 2 weeks after the firstvaccination (day 14), and 2 weeks after the second vaccination in the immunogenicity cohort. Seroconversion rates
were defined by the proportion of titres achieving at least four-fold greaterthan baseline. In A-C, error bars show 95% CIs. In B, the human convalescent serum panel
included specimens from participants with PCR-confirmed symptomatic or asymptomatic COVID-19, obtained at least 30 days after diagnosis (41 samples for
MNT). n D, randomly selected serum samples from day 28 were analysed by PRNT,, atthe National Institute of Virology for homologous (NIV-2020-770)

and heterologous (nCov-Q11 and nCoV-Q100) assessments; dots show individual datapoints and horizontal bars show medians with error bars for IQRs.
GMT=geometric mean titre. MNT ,=microneutralisation assay. PRNT, =plaque-reduction neutralisation test SARS-CoV-2=severe acute respiratory syndrome

coronavirus 2.

with Algel formulation, which is indicative of a Th1 bias.
Additionally, cell-mediated responses from other SARS-
CoV.2 inactivated vaccine candidates have not been
reported thus far.

A few animal studies of SARS-CoV and Middle East
respiratory syndrome-CoV inactivated or vectored
vaccines adjuvanted with alum have shown Th2
responses resulting in eosinophilic infiltration in the
lungs.7 Adverse events might be associated with the
induction of weakly neutralising or non-neutralising
antibodies that lead to antibody-dependent enhance-
ment or enhanced respiratory disease, thus prompting
the attempt to develop SARS-CoV-2 vaccines that
induce a CD4' Th1 response with a minimal Th2
response?” Whole-virion inactivated vaccines are
mostly developed with Algel (alum) as the adjuvant.
The response generated by alum is primarily Th?
biased, with the induction of strong humoral responses
by neutralising antibodies.” To circumvent this concern

of antibody-dependent enhancement, we have assessed
this vaccine with Algel and a TLR7 /8 agonist that results
in immune responses that are biased to Th1. Previous
studies have shown that the toll-like receptors play an
integral role in bridging the innate and adaptive
immune responses, leading to the differentiation of
CD4 T cells into Th1 cells, which produce IENy.*
Geeraedts and colleagues*” reported that the stimulation
of TLR7 by an influenza whole-virion inactivated
vaccine was a significant determinant of a greater
immune response and Th1 polarisation. Thus, it is
imperative to develop such whole-virion inactivated
vaccines with adjuvants that can synergistically
contribute to the full potential. Algel-IMDG contains an
imidaquizoquinoline class TLR7/8 agonist adsorbed to
Algel. Preclinical studies on BBVI52 adjuvanted with
this molecule reported a Thl-biased response in mice?
Furthermore, in a non-human primate and hamster
live viral challenge studies, Algel-IMDG formulations

 

www thelancet.comyinfection Published online January 21, 2021 https://doiorg/10-1016/51473-3099(20)30942-7
Articles

 

led to higher neutralising antibodies, which might have
resulted in improved upper and lower airway viral
clearance (after challenge) **

This study was done at a time of rapidly increasing daily
diagnoses of COVID-19. Among all 897 individuals
screened for this trial, 70 (8%) had positive SARS-CoV.2
nucleic acid test results and 63 (7%) had positive
SARS-CoV-2 serology results. Seroconversion (at day 28)
in the control group was reported in six (8%) of
75 participants from five separate study sites. Because
substantial SARS-CoV-2 was observed at enrolment and
some of the control group recipients seroconverted, post-
vaccination titres from the vaccinated recipients might be
slightly inflated, in the event of natural exposure to
SARS-CoV-2. No symptomatic COVID-19 cases were
reported in the control group.

Because this is an interim report, we are not reporting
any data on the persistence of vaccine-induced antibody
responses or long-term safety outcomes. The results
reported here do not permit efficacy assessments. The
analysis of safety outcomes requires more extensive
phase 2 and 3 clinical trials. Pre-vaccination laboratory
values were similar to values after vaccination. However,
transient laboratory abnormalities might have been
resolved by day 28. The analysis of Tecell responses by
Th? cytokines was not done and is planned for phase 2.
We were unable to assess other immune responses
of convalescent serum because of insufficient number
of samples. The proportion of samples collected from
asymptomatic individuals was high (39%), and no add-
itional data on the severity of disease from symptomatic
individuals was obtained. This study population did not
have ethnic diversity and most of the participants were
men, further underscoring the importance of assessing
BBVI52 in other populations.

However, this study has several strengths. To
ensure generalisability, this study was conducted with
participants from diverse geographic locations within
India (appendix p 13), enrolling 375 participants across
1 hospitals. The first 50 participants were enrolled into
the 3 pg with Algel-IMDG and control groups. Before
granting the recommendation to proceed with the
enrolment of other cohorts, masked safety data was
reviewed by the data safety monitoring board. As a result,
no operational bias was introduced. Despite enrolment
occurring during a national lockdown, which led to
several operational challenges, the overall participant
retention rate was 97%. The sample size was intentionally
large to enable the inference of meaningful conclusions
regarding neutralising responses. With several reports
questioning the efficacy of SARS-CoV-2 vaccines against
antigenically divergent strains, we report neutralising
responses to homologous and heterologous strains. The
BBV152 vaccine strain, based on the Asp614Gly mutation,
has been reported to have differential sensitivity to
neutralisation by vaccine-elicited antibodies or by anti-
bodies produced by natural infection. The increase

in Asp614Gly infectivity results in the virus being
more susceptible to neutralising antibodies,” which is
corroborated by marginal reductions in neutralising
titres in the PRNT, assays with heterologous strains,
which are devoid of the Asp614Gly mutation.

BBVI52 induced binding and neutralising antibody
responses and with the inclusion of the Algel-IMDG
adjuvant, this is the first inactivated SARS-CoV-2 vaccine
that has been reported to induce a Thl-biased response.
BBVIS52 is stored at 2-8ºC, which is compatible with
immunisation cold-chain requirements. Both Algel-
IMDG formulations were selected for the phase 2
immunogenicity trials. Further efficacy trials are
warranted.

Contributors
REand KMV accesscd and verified the data. HJ, BG, PY, and GS led the
immunogenicity experiments. KMV, SPr, VS, and RE contributed to the
analysis and manuscript preparation. SR was the study coordinator

and helped immensely with the protocol design and interim report
generation. PA, SPr, NG, and BB contributed various neutralising antibody
assays and participated in the writing of this manuscript. SPa reviewed the
manuscript. PR, SV, SKR, CS, SVR, CSG, JSK, SM, VR, and RG were
involved with the scientific revicw of this manuscript. KE vias responsible
for overall supervision of the project and review of the final paper.

Declaration of interests

RE, HJ, BG, KMV, SPr, VS, KE, and SR are employees of Bharat Biotech,
with no stock options or incentives. KE is the Chairman and Managing
Director of Bharat Biotech. PY, GS, PA, NG, SPa, and BB arc employees of
The Indian Council of Medical Research. All other authors declare no
competing interests.

Data sharing
Deidentificd individual participant data will be made available when the
trial is complete, upon requests directed to the corresponding author;
after approvalof a proposal, data can be shared through a secure online
platform.

Acknowledgments
Our sincere thanks to the principal and co-principal investigators, study
coordinators, and health-care workers that were involved in this study.
We express our gratitude to Dr Sivasankar Baalasubramaniam fiom
Indoor Biotechnologies (Bangalore), who assisted with cell-mediated
response analyses and Dr Dipankar Das from Bharat Biotech
(Hiyderabad, India), for binding antibody estimation. We thank

Dr Rakeshchandra Meka, Dr Ramulu Chintala, and Ms Spandana Sure for
cell-mediated assessment. A special thanks to Dr Arjun Dang and

Dr Leena Chatterjee of Dr Dangs Lab (New Delhi, India), vihich was the
central laboratory for clinical laboratory testing. We appreciate the
guidance from Dr William Blackwelder for sample size estimation

and statistical analysis planning. Dr Shashi Kanth Muni,

Dr Sapan Kumar Behera, Dr Jagadish Kumar, Dr Vinay Aileni,

Vamshi Sarangi, and Akhila Naidu of Bharat Biotech participated in
protocol design and clinical trial monitoring. We thank the data safety
monitoring board members (Dr Kiran Kumar, Dr Kiran Kishore,

Dr Srinivasa Rao, Dr Sudha Madhuri, and Naradamuni Naidu) for their
continued support and guidance on this ongoing clinical study.
Development of this vaccine candidate (COVAXIN) would not have been
possible without the efforts of Bharat Biotech's manufacturing team,
quality control team, and the discovery team and the supply of

Algel- IMDG adjuvant by Dr Sunil David (Virovax, Laverence, KS, USA).
AI authors would like to express their gratitude for all front-line health-
care workers during this pandemic. This work was supported and funded
by Bharat Biotech International.

References

1 WHO, Draft landscape of COVID-9 candidate vaccines.
Dec 8, 2020. https:/ Www.viho int/ publications /m/item/
drafi-landscape-of-covid-19-candidate-vaccines (accessed
Dec 8, 2020).

wuwthelancet.com/infection Published online January 21, 2021. https:/[doi.org/10.1016/51473-3099(20)30942-7
Articles

 

20

Graham BS. Rapid COVID-19 vaccine development. Science 2020;
368: 94546.

Johnson TR, Graham BS. Contribution of respiratory syncytial virus
G antigenicity to vaccine-enhanced illness and the implications for
severe disease during primary respiratory syncytial virus infection.
Pediatr Infect Dis J 2004; 23 (suppl): S46-57.

Delgado MF, Coviello S, Monsalvo AC, etal. Lackof antibody affinity
maturation due to poor tollike receptor stimulation leads to
enhanced respiratory syncytial virus discase. Nat Med 2009); 15: 34-41.
Philbin VJ, Dowling DJ, Gallington LC, etal. Imidazoquinoline toll
like receptor 8 agonists activate human newborn monocytes and
dendritic cells through adenosine-refractory and caspase-1-
dependent pathways. J Allergy Clin Immunol 2012; 130: 195-204.€9.
Shukla NM, Salunke DB, Balakrishna R, Mutz CA, Malladi SS,
David SA. Potent adjuvanticity of a pure TLR7-agonistic
imidazoquinoline dendrimer. PLoS One 2012; 7: 043612.

Ganneru B, Jogdand H, Dharam VK, etal. Evaluation of safety and
immunogenicity of an adjuvanted, TH-1 skewed, whole virion
inactivated SARS-CoV-2 vaccine—BBVIS2. bio Ri 2020; published
online Sept 9. https://doi.org/10.1101/2020.09.09.285445 (preprint).
Yaday P, Ella R, Kumar 5, etal. Remarkable immunogenicity and
protective efficacy of BBVIS2, an inactivated SARS-CoV-2 vaccine in
rhesus macaques. Res Square 2020; published online Sept 10, 2020.
https://doi.org/10.21203/rs.3.15-65715/vl (preprint).

Mohandas S, Yadav PD, Shete A, etal. Immunogenicity and
protective efficacy of BBV1S2: a whole virion inactivated

SARS CoV-2 vaccine in the Syrian hamster model. Res Square 2020,
published online Sept 16. https://doi.org/10.21203/rs.3 15-76768/vl
(preprint.

Sarkale P, Patil S, Yadav PD, etal. First isolation of SARS-CoV-2.
from clinical samples in India. Indian J Med Res 2020; 151: 24-50.
WHO. Weckdy epidemiological record. Jan 24, 2020 https:/fextranet.
who intjiris/restricted/bitstream /handle/10665/330607/W ER9504-
eng-fre.pdf2ua=1 (accessed Aug 17, 2020).

Sampath G, Madhusudana SN, Sudarshan MK, etal.
Immunogenicity and safety study of indirab: a vero cell based
chromatographically purified human rabies vaccine. Vaccine 2010;
28: 4086-90.

Vadrevu KM, Potula V, Khalatkar V, Mahantshetty NS, Shah A,

Ella R. Persistence of immune responses with an inactivated
Japanese encephalitis single-dose vaccine, JENVAC and
interchangeability with a live-attenuated vaccine. J Infect Dis 2020;
222: 1478-587.

Bhandari N, Rongsen-Chandola T, Bavdekar A, etal. Efficacy ofa
monovalent human-bovine (LIGE) rotavirus vaccine in Indian
children in the second year of life. Vaccine 2014;

32 (suppl 1): AHIO-16.

Ella R, BabjiS, Ciarlet M, Blackwelder WC, Vadrevu KM.
Arandomized, open-labelled, non-inferiority phase 4 clinical trial to
evaluate the immunogenicity and safety of the live, attenuated, oral
rotavirus vaccine, ROTAVAC in comparison with a licensed
rotavirus vaccine in healthy infants. Vaccine 2019; 37: 440713.

Ella R, Bobba R, Muralidhar 5, Babji S, Vadrevu KM, Bhan MK.

A phase 4, multicentre, randomized, single-blind clinical trial to
evaluate the immunogenicity of the live, attenuated, oral rotavirus
vaccine (116E), ROTAVAC, administered simultancously with or
without the buffering agent in healthy infants in India.

Hum Vaccin Immunother 2018; 14: 1791-99.

Potdar V, Cherian SS, Deshpande GR, etal. Genomic analysis of
SARS-CoV.2 strains among Indians retuming from Italy, Iran &
China, & Italian tourists in India. Indian J Med Res 2020; 151: 25-60.
Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/IT study of
COVID-19 RNA vaccine BNT162b1 in adults. Nature 2024
586: 589-93.

Jackson LA, Anderson E], Rouphael NG, etal. An mRNA vaccine
against SARS-CoV-2 - preliminary report. N Engl J Med 2020;

383: 1920-31.

Folegatti PM, Ewer K], Aley PK, etal. Safety and immunogenicity of
the ChAdOx] nCoV-19 vaccine against SARS-CoV-2: a preliminary
report ofa phase 1/2, single-blind, randomised controlled trial.
Lancet 2020; 396: 467-78.

 

 

 

 

a

2

23

u

25

26

2”

29

Zhu FC, Li YH, Guan X-H, etal. Safety tolerability, and
immunogenicity ofa recombinant adenovirus type vectored
COVID-19 vaccine: a dose-escalation, open-label, non-randomised,
firstin-human trial. Lancet 2020; 395: 1845-54.

Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety ofa
recombinant adenovirus type-5-vectored COVID-19 vaccine in
healthy adults aged 18 years or older: a randomised, double-blind,
placebo-controlled, phase 2 trial. Lancet 2020; 396: 479-88.

Walsh EE, Frenck RW Jr, Falsey AR, ct al. Safety and
immunogenicity oftwo RNA-bascd Covid-19 vaccine candidates.

N Engl J Med 2020; published online Oct 14. https://doi.org/10.1056/
NEJMoa2027906.

Zhang Y], Zeng G, Pan H-X, etal. Immunogenicity and safety of a
SARS-CoY.2 inactivated vaccine in healthy adults aged 18-59 years:
report of the randomized, double-blind, and placebo-controlled
phase 2 clinical trial. medRxiv 2020; published online Aug 10.
https://doiorg/10.1101/2020.0731.20161216 (preprint).

Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine
against SARS-CoY.2 on safety and immunogenicity outcomes:
interim analysis of 2 randomized clinical trials. JAMA 202
324:951-60.

Xia S, Zhang Y, Wang Y, etal. Safety and immunogenicity ofan
inactivated SARS-CoN-2 vaccine, BBIBP-CorV: a randomised,
double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis
2020; 21: 39-51.

Gracpel KW, Kochhar 5, Clayton EW, Edwards KE. Balancing
Expediency and scientific rigor in severe acute respiratory syndrome
coronavirus 2 vaccine development. J Infect Dis 2020; 222: 180-82.
Hotez PJ, Corry DE, Bottazzi ME. COVID-19 vaccine design:

the Janus face of immune enhancement. Nat Rev Immunol 2020;
20: 34748.

Diamond MS, Pierson TC. The challenges of vaccine development
against a new virus during a pandemic. Cell Host Microbe 2020;
27:699-703.

Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and
kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with
acute respiratory distress syndrome. Sci Immuno! 2020; 5: cabd2071.
Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses
to SARS-CoV.2 coronavirus in humans vith COVID-19 disease and
unexposed individuals. Cell 2020; 181: 1489-SO1.eIS.

Arvin AM, Fink K, Schmid MA, etal. A perspective on potential
antibody-dependent enhancement of SARS-CoV-2. Nature 2020;
584: 353-63.

He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based
adjuvant research and its mechanism. Hum Vaccin Immunother
2015; 11:477-88.

Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R.
TolHike receptors control activation of adaptive immune responses.
Nat Immunol 2001; 2: 947-50.

Geeraedts F, Goutagny N, Homung Vetal. Superior
immunogenicity of inactivated whole virus HSN1 influenza vaccine
is primarily controlled by toll-ike receptor signalling. PLoS Pathog
2008; 4: 1000138.

Korber E, Fischer WM, Gnanakaran S, etal. Tracking changes in
SARS-CoY.2 spike: evidence that DG14G increases infectivity of the
COVIDA19 virus. Cell 2020; 182: 812-27e19.

Anderson E), Rouphacl NG, Widge AT, et al. Safety and
immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older
adults. N Engl J Med 2020; published online Sept 29. https://doi.
org/10.1056/NEJMoa2028436.

Weissman D, Alameh M-G, de Silva T, etal. D614G spike mutation
increases SARS CoY.2 susceptibility to neutralization. medRsiv 2024
published online Sept 12. https://doi.org/10.1101/2020.0722.20159905
(preprint).

  

 

    

www helancet.comyinfection. Published online January 21, 2021 https://doiorg/10-1016/51473-3099(20)30942-7
Supplementary Appendix to Manuscript Entitled

Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BB V152: a phase 1, double-blind,

randomised control trial

Table of Contents

Supplemental methods.

 

Table S1: Ethic Committees from All Participating Trial Sites with Reference Numbers:.

 

 

Table S2: Grading Scales for Local Adverse Events and Systemic ..

Table S3: Summary of Demographics and Baseline Characteristics of the First 50 Subjects...

 

Table S4:Adverse Events of the first 50 participants (blinded) after the first Dose of Vaccine Administration...

 

Table S5: Proportion of Subjects Experiencing Solicited Adverse Events By Symptom, Severity, Dose Number, and Dose
Group..... 9

 

Table S6: Number of unsolicited, non-serious, adverse events classified by MedDRAº System Organ Class, severity,

 

 

 

 

and investigator-assigned relationship to study vaccine/control.. .. 10
Table S7: Abnormal Laboratory Parameters after two dose Vaccinations in the Phase 1 Clinical Trial 11
a.  Biochemistry.... «11
a. Haematology.... 12
b. Routine Urine Analysis 13
Table S8: Inmunogenicity Parameters analyzed... 14

 

Figures:

 

Figure S1: Indian Cities Selected For the Phase 1 Study.

Figure S2: Anti-Whole Virion Inactivated Antibody (ELISA)

 

 

Figure S3: Microneutralisation of the Human Convalescent Serum Sampl.

Figure S4: Comparison Between MNTso Assays at the Two Labs (Bharat Biotech and National Institute of
Virology) ........... ..16

 

Figure S5: Comparison Between PRNTso Assays at The Two Labs (Bharat Biotech and National Institute of Virology) .17

Figure S6: ELISpot Assay of PBMC's Stimulated with SI Peptides. .. «17

 
Documento Estudo (0019670642) SEI 25000.043170/2021-42 / pg. 105
Supplemental methods

i. RT-PCR (conducted at Dr. Dangs Lab, New Delhi) at Screening

TRUPCR SARS-CoV-2 RT gPCR (V 3.2 ) is a single tube, in vitro nucleic acid amplification test for the qualitative
detection of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)specific RNA from respiratory specimens
(nasopharyngeal or oropharyngeal aspirates, washes or swabs, bronchoalveolar lavage, sputum and tracheal aspirates)
using Real-time PCR. The human RNasePgene serves as an endogenous internal positive control for human nucleic acid
is also included in this kit.

E gene: For the detection of Sarbecovirus RdRp gene and N gene. dual targets for the detection of | SARS-CoV-2

RNase P gene: endogenous internal control, which qualifies the sample for testing and is essential for testing Viral RNA
in host organism. According to the Centre for Daises Control and prevention, Respiratory Viruses Branch, Division of
Viral Diseases, all clinical samples should be tested for human RNAse P gene to assess specimen quality for RT PCR for
detection of 2019-Novel Coronavirus

  

The assay runs for 38 cycles; however for any interpretation, threshold cut off cycle Ct is 35.
Interpretation is as follows:
Amplification Signals In

a) RNAse P+/-, E Gene +, RdRp&N gene + : SARS-CoV-2 POSITIVE

b) RNAse P+/-, E Gene -, RdRp&N gene + : SARS-CoV-2 POSITIVE

c) RNAse P+/-, E Gene +, RdRp&N gene - : SARBECOVIRUS POSITIVE
d) RNAse P+,E Gene -, RdRp&N gene - : NEGATIVE

e) RNAseP-,E Gene -, RdRp&N gene - : INVALID

100 percent concordance of results for submitted samples with ICMR designated QC Lab (ATIMS for Dr. Dangs Lab)
ii. CLIA (conducted at Dr. Dangs Lab, New Delhi) at Screening

The liaison SARS-CoV-2 IgG assay performed on the Liaison XL analyzer is an indirect chemiluminescence
Immunoassay (CLIA) for the Quantitative determination of anti-S1 and anti- S2 antibodies to SARS-CoV-2 in human
serum or plasma.The sensitivity of the above assay is 97.4 percent for 15 days post-diagnosis and specificity 98.9 percent
for Laboratory routine testing. Testing of assay-specific calibrators allows the detected Relative light unit (RLU)to adjust
the assigned master curve.The analyzer automatically calculates SARS-CoV- S1/S2 IgG antibody concentrations as
arbitrary units (AU/mL) and grades the results.

Results are interpreted as follows:

Less than 12 AU/mL: NEGATIVE (A negative result may indicate the absence or a very low level of IgG antibodies to
the Pathogen. The test could score negative in infected patients during the incubation period and during the early stages of
infection>or equal to 12 and less than 15 AU/mL: Equivocal (Retest in duplicate. Samples with 2 out of 3 results more
than or equal to 15 or less than 12 should be reported as positive or negative, respectively. A second sample should be
collected and tested no less than one to two weeks later if the results are repeatedly equivocal) >or equal to 15: Positive (A
positive result generally indicates exposure of the subject to the pathogen)

 

Enzyme-linked immunosorbent assay (ELISA) (conducted at Bharat Biotech)

ELISA tests were performed as per standard protocols. Briefly, Microtiter plates were coated with SARS-CoV-2 specific
antigens (Whole inactivated SARS CoV-2 antigen, spike (SI) (Syngene, Bangalore, India, Batch Nof
PRB026913/Receptor Binding Domain (RBD), Syngene, Bangalore, India, Batch No PRB025485/ nucleocapsid (N),
Syngene, Bangalore, India, Batch No PRB025627 at a concentration of 1ug/ml, 100ul/well in PBS pH 7.4). After
overnight incubation, wells were blocked and added serially diluted sera. After incubation, wells were added with Goat
anti-Human IgG HRP conjugate (Sigma-Aldrich, Cat A8667, dilution 1:5000) and incubated for lhr at RT. Tetramethyl
benzidine used as a substrate and measured absorbance at 450/630nm. Threshold value (Mean + 3SD) was established by
taking the absorbance of Day O sera samples and antigen-specific endpoint titers were determined for Day 28 sera
samples. The reciprocal antibody dilution, at which absorbance is above the threshold, was taken as antigen-specific
antibody endpoint titers.
Plaque Reduction Neutralisation Test (PRNTso) (conducted at Bharat Biotech and National Institute of Virology)

The Plaque reduction neutralisation test was performed in a biosafety level 3 facility. To perform PRNT»,, Vero CCL-81
cell suspension (1.0 x 10º /mL/well)was added in duplicates in 24-well tissue culture plates and cultured in a CO;
incubator at 37ºC for 16-24 hrs. Serum samples from all enrolled participants were inactivated by keeping in a 56ºC-water
bath for 30 min. Serial dilutions (4 fold) of serum samples were mixed with the virus, which can form 50 plaque-forming
units and then incubated for 1 h at 37ºC. The virus-serum mixtures were added onto the preformed Vero CCL-81 cell
monolayers and incubated 1 h at 37ºC in a 5% CO» incubator. The number of plaques was counted, and the Neutralizing
antibody titer was determined based on the 50% reduction in the number of plaque count, which was further analyzed
using 50% ProbitAnalysis(10.4103/ijmr.IIMR 2382 20). A neutralisation antibody titer < 1:20 considered negative,
while that of > 1:20 considered as positive.

iv. Microneutralisation assay (MNT) (conducted at Bharat Biotech)

The serum collected from all enrolled participants were inactivated at 56ºC in a water bath for 30 min. Serum was
successively diluted 1:8 to the required concentration by a 2-fold series, and an equal volume of challenge virus solution
containing 100 CCIDsoviruses was added. After neutralisation in a 37ºC incubator for two hours, a 1.0 x 10º /mL cell
suspension was added to the wells (0.1 mL/well) and cultured in a CO» incubator at 37ºC for 3-5 days. The Karber
method (Ramakrishnan, 2016)by observing the CPE was used to calculate the neutralisation endpoint (convert the serum
dilution to logarithm), which means that the highest dilution of serum that can protect 50% of cells from infection by
challenge with 100 CCIDso virus is the antibody potency of the serum. A neutralisation antibody potency < 1:20 is
negative, while that R 1:20 is positive.

v. Intracellular Staining: (conducted at Bharat Biotech)

Human PBMCs (1x10%ml) were cultured in 24 well plates and stimulated with inactivated SARS-COV-2 antigen (1.2
ug/ml) or PMA (25 ng/ml, cat 4 P8139; Sigma) and Ionomycin (1 ug/ml, cat 4 10634, Sigma) along with Protein transport
inhibitor (Monensin, 1.3ul/ml cat & 554724, BD biosciences) for 12-16hrs in CO» incubator at 37ºC. Cells were washed
and centrifuged at 1000rpm for 5-1Omin and stained with cell surface markers BV421 Mouse Anti Human CD3 (clone:
UCHTI, Cat é 562427, BD Biosciences), APC- Cy7 Mouse Anti Human CD4(Clone:SK3 Cat & 566319, BD
Biosciences), PE- Mouse Anti Human CD8a (Clone: HIT8a, Cat * 555635, BD Biosciences) and Per Cp-Cy5.5 Mouse
Anti Human IL-4 (Clone: 8D4-8, Cat & 561234) for 30 minutes at 4ºC. Cells were again washed twice with PBS and fixed
using fixation/Permeabilize solution (Cat & 554722, BD Biosciences) for 20 mins at 4ºC. Following
fixation/permeabilization, cells were washed with Ix permeabilization buffer and stained with intracelular cytokines IFN-
y (APC Mouse Anti Human IFN-y, Clone: 4S.B3, cat & 551385, BD Biosciences) for 30 mins at 4ºC. Cells were washed
and resuspended in 500ul FACS buffer (Cat * 554657, BD Biosciences). All samples were acquired using BD
FACS Verse (BD Biosciences).

vi. SARS-CoV2 Antibody (Ig61/1gG4) Isotyping:

Th1 -dependent IgG1 vs. Th2 -dependent IgG4 antibody subclasses were determined by ELISA from sera collected from
all vaccinated groups as described earlier. Briefly, 96 well microtiter plates were coated with spike (S1) protein (Cat:
SYNG-PRB026913, Make: Syngene), at a concentration of 1Iug/ml, in PBS pH 7.4) and blocked with 1% BSA in PBS,
pH 7.4. Serially diluted (1:50 to 1:204800) individual sera were added and incubated for 2hrs at 37ºC followed by the
addition of mouse anti-human IgG1 (Cat No: 409904, Make: Biolegend) or IgG4 (Cat No: 411202, Make: Biolegend)
antibodies at a concentration of 25ng/well. After incubation of the plate for Ihr at RT, wells were again washed, and
added Anti Mouse IgG HRP Conjuagate (Cat No: A4416, Make: Sigma Aldrich) at a dilution of 1:2500. Later, 3,3,5,5"-
tetramethylbenzidine (TMB) solution (Cat No: AR1002, Make: deNovo Biolabs) was added as a substrate to develop
color. Absorbance was read at 450nm. Cut off was determined as 1:50 dilution, by calculating Mean+3SD of absorbance
obtained at all dilutions of known negative control (unvaccinated and uninfected sera). Thl:Th2 index was calculated by
taking ratios of end point antibody titer (sera dilution at which absorbance was above the cut off) of IgG1 & IgG4.
 

ELISPOT for IFN (conducted at Indoor Biotechnologies, Bangalore):

To determine the frequency of IFN-y producing T cells generated by the vaccine, we performed an ELISPOT assay using
the IFN-y ELISPOT kit (MABTECH), as per the manufacturer"s instructions. Briefly, ELISPOT plates precoated with
IFN=y antibody were used, these were further seeded with 300,000 PBMCSs obtained from the study subjects. The PBMCs
were stimulated with SARS-CoV-2 peptide matrix (SARS-CoV-2 S1 scanning pool) (MABTECH) at a concentration of
Sug/ml for 18 hours. Unstimulated cells and anti-CD3 stimulated cells were used as a negative and positive controls,
respectively. Subsequently, the plates were washed and incubated with a biotinylated detection antibody, followed by
Streptavidin-ALP (Alkaline Phosphatase). The plates were developed with the BCIP-NBT substrate (5-bromo-4-chloro-
3"-indolyphosphate and nitro-blue tetrazolium) as per the manufacturer”s instructions until distinct spots emerged. The
number of blue spots per well was determined by using an ELISPOT reader (AiD) or under a dissection microscope
(Leica). The frequency of positive cells was calculated after subtracting the number of spots in unstimulated cells from the
peptide stimulated cells, and the results were expressed as SFU/10º PBMCS.

 

Database Handling/Procedures and Data Management Plan

The database used for this study is a fully validated, FDA 21 CFR Part 11 compliant system, proprietary, SAS (software
as a Service) based clinical data management system. Error rates for clinical database are controlled and do not exceed
0.5% as an industry-wide standard. For critical data zero errors based on a 100% review of data are obtained. This is
controlled and documented by database audits against the study CRFs. Based on Data Management Plan (DMP)
document a road map to handle the data under projected circumstances and describes the CDM activities was followed in
the trial. The DMP describes the annotations, database design, data entry and data tracking guidelines, quality control
measures, SAE reconciliation guidelines, discrepancy management, data transfer/extraction, and database locking
guidelines. Along with the DMP, a Data Validation Plan (DVP) containing all edit-checks was performed and the
calculations for derived variables are also prepared. The edit check programs in the DVP help in cleaning up the data by
identifying the discrepancies.

  

Table S1: Ethic Committees from All Participating Trial Sites with Reference Numbers:

 

Site Name Reference Number

 

Nizam's Institute of Medical Science, Hyderabad, Telangana ECR/303/INST/AP/2013/RR-19

 

All India Institute of Medical Science, New Delhi

ECR/547/INST/DL/2014/RR-17

 

PGIMS, Rohtak, Haryana

ECR/293/Inst/HR/2013/RR-19

 

 

 

 

 

 

 

All India Institute of Medical Science, Patna ECR/1387/INST/BR/2020
Redkar Hospital & Research Centre, Goa ECR/902/INST/GA/2018

IMS & SUM Hospital, Odisha ECR/627/INST/OR/2014/RR-17
Jeevan Rekha Hospital, Belgaum, Karnataka ECR/1242/INST/KA/2019
Gillukar Multispeciality Hospital, Nagpur ECR/1374/INST/MH/2020
Rana Hospital and Trauma Center, Gorakhpur, Utter Pradesh ECR/1332/INST/UP/2020
Prakhar Hospital, Kanpur, Utter Pradesh ECR/1017/INST/UP/2017

 

 

SRM Medical College Hospital & Research Centre, Chennai Tamil Nadu

 

ECR/431/INST/TL/2013/RR-19

 

 
Table 52: Grading Scales for Local Adverse Events and Systemic

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

symptoms (pruritus,

S. | Event | None=1 Mild =2 Moderate=3 Severe=4 Peba hio
No. Name threatening=5
Local Adverse Events
Interferes with activity or] prevents daily
. . , o Emergency room
1 Pain at Absent Does not interfere with)  repeated use of non- | activity or repeated (ER) visit or
injection site . activity narcotic pain reliever | use of narcotic pain ont;
. hospitalization
>24hrs reliever
Tenderness/ Mild discomfort to Discomfort with Significant Emergency room
2 Absent - (ER) visit or
Soreness touch movement discomfort at rest aliari
hospitalization
Necrosis or
3 | Redness/ | Absent 2.5-5em 5.1-10cm >10em exfoliative
Erythema e
dermatitis
Swelling/ | Absent | 2:5cm and does not | 5 | gm or interferes | >10 cm prevents .
4 - interfere with daily . . o : aa Necrosis
Induration o with daily activity daily activity
activity
itching localized to | Itching beyond injection , ,
. ans - . . Itching causing
Pruritus Absence injection site and site not generalized or |. ua
' : DA sen inability to perform
5 associated ofany |relieved spontaneously localized itching - NA
ih inianti : ' ei usual social &
with injection] Pruritus | or with<48 hours requiring >48 hours ] a
functional activities
treatment treatment
Any ai Absent |Does not interfere with| | interferes with dail revents dail; Emergency room
ó Local AB's . “dai activit activit ” º activit ” (ER) visit or
y y , y hospitalization
Systemic Adverse Events
Repeated use of non- | Any use of narcotic
: , ir mai : : : Emergency room
: Absent |Does not interfere with| narcotic pain reliever > pain reliever or na
1 Pain os . . (ER) visit or
activity 24 hours or interferes prevents daily lioar;
. . o ame hospitalization
with daily activity activity
<38.00€
(<100.40 | 38.0-38.40 €(100.4- 38.5-38.90 C(101.2-  |39.0-400C C(102.1-
2 Fever F) 101.10F) 102.00F) 1040F) > 400 C (>1040F)
No interference with Some interference Prevents daily Emergency room
Nausea/ Absent . = . ' o activity, requires (ER) visit or
3 o daily activity or 1-2. | with daily activity or > 2 . co VIE
Vomiting - - outpatient IV. hospitalization for
episodes/24 hours episodes/24 hours - .
hydration hypotensive shock
some interference with |Significant, prevents Emersency room
4 Headache Absent | No interference with |daily activity or repeated| daily activity or (E) iai tar
daily activity use of non-narcotic pain |  repeated use of ioari
. uns - hospitalization
reliever narcotic pain relievei
Emergency room
5 Fatigue Absent No interference with | some interference with |Significant, prevents| (ER) visit or
s . daily activity daily activity daily activity hospitalization
6 Myalgia Absent | No interference with | some interference with |Significant, prevents| eo Eno poi
daily activity daily activity daily activity hospitalization
Acute No interference with | some interference with Prevents daily Emergency room
7 | Allrgio | Absent daily activity daily activity actávit (ER) visit or
Reaction y y y y y hospitalization
rashes covering rashes covering 10-30 |rashes covering >30
8 Rash Rash <10%BSA with or %BSA (Body Surface %BSA with or NA
. Absent without symptoms Area) with or without | without symptoms

 

Cpruritus, burning,

 

 

 

 

Cpruritus, burning,

 

 
 

tightness)

burning, tightness),
interferes with daily

tightness), prevents
with daily activity

activity

 

Joint pain Absent

Does not interfere with

Repeated use of non-
narcotic pain reliever >

Any use of narcotic
pain reliever or

Emergency room
(ER) visit or

 

 

 

 

 

 

 

 

2 daily activity 24 hours or interferes prevents daily hospitalization
with daily activity activity
Any other . , . , R . Emergency room
10 Systemic Absent Dossaa intertere with interiores with daily prevents daily (ER) visit or
AE's y y y y hospitalization

 

Abbreviation: NA, not available

Table S3: Summary of Demographics and Baseline Characteristics of the First 50 Subjects.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parameter 3 ug with Algel-IMDG Control Arm
n=40 n=10
(Mean+SD) 312492 294£67
Age (Years) Median 29 26.5
(01:03) (23.3, 39.3) (25:34)
j >18-<25 16 (40%) 3(30%)
Age-wise (Years) >26-<40 16(40%) 6(609%)
>40-<55 8(20%) 1(10%)
Sex (Gender) Male n (%) 35 (35%) 10 (10%)
(Mean+SD) 242430 227429
Body Mass index; Median 24.1 22.89
(01:03) (22.5, 25.8) (19.8:25.7)
(Mean+SD) 97707 98007
Temperature (ºF) Median 97.7 98.15
(Q1:03) (97.4:98.2) (97.5:98.3)
Systolic (Mean+SD) 124.6+7.9 128+7.59
mm H; Median 126.5 127
Blood Pressure ó 8 (01:03) (118.5;128) (123;132)
(mm Hg) Diastoli (Mean+SD) 79.5+64 78.6 48.63
(mm Hg) Median 80 81.5
8) (Q1:03) (76.5:84) (75:84)
Respiratory Rate (Breaths/min) (McanesD) is 23 e 25
(Q1:;03) (16:18) (16:18)
Pulse Rate (MeanSD) 78.8£7.9 76.6+6.9)
(Beats/iali) Median 80 78
(Q1:03) (74:85.5) (75:80)

 

 

Results reported here are unblinded. However, the study was performed in a dose-escalation manner wherein after
completing vaccination in the first 50 participants with 3 ug with Algel-IMDG (the lowest antigen concentration) and the
control (randomisation ratio 4:1); the participants were monitored for seven days for safety. Based on the independent
Data Safety Monitoring Board (DSMB) reviewal of blinded safety data, the trial was allowed to continue with enrollment
ofthe remaining participants into all groups.

 
Table 54:Adverse Events of the first 50 participants (blinded) after the first Dose of Vaccine Administration .

 

 

 

 

 

 

 

 

 

Adverse Events after the First Dose
3 ug with Algel-IMDG

ADVERSE EVENT and Control Arms

n=50
Headache 1(2%)
Feeling Hungry 24%)
Nausea 1(2%)
Fatigue 24%)
Pain at injection site 3(6%)
Total Adverse Events 9(18%),

 

 

 

The study was performed in a dose-escalation manner wherein after completing vaccination in the first 50 participants
with 3 ug with Algel-IMDG (the lowest antigen concentration) and the control (randomisation ratio 4:1); the participants
were monitored for seven days for safety. Based on the independent Data Safety Monitoring Board (DSMB) reviewal of

blinded safety data, the trial was allowed to continue with enrollment of the remaining participants into all groups.
Table 55: Proportion of Subjects Experiencing Solicited Adverse Events By Symptom, Severity, Dose

Number, and Dose Group.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Severity
Symptoms Dose Group Dose 1 Dose 2
Mild Moderate | Severe Mild Moderate | Severe
n(%) n(%) n(%) n(%) n(%) n(%)
Local
3ug with Algel-IMDG 4(4) 1) - 2(2) - -
: o 1) - 14) - -
Pain 6ug with Algel-IMDG 4(4) q
6ug with Algel 1(1) - - 1) - -
Control 2(2.7) - - - - -
3ug with Algel-IMDG - - - - - -
Swelling Gug with Algel-IMDG - - - - - -
6ug with Algel - - - - - -
Control 1(1.3) - - - - -
Systemic
3ug with Algel-IMDG - - - 2(2) - -
6ug with Algel-IMDG 1) 1(D) - Lc) - .
Fever - TD) TO)
6ug with Algel 202) - - -
Control - - - - - -
3ug with Algel-IMDG - - - - 1(1) -
6ug with Algel-IMDG 1) 11) - - - -
Body ache -
Gug with Algel - LO) - - - -
Control - - - - - -
3ug with Algel-IMDG 1(D) 2(2) 1) 11) -
6ug with Algel-IMDG - 363) - - - .
Fatigue -
Gug with Algel - - - 3(3) - -
Control - - - - - -
3ug with Algel-IMDG 1(1D) - - - - -
6ug with Algel-IMDG 2(2) 363) - - - .
Headache -
Gug with Algel - 2(2) - - - -
Control 5 (6.7) - - - - -
3ug with Algel-IMDG 1(1D) - - - - -
Nausea/ 6ug with Algel-IMDG 2(2) . . . . -
Vomiting
6ug with Algel 2(2) - - - - -
Control 2(27) - - - - -

 

 

 

 

 

 

 

 

 
Table 56: Number of unsolicited, non-serious, adverse events classified by MedDRAO system Organ Class,

severity, and investigator-assigned relationship to study vaccine/control

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Severity Relationship to
MedDRA D IP
Soc Group Adyerse Events Mild | Moderate | Severe | Not Related
n(%) n(%) n(%) | Related
3ug with Algel-IMDG | GERD (1) LO) - - 1a) -
Gastrointestinal Sug with Algel-IMDG Somiaçã pain 65) 1a) - - 10) -
Disorders 6ug with Algel Pain/discomfort (3) - 3(3) - - 3(3)
Control - - - - - -
Feeling hungry (3) 1(1) 2(2) - 3(3) -
. Fever (2) 1) - LO) 20) -
3ug with Algel-IMDG Chills (1) - T LCD LO) T
General Sweating (1) - LO) - - LO)
Disorders and Feeling hungry (1) - 1a) - 14) -
administrative . Shivering of hand (2) - 2(2) - - 202)
site conditions | HE With Alge-IMDG Fo rering (1) - LD - - LD
Sweating (1) - LO) - - LO)
6ug with Algel Fever (3) 1(1) 2(2) - 2(2) La)
Control Fever (2) 2(2.7) - - 2(2.7) -
Infections and : : ie
Infestations 6ug with Algel-IMDG | Conjunctivitis (1) 11) - - 11) -
Tremor (2) - 202) - - 202)
3ug with Algel-IMDG | Dizziness (2) - 2(2) - - 2(2)
N Headache (1) LO) - - 1a) -
lervous ai
. Dizziness (1) La) - - 16) -
System Sug with Alge-IMDG Fo ceping disturbance (1) - LO) - LD) -
disorders Ai
6uo with Aleel Giddiness (1) 1(1) - - LC) -
ia 8 Headache (2) - 2(2) - 202) -
Giddiness (1) 1(1.3) - - 1(1.3) -
Control Vertigo (1) 10.3) - = [103 -
3ug with Algel-IMDG - - - - - -
Respiratory, 6 ith Aleel-IMDG Cold (1) - 1a) - - 1(1)
thoracic and | CHEM ÁS Cough (2) 10) LO) - 10) [ 10)
mediastinal . Cold (2) LO) LO) - 2(2)
disorders Sug with Algel* FCough (1) LO) - - - LO)
Cold (1) 1(1.3) - - - 1(1.3)
Control Throat pain (1) 141.3) - - LA3) -
Folliculitis on the
Skin and 3ug with Algel-IMDG | anterior aspect of right 11) - - 1(1) -
subcutaneous shoulder (1)
tissue disorders | 6ug with Algel-IMDG - - - - - -
Gug with Algel - - - - - -
Control - - - - - -

 

 

 

 

 

 

 

 

GERD: Gastroesophageal reflux disease, COLD: the lowest level term (LLT) in the MedDRA for the preferred term ED
Nasopharyngitis is cold.

10
Table 57: Abnormal Laboratory Parameters aíter two dose Vaccinations in the Phase 1 Clinical

Trial.

a. Biochemistry

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3 ug with 6 ug with 6 ug with
Lab Parameters Algel- IMDG Algel- IMDG Algel Cons vm
N=100 N=100 N=100
Day0 | Day 28 | Day0 | Day28 | Day0 | Day28 Day O Day 28
Total Total Total Total Total Total Total Total
Bilirubin Direct n=64 n=71 n=65 n=69 n=64 n=57 n=65 n=45
q 19 9 q 13 12 8 5
(17:2%) | (264%) | (13-9%) | (15-9%) | (20:3%) | (21:1%) | (12:3%) | (11:1%)
Bilirubin Indirect 1 15 2 12 H já 2 4
(20:3%) | (20:8%) | (13-9%) | (17-4%) | (17:2%) | (24:6%) | (13:9%) | (8:9%)
Bilirubin Total 15 18 7 15 16 17 9 7
(23-4%) | (25%) | (10:8%) | (21:7%) | (25.0%) | (29:8%) | (13:9%) | (15-6%)
Blood Glucose ! 5 t 4 ! 2 3 2
(1:6%) | (6:9%) | (1:5%) | (5:8%) | (1:6%) | (3:5%) | (4:6%) | (4:4%)
C-Reactive Protein 10 10 1 12 10 2 $ 6
(15-6%) | (13:9%) | (16:9%) | (17:-4%) | (15-6%) | (15:8%) | (9:2%) | (13:3%)
ane 1 1 1 1 3 2
Serum Creatinine as% | 0 | 0% | am | (1.6%) | 18%) | (46%) | (4:4%)
Gamma glutamyl (0%) 4 6 5 3 1 3 3
transferase (GGT) (5:6%) | (92%) | (7:3%) | (4:7%) | (1:8%) (4.6%) | (6:7%)
Serum Albumin 14 7 10 13 16 7 21 10
(21-9%) | (9:7%) | (15-4%) | (188%) | (25%) | (12:3%) | (32:3%) | (22:2%)
Serum Alkaline 2 4 9 7 10 5 3 (0%)
Phosphate (3:1%) | (5:6%) | (13:9%) | (10-1%) | (15:6%) | (8:8%) (4:6%)
Serum Lipase 1 10 4 7 2 5 4 5
(1:6%) | (13:9%) | (6:2%) | (10-1%) | (3:1%) | (8:8%) (6:2%) | (11-1%)
scoT 8 10 7 5 q 7 9 10
(12-5%) | (13:9%) | (10-8%) | (7:3%) | (17:2%) | (12:3%) | (13-9%) | (22:2%)
sGPT 18 18 15 14 20 19 20 18
(28:1%) | (25%) | (23-1%) | (20-3%) | (31:3%) | (33:3%) | (30-8%) | (40%)
Cholesterol 24 21 28 25 22 13 19 15
(37:5%) | (29-2%) | (43-1%) | (36:2%) | (34:4%) | (22:8%) | (29-2%) | (33:3%)
Blood Urea Nitrogen (66) (0%) (0%) (0%) (0%) (0%) (0%) (0%)

 

 

 

 

 

n represents total number of subjects with abnormal parameters within the arm. Percentages are the results of

counts divided by n.

11

 
a. Haematology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3ugwith 6ugwith 6ugwith
Alge-IMDG Algel-IMDG Algel Control árm
Lab Parameters N=100 N=100 N =100 o
Day 0 Day 28 | Day0 | Day 28 Day O Day 28 Day 0 Day 28
n=19 n=79 n=20 n=69 n=14 n=66 n=15 n=51
Basophils (0%) (0%) (0%) (0%) (0%) (0%) (6: 61%) (0%)
Eosinophils 4 21 1 13 2 10 1 14
(21:1%) | (26:6%) | (5.0%) | (18:8%) | (14:3%) | (152%) | (6:7%) | (27:5%)
ESR 17 49 16 30 10 31 8 27
(89:5%) | (62-0%) | (80.0%) | (43-5%) | (71-4%) | (46:9%) | (53-3%) | (52-9%)
Hemoglobin 19 14 20 17 14 12 15 16
(100%) | (17:7%) | (100%) | (24:6%) | (100%) | (18:2%) | (100%) | (31-4%)
L hocytes 4 10 (0%) 16 2 16 3 10
Ymphocy! (21:1%) | (12:7%) (23:2%) | (14:3%) | (24:2%) | (20.0%) | (19-6%)
MCH 8 37 10 25 5 17 7 25
(42:1%) | (46-8%) | (50.0%)| (36-2%) | (35:7%) | (25:8%) | (46-7%) | (49-0%)
MCHC 8 27 14 22 4 24 8 23
(42:1%) | (34:2%) | (70.0%)| (31:9%) | (28:6%) | (36:4%) | (53-3%) | (45-1%)
MCV 5 26 12 17 5 14 7 16
(26:3%) | (32-9%) | (60.0%) | (24-6%) | (35:7%) | (21:2%) | (46:7%) | (31.4%)
Monocytes (0%) ada ) ova ) osa » | 0% (0%) (0%) (0%)

a 1 2 1 2 2
Neutrophils (5:3%) (2:5%) (0%) (1:5%) (0%) (3:0%) (0%) (3.9%)
PCV 15 22 15 19 12 pal 13 20

(78:9%) | (27:9%) | (75.0%)| (27:5%) | (85:7%) | (31-8%) | (86:7%) | (39-2%)
1 4 3 4 1
Platelet Count (5:3%) (5:1%) (0%) (4:4%) (0%) (6:1%) (0%) (1:9%)
Total Leucocyte 1 1 1 4 1 5 1 1
Count (5:3%) (1:3%) | (5.0%) | (5:8%) (7:1%) (7:6%) (6:7%) (19%)

 

 

 

 

 

n represents total number of subjects with abnormal parameters within the arm. Percentages are the results of

counts divided by n.

12

 
b. Routine Urine Analysi

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3 ug with 6 ug with 6 ug with
Algel-IMDG Algel-IMDG Algel Conta em
Lab Parameters N=100 N=100 N=100 o
Day 0 | Day28 | Day 0 | Day28| Day0 | Day28 | Day0 | Day 28
n=18 n=39 n=27 n=33 n=30 n=27 n=24 n=28
Appearance 7 18 16 27 7 2 12 17
PP! (38:9%) | (46:29%) | (59-39%) | (81-8%) | (56:7%) | (81-5%) | (50%) | (60:7%)
' 1 2 1 1
Bacteria 0% | 0% | su | 0% | (7%) | OO | (42%) | (3.64)
Ter 1 1 3 1 3
Bile pigments (5.65%) | (26%) | OD | c9:1%) | g:3% arim| CM | 0%)
10 9 5 13 9 8 9 7
Crystals (55:6%) | (2319%) | (18:59%) | (39-4%) | (30%) | (29-6%) | (37-5%) | (25%)
1 1 1
Urobilinogen 6% | CO | ao | CO | 0% | 0% | 0% | 0%
Urine Ketones (0%) 26 % | 00 | 0% | 0% | 0% | 0% | (0%)
3 2 7 3 8 3 1 2
Leucocytes Pus cells (16:7%) | (5:1%) | (25:9%) | (9:1%) | (26:7%) | (11:1%) | (4:2%) | (7:1%)
e 1 3 i 1
Nitrite (0% | 0% | 3% | 00 | 0% | CO | (42%) | (3:6%)
i i 1 1
PH (5:6%) | (2:6%) | CO | 0% | qa3m | CO | 0% | (a.6m
REC 3 23 3 2 8 5 5 7
(16:7%) | (58:9%) | (11:1%) | (6:1%) | (26:7%) | (18:59%) | (20-8%) | (25%)
Urine Glucose 1 1 l 2 2 3 3 1
(5:6%) | (2:6%) | (3:7%) | (6:1%) | (67%) | (11:19%) | (12:5%) | (3:6%)
Urine Protein 5 1 4 1 6 l 5 3
(27:8%) | (2:6%) | (14:8%) | (3:0%) | (20%) | (3:7%) | (20-8%) | (10:7%)

 

 

 

 

 

 

 

 

 

n represents total number of subjects with abnormal parameters within the arm- Percentages are the results of

counts divided by n.

13

 
Table 53: Immunogenicity Parameters analyzed.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3 ug with 6 ug with :
Total Parameters / Algel IMDG | Algel-IMDG | é HE With Algel | Control
Vaccine Formulation GMT GMT GMT GMT
(95% CI) (95% CI) (95% CN) (95% CI)
Day O 500 500 500 500
SI. (500.500) (500.500) (500.500) (50,500)
Protein [5,28 48975 STLI 6380.6 2000.0
(4154.9,5772.7) | (4793.6,6948.0) | (5440.6,7482.9) [1654.6,2417.5)
500 500 500 500
ELISA rep. [Par O) (500,500) (500,500) (500,500) (500,500)
om en | Protein Day 28, 25719 31467 3745.8 1606.1
(2265.8,2919.4) | (2753.3,3596.4) | (3234.6,4337.7) [1359.1,1897.9)
Day O 500 500 500 500
N- (500.500) (500.500) (500.500) (50,500)
Protein pa, 28 31106 4053.7 2695.8 1620.2
(2667.2,3627.6) | (3376.4,4866.8) | (2544.9,3456.2) [1357.3,1934.1)
SL Days 038% 93.3% 97.9% 65.8%
Protein (877.975) (86.6.97.3) (02.699:7) | (543,76.1)
aa RBD- 5,24 83.2% 91.4% 94.7% 55.7%
oe | Protein PRY2S (74,9,89.6) (84.2,95.9) (88.1,98.3) | (44.1,669)
Navas (899% 85.6% 89.5% 49,4%
Protein (82.2,944) (175912) (81.5,94.8) | (379.609)
Esotype 33 3.3 22
Mean (o cn Day 28 (2.2,4.5) (2.2, 4.4) (4,3.1) -
Davo 6.21 6.01 5.95 6:13
(5.9.6.5) (5.8.6.2) (5.8,6:1) (5.8,6-4)
MNTa Day 14 9:14 11-20 9.45 6.07
CMT (95% CN) (8-1,10-4) (9.6,13-0) (8:2,10.9) (59,63)
Day 28 61.70 66-4 48-00 7:20
(49-5,16.9) | (534,82:4) (7-1,61-1) (6:4,8-1)
MNTs Day 28 (87:88%) (01:92%) (82-8%) (822%)
SCR (95% CI) (81:5,94:3) | (86.6,97:3) (75:1,90:5) | (1.9, 14.5)
219.6 376.4 253.7 0.30
Homologons! NIV-2020-770 | (137.5,350.9) | (269.2,52620) | (1479,4349) | (0.04,2.5)
lena ogous 215.1 157.5 170.84 0.25
Strain nenge-| nCOV-QUII | (1273,363.3) | (53.0,4679) | (984,2968) | (004,15)
05% CI 106.0 132.7 119.2 0.2
( , nCov-0100 | (751,1497) | (842,209.1) (72.4, 196.3) (0.04, 1.3)
SARS-CoV-2 | CDS 0.5 07 02 0.07
Cell-mediated (03,12) (0.4,2.1) (0.1,0.5) (0.04, 0.6)
Responses %CD4 04 0.8 01 0.08
Median (0.2.1.0) (03,1.0) (0.1,0.3) (0.02,0.3)
(95% CN) 0.04 0.05 0.02 0.01
% CD8
(0.01,0.2) (0.01,1.3) (0.01,0.05) | (0.01,0.04)
Elispot Davo LO LO 70 LO
Median (IQR) y (0.0,5.0) (1.0,5.0) (5,210) (0.0, 12.0)
Day 28 105 55.0 315 3.0
(8.5. 1660) | (220,1738) | (160,1210) | (10,230)

 

 

 

 

 

 

 

Seroconversion rates (SCR) were defined by the proportion of the titres achieving >4-Fold above baseline.

14
FIGURE 51: INDIAN CITIES SELECTED FOR THE PHASE 1 STUDY.

Q!
à
super NADHYA PRADESH

x e

A

    

Figure S2: Anti-Whole Virion Inactivated Antibody (ELISA)

 

 

 

 

    

 

ER
Ego ” A
8 =— -E- -
ES io =
E — = 2
210
s
E o
= Fo
É E e pé Ri sé
Rd as” “
RO ao e”
a e

Documento Estudo (0019670642) SEI 25000.043170/2021-42 / pg. 118

15
Shown are geometric mean IgG titers towards the whole virion inactivated antigen at 2 weeks after the second
vaccination (day 28) for the 3 ug and 6 ug with Algel-IMDG groups, the 6 ug with Algel group, and the Algel-

only control arm.

Figure S3: Microneutralisation of the Human Convalescent Serum Samples.

A B
104 10º
10

MNTsa media (OR)

MNT sy medium (IO)

 

Convalescent Sera Collected from Asvmplomatio Individuals Convalescent Sera € ec im Symptomatio Individuais

 

Shown are medians (IQR) of human convalescent serum samples. The human convalescent serum panel
included specimens from PCR-confirmed symptomatic/asymptomatic COVID-19 participants obtained at least

30 days after diagnosis (41 samples for MNTso).
Figure S4: Comparison Between MNTso Assays at the Two Labs (Bharat Biotech and National
Institute of Virology)

 

 

 

 

 

o 5
Sd
. A
8 BA
E
5 A
2 25
a to
o
o d
= o o
T T T T T
0 200 400 600 800
Means

The Bland-Altman plot for comparing two measurements of the same variable (microneutralisation [MNTs0))
analyzed at both laboratories. A strong agreement between the laboratories was established.

16
Figure 55: Comparison Between PRN Is Assays at [he Iwo Labs (Bharat Biotech and National Institute
of Virology)

 

 

 

 

 

4 3 5
o
sd
2 |
8
8 J
D
£ od
õ
A gui
8 o
T T T T
0 500 1000 1500

Means

The Bland-Altman plot for comparing two measurements of the same variable (microneutralisation [PRNTso])
analyzed at both laboratories. A strong agreement between the laboratories was established.

Figure S6: ELISpot Assay of PBMC's Stimulated with S1 Peptides.

 

Day O Day 28

3-ug with
Algel-IMDG
6-ug with
Algel-IMDG
6-ug with
Algel

Representative results from the ELISpot assay of PBMCSs stimulated with S1 peptide pool on day O and day 28.
Each row represents the vaccine formulation that they received.

 

 

 

 

 

17

Documento Estudo (0019670642) SEI 25000.043170/2021-42 / pg. 120
ANNEAXURE-2
Articles

 

Safety and immunogenicity of an inactivated SARS-CoV-2
vaccine, BBV152: interim results from a double-blind,
randomised, multicentre, phase 2 trial, and 3-month
follow-up of a double-blind, randomised phase 1 trial

Raches Ela, Siddharth Reddy, HarshJogdand, Vamshi Sarangj Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi,
Gajanan Sapkal, Pragya Yadav, Prabhakar Reday, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar,
JitendraSingh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai, Samiran Panda, Priya Abraham, Nivedita Gupta, Krishna Ella,
Balram Bhargava, Krishna Mohan Vadrevu

Summary

Background BBVIS2 is a whole-virion inactivated SARS-CoV-2 vaccine (3 pg or 6 ng) formulated with a tolllike
receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from a double-
blind, multicentre, randomised, controlled phase 1 trial on the safety and immunogenicity of three different
formulations of BBV152 (3 ng with Algel-IMDG, 6 ng with Algel-IMDG, or 6 ng with Algel) and one Algel-only
control (no antigen), with the first dose administered on day O and the second dose on day 14. The 3 pg and 6 pg with
Algel-IMDG formulations were selected for this phase 2 study. Herein, we report interim findings of the phase 2 trial
on the immunogenicity and safety of BBV152, with the first dose administered on day O and the second dose on
day 28.

Methods We did a double-blind, randomised, multicentre, phase 2 clinical trial to evaluate the immunogenicity and
safety of BBV152 in healthy adults and adolescents (aged 12-65 years) at nine hospitals in India. Participants with
positive SARS-CoV-2 nucleic acid and serology tests were excluded. Participants were randomly assigned (1:1) to
receive either 3 pg with Algel-IMDG or 6 ng with Algel-IMDG. Block randomisation was done by use ofan interactive
web response system. Participants, investigators, study coordinators, study-related personnel, and the sponsor were
masked to treatment group allocation. Two intramuscular doses of vaccine were administered on day O and day 28.
The primary outcome was SAR$-CoV-2 wild-type neutralising antibody titres and seroconversion rates (defined as a
post-vaccination titre that was at least four-fold higher than the baseline titre) at 4 weeks after the second dose
(day 56), measured by use of the plaque-reduction neutralisation test (PRNT,) and the microneutralisation test
(MNT,). The primary outcome was assessed in all participants who had received both doses of the vaccine.
Cell-mediated responses were a secondary outcome and were assessed by T-helper-1 (Th1)/Th2 profiling at 2 weeks
after the second dose (day 42). Safety was assessed in all participants who received at least one dose of the vaccine.
In addition, we report immunogenicity results from a follow-up blood draw collected from phase 1 trial participants
at 3 months after they received the second dose (day 104). This trial is registered at ClinicalTrials.gov, NCT04471519.

Findings Between Sept 5 and 12, 2020, 921 participants were screened, of whom 380 were enrolled and randomly
assigned to the 3 pg with Algel-IMDG group (n=190) or 6 pg with Algel-IMDG group (n=190). Geometric mean titres
(GMTs; PRNTs,) at day 56 were significantly higher in the 6 ug with Algel-IMDG group (197-0 [95% CI 155-6-249-4])
than the 3 pg with Algel-IMDG group (100-9 [74-1-137-4]; p=0 -0041). Seroconversion based on PRNT, atday 56 was
reported in 171 (92-9% [95% CI 88-2-96-2] of 184 participants in the 3 pg with Alge-IMDG group and 174
(98-3% [95-1-99-6]) of 177 participants in the 6 Hg with AlgelIMDG group. GMTs (MNT, at day 56 were 92.5
(95% CI 77-7-110-2) in the 3 pg with AlgelIMDG group and 160-1 (135-8-188-8) in the 6 Hg with AlgeLIMDG
group. Seroconversion based on MNT, at day 56 was reported in 162 (88-0% [95% CI82-4-92.3]) of 184 participants
in the 3 pg with AlgelIMDG group and 171 (96-6% [92-8-98-8]) of 177 participants in the 6 pg with AlgelIMDG
group. The 3 pg with Algel-IMDG and 6 pg with Algel-IMDG formulations elicited T-cell responses that were biased
to a Th1 phenotype at day 42. No significant difference in the proportion of participants who had a solicited local or
systemic adverse reaction in the 3 Hg with AlgelIMDG group (38 [20-0%; 95% CI 14.7-26-5] of 190) and the 6 pg
with AlgelIMDG group (40 [21-1%; 15-5-27 5] of 190) was observed on days 0-7 and days 28-35; no serious adverse
events were reported in the study. From the phase 1 trial, 3-month post-second-dose GMTs (MNT; were 39-9 (95% CI
32.0-49.9) in the 3pg with Algel.IMDG group, 69-5 (53.7-89.9) in the 6 pg with AlgelIMDG group, 53-3
(40-1-71.0) in the 6 ng with Algel group, and 20-7 (14.5-29-5) in the Algel alone group.

 

Interpretation In the phase 1 trial, BBV152 induced high neutralising antibody responses that remained elevated in all
participants at 3 months after the second vaccination. In the phase 2 trial, BBV152 showed better reactogenicity and

wnynnrthelancet.comjinfection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0

ro

Crank

Lancet Infect Dis 2021
Published Online

March 8, 2021
httpsy/doiorg/10:1016/
S1473-3099(21)00070-0
See Online/Comment.
httpsy/doiorg/10:1016/
S1473-3099(21)00094-3
Forthe Hinditranslation ofthe
abstract see Online for
appendixi

Bharat Biotech, Hyderabad,
India (R Ella MBBS, SReddy MSc,
HJogdand DVM V Sarangi BSe,
BGanneru PhD, Prasad SMBA,
DDas PhD, DRaju PhD,

U Praturi MSc, KEllaPhD,

KM Vadrexu PhD);

Indian Council of Medical
Rescarch-National Institute
ofVirology, Pune, India

(G Sapkal PhD, YadavP PhD,

P Abraham PhD); Nizams
Institute of Medical Sciences,
Hyderabad, India (P Reddy MD);
Pandit Bhagwat DayalSharma
PostGraduate Instituteof
Medical Sciences, Rohtak, India
(SVerma MD); All India
Instituteof Medical Sciences,
Pata, India (CSingh MD);
Redkar Hospital, Dargalim,
India (SV Redkar MD); Gilurkar
Hospital, Nagpur, India

(CS Gillurkar MD); Prakhar
Hospital, Kanpur, India

(1 SKushwaha MD); SRM
Hospitaland Research Centre,
Kattankulathur, India

(8 Mohapatra MD) Jeevan
Rekha Hospital, Belgaum, India
(A Bhate MD); Al India Institute
of Medical Sciences, New Delhi,
India (S Rai MD); Indian Council
of Medical Research,

New Delhi, India (5 Panda MD,
NGupta MD, B Bhagrava MD)

 

Correspondenceto:
Dr Krishna Mohan Vadrevo,
Bharat Biotech, Genome Valley,
Hyderabad 500 078, India
kmohangbharathiotech.com
Articles

 

For moreonthe WHO
Coronavirus Disease Dashboard
see https covid19 whoink/

safety outcomes, and enhanced humoral and cell-mediated immune responses compared with the phase 1 trial. The
6 Hg with Algel-IMDG formulation has been selected for the phase 3 efficacy trial.

Funding Bharat Biotech International.
Copyright O 2021 Elsevier Ltd. All rights reserved.

Introduction

The novel human coronavirus SARS-CoV-2 has spread
worldwide. To date, 194 vaccine candidates are being
developed to prevent COVID-19: Vaccines from multiple
manufacturers will be needed to address the global
need for SARS-CoV-2 vaccines. Several such vaccines
(inactivated, viral vector, or mRNA) have received
emergency use authorisation for immunisation of
health-care workers and at-risk individuals?” There is
currently an insufficient supply of vaccines, and the
mRNA-based vaccines have cold chain hurdles that
countries need to overcome.

BBVI52 is a whole-virion inactivated SARS-CoV-2
vaccine formulated with a tolllike receptor (TLR)
7/8 agonist molecule adsorbed to alum (Algel IMDG).
BBV152 is stored between 2ºC and 8ºC, which will ease
immunisation cold chain requirements.

Research in context

Evidence before this study
We searched PubMed on Jan 23, 2021, using the search terms
“SARS-CoV-2", “COVID-19", “vaccine”, and “clinical trial”.

We searched for research articles published from database
inception to the date ofthe search, with no language
restrictions. We found 12 clinical trials of COVID-19 mRNA,
adenovirus vectored, protein subunit, and inactivated virus
vaccines, A preferred characteristic ofany COVID-19 vaccine
candidate is its ability to induce T-helper-1 (Th1) responses.
Whole-virion inactivated vaccines are mostly developed with
alum (Algel) as the adjuvant. The response generated by alum
is primarily biased to Th2. Clinical trial results from two other
inactivated virus vaccines (manufactured by Sinovac and
Sinopharm) reported humoral responses but minimal
cell-mediated responses. Bharat Biotech developed aVero
cell-based whole-virion inactivated SARS-CoV-2 vaccine
(BBV152), formulated with alum and atolk-ike receptor

7/8 agonist, producing a Thi-skewed response. BBV152
showed protection in non-human primate and hamster
challenge models. Data from a phase 1 study suggested
adequate safety and immunogenicity findings. In January 2021,
serum samples taken from 38 participants in the 6 pg with
Algel-MDG group at 4 weeks after the second dose (day 56)
in the phase 2 trial were foundto effectively neutralise a
SARS-CoV-2 variant of concern (B.1.177 or20B/501Y. V1).

Added value of this study
We report preliminary analyses for the immunogenicity and
safety of BBV152 in 380 vaccinated adults and adolescents.

Preclinical studies in mice, rats, and rabbits showed
appropriate safety profiles and humoral and cell-mediated
responses. Live viral challenge protective efficacy studies
in hamsters and non-human primates showed rapid viral
clearance in the lower and upper respiratory tracts, and
the absence of lung pathology after viral challenge

We previously reported interim findings from a
double-blind, randomised, phase 1 trial on the safety and
immunogenicity of three different formulations of
BBVI52 (3 pg with Algel-IMDG, 6 pg with Algel-IMDG,
and 6 gg with Algel) and one Algel only control (without
antigen).º This phase 1 trial was done with the intention
of selecting two formulations. Based on acceptable safety
outcomes, and humoral and cell-mediated responses, the
3 ug with Algel-IMDG and 6 pg with Algel-IMDG
formulations were selected for progression to a phase 2
trial. The decision to change the dosing schedule from a

BBV152 led to enhanced immune responses and induced T-cell
responses that were biased to Th1. Due to the difference in
dosing regimens between phase 1 (two doses given 2 weeks
apart) and phase 2 (two doses given 4 weeks apart) trials,
neutralisation responses were significantly higher in the
phase 2 trial than in the phase 1 trial. Immunological
differences between men and women, and across age groups
were not observed. Overall, both 3 |g with Algel-IMDG and

6 ug with Algel-IMDG vaccine groups had similar safety
outcomes. Follow-up data from the phase 1 trial shows that
BBV152 induces durable humoral and cell-mediated immunity
at 3 months afterthe second dose (day 104).

Implications of all the available evidence

Humoral immune responses from other inactivated
SARS-CoV-2 vaccine candidates are consistent with the
findings of this study. However, this is the only study of an
inactivated COMID-19 vaccine candidate to report athorough
evaluation of cell-mediated responses. The 6 pg with
Algel-IMDG formulation has been selected for the phase 3,
efficacy trial. BBV152 (developed using a well established
manufacturing platform) was safe, immunogenic (persisting
for3 months), and can be stored at 2-8ºC, which is compatible
with the immunisation cold chain requirements of most
countries. Follow-up studies to assess efficacy and immune
responses in older adults and in people with comorbidities
are underway.

wrwnwrthelancet com/infection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0
Articles

 

14-day interval between the first and second doses
(phase 1 trial), to a 28-day interval between the two doses
(phase 2 trial) was based on ensuring commonality with
other licensed COVID-19 vaccines. In the phase 1 trial,
no difference in the safety and immunogenicity between
the 3 pg with Algel-IMDG and 6 pg with Algel.IMDG
groups was observed. In this phase 2 trial, the inclusion
of a placebo group was not planned. Our objective was to
increase the sample size to establish whether there
are differences in immunogenicity between the 3 pg
with Agel. IMDG and 6 pg with Algel-IMDG groups.
Therefore, no control or Algel alone group was included
in this study.

Herein, we report interim findings from the phase 2
trial on the immunogenicity and safety of 3 ug with
Algel-IMDG and 6 pg with Algel-IMDG formulations of
BBVI52. Additionally, this paper reports follow-up
immunological results from the phase 1 trial at 3 months
after participants received the second dose (day 104).

Methods

Study design and participants

This is a randomised, multicentre, phase 2 clinical trial
to evaluate the immunogenicity and safety of the
whole-virion inactivated SARS-CoV-2 vaccine BBV152 in
healthy male and female volunteers at nine hospitals
across nine states in India. Participants were aged
12-65 years at the time of enrolment. At the screening
visit, participants were tested using both SARS-CoV-2
nucleic acid and serology tests, which were done at a
central laboratory (Dr Dangs Laboratory, New Delhi,
India) using commercially available assays. Ifindividuals
were positive for either test, they were excluded from the
trial. The median time between the screening visit and
vaccination visit was 3 days (tange 2-4). Individuals
aged older than 65 years, pregnant or lactating women,
and individuals with comorbidities were excluded. All
study-related activities and the opportunity to decline or
withdraw from the study were explained to participants.
All participants were screened for eligibility on the
basis of their health status, including their medical
history, vital signs, and physical examination results,
and were enrolled after providing signed and dated
informed consent forms. Details of the inclusion
and exclusion criteria can be found in the protocol
(appendix 2 pp 50-51).

The trial was approved by the National Regulatory
Authority (India) and the respective ethics committees
of each participating hospital and was conducted
in compliance with all International Council for
Harmonization Good Clinical Practice guidelines.

Randomisation and masking
The master randomisation list was uploaded to the
interactive web response system, which contained
the randomisation number and intended allocation. A
central depot manager uploaded the kit numbers to the

respective sites. At the site-level, the system would set
the randomisation number and the allotment of the kit
without displaying the true group allocation; the system
would allocate the same treatment group for the
second visit. A block size of four was used to randomly
assign (1:1) participants to either the 3 pg with
Algel-IMDG group or the 6 pg with Algel-IMDG group.
An unmasked contract research organisation (Sclin Soft
Technologies, Hyderabad, India) generated the master
randomisation code, and dispatched and labelled the
vaccine vials.

Participants, investigators, study coordinators, study-
related personnel, and the sponsor were masked to the
treatment group allocation (excluding the unmasked
contract research organisation). Participants were assigned
a computer-generated randomisation code that maintained
masking. A masked study nurse prepared and adminis-
tered the vaccines. Each vial contained a unique code that
ensured appropriate masking.

Procedures

BBVI52 (manufactured by Bharat Biotech) is a
wholevirion B.propiolactone-inactivated SARS-CoV-2
vaccine. The NIV-2020-770 strain was isolated from a
patient with COVID-19, sequenced at the Indian Council
of Medical Research-National Institute of Virology,
and provided to Bharat Biotech.” Biosafety level 3
manufacturing facilities and a well established Vero cell
manufacturing platform aided the rapid development of
BBV152. The NIV-2020-770 strain contains the Asp614Gly
mutation, which is characterised by an aspartic acid
to glycine shift at amino acid position 614 of the
spike protein.” Studies suggest that the mutation is
associated with higher viral loads in patients and animal
models compared with the wild-type strain” and that
NIV-2020-770 is considered to be the dominant strain in
the pandemic.”

The candidates were formulated with the Algel-IMDG
adjuvant, which is an imidazoquinoline class molecule
(TLR 7/8 agonist) adsorbed onto Algel. After confirming
their eligibility, participants were randomly assigned to
the two groups. Both vaccines were stored at 2-8ºC in
a single-use glass vial. The appearance, colour, and
viscosity of the two formulations were identical.

Vaccines were provided as a sterile liquid that was
injected through an intramuscular route (deltoid muscle)
ata volume of 0-5 mL per dose in a two-dose regimen on
day O and day 28. Each glass vial contained a single dose
of one of the vaccine formulations and required no
additional dilution steps, therefore, no on-site dose
preparation was required. No prophylactic medication
(ibuprofen or acetaminophen) was prescribed either
before or after vaccination. The follow-up visits were
scheduled on days 42, 56, 118, and 208 after vaccination
for blood collection.

Anti-IgG responses against the spike (S1) glycoprotein,
receptor-binding domain (RBD), and nucleocapsid protein

wntnurthelancet.com/infection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0

See Online forappendix 2
Articles

 

See Online forappendix3

of SARS-CoV.2 were assessed by ELISA (Syngene,
Bangalore, India), and are expressed as geometric mean
titres (GMT). Wildtype virus neutralising antibody
titres in serum samples were analysed with a micro-
neutralisation test (MNT) and a plaque-reduction
neutralisation test (PRNT.,,) at Bharat Biotech in a masked
manner MNT, and PRNT, were developed in-house.
Seroconversion was defined as a post-vaccination titre at
least four-fold higher than the pre-vaccination titre. To
ensure the validity of our assay, an arbitrary number of
serum samples (n=40) were selected at random and tested
by PRNT, at the National Institute of Virology.

Due to the absence of established SARS-CoV-2-specific
correlates of protection, to compare vaccine-induced
immune responses with those elicited by natural
SARS-CoV-2 infections, 50 convalescent serum samples
(collected 1-2 months after a nucleic acid test-based
diagnosis) were tested by PRNT, and MNT. These
serum samples were collected from selfreported
symptomatic (n=35) and asymptomatic (n=15) adult
(age-range not known) patients with COVID-19, and
were provided by the National Institute of Virology
(Pune, India). For symptomatic patients, ascertainment
of severity grading and the requirement for supplemental
oxygen was not available.

Cell.mediated responses were assessed in a subset of
participants at three sites on day 42 and day 56. The
contract research organisation generated a random code
containing randomisation numbers, which was provided
to the staff to identify this subset of participants. Blood
(3-5 mL) was collected from participants who consented
to have additional blood volume collected on day 42.
Serum was used to evaluate Thi-dependent and
Th?-dependent antibody isotypes, and peripheral blood
mononuclear cells (PBMCs) were used to assess Th1 and
Th? cytokines. PBMCs were collected from 58 participants
(29 from each group). Ten pre-vaccination samples
(five from each group) collected on day O served as the
control. Formal sample size estimations for cell-mediated
responses were not done. PBMCs collected on day 42
were used to assess Th (interferon-y [[FNy), tumour
necrosis factor.a [TNFa], and IL-2) and Th? (IL-5, IL-10,
and IL-13) cytokines using a Luminex multiplex assay
(Luminex Corporation, Austin, TX, USA) at Indoor
Biotechnologies (Bangalore, India).

PBMCSs collected on day 56 were used to assess Th1 and
Th2 cytokines using a cytokine bead array multiplex assay
(CBA Kit, BD Biosciences, New Jersey, USA) These tests
were done at Bharat Biotech.

PBMCSs from a subset of randomly selected participants
who consented to the additional blood volume were
collected on day 104 of the phase 1 trial, and used to assess
Teell memory responses (CD4CDASRO" T cells and
CD4'CD45RO*CD27" T cells) at Bharat Biotech. Wild-type
virus neutralisation assays (GMTs and seroconversion
[MNT,) assays) were done in phase 1 participants at day
104. After antigen stimulation of these PBMCs, culture

supernatants were collected on day 3 to assess cytokines
and secreted SARS-CoV.2 IgG antibodies (by ELISA) on
day 6. All samples were analysed in a masked manner.
The details of all assay methods can be found in
appendix 3 (pp 3-4).

Outcomes

The primary outcome was SARS-CoV-2 wild-type neutra-
lising antibody titres and seroconversion rates at 4 weeks
after the second dose (day 56).

A key secondary outcome was the number and
proportion of participants with solicited local and systemic
reactogenicity. Participants were observed for 2 h post-
vaccination to assess reactogenicity. They were instructed
to record local and systemic reactions within 7 days
(days 0-7 and days 28-35) post=vaccination using a paper
based memory aid. The memory aid contained fields for
symptom onset, severity, time to resolution, and con-
comitant medications, and participants were instructed to
complete the form daily. The form was collected during the
next visit to the site. Routine telephone calls were
scheduled following the first 7 days after each vaccination.
Solicited local adverse events were pain and swelling at the
injection site, and systemic adverse events were fever,
fatigue or malaise, myalgia, body aches, headache, nausea
or vomiting, anorexia, chills, generalised rash, and
diarrhoea. Al unsolicited adverse events were reported by
participants throughout the study. The grading scale for
most adverse events was based on the US Food and Drug
Administration (FDA) document for the toxicity grading
scale for healthy adult and adolescent volunteers enrolled
in preventive vaccine clinical trials. Adverse events for
which grading was not described in the FDA guidance
document were graded by use of the Common Terminology
Criteria for Adverse Events. Adverse events were graded
according to severity score (mild, moderate, or severe) and
whether they were related orunrelated to the investigational
vaccine, as detailed in the protocol (appendix 2).

Statistical analysis
We calculated that 171 participants per group were required
for 90% power to detect a significant difference between
GMTs in two equally sized groups, assuming the log,
(titre) is normally distributed with an SD of 0-5, the true
GMT ratio is 1.5, and the groups are compared with a two-
sample + test on log, (titre) at a two-sided 5% significance
level. Assuming a 10% loss of participants due to drop-out
during the study, the sample size was calculated as
190 participants in each group. Sample size was calculated
by use of PASS 13 software (Number Cruncher Statistical
Systems, Kaysville, UT, USA).

The primary outcome was assessed in all participants
who received two doses of the vaccine. Safety was
assessed in all participants who received at least one dose
of the vaccine. Safety endpoints are described as
frequencies. GMTs with 95% Cls are presented for
immunological endpoints. For continuous variables

wrwnwrthelancet com/infection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0
Articles

 

(those with <20 observations), medians and IQRS are
reported. The exact binomial calculation was used for
the CI estimation of proportions. Wilson's test was
used to test differences in proportions. CI estimation for
the GMT was based on the logy (titre) and the assumption
that the log, (titre) was normally distributed. GMTs were
compared with t tests using the means of the log, (titre).
Significance was set at p<0-05 (two-sided).

This preliminary report presents results regarding
immunogenicity (days 0-56) and safety outcomes
(days 0-42). Descriptive and inferential statistics were
assessed using SAS, version 9.2.

The trial is registered at Clinical Trials.gov, NCT04471519.

Role of the funding source
The funder of the study had no role in data collection, data
analysis, data interpretation, or writing of this report or the
statistical report, but was involved in study design. Data
cleaning and analysis was done by the third party
contract research organisation (Sclin Soft Technologies).
Masked laboratory assessments were done at the respective
laboratories, and masked datasheets were sent to the
contract research organisation for decoding and analysis.
The unmasked randomisation list was not shared with the
study sponsor.

Results

Between Sept 5 and 12, 2020, 921 potential participants
were screened, 380 of whom were enrolled and
randomly assigned to either the 3 pg with AlgelIMDG
group (n=190) or the 6 pg with AlgelIMDG group
(n=190; figure 1). Among the 541 individuals who
were initially screened but excluded, 48 had positive
nucleic acid tests and 123 had positive serology tests
for SARS-CoV-2. Due to competitive recruitment,
190 individuals who were screened and found to be
eligible were not enrolled. Other notable exclusions
were due to inconclusive RT-PCR results (n=168).
The retention rates at day 56 were 97% (184 of
190 participants) in the 3 pg with Algel-IMDG group
and 93% (177 of 190 participants) in the 6 pg with
Algel-IMDG group. The demographic characteristics of
participants are shown in table 1.

GMT (PRNT,) at day O were 0-1 (95% CI 0-1-0-1) in
both groups, increasing to 100-9 (74-1-137.4) in the 3 pg
with Algel-IMDG group and 197-0 (155-6-249-4) in the
6 ug with AlgelIMDG group at day 56 (figure 24). The
GMT (PRNT,) at day 56 was significantly higher in
the 6 ug with Algel-IMDG group than in the 3 pg with
Algel-IMDG group (p=0-0041), and was not significantly
different to the GMT (PRNT,;) observed in convalescent
serum collected from patients who had recovered
from COVID-9 (p=0-54. Seroconversion based on
PRNT, at day 56 was reported in 171 (92-9% [95% CI
88.2-96.2]of 184 participants in the 3 ag with Algel IMDG
group and 174 (98-3% [95-1-99-6]) of 177 participants in
the 6 pg with Algel.IMDG group (figure 2B).

 

 

 

921 patients assessed for eligibilty

 

 

 

 

541 excluded
48 RTPCR positive
133 ELISA positive
PP 12 didnothaveatest
168 invalid RT-PCR resulte
agoeligiblebut not enroledt

 

 

 

 

 

380 enrolled and randomised

Da

190 randomlyassignedto
3 pg with Algel1MDG

b t

 

 

 

 

 

190 randomlyassigned to
6 pg with AlgelMDG

 

 

 

 

 

 

 

 

 

 

 

290 received dose à (dy 0) 290 received dose à (day 0)
189 received dose 2 (day 28) 187 received dose? (day28)
Iwithdrew consent Awithdrewconsent
[| alosttofollow-up [PP alostto followup

 

 

 

 

 

 

 

 

 

 

 

 

 

187 analysed for 179 analysed for
immunogenicity(day42) immunogenidity (day 42)

184 analysed for 177 analysed for
immunogeniiy(day56) immunogeniiy (day 56)

 

 

 

 

 

 

 

 

 

Figure 1: Trial profile

“Caused by cold chain excursions during transport of the nasopharyngeal swabs
fromthe field site to the central laboratory. fDue to competitive recruitment,
allsites were screening participants individually; therefore, there was an excess
ofeligible participants who were notenrolled because the recruitment target
was met.

GMTs (MNT, at day 56 were 92-5 (95% CL77-7-110-2)
in the 3 pg with Algel-IMDG group and 160-1(135-8-188-8)
in the 6 pg with AlgelIMDG group (figure 20).
Seroconversion based on MNT, at day 56 was reported
in 162 (88-0% [95% CI 82-4-92-3]) of 184 participants
in the 3 ug with AlgelIMDG group and 171 (96-6%
[92-8-98-8]) of 177 participants in the 6 ug with
Algel.IMDG group (figure 2D; appendix 3, p 6). The
PRNT. and MNT, GMTs at day 56 were significantly
higher in the 6 pg with Algel-IMDG group than the 3 pg
with Algel-IMDG group. No differences in the GMTs
(PRNT,) were observed in a subset of paired serum
samples from both groups (20 samples from each group)
analysed at the National Institute of Virology and Bharat

wntnurthelancet.com/infection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0
Articles

 

Biotech on day 42 (2 weeks after the second vaccination;
appendix 3, p 13). Seroconversion rates and GMTs across
three age groups (=12 to <I8 year, =18 to <55 year, and
=55 to <65 year groups) and between both sexes were

similar, but only small numbers of participants were
included in the youngest and oldest age groups
(appendix 3, p7).

IgG antibody titres (GMTs) to all epitopes (spike glyco-

protein, receptorbinding domain, and nucleocapsid
3 ig váth Algel-IMDG 6 pq with Algel.IMDG protein) were detected after the administration of both
(n=190) (n=190) doses (table 2). Anti-spike glycoprotein IgG GMTs at day
56 were 10413-9 (95% CI 9142.4-11862.2) in the 3 pg with

 

 

 

Age, years
Em ECO Algel-IMDG group and 9541-6 (8245-9-11041.0) in the
as DE) pra 6 ng with AlgelIMDG group. Both the 3 ng and
=18to «55 173 (91%) 176 (93%) 6 ng with Algel-IMDG groups showed similar
pa 748) 10654) anti-spike glycoprotein, anti-receptor-binding domain, and

o anti-nucleocapsid protein GMTs. At day 42, the anti-spike
Rana Em oo isotype mean ratios (LgG1/1gG4) were 2-4(9596CI1.9-2.9)
e in the 3 ug with AlgelIMDG group and 2.2 (1:7-2.6) in

le 140 (74%) 145 (76%) the6 ith Aloe. IMDG

Body-mass index”, kg/m? 251(34) 24.9 (2:8) «6 pg wita Álge Sroup.

The Th1/Th2 cytokine ratio indicated bias to a Th! cell
response at day 42 (figure 34). Th2 responses were
detected at minimal levels in both vaccine groups, as
shown by IL5, IL-10, and IL-13 levels (figure 3B). We
observed a significant increase in the levels of Th1
cytokines, IFNy, IL-2, and TNFo, on day 56 compared with

Dataare median (IQR), n(%), or mean (SD). The intention-to-treat population
included al participants who received at least one dose” Calculated bythe
partcipant's weight (kg) divided by the square of their height (m), measured at
thetimeof screening.

 

 

Table 1: Demographics of participants in theintention-to-treat popu:

 

 

 

 

 

 

 

 

A e 3ugwithAlgeHMDG B
e G pg with Algel-IMDG , ed:
= 3 0 POLO prosa 100, E972m qua 18%
E Col el Z 5 Ea Joss» Jo2s
fo 1 EEE Es E do]
Ê . Ê
É Ed : Êo
E o e E E a + 28 74
É : & AA É EE co
z - SETE ia
Ejs E 5 : &E so fosse
a BS so 393%
» + EÊ I
És + Si oo
À aoj=5  — — e uu a É 20
E 10)
E ao o
c D
ya Human convalescent serum
to F966% p966%
Fesrs frzox
iriEESE
TESES
Er =
ESAsã: Fose Prs
o
28 42 56 Asymptomatid 28 42 56

 

symptomatic

Time sincevacination (days) Timesince vaccination (days)

 

 

 

Figure 2:SARS-CoV-2 wild-type PRNT,. GMTs (A), and seroconversion rates (B), and wild-type MNT,, GMTs (C) and seroconversion rates (D)
SARS-CoV-2wild-type PRNT, and MNT,, GMTs at baseline (day 0), 4 weeks after the first vaccination (day 28), 2 weeks after the second vaccination (day 42),

and 4 weeksafter the second vaccination (day 56) in the 3 pg with Algel-IMDG (n=190) and 6 jg (n=190) with Algel-IMDG groups are shown. Seroconversion rates
weredefined bythe proportion of post-vaccination titres that were at least four-fold higher than baseline. In A andC, the human convalescent sera panel included
specimens from participants with PCR-confirmed symptomatic and asymptomatic COVID-19 obtained at least 30-60 days after diagnosis (50 samples); dots represent
individual datapoints, the horizontal bars show the GMTs, andthe error bars represent the 95% CI. In Band D, the dots represent the seroconversion rates and error
bars represent 95% CIs. PRNT.,=plaque-reduction neutralisation test. GMT=geometric mean titre. MNT. =microneutralisation assay.

wrwnwrthelancet com/infection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0
Articles

 

 

Geometric meanttitre (95% CI)

Seroconversion rate* (95% C1)

 

3 pg with Algel-IMDG 6 ug with Algel-IMDG

3 ug with Algel-IMDG 6 ugwithAlge-MDG

 

Anti-spike glycoprotein IgG

 

was at cast four-fold higher than the baseline titre.

Dayo 500.0 (500.0-500.0) 500.0 (500.0-500-0)
Day28 25742 (2228929734) 22405(1942:4-258455)
Day42 115288 (100027-13287.8) 10040.0 (8667.0-11630:5)
Day56 104139 (9142-4-11862:2) 9541-6 (8245:9-11041.0)
Anti-receptor binding domain IgG

Dayo 500.0 (500.0-500.0) 500.0 (500.0-500-0)
Day28 19627 (1726222316) 2031.6 (1777323223)
Day42 55723 (48975, 63399) 49808 (4366-7, 56813)
Day56 58740 (5194, 66420) 5558.0 (4859.9, 63565)
Anti-nucleocapsid protein IgG

Dayo 500.0 (500.0-500.0) 500.0 (500.0-500-0)
Day28 27341(23751-31475) 2490-4(216177-28692)
Day42 89572 (7778:6-103143) 9211:2(79393-106868)
Day 56 8626.0(75286-9883.4) 87540 (7589-4-10097.4)

ELISA resultsat baseline (day 0), 4 weeks after the fist vaccination (day 28), 2 weeks afterthe second vaccination (day 42), and 4 weeks after the second vaccination (day 56)
forthe3 pg with Algel-MDG andthe 6 pg with Algel-IMDG groupsare shown. The number of participantsin the3 pg with Algel- IMDG group included in the immunogenicity
analysis was 190 on day, 189 on day 28, 187 on day 42, and 184 on day 56. The number of participants in the 6 pg with Algel-IMDG group included in the immunogenicity
analysis was 190 on day 0, 187 onday 28, 179onday 42, and 177 on day 56. The cutoff for detectable antibodies was 1/500. Endpointtitre dilution for days 28, 42, and 56
serasamples were established with baseline (day 0) and interpolated from the raw optical density data of the corresponding day O sample. The cutof (mean 43 SD) for day O
was caleulated considering the absorbance ofal sera dilutions (1/500 to 1/3200) tested, except the lowest dilution (1/50). “Defined as a post=accination IgG titre that

712% (641776)
984% (95:3-997)
984% (95:3-997)

65:0%(57:5-72:0)
983% (951-99:7)
966% (928-98.8)

587% (512-65:9)
94.0% (89:6, 970)
962% (92:3, 985)

582% (50.6-656)
932% (8855,965)
944% (89:9,97:3)

723% (652786)
973% (9328-991)
973% (953-1000)

712% (639777)
955% (913-98:0)
96.6% (928-988)

 

 

Table 2:SARS-CoV-2 IgG titres against the spike glycoprotein, receptor-binding domain, and nucleocapsid protein

 

 

day O (p<0-0001), as measured with the Luminex multiple
assay (appendix 3, p 12).

Solicited local adverse reactions after dose 1 (days 0-7)
were reported in nine (4:7% [95% CI 2:2-8-8]) of
190 participants in the 3 pg with Algel-IMDG group and
eight (42% [1-8-8-1)) of 190 participants in the 6 ng
with Algel.IMDG group (table 3). Solicited systemic
adverse reactions after dose 1 were reported in
nine (4:7% [2-2-8-8]) participants in the 3 pg with
Algel.IMDG group and 14 (7-4% [4.1-12.1]) participants
in the 6 pg with Algel-IMDG group. Solicited local
adverse reactions after dose 2 (days 28-35) were reported
in eight (4:2% [1-8-8-1)) participants in the 3 pg
with AlgelIMDG group and seven (3:7% [1:6-7-7])
participants in the 6 pg with Algel-IMDG group. Solicited
systemic adverse reactions after dose 2 were reported in
12 (6-3% [3-3-10-8]) participants in the 3 ug with
Algel.IMDG group and 11 (5-8% [3-0-10-1]) participants
in the 6 pg with Algel-IMDG group (table 3; unsolicited
adverse events are included in appendix 3, p 9).

No association between the dose of vaccine and the
number of adverse events was observed. After both
doses, the most common solicited adverse events were
injection site pain, reported in five (2-6% [95% CI
0-9-6-0]) of 190 participants in the 3 pg with Algel-
IMDG group and six (32% [1-2-6-8]) of 190 participants
in the 6 pg with Algel-IMDG group. Most adverse events
were mild (69 [89%] of 78 participants) and resolved
within 24 h of onset. At 7 days after the second dose,
solicited local and systemic adverse reactions were

reported in 38 (20-0% [14.7-26-5]) of 190 participants
in the 3 jg with Algel IMDG group and 40 (21-1%
[15:6-27-7]) of 190 participants in the 6 ug with
Algel-IMDG group.

In the phase 1 trial, 97 (97%) of 100 participants in the
3 ug with Algel-IMDG group, 95 (95%) of 100 participants
in the 6 pg with AlgelIMDG group, 92 (92%) of
100 participants in the 6 pg with Algel group, and 69 (92%)
of 75 participants in the Algel.only control group were
followed up to day 104 (3 months after the second dose).
GMTs (MNT, at day 104 were 39.9 (95% CI 32:0-49.9)
in the 3 pg with Algel-IMDG group, 69-5 (53.7-89.9) in
the 6 ug with Algel-IMDG group, 53-3 (40-1-71.0) in the
6 ug with Algel group, and 20-7 (14-5-29-5) in the
Algel-only control group (figure 44). Seroconversion
based on MNT, was reported in 72 (73:5% [95% CI
63-6-81.9) participants in the 3 ug with Algel-IMDG
group, 76 (81-1% [71.4-88-1]) participants in the 6 pg
with Algel-IMDG group, and 68 (73-1% [62-9-81-8))
participants in the 6 pg with Algel group (figure 4B).
GMT in the 6 ug with Alge-IMDG group were
significantly higher than the 3 pg with Algel-IMDG group
(appendix 3, p7). There were no significant differences in
GMT: between day 42 (2 weeks after the second dose) and
104 (3 months after the second dose) across the vaccine
groups (appendix 3, p 7). Post-hoc analyses of MNT, wild-
type neutralising antibody responses in phase 1 and
phase 2 participants in the 3 pg with Algel-IMDG and 6 pg
with AlgelIMDG groups, showed that GMTs were
significantly higher in phase 2 participants (at day 56)

wrunwthelancet.com/infection Published online March 8, 2021 https://doi.org/10-1016/51473-3099(21)00070-0
Articles

 

 

A
200º
º
150º
E º
E %º º
& 00 º
Ê
Ê
so

 

Presvaccination
; day 0)

3 ug with AlgelIMDG
(n=29; day 42)

6 ngwith AlgelMDG
(n=29 day 42)

 

Thacels

Thicels

 

Mean Tha and Th? cytokine levels (pg/ml)
& g
g ê

 

3 powith Algel-IMDG
(n=29;day 42)

6 ngwith AlgelMDG
(n=29; day 42)

Presvaccination
(n=10;day0)

 

 

 

Figure 3: Th4/Th2 cytokine ratios (A) and mean Thi and Th cytokine levels (B) atday 42 in phase 2 participants
In A and B, cell-mediated responses in blood samples from 58 participants (29 each from the 3 pg with Algel-IMDG
and 6 pg with Algel-IMDG groups), with proliferative responsesto vaccination at 2 weeks after the second dose
(day 42), and inten control participants (five pre-vaccination samples from each group) are shown. In A, the
Tha/Th2 tatiowas calculated by the sum of IENyplusIL-2 eytokine levels divided by the sum of IL-S plus IL-13
eytokine levels; horizontal bars showthe mean ratios and error bars show the 95% CIs. In B, mean cytokine

levels in the cel culture supenatants obtained from PBMCS stimulated with SARS-CoV-2 peptides are shown;

Tha (IFNy, IL-2, and TNFo) and Th2 (1-5, L-13, and 11-10) cytokines are represented by stacked bars. Th=T-helper.
IFNy=interferon-y. TNFo=tumour necrosis factor-o. IL=interteukin.

than in phase 1 participants (at day 42) at 4 weeks after
receiving the second dose (figure 4C). At 4 weeks after the
second dose of 6 pg with Algel-IMDG, the phase 1-2 GMT
(MNT) ratio was 1.9 (95% CI 1-5-2:6).

PBMCSs from a subset of phase 1 participants at one site
were collected to evaluate Tell memory responses at
day 104. Formulations with Algel-IMDG generated a

cell memory response, as shown by an increase in the
frequency of effector memory CD4'CDASRO T cells and
CD4'CD45RO*CD27' T cells compared with pre-vaccination
(day 0) samples (figure 4D, E). Samples from Algel-alone
recipients also showed a Tell memory response. We
also detected secreted IgG antibodies in the cell culture
supernatant by ELISA, and the antibody titres ranged from
neat (undiluted) to 1/64 (appendix 3 p 8). Further effector
function of activated and differentiated T cells was shown
by the levels of Thi cytokines (appendix 3 p 8).

In phase 2 participants, nine (33%) of 27 unsolicited
adverse events were reported to be related to the vaccine,
as judged by a masked investigator No significant
difference in the number of unsolicited adverse events
was observed between the groups (appendix 3 p 9).
Severity grading scales for adverse events and the
evaluation of adverse events related to the vaccine are
described in appendix 3 (pp 10-11). No symptomatic
SARS-CoV-2 infections were reported to the site
investigators (via follow-up telephone calls or site visits)
between days O and 118 (a scheduled visit) in phase 2
participants. However, illness visits were not scheduled
and no routine SARS-CoV-2 nucleic acid testing was
done. No serious adverse events were reported up to
day 118 in phase 2 participants.

No new solicited or unsolicited adverse events that
occurred between days 42 and 104 in phase 1 participants
were considered to be related to the vaccine by the
investigators. Additionally, no new serious adverse events
were reported. One case of symptomatic COVID-19 was
reported in the Algel-only control group. This participant
received the first dose on July 17, 2020, but was considered
to be lost to follow-up before the second dose was
administered. The participant visited the site on
Nov 27, 2020, with complaints of chronic anosmia and a
history of a positive SARS-CoV-2 rapid antigen test on
Aug 16, 2020.

Discussion

Im this report, we present interim findings from the
phase 2 clinical trial of BBV152, a whole-virion inactivated
SARS-CoV.2 vaccine. The overall participant retention
rates were 97% in the 3 pg with Algel IMDG group and
93% in the 6 pg with Algel-IMDG group. Neutralising
antibody titres were similar to a panel of convalescent
serum samples. All elicited cytokine responses to
BBV152 were biased to Th1 cells. The vaccine was well
tolerated in both groups with no serious adverse events.
Iong-term follow-up of phase 1 trial participants showed
that neutralising antibody titres persisted, and T-cell
memory responses were more pronounced in the 6 pg
with Algel.IMDG group compared with pre-vaccination
samples.

The most common adverse event in the phase 2 trial
was pain at the injection site, followed by headache,
fatigue, and fever No severe or life-threatening (ie,
grade 4 and 5) solicited adverse events were reported. No

8 wrwnwrthelancet cominfection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0
Articles

 

significant differences in safety were observed between
the two groups. However, the study was not powered
to compare such differences. After either dose, the
combined incidence of local and systemic adverse events
in this study is lower than that of other SARS-CoV-2
vaccine platform candidates,* and similar to that of
other inactivated SARS-CoV-2 vaccine candidates.”'s
However, other vaccine studies have enrolled different
populations and have employed varying approaches to
measure adverse events.

BBVI52 induced antibody binding (to spike glycoprotein
and nucleocapsid protein epitopes) and neutralising
antibody responses that were similar to those induced by
other SARS-CoV-2 inactivated vaccine candidates.”*
Studies have reported the variable persistence of humoral
and cell-mediated responses acquired from natural
infection” In the phase 1 trial of BBV152, we evaluated
an accelerated schedule, in which the two doses were
administered 2 weeks apart. At day 104 (3 months after
the second dose), we observed detectable humoral
and cell-mediated responses to SARS-CoV-2. Serum
neutralising antibodies were detected in all phase 1
participants at day 104, and the levels of these antibodies
were similar to the panel of convalescent serum samples.
These findings are in accordance with those of the
mRNA-1273 (Moderna) vaccine, which has received
emergency use authorisation >” A sizeable T-cell memory
population was also observed at this timepoint. A routine
schedule, in which the two doses are administered 4 weeks
apart, was evaluated in the phase 2 trial of 3 ug with
Algel-IMDG and 6 ng with Alge-IMDG. We found
that immune responses (MNT, were significantly higher
with the routine schedule (phase 2) than with the
accelerated schedule (phase 1), which is consistent with
other reports.

BBV152 is a wholevirion inactivated SARS-CoV-2
vaccine adjuvanted with AlgelIMDG. An imidazo-
quinoline molecule (IMDG), which is a TLR7/8 agonist,
has been used to augment cell-mediated responses.”*
Both 3 pg with Algel-IMDG and 6 pg with Algel. IMDG
formulations induced responses that were biased to a
Th1 phenotype, with IgG1/IgG4 ratios greater than 1. The
ratio of Thl/Th? cytokines was clearly biased to a Th1
response, with increased IFNy generation.

In the present study, BBV152 induced Tcell memory
responses, which was shown by an increased frequency
of antigen-specific CD4 T cells expressing the memory
phenotype marker CD4SRO*. The increase in the
CD4'CDA4SRO*CD27' T-cell population also indicates the
activation of the co-stimulatory marker CD27, and
confirms the antigen recall memory Tell response.”
Further, the effector function of these cells was supported
by the Th1 cytokine secretion observed in ex vivo
responses after stimulation of PBMCSs for 3 days.“ These
results further corroborate our phase 1 results showing
an increased frequency of CD4 T cells producing IFNy
in participants who received Algel-IMDG-containing

 

 

 

 

 

Doses Dose2
39 with Algel-IMDG 6 pg with Algel-IMDG 3 pg with Alge-IMDG 6 pg with Algel-IMDG
(n=190) (n=190) (n=190) (n=190)
Local reactions
Painatinjectionsite
Mild 56%) 6(3%) 7(4%) 40%)
Moderate 1(1%) o o 1(1%)
Redness at injectionsite
Mid 1(1%) 1(1%) o o
Moderate O o o o
ttching
Mid 1(1%) 1(1%) o 2(1%)
Moderate O o o o
Stifíness in upper arm
Mid 1(1%) o o o
Moderate O o o o
Weakness in injection arm
Mid o o 1(1%) o
Moderate O o o o
Systemic reactions
Bodyache
Mid o 2 (134) 1(1%) 2(1%)
Moderate O 1(1%) o o
Fever
Mild 2(1%) 5(3%) 5 (3%) 4(2%)
Moderate 1(1%) 3(2%) o o
Headache
Mid 2(1%) 1(1%) 1(1%) 2(1%)
Moderate O o o 1(1%)
Malaise
Mid 4(2%) 1(1%) 3(2%) o
Moderate O o o o
Weakness
Mid o o 1(1%) 2(1%)
Moderate O 1(1%) o o
Rashes
Mid o o 1(1%) o
Moderate O o o
Data aren (3%). The safety analysis set includes all participants who received one dose of the vaccine (n=380),
The number of participants who hadasolicited adverse event after receiving dose (days 0-7) and dose 2
(days 28-35) isshown.
Table 3: Mild and moderate solicited adverse events inthe safety analysis set

 

formulations. Samples from participants in the Algel-
only control group also showed a Tcell memory response,
which corroborates a recent study published in 2020
indicating the presence of cross-reactive Tcells in
individuals unexposed to SARS-CoV-2” Additionally,
two participants in the Algel-only group showed high
neutralising antibody titres and IL-6 levels at day 104 of
the phase 1 study. In the phase 1 trial, the ability to secrete
anti-spike glycoprotein IgG antibodies at day 104 further
shows the long-lasting T-cell memory response generated
by BBVI5S2. Similar findings supporting long-term
immunity were reported by Sekine and colleagues' in

wrunwthelancet.com/infection Published online March 8, 2021 https://doi.org/10-1016/51473-3099(21)00070-0

 
Articles

 

 

 

 

   

 

     

 

 

 

   

 

A B

g o 10

õ e pr 9199 | pes 912%

É os Ea gras

Ê E ul [rs a “

É e 1 1 EÉ

E 1 Vir RR! | 25 60

ER ! | Eé

& Ei

a 34
& . . . . o from 183%
suor z 101%

Ee & I I ox Fo
SDS BS E fd Odd Sao fuma PLS MD A
[LS LOS Ls serum LS LIL 4

3ugwith 6 ug with 6 pg with Control (n=41) 3ugwith Gugwith Gugwith Control
AlgeMDG  Algel-IMDG Algel (n=73) AlgeHMDG  AlgebMDG Algel (n=74)
(ne99) (n=99) (n=93) (n=99) (n=99) (n=s3)
Timesince vaccination (days) Timesince vaccination (days)
c
p=00013  p=00017

E e

ê

ER) : otimo EN

& Ê e =

É ao E EE

ê EEE EE es

g se = 5

7 07 cê Em E

ê

z Í

É

3 pgwith 6ugwith 3 pg with 6 ug with

AIgeMMDG  AIgeHMDG  AlgelMDG  AlgehMDG
(n=97) (n=96) (n=184) (n=177)

[a Los
Phase trial Phase 2 trial
4weeksaftertheseconddose — 4 weeks after the second dose
(day42) (day 56)
D 0094 E p=0:037
100 so
. £

E z

ç» Z 6 e

= o º Ê

É 6 b º

ê 8 0) o 1

É a 5 .

ê de & —p-

2 oto
E º 8 : +
8 & .
o o+
3ugwith " Gpgwith " Gugwith ” Control Pre. 3powith  Gugwith  Gugwith Control Pre.
Algel-IMDG AlgeHIMDG Algo! (n=6; — vaccination AlgelAMDG Algel-IMDG  Algel (n=6; — vaceination
) (n=12; (n=15 — day104) (n=5; (n=13; (net2; (n=15  day104) (n=5;
day104) — day104) — day104) day0) day104)  day104) — day104) dayo)

 

 

 

Figure 4:SARS-CoV-2 wild-type MNT,, GMTs (A) and seroconversion rates (B) in phase 1 participants, SARS-CoV-2 wild-type MNT, GMTsin phase 1 and phase 2.
participantsat 4 weeks after thesecond vaccination (C), andthe proportion of CD4CD4SRO! (D) and CD4'CD4SRO'CD27' (E) Tcellsat day 104 in phase participants
Inthe phase 1 trial the dosing schedulewas day O for the first doseof the vaccine and day 14 for the second dose. In the phase 2 trial the dosing schedule was day O
forthe frstdose ofthe vaccine and day 28 for the second dose. In A, results at baseline (day 0), 2weeks after the second vaccination (day 28), 4 weeks after the
second vaccination (day 42), and 3 months afterthe second vaccination (day 104) forthe 3 pg and 6 pg with Algel-IMDG groups, the 6 jg with Algel group, and the
Algel-onty control group in the phase 1 trial are shown. The human convalescent serum panel included specimens from participants with PCR-confirmed
symptomatic and asymptomatic COVID-19 obtained at least at least 30 days after diagnosis (41 samples). In B, seroconversion rates were defined bythe proportion
of post-vaccination titres that were at least four-fold higherthan baseline. In D and E, the frequencies of antigen-specific T-cell memory responses at 3 months after
the second dose (day 104) in ll groups from the phase 1 trialare shown; dots are individual datapoints, and horizontal bars are medians with error bars for IQRs.
GMT-geometric meantitre. MNT50=microneutralisation assay

wrwnwrthelancet com/infection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0
Articles

 

convalescent patients who had previously had COVID-19.
Memory B-cell responses from BBVI52 are currently
being evaluated. Thus far, cell-mediated responses after
receipt of other SARS-CoV-2 inactivated vaccine
candidates have been minimally reported.

This study was done at a time when the number of daily
diagnosed COVID-19 cases was increasing rapidly. In the
Algel.only control group (phase 1 trial), seroconversion
was reported in six (8:2% [95% CI 1.9-14.5]) of
73 participants at day 28, 13 (18:8% [10-8-30-4])
of 69 participants at day 42, and 23 (33-39 [22-7-45-8]) of
69 participants at day 104. These results suggest that both
phase 1 and 2 trials are being done during a period of
high ongoing SARS-CoV.2 circulation. Since substantial
SARS-CoV.2 PCR positivity was observed in the general
population during the study period, in the event of
natural exposure to SARS-CoV-2, it is possible that post-
vaccination antibody titres in vaccinated participants
could be slightly inflated. No cases of COVID-19 were
reported in either group of the phase 2 trial, whereas one
case of symptomatic COVID-19 was reported in the Algel-
only control group of the phase 1 trial. However, illness
visits were not scheduled, and routine SARS-CoV-2
nucleic acid testing was not done.

The results reported in this study do not permit efficacy
assessments. The evaluation of safety outcomes requires
extensive phase 3 clinical trials. We were unable to assess
other immune responses (ie, binding antibody and cell-
mediated responses) in convalescent serum samples due
to the low quantity. Furthermore, no additional data on the
age of the participant or the severity of disease from
symptomatic individuals were obtained. Comparisons
between phase 1 and 2 trials were not done in a randomised
set of participants, and no adjustments on baseline
parameters were made. Conclusions are to be considered
as post-hoc analyses. Even though direct comparisons
between the phase 1 and 2 trials cannot be made, the
reactogenicity assessments reported in this study were
substantially better in the phase 2 trial than the phase 1
trial and other trials with a placebo group. Additionally,
the proportion of participants reporting adverse events in
the phase 2 trial were lower than in the phase 1 trial. The
study coordinators had verified all source documents to
ensure that no data were missing or that errors had
occurred. Further corroboration with phase 3 safety results
is required. This study enrolled a small number of
participants aged 12-18 years and 55-65 years. Follow-on
studies are required to establish immunogenicity in
children and in those aged 65 years and older. Withdrawals
in the 6 pg with Algel.IMDG group were higher than the
3 pg with Algel-IMDG group but were not associated with
adverse events. Lastly, this study population lacked ethnic,
racial, and gender diversity, further underscoring the
importance of evaluating BBVI52 in other populations.
Longitudinal follow-up of additional post-vaccination visits
(at months 3, 6, and 12) is important for understanding the
durability of immune responses, and is ongoing.

This study has several strengths. To ensure generalisability
of the results, this study included participants from diverse
geographic locations, enrolling 380 participants across
nine hospitals across nine states in India. Based on
follow-up data from the phase 1 trial, despite a marginal
expected decline in neutralising antibody titres at day 104,
BBVI52 has shown the potential to provide durable
humoral and cellmediated immune responses. With
several reports questioning the efficacy of SARS-CoV.2
vaccines against antigenically divergent strains, we
previously reported neutralising antibody responses in
homologous and heterologous strain assessments. Day 56
serum samples from 38 participants in the 6 pg
with AlgeLIMDG group of the phase 2 trial effectively
neutralised à SAR$-CoV-2 variant of concern (lineage
B.LL7 or 20B/501Y. VI)” On the basis of superior cell.
mediated responses in the phase 1 trial, the 6 ug with
AlgelIMDG formulation was selected for the phase 3
efficacy trial, which involves 25800 volunteers and is
currently underway (NCTO4641481). BBVI52 (COVAXIN)
has received emergency use authorisation in India.

Contributors

AI authors met the criteria for authorship set forth by the International
Committee for Medical Editors. HJ, DD, DR, UP, BG, PY, and GS did the
immunogenicity experiments. The contract research organisation

(Sclin Soft Technologies) was responsible for analysing the data and
gencrating the report. KMV, SRe, VS, SPr, and RE contributed to the
manuscript preparation. SRe was the study coordinator and helped
immensely with designing the protocol and generating the interim report.
PA, SPr, NG, and BB from the Indian Council of Medical Research
contributed to the writing of this paper. KE was responsible for overall
supervision of the project and revicw of the final paper. AU principal
investigators (PR, SV, SKR, CS, SVR, CSG, JSK, SM, VR, and RG) were
involved in the scientific review of this paper. All authors and the contract
rescarch organisation had full access to masked data in the study and all
authors had final responsibility for the decision to submit for publication.

Declaration of interests

RE, HJ, BG, KMV, SRe, DD, DR, UP, SPr, and VS are employees of
Bharat Biotech, with no stock options or incentives. KE is the Chairman
and Managing Director of Bharat Biotech. PY, GS, PA, NG, SPa, and BB
are employees of the Indian Council of Medical Research. PR, SV, SKR,
CS, SVR, CSG, JSK, SM, VR, and RG were principal investigators
representing the study sites.

Data sharing
The study protocol is provided in appendix 2. De-identificd, individual
participant data will be made available when the trial is complete, upon
requests directed to the corresponding author; after the approval of a
proposal, data can be shared through a secure online platform.

Acknowledgments
This work was supported and funded by Bharat Biotech International.
We sincerely thank the principal and co-principal investigators, study
coordinators, and health-care workers viho wiere involved in this study.
We express our gratitude to Sivasankar Baalasubramaniam from Indoor
Biotechnologies (Bangalore), viho assisted with cell-mediated response
analyses. A special thanks to Arjun Dang and Leena Chatterjee of

Dr Dangs Lab (New Delhi, India), vihich was the central laboratory for
clinical laboratory testing. We appreciate the guidance from William
Blackwielder on sample size estimation and statistical analysis planning.
Shashi Kanth Muni, Sapan Kumar Behera, Jagadish Kumar, Vinay Aileni,
Sandya Rani, Aparna Bathula, Amaravani Pittala of Bharat Biotech
participated in protocol design and clinical trial monitoring. We thank
Rakeshchandra Meka and Ramulu Chintala, and Spandana Sure of
Bharat Biotech for cellmediated assessments. This vaccine candidate
could not have been developed without the efforts of Bharat Biotech's

wntnurthelancet.com/infection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0

u
Articles

 

manufacturing, quality control teams. ALI authors would like to express
their gratitude to all frontline healthr-care workers during this pandemic.

References

1

WHO. Draft landscape and tracker of COVID-19 candidate vaccines.
Jan 21, 2021. https: //wwweho int/publications/m item /draft-
landscape-of-covid-19-candidate-vaccines (accessed Jan 21, 2021).
Baden LR, El Sahly HM, Essink B, ct al. Efficacy and safety of the
mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020; 384: 403-16.
Polack EP, Thomas SJ, Kitchin N, etal. Safety and efficacy of the
BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15.
Voysey M, Clemens SAC, Madhi SA, etal. Safety and efficacy of the
ChadOx1 nCoV-19 vaccine (AZ D1222) against SARS-CoV-2:
an interim analysis of four randomised controlled trials in Brazil,
South Africa, and the UK. Lancet 2021; 397: 99-111.

Xia S, Zhang Y, Wang Y, etal. Safety and immunogenicity of an
inactivated SARS-CoW-2 vaccine, BBIBP-CorV: a randomised,
double-blind, placebo-controlled, phase 1/2 trial.

Lancet Infect Dis 2021; 21: 39-51.

Ganneru B, Jogdand H, Dharam VK, tal. Evaluation of safety and
immunogenicity of an adjuvanted, TH-1 skewed, whole virion
inactivated SARS-CoV-2 vaccine - BBVIS2. bioRxiv 2020; published
online Sept 12. https://doi.org/10.1101/2020.09.09.285445 (preprint).
Yaday P, Ella R, Kumar 5, etal. Remarkable immunogenicity and
protective efficacy of BBVIS2, an inactivated SARS-CoV-2 vaccine in
rhesus macaques. Res Square 2020; published online Sept 10.
https://doi.org/10-21203/1s.3.15-65715 Vl (preprint).

Mohandas S, Yadav PD, Shete-Aich A, etal. Immunogenicity and
protective efficacy of BBVI52, viole virion inactivated SARS-CoV-2
vaccine candidates in the Syrian hamster model. iScience 20
24: 102054.

Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity
ofan inactivated SARS-CoY:2 vaccine, BBV1S2: a double-blind,
randomised, phase 1 trial. Lancet Infect Dis 2021; published online
Jan 21. https://doi.org/10.1016/S1473-3099(20)30942:7

Sarkale P, Patil 5, Yadav P, etal. First isolation of SARS-CoV-2 from
clinical samples in India. Indian J Med Res 2020; 151: 244-S0.

Zeng W, Liu G, Ma H, etal. Biochemical characterization of
SARS-CoV-2 nudleocapsid protein. Biochem Biophys Res Commun
2020; 527: 618-23.

Zhang Y, XiH, Juhas M. Biosensing detection ofthe SARS-CoV-2
D614G mutation. Trends Genet 2020; published online Dec 24.
https://doi.org/10.1016/].tig.2020.12.004.

Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/IT study of
COVID-19 RNA vaccine BNT162b1 in adults. Nature 2024
586: 589-93.

Jackson LA, Anderson E], Rouphael NG, etal. An mRNA vaccine
against SARS-CoV-2 - preliminary report. N Engl J Med 2020;

383: 1920-31.

Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of
the ChAdOxi nCoV-19 vaccine against SARS-CoV-2: a preliminary
report ofa phase 1/2, single-blind, randomised controlled trial.
Lancet 2020; 396: 467-78.

 

  

 

 

 

 

20

a

2

23

u

25

26

2”

29

Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity
of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2024
383: 2439-50.

Zhang Y-], Zeng G, Pan H-X, etal. Immunogenicity and safety of a
SARS-CoY.2 inactivated vaccine in healthy adults aged 18-59 years:
report of the randomized, double-blind, and placebo-controlled
phase 2 clinical trial. medRxiv 2020; published online Aug 10.
https://doiorg/10.1101/2020.0731.20161216 (preprint).

Xia S, Duan K, Zhang Y, etal. Effect of an inactivated vaccine against
SARS-CoV-2 on safety and immunogenicity outcome: i
analysis of 2 randomized clinical trials. JAMA 2020; 324:
Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune
response to SARS-CoV-2 in Iceland. N Engl J Med 2020;

383: 1724034.

Dan JM, Mateus ], Kato Y, et al. Immunological memory to
SARS-CoY.2 assessed for greater than six months after infection.
bioRxiv 2020; published online Dec 18. https://doi.
org/10.1101/2020.11.15.383323 (preprint.

Widge AT, Rouphacl NG, Jackson LA, etal. Durability of responses
after SARS-CoV-2 mRNA-1273 vaccination. N Engl Med 2020;
384:80-82.

Zhang Y, Zeng G, Pan H, etal. Safety, tolerability, and
immunogenicity ofan inactivated SARS-CoV-2 vaccine in healthy
adults aged 18-59 years: a randomised, double-blind, placebo-
controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21: 181-92.
Philbin V], Dowling DJ, Gallington LC, etal. Imidazoquinoline
TolHike receptor 8 agonists activate human newborn monocytes
and dendritic cells through adenosine-refractory and caspase-1-
dependent pathways. J Allergy Clin Immunol 2012; 130: 195-204.09.
Shulda NM, Salunke DB, Balakrishna R, Mutz CA, Malladi SS,
David SA. Potent adjuvanticity ofa pure TLR7-agonistic
imidazoquinoline dendrimer. PLoS One 2012; 7: 043612.

Li CK£, Wu H, Yan H, etal. T cell responses to whole SARS
coronavirus in humans. J Immunol 2008; 181: 5490-500.

Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The viho's
who of T-cell differentiation: human memory T-cell subsets.

Eur J Immunol 2013; 43: 2797-809.

Mateus ], Grifoni A, Tarke A, et al. Selective and cross-reactive
SARS-CoV.2 T cell epitopes in unexposed humans. Science 2020;
370:89-94,

Sekine T, Perez-Potti A, Rivera-Ballesteros O, etal. Robust T cell
immunity in convalescent individuals with asymptomatic or mild
COVID-19. Cell 2020; 183: 158-68.e14.

Sapkal GN, Yadav PD, Ella R, ct al. Neutralization of UK-variant
VUI-202012/01 vith COVAXIN vaccinated human serum.

bioRxiv 2021; published online Jan 26. https://doi.
org/10.1101/2021.01.26.426986 (proprint).

  

 

 

 

wrwnwrthelancet com/infection Published online March 8, 2021 https://doi.org/10.1016/51473-3099(21)00070-0
Supplementary Appendix to Manuscript Entitled

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine,
BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of

immune responses from a phase 1 follow-up report

Table of Contents

 

Supplemental methods...

 

Table S1: Ethic Committees from All Participating Trial Sites with Reference Numbers: .

 

Table S2: SARS-CoV-2 Neutralising Antibody Responses and Cell-mediated responses......

Table S3: PRNTso Neutralising antibody titres across age groups and gender on day 56 (four weeks after the
second dose)...
Table S4: Phase 1 Long term Follow-up immun ogenicity analysis. ....

 

 

Table S5: Secreted antibodies upon PBIMC stimulation from samples collected on day 104 (three months after
the second dose) in the phase 1 trial. 9

 

Table S6: Further effector function of activated and differentiated T cells from PBMICs from the Phase 1 study
(at day 104, three months after the second dose).

 

Table S7: Solicited Adverse Events After Two Doses in the Safety Set ....

 

 

Table S8: Number of unsolicited, non-serious, adverse events classified by MedDRA” System Organ Class,
severity, and investigator-assigned relationship to study vaccine/control.
Table S9: Grading Scales for Local and Systemic Adverse Events. .

 

Figure S1: Cytokine profile measured from culture supernatant upon stimulation of PBMCSs with antigen ... 15

Figure S2: comparison between PRNTso assays at the two laboratories (Bharat Biotech and National Institute
of Virology). .

 

FigureS3: Solicited Adverse Events After Two Doses in the Safety Set ....

 

This supplementary material has been provided by the authors to give readers additional information
about their work.
Supplemental methods

i. RT-PCR (conducted at Dr. Dangs Lab, New Delhi) at Screening
TRUPCR SARS-CoV-2 RI qPCR (V 5.2) is a single tube, in vitro nucleic acid amplification test for the qualitative
detection of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)specific RNA from respiratory
specimens(nasopharyngeal or oropharyngeal aspirates,washes or swabs, bronchoalveolar lavage, sputum and
tracheal aspirates)using Real-time PCR. The human RNasePgene serves as an endogenous internal positive
control for human nucleic acid is also included in this kit.

E gene: For the detection of SarbecovirusRdRp gene and N genedual targets for the detection of SARS-CoV-2

RNase P gene:endogenous internal control, which qualifies the sample for testing and is essential for testing Viral
RNA in host organism. According to the Centre for Daises Control and prevention, Respiratory Viruses Branch,
Division of Viral Diseases, all clinical samples should be tested for human RNAse P gene to assess specimen
quality for RT PCR for detection of 2019-Novel Coronavirus

  

The assay runs for 38 cycles;however for any interpretation,threshold cut off cycle Ctis 35.
Interpretation is as follows:
Amplification Signals In

a) RNAseP+/-, E Gene +, RdRp&N gene + : SARS-CoV-2 POSITIVE

b) RNAseP+/-, E Gene -, RARp&N gene + : SARS-CoV-2 POSITIVE

c) RNAseP+/-, E Gene +, RdRp&N gene - : SARBECOVIRUS POSITIVE
d) RNAseP+,E Gene -, RdRp&N gene - : NEGATIVE

e) RNAseP-,E Gene -, RdRp&N gene - : INVALID

100 percent concordance of results for submitted samples with ICMR designated QC Lab(AIMS for Dr. Dangs
Lab) ii. CLIA (conducted at Dr. Dangs Lab, New Delhi) at Screening

The liaison SARS-CoV-2 IgG assay performed on the Liaison XL analyzer is an indirect chemiluminescence
Immunoassay (CLIA) for the Quantitative determination of anti-S1 and anti- S2 antibodies to SARS-CoV-2 in
human serum or plasma.The sensitivity of the above assay is 97.4 percent for 15 days post-diagnosis and
specificity 98.9 percent for Laboratory routine testing. Testing of assay -specific calibrators allows the detected
Relative light unit (RLUJto adjust the assigned master curve.The analyzer automatically calculates SARS-CoV-
S1/S2 IgG antibody concentrations as arbitrary units (AU/mL)and grades the results.

Results are interpreted as follows:

Less than 12 AU/mL: NEGATIVE (A negative result may indicate the absence or a very low level of IgG
antibodies to the Pathogen. The test could score negative in infected patients during the incubation period and
during the early stages of infection>or equal to 12 and less than 15 AU/mL: Equivocal (Retest in duplicate.
Samples with 2 out of 3 results more than or equal to 15 or less than 12 should be reported as positive or negative,
respectively.A second sample should be collected and tested no less than one to two weeks later if the results are
repeatedly equivocal)>or equal to 15: Positive (A positive result generally indicates exposure of the subject to the
pathogen) iii. Enzyme-linked immunosorbent assay (ELISA) (conducted at Bharat Biotech)

 

ELISA tests were performed as per standard protocols. Briefly, Microtiter plates were coated with SARS-CoV-2
specific antigens (Whole inactivated SARS CoV-2 antigen, spike (S1) (Syngene, Bangalore, India, Batch Not
PRB026913/Receptor Binding Domain (RBD), Syngene, Bangalore, India, Batch NoHPRB025485/ nucleocapsid
(N), Syngene, Bangalore, India, Batch Noé PRB025627 at a concentration of 1ug/ml, 100u]/well in PBS pH 7.4).
After overnight incubation, wells were blocked and added serially diluted sera. After incubation, wells were added
with Goat anti-Human IgG HRP conjugate (Sigma-Aldrich, Cat! A8667, dilution 1:5000) and incubated for 1hr
atRT. Tetramethyl benzidine used as a substrate and measured absorbance at 450/630nm. Threshold value (Mean
+ 3SD) was established by taking the absorbance of Day O sera samples and antigen-specific endpoint titers were
determined for Days 28, 42, and 56 sera samples. The reciprocal antibody dilution, at which absorbance is above
the threshold, was taken as antigen-specific antibody endpoint titers. Since, Bharat Biotech is a vaccine
manufacturing company, all serological assays such as ELISA/ PRNTS5O were routinely performed for various
vaccines before releasing every batch into the market. All methods were validated with respect to sensitivity and
specificity. In the case of SARS-CoV-2 vaccine development, all these methods were used, while maintaining
proper negative and positive controls.

Known unvaccinated and uninfected individual serum was used as a negative control. Simultaneously, ELISA
blank (without coating antigen) was also maintained as a negative control. Apart from this, cut off (Mean+3SD)

2
was drawn from the absorbance obtained at various dilutions (1:1000 to 1:52000) of sera collected on day O (before
vaccination), who is found negative for RT-PCR and Serology test.

iv. Plaque Reduction Neutralisation Test (PRNT 50) (conducted at Bharat Biotech)

The Plaque reduction neutralisation test was performed in a biosafety level 3 facility. To perform PRNTso, Vero
CCL-81 cell suspension (1.0 x 10º /mLAvell)was added in duplicates in 24-well tissue culture plates and cultured
in a CO» incubator at 37ºC for 16-24 hrs. Serum samples from all enrolled participants were inactivated by keeping
in a 56ºC-water bath for 30 min. Serial dilutions (4 fold) of serum samples were mixed with the virus, which can
form 50 plaque-forming units and then incubated for 1 hat 37ºC. The virus-serum mixtures were added onto the
preformed Vero CCL-81 cell monolayers and incubated 1 hat37ºCin a 5% CO» incubator. The number of plaques
was counted, and the Neutralizing antibody titer was determined based on the 50% reduction in the number of
plaque count, which was further analyzed using 50% ProbitAnalysis(10.4103/ijmr. MR 2382 20). Inoculation
dose used was 100 CCIDso in 50 microlitre.

v. Microneutralisation assay (MNT) (conducted at Bharat Biotech)

The serum collected from all enrolled participants were inactivated at 56ºC in a water bath for 30 min. Serum was
successively diluted with start dilution 1:8 to the required concentration by a 2-fold series, and an equal volume
of challenge virus solution containing 100 CCIDsoviruses was added. After neutralisation in a 37ºC incubator for
two hours, a 1.0x 10º /mL cell suspension was added to the wells (0.1 mL/well) and cultured in a CO; incubator
at 37ºC for 3-5 days. The Karber method (Ramakrishnan, 2016)by observing the CPE was used to calculate the
neutralisation endpoint (MNT 59) (convert the serum dilution to logarithm), which means that the dilution of serum
that can protect 50% of cells from infection by challenge with 100 CCIDso virus. Inoculation dose used was 100
PFU in 100 microlitre

During each assay, known antibody titre from animal sera is used as a positive control. Pre-immune sera used as
a negative control. T-cell Memory Response (Phase 1 PBMCSs collected on Day 104):

PBMCSs were cultured in 24 well plate with 0.5x10º cells/ml/well and stimulated with Whole virion Inactivated
SARS CoV2 antigen (1.2 ug/ml) for 6days by keeping the plate at 37ºC in 5% COZ incubator. Cells stimulated
with phorbol 12-myristate 13-acetate (PMA)(25 ng/ml, Sigma) and Ionomycin (1 ug/ml, Sigma) were used as
positive control and unstimulated cells and PBMCSs collected on Day O stimulated with inactivated SARS CoV 2
antigen were used as negative control. On Day 6, cells were harvested and stained with human specific
fluorochrome conjugated B & T cell surface marker antibodies for 30 minutes at 4ºC. The list of fluorochrome
conjugated cell surface marker antibodies procured from BD Biosciences, USA are as follows, Mouse anti- human
CD3 BV450 (clone UCHT1, Cat560365), Mouse anti- human CD4 PE-Cy 7 (clone! SK3, Cat& 348789), Mouse
anti- human CD8 APC-H7 (clone SK1, Catf 560179), Mouse anti- human CD19 PE (clone SJ25C1, Catf
340364) and Mouse anti- human CD27 APC (clonet M-T271, Cat 558664). Mouse anti- human CD4SRO PerCp
Cy5.5 (clone UCHLI1, Cat& 130-113-552) was procured from Miltenyi Biotec, Germany). Cells were again
washed twice with PBS and resuspended in 500ul FACS buffer (BD Biosciences). All samples were acquired
using BD FACSVerse (BD Biosciences, CA, USA) and data was analyzed using FlowJo software (Tree Star). To
assess the T cell memory responses, gating was done from CD3*T cell population and to CD4* T cell population
and to assess the B cell memory response, gating was done on CD3" Iymphocyte population. Additionally, on Day
3, 50ul cell culture supernatant was tested to determine Th1/Th2/Th17 cytokine profile using human CBA kit
(Cytokine Bead Array Kit, Cat 560484, BD Biosciences, USA). Further, Cell culture supernatant collected on
Day 6 was also tested for secreted IgG antibodies by ELISA.

vi. T-cell Memory Response (Phase 1 PBMCSs collected on Day 104):

PBMCSs were cultured in 24 well plate with 0.5x10º cells/ml/well and stimulated with Whole virion Inactivated
SARS CoV2 antigen (1.2 ug/ml) for 6days by keeping the plate at 37ºC in 5% COZ incubator. Cells stimulated
with PMA (25 ng/ml, Sigma) and Ionomycin (1 ug/ml, Sigma) were used as positive control and unstimulated
cells and PBMCSs collected on Day O stimulated with inactivated antigen were used as negative control. On Day
6, cells were harvested and stained with human specific fluorochrome conjugated B & T cell surface markers for
30 minutes at 4ºC. The list of fluorochrome conjugated cell surface marker antibodies procured from BD
Biosciences, USA are as follows, Mouse anti- human CD3 BV450 (cloneft UCHTI, Catt560365), Mouse anti-
human CD4 PE-Cy 7 (clone SK3, Cat 348789), Mouse anti- human CD8 APC-H7 (clonek SK1, Catf 560179),
Mouse anti- human CD19 PE (clonef SJ25C1, Cati 340364) and Mouse anti- human CD27 APC (cloneft MT271,
Catf 558664). Mouse anti- human CD4SRO PerCp Cy5.5 (clonef UCHL1, Cat 130-113-552) was procured from
MiltenyiBiotec, Germany). Cells were again washed twice with PBS and resuspended in 500ul
FACS buffer (BD Biosciences). All samples were acquired using BD FACSVerse (BD Biosciences, CA, USA)
and data was analyzed using FlowJo software (Tree Star). To assess the T cell memory responses, gating was
done from CD3*T cell population and to CD4* T cell population and to assess the B cell memory response, gating
was done on CD3: Iymphocyte population. Additionally, on Day 3, 50ul cell culture supernatant was tested to
determine Th1/Th2/Th17 cytokine profile using human CBA kit (Cytokine Bead Array Kit, Caté 560484, BD
Biosciences, USA). Further, Cell culture supernatant collected on Day 6 was also tested for secreted IgG
antibodies by ELISA.

vii. SARS-CoV2 spike (S1) Antibody (IgG1/1gG4) Isotyping:

Thl-dependent IgG1 vs. Th2 -dependent IgG4 antibody subclasses were determined by ELISA from sera collected
from all vaccinated groups as described earlier. Briefly, 96 well microtiter plates were coated with spike (S1)
protein (Cat: SYNG-PRB026913, Make: Syngene), at a concentration of Iug/ml, in PBS pH 7.4) and blocked
with 1% BSA in PBS, pH 7.4. Two fold serially diluted (1:50 to 1:204800) individual sera were added and
incubated for 2hrs at 37 C fóllowed by the addition of mouse anti-human IgG1 (Cat No: 409904, Make: Biolegend)
or IgG4 (Cat No: 411202, Make: Biolegend) antibodies at a concentration of 25ng/well. After incubation of the
plate for lhr at RT, wells were again washed, and added Anti Mouse IgG HRP Conjugate (Cat No: A4416, Make:
Sigma Aldrich) at a dilution of 1:2500. Later, 3,3',5,5'-tetramethylbenzidine (TMB) solution

(Cat No: AR1002, make: deNovo Biolabs) was added as a substrate to develop color. Absorbance was read at
450nm. Cut off was determined as 1:50 dilution, by calculating threshold (Mean+3SD) of absorbance obtained at
remaining all dilutions of known negative control (unvaccinated and uninfected sera). Thl:Th2 index was
calculated by taking ratios of end point antibody titer (sera dilution at which absorbance was above the cut off) of
IgG1 & IgG4. Thl/Th2 Immunophenotyping (conducted at Indoor Biotechnologies, Bangalore):

viii. — Luminex Based Multiplex Assay

PBMCSs from the study subject were thawed as per the SOP and washed with RPMI containing 10% FBS twice.
Subsequently cells were washed twice with AIM-V Media with 10% Human AB Serum and resuspended at a
density of 6x 10º cells per ml. 300,000 cells (50u1) were aliquoted to individual wells in a U bottom tissue culture
plate (Nunclon Delta-Treated cat no: 163320 ) and added with 50ul of plain media (for unstimulated condition)
or 50ul of COVID peptide cocktail (peptides from S,N & M protein at 2ug/mI(for each peptide))(stimulated
condition) or anti-CD3 antibody (Positive Control). Peptides and anti-CD3 were diluted in AIM-V media with
10% AB serum. Each condition was performed in duplicates. The cells were incubated in CO» incubator at 37ºC
for 48 hours.

At the end of 48 hours of incubation the culture supernatant from the wells were collected and analyzed for
cytokine levels using a Bio-plex Pro Human Cytokine panel (BIORAD, cat no: M5000031YV). Briefly, array of
beads specific for the analytes (via the capture antibody) were either incubated with culture supernatant or
standards. After washing the beads, biotinylated detection antibody was added and after washing the bead were
incubated with Streptavidin PE. After washing the beads were acquired in a Bio plex 200 (BIORAD) machine.
The data was analyzed using the Bioplex Manager software 6.1 ix. Cytokine Bead Array based Multiplex Assay

PBMCSs collected on Day 56 of Phase II & Day 104 of Phase I from vaccinated individuals were stimulated with
whole virion inactivated SARS CoV-2 antigen (1.20g/ml) for 72hrs. Cell culture supernatants were collected and
used for the simultaneous detection of multiple cytokines using Human Th1/Th2/Th17 BD CBA Kit (BD
Bioscience, San Jose, CA, USA). Supernatant samples were processed as per the manufacturer"s instructions.
Briefly, the kit was used for the simultaneous detection of human IL-2, IL-4, IL-6, IFN-y, TNF, IL-I7A, and IL-
10 cytokines in a single sample. For each sample, 50 uL of the mixed captured beads, 50 uL of the unknown
serum sample or standard dilutions, and 50 uL of phycoerythrin (PE) detection reagent were added consecutively
to each assay tube and incubated for 3 h at room temperature in the dark. The samples were washed with 1 mL of
wash buffer for 5 min and centrifuged. The bead pellet was resuspended in 300 uL buffer after discarding the
supernatant. Samples were measured on the BD FACS Verso and analyzed by FCAP Array Software (BD
Bioscience). Unstimulated cells or PBMCs collected on Day O were maintained as a negative control. PBMCs
stimulated with PMA & ionomycin were maintained as a positive control.

x. Database Handling/Procedures and Data Management Plan

The database used for this study is a fully validated, FDA 21 CFR Part 11 compliant system, proprietary, SAS
(software as a Service) based clinical data management system. Error rates for clinical database are controlled and

4
do not exceed 0.5% as an industry -wide standard. For critical data zero errors based on a 100% review of data are
obtained. This is controlled and documented by database audits against the study CRFs. Based on Data
Management Plan (DMP) document a road map to handle the data under projected circumstances and describes
the CDM activities was followed in the trial. The DMP describes the annotations, database design, data entry and
data tracking guidelines, quality control measures, SAE reconciliation guidelines, discrepancy management, data
transfer/extraction, and database locking guidelines. Along with the DMP, a Data Validation Plan (DVP)
containing all edit-checks was performed and the calculations for derived variables are also prepared. The edit
check programs in the DVP help in cleaning up the data by identifying the discrepancies.

xi. Definition of Reactogenicity and Safety.

Reactogenicity refers to a subset of reactions that occur soon after vaccination, and are a physical manifestation
of the inflammatory response to vaccination. In clinical trials, information on expected signs and symptoms after
vaccination is actively sought (or “solicited”). These symptoms may include pain, redness, swelling or induration
for injected vaccines, and systemic symptoms, such as fever, myalgia, headache, or rash. The broader term “safety”
profile refers to all adverse events (AEs) that could potentially be caused/ triggered or worsened at any time after
vaccination, and includes AEs, such as anaphylactic reactions, diseases diagnosed after vaccination and
autoimmune events. (Reference: Hervé C, Laupêze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The
how”s and what"s of vaccine reactogenicity. NPJ Vaccines. 2019;4:39.)

Table Sl: Ethic Committees from All Participating Trial Sites with Reference Numbers:

 

 

 

 

 

 

 

 

 

 

 

 

Site Name Reference Number
Nizam's Institute of Medical Science, Hyderabad, Telangana ECR/303/INST/AP/2013/RR-19
All India Institute of Medical Science, New Delhi ECR/547/INST/DL/2014/RR-17
PGIMS, Rohtak, Haryana ECR/293/Inst/HR/2013/RR-19
All India Institute of Medical Science, Patna ECR/1387/INST/BR/2020
Redkar Hospital & Research Centre, Goa ECR/902/INST/GA/2018
Jeevan Rekha Hospital, Belgaum, Karnataka ECR/1242/INST/KA/2019
Gillukar Multispecialty Hospital, Nagpur ECR/1374/INST/MH/2020
Prakhar Hospital, Kanpur, Utter Pradesh ECR/1017/INST/UP/2017
SRM Medical College Hospital & Research Centre, Chennai Tamil Nadu | ECR/431/INST/TL/2013/RR-19

 

 
Tables
2: SARS-CoV-2 Neutralising Antibody Responses and Cell-mediated responses.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3 ug with 6 ug with
Parameters Algel IMDG Algel-IMDG
(n=190) (n=190)
O.11 0.10
Day O (0.10, 0.13) (0.09, 0.11)
123 1.54
Day 28
PRNTs GMT ay (0:78, 1.94) (0.99, 2.4)
(95% CI 784 161.8
Day 42 (54.8, 112.0) (126.2, 207.4)
100.9 197.0
Day 56 (74.1, 137.4) (155.6, 249.4)
39.3 475
Day 28 (22.2, 46.8) (29.9, 55.1)
PRNTs SCR Dav4z 88.5 97.2
(95% CI) 7 (83.0,92.8) (93.5, 99.1)
92.9 98.3
Day 56 (88.2, 96.2) (95.1,99:7)
63 6.0
Day O (6.02, 6.68) (5.8, 6.1)
126 120
MNT GMT Day 28 (10.8, 147) (10.2, 14.0)
(95% CI 785 134.8
Day 42 (64.6, 95.2) (1444, 158.8)
92.5 160.1
Day 56 (77.7,110.2) (135.8, 188.8)
23.5 21.5
Day 28 (17.6, 30.3) (15.7,28.3)
MNTso Dav4z 847 96.6
SCR (95% CI) 7 (78.7, 89.6) (92.8, 98.8)
88.0 96.6
Day 56 (82.4,92.3) (92.6, 98.5)
11672 1082.5
TEN — gamma (445.9, 1888) (110.9, 2054)
45771 3612.7
TEN-Alpha (4015, 5139) (2918, 4307)
SARS-CoV-2 Cell 213 281
mediated Responses IL-2 (31.0,53.2) (22.9,33.3)
(on Day 42)
334 30.9
Mean (95% CD IL-s (29.2, 37.5) (27.2,34.6)
(pg/mL) 27.3 72.2
IL-10 (21.5,33.1) (53.9, 90.5)
20.1 16.3
IL-13 (14.6, 25.6) (9.4,23.1)
Thl: Th2 Ratio (IFN- gamma
59.2 42.5
+TNFAlpha+ IL-2) /
(LS + 113) (48.5, 69.7) (28.6, 56.3)

 

 

 

Shown are neutralising antibody and cell-mediated immunity results at baseline (day 0), 4 weeks after the first
vaccination (day 28), 2 weeks after the second vaccination (day 42), and 4 weeks after the second vaccination
(day 56) for the 3 ug (n=190) and 6 ug (n=190) with Algel-IMDG groups. Shown are the cytokine levels in 2day
Tables

supernatants for 58 participants (n=29 in each the 3 ug- and 6 ug with Algel-IMDG groups) with proliferative
responses to BBV152 vaccination whose PBMC were evaluated after stimulation with SARS-CoV-2 peptides.

3: PRNTs Neutralising antibody titres across age groups and gender on day 56 (four weeks after

the second dose).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3 ug with Algel- 6 ug with
Parameter IMDG Algel-IMDG
Age n SCR Median N SCR Median
Group (95%CI (QL, Q3) (95%CI (Q1, Q3)
100% 231.8 100% 224.5
>12-
212-<18 | 10 (69.2,100) (171.0,1036.5) 4 (39.8,100) (76.6,840.7)
92.2% 137.7 toa 98.17% 1824
>18-<55 | 166 | (87.0,95.8) (63.9,273.4) (94.8,99.6) (83.9,423.7)
100% 707 100% 199.5
>55-<
255<65 | 7 (59,100) (21.6,186.8) ? (66.4,100) (72.3,344.7)
Gender | n SCR GMT n SCR GMT
(95%CI (95%CI (95%CI (95%CI
911% 89.1 97.8% 2113
Male | 135 (85.095.3) (60.3, 131.8) 137 (93.7,99.6) (158.3, 282.2)
97.9% 143 (9355, 100% 154.8
Female | 48 (88.9,100.0) 218.8) 40 (91.2,100) (109.9, 218)
Table S4: Phase 1 Long term Follow-up immunogenicity analysis.
3ug with 6ug with 6 ug with
Total Parameters Algel-IMDG | Algel-IMDG Algel dio
(n=100) (n=100) (n=100) =
Dao 6.22 602 5.95 6.09
7 (5.9,6.5) (5.8,6.2) (5.8,6.1) (5.1,6.4)
Dav28 60.33 65.96 48.37 7.20
MNT GMT Y (48.5, 75.03) (53.2,81.8) (37.9,61.7) (6.38,8.1)
(95% CI 45.96 81.95 64.93 11.79
Day 42
(36.1, 58.5) (64.6, 103.9) (53.7,78.5) (9.4,14.8)
39.96 69.52 53.34 20.67
Day 104 (22.0,49.9) (53.7,90.0) (40.1,71.0) (14.5,29.5)
MNTã Dav28 87.88 91.92 82.80 8.22
SCR (95% CN) 7 (81.5,94.3) (86.6,97.3) (75.1,90.5) (1.9,14.5)

 

 

 
Tables

 

 

 

 

 

 

 

Day42 74.23 88.42 91.21 18.13
y (64.2,82.3) (80.94.1) (83.4,96.1) (10.129.3)
7347 81.05 73.12 32.88
Day 104 (63.6,81.9) (71.4,88.1) (62.9.81.8) (22.3,44.9)

 

Shown are geometric mean titers of the wild-type SARS-CoV-2 microneutralisation assay (MNTso) at baseline

(day 0), 2 weeks after the second vaccination (day 28), 4 weeks after the second vaccination (day 42), and 3

months after the second vaccination (day 104) for the 3 ug and 6 ug with Algel-IMDG groups, the 6 pg with Algel
group, and the Algel-onty control arm (from the immunogenicity cohort). Seroconversion rates (SCR) were

defined by the proportion of titers achieving >4-fold above baseline.

5: Secreted antibodies upon PBMC stimulation from samples collected on day 104 (three months

after the second dose) in the phase 1 trial.

 

Mean

 

 

3ug with
Algel IMDG

12.63

 

6 ug with Algel-
IMDG

16.60

 

6 ug with
Algel

19.73

 

Algel alone

2.33

 

 

Values represented in Mean+SD indicates spike specific secreted IgG titers measured as end point antibody
dilution by ELISA from cell culture supernatant, after stimulation of PBMCs with antigen for 6days (Ex-vivo).

The value for pre-vaccination samples were O.

 
Table 56: Further effector function of activated and differentiated T cells from PBMCs from the Phase 1 study
(at day 104, three months after the second dose).

 

 

 

 

 

 

 

 

3ug Ag+ Algel- | 6ug Ag+ Algel-| 6ug Ag+ Algel Algel Alone (n=6) Pre-
IMDG IMDG (n=10) vaccination
(n=10) (n=10) (n=5)
IL-I7A 4.39+4.29 3.40+3.41 14.70428.75 9.58+8.79 5.23+2.97
IFNg 82+172.8 124.69+224.73 13.03+16.50 26.77+60.27 0.01+0.02
TNF-alph: 3.99+4.93 3.25+5.63 1.30+0.58 3.37+6.54 0.00+0.00
IL-2 30.55+46.83 55.84+69.15 17.05+9.40 6.14+8.50 0.29+0.36
IL-4 0.2+0.29 0.35+0.48 0.13+0.13 0.08+0.16 0.00+0.00
IL-10 37.87+60.28 22.47+41.76 6.35+6.76 6.2348.18 1.22+1.06
IL-6 297.15+410.52 | 464.24+470.51 218.54+327.33 544.56+1057.95 27.61+30.19

 

 

 

 

 

 

 

 

Values shown in Mean+SD represents cytokines levels measured in pg/ml by CBA method from culture supernatants,
obtained after stimulation of PBMCs with antigen for 6days (Ex-vivo). Release of Th] biased cytokines (IFNy, TNF-a
and IL-2) as a function of effector cells of CD4* T cells, which further supports towards T cell dependent memory
response. No or negligible levels of Th2 cytokines (IL-4) and IL-17Acytokine levels were observed, whereas, IL-6
cytokine levels were observed in 3ug and 6ug with Algel-IMDG formulation predicted to be due to activation of both
T&B cells.
Table 57: Solicited Adverse Events After Iwo Doses in the Safety Set

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Severity
Symptoms Dose Group Desei Dose 2
Mild n(%) Moderate Mild n(%) Moderate n(%)
n(%)
Local
3ug with Algel-IMDG 5 (2.63%) 1(0.53%) 7(3.68%) -
Pain at injection Site
6ug with Algel-IMDG 6(3.16%) - 4 (2.10%) 1 (0.53%)
3 ith Algel-IMDG 1(0.53' - - -
Redness at Injection gw se ( 2)
site l 1(0.53%) . . .
6ug with Algel-IMDG
1(0.53%) . . .
34ug with Algel-IMDG
Itching 1 (0.53%)
6ug with Algel-IMDG . 2 (1.05%) .
. . 1(0.53%) . . .
Stifíness in 34g with Algel-IMDG
upper arm ”
6ug with Algel-IMDG - - - -
Weakness in Right 34g with Algel-IMDG - - 1(0.53%) -
Arm 6ug with Algel-IMDG . - - -
Mild & Moderate 3ug with Algel-IMDG 9 (4:7%) (2-2, 8:8) 8(4.2%) (1.8,8.1)
(After Dose 1 & 2) 6Lg with Algel-IMDG 8 (4.2%) (1.8,8.1) 7(3.7%) (1.6, 7.7)
Systemic
3ug with Algel-IMDG - - 1(0.53%) -
Body ache
6ug with Algel-IMDG 2(1.05%) 1(0.53%) 2(1.05%) -
F 3ug with Algel-IMDG 2(1.05%) 1(0.53%) 5 (2.63%) -
ever
6ug with Algel-IMDG 5 (2.63%) 3 (1.58%) 4(2.10%) -
3ug with Algel-IMDG 2(1.05%) - 1(0.53%) -
Headache
6ug with Algel-IMDG 1 (0.53%) - 2(1.05%) 1 (0.53%)
3ug with Algel-IMDG 4(2.10%) - 3 (1.58%) -
Malaise
6ug with Algel-IMDG 1 (0.53%) - - -
3ug with Algel-IMDG - - 1(0.53%) -
Weakness
6ug with Algel-IMDG - 1(0.53%) 2(1.05%) -
3ug with Algel-IMDG - - 1 (0.53%) -
Rashes
6ug with Algel-IMDG - - - -
Mild & Moderate 3ug with Algel-IMDG 9 (4.7%) (95% CI: 2.2, 8.8) 12 (6.3%) (95% CI: 3.3, 10.8)
(After Dose 1 & 2) 6Lg with Algel-IMDG 14 (7.4%) (95% Cl:4.1, 12.1) | 11(5.8%) (95% CI: 3.0, 10.1)
Total 33 (8.68%) 7(1.84%) 36 (9.47%) 2 (0.53%)
Adverse events after 34g with Algel-IMDG 38 (10.0%) (95% Cl:7.2,13.5)
two doses 6Hg with Algel-IMDG 40 (10.5%) (95% Cl: 7.6,14.1)

 

 

 

 

 

The groups received 3 ug with Algel-IMDG or 6 ug with Algel-IMDG. Data are shown as the number of participants who
experienced an event (%) after receiving either dose 1 (0-7) or dose 2 (28-35 days). The grading scale for most adverse
events was based on the FDA guidance document for the Toxicity Grading Scale for Healthy Adult and Adolescent
Volunteers Enrolled in Preventive Vaccine Clinical Trials. For adverse events where grading was not described in the FDA
guidance document, we used the Common Terminology Criteria for Adverse Events (CTCAE) grading

10
Table S8: Number of unsolicited, non-serious, adverse events classified by MedDRAº? System Organ Class,

severity, and investigator-assigned relationship to study vaccine/control.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MedDRA SOC Dose Group Adverse Events Severity Relationship to IP
Mild Moderate | Not Related Related
N(%)
N(%)
Gastrointestinal Bug with — Algel- | Mouth Ulcer (1) 1(0.53%) - 1(0.53%) -
Disorders IMDG
ug with — Algel- | Gastric Problem (1) 1(0.53%) - 1(0.53%) -
IMDG
General Bug with —Algel- | Weakness (2) 1.05%) - 2(1.05%) -
Disorders IMDG
and
administrativo bug with Algel- | Fever (1) - 1(0.53%) - 1(0.53%)
site conditions IMDG
Body ache (1) - 1(0.53%) - 1(0.53%)
Nervous system Bug with — Algel- | Headache (1) 1(0.53%) - 1(0.53%) -
disorders IMDG
ug with — Algel- | Dizziness (1) 1(0.53%) - - 1(0.53%)
IMDG
Headache (1) 1(0.53%) - 1(0.53%) -
Respiratory, Bug with — Algel- | Cold (3) 1.05%) 1(0.53%) 2(1.05%) 1(0.53%)
thoracic and) IMDG
mediastinal Breathlessness (1) 1(0.53%) - 1(0.53%) -
disorders
Cough (1) 1(0.53%) - 1(0.53%) -
Heaviness in chest (1) 1(0.53%) - 1(0.53%) -
Running nose (1) 1(0.53%) - 1(0.53%) -
ug with — Algel- | Cold (2) 1.05%) - 2(1.05%) -
IMDG
Running nose (1) - 1(0.53%) - 1(0.53%)
Sneezing (1) 1(0.53%) - 1(0.53%) -
Skin and | 3ug with Algel- | Rashes (1) - 1(0.53%) - 1(0.53%)
subcutaneous IMDG
tissue disorders
ug with — Algel- - - a - -
IMDG
Total 16(76.2%) 5 (23.8%) 15 (714%) 6 (28.6%)

 

 

 

 

 

 

GERD: Gastroesophageal reflux disease, COLD: the lowest level term (LLT) in the MedDRA for the preferred term
(PT) Nasopharyngitis is cold

11

 
Documento Estudo (0019670642)

SEI 25000.043170/2021-42 / pg. 145

12
Table 59: Grading Scales for Local and Systemic Adverse Events.

 

Event

ER None=1

Mild =2

Moderate=3

Severe=4

Potentially life
threatening=5

 

Local Adverse Events

 

Interferes with activity

prevents daily

Emergency room

 

 

 

 

 

 

 

 

 

 

 

 

 

Pain at Absent Does not interfere |or repeated use of non- Jactivity or repeated|
injection site . with activity narcotic pain reliever |use of narcotic pain) (ER) visitor
>2Ahrs reliever hospitalization
Tenderness/ Mild discomfort to | — Discomfort with significant | Emergency room
Absent - (ER) visit or
Soreness touch movement discomfort at rest nlizati
hospitalization
Necrosis or
Redness/ | Absent 2.5-5em 5.1-10cm >10cm exfoliative
Erythema e
dermatitis
Swelling | absent | 23-50m and does | 5 4 1gm or interferes) >10 cm prevents .
. not interfere with . . nm . o Necrosis
Induration - a with daily activity daily activity
daily activity
itching localized to|
injection site and Itching beyond, Itching causing) NA
Pruritus | Absence of] injection site not  |inability to perform
associated any relieved 'generalized or localized|
with injection) Pruritus | spontaneously or | itching requiring >48 usual social &
with<48 hours hours treatment functional activities]
treatment
Any other . . : : . Emergency room
. Absent | Does not interfere | interferes with daily prevents daily a
Local AEºs . . as ao ao (ER) visit or
with daily activity activity, activity car;
hospitalization
Systemic Adverse Events
Repeateduseof | Any use of narcotic)
. Absent | Does not interfere nonnarcotic pain pain reliever or Emergency room
Pain ith activit reliever > prevents daily (ER) visit or
da y 24 hours or interferes| activity hospitalization
with daily activity
SBC | 38038. 40C(1004- 38.5-38.9º C (101.2 39.0-40º€
<100.4º F) 9 do A na > 40º (>104º
Fever ( ) ou F) 102.0ºF) CaO2.1104ºF) 40ºC (>104ºF)
No interference with Some interference Prevents iaily Emergency Foom
Nausea/ Absent . o . ' no activity, requires (ER) visit or
na daily activity or 1-2 | with daily activity or > . aivati
Vomiting : . outpatient IV | hospitalization for
episodes/24 hours | 2 episodes/24 hours . .
hydration hypotensive shock
some interference with Significant,
, . daily activity |  prevents daily | Emergency room
Headache | Absent |No terierence vit op repeated use of [activity or repeated, (ER) visitor
Y Y nonnarcotic pain Juse ofnarcotic pain) hospitalization
reliever reliever
ori fi Emergency room
. No interference with some interference with] Significant, (ER) visit or
Fatigue Absent - na . na prevents daily io ati
daily activity daily activity a hospitalization
activity
Myalgia Absent |No interference with|some interference witl Signiicant, Emergency *oom
: ne . o prevents daily (ER) visit or
daily activity daily activity a car;
activity hospitalization
jAcute Allergic) No interference with|some interference with) Prevents daily Emergency foom
. Absent . na. . o no (ER) visit or
Reaction daily activity daily activity activity

 

 

 

 

 

 

 

hospitalization

 

13
 

 

 

 

 

 

 

 

 

rashes covering 10-30 rashes coverin:
rashes covering | %BSA (Body Surface 530 WBSA boi
<10%BSA with or | Area) with or without |U.
Rash Rash without symptoms : without symptoms NA
as, Absent ut symptoms symptoms (pruritus, (pruritus, burning,
(pruritus, burning, | burning, tightness), |
. . . : tightness), prevents|
tightness) interferes with daily with daily activit
activity Y Y
Repeateduseof | Any use of narcotic, Emergency room
Joint pain Absent Does not interfere nonnarcotic pain pain reliever or (ER) visit or
P . with daily activity reliever > prevents daily hospitalization
24 hours or interferes| activity
with daily activity
Any other Absent Does not interfere | interferes with daily prevents daily O cravos
Systemic AEs| . with daily activity activity activity hospitalization

 

Abbreviation: NA, not available. The grading scale for most AEs was based on the FDA guidance document for
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical

Trials. The causality assessment was done based on the investigator's taking the following factors into
consideration: Temporal (time-based) relationship between the event and administration of the study vaccine.
Possible alternative etiology for the AE, such as concurrent illness or natural history of underlying diseases, or
concomitant medications. Adverse events of similar nature having previously been observed with the study
vaccine. The adverse event having often been reported in literature for similar types of treatments.

14
Figure 51: Cytokine profile measured from culture supernatant upon stimulation of PBMCs with antigen

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IFN=y
”
E
500:
B ao
EE
= 200
150.
100:
so T
o
so.
3ug Ag+ AlgelIMDG 6ug Agt Algel-MDG
TNF-a
30.
E» Es
a
8
o e
Ê
o
A dee pe e
3ug Ag+ AlgelIMDG Gg Ag+ Alge IMDG
IL-10
250:
.
g mo
8 150
e ai
3 100
º| E

 

 

 

 

3ug Ag+ AlgelIMDG 6ug Ag+ AlgelIMDG

IL-2

IL-2 (pg/ml)
8

IL-4 (pgfml)

1
3ug Agt AlgelIMDG 64g Ag+ Algel-IMDG

IL-6
4000:
— 3000
E º
B 200
8 1000
o OT

000:
3ug Ag+ AlgelIMDG Gg Agt AlgelIMDG

Box plot represents mean with 95% Cl values of secreted cytokine levels measured in the cell culture supernatant
after 72hrs of whole virion inactivated antigen stimulation. PBMCs collected on Day 56 were used to measure
Th1/Th2/ThI7 cytokines by CBA method. Graphs and statistics done using Tukey test.

Figure S2: comparison between PRNTs assays at the two laboratories (Bharat Biotech and National

Institute of Virology).

15
e 3ug Algel-IMDG
1043 e ug Algel-IMDG

S
q
essa

PRNTso
GMT (95%CI)
Ss
=:

 

 

 

NIV Bharat NIV Bharat
Biotech Biotech

FigureS3: Solicited Adverse Events After Two Doses in the Safety Set

E Mild m Moderate =» Severe

 

    

 

  

 

  
      
  

 
   
       

 

 

 

 

POsEGROUE DOSE-1 DOSE GROUP. DOSE-2
serons (uocay semerons oca
sugvam alpes
sugvihgivo suga mos
sgh algevos “ore venaiçeos |
3ug with AlgeHMOG ag with Algei-IMDG
Gug with AlgeliMoG ug with algetAmoS
sugvithalgvos suga mo
E RE

ge puihagõnoo | ug veios
Et omsame | TE

presos pesto | a smarroms trees

É amguanagenmos | É suevinagetmos

É cugurthAlgetanos É cupwihalgeLMOG

E 3MpuihAlgeL MOS | 5 MEWRNAgoNMDG

É euevitnaçenno | ug vthalgdimos

E auevinnçemos |

É cspunhapenmios ug vin Agamos

8 SuguihAge-OG, Ps duetos

É “esunnaçeimos —

E EI
É suguhagevos EM
E Dumaraçõnos | odiar

 

 

 

 

 

 

 

ou 1% 2% % a% sx o% 1% 2% »

Percentage of Participants

16
ANNEAURE-3
 

 

BBIL/BBV152-C/2020

DOC
BHARAT

BIOTECH
Lead Sncaliom

Bharat Biotech International Limited

INTEGRATED CLINICAL AND STATISTICAL REPORT

Title:

Protocol Number:

Design:

Phase:

Version:

Sponsor:

Study Initiation Date:
Study Completion Date:

Co-ordination Unit
(Responsible for
Preparation of the
Report) Clinical
Operations
Management Unit

An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled,
Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity, and
Lot-to-Lot consistency of BBV 152, a Whole-virion Inactivated SARS-CoV-
2 Vaccine in Adults >18 Years of Age.

BBIL/BBV152-C/2020

This is a randomized, double-blind, phase 3 study to evaluate the Efficacy,
Safety, and Immunogenicity of BBV152B, a Whole-Virion Inactivated
SARS-CoV-2 Vaccine in Volunteers aged 18 years and above.

DI

1.0

Bharat Biotech International Limited (BBIL),

Genome Valley, Shameerpet, Hyderabad,
Telangana, India.

&

Indian Council of Medical Research (ICMR),
New-Delhi, India

16º November 2020

Ongoing

IQVIA
&

BHARAT BIOTECH INTERNATIONAL LIMITED

Page 1of 18

 

 
 

 

BBIL/BBV152-C/2020

Sponsor Representative:

GCP Statement:

Date of Report:
Prepared by:

Study period (years):

Date of 1º Dose 1º Subject:

Date of 1º Dose last subject:

Trial Registration:

S0€
Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

Dr. V. Krishna Mohan

Whole-time Director

Bharat Biotech International Limited (BBIL)
Genome Valley, Hyderabad India

Tel +91 40 2778 4003 Fax: +91 40 2348 0560
Email:kmohan E bharatbiotech.com.

and

Dr. Nivedita Gupta

Scientist F, Epidemiology and Communicable Diseases,
Indian Council of Medical Research (ICMR),
New-Delhi, India

Tel: +91-11-26589397

Email: guptanivedita hgO icmr.gov.in

The trial is being conducted in compliance with the protocol, GCP,
Schedule Y (Drugs and Cosmetics Act, 2005) and Ethical Guidelines for
Biomedical Research on Human Participants (Indian Council of Medical
Research, 2006)

05º March 2021

Medical Affairs Department
Bharat Biotech International Limited

1 Year

November 16, 2020
January 8, 2021

CTRI/2020/11/028976

Page 20f 18

 

 
 

 

 

 

 

 

 

 

 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited

 

Signature Page:

Study Title: An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
to Evaluate the Efficacy, Safety, Immunogenicity. and Lot-to-Lot consistency of BBV152, a Whole-virion
Inactivated SARS-CoV-2 Vaccine in Adults 218 Years of Age.

Review and approval of the Integrated Clinical and Statistical report.

Wc have read this report and confirm that, to the best of our knowledge, it accurately describes the conduct
and results of the trial.

Signature & Date
[e Io cafo A z0U

Dr. V. Krishna Mohan

Whole-time Director

Bharat Biotech International Limited (BBIL)
Genome Valley, Hyderabad India

Tel +91 40 2778 4003 Fax: +91 40 2348 0560
Email: kmohan(dbharatbiotech.com

Page 3 of 18

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT
BIOTECH
Lot Snomalioo

Title: An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to
Evaluate the Efficacy, Safety, Immunogenicity, and Lot-to-Lot consistency of BBV152, a Whole-virion
Inactivated SARS-CoV-2 Vaccine in Adults >18 Years of Age.

Protocol No.: BBIL/BBV152-C/2020

Investigational Vaccine: Whole-Virion Inactivated SARS-CoV-2 vaccine (BBV152B).

Study Population: A total sample size of 25,800 volunteers ages 18 years and above were
recruited and administered with vaccine and placebo in 1:1 ratio.

The study was conducted in 25 sites all zone of India.

Study Centres and Investigators:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RA . as Site Name & Location Zone
1 308 MG Medical College, Sri Balaji Vidyapeeth - Dr. PajanivelRanganadin South
(Pondicherry)
2 311 | Vydehi institute of medical sciences — Dr. Akshata (Bangalore) South
3 312 Director of Public Health & Preventive Medicine — Dr. SelvaVinayagam - South
(Chennai)
4 317 || Government Fever Hospital, Guntur - Dr. Laxmi Kumari (Guntur) South
5 320 | Nizam's institute of Medical Sciences -Dr. Prabhakar Reddy (Hyderabad) South
6 325 | SRM Hospital & Research Center - Dr. Satyajit Mohapatra (Chennai) South
7 326 | Jeevan Rekha Hospital - Dr Amit Bhate, (Belgaum) South
8 309 | People's University - Dr. Raghavendra Gumashta (Bhopal) Central
9 302 | All India Institute of Medical Sciences — Dr. Chadramani Singh (Patna) East
ICMR-National Institute of Cholera and Enteric Diseases - Dr. Suman
10 305 East
Kanungo (Kolkata)
1 318 | (IMS) & SUM Hospital - Dr. E Venkata Rao (Bhubaneswar) East
12 301 | All India Institute of Medical Sciences — Dr. Sanjay Rai (New Delhi) North
13 303 | ESIC Medical College and Hospital — Dr. Anil Pandey (Faridabad) North
14 313 | Aligarh Muslim University - Dr. Md. Shameem (Uttar Pradesh) North
15 321 PGIMS - Dr. Savita Verma (Rohtak) North
16 323 | Gangaram - Dr Anupam Sachdeva (New Delhi) North
17 324 | Prakhar Hospital — Dr. Jitendra Kushwaha, Kanpur North
18 307 | Lokmanya Tilak Municipal General Hospital-Dr. N.T. Awad (Mumbai) West
19 310 || Rahate Surgical Hospital & ICU - Dr. Manish Multani (Nagpur) West
o) 315 GMERS Medical College and Civil Hospital - Dr. Parul Bhatt West
(Ahmedabad)
21 316 | Sir J.J. Group of Hospitals - Dr. PritiMeshram (Mumbai) West
22 322 | Redkar Hospital and Research Centre - Dr. Sagar Redkar (Goa) West
23 327 Maharaja Agrasen Multi speciality Hospital — Dr. Manish Kumar Jain - West
(Jaipur)
24 328 RCSMGMC & CPR Hospital — Dr. Sunita Jaiprakash Ramanand West
(Kolhapur)
o) 329 E Institute of Medical Science & Research — Dr. Vijaykumar Patil West

 

 

 

Page 40f 18

 

 
 

 

DOC

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
PiGReçh
Table of Contents
1. | INTRODUCTION.............. remate ram arara aeaaram ceara ceara e aeaate ceara aerea eeananea 6
2. STUDY DESIGN... eee eee eee eeane aeee rea aaa aaa amena rama rara 7
3. STUDY POPULATION... eeeeeemeeee emana e ane e aeee ana a manera mearaaramaaaa 8
3.1 AT-RISK POPULATION ............. ereta aeee aerea aaa meramente 9
3.2 GENDERAND AGE WISE CLASSIFICATION OF THE PARTICIPANTS............ 10
3.3 INFECTION RATE & SEROPREVALENCE ............... rm eeemaeeeamaearamermaias 10
4. SAFETY... een eeae cerne eeaea eae aeee aaa ane aeee aaa aaa aaa aerea rama arartama atas 12
4.1 SERIOUS ADVERSE EVENTS............. tener emeeee emana remeeeeremeerer remate 12
5. | IMMUNOGENICITY .......... remetem ram raramente arara ae arara arara eeanes 17
6. EFFICACY ...... eee ceara remar e mean rame aaa ra mataram cantam aaara ataca arara aeee reaeates 17
7. CONCLUSION ........... ease rama arara aaa ceara ataca ara area aeee reaeanes 17
8. REFERENCES... ienes ea marea aa manera ceara ataca are ate ae aeee reaeanea 18

Page 5 of 18

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

1. INTRODUCTION

The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19) has, as on
March 05",2021, spread to over 216 countries across the globe, with a total of -115 Million confirmed cases
and - 2.5 Million deaths. The number of reported SARS-CoV-2 cases in India is also on an increase with
-11 Million confirmed cases and -157000 deaths(1). Coronaviruses are a severe threat to the humans and
other animals, earlier other members of the same family coronaviridae, SARS-CoV infected -8000 people
with a death rate of 10% and another member Middle East Respiratory Syndrome (MERS) virus was
outbroken in the Middle East region and infected -2000 people with 35% fatality rate(2) . Porcine epidemic
diarrhea coronavirus (PEDV) has swept throughout the United States of America, causing an almost 100%
fatality rate in piglets and wiping out more than 10% of America's pig population in less than a year(2).

Coronaviruses are the enveloped positive-stranded RNA viruses which have the largest genome among all
RNA viruses with approximately 27 to 32 kb2. The viral genome is packed inside a helical capsid formed by
the nucleocapsid protein (N) which is surrounded by an envelope. SARS-CoV viral envelope is associated
with at least three structural proteins: The membrane protein (M) and the envelope protein (E) are involved
in virus assembly, whereas the spike protein (S) mediates virus entry into host cells. Among these structural
proteins, the spike forms large protrusions from the virus surface, giving coronaviruses the appearance of
having crowns(2).

The SARS-CoV-2 virus transmits from person to person mainly through respiratory droplets(3).

The inhaled virus SARS-CoV-2 likely binds to epithelial cells in the nasal cavity and starts replicating.
ACEZ2 is the main receptor for both SARS-CoV-2 and SARS-CoV(4,5). There is local propagation of the
virus but a limited innate immune response. At this stage, the virus can be detected by nasal swabs. Although
the viral burden may be low, these individuals are infectious. The RT-PCR value for the viral RNA might be
useful to predict the viral load and the subsequent infectivity and clinical course. The virus propagates and
migrates down the respiratory tract along the conducting airways, and a more robust innate immune response
is triggered. Nasal swabs or sputum should yield the virus (SARS-CoV-2) as well as early markers of the
innate immune response(6). The symptoms of SARS-CoV-2 infection appear after an incubation period of
-5 days(7). The period from the onset of SARS-CoV-2 symptoms to death ranged from 6 to 41 days with a
median of 14 days. This period is dependent on the age of the patient and the status of the patient's immune
system. It was shorter among patients >70 years old compared with those under the age of 70(8). The most
common symptoms at the onset of SARS-CoV-2 illness are fever, cough, and fatigue, while other symptoms
include sputum production, headache, hemoptysis, diarrhea, dyspnoea, and lymphopenia(9).

Till date, no specific treatment was recommended for SARS-CoV-2 infection hence, vaccines are a critical
new tool in the battle against COVID-19. Various types of COVID-19 vaccines, such as DNA, RNA- based
formulations, Recombinant subunit vaccines containing the viral protein (Spike) epitopes, vector based
formulations (eg: Adeno virus) and traditional inactivated vaccines were developed(10-12). Bharat Biotech
Int. Ltd., India has developed a whole-virion inactivated Covid-19 vaccine and evaluated for its safety and
immunogenicity in a Phase 1 followed by phase 2 study and found that vaccine is safe and
immunogenic(13,14). Bharat Biotech has been conducting a phase 3 efficacy study in 25,800 participants to
evaluate the efficacy of the vaccine.

Page 60f 18

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

2. STUDY DESIGN

The study is an endpoint-driven randomized, double-blind, phase 3 study to evaluate the Efficacy, Safety,
and Immunogenicity of BBV152B, a Whole-Virion Inactivated SARS-CoV-2 Vaccine in Volunteers aged
18 years and above.

A total of 25,800 subjects were enrolled across India in 25 sites (3 Categories) and randomized in a 1:1 ratio
to receive BBV152B vaccine and control. All participants will be assessed for efficacy and safety endpoints
and provide a NP swab and blood sample before the first dose of IP. The NP swab and blood collected will
be subject to RT-PCR and Anti-SARS-CoV-2 IgG antibodies. The results of this will not affect enrolment of
the participant. Participants who are found to be positive for either RT-PCR or Anti-SARS-CoV-2 IgG
antibodies will be excluded from the primary efficacy analysis.

The purpose of this Phase 3 study is to evaluate the protective efficacy, safety, and immunogenicity of the
whole-virion inactivated SARS-CoV-2 vaccine, BBV152B. The Phase 3 study will follow randomized study
participants for efficacy until virologically confirmed (RT-PCR positive) symptomatic COVID-19
participants will be eligible for the primary efficacy analysis. After reaching the target number (n=130) of
symptomatic COVID-19 cases, the study will continue to assess safety until the completion of the study
duration.

Case Definition of symptomatic COVID-19

The study is designed to acerue 130 symptomatic COVID-19 cases.This includes any participant who meets
any of the two below following criteria:

* Case Definition for Primary Efficacy Symptomatic Endpoint

* Case Definition for Severe Symptomatic COVID-19

Any one of the below mentioned criteria (A or B) must be met, along with a positive SARS-CoV-2 RT-PCR
confirmation to be a confirmed symptomatic case

 

 

 

 

 

 

Criteria A: One or More Criteria B: Two or More

1. Shortness of Breath/Difficulty in 1. Fever

Breathing 2. Chills
2. New onset Anosmia/Aguesia 3. New cough
3. Oxygen saturation of <94% or 4. Myalgia/Fatigue

escalation by requiring or 5. Headache

supplemental Oxygen. 6. Sore throat
4. Pneumonia: diagnosed by chest X 7. Nausea/Vomiting

ray or CT scan 8. Diarrhea
5. Evidence of Shock 9. Congestion/ Runny Nose
6. ICU Admission/Death

AND
Positive SARS-CoV-2 RT-PCR test

 

 

 

Page 7 of 18

 

 
 

DOC

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
DR
SITE CATEGORIES:

Category 1 (Symptomatic): In addition to administering the IP, a series of post-dose telephonic follow-up
visits will be scheduled to detect suspect symptomatic COVID-19 infections. If a suspect is identified, a
nasopharyngeal sample will be collected from the participant for detecting the presence of COVID-19
infection. Telephonic follow-up will occur at 15 day intervals.

Category 2 (Symptomatic/Asymptomatic): In addition to administering the IP, a series of post-dose
Nasopharyngeal samples for detecting incidence of Asymptomatic COVID-19 infection at 1-Month intervals
will be collected.

Category 3 (Symptomatic/Asymptomatic+Immunogenicity): In addition to administering the IP, repeated
NP swabs for asymptomatic, a series of blood samples will be collected for analyzing serum for
immunological assessments.

3. STUDY POPULATION

As per the approved protocol, a total of 25,800 subjects were enrolled and received either vaccine or placebo
in 1:1 ratio. Among these 25,800 participants 24,455 were received second dose and detailed site wise
enrolled participants, second dose recipients and the participants who were followed up till Day 42 were

listed in the Table 1.

TABLE 1: SUMMARY OF ENROLLED SUBJECTS AT EACH SITE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Subjects Subjects Subjects
SNo. Site Name and Location po a TE
Day 42)
Category 1: Sites
1 Al India Institute of Medical Sciences - (New Delhi) 659 629 629
2 Al India Institute of Medical Sciences - (Patna) 1216 1137 1129
3 ESIC Medical College and Hospital - (Faridabad) 1126 1002 997
4 ICMR National Institute of Cholera and Enteric Diseases - (Kolkata) 988 969 967
5 Lokmanya Tilak Municipal General Hospital - (Mumbai) 197 191 191
6 MG Medical College, Sri Balaji Vidyapeeth - (Pondicherry) 901 868 831
7 People's University - (Bhopal) 1725 1426 1424
8 Rahate Surgical Hospital & ICU - (Nagpur) 1670 1594 1579
9 Vydehi institute of Medical Sciences - (Bangalore) 496 476 429
10 | Director of Public Health & Preventive Medicine - (Chennai) 29 27 27
1 Gangaram - (New Delhi) 318 276 276
12 Prakhar Hospital — (Kanpur) 2250 2244 2243
13 Jeevan Rekha — (Karnataka) 2227 2216 2216
14 | Maharaja Agrasen Multi speciality Hospital - (Jaipur) 1494 1431 1124
15 Sunita Jaiprakash Ramanand - RESMGMC & CPR Hospital - (Kolhapur) 887 882 737
16 | Vijaykumar Patil - Prakash Institute of Medical Science & Research - (Sangli) 611 594 409

 

17 | Aligarh Muslim University - (Uttar Pradesh) 1008 938 937

 

 

Page 80f 18

 

 

 
 

DOC

 

 

 

 

 

 

 

 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
Cisnes

18 Gmers Medical College and Civil Hospital - (Ahmedabad) 1081 1018 1018
19 | Sir J.J. Group of Hospitals - (Mumbai) 438 379 378
20 Government Fever Hospital - (Guntur) 1358 1351 1350
21 (IMS) & SUM Hospital - (Bhubanes war) 510 495 494
22 SRM Hospital & Research Center — (Chennai) 603 446 40

Category 3: Sites

23 Nizam's institute of Medical Sciences - (Hyderabad) 1998 1888 1883
24 | PGIMS - (Rohtak) 456 433 433
25 Redkar Hospital and Research Centre - (Goa) 1554 1544 1544

Total 25800 24454 23649

 

 

 

 

 

3.1 AT-RISK POPULATION

In this study both healthy volunteers and participants with high risk for Covid-19 who is, either > 60 years of
age or < 60 years of age with co-morbid conditions, and HCPs were recruited.

Participants who are < 60 years old will be categorized as at risk for severe COVID-19 illness if they have at
least 1 of the following risk factors at Screening:

> Stable chronic lung disease (eg, emphysema and chronic bronchitis), idiopathic pulmonary fibrosis

and cystic fibrosis) or mild to moderate asthma.

> Stable cardiac disease (eg, heart failure, coronary artery disease, congenital heart disease,

cardiomyopathies, hypertension, and pulmonary hypertension).
> Severe obesity (body mass index > 35 kg/m2).
» Controlled Diabetes (Type 1, Type 2).
> Stable Liver disease.

Participants who has high risk for Covid-19 were summarized in the Table 2 (>60 Years) and Table 3 (< 60
with Co-morbid condition).

TABLE 2: SUMMARY OF AT RISK PARTICIPANTS

 

 

 

 

 

 

 

 

 

 

 

Treatment Arm
Description BBVIS2 Placebo Total
sertp! (N= 12,900) (N= 12,900) (N= 25,800)
n(%) n (%) n (%)
At Risk Participants at baseline, Age > 60
ears
Stable chronic heart disease 158 (1.22) 142 (1.10) 300 (1.16)
Stable chronic lung disease 12(0.09) 16 (0.12) 28 (0.11)
. . 107 (0.83)

Controlled Diabetic 101 (0.78) 208 (0.81)
Stable Liver Disease 4(0.03) 8 (0.06) 12(0.05)
Severe obesity (BMI >35) 2(0.02) 2( 0.02) 4( 0.02)
Other stable co-morbid condition 129 (1.00) 142 (1.10) 21 (1.05)
None of the above 32(0.25) 28 (0.22) 60 (0.23)
Multiple risk categories* 245 (1.90) 296 (2.29) 541 (2.10)

 

 

 

 

 

* Multiple risk categories count contain for subject selected multiple categories (i.e. more than one)

 

 

Page 9 of 18

 

 

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

TABLE 3: SUMMARY OF AT RISK PARTICIPANTS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Description Treatment Arm

BBV152 (N= 12,900) Placebo (N= 12, 900) Total

n(%) 1 (0) (N = 25,800)

º : n(%)

At Risk Participants at
baseline, Age < 60 years
Stable chronic heart disease 370 (2.87) 357 (2.77) 727 (2.82)
Stable chronic lung disease 108 (0.84) 148 (1.15) 256 (0.99)
Controlled Diabetic 593 (4.60) 613 (4.75) 1206 ( 4.67)
Stable Liver Disease 17 (0.13) 17 (0.13) 34 (0.13)
Severe obesity (BMI >35) 53 (0.41) 90 (0.70) 143 (0.55)
Other stable co-morbid 613(4.75) 676 (5.24) 1289 (5.00)
condition
None of the above 125 (0.97) 118 (0.91) 243 (0.94)
Multiple risk categories * 209( 1.62) 200 (1.55) 409 (1.59)
* Multiple risk categories count contain for subject selected multiple categories (i.e. more than one)

 

3.2 GENDER AND AGEWISE CLASSIFICATION OF THE PARTICIPANTS:

In the study both the genders were recruited, among 25800 participants 17332 (67.2%) were male and 8468
(32.8%) were female participants. Detailed description of the participants categorized by their age and
gender was depicted in the Table 4.

TABLE 4: GENDERAND AGE WISE CLASSIFICATION OF THE PARTICIPANTS

 

 

 

 

 

 

 

Gender >18 to <50 >51 to <60 >61 to above
Male 13790 2085 1457
(53.45%) (8.08%) (5.65%)
Female 6242 1250 976
(24.19%) (4.84%) (3.78%)

 

 

3.3 INFECTION RATE & SEROPREVALENCE

As per the protocol, all the participants were examined for their status on the Covid-19 infection and
seroprevalence at baseline. Nasopharyngeal swab and serum were collected from all the participants and
estimated the COVID-19 infection rate and seroprevalence among all the sites across India. The results were
reported that 0.82% infection rate and 34.33% of the seroprevalence across the India. Site wise and zone
wise seroprevalence and infection rate is depicted in the Table 5.

Page 10 of 18

 

 

 
 

DOC

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Peoples University,

309 me 1746 26 149 1736 | 234 13.48

 

 

 

 

 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
As
TABLE 5: INFECTION RATE AND SEROPREVALENCE OF THE COVID-19
Site RTPCR | RTPCR Infection ELISA Posit | Seroprevale
Code | Site Tested Positive Rate (%) nn ive nce (%)
301 | AIIMS, Delhi 658 3 046 658 | 293 44.53
303 | ESIC, Faridabad 1126 8 07 1126 | 290 25.15
313 | AMU, Aligarh 1008 20 1.98 1002| 311 31.04
321 | PGIMS, Rohtak 456 14 3.07 456 72 15.79
Gangaram, New-
323 | Delhi 319 2 0.63 319] 107 33.54
PRAKHAR,
324 | Kanpur 2250 5 0.22 2250 | 1031 45.82
1.18 32.75
Lo ET O
302 | AIIMS, Patna 1216 20 1.64 1216 | 801 65.87
305 | NICED, Kolkata 989 8 0.81 989 | 264 26.69
318 | IMS, Odisha 510 3 0.59 510 | 123 24.12
1.01 38.89
[oc wto
Sion Hospital,
307 | Mumbai 202 3 149 197 | 105 53.30
310 | RAHATE, Nagpur 1672 1 0.66 1672 | 192 11.48
GMERS,
315 | Ahmadabad 1081 25 231 1081 | 387 35.80
JJ Hospital,
316 | Mumbai 437 5 1.14 437 | 200 45.77
322 | REDKAR, Goa 1554 1 0.06 1554 | 497 31.98
Jeevan Rekha,
326 | Belgavi 2221 4 0.18 2227 | 936 42.03
327 | MAMSH, Jaipur 1494 12 0.80 1494 | 698 46.72
RCSMGMC &
328 | CPR, Kolhapur 887 0 0.00 887 | 248 27.96
PIMSR, Sangli,
329 | MH 611 0 0.00 611] 198 32.41
0.74 36.38
[som
MGMCR,
308 | Pondicherry 901 3 0.33 901 | 433 48.06
311 | VIMS, Bangalore 496 2 0.40 496 | 172 34.68
312 | DPH, Chennai 29 1 345 29 13 44.83
317 | Guntur, AP 1358 5 0.37 1358 | 380 27.98
320 | NIMS, Hyderabad 1998 31 1.55 1998 | 423 21.17
325 | SRM, Chemnai 605 0 0.00 605 | 453 74.88
1.02 41.93

 

Page 11 of 18

 

 
 

 

DOC

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
DR
4. SAFETY

There are 25,800 participants were recruited in the study. It is decided to consider all AEs reported till 11 am
(IST) March 1, 2021 for first 8000 enrolled participants. All the participants were followed up telephonically
for 7 days after each dose of vaccination and reported all the solicited AEs. Unsolicited AEs from all the
participants were reported throughout follow-up period (Till Day 42). A total of 655 adverse events were
reported and equally distributed in both vaccine and placebo groups. Among these 655 AEs 605 were mild, 34
were moderate and 16 were severe and the severity of the AEs is similar in both the groups. All the AEs
except 20 were resolved without sequelae. Detailed AEs list is summarized in the Table 6.

TABLE 6: SUMMARY OF ADVERSE EVENTS

 

Treatment Arm

 

Description BBV152 Placebo Total
(N=4,061) (N=3,804) (N=7,865)
n(%) n(%) n(%)

 

 

No of Subject with at least one

|Adverse Event 335 (8.25) 300 (7.89) 635 (8.07)

 

INo of Subjects with at least one Local Solicited AE
within 7 days after Day O Vaccination 99 (2.44) 94 (2.47) 193(245)
(1 event not resolved)

INo of Subjects with at least one Local Solicited AE
within 7 days after Day 28 Vaccination 55 (1.35) 39 (1.03) 94 (1.20)
(1 event not resolved)

 

 

No of Subjects with at least one Systemic Solicited AE
within 7 days after Day O Vaccination 94 (2.31) 55 (1.45) 149 (1.89)
(1 event not resolved)

 

INo of subjects with at least one Systemic Solicited AE
within 7 days after Day 28 Vaccination 30 (0.74) 23 (0.60) 53 ( No 0.67)
(1 event not resolved)

INo of subjects with at least one Unsolicited Adverse

 

 

 

 

 

 

 

 

 

 

 

Events 50(1.23) 67(1.76) 117 (1.49)

|AIl Ongoing Adverse Events 9(0.22) 11(0.29) 20(0.25)
Severity

Mild 317(781) 288 (7.57) 605 (7.69)

Moderate 17(0.42) 17 (0.45) 34 (0.43)

Severe 9(0.22) 7(0.18) 16 (0.20)

 

4.1 SERIOUS ADVERSE EVENTS

All the participants (25800) were followed up for serious adverse events (SAEs) and 43 SAEs were reported
till date and among those cases 33 were resolved, 3 cases are ongoing and 7 deaths were reported. All the
SAEs were not related to the vaccine and distributed equally among the two treatment groups. Detailed
description of the SAESs is given in the Table 7.

Page 12 0f 18

 

 
 

 

DOC

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT
BIOTECH
Lene Snemealiaa
TABLE 7: SAEs Line Listing
Study site E E
s. (Sereening Date of Seriousness | Diagnosis ofthe | Causalioy | Causalty | Quteome ot
No Number) occurrence of | “Crif Event Assessment | Assessment | mo Fyent
SAE by PI by Sponsor
19-11-2020 Road traffic
NIMs (1º Dose) accident (RTA)- Recovered and
j Hydorbia | (VaccinelPhcob | »9.112020 | Hospitalizaio | Crushlnjuryloh | Unrelaicd | trreied | discharged from
GSO0OLOT) o; Blinded) n foot and Fracture hospital on 23
2º dose was not neck of 2" 3º Nov 2020.
administered and 4ºmetatarsal.
Uncontrolled
18-11-2020 y
(1º Dose) Type-2 Diabetes Recovered and
NIMS, (Vaccine/Placeb Hospitalizatio | mellitus with Unlikely discharged from
2 Hyderabad e ltdod 29-11-2020 S Diabetic Unrelated | ion 19%
(32000073) & Blinded) n ketoacidosis and ospital on
2º dose was not dyselectrolvtemia Dec 2020
administered ys temia
20-11:2020 Recovered and
PGIMS, Robak | (VascineiEiesh Hospitalizatio Unrelated lischarged from
3 y É E Blindea 05-12-2020 spitaliza COVID-19 É Unrelated hospital 30º”
(32100001) o; Blinded) n :
rá Dec 2020 in
dose was not ir
se stable condition
administered
28-11-2020 :
NIMS, (1º Dose) Shortness of cisto om
4 Hyderabad | (VaccinePaceb | 95 52020 | Hospitalizatio | breath, pedal | Unlikely | tried | hospital 6º Dee
o; Blinded) n edema and fever à
(32000428) na 2020 in stable
2º dose was not (3 days). 1
se condition
administered
25-11-2020 Recovered and
NIMS, (vascinielaceb Hospitalizatio Untiket slischarged from
5 Hyderabad à; Blindod) 07-12-2020 praia CovID-19 * | Unreiated | hospital tl”
(82000272) | mi Dec 2020 in
dose was not ir
se stable condition
administered
28 zozo Recovered and
NIMS, (Vabcinoibice Hospitalizatio Uniikel discharged from
6 Hyderabad à; Blinded) 10-12-2020 praia CovID-19 * | Unriated | hospital Is?
(32000242) | om Dec 2020 in
dose was not ir
se stable condition
administered
: 08-12-2020 Recovercd and
E (1º Dose) discharged from
4 Hospital, (WaccinelPlceb | 4, 52020 | Hospializaio | Homocystcine | prega | Unrclacd hospital in
a o; Blinded) n stable condition
Fe 600192) 2º" dose was not on 26º Dec
administered 2020
- 07-12-2020
SRM Medical (1º Dose) a . Recovered and
College & | (yaceineiPlaceb Hospitalizatio | Clinical enteric discharged from
8 Hospital, cen 15-12-2020 S fever with Unrelated | Unrclated | Gsi o
E o; Blinded) n Á hospital on 17
Chennai q dehydration. DO
(32500018) dose was not
administered
People's College Recovered and
Rr fadical 10-12-2020 , discharged from
Sciences E (1º Dose) Left non- hospital on 18º
9 | Rescarch Contr, | (VaccinelPlacob | 17.12.2020 | Hospitlizatio | | funciioning Uneiated | Unrciaed | Dec 2020 wih
Bona Maisa | 9: Blindod) n ydronephrotic advice to follow
Pradesh 2º dose was not kidney up for further
G 409005 46) administered treatment plan
Pooplos College
of Medical q Doo
Sciences & | (yaccine/Placeb
10 | Rescarch Centre, | MISSIME as 21-12-2020 Death Death Unrelated | Unrclated Fatal
Bhopal, Madhya | ma
nto dose was not
0000800) administered
MGMCRLSBV, | 26122020 “Hollow viscus
u Puduchemry (1 Dose) 01.01.2020 | Hospitalizatio | perforation with | yroiated Unrelated Recovered
(30800300) | (VaecinelPinceb n Acute Kidney
o: Blinded) Injury -? Cause”

 

 

 

 

 

 

 

 

 

 

Page 130f 18

 

 

 
 

BBIL/BBV152-C/2020

Bharat Biotech International Limited

DOC

BHARAT

BIOTECH
Lead Sncaliom

 

2º dose was not
administered

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

People Colioge 10-12:2020 (1º
Sciences & Dose) ao Recovered and
12 | Research Centre, (VaccineiP! ace 06-01-2021 Hospitalizatio Liver abscess Unrelated Unrelated | discharged from
Bhopal, Madhya o; Blinded) n hospital on 15'
, 2" dose was not Jan 2021
Pradesh administered
(30900578) É o
Vydehi Institute 09-12-2020 (18
sã e Dose) aaa Hospitalizatio Recovered and
13 | pa (Vaceine/Placeb AA SPitaliziio | (ef ungopacity- | Unrelated | Unrelated | discharged from
escarch Centre, o: Blinded) awareness 0! n LRTI Hospital on 23º!
Bangalore. | 2 gose was not December 2020
(31100060) administered
People's College | go (1*
— of medical Dose) a Left non- Recovered and
14 | fescarch center, | (yaccine/Placeb Hospitalizatio | gnetioning discharged from
Bhopal, Madhya o: Blinded) 07-01-2021 n hiydronephrotic Unrelated Unrelated Hospital on
Pradesh 2º! dose was not kidney 21“Jan 2021.
(30900546) administered
Pcoples College
of Medical 18-12-2020 (1º
Sciences & Dose) ao ui Recovered and
15 | Research Centre, | (VaccinefPlaceb | 08-01-2021 | Hospitalizaio ie | gureted | Unciaed | discharged from
Bhopal, Madhya 0: blinded) » ante) ê ê Hospital on 19º
Pradesh 2" dose was not É Feb2021.
(30901496) administered
Pcoples College | 16/12/2020 (1º
of Medical Dose) 30-12-2020 Recovered and
16 Sciences & (Vaccine/Placeb (Date of Hospitalizatio discar ed fim
Rescarch Centre, o; Blinded) awareness of n Mature cataract Unrelated Unreclated | og al on IE
Bhopal, Madhya | 2" dose was not | SAE:13/01/202 2021
Pradesh administered 1) É .
(30901257)
People's College a :
of Medical 16/12/2020 (1 03/01/2021 CAD with ,
: Dose) a micro | hypertension with Recovered and
Sciences & : (Date of Hospitalizatio e Í
17 (Vaccine/Placeb e B/L Pneumi s discharged from
Research Centre, - Bi awareness of n Unrelated Unrelated e ih
o; Blinded) /ACS/TVD. She hospital on 6
Bhopal, Madhya | má SAE: o
2º! dose was not was also positive Jan 2021.
Pradesh dministered 13/01/2021) ith COVID-19.
(80901279) administer vei - 19.
People's College | 17/12/2020 (1º
of Medical Dose) Recovered and
18 Sciences & 14/01/2021 (2! Hospitalizatio discharged fr
Research Centre, Dose) 15/01/2021 n Unrelated Unrelated the hosvit om
Bhopal, Madhya | (Vaccine/Placeb cholelithiasis. » E DI
Pradesh o; Blinded) na
(30901436)
Pcople's College | 14-12-2020 (1º
of medical Dose) Recovered and
19 sciences and 11-01-2021 (2º Hospitalizatio | Renal Caleuli & soam ' fo
Research centre, dose) 18-01-2021 n with Unrelated Untelated | Sischarged from
e the hospital on
Bhopal, (Vaccine/Placeb Hepatomegaly. 19-01-2021
Madhya Pradesh o; Blinded) aa
(30901004)
21-12-2020 (1º
Nnvs, Do | 160202
20 Hyderabad (VaccinePiaceb | noss of the Death Death Unrelated | Unrelated Fatal
(32001 o; Blinded)
ni SAE21-01-
145) 2" dose was not 2021)
administered
Jawaharlal 25-11-2020 (1º
Nehru Medical Dose) baço
” a
21 | golegeand | 24122020 00 | arnessortho | Death Death Unrclated | Unrelated Fatal
Hospital, AMU, dose)
Ui e SAE-
Aligarh (Vaccine/Placeb 21012021)
(31300207) o; Blinded)

 

 

Page 14 0f 18

 

 

 
 

BBIL/BBV152-C/2020

Bharat Biotech International Limited

DOC

BHARAT

BIOTECH
Lead Sncaliom

 

Vydehi Institute

28-12-2020 (1º

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

chi Ins 11-01-2021
of Nursing Dose) o enticati, Recovered and
22 | Sciencesand | (Vaccine/Placeb (Dateot | Hospitalizaio | Ammica] viral discharged from
cine awareness of the n vn Unrelated | Unrelated
Rescarch Centre, | o; Blinded) SAE TIO pneumonia the hospital on
Bangalore 2º dose was not 2021) ” 15-01-2021
(81100290) administered
People's College 18-12.2020 (1º
É Dose) o . Recovered and
sciences and a Hospitalizatio | Generalised body R à
23 | Research centre, | 20012021 (2 21-01-2021 n pain Unrelated | Unclated | discharged from
Blhopal, Madhya dose) the hospital on
radesh (Vaccine/Placeb 25-01-2021
GOMISIo o; Blinded)
5122000 (5
Dose) 22-01-2021
ATIMS, New : e
2” Delhi (Vaccine/Placeb | (Date of SAE Death Death Unrelated | Unelated Fatal
30100090) o; Blinded) Awareness:
2º dose was not 24-01-2021)
administered
'GMERS 28-12-2020 (1%
Medical College Dose) aaoE
25 and Civil (Vaccine/Placeb | q areness of Death Death Unlikely Unlikely Fatal
Hospital, Sola, o; Blinded) SAEDTOL
Ahmedabad 2" dose was not 2021)
(81500928) administered
People's Colege 13-12.2020 (1º
f a Dose) a . Recovered and
26 sciences and 10012021 Hospitalizatio | Right eye mature eischarged tom
Research centre, 4, 01-02-2021 n cataractand left | Unrclated | Unreiated | dscha m
Bhopal, Madhya (2!Dose) eye pseudophakia Hospital on 12
a Hesh Ya | (Vaccine/Placeb ye pseudophakia Feb 2021.
(0900901) o; Blinded)
aaa 28-122020 (1º | 31012021
no Dose)
& Rescarch e
2” Centre, Ez Deo Death Death Unrclated | Unrelated Fatal
Kanchipuram, Ta (2 Dose) Awareness by
tiara Te | (VaccinefPlaceb | Sponsor: 01-02-
2500447) o; Blinded) 2021)
SRM Medical
College Hospital | 23-12-2021 (1º .
& Research Dose) 27-01-2021 iai Reco vered and
a D 2 Hospitalizatio | q; . discharged from
28 Centre (Vaceine/Placeb (Date of Viral pneumonia
Kanchipuram, o: Blinded) | avreness-02-02- n dueto COVID-I9 | Unrelated | Unrelated || the hospital on
Td nd à, 12 9º Feb 2021 in
Tamil Nadu 2º dose was not 2021) stable condition
(32500303) administered 2
People's College 12-12.2020 (1º
sciences and Dose) Hospitalizatio Recovered and
29 | poa ado | 09012021 E” | 02:02:2021 5 Chronic Otitis | Unrciated | Unrelated | discharged from
S Bh ao Dose) n media the hospital
Madh im tdesh | (Vaccine/Pinceb 0n18-02-2021
6 ODOOTTO o: Blinded)
People's College 10-12:2020 (1º
30 scienes and 070 Cada em Hospitalizatio Unelated | Unrelated cisstugea Hom
Rescarch centre, Do 02-02-2021 n Bronchial asthma nrelate nrelato. he host
Bhopal, Madhya Dose) the hospital on
Pradesh (Vaccine/Placeb 15-02-2021
cS0900606) o; Blinded)
- 27-12-2020 (1º
Maharaja
a1 | Agrasen Super 240 Cada em Hospitalizatio Unrelated isstugea Hom
speciality Do 04-02-2021 n COVID-I9 Unrelated A ho rec al
Hospital, Jaipur Dose) the hospital on
PD | (Vaccine/Placob 04-02-2021
6 ) o: Blinded)
, 27-12-2020 (1º
Maharaja
32 | Agrasen Super 240030 qu Hospitalizatio Unretaed | Unretuea | disstagoa Hom
speciality Do 04-02-2021 n COVID-I9 A A ho rec a
Hospital, Jaipur Dose) the hospital on
SRD | (Vaccine/Placob 04-02-2021
6 ) o: Blinded)

 

 

Page 15 of 18

 

 

 
 

DOC

 

 

 

 

 

 

 

 

  

 

 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT
BIOTECH
Lene Snemealiaa
Tamo ds | 05022021
Dose) (Date of as Could be Recovered and
33 | ANMS New | 26122020 (2º | avrencss-06-02- | Bospitalizatio Immune | associated | Under — | discharged from
Delhi n Thrombocytopeni j t
Gotomoia) Dose) 2021) aa with the Evaluation | the hospital on
(Vaccine/Placeb a Purpura. vaccine. 08-02-2021
o; Blinded)
Directorot | 09122020 (14
tá Dose) o Recovered and
Public Health & na Hospitalizatio o 2
34 | Medicine study | 060201 O 12-02-2021 n coviD-19 Unrelated | Unreiated | discharged from
site, Chennai Dose) the hospital on
(SI20000D | (accinefPiaceb 16-02-2021
o; Blinded)
People's College | q 12020 (14
of medical
, sciencesand | pg OL os Hospitaizaio | cnronic ot perna ana
S | Rescarch centre, 22021 ( 12-02-2021 n ronic otítis Unrelated | Untelated | discharged írom
Bhopal Dose) media the hospital on
pal, (Vaccine/Placeb 22-02-2021
Madhya Pradesh à; Blindod)
(30900291) :
Prakash Institute | 2912.2020 (1º
of Medical o
Science & Dose) Hospitalizatio | Fever, headache. Recovered and
36 R h 26-01-2021 (2º 13-02-2021 . dá h . Unrelated Unrelated discharged from
eat Dose) < n and coug relate mreited | o possíal om
angli, (Vaccine/Placeb 14-02-2021
Maharashtra * Blindod
(82900012) &: Blinded)
02-12-2020 (1º
ATIMS, New Dose) Hospitalizatio Recovered and
37 Delhi 30-12-2020 (2º! RE Myocardial . . discharged from
(30100044) Dose) 19-02-2021 n infaretion (MI) Uniikely | Unreiated | mo hospital on
(Vaecine/Placeb 01-03-2021
o; Blinded)
22-12-2020 (1º .
Dose) 24-02-2021 o Ongoing atthe
NIMS, má 2 Hospitalizatio o time of
38 H 19-01-2021 (2! (Date of i Under cs e
Iyderabad ” n CovID-19 Unlikely t submission of
(32001185) Dose) awareness: 25- Evaluation | ie repor by the
(VaecineiPlaceb | 022021) e report by
à Blindod) investigator
Sir Ganga Ram | 19-122020 (1 2A-02-2021 Ongoing at the
Hospital Marg, Dose) (Date of Hospitalizatio time of
39 = ” 20-01-2021 (2º awareness: 25- o Fever and body Under Under ici e
Rajinder Nagar, n submission of
8 Dose) 022021) ache Evaluation | Evaluation
New Delhi : the report by the
(32300066) | (Vaccine/Placeb investigator
o: Blinded) sea
30-11-2020 (1º
Aligarh Muslim Dose) ano Hospitalizaio Recovered and
“0 E 31-12-2020 (2º a spltatiza Epistaxis Under | discharged from
: awareness: 27- n Unrelated . B
Aligarh Dose) 022021 Evaluation the hospital on
(31300560) | (Vaccine/Placeb 2021) 27-02-2021
o; Blinded)
People's College a
of medical 10-12-2020 (1 01-03-2021
i d Dose) (Datcof Hospitalizatio Acute
41 Sciences an 07-01-2021 (2! à spitatiza a Under .
Rescarch centre, Do awareness: 03- n exacerbationot | Untciated | puaguat Ongoing
Bhopal, Madhya Dose) 032021) COPD valuation
Pr: (Vaccine/Placeb
radesh o: Blinded)
(30900606) Ê
26-122020 (15
Dose) 01-03-2021 enticati, Recovered and
42 | ANMS, New | o3 012021 (9 (Dateof Hospitalizatio =» . Under - | discharged from
Delhi Do 5 n Choleeystitis Unikeiy | pundo area
Gois Dose) awareness: 05- valuation | the hospital on
(Vaccine/Placeb | 032021) 02-03-2021
o; Blinded)
Vydehi Institute 06-01-2021 (1º
of Nursing Dose) 03-03-2021
43 Sciences and 03-02-2021 (2º (Date of Death Death Under Under Fatal
Research Centre, Dose) Awareness:05- a Evaluation | Evaluation ata
Bangalore | (VaccinefPlaceb | — 03:2021)
(31100476) o; Blinded)

 

 

 

 

 

 

 

 

 

 

Page 16 of 18

 

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

5. IMMUNOGENICITY

The Immunogenicity assessment was planned on the subset of the 600 participants who were recruited in the
category 3 sites. All the blood samples from these participants were collected on Day 0, Day 28, Day 56 and
these samples are being analysed. The immunogenicity data in terms geometric mean titers (GMTs) by
neutralizing antibody, S-protein, and RBD specific anti-IgG binding titer will be submitted to CDSCO.

6. EFFICACY (INTERIM ANALYSIS)

We are considering first 43 RT-PCR (1/3 of 130 as proposed in 1º interim analysis) positive events and
analysis has been done by taking data confirmed by sites. Participants who received two doses and not having
PD (protocol deviation) are considered in efficacy population. The first interim analysis is based on 43 cases,
of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the BBV152
(COVAXIN") group, resulting in a point estimate of vaccine efficacy of 80.69%.

TABLE 7: EFFICACY of BBV152

 

 

 

 

 

 

 

 

Treatment Arm
Description
BBV152 Placebo Total
(N = 12218) (N=12199) (N =24417)
First occurrence of Virologically confirmed
(RT-PCR) n (%) 7(0.057) 36(0.295) 43(0.176)

VE(%) 80.6

95% CI [78.1, 82.7]

p value <0.0001

 

 

 

 

 

7. CONCLUSIONS

Phase 3 study is conducted to evaluate the efficacy and safety of the COVAXINº vaccine. A total of 25800
participants were recruited, among these 67.2% were males and 32.8% were females. At-risk population,
ages > 60 years (9.4%), participants (<60 Years) with co-morbid conditions (16.7%) were enrolled. COVID-
19 seroprevalence was assessed among these 25800 participants at baseline and results reported that 34.3%
of the participants were Seropositive.

All the participants were followed up for their safety, 43 SAEs were reported and among these 33 were
resolved, 3 were ongoing and 7 deaths were reported. Among 25800 participants first 8000 enrolled
participants AEs were recorded. A total of 655 AEs were reported and most of them were mild in severity.
All the reported SAEs were not related to the vaccine.

COVAXINº vaccine efficacy was assessed based on the 43 accrued COVID-19 cases and reported that the
vaccine efficacy is 819%.

Page 17 of 18

 

 
 

 

DOC

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT

6.

10.

1.

12.

13.

14.

BIOTECH
Lead Sncaliom

8. REFERENCES

WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2021 Mar 5). Available from:
https://covidl9.who.int

Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016 Sep
29:3(1):237-61.

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when
COVID-19 disease is suspected. Interim guidance. Pediatr Med Rodz. 2020 May 20;16(1):9-26.

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from
Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. Journal of
Virology [Internet]. 2020 Mar 17 [cited 2020 Oct 15];94(7). Available from:
https://jviasm.org/content/94/7/e00127-20

Hoffmann M, Kleine-Weber H, Schroeder S, Kriiger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell
Entry Depends on ACE2 and TMPRSS?2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell.
2020 16;181(2):271-280.e8.

Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. European Respiratory Journal
[Internet]. 2020 Apr 1 [cited 2020 Oct 15];55(4). Available from:
https://erj ersjournals.com/content/55/4/2000607

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China,
of Novel Coronavirus-Infected Pneumonia. New England Journal of Medicine. 2020 Mar
26:382(13):1199-207.

Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus
(2019-nCoV) in Wuhan, China. J Med Virol. 2020 Apr;92(4):441-7.

Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J
Respir Crit Care Med. 2020 15;201(4):P7-8.

Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. New
England Journal of Medicine. 2020 May 21;382(21):1969-73.

Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging
coronavirus infection: advances and prospects in designing and developing vaccines,
immunotherapeutics, and therapeutics. Hum Vaccin Inmunother. 2020 Mar 18;1-7.

Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, et al. Microneedle array delivered
recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
EBioMedicine. 2020 May 1;55:102743.

Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity clinical
trial of an inactivated SARS-CoV-2 vaccine, BBV 152 (a phase 2, double-blind, randomised controlled
trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv. 2020 Dec
22:2020.12.21.20248643.

Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an

inactivated SARS-CoV-2 vaccine, BBV 152: a double-blind, randomised, phase 1 trial. Lancet Infect
Dis. 2021 Jan 21;

Page 18 0f 18

 

 
ANNEAURE-4
 

 

DOC
BHARAT
BIOTECH
Land Setor

INTERIM CLINICAL REPORT - RESTRICTED USE OF COVAXINº UNDER

TITLE:

PROTOCOL NO.:

VERSION NO.:

PRODUCT DETAILS:

SPONSOR:

INITIATION DATE:

DATE OF INTERIM
REPORT:

VERSION:

PREPARED BY:

CLINICAL TRIAL MODE

Restricted use of COVAXINº under clinical trial mode.

Protocol No: BBIL/COV AXTN/2021

4.0; Date: 12-01-2021

Whole-Virion Inactivated SARS-CoV-2 vaccine (BBVI52),
COVAXINM

Bharat Biotech International Limited (BBIL),
Genome Valley, Shameerpet, Hyderabad,
Telangana, India.

16/JAN/2021

06/MAR/2021

1.0

Medical Affairs Department, Bharat Biotech International
Limited and Sclin Soft technologies Pvt. Ltd.

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 10f 15

 

 

 

 
 

 

BHARAT
BIOTECH
Leme Senematino

Signature Page:
TITLE: Restricted use of COVAXINº under clinical trial mode.
PROTOCOL NO.: Protocol No: BBIL/COV AXTN/2021

VERSION NO.: 4.0; Date: 12-01-2021

We have read this report and conform that, to the bset of our knowledge it accurately
describes the conduct and results of the trial.

Signature & Date

Dr. V. Krishna Mohan,

Executive Director,

Bharat Biotech International Limited
Genome Valley, Hyderabad, India

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 20f 15

 

 

 

 
 

 

BHARAT

BIOTECH
Lot Snomalioo
Table of Contents

 

1. INTRODUCTIO)
2. ROLE OF ICMR:.

 

3. IMPLEMENTATION PLAN — PROCEDURES: ................... irem reeerecerece rece recerecere 5

 

3.1 | Vaccination Procedure:

 

3.2  Adverse Events and SAEs Collection Procedure:.................c ie rererecerece rece recerecene 6
4.
5.
6. SUMMARY OF ADVERE EVENTS REPORTED (Available data): ....................s 11
7. CONCLUSIONS:............... rece cre ereeereeeree eres are cere core cere cera cene cena cene cena cene cena senes 15

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 30f 15

 

 

 

 
 

 

BHARAT

BIOTECH
Lead Sncaliom

1. INTRODUCTION:

Bharat Biotech International Limited (BBIL) in collaboration with Indian Council of Medical
Research (ICMR) has developed an inactivated whole virion COVID-19 vaccine,
COVAXINº. The COVAXINº has been evaluated for safety, reactogenicity and
immunogenicity in phase 1 and 2 clinical trials and the trial reports were submitted to the
Central Drugs Standard Control Organization (CDSCO) India. COVAXINº has been
approved under emergency use authorization with permission number MF/BIO/21/000002,
dated 03.01.2021, F. No: BIO/MA/20/000103. This permission is given for restricted use in
emergency situation in public interest as an abundant precaution, in clinical trial mode, where
COVAXINº vaccine will be administered to the vaccine recipients and they will be followed

up for safety.

COVAXINº (prepared under Good manufacturing practices, as required under the Drugs and
Cosmetics Act, 1940 and the NCDT Rules 2019) has been approved by CDSCO for
Restricted Use in Emergency situation in Public Interest as an abundant precaution in Clinical

Trial Mode, in India on 3rd January 2021.

2. ROLE OF ICMR:

The scientists of ICMR have played a substantial role in the “Implementation Plan” of
Restricted use of COVAXINº under clinical trial mode. Scientists and research associates
from the following inistitutes were involved:

e National Institute of Nutrition, Hyderabad

e | ICMR-RMRCNE, Dibrugarh

e ICMR-RIRMS, Patna

e ICMR-National Institute of Malaria Research, New Delhi
e ICMR-NICPR, Noida

e ICMR-NCDIR, Bengaluru

e ICMR-National AIDS Research Institute. Pune

e ICMR-RMRC, Bhubaneswar

e | ICMR-DMRC, Jodhpur

e ICMR-National Institute for Research in Tuberculosis, Chennai
e | ICMR- RMRC, Gorakhpur

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 40f 15

 

 

 

 
 

 

BHARAT

BIOTECH
Lead Sncaliom

3. IMPLEMENTATION PLAN - PROCEDURES:

Bharat Biotech along with ICMR has taken approval for the Implementation Plan from the
Cental Ethic Committee of ICMR and and SEC committee of CDSCO. Subsequently, BBIL
has sent lakhs of hard copies of Fact Sheets, Informed Consent forms and Information

Leaflets to each designated vaccination sites across the country.

1. The Fact sheet in regional language was provided to the vaccine recipient before
vaccination and vaccine recipients were given time to read (in case of inability to read — it
was read out to him/her by vaccination staff) to understand it. Opportunity was given to
the vaccine recipients to ask clarifying questions to the vaccinator. Vaccinator has used
the information leaflet to answer the queries raised by the vaccine recipient. Following
questions and clarifications, the fact sheet was returned by the vaccine recipients to the

vaccinator.

2. If the vaccine recipient agrees to be vaccinated with COVAXINS, he/she has to sign an
informed consent form (ICF) (in case of inability to write, he/she has put a left thumb
impression on the ICF). Only after signing the informed consent, the vaccine recipients

were vaccinated with COVAXINº.

3. The informed consent is required at the time of first dose only. The separate consent is

not required for subsequent dose.
3.1 Vaccination Procedure:

Vaccine recipients were provided information in local language pertaining to the vaccine
administration with the help of a Fact Sheet containing details about COVAXINS. On day 01
(Visit 1) and day 28 (Visit 2) recipients were administered with the doses of the COVAXINº

via the intramuscular route.

After Day 1 and Day 28 vaccination, Vaccine recipients were given Adverse Event Form to
record the adverse events and they were made to remain for at least 30 minutes after

vaccination for observation to record any adverse event.

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 5of 15

 

 

 

 
 

 

BHARAT

BIOTECH
Lead Sncaliom

3.2 Adverse Events and SAEs Collection Procedure:

1. The designated staff has collated the consent forms obtained on the previous day for
record keeping. These were files with date of vaccination, session site specifications and
planning unit mentioned on it. A team, consisting of about 150 BBIL sales and marketing
employees and ICMR employees, was set-up at the regional level to telephonically
contact and enquire about the adverse events based on grouping of vaccine recipients as
follows:

e Day 7 after dose 1 including symptoms related to Covid-19 and positive RT-PCR
test (if any)

e Day 28 after dose 1 including symptoms related to Covid-19 and positive RT-PCR
test (if any)

e Day 7 after dose 2 including symptoms related to Covid-19 and positive RT-PCR
test (if any)

e Day 28 after dose 2, including symptoms related to Covid-19 and positive RT-
PCR test (if any)

2. The list of the vaccine recipients was generated on a daily basis with contact numbers.

3. Adverse events and serious adverse events following immunization (AEFI) informed
during the aforementioned contacts were recorded application against the respective

personnel identified of a vaccine recipient.

4. Grouping of the vaccine recipients in minor, severe and serious adverse event (as the case
may be) was done by District Immunization Officer (DIO) on a daily basis. For all serious
and severe cases, the Case Report Form (CRF) has been raised for further investigation

by District AEFI Committee.

5. In case of any serious adverse events linked to the COVAXIN immunization program,
the details of the serious adverse events were recorded by the designated Immunization
officers or Health care workers of the vaccination site. BBIL has coordinated through

email/telephone/other means to coordinate with the Immunization officers/Health care

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 60f 15

 

 

 

 
 

 

BHARAT

BIOTECH
Lead Sncaliom

workers to get the required details of SAE. Upon receipt of these details, submitted SAE
report to DSMB, ICMR Central Ethics Committee CDSCO/DCGI.

6. Causality of all SAEs was assessed by the Immunization officer, BBIL, ICMR Central

Ethics Committee.

7. Drug regulators (Drugs Controller General of India, DCGI) has been provided with the

collated data for review and assessment on vaccine safety, on a monthly basis.

8. The end point and the final outcome of the aforementioned AEFI monitoring related to

COVAXIN was based on the recommendations made by the regulatory authority (DCGD).

A toll-free number and an email, the details of which are in the fact sheet, were assigned
at BBIL to answer the queries of vaccine beneficiaries. Numerous queries via telephone

and emails were addressed on a daily basis.

4. COVERAGE OF COVAXINº:

As of 05” March 2021, a total of approximately 13.9 lakh doses of COVAXINº have been
administred in approximately 13.3 lakh beneficiaries. The beneficiaries included healthcare
workers and frontline workers as designated by the Ministry of Health, Government of India.
These doses were admininsterd in 18 States across India. A total of 20 Serious Adverse
events have been reported in these beneficiaries. The cumulative coverage report of

COVAXINº across India, as of 05! March 2021, is given in Table 1.

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 7of15

 

 

 

 
 

 

 

BHARAT

Table 1: Cumulative Coverage Report of COVAXIN (05.03.2021)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cumulative Coverage of COVAXIN
AEFI reported
Cumulative Achievement Severe/Serious Deaths reported
S.No. State/UT AEFIs
Ist Dose | 2nd Dose Total pos pa pa pd
1 pa 74405 4219 78624 0 0 0 0
2 | Assam 40772 2876 43648 1 0 0 0
3 | Bihar 30777 5629 36406 0 0 0 0
4 | Delhi 89743 4076 93819 9 0 0 0
5 | Gujarat 222166 11096 233262 1 0 0 0
6 | Haryana 37484 2619 40103 0 0 0 0
7 | Jharkhand 32333 83 32416 0 0 0 0
8 | Karnataka 6169 3111 9280 0 0 0 0
9 | Kerala 64003 0 64003 0 0 0 0
10 | Madhya 123006 0 123006 1 0 0 0
Pradesh

11 | Maharashtra 19673 2420 22093 1 0 0 0
12 | Odisha 47920 12972 60892 1 0 0 0
13 | Punjab 1307 0 1307 0 0 0 0
14 | Rajasthan 177407 4696 182103 2 0 0 0
15 | Tamil Nadu 13076 2411 15487 3 0 0 0
16 | Telangana 48103 0 48103 1 0 0 0
17 | Uttar Pradesh 173971 5951 179922 0 0 0
18 | West Bengal 130175 282 130457 0 0 0 0

Total 1332490 62441 1394931 20 0 0 0

 

 

 

 

 

 

 

 

 

 

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 80f 15

 

 

 
 

 

BHARAT

BIOTECH
Lead Sncaliom

5. FOLLOW-UP OF THE BENEFICIARIES:

The list of beneficiaries was generated on a daily basis with contact numbers. A team,
consisting of about 150 BBIL sales and marketing employees and ICMR employees, was set-
up at the regional level to telephonically contact and enquire about the adverse events.
Adverse events and serious adverse events following immunization (AEFI) informed during
the calls were recorded application against the respective personnel identified as a

beneficiary.

With the best efforts of both BBIL and ICMR teams, we connected with the vaccine
beneficiaries. Most of the telephonic calls were not answered and in many cases the phone
numbers of the beneficiaries were incorrectly give. The summary of adverse events of
enrolled beneficiaries is given in Table 2. The State-wise data of beneficiaries is given in
Table 3.

A total of 20 serious adverse events have been reported in this implementation plan. Despite
numerous attempts by BBIL and ICMR, data was not shared by the site immunization
officers, and we could collect the data of 11 serious adverse events. The summary of serious

adverse events is given in Table 4.

Table 2: Summary of Adverse Events of Enrolled Beneficiaries (Available data)

 

 

 

 

 

 

S. No Parameter Total
1 Number of Beneficiaries with AEFl in less than 30 mins 914
2 Number of Beneficiaries with AEFIin 7 days 6835
3 Number of Beneficiaries with AEFI in 28 days 400
4 Beneficiaries Hospitalised Due to SAE 20
5 SAE Death 0

 

 

 

 

 

*AEFI-Adverse Event following immunization.

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 90f 15

 

 

 

 
 

 

DOC
BHARAT
BIOTECH
Land Setor

Table 3: State-wise Call-logs of Enrolled Beneficiaries (Available data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SNo District/ | AEFI In less than vo 7 AEFI Within SAE
State 30 Minutes 28 Days (Death)
Days
1 Delhi 112 1366 40 0
2 Rajasthan 44 202 18 0
3 | Tamil Nadu 51 1366 285 0
4 Assam 0 595 0 0
5 Orrisa 0 446 0 0
6 West 0 7 0 0
Bengal
7 UP 0 431 0 0
8 Bihar 0 445 0 0
9 Jharkhand 0 197 0 0
10 | Andhra 0 0 0 0
Pradesh
11 | Telangana 1 0 0 0
12 | Kamataka 0 259 24 0
13 | Kerala 0 0 0 0
14 | Gujarat 0 82 0 0
15 | Maharashtra 706 732 36 0
16 | Haryana 0 637 0 0
17 | Madhya 0 0 0 0
Pradesh
Total 914 6835 400 0

 

 

 

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 10 of 15

 

 

 

 
 

 

6. SUMMARY OF ADVERE EVENTS REPORTED (Available data):

e A total of 914 beneficiaries had Adverse event Following immunization within 30
mins.

e A total of 6835 beneficiaries had Adverse event Following immunization within 7
days

e A total of 400 beneficiaries had Adverse event Following immunization within 28
days.

e Atotal of 20 beneficiaries were hospitalized due to SAEs.

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 110f 15

 

 

 

 
 

DOC
BHARAT

BIOTECH
Lead Sncaliom

Table 4: Summary of Serious Adverse Events (Available data)

 

Place of

S.No na fi
vaccination

Date of
administration

Date of
occurrence
of SAE

Seriousness
Criteria

Brief description about the Serious Adverse
Event (SAE)

Outcome
of the
Event

Date of
Submission of
Initial Report to
CDSCO, EC, and
Sponsor by the PI

Date of
submission
report to
DSMB

 

1. New Delhi

16/01/2021

(1º Dose)

19/01/2021

Hospitalization

A male vaccine recipient of age 42 years was
administered with the first-dose of COVAXIN
on 16º January 2021. During the Day 7
follow-up, we came to know that a vaccine
recipient who took COVAXIN atESI
Hospital, Basaidarapur, New Delhi has been
admitted to the hospital with complaints of
weakness on one side of the body (hemiparesis
on one side of the body from the a” Day
onwards) as per the information written on the
Adverse Event Form filled by the vaccine
recipient. No immediate adverse event(s) was
reported within 30 minutes after vaccination.
On further telephonic follow-up with the
concerned doctor of the hospital, he informed
that the power in the limbs are 5/5 and it may
not be hemiparesis, but the person has
weakness on one side of the body. The details
of the hospital records, laboratory reports, and
treatment are still awaited from the
vaccination centre.

Discharged
from the
hospital

25-01-2021

25-01-2021

 

2. Tamil Nadu

 

 

 

 

 

09/02/2021 (1º
Dose)

 

09/02/2021

 

Hospitalization

 

A female vaccine recipient of age 23 years
was administered with the first dose of
COVAXIN on 9º Feb 2021. She was admitted
to the hospital within 30 minutes after
vaccination with complaints of itching and
rashes, treated accordingly, recovered and was
discharged from the hospital on 11º Feb 2021.
The details of the events are still awaited from
the vaccination center.

Page 12 0f 15

 

Recovered
on 11-02-
2021

 

18-02-2021

 

18-02-2021

The information contained in this report is strictly confidential. It is not to be published or disclosed to third parties, without written authorization from the sponsor

 

 

 

 

 
 

 

BHARAT

BIOTECH

   

 

 

 

 

 

Lenda
3. Tamil Nadu | 17/02/2021 13/02/2021 | Hospitalization A female vaccine recipient of age 59 years | Details 22-02-2021 22-02-2021
(1º Dose) was vaccinated with the first-dose of | awaited
COVAXIN on 17” Jan 2021. She developed | from the
fever, and was tested positive for COVID-19 | vaccination
and was admitted to the hospital from 13º” Feb | centre
2021. The details of the events are still
awaited from the vaccination center.
4. Gujarat 13/02/2021 15/02/2021 | Hospitalization A male vaccine recipient of age 48 years was | Details 22-02-2021 22-02-2021
(1º Dose) administered with the first-dose of COVAXIN | awaited
on 13º Feb 2021. He had no immediate | from the
adverse events within 30 minutes after | vaccination
vaccination. He was admitted to the hospital | centre
from 3"! day of vaccination with complaints of
fever, and diarrhoea, and is being treated in the
hospital. The details of the events are still
awaited from the vaccination center.
5. Tamil Nadu | 20/02/2021 29/02/2021 | Hospitalization A male vaccine recipient of age 55 years was | Details 25-02-2021 25-02-2021
administered with the first-dose of COVAXIN | awaited
on 20 Feb 2021. She had no immediate | from the
adverse events within 30 minutes after | vaccination
vaccination. He was admitted to the hospital | centre
with complaints of Pain for 2days, Upper
respiratory tract infection for 3days, Sugar
level increased, admitted for COVID positive
on 29-01-2021 and discharged on 02-02-2021.
The details of the events are still awaited from
the vaccination center.
6. Delhi 01/02/2021 01/02/2021 | Hospitalization A Female vaccine recipient was administered | Discharged | 05-03-2021 05-03-2021
(1º Dose) with the first dose of COVAXIN on 1º Feb | within 4
2021. She was admitted to the hospital after | hours
vaccination with complaints of shivering,
unconscious and was discharged within 4
hours from the hospital on 1º Feb 2021.
7. Delhi 01/01/2021 20/01/2021 | Hospitalization A male vaccine recipient was administered | Details 05-03-2021 05-03-2021
(1º dose) with the first dose of COVAXIN on 18º Jan | awaited
2021. He was admitted to the hospital on 20” | from the
Jan 2021 with complaints of precipitation of | vaccination

 

 

 

 

 

 

 

 

 

 

The information contained in this report is strictly confidential. It is not to be published or disclosed to third parties, without written authorization from the sponsor

Page 130f15

 

 

 

 

 
   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BHARAT
BIOTECH
Lenda

liver disease for hepatic encephalopathy and | centre
Shifted to ICU 25” Jan 2021.

8. Delhi 12/02/2021 17/02/2021 | Hospitalization A male vaccine recipient was administered | Details 05-03-2021 05-03-2021

(1º dose) with the first dose of COVAXIN on 12 Feb | awaited

2021. He was admitted to the hospital on 17 | from the
Feb 2021 after vaccination with complaints of | vaccination
low BP, Rashes, Fever, Itching Redness of | centre
Skin, Weakness, Vertigo, from the hospital
on 22" Feb 2021.

9. Chennai 25/02/2021 05/03/2021 | Hospitalization A female vaccine recipient was administered | Details 05-03-2021 05-03-2021
with the first dose of COVAXIN on 25” Feb | awaited
2021. She was admitted to the hospital after | from the
vaccination on 5” Mar 2021 with complaints | vaccination
of pain, fever, body ache and malaise. centre

10. Delhi 16/01/2021 16/01/2021 | Hospitalization A 21 year old Male vaccine recipient from | Recovered | 05-03-2021 05-03-2021
Delhi was administered with the first dose of | &
COVAXIN 0n16” Jan 2021. The subject Discharged
developed an anaphylactic reaction following
on 16º Jan 2021 Thereafter the subject
presented with complaints of rash with
predominance on chest and upper back
associated with itching. A diagnosis of post
vaccination allergic reaction was Kkept.
Steroids were administered along with
antihistamines. The subject is now
symptomatically better at the time of discharge

11. Delhi 25/01/2021 25/01/2021 | Hospitalization A 41 year female vaccine recipient was | Recovered | 05-03-2021 05-03-2021
administered with the first dose of COVAXIN | &
on 25” Jan 2021. She had no immediate Discharged
adverse events within 30 minutes after | On 3º Feb
vaccination. From day 3 onwards developed | 2021.
difficulty in breathing and chest pain admitted
to the hospital on 29º Jan 2021 and discharged
on 3º Feb 2021.

The information contained in this report is strictly confidential. It is not to be published or disclosed to third parties, without written authorization from the sponsor
Page 140f15

 

 

 

 

 
 

 

Soc
BHARAT BBIL/BBV152/2020 Bharat Biotech International Limited

BIOTECH
Lead Sncaliom

7. CONCLUSIONS:

The Restricted use of COVAXINº under clinical trial mode was initiated on 16º Jan 2021.
Under this program, a total of more than 13 lakh beneficiaries have been vaccinated with
COVAXINº.

Despite numerous attempts by BBIL and ICMR, data was not shared in a timely manner by
the site immunization officers. A total of 8149 beneficiaries have reported adverse events
following immunization. No death cases were reported in the restricted use of COVAXINº

under clinical trial mode. M conclusion, the COVAXINº can be considered as a safe vaccine.

The information contained in this report is strictly confidential. It is not to be published or disclosed to third
parties, without written authorization from the sponsor

Page 15 0f 15

 

 

 

 
ANNEAURE-5
Diorxiv preprint doi: htips.//Goi.org/10.1101/2021.01.20.420966; this version posted January 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the authorflunder, who has granted bioRxiv a license to display the preprint in perpetuity. Itis made
available under aCC-BY-NC 4.0 International license.

Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum
Gajanan N.Sapkal!, Pragya D. Yadav”!, Raches Ella?, Gururaj R. Deshpande', Rima R. Sahay!,
Nivedita Gupta”, V Krishna Mohan?, Priya Abraham!, Samiran Panda”, Balram Bhargava”
Author”s affiliations:

Hndian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India
Pin-411021

?Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana, India
Pin-500078

“Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari
Nagar, New Delhi, India Pin-110029

“Corresponding author:

Dr. Pragya D. Yadav,

Scientist “E” and Group Leader,

Maximum Containment Facility,

Indian Council of Medical Research-National Institute of Virology,
Sus Road, Pashan, Pune, India Pin-411 021.

Phone: +9120-26006111, Fax No. 91-20-26122669

Email: hellopragya22 O gmail.com

Abstract

We performed the plaque reduction neutralization test (PRNT'so) using sera collected from the 26
recipients of BBVI52/COVAXINTM against hCoV-19/India/20203522 (UK-variant) and
hCoV27 19/India/20200111 (heterologous strain). A comparable neutralization activity of the
vaccinated individuals sera showed against UK-variant and the heterologous strain with similar

efficiency, dispel the uncertainty of possible neutralization escape.
Diorxiv preprint doi: htips.//Goi.org/10.1101/2021.01.20.420966; this version posted January 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the authorflunder, who has granted bioRxiv a license to display the preprint in perpetuity. Itis made
available under aCC-BY-NC 4.0 International license.

Main text

The rapid surge inSARS-CoV-2 cases due to the Variant of Concemn (VOC) 202012/01, also
known as lineage B.1.1.7 or 20B/501Y.V1, in the United Kingdom (UK)! raised concerns in
several countries. Many of these countries had direct flights to and from UK and the variant was
associated with high transmissibility. Identification of other variants from South Africa?also
initiated a global discussion on the challenges that these new variants could pose to the current
vaccine candidates. The genome of the UK-variant has seventeen mutations, eight of which
were found in spike receptor-binding domain (RBD) mediating the attachment of the virus to the
angiotensin converting enzyme 2 (ACE2) receptor on the surface of human cells.”Therefore, it
appeared that the majority of the vaccine candidates, being either recombinant or specifically
targeting the single epitope of original D614G ancestral spike sequence, might not be able to
generate an efficient immune response against the new variants. Here, we successfully isolated
and characterized the hCoV-19/India/20203522 SARS-CoV-2 (VOC) 202012/01 from UK-
returnees in India with all signature mutations of the UK-variant.* Earlier, we have reported
development of an inactivated whole-virion SARS-CoV-2 vaccine BBV152 (COVAXINTM),
which elicited remarkable neutralizing antibody response in phase I clinical trial against hCoV-
19/India/2020770 (homologous), and two heterologous strains from the unclassified cluster
namely hCoV-19/India/2020Q111 and hCoV-19/India/2020Q100.º In phase TI clinical trial, the
vaccine candidate showed noteworthy results withplaque reduction neutralization test (PRNTso).
The sero-conversion rate with neutralizing antibodies (NAb) following vaccination with
BBVI52 was 99.6%. Here, we present the NAb titers (PRNTso) to underline the efficacy of
BBVI52 vaccine candidate against SARS-CoV-2 UK-variant and one of the heterologous

strains hCoV-19/India/2020Q111 (unclassified cluster)”. Sera collected from 38 vaccine
Diorxiv preprint doi: htips.//Goi.org/10.1101/2021.01.20.420966; this version posted January 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the authorflunder, who has granted bioRxiv a license to display the preprint in perpetuity. Itis made
available under aCC-BY-NC 4.0 International license.

recipients, who received BBV152 vaccine-candidate in phase-I trial4 had equivalent NAb titers
to hCoV-19/India/2020770 homologous strain and two heterologous strains with the
characteristic N501Y substitution of the UK-variant; hCoV-19/Tndia/20203522 (UK strain) as
well as hCoV-19/India/20200111 (Figure 1 A and B). The median ratio of 50% neutralization of
sera was found to be 0.8 when compared with hCoV-19/India/2020770 against mutant
hCoV19/India/20203522 (UK strain), and 0.9 while compared with hCoV-19/India/2020Q111.
Non parametric Kruskal-Wallis test for the comparison of the PRNTso values from different
groups revealed non-significant difference (p >0.05; Figurel). Andreano E et al. reported an
escape of the UK-variant with E484K substitution, which was followed by an 11-amino-acid
insertion in the NTD N5 loop (248aKTRNKSTSRRE248k) from high NAb in convalescent
plasma, which was a serious concem pertaining to the potential efficacy of the vaccines.” Our
study evidently highlighted comparable neutralization activity of vaccinated individuals sera
against variant as well as heterologous SARS-CoV-2 strains. Importantly, sera from the vaccine
recipients could neutralise the UK-variant strains discounting the uncertainty around potential
escape. It was reassuring from the PRNTso data generated in our laboratory that the indigenous
BBV152/ COVAXINTM, following its roll out in vaccination program, could be expected to
work against the new UK-variant. It is unlikely that the mutation 501Y would be able to dampen
the potential benefits of the vaccine in concern.

Acknowledgement

We thank the scientific staff of Maximum Containment Facility, ICMR-NIV, Pune Dr. Dimpal
A. Nyayanit, Scientist C and Dr. Deepak Y. Patil, Scientist-B for providing excellent support.
Also, authors are thankful to Darpan Phagiwala, Technician C, Prasad Gomade, Data Entry

Operator, Diagnostic Virology Group, ICMR-NIV, Pune for excellent technical support.
Diorxiv preprint doi: htips.//Goi.org/10.1101/2021.01.20.420966; this version posted January 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the authorflunder, who has granted bioRxiv a license to display the preprint in perpetuity. Itis made
available under aCC-BY-NC 4.0 International license.

Data availability

The data that support the findings of this study are available from the corresponding authors

upon reasonable request.

Author Contributions

PDY and GNS contributed to study design, data collection, data analysis, interpretation, writing
and critical review. GRD and RE contributed to data analysis and interpretation, writing and
critical review. RRS, NG, VKM and SP contributed to data collection, writing and critical

review. PA and BB contributed to writing and critical review of the manuscript.

Conflicts of Interest

The authors declared no competing interest

Financial support

Financial support was provided by the Department of Health Research, Ministry of Health and

Family Welfare, New Delhi, at ICMR-National Institute of Virology, Pune.

References:

1. Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir
Med. 2021 Jan 5:$2213-2600(21)00005-9. doi: 10.1016/$2213-2600(21)00005-9. Epub
ahead of print. PMID: 33417829; PMCID: PMC7784534.

2. Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS-CoV-2
receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;

182(5):1295-310.
Diorxiv preprint doi: htips.//Goi.org/10.1101/2021.01.20.420966; this version posted January 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the authorflunder, who has granted bioRxiv a license to display the preprint in perpetuity. Itis made
available under aCC-BY-NC 4.0 International license.

3. Yadav PD, Nyayanit DA, Sahay RR, et al. Isolation and characterization of VUI97
202012/01, a SARS-CoV-2 variant in travellers from the United Kingdom to India. J
Travel Medicine. DOI: 10.1093/jtm/taab009

4. Ella R,Vadrevu KM Jogdand H,et al.A Phase 1: Safety and Immunogenicity Trial of an
Inactivated SARS-CoV-2 Vaccine-BBV 152medRxiv 2020.12.11.20210419.

5. Ella R, Reddy S,JogdandH,et al. Safety and immunogenicity clinical trial of an
inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised
controlled trial) and the persistence of immune responses from a phase 1 follow-up report
medRxiv 2020.12.21.20248643.

6. Deshpande GR,SapkalGN,Tilekar BN,et al. Neutralizing antibody responses to SARS-
CoV-2 in COVID-I9 patients. Indian J Med Res. 2020 Aug 28. doi:
10.4103/;jmr.IMR 2382 20. Epub ahead of print. PMID: 32859866

7. AndreanoE,PicciniG,Licastro D,et al. SARS-CoV-2 escape in vitro from a highly

neutralizing COVID-19 convalescent plasma. bioRxiv. 2020
Diorxiv preprint doi: htips.//Goi.org/10.1101/2021.01.20.420966; this version posted January 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the authorflunder, who has granted bioRxiv a license to display the preprint in perpetuity. Itis made
available under aCC-BY-NC 4.0 International license.

 

A =0.9999(n6)

d.4540 (ns) casrots;

 

Loga PRNTso

 

oriumazo

” O icovasamaianoz

O tonta

de ph, Rostos a,qo ee

 

e
et Ema,

Log, PRNTsn

 

vruno oo
a
fds
e+o
Ato
nto
a
esta
a
uja
ea
2

TI TI TT TT
PA AA AP A A an
SPDP SDS

Sd
8
So
Sd
Sd
So
8
Sd
So
Zo À
27
%o
Zo
Za À
25
Ze
2a |

Individuais samples

 

 

 

Figure 1: (A) Neutralising antibody response of BBV152/COVAXIN!M vaccinated sera
against SARS CoV-2 strains: Neutralizing antibody titers (PRNTso) of vaccine's sera against
hCoV-19/India/2020770 (homologous), hCoV-19/India/20203522 (heterologous UK strain) and
hCoV-19/India/2020Q111 (heterologous unclassified cluster). The bar represents the geometric
mean and standard deviation of the respective group titers. Non-parametric Kruskal-Wallis test
was used for the comparison of the PRNTso values from different groups. The p-values above
0.05 were considered non-significant and are marked on the figure (ns-non-significant). (B)
Comparison of PRNTs value of each vaccine recipient's sera with three strains of SARS
CoV-2: Neutralizing antibody titers (PRNTs9) of each vaccinees' sera against hCoV-

19/India/2020770 (homologous), hCoV-19/India/20203522 (heterologous UK strain) and hCoV-
Diorxiv preprint doi: htips.//Goi.org/10.1101/2021.01.20.420966; this version posted January 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the authorflunder, who has granted bioRxiv a license to display the preprint in perpetuity. Itis made
available under aCC-BY-NC 4.0 International license.

19/India/20200111 (heterologous unclassified cluster).The bar represents the mean and standard

deviation of the respective sera.
 

 

BBIL/BBV152-C/2020

DOC
BHARAT

BIOTECH
Lead Sncaliom

Bharat Biotech International Limited

INTEGRATED CLINICAL AND STATISTICAL REPORT

Title:

Protocol Number:

Design:

Phase:

Version:

Sponsor:

Study Initiation Date:
Study Completion Date:

Co-ordination Unit
(Responsible for
Preparation of the
Report) Clinical
Operations
Management Unit

An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled,
Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity, and
Lot-to-Lot consistency of BBV 152, a Whole-virion Inactivated SARS-CoV-
2 Vaccine in Adults >18 Years of Age.

BBIL/BBV152-C/2020

This is a randomized, double-blind, phase 3 study to evaluate the Efficacy,
Safety, and Immunogenicity of BBV152B, a Whole-Virion Inactivated
SARS-CoV-2 Vaccine in Volunteers aged 18 years and above.

DI

1.0

Bharat Biotech International Limited (BBIL),

Genome Valley, Shameerpet, Hyderabad,
Telangana, India.

&

Indian Council of Medical Research (ICMR),
New-Delhi, India

16º November 2020

Ongoing

IQVIA
&

BHARAT BIOTECH INTERNATIONAL LIMITED

Page 1of 18

 

 
 

 

BBIL/BBV152-C/2020

Sponsor Representative:

GCP Statement:

Date of Report:
Prepared by:

Study period (years):

Date of 1º Dose 1º Subject:

Date of 1º Dose last subject:

Trial Registration:

S0€
Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

Dr. V. Krishna Mohan

Whole-time Director

Bharat Biotech International Limited (BBIL)
Genome Valley, Hyderabad India

Tel +91 40 2778 4003 Fax: +91 40 2348 0560
Email:kmohan E bharatbiotech.com.

and

Dr. Nivedita Gupta

Scientist F, Epidemiology and Communicable Diseases,
Indian Council of Medical Research (ICMR),
New-Delhi, India

Tel: +91-11-26589397

Email: guptanivedita hgO icmr.gov.in

The trial is being conducted in compliance with the protocol, GCP,
Schedule Y (Drugs and Cosmetics Act, 2005) and Ethical Guidelines for
Biomedical Research on Human Participants (Indian Council of Medical
Research, 2006)

05º March 2021

Medical Affairs Department
Bharat Biotech International Limited

1 Year

November 16, 2020
January 8, 2021

CTRI/2020/11/028976

Page 20f 18

 

 
 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited

EIQLECH

Signature Page:

Study Title: An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled. Multicenter Study
to Evaluate the Efficacy. Safety, Imnmunogenicity, and Lot-to-Lot consistency of BBV 152, a Whole-virion
Inactivated SARS-CoV-2 Vaccine in Adults =18 Years of Age.

  

Review and approval of the Integrated Clinical and Statistical report.

We have read this report and confirm that, to the best of our knowledge, it accurately describes the conduct
and results of the trial.

Signature & Date

Dr. V. Krishna Mohan
Whole-time Director
Bharat Biotech International Limited (BBIL)
Genome Valley, Hyderabad India

Tel +91 40 2778 4003 Fax: +91 40 2348 0560
Email: kmohanBbharatbiotech com

  

Page 3 0f 18

 

 

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT
BIOTECH
Lot Snomalioo

Title: An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to
Evaluate the Efficacy, Safety, Immunogenicity, and Lot-to-Lot consistency of BBV152, a Whole-virion
Inactivated SARS-CoV-2 Vaccine in Adults >18 Years of Age.

Protocol No.: BBIL/BBV152-C/2020

Investigational Vaccine: Whole-Virion Inactivated SARS-CoV-2 vaccine (BBV152B).

Study Population: A total sample size of 25,800 volunteers ages 18 years and above were
recruited and administered with vaccine and placebo in 1:1 ratio.

The study was conducted in 25 sites all zone of India.

Study Centres and Investigators:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RA . as Site Name & Location Zone
1 308 MG Medical College, Sri Balaji Vidyapeeth - Dr. PajanivelRanganadin South
(Pondicherry)
2 311 | Vydehi institute of medical sciences — Dr. Akshata (Bangalore) South
3 312 Director of Public Health & Preventive Medicine — Dr. SelvaVinayagam - South
(Chennai)
4 317 || Government Fever Hospital, Guntur - Dr. Laxmi Kumari (Guntur) South
5 320 | Nizam's institute of Medical Sciences -Dr. Prabhakar Reddy (Hyderabad) South
6 325 | SRM Hospital & Research Center - Dr. Satyajit Mohapatra (Chennai) South
7 326 | Jeevan Rekha Hospital - Dr Amit Bhate, (Belgaum) South
8 309 | People's University - Dr. Raghavendra Gumashta (Bhopal) Central
9 302 | All India Institute of Medical Sciences — Dr. Chadramani Singh (Patna) East
ICMR-National Institute of Cholera and Enteric Diseases - Dr. Suman
10 305 East
Kanungo (Kolkata)
1 318 | (IMS) & SUM Hospital - Dr. E Venkata Rao (Bhubaneswar) East
12 301 | All India Institute of Medical Sciences — Dr. Sanjay Rai (New Delhi) North
13 303 | ESIC Medical College and Hospital — Dr. Anil Pandey (Faridabad) North
14 313 | Aligarh Muslim University - Dr. Md. Shameem (Uttar Pradesh) North
15 321 PGIMS - Dr. Savita Verma (Rohtak) North
16 323 | Gangaram - Dr Anupam Sachdeva (New Delhi) North
17 324 | Prakhar Hospital — Dr. Jitendra Kushwaha, Kanpur North
18 307 | Lokmanya Tilak Municipal General Hospital-Dr. N.T. Awad (Mumbai) West
19 310 || Rahate Surgical Hospital & ICU - Dr. Manish Multani (Nagpur) West
o) 315 GMERS Medical College and Civil Hospital - Dr. Parul Bhatt West
(Ahmedabad)
21 316 | Sir J.J. Group of Hospitals - Dr. PritiMeshram (Mumbai) West
22 322 | Redkar Hospital and Research Centre - Dr. Sagar Redkar (Goa) West
23 327 Maharaja Agrasen Multi speciality Hospital — Dr. Manish Kumar Jain - West
(Jaipur)
24 328 RCSMGMC & CPR Hospital — Dr. Sunita Jaiprakash Ramanand West
(Kolhapur)
o) 329 E Institute of Medical Science & Research — Dr. Vijaykumar Patil West

 

 

 

Page 40f 18

 

 
 

 

DOC

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
PiGReçh
Table of Contents
1. | INTRODUCTION.............. remate ram arara aeaaram ceara ceara e aeaate ceara aerea eeananea 6
2. STUDY DESIGN... eee eee eee eeane aeee rea aaa aaa amena rama rara 7
3. STUDY POPULATION... eeeeeemeeee emana e ane e aeee ana a manera mearaaramaaaa 8
3.1 AT-RISK POPULATION ............. ereta aeee aerea aaa meramente 9
3.2 GENDERAND AGE WISE CLASSIFICATION OF THE PARTICIPANTS............ 10
3.3 INFECTION RATE & SEROPREVALENCE ............... rm eeemaeeeamaearamermaias 10
4. SAFETY... een eeae cerne eeaea eae aeee aaa ane aeee aaa aaa aaa aerea rama arartama atas 12
4.1 SERIOUS ADVERSE EVENTS............. tener emeeee emana remeeeeremeerer remate 12
5. | IMMUNOGENICITY .......... remetem ram raramente arara ae arara arara eeanes 17
6. EFFICACY ...... eee ceara remar e mean rame aaa ra mataram cantam aaara ataca arara aeee reaeates 17
7. CONCLUSION ........... ease rama arara aaa ceara ataca ara area aeee reaeanes 17
8. REFERENCES... ienes ea marea aa manera ceara ataca are ate ae aeee reaeanea 18

Page 5 of 18

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

1. INTRODUCTION

The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19) has, as on
March 05",2021, spread to over 216 countries across the globe, with a total of -115 Million confirmed cases
and - 2.5 Million deaths. The number of reported SARS-CoV-2 cases in India is also on an increase with
-11 Million confirmed cases and -157000 deaths(1). Coronaviruses are a severe threat to the humans and
other animals, earlier other members of the same family coronaviridae, SARS-CoV infected -8000 people
with a death rate of 10% and another member Middle East Respiratory Syndrome (MERS) virus was
outbroken in the Middle East region and infected -2000 people with 35% fatality rate(2) . Porcine epidemic
diarrhea coronavirus (PEDV) has swept throughout the United States of America, causing an almost 100%
fatality rate in piglets and wiping out more than 10% of America's pig population in less than a year(2).

Coronaviruses are the enveloped positive-stranded RNA viruses which have the largest genome among all
RNA viruses with approximately 27 to 32 kb2. The viral genome is packed inside a helical capsid formed by
the nucleocapsid protein (N) which is surrounded by an envelope. SARS-CoV viral envelope is associated
with at least three structural proteins: The membrane protein (M) and the envelope protein (E) are involved
in virus assembly, whereas the spike protein (S) mediates virus entry into host cells. Among these structural
proteins, the spike forms large protrusions from the virus surface, giving coronaviruses the appearance of
having crowns(2).

The SARS-CoV-2 virus transmits from person to person mainly through respiratory droplets(3).

The inhaled virus SARS-CoV-2 likely binds to epithelial cells in the nasal cavity and starts replicating.
ACEZ2 is the main receptor for both SARS-CoV-2 and SARS-CoV(4,5). There is local propagation of the
virus but a limited innate immune response. At this stage, the virus can be detected by nasal swabs. Although
the viral burden may be low, these individuals are infectious. The RT-PCR value for the viral RNA might be
useful to predict the viral load and the subsequent infectivity and clinical course. The virus propagates and
migrates down the respiratory tract along the conducting airways, and a more robust innate immune response
is triggered. Nasal swabs or sputum should yield the virus (SARS-CoV-2) as well as early markers of the
innate immune response(6). The symptoms of SARS-CoV-2 infection appear after an incubation period of
-5 days(7). The period from the onset of SARS-CoV-2 symptoms to death ranged from 6 to 41 days with a
median of 14 days. This period is dependent on the age of the patient and the status of the patient's immune
system. It was shorter among patients >70 years old compared with those under the age of 70(8). The most
common symptoms at the onset of SARS-CoV-2 illness are fever, cough, and fatigue, while other symptoms
include sputum production, headache, hemoptysis, diarrhea, dyspnoea, and lymphopenia(9).

Till date, no specific treatment was recommended for SARS-CoV-2 infection hence, vaccines are a critical
new tool in the battle against COVID-19. Various types of COVID-19 vaccines, such as DNA, RNA- based
formulations, Recombinant subunit vaccines containing the viral protein (Spike) epitopes, vector based
formulations (eg: Adeno virus) and traditional inactivated vaccines were developed(10-12). Bharat Biotech
Int. Ltd., India has developed a whole-virion inactivated Covid-19 vaccine and evaluated for its safety and
immunogenicity in a Phase 1 followed by phase 2 study and found that vaccine is safe and
immunogenic(13,14). Bharat Biotech has been conducting a phase 3 efficacy study in 25,800 participants to
evaluate the efficacy of the vaccine.

Page 60f 18

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

2. STUDY DESIGN

The study is an endpoint-driven randomized, double-blind, phase 3 study to evaluate the Efficacy, Safety,
and Immunogenicity of BBV152B, a Whole-Virion Inactivated SARS-CoV-2 Vaccine in Volunteers aged
18 years and above.

A total of 25,800 subjects were enrolled across India in 25 sites (3 Categories) and randomized in a 1:1 ratio
to receive BBV152B vaccine and control. All participants will be assessed for efficacy and safety endpoints
and provide a NP swab and blood sample before the first dose of IP. The NP swab and blood collected will
be subject to RT-PCR and Anti-SARS-CoV-2 IgG antibodies. The results of this will not affect enrolment of
the participant. Participants who are found to be positive for either RT-PCR or Anti-SARS-CoV-2 IgG
antibodies will be excluded from the primary efficacy analysis.

The purpose of this Phase 3 study is to evaluate the protective efficacy, safety, and immunogenicity of the
whole-virion inactivated SARS-CoV-2 vaccine, BBV152B. The Phase 3 study will follow randomized study
participants for efficacy until virologically confirmed (RT-PCR positive) symptomatic COVID-19
participants will be eligible for the primary efficacy analysis. After reaching the target number (n=130) of
symptomatic COVID-19 cases, the study will continue to assess safety until the completion of the study
duration.

Case Definition of symptomatic COVID-19

The study is designed to acerue 130 symptomatic COVID-19 cases.This includes any participant who meets
any of the two below following criteria:

* Case Definition for Primary Efficacy Symptomatic Endpoint

* Case Definition for Severe Symptomatic COVID-19

Any one of the below mentioned criteria (A or B) must be met, along with a positive SARS-CoV-2 RT-PCR
confirmation to be a confirmed symptomatic case

 

 

 

 

 

 

Criteria A: One or More Criteria B: Two or More

1. Shortness of Breath/Difficulty in 1. Fever

Breathing 2. Chills
2. New onset Anosmia/Aguesia 3. New cough
3. Oxygen saturation of <94% or 4. Myalgia/Fatigue

escalation by requiring or 5. Headache

supplemental Oxygen. 6. Sore throat
4. Pneumonia: diagnosed by chest X 7. Nausea/Vomiting

ray or CT scan 8. Diarrhea
5. Evidence of Shock 9. Congestion/ Runny Nose
6. ICU Admission/Death

AND
Positive SARS-CoV-2 RT-PCR test

 

 

 

Page 7 of 18

 

 
 

DOC

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
DR
SITE CATEGORIES:

Category 1 (Symptomatic): In addition to administering the IP, a series of post-dose telephonic follow-up
visits will be scheduled to detect suspect symptomatic COVID-19 infections. If a suspect is identified, a
nasopharyngeal sample will be collected from the participant for detecting the presence of COVID-19
infection. Telephonic follow-up will occur at 15 day intervals.

Category 2 (Symptomatic/Asymptomatic): In addition to administering the IP, a series of post-dose
Nasopharyngeal samples for detecting incidence of Asymptomatic COVID-19 infection at 1-Month intervals
will be collected.

Category 3 (Symptomatic/Asymptomatic+Immunogenicity): In addition to administering the IP, repeated
NP swabs for asymptomatic, a series of blood samples will be collected for analyzing serum for
immunological assessments.

3. STUDY POPULATION

As per the approved protocol, a total of 25,800 subjects were enrolled and received either vaccine or placebo
in 1:1 ratio. Among these 25,800 participants 24,455 were received second dose and detailed site wise
enrolled participants, second dose recipients and the participants who were followed up till Day 42 were

listed in the Table 1.

TABLE 1: SUMMARY OF ENROLLED SUBJECTS AT EACH SITE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Subjects Subjects Subjects
SNo. Site Name and Location po a TE
Day 42)
Category 1: Sites
1 Al India Institute of Medical Sciences - (New Delhi) 659 629 629
2 Al India Institute of Medical Sciences - (Patna) 1216 1137 1129
3 ESIC Medical College and Hospital - (Faridabad) 1126 1002 997
4 ICMR National Institute of Cholera and Enteric Diseases - (Kolkata) 988 969 967
5 Lokmanya Tilak Municipal General Hospital - (Mumbai) 197 191 191
6 MG Medical College, Sri Balaji Vidyapeeth - (Pondicherry) 901 868 831
7 People's University - (Bhopal) 1725 1426 1424
8 Rahate Surgical Hospital & ICU - (Nagpur) 1670 1594 1579
9 Vydehi institute of Medical Sciences - (Bangalore) 496 476 429
10 | Director of Public Health & Preventive Medicine - (Chennai) 29 27 27
1 Gangaram - (New Delhi) 318 276 276
12 Prakhar Hospital — (Kanpur) 2250 2244 2243
13 Jeevan Rekha — (Karnataka) 2227 2216 2216
14 | Maharaja Agrasen Multi speciality Hospital - (Jaipur) 1494 1431 1124
15 Sunita Jaiprakash Ramanand - RESMGMC & CPR Hospital - (Kolhapur) 887 882 737
16 | Vijaykumar Patil - Prakash Institute of Medical Science & Research - (Sangli) 611 594 409

 

17 | Aligarh Muslim University - (Uttar Pradesh) 1008 938 937

 

 

Page 80f 18

 

 

 
 

DOC

 

 

 

 

 

 

 

 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
Cisnes

18 Gmers Medical College and Civil Hospital - (Ahmedabad) 1081 1018 1018
19 | Sir J.J. Group of Hospitals - (Mumbai) 438 379 378
20 Government Fever Hospital - (Guntur) 1358 1351 1350
21 (IMS) & SUM Hospital - (Bhubanes war) 510 495 494
22 SRM Hospital & Research Center — (Chennai) 603 446 40

Category 3: Sites

23 Nizam's institute of Medical Sciences - (Hyderabad) 1998 1888 1883
24 | PGIMS - (Rohtak) 456 433 433
25 Redkar Hospital and Research Centre - (Goa) 1554 1544 1544

Total 25800 24454 23649

 

 

 

 

 

3.1 AT-RISK POPULATION

In this study both healthy volunteers and participants with high risk for Covid-19 who is, either > 60 years of
age or < 60 years of age with co-morbid conditions, and HCPs were recruited.

Participants who are < 60 years old will be categorized as at risk for severe COVID-19 illness if they have at
least 1 of the following risk factors at Screening:

> Stable chronic lung disease (eg, emphysema and chronic bronchitis), idiopathic pulmonary fibrosis

and cystic fibrosis) or mild to moderate asthma.

> Stable cardiac disease (eg, heart failure, coronary artery disease, congenital heart disease,

cardiomyopathies, hypertension, and pulmonary hypertension).
> Severe obesity (body mass index > 35 kg/m2).
» Controlled Diabetes (Type 1, Type 2).
> Stable Liver disease.

Participants who has high risk for Covid-19 were summarized in the Table 2 (>60 Years) and Table 3 (< 60
with Co-morbid condition).

TABLE 2: SUMMARY OF AT RISK PARTICIPANTS

 

 

 

 

 

 

 

 

 

 

 

Treatment Arm
Description BBVIS2 Placebo Total
sertp! (N= 12,900) (N= 12,900) (N= 25,800)
n(%) n (%) n (%)
At Risk Participants at baseline, Age > 60
ears
Stable chronic heart disease 158 (1.22) 142 (1.10) 300 (1.16)
Stable chronic lung disease 12(0.09) 16 (0.12) 28 (0.11)
. . 107 (0.83)

Controlled Diabetic 101 (0.78) 208 (0.81)
Stable Liver Disease 4(0.03) 8 (0.06) 12(0.05)
Severe obesity (BMI >35) 2(0.02) 2( 0.02) 4( 0.02)
Other stable co-morbid condition 129 (1.00) 142 (1.10) 21 (1.05)
None of the above 32(0.25) 28 (0.22) 60 (0.23)
Multiple risk categories* 245 (1.90) 296 (2.29) 541 (2.10)

 

 

 

 

 

* Multiple risk categories count contain for subject selected multiple categories (i.e. more than one)

 

 

Page 9 of 18

 

 

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

TABLE 3: SUMMARY OF AT RISK PARTICIPANTS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Description Treatment Arm

BBV152 (N= 12,900) Placebo (N= 12, 900) Total

n(%) 1 (0) (N = 25,800)

º : n(%)

At Risk Participants at
baseline, Age < 60 years
Stable chronic heart disease 370 (2.87) 357 (2.77) 727 (2.82)
Stable chronic lung disease 108 (0.84) 148 (1.15) 256 (0.99)
Controlled Diabetic 593 (4.60) 613 (4.75) 1206 ( 4.67)
Stable Liver Disease 17 (0.13) 17 (0.13) 34 (0.13)
Severe obesity (BMI >35) 53 (0.41) 90 (0.70) 143 (0.55)
Other stable co-morbid 613(4.75) 676 (5.24) 1289 (5.00)
condition
None of the above 125 (0.97) 118 (0.91) 243 (0.94)
Multiple risk categories * 209( 1.62) 200 (1.55) 409 (1.59)
* Multiple risk categories count contain for subject selected multiple categories (i.e. more than one)

 

3.2 GENDER AND AGEWISE CLASSIFICATION OF THE PARTICIPANTS:

In the study both the genders were recruited, among 25800 participants 17332 (67.2%) were male and 8468
(32.8%) were female participants. Detailed description of the participants categorized by their age and
gender was depicted in the Table 4.

TABLE 4: GENDERAND AGE WISE CLASSIFICATION OF THE PARTICIPANTS

 

 

 

 

 

 

 

Gender >18 to <50 >51 to <60 >61 to above
Male 13790 2085 1457
(53.45%) (8.08%) (5.65%)
Female 6242 1250 976
(24.19%) (4.84%) (3.78%)

 

 

3.3 INFECTION RATE & SEROPREVALENCE

As per the protocol, all the participants were examined for their status on the Covid-19 infection and
seroprevalence at baseline. Nasopharyngeal swab and serum were collected from all the participants and
estimated the COVID-19 infection rate and seroprevalence among all the sites across India. The results were
reported that 0.82% infection rate and 34.33% of the seroprevalence across the India. Site wise and zone
wise seroprevalence and infection rate is depicted in the Table 5.

Page 10 of 18

 

 

 
 

DOC

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Peoples University,

309 me 1746 26 149 1736 | 234 13.48

 

 

 

 

 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
As
TABLE 5: INFECTION RATE AND SEROPREVALENCE OF THE COVID-19
Site RTPCR | RTPCR Infection ELISA Posit | Seroprevale
Code | Site Tested Positive Rate (%) nn ive nce (%)
301 | AIIMS, Delhi 658 3 046 658 | 293 44.53
303 | ESIC, Faridabad 1126 8 07 1126 | 290 25.15
313 | AMU, Aligarh 1008 20 1.98 1002| 311 31.04
321 | PGIMS, Rohtak 456 14 3.07 456 72 15.79
Gangaram, New-
323 | Delhi 319 2 0.63 319] 107 33.54
PRAKHAR,
324 | Kanpur 2250 5 0.22 2250 | 1031 45.82
1.18 32.75
Lo ET O
302 | AIIMS, Patna 1216 20 1.64 1216 | 801 65.87
305 | NICED, Kolkata 989 8 0.81 989 | 264 26.69
318 | IMS, Odisha 510 3 0.59 510 | 123 24.12
1.01 38.89
[oc wto
Sion Hospital,
307 | Mumbai 202 3 149 197 | 105 53.30
310 | RAHATE, Nagpur 1672 1 0.66 1672 | 192 11.48
GMERS,
315 | Ahmadabad 1081 25 231 1081 | 387 35.80
JJ Hospital,
316 | Mumbai 437 5 1.14 437 | 200 45.77
322 | REDKAR, Goa 1554 1 0.06 1554 | 497 31.98
Jeevan Rekha,
326 | Belgavi 2221 4 0.18 2227 | 936 42.03
327 | MAMSH, Jaipur 1494 12 0.80 1494 | 698 46.72
RCSMGMC &
328 | CPR, Kolhapur 887 0 0.00 887 | 248 27.96
PIMSR, Sangli,
329 | MH 611 0 0.00 611] 198 32.41
0.74 36.38
[som
MGMCR,
308 | Pondicherry 901 3 0.33 901 | 433 48.06
311 | VIMS, Bangalore 496 2 0.40 496 | 172 34.68
312 | DPH, Chennai 29 1 345 29 13 44.83
317 | Guntur, AP 1358 5 0.37 1358 | 380 27.98
320 | NIMS, Hyderabad 1998 31 1.55 1998 | 423 21.17
325 | SRM, Chemnai 605 0 0.00 605 | 453 74.88
1.02 41.93

 

Page 11 of 18

 

 
 

 

DOC

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT
DR
4. SAFETY

There are 25,800 participants were recruited in the study. It is decided to consider all AEs reported till 11 am
(IST) March 1, 2021 for first 8000 enrolled participants. All the participants were followed up telephonically
for 7 days after each dose of vaccination and reported all the solicited AEs. Unsolicited AEs from all the
participants were reported throughout follow-up period (Till Day 42). A total of 655 adverse events were
reported and equally distributed in both vaccine and placebo groups. Among these 655 AEs 605 were mild, 34
were moderate and 16 were severe and the severity of the AEs is similar in both the groups. All the AEs
except 20 were resolved without sequelae. Detailed AEs list is summarized in the Table 6.

TABLE 6: SUMMARY OF ADVERSE EVENTS

 

Treatment Arm

 

Description BBV152 Placebo Total
(N=4,061) (N=3,804) (N=7,865)
n(%) n(%) n(%)

 

 

No of Subject with at least one

|Adverse Event 335 (8.25) 300 (7.89) 635 (8.07)

 

INo of Subjects with at least one Local Solicited AE
within 7 days after Day O Vaccination 99 (2.44) 94 (2.47) 193(245)
(1 event not resolved)

INo of Subjects with at least one Local Solicited AE
within 7 days after Day 28 Vaccination 55 (1.35) 39 (1.03) 94 (1.20)
(1 event not resolved)

 

 

No of Subjects with at least one Systemic Solicited AE
within 7 days after Day O Vaccination 94 (2.31) 55 (1.45) 149 (1.89)
(1 event not resolved)

 

INo of subjects with at least one Systemic Solicited AE
within 7 days after Day 28 Vaccination 30 (0.74) 23 (0.60) 53 ( No 0.67)
(1 event not resolved)

INo of subjects with at least one Unsolicited Adverse

 

 

 

 

 

 

 

 

 

 

 

Events 50(1.23) 67(1.76) 117 (1.49)

|AIl Ongoing Adverse Events 9(0.22) 11(0.29) 20(0.25)
Severity

Mild 317(781) 288 (7.57) 605 (7.69)

Moderate 17(0.42) 17 (0.45) 34 (0.43)

Severe 9(0.22) 7(0.18) 16 (0.20)

 

4.1 SERIOUS ADVERSE EVENTS

All the participants (25800) were followed up for serious adverse events (SAEs) and 43 SAEs were reported
till date and among those cases 33 were resolved, 3 cases are ongoing and 7 deaths were reported. All the
SAEs were not related to the vaccine and distributed equally among the two treatment groups. Detailed
description of the SAESs is given in the Table 7.

Page 12 0f 18

 

 
 

 

DOC

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT
BIOTECH
Lene Snemealiaa
TABLE 7: SAEs Line Listing
Study site E E
s. (Sereening Date of Seriousness | Diagnosis ofthe | Causalioy | Causalty | Quteome ot
No Number) occurrence of | “Crif Event Assessment | Assessment | mo Fyent
SAE by PI by Sponsor
19-11-2020 Road traffic
NIMs (1º Dose) accident (RTA)- Recovered and
j Hydorbia | (VaccinelPhcob | »9.112020 | Hospitalizaio | Crushlnjuryloh | Unrelaicd | trreied | discharged from
GSO0OLOT) o; Blinded) n foot and Fracture hospital on 23
2º dose was not neck of 2" 3º Nov 2020.
administered and 4ºmetatarsal.
Uncontrolled
18-11-2020 y
(1º Dose) Type-2 Diabetes Recovered and
NIMS, (Vaccine/Placeb Hospitalizatio | mellitus with Unlikely discharged from
2 Hyderabad e ltdod 29-11-2020 S Diabetic Unrelated | ion 19%
(32000073) & Blinded) n ketoacidosis and ospital on
2º dose was not dyselectrolvtemia Dec 2020
administered ys temia
20-11:2020 Recovered and
PGIMS, Robak | (VascineiEiesh Hospitalizatio Unrelated lischarged from
3 y É E Blindea 05-12-2020 spitaliza COVID-19 É Unrelated hospital 30º”
(32100001) o; Blinded) n :
rá Dec 2020 in
dose was not ir
se stable condition
administered
28-11-2020 :
NIMS, (1º Dose) Shortness of cisto om
4 Hyderabad | (VaccinePaceb | 95 52020 | Hospitalizatio | breath, pedal | Unlikely | tried | hospital 6º Dee
o; Blinded) n edema and fever à
(32000428) na 2020 in stable
2º dose was not (3 days). 1
se condition
administered
25-11-2020 Recovered and
NIMS, (vascinielaceb Hospitalizatio Untiket slischarged from
5 Hyderabad à; Blindod) 07-12-2020 praia CovID-19 * | Unreiated | hospital tl”
(82000272) | mi Dec 2020 in
dose was not ir
se stable condition
administered
28 zozo Recovered and
NIMS, (Vabcinoibice Hospitalizatio Uniikel discharged from
6 Hyderabad à; Blinded) 10-12-2020 praia CovID-19 * | Unriated | hospital Is?
(32000242) | om Dec 2020 in
dose was not ir
se stable condition
administered
: 08-12-2020 Recovercd and
E (1º Dose) discharged from
4 Hospital, (WaccinelPlceb | 4, 52020 | Hospializaio | Homocystcine | prega | Unrclacd hospital in
a o; Blinded) n stable condition
Fe 600192) 2º" dose was not on 26º Dec
administered 2020
- 07-12-2020
SRM Medical (1º Dose) a . Recovered and
College & | (yaceineiPlaceb Hospitalizatio | Clinical enteric discharged from
8 Hospital, cen 15-12-2020 S fever with Unrelated | Unrclated | Gsi o
E o; Blinded) n Á hospital on 17
Chennai q dehydration. DO
(32500018) dose was not
administered
People's College Recovered and
Rr fadical 10-12-2020 , discharged from
Sciences E (1º Dose) Left non- hospital on 18º
9 | Rescarch Contr, | (VaccinelPlacob | 17.12.2020 | Hospitlizatio | | funciioning Uneiated | Unrciaed | Dec 2020 wih
Bona Maisa | 9: Blindod) n ydronephrotic advice to follow
Pradesh 2º dose was not kidney up for further
G 409005 46) administered treatment plan
Pooplos College
of Medical q Doo
Sciences & | (yaccine/Placeb
10 | Rescarch Centre, | MISSIME as 21-12-2020 Death Death Unrelated | Unrclated Fatal
Bhopal, Madhya | ma
nto dose was not
0000800) administered
MGMCRLSBV, | 26122020 “Hollow viscus
u Puduchemry (1 Dose) 01.01.2020 | Hospitalizatio | perforation with | yroiated Unrelated Recovered
(30800300) | (VaecinelPinceb n Acute Kidney
o: Blinded) Injury -? Cause”

 

 

 

 

 

 

 

 

 

 

Page 130f 18

 

 

 
 

BBIL/BBV152-C/2020

Bharat Biotech International Limited

DOC

BHARAT

BIOTECH
Lead Sncaliom

 

2º dose was not
administered

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

People Colioge 10-12:2020 (1º
Sciences & Dose) ao Recovered and
12 | Research Centre, (VaccineiP! ace 06-01-2021 Hospitalizatio Liver abscess Unrelated Unrelated | discharged from
Bhopal, Madhya o; Blinded) n hospital on 15'
, 2" dose was not Jan 2021
Pradesh administered
(30900578) É o
Vydehi Institute 09-12-2020 (18
sã e Dose) aaa Hospitalizatio Recovered and
13 | pa (Vaceine/Placeb AA SPitaliziio | (ef ungopacity- | Unrelated | Unrelated | discharged from
escarch Centre, o: Blinded) awareness 0! n LRTI Hospital on 23º!
Bangalore. | 2 gose was not December 2020
(31100060) administered
People's College | go (1*
— of medical Dose) a Left non- Recovered and
14 | fescarch center, | (yaccine/Placeb Hospitalizatio | gnetioning discharged from
Bhopal, Madhya o: Blinded) 07-01-2021 n hiydronephrotic Unrelated Unrelated Hospital on
Pradesh 2º! dose was not kidney 21“Jan 2021.
(30900546) administered
Pcoples College
of Medical 18-12-2020 (1º
Sciences & Dose) ao ui Recovered and
15 | Research Centre, | (VaccinefPlaceb | 08-01-2021 | Hospitalizaio ie | gureted | Unciaed | discharged from
Bhopal, Madhya 0: blinded) » ante) ê ê Hospital on 19º
Pradesh 2" dose was not É Feb2021.
(30901496) administered
Pcoples College | 16/12/2020 (1º
of Medical Dose) 30-12-2020 Recovered and
16 Sciences & (Vaccine/Placeb (Date of Hospitalizatio discar ed fim
Rescarch Centre, o; Blinded) awareness of n Mature cataract Unrelated Unreclated | og al on IE
Bhopal, Madhya | 2" dose was not | SAE:13/01/202 2021
Pradesh administered 1) É .
(30901257)
People's College a :
of Medical 16/12/2020 (1 03/01/2021 CAD with ,
: Dose) a micro | hypertension with Recovered and
Sciences & : (Date of Hospitalizatio e Í
17 (Vaccine/Placeb e B/L Pneumi s discharged from
Research Centre, - Bi awareness of n Unrelated Unrelated e ih
o; Blinded) /ACS/TVD. She hospital on 6
Bhopal, Madhya | má SAE: o
2º! dose was not was also positive Jan 2021.
Pradesh dministered 13/01/2021) ith COVID-19.
(80901279) administer vei - 19.
People's College | 17/12/2020 (1º
of Medical Dose) Recovered and
18 Sciences & 14/01/2021 (2! Hospitalizatio discharged fr
Research Centre, Dose) 15/01/2021 n Unrelated Unrelated the hosvit om
Bhopal, Madhya | (Vaccine/Placeb cholelithiasis. » E DI
Pradesh o; Blinded) na
(30901436)
Pcople's College | 14-12-2020 (1º
of medical Dose) Recovered and
19 sciences and 11-01-2021 (2º Hospitalizatio | Renal Caleuli & soam ' fo
Research centre, dose) 18-01-2021 n with Unrelated Untelated | Sischarged from
e the hospital on
Bhopal, (Vaccine/Placeb Hepatomegaly. 19-01-2021
Madhya Pradesh o; Blinded) aa
(30901004)
21-12-2020 (1º
Nnvs, Do | 160202
20 Hyderabad (VaccinePiaceb | noss of the Death Death Unrelated | Unrelated Fatal
(32001 o; Blinded)
ni SAE21-01-
145) 2" dose was not 2021)
administered
Jawaharlal 25-11-2020 (1º
Nehru Medical Dose) baço
” a
21 | golegeand | 24122020 00 | arnessortho | Death Death Unrclated | Unrelated Fatal
Hospital, AMU, dose)
Ui e SAE-
Aligarh (Vaccine/Placeb 21012021)
(31300207) o; Blinded)

 

 

Page 14 0f 18

 

 

 
 

BBIL/BBV152-C/2020

Bharat Biotech International Limited

DOC

BHARAT

BIOTECH
Lead Sncaliom

 

Vydehi Institute

28-12-2020 (1º

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

chi Ins 11-01-2021
of Nursing Dose) o enticati, Recovered and
22 | Sciencesand | (Vaccine/Placeb (Dateot | Hospitalizaio | Ammica] viral discharged from
cine awareness of the n vn Unrelated | Unrelated
Rescarch Centre, | o; Blinded) SAE TIO pneumonia the hospital on
Bangalore 2º dose was not 2021) ” 15-01-2021
(81100290) administered
People's College 18-12.2020 (1º
É Dose) o . Recovered and
sciences and a Hospitalizatio | Generalised body R à
23 | Research centre, | 20012021 (2 21-01-2021 n pain Unrelated | Unclated | discharged from
Blhopal, Madhya dose) the hospital on
radesh (Vaccine/Placeb 25-01-2021
GOMISIo o; Blinded)
5122000 (5
Dose) 22-01-2021
ATIMS, New : e
2” Delhi (Vaccine/Placeb | (Date of SAE Death Death Unrelated | Unelated Fatal
30100090) o; Blinded) Awareness:
2º dose was not 24-01-2021)
administered
'GMERS 28-12-2020 (1%
Medical College Dose) aaoE
25 and Civil (Vaccine/Placeb | q areness of Death Death Unlikely Unlikely Fatal
Hospital, Sola, o; Blinded) SAEDTOL
Ahmedabad 2" dose was not 2021)
(81500928) administered
People's Colege 13-12.2020 (1º
f a Dose) a . Recovered and
26 sciences and 10012021 Hospitalizatio | Right eye mature eischarged tom
Research centre, 4, 01-02-2021 n cataractand left | Unrclated | Unreiated | dscha m
Bhopal, Madhya (2!Dose) eye pseudophakia Hospital on 12
a Hesh Ya | (Vaccine/Placeb ye pseudophakia Feb 2021.
(0900901) o; Blinded)
aaa 28-122020 (1º | 31012021
no Dose)
& Rescarch e
2” Centre, Ez Deo Death Death Unrclated | Unrelated Fatal
Kanchipuram, Ta (2 Dose) Awareness by
tiara Te | (VaccinefPlaceb | Sponsor: 01-02-
2500447) o; Blinded) 2021)
SRM Medical
College Hospital | 23-12-2021 (1º .
& Research Dose) 27-01-2021 iai Reco vered and
a D 2 Hospitalizatio | q; . discharged from
28 Centre (Vaceine/Placeb (Date of Viral pneumonia
Kanchipuram, o: Blinded) | avreness-02-02- n dueto COVID-I9 | Unrelated | Unrelated || the hospital on
Td nd à, 12 9º Feb 2021 in
Tamil Nadu 2º dose was not 2021) stable condition
(32500303) administered 2
People's College 12-12.2020 (1º
sciences and Dose) Hospitalizatio Recovered and
29 | poa ado | 09012021 E” | 02:02:2021 5 Chronic Otitis | Unrciated | Unrelated | discharged from
S Bh ao Dose) n media the hospital
Madh im tdesh | (Vaccine/Pinceb 0n18-02-2021
6 ODOOTTO o: Blinded)
People's College 10-12:2020 (1º
30 scienes and 070 Cada em Hospitalizatio Unelated | Unrelated cisstugea Hom
Rescarch centre, Do 02-02-2021 n Bronchial asthma nrelate nrelato. he host
Bhopal, Madhya Dose) the hospital on
Pradesh (Vaccine/Placeb 15-02-2021
cS0900606) o; Blinded)
- 27-12-2020 (1º
Maharaja
a1 | Agrasen Super 240 Cada em Hospitalizatio Unrelated isstugea Hom
speciality Do 04-02-2021 n COVID-I9 Unrelated A ho rec al
Hospital, Jaipur Dose) the hospital on
PD | (Vaccine/Placob 04-02-2021
6 ) o: Blinded)
, 27-12-2020 (1º
Maharaja
32 | Agrasen Super 240030 qu Hospitalizatio Unretaed | Unretuea | disstagoa Hom
speciality Do 04-02-2021 n COVID-I9 A A ho rec a
Hospital, Jaipur Dose) the hospital on
SRD | (Vaccine/Placob 04-02-2021
6 ) o: Blinded)

 

 

Page 15 of 18

 

 

 
 

DOC

 

 

 

 

 

 

 

 

  

 

 

 

 

BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT
BIOTECH
Lene Snemealiaa
Tamo ds | 05022021
Dose) (Date of as Could be Recovered and
33 | ANMS New | 26122020 (2º | avrencss-06-02- | Bospitalizatio Immune | associated | Under — | discharged from
Delhi n Thrombocytopeni j t
Gotomoia) Dose) 2021) aa with the Evaluation | the hospital on
(Vaccine/Placeb a Purpura. vaccine. 08-02-2021
o; Blinded)
Directorot | 09122020 (14
tá Dose) o Recovered and
Public Health & na Hospitalizatio o 2
34 | Medicine study | 060201 O 12-02-2021 n coviD-19 Unrelated | Unreiated | discharged from
site, Chennai Dose) the hospital on
(SI20000D | (accinefPiaceb 16-02-2021
o; Blinded)
People's College | q 12020 (14
of medical
, sciencesand | pg OL os Hospitaizaio | cnronic ot perna ana
S | Rescarch centre, 22021 ( 12-02-2021 n ronic otítis Unrelated | Untelated | discharged írom
Bhopal Dose) media the hospital on
pal, (Vaccine/Placeb 22-02-2021
Madhya Pradesh à; Blindod)
(30900291) :
Prakash Institute | 2912.2020 (1º
of Medical o
Science & Dose) Hospitalizatio | Fever, headache. Recovered and
36 R h 26-01-2021 (2º 13-02-2021 . dá h . Unrelated Unrelated discharged from
eat Dose) < n and coug relate mreited | o possíal om
angli, (Vaccine/Placeb 14-02-2021
Maharashtra * Blindod
(82900012) &: Blinded)
02-12-2020 (1º
ATIMS, New Dose) Hospitalizatio Recovered and
37 Delhi 30-12-2020 (2º! RE Myocardial . . discharged from
(30100044) Dose) 19-02-2021 n infaretion (MI) Uniikely | Unreiated | mo hospital on
(Vaecine/Placeb 01-03-2021
o; Blinded)
22-12-2020 (1º .
Dose) 24-02-2021 o Ongoing atthe
NIMS, má 2 Hospitalizatio o time of
38 H 19-01-2021 (2! (Date of i Under cs e
Iyderabad ” n CovID-19 Unlikely t submission of
(32001185) Dose) awareness: 25- Evaluation | ie repor by the
(VaecineiPlaceb | 022021) e report by
à Blindod) investigator
Sir Ganga Ram | 19-122020 (1 2A-02-2021 Ongoing at the
Hospital Marg, Dose) (Date of Hospitalizatio time of
39 = ” 20-01-2021 (2º awareness: 25- o Fever and body Under Under ici e
Rajinder Nagar, n submission of
8 Dose) 022021) ache Evaluation | Evaluation
New Delhi : the report by the
(32300066) | (Vaccine/Placeb investigator
o: Blinded) sea
30-11-2020 (1º
Aligarh Muslim Dose) ano Hospitalizaio Recovered and
“0 E 31-12-2020 (2º a spltatiza Epistaxis Under | discharged from
: awareness: 27- n Unrelated . B
Aligarh Dose) 022021 Evaluation the hospital on
(31300560) | (Vaccine/Placeb 2021) 27-02-2021
o; Blinded)
People's College a
of medical 10-12-2020 (1 01-03-2021
i d Dose) (Datcof Hospitalizatio Acute
41 Sciences an 07-01-2021 (2! à spitatiza a Under .
Rescarch centre, Do awareness: 03- n exacerbationot | Untciated | puaguat Ongoing
Bhopal, Madhya Dose) 032021) COPD valuation
Pr: (Vaccine/Placeb
radesh o: Blinded)
(30900606) Ê
26-122020 (15
Dose) 01-03-2021 enticati, Recovered and
42 | ANMS, New | o3 012021 (9 (Dateof Hospitalizatio =» . Under - | discharged from
Delhi Do 5 n Choleeystitis Unikeiy | pundo area
Gois Dose) awareness: 05- valuation | the hospital on
(Vaccine/Placeb | 032021) 02-03-2021
o; Blinded)
Vydehi Institute 06-01-2021 (1º
of Nursing Dose) 03-03-2021
43 Sciences and 03-02-2021 (2º (Date of Death Death Under Under Fatal
Research Centre, Dose) Awareness:05- a Evaluation | Evaluation ata
Bangalore | (VaccinefPlaceb | — 03:2021)
(31100476) o; Blinded)

 

 

 

 

 

 

 

 

 

 

Page 16 of 18

 

 

 
 

 

S0€
BBIL/BBV152-C/2020 Bharat Biotech International Limited BHARAT

BIOTECH
Lead Sncaliom

5. IMMUNOGENICITY

The Immunogenicity assessment was planned on the subset of the 600 participants who were recruited in the
category 3 sites. All the blood samples from these participants were collected on Day 0, Day 28, Day 56 and
these samples are being analysed. The immunogenicity data in terms geometric mean titers (GMTs) by
neutralizing antibody, S-protein, and RBD specific anti-IgG binding titer will be submitted to CDSCO.

6. EFFICACY (INTERIM ANALYSIS)

We are considering first 43 RT-PCR (1/3 of 130 as proposed in 1º interim analysis) positive events and
analysis has been done by taking data confirmed by sites. Participants who received two doses and not having
PD (protocol deviation) are considered in efficacy population. The first interim analysis is based on 43 cases,
of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the BBV152
(COVAXIN") group, resulting in a point estimate of vaccine efficacy of 80.69%.

TABLE 7: EFFICACY of BBV152

 

 

 

 

 

 

 

 

Treatment Arm
Description
BBV152 Placebo Total
(N = 12218) (N=12199) (N =24417)
First occurrence of Virologically confirmed
(RT-PCR) n (%) 7(0.057) 36(0.295) 43(0.176)

VE(%) 80.6

95% CI [78.1, 82.7]

p value <0.0001

 

 

 

 

 

7. CONCLUSIONS

Phase 3 study is conducted to evaluate the efficacy and safety of the COVAXINº vaccine. A total of 25800
participants were recruited, among these 67.2% were males and 32.8% were females. At-risk population,
ages > 60 years (9.4%), participants (<60 Years) with co-morbid conditions (16.7%) were enrolled. COVID-
19 seroprevalence was assessed among these 25800 participants at baseline and results reported that 34.3%
of the participants were Seropositive.

All the participants were followed up for their safety, 43 SAEs were reported and among these 33 were
resolved, 3 were ongoing and 7 deaths were reported. Among 25800 participants first 8000 enrolled
participants AEs were recorded. A total of 655 AEs were reported and most of them were mild in severity.
All the reported SAEs were not related to the vaccine.

COVAXINº vaccine efficacy was assessed based on the 43 accrued COVID-19 cases and reported that the
vaccine efficacy is 819%.

Page 17 of 18

 

 
 

 

DOC

BBIL/BBV152-C/2020 Bharat Biotech International Limited BH AR AT

6.

10.

1.

12.

13.

14.

BIOTECH
Lead Sncaliom

8. REFERENCES

WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2021 Mar 5). Available from:
https://covidl9.who.int

Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016 Sep
29:3(1):237-61.

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when
COVID-19 disease is suspected. Interim guidance. Pediatr Med Rodz. 2020 May 20;16(1):9-26.

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from
Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. Journal of
Virology [Internet]. 2020 Mar 17 [cited 2020 Oct 15];94(7). Available from:
https://jviasm.org/content/94/7/e00127-20

Hoffmann M, Kleine-Weber H, Schroeder S, Kriiger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell
Entry Depends on ACE2 and TMPRSS?2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell.
2020 16;181(2):271-280.e8.

Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. European Respiratory Journal
[Internet]. 2020 Apr 1 [cited 2020 Oct 15];55(4). Available from:
https://erj ersjournals.com/content/55/4/2000607

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China,
of Novel Coronavirus-Infected Pneumonia. New England Journal of Medicine. 2020 Mar
26:382(13):1199-207.

Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus
(2019-nCoV) in Wuhan, China. J Med Virol. 2020 Apr;92(4):441-7.

Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J
Respir Crit Care Med. 2020 15;201(4):P7-8.

Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. New
England Journal of Medicine. 2020 May 21;382(21):1969-73.

Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging
coronavirus infection: advances and prospects in designing and developing vaccines,
immunotherapeutics, and therapeutics. Hum Vaccin Inmunother. 2020 Mar 18;1-7.

Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, et al. Microneedle array delivered
recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
EBioMedicine. 2020 May 1;55:102743.

Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity clinical
trial of an inactivated SARS-CoV-2 vaccine, BBV 152 (a phase 2, double-blind, randomised controlled
trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv. 2020 Dec
22:2020.12.21.20248643.

Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an

inactivated SARS-CoV-2 vaccine, BBV 152: a double-blind, randomised, phase 1 trial. Lancet Infect
Dis. 2021 Jan 21;

Page 18 0f 18

 

 
Y PRECISA

Medicamentos
DECLARAÇÃO

Importação de vacina contra Covid-19 nos termos da Lei 14.124/21 e
RDC/ANVISA 476, de 10 de março de 2021 artigo 12 inciso |

A PRECISA - COMERCIALIZACAO DE MEDICAMENTOS LTDA,, pessoa
jurídica de direito privado, com endereço na Avenida Portugal, n.º 1100, Rua 5, parte
A-14, Bairro Itaqui, Cidade de Itapevi, Estado de São Paulo, CEP 06696-060, CNPJ
03.394.819/0005-00, neste ato representada por Emanuela Batista de Souza
Medrades, brasileira, farmacêutica, portador do RG 35.435.759-1- SSP-SP e CPF
330.976.208-42, considerando o disposto na Resolução de Diretoria Colegiada - RDC
nº 476, de 10 de março de 2021, DECLARA, sob as penas da lei, que trata-se de
importação de vacina contra a Covid-19 nos termos da Lei 14.124/21 e
RDC/ANVISA 476, de 10 de março de 2021, conforme art. 12 inciso I.

Por ser expressão da verdade, firmamos a presente para que surta os seus
efeitos legais.

Brasília/DF, 17 de março de 2021.

EMANUELA BATISTA DE Assinado de forma digital por

SOUZA EMANUELA BATISTA DE SOUZA
MEDRADES:33097620842

MEDRADES:33097620842 Dados: 2021.03.22 10:19:58 -03'00'

EMANUELA BATISTA DE SOUZA MEDRADES
CPF 330.976.208-42
Representante Legal/Técnica

      
 
      

Office: Av. Tamboré, 267, 28º andar - Barueri— SP | Pharma: Av. Portugal, 1100 - Itapevi - SP
Phone: +55 11 3080-5140 | www.precisamedicamentos.com.br

Documento, Declaração Precisa Medicamentos (00196/0701) SEI 25000.043170/2021-42 / pg. 211
 

MADISON

Biotech PTE Ltd

 

BROFORMA. INVOICE

 

 

 

 

 

DISTRIBUIÇÃO DE MEDIGAMENTOS
RUA JAMIL JOÃO ZARIF, 684, JARDIM SANTA.
YICÊNCIA, UNIDADES 11 A 17 E 1BA. CEP: U7443-000-

EXPORTER No & Date Exportor's Ref
MADISON BIDTECH PTE LIMITED: No: MAD/HM/2021/07
35 Cantonment Road 2021
Singapora 089747 , E Mer er NS
Sompany Registration dy 202006277E Bugre T No:
. Diher Reference(s)
TENSIGNEE HINER
HExCTeS Minister HEALTIÁ MINISTRY
(ATNa DEPTO DE LOGÍSTICA EM SAÚDE DEOG SAD KATIE: DEPTO DE LOGÍSTICA EM SAÚDE — LOG SAB»
— SERVIÇO DE ARMAZENAMENTO E “SERVIÇO DE ARMAZENAMENTO E

DISTRIBUIÇÃO DE MEDIGAMENTOS
RUA JAMIL JOÃO ZARIF, 884, JARDIM SANTA VICÊNEIA,
UNIDADES 11. 17:E-18A. CEP: 07143-000-

 

 

 

 

 

 

 

 

 

 

 

 

 

MUSICÍPIO DE GUARULHOS MUNICÍPIO DE GUARULHOS

ErstamagcEy | Fico oi Racaipk By Pre-Garrier Tony of Origin ofGcods = | Esustry of Final Desinaion

. . INDIA FRAZiL.
[ Vessat/ Flight No: | Portaf Loading

HEDERABAS, INDIA
Frotef Discharas | Final Desônation Terms: Payarient : 4609 Avance payment
Dispatehed by :'FGA Hydersbad
| Disifatoh 3 in the month of April 2021
. Cursos USD no
| No | PRODUCT PAGESIZE | Quantiy | Un Price Amouot
o = . UsD uso
q | COVAXIN Sm a00,000 150,00 45,808,000.00
IyiholoVior Jnactivated Corona Virus Vacoinef
: Total: OP 45,000,000.00
Abba Hi Mlords: USD EDRY FIV MION NTE,

 

 

 

 

“Bank mame DBS Bank.

Address: 4É Marina Boniltuara, DÁS Ásia. Cesifral, Marina Bay
Einantiel Ceniré Tower 5 Sihgspof G1B5B7.

Ascbuht number: 0720224550

1FSGEnde; DESSOINDE 11

trt Codás DESSSGsG: .

 

Decleratioa:

Wa deciara thai His -imvolce show tha actual firica ot the gps: “

desgribed and that all particulares ere teus sad correst

 

 

Acsepiad
For, HEALTH'S MINISTRY

AUTHORISED siGNATORY

 

For MAISON BIGTEGH PTE LTO.
nm

apto Gstoibias Is
e AUTHORISED SISNATORY

 

 

 

31 Cantonment Road , Singapore - 089747

 

 
22/03/2021 SEI/ANVISA - 13/9496 - Recibo Eletrônico de Protocolo

Recibo Eletrônico de Protocolo - 1379496

 

Usuário Externo (signatário): William Amorim Santana
IP utilizado: 189.28.128.242

Data e Horái 22/03/2021 15:22:54
Tipo de Peticionamento: Processo Novo

Número do Processo: 25351.908110/2021-03

Interessados:

MINISTERIO DA SAUDE/DEPARTAMENTO DE LOGISTICA EM SAUDE-DLOG/CGLOG/DIIMP
Protocolos dos Documentos (Número SEI):

- Documento Principal:

- Ofício 62/2021/DLOG/SE/MS 1379489
- Documentos Complementares:
- Estudo Eficácia 1379495
- Documento INVOICE 1379494
- Registro Índia 1379493
- Declaração Empresa Precisa Medicamentos 2 1379492
- Declaração Empresa Precisa Medicamentos 1379491
- Estudo Fase 03 1379490

O Usuário Externo acima identificado foi previamente avisado que o peticionamento importa na aceitação dos termos
e condições que regem o processo eletrônico, além do disposto no credenciamento prévio, e na assinatura dos
documentos nato-digitais e declaração de que são autênticos os digitalizados, sendo responsável civil, penal e
administrativamente pelo uso indevido. Ainda, foi avisado que os níveis de acesso indicados para os documentos
estariam condicionados à análise por servidor público, que poderá alterá-los a qualquer momento sem necessidade
de prévio aviso, e de que são de sua exclusiva responsabilidade:

* a conformidade entre os dados informados e os documentos;

* a conservação dos originais em papel de documentos digitalizados até que decaia o direito de revisão dos atos
praticados no processo, para que, caso solicitado, sejam apresentados para qualquer tipo de conferência;

* a realização por meio eletrônico de todos os atos e comunicações processuais com o próprio Usuário Externo
ou, por seu intermédio, com a entidade porventura representada;

* a observância de que os atos processuais se consideram realizados no dia e hora do recebimento pelo SEI,
considerando-se tempestivos os praticados até as 23h59min59s do último dia do prazo, considerado sempre o
horário oficial de Brasília, independente do fuso horário em que se encontre;

* a consulta periódica ao SEI, a fim de verificar o recebimento de intimações eletrônicas.

A existência deste Recibo, do processo e dos documentos acima indicados pode ser conferida no Portal na Internet
do(a) Agência Nacional de Vigilância Sanitária.

https://sei anvisa.gov.br/sei/documento, consulta. externa.php?id, acesso extemo=226728id. documento=15469978id. orgao acesso extemo=0... 1/1
Genome Valley, Turkapally, Shameerpet

BHARAT
BIOTECH
Eau Saeradioos

 

 

Hyderabad-500078, INDIA

 

 

Department: Quality Control
CERTIFICATE OF ANALYSIS

 

 

Product : WHOLE VIRION, INACTIVATED CORONA VIRUS BULK
Batch Number  : 376200014 AR. Number : IP-37-20-047
Batch size :NLTIOL Datc of Receipt : 27/10/2020
Mfg. Date : 10/20 Qty. Sampled : 102 mL
Exp. Date : To be established Batch Release Date : 30/12/2020
Specification No. : FPS306

TESTS SPECIFICATIONS RESULTS

Identity test for vaccine virus (In- | ELISA test and SDS PAGE serve Complies

vitro)

as an identity test

 

Clear colourless, translucent Clear colourless, translucent liquid,

 

 

Deseriplion liquid, free from particulate matter | free from particulate matter
pH 7.00 - 8.00 7.20 o
Sterility No growth should be observed No growth observed

e (Sterile)

 

| Total Protein content (Lowry et al)

NLT 15.00 ug/mL, ] 154.88 ug'mL

 

Corona virus amplification test

No residual live virus should be
observed in Corona virus
Amplification test

No residual live virus observed

 

Corona virus inactivation test

No CPE should be observed | No CPE observed

 

Residual cellular DNA Content

NMT 10.00 ng/SHD 0.02 ng/SHD

 

Residual Bovine serum Albumin
content

NMT 50.00 ng/SHD 2.16 ng'SHD

 

Antigenic purity by SDS-PAGE

Should show only Corona virus

specific bands Complies

 

Bacterial Endotoxin

Less than 25 international Units

(U) per mL <12.5 IU per mL

 

Residual BPL Content

No Residual BPL Content should

No Residual BPL Content present
be present

 

Residual trypsin content by
ELISA method

 

 

For information only O ng/mL

 

 

 

Ra
OPINION: Sample COMPLIES/DOES-NOT-COMPEY as per specification No.: FPS306

 

Prepared By:
E Será

30 E, 20

Checked By: fo Approved By:
o

[ fl, DD provo
= poe Cub — Quality nba

 

 

Form No.: FMQCG/024/001.00

Page No.: 01 of 01
FOR RESTRICTED CIRCULATION

UNCONTROLLED COPY
. ]
DOC
BHARAT

BIOTECH
Lat Sinermadito

Genome Valley, Turkapally, Shameerpet
Hyderabad-500078, INDIA
Department: Quality Control

CERTIFICATE OF ANALYSIS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product -: WHOLE VIRION, INACTIVATED CORONA VIRUS BULK
Batch Number — : 37620002A AR. Number : 1P-37-20-048
Batch size :NLTIOL Date of Receipt : 07/11/2020
Mig. Date : 11/20 Qty. Sampled : 102 mL
Exp. Date : To be established Batch Release Date : 30/12/2020
Specification No. : FPS306
TESTS SPECIFICATIONS RESULTS 1]
Tdentity test for vaccine virus (In- ELISA test and SDS PAGE serve :
E a s Complies
vitro) as an identity test
Desesipiióii Clear colourless, translucent Clear colourless, translucent liquid,
P liquid, free from particulate matter free from particulate matter
pH 7.00 - 8.00 7.4)
Stenility Ho growth should be observed No growth observed
- (Sterile)
Total Protein content (Lowry etal) | NLT 15.00 ug'mL 124.61 ug/mL
No residual live virus should be
Corona virus amplification test observed in Corona virus No residual live virus observed
Amplification test |
| Corona virus inactivation test No CPE should be observed No CPE observed
Residual cellular DNA Content NMT 10.00 ng/SHD 0.18 ng/SHD
Residual Bovine serum Albumin | NMT 50.00 ng/SHD 12.42 ng/SHD
content
ou . . Should show only Corona virus z
Antigenic purity by SDS-PAGE specific bands Complies
Bacterial Endotoxin Less than 25 international Units «12.5 IU per mL
(TU) per mL
Residual BPL Content No Residual BPL Content should No Residual BPL Content present
º be present
Residual trypsin content by RR ,
ELISA method For information only 0 ng/ml |

 

 

ad
OPINION: Sample COMPLIES/DOES NOT-COMPEY as per specification No.: FPS306

 

 

 

 

 

Prepared By: Checked By: | ] Approved By:
a
q Co fra MA
ae E rouhab one
ao asnuitovo (Head - Quality Control) |
Form No.: FMQCG/024/001.00 Page No.: 01 of 01

FOR RESTRICTED CIRCULATION

UNCONTROLLED COPY
 

>0€
BHARAT

BIOTECH
Lent Genemealtam

Genome Valley, Turkapally, Shameerpet

Product

Hyderabad-500078, INDIA
Department: Quality Control

CERTIFICATE OF ANALYSIS

 

: WHOLE VIRION, INACTIVATED CORONA VIRUS BULK

 

 

Batch Number |: 37620003A A.R. Number : TP-37-20-049
Batch size :NLTIOL Date of Receipt : 28/11/2020
Mig. Date : 11/20 OQty. Sampled : 102 mL
Exp. Date : To be established Batch Release Date : 30/12/2020
Specification No. : FPS306

TESTS SPECIFICATIONS RESULTS

Identity test for vaccine virus (In- | ELISA test and SDS PAGE serve E
Complies

vitro)

as an identity test

 

 

Clear colourless, translucent

Clear colourless, translucent liquid,

 

 

Description liquid, free from particulate matter | free from particulate matter
pH 7.00 - 8.00 74 = o
Stenility No growth should be observed No growth observed

(Sterile)

 

Total Protein content (Lowry et al)

NLT 15.00 ug/mL

 

Corona virus amplification test

106.13 ug'imL

 

No residual live virus should be
observed in Corona virus
Amplification test

No residual live virus observed

 

 

| Corona virus inactivation test

No CPE should be observed

No CPE observed

 

 

 

 

Residual cellular DNA Content NMT 10.00 ng/SHD 0.41 ng/SHD

Residual Bovine serum Albumin NMT 50.00 ng/SHD 13.56 ng/SHD

content no
Antigenie purity by SDS-PAGE Should showronly/Corona virus Complies

specific bands

 

 

Bacterial Endotoxin

Less than 25 international Units
(TU) per mL

<12.5 IU permL

 

Residual BPL Content

No Residual BPL Content should
be present

No Residual BPL Content present

 

 

Residual trypsin content by
ELISA method

 

For information only

 

O ng/mL

 

 

pa
OPINION: Sample COMPLIES/BOES NOF-EOMPEY as per specification No.: FPS306

 

 

Prepared By:

 

Checked By:

 

£ Approved By:

 

 

So st
Auoloo 20 eita ada solo
Bo ex (Head — Quality Control)
Form No.: FMQCG/024/001.00 Page No.: 01 of 01

FOR RESTRICTED CIRCULATION

UNCONTROLLED COPY

 

 
DRUGS CONTROL ADMINISTRATION

 

et De GOVERNMENT OF TELANGANA
L.Dis.No. : 35698/TS/2020 Dated :.06.2020
MP CERTIFICATE

“This is to certify that M/s. Bharat Biotech International Limited, situated at Sy. No. 230,
231 & 235, Genome Valley, Turkapally, Shamirpet Mandal, Medchal-Malkajgiri District -
500 078, Telangana State, India are holding Drug Licence in Form-28D bearing No.
03/HD/AP/98/V/R, Dated:14.10.1998 valid up to 31.12.2021 for the manufacture for sale or
distribution of the drugs approved by this Department. The firm is subject to periodical
inspection by this Department.

“The firm is following GOOD MANUFACTURING PRACTICES as stipulated under
the provisions of Schedule “M” of Drugs and Cosmetics Rules, 1945.

The firm should however carry out self-inspection from time (o time to ensure that the
requirements of Good Manufacturing Practices are complied with.

This certificate is valid for one year from the date ofissue.

Yours faithfully,

A.
als) fo
Dr. B.VENKATESWARLU

Deputy Director

 

To,

Ms. Bharat Biotech International Limited,
Sy. No. 230, 231 & 235, Genome Valley,
Turkapally, Shamirpet Mandal,
Medchal-Malkajgiri District — 500 178,
Telangana State, India.
DRUGS CONTROL ADMINISTRATION
GOVERNMENT OF TELANGANA

   

L. Dis.No. 1646/STORES/2020 Date: 2/1 12020

To

Ms. Bharat Biotech International Limited,
Sy. No. 230, 231 & 235, Genome Valley,
Turkapally, Shamirpet Mandal,

Medcehal - Malkajgiri District-500078,
Telangana State, India.

Sir,

Sub: Drugs and Cosmetics Act, 1940 and Rules made thereunder-Issue of World Health
nization G.M.P Certificate - Regarding.

 

Ref: 1, Your letter dated: 17/03/2020
2. Joint Inspection report dt: 04/03/2020 to 06/03/2020 and further on 08/07/2020 to
10/07/2020.

-X-R-X-X-
With reference to your application cited, 1 forward herewith WORLD HEALTH
ORGANISATION GOOD MANUFACTURING PRACTICE Certificate for the products

mentioned in Lhe joint Inspection Report of the officers of Drugs Control Administration,
Telangana State and CDSCO, ZONAL Office, Hyderabad vide reference 2"“ cited.

“This Certificate is valid for a period of Three years from the date of issue.

Yours faithfully,

  

Joint Director (FAC) & Licensing Authority

Page 1 of 4
DRUGS CONTROL ADMINISTRATION
GOVERNMENT OF TELANGANA

   

L. Dis.No. 1646/STORES/2020 Date: 2211/2020

LIST OF PRODUCTS APPROVED UNDER WHO-GMP
CERTIFICATION SCHEME FOR EXPORT PURPOSE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    
 
 

 

 

 

 

 

 

 

 

Purified Rabies Final Bulk Vaceine BP (For Export Purpose)
Presentation: 10L & 20 L Bottles l
Composition: Each | mL contains:
j Vero Cell derived Purificd BPL Inactivated Pitman Moore strain of Rabies Virus
. Potency, o . NLT 4.0 1.4.
Thiomersal BP o NMT 0.01% wiv
Maltose NH ne up to 1 immunizing dose
Human Albumin BP up to 1 immunizing dose
Typhoid Polysaccharide Final Bulk Vaccine BP (For Export Purpose) |
Presentation: 1 L,5T., & 101,20 L Bottles
2 Composition: Each ! ml. contains:
: Purified Vi Capsular Polysaccharide of Salmonella typhi Ty2 [50 ug
Phenol BP NMT 0.25% wiv.
Phosphate Bullered Saline no q.sto 1.0 ml.
Poliomyelitis Vaccine, Live (Oral) BP (For Export Purpose)
Brand Name: BIOPOLIO
Presentation: 1.0 mL (10-dose) vial & 2.0 mL. (20-dose) vial
Route of Administration: Oral
Composition: | dose = 0.ImL (2 Drops) contains:
, Primary Monkey Kidney Cell Culture-derived
> Pohovirus l'ype 1 (Sabin) , NLT 108º CCIDso o
Poliovirus Type 2 (Sabin) NLT 105! CCIDso
| Poliovirus Type 3 (Sabin) NLT 10% CCIDso
Stabilized with esium Chloride (MgCl IM)
Neomycin Sulp) BP 15 ug =
Kanamycin Acid Sulphate BP 15 ug
Monovalent Poliompyelitis Vaceine Type 1 Live (Oral) (For Export Purpose)
Brand Name: BIOPOLIO M1
| Presentation: 1.0 mL (10- dose) vial & 2.0 ml. (20- dose) vial
| Route of Administration: Oral
4 Pol Do . NLT 10 “CCIDso
Stabiliz; ith o um Chloride (MgCly IM) no o
Neomycin Sulphate BP Co I5ug
i ug
q.s to 0.1 mL

 

 

 

 

Page 2 0f 14

&( HYDERABAD JE
a 1

 
 

L. Dis.No. 1646/STORES/2020
Poliomyelitis Vaccine Live (ORAL) BP

DRUGS CONTROL ADMINISTRATION
GOVERNMENT OF TELANGANA

 

Date: 29/11/2020
(For Export Purpose)

 

Brand Name : BIOPOLIO

 

Presentation: 1.0 mL (10-dose) vial & 2.0 mL (20-dose) vial

 

Route of Administration: Oral

 

 

Composition: | dose = 0.ImL (2 Drops) contains:
MRC-5 Cell Line -derived

 

5. | Poliovirus Type 1 (Sabin)

NLT 10 SCCIDso

 

Poliovitus Type 2 (Sabin)

[NLT 0 PÍECIDS

 

 

Poliovirus Type 3 (Sabin)

[NLT 10 ** CCIDs

 

Stabilized with Magnesium Chloride (MgCl IM)

 

Neomycin Sulphate BP

15 pg

 

Kanamycin Acid Sulphate BP

15 ug

 

[Water for Injections BP

 

q.s. to 0.1 mL

 

 

| Rabies Vaccine BP

(For Export Purpose)

 

Brand Names : INDIRAB & CELLRAB

 

Presentation: Lyophilized Vaccine vial supplied along with 0.5 mL diluent ampoule |

 

Route of Administration: Intramuscular

 

Composition: Each dose (0.5mL) of reconslituted vaccine contains:

 

Vero Cell derived Purified BPL Inactivated Pitman Moore strain of Rabies Virus

 

 

 

6. | Poteney o >25TU .
Thiomersal BP o NMT 0.01% wiv
Maltose NF upto 1 immunizing dose

 

Human Albumin BP

upto 1 immunizing dose

 

Each 0.5 mL Diluent ampoule contains:

 

| Sodium Chloride IP/BP

1.5mg

 

| Water for Injections IP/BP

q.s to 0.5mL.

 

 

 

 

Rabies Vaceine BP

(For Export Purpose)

 

Brand Names : INDIRAB & CELLRAR

 

| Presentation : Lyophilized Vaccine vial supplied along with 0.5 mL diluent ampoule |

 

Injection 00.5 mL

Route ot Administration : Intradermal Injection of 0.1 mL per site & Intramuscular

 

| Composition: Each dose (0.5mL) of reconstituted vaccine contains:

 

Vero Cell derived Purificd BPL Inactivated Pitman Moore strain of Rabics Virus

 

Potency

=2510

 

Thiomersal BP

NMT 0.01% wiv

 

| Maltose NF

upto | immunizing dose

 

Buman Albumin BP

 

upto 1 immunizing dose

 

Each 0.5 mL Diluent ampoule contains:

 

Sodinm Chloride IP/BP

| 1.5 mg

 

 

Water for Injections IP/BP

|gslto 0,5 mL

 

 

 

 

 

a

Page 3 of lá
D e A DRUGS CONTROL ADMINISTRATION
ia ca GOVERNMENT OF TELANGANA

 

   

L. Dis.No. 1646/STORES/2020 Date: 2211/2020
| Rabies Vaccine BP . (For Export Purpese)
Presentation : Lyophilized Vaccine vial supplied along with 0.5 ml. diluent ampoule |
Route of Administration : Intradermal Injection of 0.1 mL per site & Intramuscular
| Injection 070.5 mL

Cumposition: Each dose (0.5mL) of reconstituted vaccine contains:
Vero Cell derived Purified BPL Inactivated Pitman Moore strain of Rabies Virus

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8. | Poteney 22.51U |

Thiomersal BP NMT 0.01% wiy
Maltose NF upto 1 immunizing dose

- Human Albumin BP upto | immunizing dose
Each 0.5 mL Diluent ampoule contains:
Sodium Chloride IP/BP (ISmg
Water for Injections 1P/BP Lg. to 0.5 mL
Rabies Vaccine BP (For Export Purpose)

 

| | Brand Names : INDIRAB & CELLRAB
Presentation : Lyophilized Vaccine vial supplied along with 1.0 mL diluent ampoule

Route of Administration : Intradermal Injection of 0.1 mL per site |

| Composition: Each dose (1.0 mL) of reconstituled vaceine contains:

Vero Cell derived Purilicd BPL Inactivated Pitman Moore strain of Rabies Virus

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9. Potency >2.51U
Thiomersal BP NMT 0.01% v/v
Maltose NF . upto 1 immunizing dose
Human Albumin BP | upto | immunizing dose
Each 1.0 mL Diluent ampoule contains:
Sodium Chloride IP/BP 3mg
Water for Injections IP/BP . q.s to 1.0 mL
' Rabies Vaccine BP (For Export Purpose)

 

Brand Names : INDIRAB & CELLRAB

Presentation: Lyophilized Vaccine vial supplied along with 1.0 mL diluent ampoule
Route of administration: Intramuscular Injection of 1.0 mL per dose or Intradermal
Injection of 0.1 mL per site

Composition: Each dose (1.0 ml.) of reconstituted vaccine contains:

 

 

 

 

Vero Cell derived Purified BPL Inactivated Pitman Moore strain of Rabies Virus

 

 

 

 

 

 

 

 

10. | Potency [=251U.
Thiomersal BP NMT 0.01% w/v
| Maltose NF upto 1 immunizing dose
Human Albumin BP upto 1 immunizing dose
Each 1.0 mL Diluent ampoule contains:
Sodium Chloride IP/BP . 3 mg
Water for Injections IP/BP q.sto 1.0 mL

 

 

 

 

Cega

 

HYDERABAD 15

JO(FAC)

Page 4 of 4

 
D

CA

 

L. Dis.No. 1646/STORES/2020

Rabies Vaccine BP
Brand Name : INDIRAB & CELLRAB

DRUGS CONTROL ADMINISTRATION
GOVERNMENT OF TELANGANA

Presentation: Lyophilized Vaccine vial supplied along «with 1.0 mL diluent ampoule

  

Date: 2111/2020
(For Export Purpose) 1

 

Route of administration: Intramuscular

 

Composition: Each dose (1.0 mL) of reconslituted vaccine contains:

 

Vero Cell derived Purificd BPL Inactivated Pitman Moore strain of Rabies Virus

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11. | Potency >25IU
| Thiomersal BP NMT 0.01% wiv
| Maltose NF upto | immunizing dose
Human Albumin BP upto 1 immunizing dose
Each 1.0 mL diluent ampoule contains:
Sodium Chloride IP/BP 3mg
Do Water for Injections IP/BP q.s to 1.0 mL
Do [ Rabies Vaccine BP
(Thiomersal-free) (For Export Purpose)
Brand Name : INDIRAB
Presentation : Lyophilized Vaccine vial supplied along with 0.5 ml, diluent ampoule
Route of Administration: Intramuscular
Compusition: Each dose (0.5 mL) of reconstituted vaccine contains:
12. [Vero Cell derived Purified BPL Inactivated Pitman Moore strain of Rabies Virus
Potency >2.5IU
Maltose NF upto | immunizing dose
Human Albumin BP | upto 1 immunizing dose
Each 0.5 mL Diluent ampoule contains:
”Sodium Chloride IP/BP 1.5mg
Water for Injections IP/BP q.sto 0.5 mL
Rabies Vaceine BP
| (Thiomersal-free) (For Export Purpose)
Presentation : Lyophilized Vaccine vial supplied along with 0.5 mL diluent ampoule |
Route of Administration : Intramuscular
Composition: Each dose (0.5 mL) of reconstituted vaccine contains:
Vero Cell derived Purified BPI. Inactivated Pitman Moore strain of Rabies Virus
13. [Potency >251U
Maltose NF upto 1 immunizing dose

 

 

 

 

 

 

 

Human Albumin BP

upto | immunizing dose

 

Each 0.5 mL Diluent ampoule contains:

 

Sodium Chloride IP/BP

1.5 mg

 

 

Water for Injections IP/BP

 

q.sto 0.5 mL

 

 

 
 

 

 

      
 

Lo a ORUPE

      

  

EN CT

NDERABAD 18]
JD(FAC)

Page 5 of ld
À DRUGS CONTROL ADMINISTRATION
o GOVERNMENT OF TELANGANA

   

L. Dis.No. 1646/STORES/2020 Date: 22 111/2020

(TEN) HUMAN RABIES VACCINE BP (INDIRAB) LYOPHILIZED VIAL +
(TEN) 0.5ML DILUENT + (TEN) 2 ML DISPOSABLE SYRINGE:
(MUL'TICARTON) FOR INTRAMUSCULAR USE (For Export Purpose)
(a) (Ten) Human Rabies Vaccinc BP

 

 

| Composition: On Reconstitution each Vial (0.5mL) contains:

 

Purified BPL Inactivated Rabies Virus

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Potency | 22.5 IU
(Prepared on Vero Cells Pitman Moore strain of Rabies V' irus) o
14. | Thiomersal BP NMT 0.01% wiv |

Maltose NF upto 1 immunizing dose
Human Albumin BP . upto 1 immunizing dose

* Dosage: 0.5mL (Intramuscular Injcetion)

[(b) (Ten) Diluent for Reconstitution
Composition: Each 0.5 mL Diluent ampoule contains:
Sodium Chloride IP/BP 1.5mg
Water Tor Injections IP/BP 0.5 mL
(c) (Ten) 2 mL disposable syringe with 25 gauge nocdle

| (TEN) HUMAN RABIES VACCINE BP (INDIRAB) LYOPHILIZED VIAL +
(TEN) 1 ML DILUENT + (HUNDRED) 1 ML INSULIN SYRINGE WITH 30
GAUGE NEEDLE: (MULTICARTON) FOR INTRADERMAL USE
à na o (For Export Purpose)
(a) (Ten) Human Rabies Vaccine BP
Composition: On Reconstitution each Vial (0.5ml.) contains:
Purified BPL Inactivated Rabies Virus É
Potency | 2.5 IU
(Prepared on Vero Cells Pitman Moore strain of Rabies V irus)

15. | Thiomersal BP NMT 0.01% w/y

| Maltose Ê upto 1 immunizing dose

Human Albumin BP É upto | immunizing dose

 

Dosage: 0.1 mL (Intradermal Injection)

 

 

| (b) (Ten) Diluent for Reconstitution

 

Composition: Each 1 mL Diluent ampoule contains:

 

 

Sodium Chloride IP/BP 3.0mg

 

Water for Injections IP/BP “ImL
(c) Hundred 1 ML Insulin Syringe with 30 Gauge Needle

 

 

 

 

 

Capa

Page 60 14

 
DOCA DRUGS CONTROL ADMINISTRATION

 

GOVERNMENT OF TELANGANA

 

L. Dis.No. 1646/STORES/2020 Date: 2/11/2020

| ADJUVANTED HINI VACCINE (For Export Purpose) |
| Brand Name : HIN-VAC

Presentation: 0.5 mL (Single dose) vial & 5.0 ml. (Multi dose) vial

Routc of Administration : Intramuscular

Composition: Each dose of 0.5 mL contains:

MDCK Cell-derived Hemagglutinin Antigen (HA) equivalent of Purificd, Inactivated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

16. | Influenza A (HIN1) Pandemie Virus Bulk [A/California/7/2009/NYMCX-179-
A(HINI) virus]
Potency 215 ug
Aluminium Hydroxide Gel equivalent to Aluminium 0.25 mg
(ALT)
| Thiomersal BP 0.025 mg
Phosphate Buflered Saline q.s to 0.5 mL
Typhoid Polysaccharide Vaccine BP (For Export Purpose)
Brand Name : [YPBAR-PFS
Presentation : 0.5mL (Single dose) in PFS
Route of Administration : Intramuscular
17. | Composition: Each dose of 0.5 mL contains:
Purificd Vi Capsular Polysaccharide of Salmonella typhi [25 ug
172
Phenol BP NMT 0.25% wuiv
Phosphate Buffered Saline q.s. to 0,5 ml.
Typhoid Vi Conjugate Vaceine (For Export Purpose)
| Brand Name : Typbar TCV
Presentation: 0.5 mL (Single dose) vial, 2.5 ml. (Multi dose) vial & 0.5 mL (Single
dose) in PES
Route of Administration: Intrumuscular
a) Composition for Single dose presentation in Vial and PFS:
| Each dose of 0.5 mL contains
Purified Vi Capsular Polysaccharide of Salmonella 25 ug
18 typhi Ty2 conjugated to Tetanus Toxoid
* | Sodium Chloride BP 4.5 mg
Water for Injections BP | q.s. to 0.5 mL
| b) Composition for Multi dose presentation in Vial:
Each dose of 0.5 mL contains
Purified Vi Capsular Polysaccharide of Salmonella 25 ug
typhi Ty2 conjugated to Tetanus Toxoid
Sodium Chloride BP 4,5 mg
2-Phenoxyethano! BP 5.0 mg
Water for Injections BP | g.s. to 0.5 mL

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANP

 

 

Page 7 of 4
D

 

CA

L. Dis.No. 1646/STORES/2020

DRUGS CONTROL ADMINISTRATION
GOVERNMENT OF TELANGANA

 

Date: 2ºn1/2020

 

Haemophilus Type b Conjugate Vaccine BP

(For Export Purpose)

 

Brand Name : BivHib

 

| Presentation : Lyophilized Vaccine vial supplied along with 0.5 ml. diluent ampoule
pá

 

Route of Administration : Intramuscular

 

Composition :On reconstitution each dose of 0.5mL reconstituted Vaccine contains:

 

Purified Capsular polysaccharide of Hib [Covalently
bound to 20-40 ug Tetanus Toxoid (PRP-TT)]

10 ug

 

Each 0.5 mL Diluent ampoule contains:

 

Sodium Chloride IP

4.5 mg (0.9% w/v)

 

 

Water for Inections IP

q.s. to 0.5 mL

 

 

20.

'“Hepatitis B Vaccine (rDNA) BP
(Pediatric dose)

(For Export Purpose)

 

Brand Names : Revac-B+ / Revac-B / Hepliv / Heptec-B / Unihep-B*

 

dose) Vial

Presentation : 0.5mL (Single dose) Vial, 2.5 mL (Multi dose) vial & 5.0 ml. (Multi

 

Route of Administration : Intramuscular

 

Composition: Each pediatric dose of 0.5 mL contains:

 

Hepatitis B surface Antigen (HBsAg)

>10ug

 

 

Aluminium Hydroxide Gel equivalent to Aluminium
(ADO)

0.25 mg

 

Thiomersal BP

0.025 mg

 

Phosphate Buffered Saline

 

q.s. to 0.5 mL.

 

 

Hepatitis B Vaceine (FDNA) BP
(Adult dose)

(For Export Purpose)

 

Brand Names : Revac-B+ / Revac-B / Hepliv / Heptee-B / Unihep-B*

 

Presentation : 1.0 mL (Single dosc) vial & 10.0 mL (Multi dose) vial

 

Route of Administration : Intramuscular

 

Composition : Each adult dose of 1.0 mL contains:

 

Hepatitis B surface Antigen (HBsAg)

>20 ug

 

Aluminium Hydroxide Gel equivalent to Aluminium
(Alt

0.5 mg

 

Thiomersal BP

0.05 mg

 

Phosphate Buffered Saline

 

q.sto 1.0 mL

 

 

19
t3

 

Hepatitis B Vaccine (rDNA) BP
(Pediatric Dose) (Thiomersal-Free)

(For Export Purpose)

 

Brand Name : Revac-B mcf

 

Presentation: 0:5 mL (Single dose) vial, 0.5 mL PFS

 

Route of Administration : Intramuscular

 

Composition: Each Pediatric dose of 0.5 mL. contains:

 

Hepatitis B surface Antigen (HBsAg)

210 ug

 

Aluminium Hydroxide Gel equivalent to Aluminium
(ALT S

0.25 mg

 

 

Phosphate Buffered Saline ' DEE say

 

q.s. to 0.5 mL

 

 

 

CNE

Page 8 of 14

 
D CA DRUGS CONTROL ADMINISTRATION é
E a GOVERNMENT OF TELANGANA a

   

 

L, Dis.No, 1646/STORES/2020 Date: 20/11/2020

 

 

Hepatitis B Vaccine (rDNA) BP (For Export Purpese)

(Adult Dose) (Thiomersal-Free)

Brand Name : Revac-B mcf

Presentation : 1,0 mL (Single dose) vial

Route of Administration : Intramuscular
Composition: Each adult dose of 1.0 mL contains:

Heparitis B surface Antigen (HBsAg) >20 ug
Aluminium Hydroxide Gel equivalent to Aluminium 0.5 mg
(ALT
Phosphate Buffered Saline q.s. to 1.0 mL

 

 

 

  

  

 

 

 

 

 

 

Diphtheria, Tetanus and Pertussis (Whole Cell) Vaceine (Adsorbed) BP
(For Export Purpose)
Brand Name : ComVac3

| Presentation : 0.5 ml, (Single dose) vial, 0.5 mL PFS (Single dose), 2.5 mL (Multi
: dose) vial & 5.0 mL (Multi dose) vial
Route of Administration : Intramuscular
24. Composition: Each dose of 0.5 mL contains:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

' Diphtheria Toxoid >20Lfto<30LI(30 TU) |
| Tetanus Toxoid >5Lfto <25Lf(> 60 IU)

B. pertussis (Whole Cell Inactivated) 2410

Aluminium Phosphate Gel equivalent to Aluminium | 0.3 mg

(AN), |

Thiomersal BP NMT 0.029 mg

 

 

 

 

Adsorbed Diphtheria, Tetanus, Pertussis (whole Cell) and Hepatitis B(rDNA)
Vaccine — (For Export Purpose)
Brand Name : ComVac-4 HB o

Presentation : 0.5 mL (Single dose) vial, 2.5 mL (Multi dose) vial & 5.0 mL (Multi
dose) vial

Route of Administration : Intramuscular
Composition: Fach dose of 0.5 mL contains:

 

 

 

 

 

 

 

 

 

Diphtheria Toxoid | > 20 Lfto<30Lf(> 30 TU)
Tetanus Voxoid É > SLfto <25 Lf (> 60 IU)
B. pertussis (Whole Cell Inactivated) >4IU

| Hepatitis B surface Antigen (HBsAg) >10ug
Aluminium Phosphate Gel equivalent to Aluminium | 0.3mg
(AITS
Thiomersal BP NMT 0.029 mg

 

 

 

 

 

Page 9ofl4

 
D BA DRUGS CONTROL ADMINISTRATION
E e GOVERNMENT OF TELANGANA

   

 

L. Dis.No. 1646/STORES/2020 Date: ZÉ 113/2020

 

Diphtheria, Tetanus, Pertussis (Whole cell), Hepatitis B (rDNA) and
Haemophilus influençae Type b Conjugate vaccine (Adsorbed)
(For Export Purpose)

 

Brand Name : Comvac 5

 

| Presentation : 0.5 mL (Single dose) vial, 0.5 mL PFS (Single dose), 2.5 mT. (Multi
dose) vial & 5.0 mL (Multi dose) vial

 

Route of Administration : Intramuscular

 

Composition: Fach dose of 0.5 mL contains:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

26. | Diphtheria Toxoid > 20 Lfto < 30 Lf (230 IU)
Tetanus Toxoid l >5 Lito <25 Lf (> 60 IU)
B. Pertussis (Whole Cell Inactivated) . >4IU
Hepatitis B surface Antigen (HBsAg) >10 ug
| Hib PRP- TT Conjugate >10ug o
Aluminium Phosphate Gel equivalent to Aluminium | 0.3 mg
(AL)
| Thiomersal BP NMT 0.029 mg
Recombinant Human Epidermal Growth Factor Gel — For Export Purpose)
Brand Name : REGEN-D 10
Presentation : 7.5 gm, 15 gm, 30 gm, 60 gm & 150 gm o
Route of Administration : For External Use only o
27. | Composition: Each gram contains: o
Purified Bulk of rh-Epidermal Growth Factor 10 ug
Sodium Methylparaben BP 1.8 mg
| Sodium Propylparaben BP 0.2 mg
' Excipients qs

 

 

 

Japanese Encephalitis Vaccine, Inactivated (Adsorbed, Human)
(For Export Purpose)

 

Brand Name: JENVAC

 

Presentation : 0.5 mL (Single dose) Vial, 2.5 mL (Multi Dose) Vial and 0.5 mL in
Pre-Filled Syringe (PFS)

 

Route of Administration : Intramuscular

 

Composition: Each dose of 0.5 mL contains:

 

Vero Cell derived Purified, Inactivaled Japanese Encephalitis Virus (JEV strain
821564-XY) Protein

 

 

 

 

 

Potency o , . NLI Sug
Aluminium Ilydroxide Gel equivalent to 0.25 mg
Aluminium(A O . o
Thiomersal BP . 0.025 mg

' Phosphate Buffered Saline q.s. to 0.5 mL

 

 

 

 

 

 

    
 

HYDERABAD

FAC)

JU

   

Page 10 of 14
 

DRUGS CONTROL ADMINISTRATION
GOVERNMENT OF TELANGANA

 

L. Dis.No. 1646/STORES/2020 Date: 21/2020

 

Japanese Encephalitis Vaccine Tnactiv: ated (Adsorbed, Human)
(For Export Purpose)

 

' Brand Name : JENVAC

 

Presentation : 0.5 mL in Pre-Filled Syringe

 

Route of Administration : Intramuscular

 

 

Composition :Each dose of 0.5 mL contains:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

29. | Vero Cell derived Purified, Inactivated Japanese Encephalitis Virus (821564-XY)
Protein
Poteney NLT 5.0 ug
Aluminium Hydroxide Gel equivalent to 0.25 mg
Aluminium(A1 .
| 2-Phenoxyethanol BP 2.0mg to 3.0mg
Phosphate Buffered Saline . | q.s. to 0.5 mL
DTP+Hib (Combopack) (For Export Purpose)
DTP- Liquid suspension (0.Sml,)
Hib- Lyophilized Powder Reconstitute Hib component with DTP Vaccine (0.5 mL)
Brand Name : ComVac 3+ Biollib
Composition: Each reconstituted dose of 0.5 mL contains:
ajDiphiheria Toxoid =20 Lfto <30 LF (2301U)
+. | Tetanus Toxoid =5Lflo <25 LEE 60 TU)
30. Inactivated B. pertussis (w) >4 TU
Aluminium Phosphate Gel equivalent to Aluminium | 0.3 mg
(ALTO
Thiomersal BP | NMT 0.029 mg
bjLyophilized dose of 0.5mL
Purified Capsular polysaccharide of Hib | 10 ug
[Covalently bound to 20-40 ug Tetanus Toxoid PRP-TT)]
É Typhoid Vi Conjugate Vaceine (For Export Purpose)
Brand Name : Typbar TCV
Presentation : 5.0 mL Vial (Multi Dose)
Route of Auministration : Intramuscular (IM)
8 Composition : Each dose of 0.5 mL contains:

 

| Purified Vi Capsular Polysaccharide of S.typhi Ty2 25.0 ug
conjugated to Tetanus Toxoid

 

 

 

 

 

Sodium Chloride BP 4.5 mg
2-Phenoxyethanol BP (as preservative) 5.0 mg
Water for Injcctions BP q.s. to 0.5 mL

 

 

Aang

Page ll of l4

 
 

L. Dis.No. 1646/STORES/2020

6 Ã DRUGS CONTROL ADMINISTRATION
bi GOVERNMENT OF TELANGANA

 

Date: 2/11/2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SILVER SULFADIAZINE, CHLORHEXIDINE GLUCONATE AND RECOMBINANT
HUMAN EPIDERMAL GROWTH FACTOR CREAM (For Export Purpose)
Brand Names: SLYRGEN & SIMGEN
Pack Size : 50 gms & 100 gms o = o
Composition : Each gram of cream contains

32. | Recombinant Human Epidermal Growth Factor 10 ug
Silver Sulfadiazine USP 1% wiw
Chlorhexidine Cluconate USP 2% www
Sodium Methylparaben USP 0.18% ww
Sodium Propylparaben USP 0.02% ww
Purified Water USP qs
Rotavirus Vaccine (Live, Oral) BP (For Export Purpose)
Brand Name: ROTAVAC 5D º
Presentation : 0.5 mL (Single dose) vial and 2.5 ml. (Multi dose) vial
Route of Administration : Oral
Composition: Each Dose of 0.5 mL (Sdrops) contains:
Vero Cell derived Rotavirus 116E Bulk, Live NLT 10º FFU
Attenuated
Ncomycein Sulphate BP 15 ug

33. | Kanamycin Acid sulphate BP 15 ug

 

Sucrose BP

0.25 gms

 

Trehalose BP

 

Lactalbumin Hydrolysate (LAH)

 

Human Albumin BP

 

 

 

 

 

 

 

Potassium Di hydrogen orthophosphate BP 1.65 mg
Di Potassium hydrogen orthophosphate BP 10mg
Tri Sodium Citrate Dihydrate BP 7.75 mg
Water for Injections BP q.s

 

Rotavirus Vaccine (Live, Oral) BP
Brand Name: ROTAVAC 5D ”

(For Export Purpose)

 

Presentation : 0.5 mL (Single dose) PES

 

Route of Administration : Oral

 

Composition: Each Dose of 0.5 ml. contains:

 

Vero Cell derived Rotavirus 1 I6E Bulk, Live
Atrenuated

NLT 10º FFU

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Neomycin Sulphate BP 15 ug
34. | Kanamycin Acid sulphate BP 15 ug
Sucrose BP 0.25 gms
Trehalosc BP 2.5 mg
Lactalbumin Hydrolysate (LAH) 2.5 mg
Human Albumin BP 10.35 %
Potassium Di hydrogen orthophosphate BP | 1.65 mg
Di Potassium hydrogen orthophosphate BP 10 mg
Tri Sodium Citrate Dihydrate BP 7.75 mg
Water for Injections BP q.s

 

 

Asa”

Page Dofl4
D CA DRUGS CONTROL ADMINISTRATION
e o GOVERNMENT OF TELANGANA

    

L. Dis.Nu. 1646/STORES/2020 Date: 2/11/2020

 

 

Bivalent Poliomyelitis Vaccine Type 1& 3 Live (Oral) (For Export Purpose)

 

Brand Name: BIOPOLIO B1/3

 

Presentation: 1.0 mL (10-dosc) vial & 2.0 mL (20-dose) vial
Route of Administration: Oral

 

Composition: | dose = 0.1 mL (2 Drops) contains:

 

Primary Monkey Kidney Cell Culture-derived

 

35.

 

 

 

 

 

 

 

 

 

 

Poliovirus Type | (Sabin) NLTIGÊÊ CCIDs
Poliovirus Type 3 (Sabin) NLT 107º CCIDso
Stabilized with Magnesium Chloride (MgCly IM)
Neomycin Sulphate BP 15 ug
Kanamycin Acid Sulphate BP 15 ug
Water for Injections BP [ q.s to 0. ml,
| Monovalent Poliomyelitis Vaccine Type 3 Live (Oral) (For Export Purpose)

 

| Brand Name: BIOPOLIO M3 o
Presentation: 1.0 mL (10-dosc) vial & 2.0 mL (20-dose) vial

 

' Route of Administration : Oral

 

Composition: | dose = 0.1 ml. (2 Drops) contains:

 

 

 

 

 

 

 

 

 

 

36. | Primary Monkey Kidney Cell Culture-derived o
Poliovitus Type 3 (Sabin) [NLT 10FCCIDso
Stabilized with Magnesium Chloride (MgCl; IM) |
Neomycin Sulphate BP 15 ug
Kanamycin Acid Sulphate BP 15 ug
Water for Injections BP gusto 0.] mL
Manufacturer : M/s. Bharat Biotech International Limited,

Sy. No. 230, 231 & 235, Genome Valley,
Turkapally, Shamirpet Mandal, Medchal-
Malkajgiri  District-500078, —Telangana
State, India.

When applicable : Placing the product on the market as
detailed above

 

 

K is certified that the above products had been authorized to be placed en the market for
use in the Country and exporting countries.

Drug Licence No. : 03/HD/AP/98/V/R, dated: 14/10/1998
under Form.28D valid up to 31/12/2021.

Itis also certified that (a) the manufacturing plant in which the product is produced is
subject to inspection at suitable intervals

ya”

Page 13 0f 14

 
 

D CA DRUGS CONTROL ADMINISTRATION
E a GOVERNMENT OF TELANGANA

 

L. Dis.Xo. 1646/STORES/2020 Date: 2/11/2020

The Unit M/s. Bharat Biotech International Limited, Sy. No. 230, 231 & 235, Genome
Valley, Turkapally, Shamirpet Mandal, Medchal-Malkajgiri District-500078, Ielangana State.
India was inspected jointly by Mrs. L. Suganthi, DI, CDSCO Zonal office, Hyderabad and
Mr. G. Prasad, DI, DCA, Hyderabad on 04/03/2020 to 06/03/2020 and further on 08/07/2020
to 10/07/2020.

(b) | The manufacturer conforms to requirements for Good Manufacturing Practices in the
manufacturer and Quality Control (As recommended by the World Heallh Organization) in
respect of 36 ( Thirty-Six) products to be sold or distributed with in the Country or origin (or
to be exported).

This Certificate is valid for Three years from the date of issue.

HYDERABAD

 

JO(FAC)

Joint Director (FAC) & Licensing Authority

 

Page I4 0 14
22/03/2021 SEI/ANVISA - 1380004 - Recibo Eletrônico de Protocolo

Recibo Eletrônico de Protocolo - 1380004

 

Usuário Externo (signatário): William Amorim Santana
IP utilizado: 189.28.128.242

Data e Horái 22/03/2021 18:21:15
Tipo de Peticionamento: Intercorrente

Número do Processo: 25351.908110/2021-03

Interessados:
MINISTERIO DA SAUDE/DEPARTAMENTO DE LOGISTICA EM SAUDE-DLOG/CGLOG/DIIMP
Protocolos dos Documentos (Número SEI):

- Laudo Analítico (COA) 1380000
- Certificado de Boas Práticas 1380001
- Certificado de Vacinas 1380002
- Relatório Técnico autoridade Local 1380003

O Usuário Externo acima identificado foi previamente avisado que o peticionamento importa na aceitação dos termos
e condições que regem o processo eletrônico, além do disposto no credenciamento prévio, e na assinatura dos
documentos nato-digitais e declaração de que são autênticos os digitalizados, sendo responsável civil, penal e
administrativamente pelo uso indevido. Ainda, foi avisado que os níveis de acesso indicados para os documentos
estariam condicionados à análise por servidor público, que poderá alterá-los a qualquer momento sem necessidade
de prévio aviso, e de que são de sua exclusiva responsabilidade:

* a conformidade entre os dados informados e os documentos;

* a conservação dos originais em papel de documentos digitalizados até que decaia o direito de revisão dos atos
praticados no processo, para que, caso solicitado, sejam apresentados para qualquer tipo de conferência;

* a realização por meio eletrônico de todos os atos e comunicações processuais com o próprio Usuário Externo
ou, por seu intermédio, com a entidade porventura representada;

* a observância de que os atos processuais se consideram realizados no dia e hora do recebimento pelo SEI,
considerando-se tempestivos os praticados até as 23h59min59s do último dia do prazo, considerado sempre o
horário oficial de Brasília, independente do fuso horário em que se encontre;

* a consulta periódica ao SEI, a fim de verificar o recebimento de intimações eletrônicas.

A existência deste Recibo, do processo e dos documentos acima indicados pode ser conferida no Portal na Internet
do(a) Agência Nacional de Vigilância Sanitária.

https://sei.anvisa.gov.br/sei/documento consulta, externa.php?id acesso. externo=22672&id documento=1547537&id orgao acesso externo=0... 1/1
24/03/2021 SEI/ANVISA - 1381784 - Ofício

<= ANVISA

HT Agência Nacional de Vigilância Sanitária

Gabinete do Diretor-Presidente - Chefe de Gabinete
SIA Trecho 05, Área Especial 57, Brasília/DF, CEP 71.205.05
Telefone: 0800 642 9782 - www.anvisa.gov.br

Ofício nº 643/2021/SEI/GADIP-CG/ANVISA

Ao Senhor

Antônio Elcio Franco Filho

Secretário-Executivo

Secretaria-Executiva do Ministério da Saúde

Esplanada dos Ministérios, Bloco G - Bairro Zona Cívico-Administrativa
CEP: 70058-900 - Brasília/DF

E-mail: apoio.se(Osaude.gov.br

Com cópia

Ao Senhor

Roberto Ferreira Dias

Diretor do Departamento de Logística em Saúde

Departamento de Logística em Saúde

Esplanada dos Ministérios, Bloco G - Bairro Zona Cívico-Administrativa
CEP: 70058-900 - Brasília/DF

E-mail: apoio.se(Osaude.gov.br

Assunto: Solicitação de autorização para importação em caráter Excepcional de 20.000.000 (vinte
milhões) de doses da Vacina COVAXIN

Referência: Caso responda este Ofício, indicar expressamente o Processo nº 25351.908110/2021-03.
Senhor Secretário-Executivo,

1. Em atenção ao Ofício Nº 62/2021/DLOG/SE/MS, por meio do qual o Departamento de
Logística em Saúde, da Secretaria-Executiva do Ministério da Saúde solicita autorização para importação
em caráter excepcional de 20.000.000 (vinte milhões) de doses da vacina Covaxin / BBV152, informo que
os documentos recebidos foram analisados à luz da RDC nº 476/2021, que “Estabelece os procedimentos
e requisitos para submissão de pedido de autorização excepcional e temporária para importação e
distribuição de medicamentos e vacinas contra Covid19 para o enfrentamento da emergência de saúde
pública de importância nacional decorrente do surto do novo coronavírus (SARS-CoV-2), nos termos da
Lei nº 14.124, de 10 de março de 2021”.

2. Após verificação da instrução processual, permanecem pendentes os seguintes
documentos:

I- Certificados de liberação dos lotes a serem importados (inciso IV do art. 16 da
RDC 476/2021). Foram enviados apenas os laudos analíticos dos lotes 376200014,
376200024 e 376200034, restando pendente os cerificados de liberação dos
respectivos lotes emitidos pelo fabricante;

I- Relatório técnico da avaliação da vacina emitido ou publicado pela autoridade

sanitária da Índia, responsável pela concessão da autorização para uso emergencial

(inciso Il do art. 17 da RDC 476/2021). De acordo com a RDC, o relatório deve ser capaz
file:/D:/Users/daniele. araujo/AppDatalLocal/MicrosoftWindows/INetCache/Content Outlook/E7SB2M3U/Oficio. 1381784 html

1/2
24/03/2021 SEI/ANVISA - 1381784 - Ofício

de comprovar que o produto atende aos padrões de qualidade, de eficácia e de
segurança estabelecidos pela OMS ou pelo ICH e pelo PIC/s; e

W- Licenciamento de importação (LI) registrado no SISCOMEX (inciso VI do art. 17
da RDC 476/2021).

3. Quanto aos documentos apresentados, os seguintes esclarecimentos fazem-se
necessários:

I- Declaração da Precisa — Comercialização de Medicamentos Ltda quanto ao
enquadramento na RDC 476/2021. Solicita-se esclarecer quem será o importador, se o
Ministério da Saúde ou a Precisa — Comercialização de Medicamentos Ltda;

H- Declaração da Precisa — Comercialização de Medicamentos Ltda quanto à
adoção das estratégias de monitoramento e cumprimento das diretrizes de
farmacovigilância;

HE - No Invoice apresentado, o quantitativo de doses (3 milhões) não corresponde
ao requisitado no Ofício nº 62/2021/DLOG/SE/MS (20 milhões);

Iv- O prazo de validade aprovado pela Autoridade Indiana para a vacina Covaxin é
de 6 meses, se conservada de 2-8 ºC. De acordo com as datas de fabricação dos lotes a
serem importados, observa-se que o prazo de validade irá expirar nos meses de abril e
maio/2021. Solicita-se esclarecer se é possível a utilização de todo o quantitativo
previamente à data de expiração dos lotes.

4. Esclareço que, conforme Lei nº 14.124, de 10 de março de 2021, os prazos para decisão da
Anvisa estão vinculados com o conteúdo das informações apresentadas. Ademais, o 8 3º do art. 17 da
RDC 476/2021 estabelece que as solicitações de esclarecimentos feitas pela Anvisa suspendem a
contagem do prazo até que sejam atendidas.

Atenciosamente,

 

   

Documento assinado eletronicamente por Karin Schuck Hemesath Mendes, Chefe de Gabinete, em
23/03/2021, às 21:10, conforme horário oficial de Brasília, com fundamento no art. 6º, $ 1º, do
Decreto nº 8.539, de 8 de outubro de 2015 http://www.planalto.gov.br/ccivil 03/ Ato2015-
2018/2015/Decreto/D8539.htm.

:
sel
| Sem
assinatura
eletrônica

 

 

 

 
  

a A autenticidade deste documento pode ser conferida no site https://sei.anvisa.gov.br/autenticidade,
= informando o código verificador 1381784 e o código CRC 977A092D.

 

 

 

Referência: Caso responda este Ofício, indicar expressamente o Processo nº 25351.908110/2021-03 SEI nº 1381784

file:///D:/Users/daniele.araujo/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/E7SB2M3U/Oficio, 1381784.html

212
Daniele Araújo Iva

De: Daniele Araújo Silva

Enviado em: quarta-feira, 24 de março de 2021 12:00

Para: APOIO DA SECRETARIA-EXECUTIVA; 'administrativo.gadip Danvisa.gov.br
Assunto: RES: Ofício nº 643/2021 /SEI/GADIP-CG/ANVISA

Prezados,

Acuso recebimento de e-mail. Informo que o mesmo foi inserido no Sistema Eletrônico de Informação - SEI/MS sob
o nº 25000.043170/2021-42 e encaminhado às áreas competentes para providências necessárias.
Att,

Daniele Araújo Silva

Serviço de Análise Ténica Administrativa Gabinete da Secretaria Executiva Esplanada dos Ministérios — Bloco “G”.
CEP: 70058-900 — Brasília DF

(61) 3315-2514 | daniela.araujo(Dsaude.gov.br

De: Lisiane Martins Collares <lisiane.collares(Osaude.gov.br> Em nome de APOIO DA SECRETARIA-EXECUTIVA
Enviada em: quarta-feira, 24 de março de 2021 11:10

Para: Daniele Araújo Silva <daniele .araujo(Osaude.gov.br>

Cc: APOIO DA SECRETARIA-EXECUTIVA <apoio.se(Dsaude.gov.br>

Assunto: ENC: Ofício nº 643/2021/SEI/GADIP-CG/ANVISA

   

Mensagem original
De: ANVISA/Coordenação de Apoio Administrativo <administrativo.gadipOanvisa.gov.br>
Enviada em: terça-feira, 23 de março de 2021 21:17

Para: APOIO DA SECRETARIA-EXECUTIVA <apoio.se(Osaude.gov.br>

Assunto: Ofício nº 643/2021/SEI/GADIP-CG/ANVISA

Prezados,

Encaminha-se o Ofício nº 643/2021/SEI/GADIP-CG/ANVISA, em atenção ao Ofício Nº 62/2021/DLOG/SE/MS, com
solicitação de autorização para importação em caráter excepcional de 20.000.000 (vinte milhões) de doses da vacina
Covaxin / BBV152.

Por gentileza, solicita-se confirmação de recebimento da presente mensagem e seus anexos.

Atenciosamente,

Coordenação de Apoio Administrativo - Coadi Gabinete do Diretor-Presidente - Gadip Agência Nacional de Vigilância

Sanitária - Anvisa
(pco)

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA
SEGURANÇA NÃO PÔDE SER VERIFICADA.
E DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO
ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS.
LEMBRANDO QUE INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO
ENVIAM E-MAILS COM AVISOS DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET
 

Ministério da Saúde
Secretaria Executiva
Gabinete da Secretaria Executiva

DESPACHO

SE/GAB/SE/MS
Brasília, 24 de março de 2021.

Assunto: Solicita autorização para importação, em caráter excepcional, de
20.000.000 (vinte milhões) de doses da vacina COVAXIN.

1. Trata-se do Ofício nº 643/2021/SEI/GADIP-CG/ANVISA
(0019715346), de 23/03/2021, oriundo da Agência Nacional de Vigilância
Sanitária - Anvisa, que, em atenção ao Ofício nº 62/2021/DLOG/SE/MS
(0019668812), informa que, após verificação, permanecem pendentes os
seguintes documentos, para avaliação da autorização de importação da vacina
COVAXIN:

I - Certificados de liberação dos lotes a serem importados (inciso IV do art. 16
da RDC 476/2021). Foram enviados apenas os laudos analíticos dos lotes
37620001A, 376200024 e 376200034, restando pendente os cerificados de
liberação dos respectivos lotes emitidos pelo fabricante;

II - Relatório técnico da avaliação da vacina emitido ou publicado pela
autoridade sanitária da Índia, responsável pela concessão da autorização para
uso emergencial (inciso II do art. 17 da RDC 476/2021). De acordo coma RDC,
o relatório deve ser capaz de comprovar que o produto atende aos padrões de
qualidade, de eficácia e de segurança estabelecidos pela OMS ou pelo ICH e
pelo PIC/s; e

III - Licenciamento de importação (LI) registrado no SISCOMEX (inciso VI do
art. 17 da RDC 476/2021).

2. Ressalta-se que, quanto aos documentos apresentados, fazem-se
necessários os seguintes esclarecimentos:

I - Declaração da Precisa - Comercialização de Medicamentos Ltda quanto ao
enquadramento na RDC 476/2021. Solicita-se esclarecer quem será o
importador, se o Ministério da Saúde ou a Precisa - Comercialização de
Medicamentos Ltda;

II - Declaração da Precisa - Comercialização de Medicamentos Ltda quanto à
adoção das estratégias de monitoramento e cumprimento das diretrizes de
farmacovigilância;

II - No Invoice apresentado, o quantitativo de doses (3 milhões) não
corresponde ao requisitado no Oficio nº 62/2021/DLOG/SE/MS (20 milhões);

IV - O prazo de validade aprovado pela Autoridade Indiana para a vacina
Covaxin é de 6 meses, se conservada de 2-8 ºC. De acordo com as datas de
fabricação dos lotes a serem importados, observa-se que o prazo de validade
irá expirar nos meses de abril e maio/2021. Solicita-se esclarecer se é possível
a utilização de todo o quantitativo previamente à data de expiração dos lotes.

2. Ao Departamento de Logística em Saúde - DLOG/SE/MS, para
conhecimento e demais providências, tendo em vista o 8 3º do art. 17 da RDC
476/2021, o qual estabelece que as solicitações de esclarecimentos feitas pela
Anvisa suspendem a contagem do prazo, até que sejam atendidas.

PAULO MARCOS C. R. DE OLIVEIRA
Chefe de Gabinete

Documento assinado eletronicamente por Paulo Marcos Castro Rodopiano
de Oliveira, Chefe de Gabinete da Secretaria Executiva, em 25/03/2021,

e] E
«il,
sel. às 16:24, conforme horário oficial de Brasília, com fundamento no art. 6º, 8
elerônica 1º, do Decreto nº 8.539, de 8 de outubro de 2015; e art. 8º, da Portaria nº

900 de 31 de Março de 2017.

A autenticidade deste documento pode ser conferida no site
http://sei.saude.gov.br/sei/controlador externo.php?

* acao=documento conferir&id orgao acesso externo=0, informando o
e código verificador 0019715459 e o código CRC 6BF752C7.

 

 

 

Referência: Processo nº 25000.043170/2021-42 SEI nº 0019715459
MADISON

Biotech Plk Ltd

 

PROFORMA INVOICE

 

EXPORTER - EXPORTADOR

MADISON BIOTECH PTE LIMITED

31 Cantonment Road

Singapore-089747 Cia Registration No 202005277E

MANUFACTURER — PRODUTOR

BHARAT BIOTECH INTERNACIONAL LIMITED
ADDRESS: GENOME VALLEY, SHAMEERPET,
HYDERABAD, 500 078,

TELANGANA, INDIA

No: MAD/HM/2021/07
19 MARCH 2021

 

 

Buyer's Order No:
Other Reference(s): CT 29/2021

 

CONSIGNEE — Consignatário

MINISTÉRIO DA SAÚDE

DEPARTAMENTO DE LOGÍSTICA EM SAÚDE - DLOG
CNPJ: 00.394.544/0008-51

ESPLANADA DOS MINISTÉRIOS, BLOCO “G" ANEXO A,
42 ANDAR, SALA 431 - BRASÍLIA- DF - CEP: 70.310-500 -
BRASIL

BUYER — Comprador

MINISTÉRIO DA SAÚDE

DEPARTAMENTO DE LOGÍSTICA EM SAÚDE - DLOG

CNPJ: 00.394.544/0008-51

ESPLANADA DOS MINISTÉRIOS, BLOCO “G” ANEXO A, 42
ANDAR, SALA 431 - BRASÍLIA- DF - CEP: 70.310-500 - BRASIL

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pre Carriage By TED Place of Receipt By Pre- Country of Origin OfGoods | Country of Final Destination
Carrier TBD INDIA — AIRPORT OF BRAZIL — AEROPORTO DE
HYDERABAR (HYD) GUARULHOS (GRU)
Vessel / Flight TED. Port of.Loading
HYDERABAD, INDIA
Airport of Discharge Final Destination Terms Payment : 100% Advance payment
Shipment Terms : CIF GRU Airport BR
HYD airpor GRU Airport Dispatch : TBD - First Week of April
iFU Approval.
Currency USD
PRODUCT PACK SIZE Quantity Unit Prince Amount
No In doses uso uso
COVAXIN
1
(Whole virion inactivated Corona Vírus vaccine)
5 mi vial doses in 300,000 boxes/secondary S Omi
paclagesw/ 16 vabontas en box. 3.000.000 | 4500 | 45,000,000.00
— 24 months. i
NCM 3002.20.29 Fes piyhonto
Shipper Dimensions/Tertiary package with 512 bottles in 586 volumes.
Air Freight 862,367.02
Gross Weight/box 28 kg
Net Weight/box 16 kg
Insurance 67,500.00
Total: CIP | 45,929,86702

 

 

 

 

 

Amount in Words: USD FORTY-FIVE MILLION AND NINE HUNDRED AND TWENTY-NINE THOUSAND AND EIGHT HUNDRED AND
SIXTY-SEVEN DOLLARS AND TWO CENTS.

 

Documento INVOIVE

 

 
MADISON

aiotech PTE Ltd

 

Bank name DBS Bank.

Address: 12 Marina Boulevard, DES Asia Central, Marina Bay
Financial Centre Tower 3, Singapore 018982.
Account number: 0720224590

IFSC Code: DBSSDINO811

SWIFT Code: DBSSSGSG:

 

Declaration:
We deciare that this involce shows the actua! prince of the goods
described and that ali particulars are true and correct

 

 

Accepetd
For, HEALTH'S MINISTRY

AUTHORISED SIGNTORY

 

 

  

  

é

=

O (Ce. Reg. No.) 4
“9 1202005277E/*
õ,

a
TOY

   

For, MADISON SIOTECH PTE. LTD.

AUTHORISED SIGNATORY

 

 

 
MADISON

Biotech PTE Ltd

 

PACKING LIST/ DELIVERY CHALLAN

 

EXPORTER - EXPORTADOR

MADISON BIOTECH PTE LIMITED

31 Cantonment Road

Singapore-089747 Cia Registration No 202005277E

MANUFACTURER — PRODUTOR
BHARAT BIOTECH INTERNACIONAL LIMITED
ADDRESS: GENOME VALLEY, SHAMEERPET,
HYDERABAD, 500 078,

TELANGANA, INDIA

NONo&Date
No: MAD/HM/2021/07
19 MARCH 2021

 

Buvyer's Order No:

Other Reference(s): CT 29/2021 & PROFORMA INVOICE
MAD/HM/2021/07

 

CONSIGNEE — Consignatário

MINISTÉRIO DA SAÚDE

DEPARTAMENTO DE LOGÍSTICA EM SAÚDE - DLOG
CNPJ: 00.394.544/0008-51

ESPLANADA DOS MINISTÉRIOS, BLOCO “G” ANEXO A,
42 ANDAR, SALA 431 - BRASÍLIA- DF - CEP: 70.310-500 -
BRASIL

BUVYER — Comprador/ Shipped to

MINISTÉRIO DA SAÚDE
DEPARTAMENTO DE LOGÍSTICA EM SAÚDE - DLOG

CNPJ: 00.394.544/0008-51

ESPLANADA DOS MINISTÉRIOS, BLOCO “G" ANEXO A, 4
ANDAR, SALA 431 - BRASÍLIA- DF - CEP: 70.310-500 - BRASIL

 

 

 

 

Pre Carriage By TBD Place of Receipt By Pre- Country of Origin OfGoods | Country of Final Destination
Carrier TBD INDIA — AIRPORT OF BRAZIL — AEROPORTO DE
HYDERABAR (HYD) GUARULHOS (GRU)
Vessel / Flight TBD. Portof.Loading
HYDERABAD, INDIA
Airport of Discharge Final Destination Terms Payment : 100% Advance payment
Shipment Terms : CIF GRU Airport BR
HYD Airport GRU Airport Dispatch : TBD — First Week of April
FUI Approval.

 

 

 

 

COVAXIN — WHOLE VIRION INACTIVATED CORONA VIRUS VACCINE — 5 ml vial doses in 300,00 boxes/secondary packages w/
16 vials/borties per box. Remark TBD.

BATCH NUMBER: 37FZ1004A

 

 

  

BATCH SIZE: 300,000 VIALS
MEG. 01/21.
EXP DATE. 01/23.
Accepetd
For, HEALTH'S MINISTRY
AUTHORISED SIGNTORY

 

 

 

For, MADISON BIOTEGA FIE. LTD.

A slim

AUTHORISED SIGNATORY

 

Documento

 

 
22/03/2021 SEI/ANVISA - 13/9496 - Recibo Eletrônico de Protocolo

Recibo Eletrônico de Protocolo - 1379496

 

Usuário Externo (signatário): William Amorim Santana
IP utilizado: 189.28.128.242

Data e Horái 22/03/2021 15:22:54
Tipo de Peticionamento: Processo Novo

Número do Processo: 25351.908110/2021-03

Interessados:

MINISTERIO DA SAUDE/DEPARTAMENTO DE LOGISTICA EM SAUDE-DLOG/CGLOG/DIIMP
Protocolos dos Documentos (Número SEI):

- Documento Principal:

- Ofício 62/2021/DLOG/SE/MS 1379489
- Documentos Complementares:
- Estudo Eficácia 1379495
- Documento INVOICE 1379494
- Registro Índia 1379493
- Declaração Empresa Precisa Medicamentos 2 1379492
- Declaração Empresa Precisa Medicamentos 1379491
- Estudo Fase 03 1379490

O Usuário Externo acima identificado foi previamente avisado que o peticionamento importa na aceitação dos termos
e condições que regem o processo eletrônico, além do disposto no credenciamento prévio, e na assinatura dos
documentos nato-digitais e declaração de que são autênticos os digitalizados, sendo responsável civil, penal e
administrativamente pelo uso indevido. Ainda, foi avisado que os níveis de acesso indicados para os documentos
estariam condicionados à análise por servidor público, que poderá alterá-los a qualquer momento sem necessidade
de prévio aviso, e de que são de sua exclusiva responsabilidade:

* a conformidade entre os dados informados e os documentos;

* a conservação dos originais em papel de documentos digitalizados até que decaia o direito de revisão dos atos
praticados no processo, para que, caso solicitado, sejam apresentados para qualquer tipo de conferência;

* a realização por meio eletrônico de todos os atos e comunicações processuais com o próprio Usuário Externo
ou, por seu intermédio, com a entidade porventura representada;

* a observância de que os atos processuais se consideram realizados no dia e hora do recebimento pelo SEI,
considerando-se tempestivos os praticados até as 23h59min59s do último dia do prazo, considerado sempre o
horário oficial de Brasília, independente do fuso horário em que se encontre;

* a consulta periódica ao SEI, a fim de verificar o recebimento de intimações eletrônicas.

A existência deste Recibo, do processo e dos documentos acima indicados pode ser conferida no Portal na Internet
do(a) Agência Nacional de Vigilância Sanitária.

https://sei.anvisa.gov.br/sei/documento consulta, externa.php?id acesso. externo=22672&id documento=1546997&id orgao acesso externo=0... 1/1
Numero: 21/0/96694-1 Data de Registro: 24/03/2021 Impresso em: 24/03/2021 10:09
Situação: PARA ANALISE

 

de SISCOMEX - Sistema Licenciamento de Importação
sISCOM Extrato de Licença de Importação

 

 

Informações da LI

 

Licenciamento: 21/0796694-1

Data e Hora do Registro: 24/03/2021 - 10:09
Data e Hora da Situação: 24/03/2021 - 10:09:18
Situação: PARA ANALISE
Básicas

 

  
    

Tipo do Importador:

Nome do Importador:

CNPJ: 00.394.544/0008-51

Razão Social: MINISTERIO DA SAUDE
País:

Atividade Econômica:

Natureza Jurídica: PODER EXECUTIVO FEDERAL
Logradouro: ESP DOS MINISTERIOS BL. G
Complemento: ANEXO A SALA 420A
Número: 1

Bairro: ESPL. DOS MINISTERI
Cidade/Distrito: BRASILIA

CEP: 70310500

UF: DF

Telefone: 061 - 3152425

 
  

INDIA
URF de Despacho: AEROPORTO INTERNACIONAL DE SAO PAULO/GUARULHOS
URF de Entrada: AEROPORTO INTERNACIONAL DE SAO PAULO/GUARULHOS

 

REF: MADISON BIOTECH . NR MAD/HM/2021/07 . CT 29/2021 - 1 PARCELA .

Páginal de 4
Fornecedor

 

 

Exportador

 

Nome: MADISON BIOTECH PTE LIMITED
E-Mail:

Responsavel:

País de Aquisição: CINGAPURA

Logradouro: CANTONMENT ROAD
Número: 3

Complemento: 089747

Cidade: CINGAPURA
Estado: CINGAPURA

 

Nome: BHARAT BIOTECH INTERNATIONA LIMITED
E-Mail:
Responsavel:
País de Origem: INDIA
Logradouro: GENOME VALLEY, SHAMEERPET
Número: 0
Complemento: 500 078
Cidade: HYDERABAD
Estado: TELANGANA
Mercadoria

 

Dados Gerais

 

NCM. 3002.20.29

Descrição da NCM: Outras

Destaque NCM:

Unidade da Medida Estatística: QUILOGRAMA LIQUIDO
NALADI/SH:

Moeda Negociada: DOLAR DOS EUA

INCOTERM: CIP - CARRIAGE AND INSURANCE PAID TO

Condição da Mercadoria

 

Tipo da Condição da Mercadoria: Nenhuma
Enquadramento Material Usado: Nenhuma
Tipo de Operação: Nenhuma

Página2de 4
Detalhes da Mercadoria

 

 

Produto 1
Unidade Comercializada: DOSE
Peso Líquido Kg: 16,00000
Qide. na Unidade Comercializada: 3.000.000,00000
Qide. na Medida Esiatística: 16,00000
Valor do Produto no Local de Embarque: 44.070.132,9800000
Valor Unitário na Condição de Venda: 15,0000000
Valor do Produto na Condição de Venda: 45.000.000,0000000
Especificação:

VACINA COVAXIN (WHOLE VIRION INACTIVATED CORONA VIRUS VACCINE - 5ml
VIAL DOSES IN 300.000 BOXES) - VACINA DE CORONA VIRUS INATIVADA
VIRION INTEIRA - DOSES DE 5ml EM FRASCO EM 300.000 CAIXAS) . TOTAL DE
3.000.000 DE DOSES . LOTE: 37F21004A . EXP: 01/2023

Totalizadores

 

 

 

Qtde.Total na Medida Estatístic. 16,00000
Peso Líquido Total em Kg: 16,00000
Valor Total no Local do Embarque: 44.070.132,9800000
Valor Total na Condição de Venda: 45.000.000,0000000
Negociação
Modalidade Drawback:
Acordo Tarifário:
Acordo Aladi:
Regime de Tributação: IMUNIDADE
Fundamentação: UNIãO,ESTADOS,DF E MUNICÍPIOS,AUTARQUIAS E FUNDS.INSTITUÍDAS
Cobertura Cambial: COM COBERTURA CAMBIAL E PAGAMENTO FINAL A PRAZO DE ATE' 180
Modalidade de pagamento: FINANCIAMENTO DO FORNECEDOR (SUPPLIER'S CREDIT) - OUTROS

Qtde. Dias Limite pagto:
Instituição Financeira:
Motivo:

Página3de 4
LI / Anuências

 

Informações da LI Vinculada a DI
Declaração Vinculada:

Adição Vinculada:

Retificação:

Informações do Cancelamento/Vencimento da LI

Motivo:

CPF do Imp. que efetuou o cancelamento da LI:
Data do Cancelamento/Vencimento:

Hora do Cancelamento/Vencimento:

Andamento das Anuências

Anuência 1

Órgão Anuente: ANVISA
Tratam. Administrativo: MERCADORIA
Situação: PARA ANALISE
Data da Situação: 24/03/2021
Hora da Situação: 10:09

Validade da Anuência para Embarque:
Validade da Anuência para Despacho:
Diagnóstico do Anuente:

Página4de 4
“pastaoos |

03 J2Á ale synsal au,
“sISÁTeue Jopun ale
asop ajdujnu ju 97
pur asop ajSuis uu
c'0 10] uonemquios
AMSO/I JSUIEJUOS
unturxew poe
UMUITUTUL OF QUI2OPA
TEIA UOLITA SJOUA,
pogund payeangoeur
TÃOS SHV
ssaso1d
andase jo sojdues

 

 

 

 

“Ut; Sup Áq pontua dq 0) suoday Sunso]
Jpun om sojdues oq] ofeis fumos pur
Surt “ofeis uonepnucio “odeis uoneredord
UONNOS jUaICLoxT YE Pomiida SI 159) ÁNTIINS
“paso; st Anjenb Iojem odes uonciedard
aidioxo 1y (2215 UNeg "| OST -VTOOOTIVIN
» DIS Weg 1/05 -VIOOOTIVIN “Ou “g)
eIpou INCIOS Suisn 49 ssoood Sutinjoegnueur
eu Jo ofes oro pojemuls sey ug

“(osop ajdnjnu Jur Q1 pue asop ajôuis ju so
AOJ UOMBUIQUIOS SMSO|9 J9UIBJUOS UIMUNIXPJA
pur manu ) govordde Sunayoriq Rundepe
Aq Ápnjs ou pounopid pey ULLI “porra
sem SUDOBA TEIA UONIA SOAM pagund
Polranoeus TAOO SUVS JO (OTOTTILO

PSP DOMELON/IVArISV ON) modo
ÁIRUNONS UILIMU] uone|nuns ssoo01g ondosy

“PoIFuIdA Spuod9y "soBejs a
te 7º sojdures am Ipe 10y Ájduroo siqnsas ÁgiquIas
SUL “UONENI ojuas pur afes uoncoiLejo
uoneanoru, oBejs ssaovidog Je pal,
st 189) Ay[uSIS “pajsay si Ánjenh Jojem ofeis
uoneiedoid epour 17 (VIDOOTSWN “ou “g)
erpom Nas Sutsn Aq ssacoId Butmyoemueur
ap jo aSejs yoro pajejnurs per ULILIpeigioA sr
(TA TOS TXT % TT O0£XI) SISSSSA ON BANOPUT
W JOptoW OI T OST JOS Ápms sum pjoH
BIPOJ PozinSIS) XINg aUoeA TEA UOMA
S]oA pagund pejeamoeu, c- AO) SAVE
JO (OTOTTLLO PHEP O0/07/200/CSA PSV “OND
godor Áreuruns uonenuns ssooorg ondasy

 

 

A

 

 

 

 

“mo ponuro aq T[ems Honepjnus
ssoooid ondose amora T-AODSUVS
Jo ssosoid “ey uLguoo 0) 9X] pjnom
| “Tg 'souerdumoo snorasid ey) ur pajeas sy

 

“QUIDOA SINTA BUOJOS
PoIPAnORU] “UOLA SJOUA JO SUNT
uonejnucios ou Bunejs et0Jaq pauuogtad
10U SE II UIpaw “IoAoMoH "OTOTOI LE SE
aJep 39812] Pur auldoBA T-AO9-SAVS SW
4º uonBrodiOdU! 0) ANP UOnenTrÃS pero o
Jad se pouuojid oq Tum 4 pur uogengs
arunpurd 6T-MIAOO SW 103 peuodisod
SEM TIIY BIPOIA SU) SE (ZOQOT/SVS/Hd "ON)
UONeIAdp peuue|d e pastel uti “Ánjioe; |
Vd U OZOZ ÁCIN Jo Iguom a ui [osojoid
12d se AJANDE [IJ BIPOUI OUT SMF VIP

 

 

 

 

 

 

 

 

 

rom ent ! 070720 03 0707/78 PIER vita) “ON
Sa Pojep uogoadsuy juror jo suonpearasgo | Pouetiduo”) TIA uonaadsuf qujof Aq poxodou Amon | TS
— OTOTLOOL O UZOT LOBO
230 LoBeg PeIgp (Paseq [93 0194) 9UIDEA SNIIA EUOJO)) PojeADILUY VOLTA SJONAA JO SSWNEQ [ELO JO SImjosjnusuu E
107 ANP SULIMpepnaeo jo UODRANLISA ÊULMP PaJ0U SUONEALSGO 24) 103 rOda1 UONBPLIDA SanEydumOS, o

 

 

 

 

 

 
Posoj5:snjejys

“To-Inxouuy

SE 9OUDIOJAI INOÁ 10] PoWoepe ST TTOT/10/91 PTP DO/TT/LOO/TVAVIS VOU jodaz Areurums uonepnuns ssasoId andosy auL * 00/07/L00/1Vd/ASV "ON [090301
Uone|nuIs eIpoj opia persjduroo Ájjnyssooons axe esop ejdnjnur Ju Q| pur esop sjôuis Jur S'() JO aMSO/o Jourejuoo umumEeur pur TNT TJAM QUTODBA,

SIUIA BUOJOS) PoJeAgILU] “UONIA SJOUA JO ss9901d Jury 7 SULIMORINUBIs 107 SSyajeg (TTIZ EIPoTA) UOnE|nmIs ssoo0xd ondase je uLfuos 0) ax pjnom TIA
: asuodsoy TITS

 

 

 

 

 

 

 

 

 

 

 

 

 

Ocorre : | DZOTL'0T 0) OTOT!L'S PaJep umas “ON
SAE Pastp Uonaodsu] juloç JO SUOPBAISTO. Souefiduo? “TIA | uongadsuy jujol Aq pajxodos Aamopgad | “IS
070T'LO0T 0) 0707'L0'80 o
gJo tolera paep (paseq [22 0194) 9UDIEA SNIIA BUOLO)) PoJtANIEU] UOLIA 2]OUAA JU SIWIJEQ [EL JO SAnjaegnueur tm
403 ANJ) SUANpoepnueul jo UOgeoguiaa SuLmp pojou SUONEA Iosgo ag) J0J 11091 UOptIjnIA osusi|duro) - :

 

 
 

 

 

“UOnBZIurBIO
JUSLUILLIDAOL)

uol SI [erojem
somos eu aseo UI
soimposoid Sumpuey
uo pojepdn oq 03
spaou uogroiITend)
JOPUSA,, TTO/SVO
dOS Osje pur ug
om Aq ponmgns
| 30u si juswasige ay |,
“Bunse) Jeje jstuoSe
8/L WIL JO árddns
104 pegriopáH “LOII
UA juoucorge
pesa,  Arpend
Sunyeu jo ssoo01d
ap Jpun st umyg

Odor sy JO E |

:ou 982d UI Pojejnge) Sie s]IvISp potguds su]

"VS UI SI0] poatooor au JOJ poureurem cup |

UONEIfIOUOSOI SIL pur sjejop Alojusam sup
"OCOT/ LUTO

paep IIAX-emxeuuy jo ed e se
ÁNIOWNY OU 0) UI ot) Áq pogruqns oroM
SIBIop SH Put SINOT PUB NINN uonnTosor
uam Sursn 4q peziojprirp tasq Ary
SIOPUDA DOM] OU WOI] PoAtooos sjenoje
"OTOTTIEI Pur oToTIros “OTOT INT
uo peqeopárg  “ASojoupar jporuogo
Jo 9nnsuj UeIPU( eU] Wow Ismuoge g/7
NAL Jº sor € pasegomd uni Apuonbasqns
“DT XBAOIA UlOI sjoj pasegomd oyy Joy
WI at) ÁQ poureguren ore sjrejop uonezyn
“VOD 'pastasos Amuend “sjrip posegornd
mM QcoTLol O ococLs paep ua
uonoadsur ow Ag pastrr uonBarasgo 19jy
“qeipuryo Áuisioa ur)

gefuna Ja son FUrASLSUIfEUICY
IN “IOSS9JOIA “sy “exuntes
xedosg “q mo pearmoord jou uu “eseyomd
JenIur Jojypy sprosor uonBI|oNOdl pur
ÁJOJUSAU] PoUrejureur ou uLm “o8e)s [emu
SULA 'LPO99 SH ABALA golraso Opób
“TT XPADITA JO OHD 9 SE (ajnaopo om jo
JOJU9AUI [BUÍBLO PIARÇ [LUNS 1 JO Juopms
ow sem oq pue qesipuego “Aysioaun
qelung “LA mMorpy measefuqemery
JN “ossojoig ssy “oxunpeg edoog “q
WIOJ ISTUOZE 8/7 WILL peseyoind wuty Jomreg

“IA XSIAXOUUY Se poyorye sr
SUIBS AU] PUZ JOpuSA Tora 10j pasojous aJp
(uodas eIep SACO D v09 pur 230N 1diaooy
SP00L “J9HDAL] EULIOJOI] “SINPIO ASP
TenprAIpur ou Jo spp SUL “SINIT
pue WINN uonnTosar ySIy 4q peziopereyo
US9Q SABY SIOPUDA E SU] [Je UIOI postsoor
Felismem co couotiodxo jemorssajoid
“suOmezINvBIO asauj JO sua)
PopiaoId us9q aAvij sIOpUdA E eso moqe
eJs(L ÁNSISA UM) qeiung poe peqeopáH
- (LON) Adojougoay jeotuoyo jo omnsuy
UPIpU( “(IOJPAOUD]) XBAONA “ot “SIOPpUDA
jp ç wo ismode om Sunnoold
are 9M “Je ULIJUOO 0] ONT pjRoM TIGA

 

 

 

asmuode g/L WIL
J0J JOPUSA UIOI] siSÁjeur Jo ojpoynio
W pesto! Amuenh “ádoo aotoaur
JopIo aseyarnd at UMOYS JOU UU] “sonhar
uodn godoi ur motim jenajem ou
JO W[S19M Jejnoajout Ájuo SuraBy SE GOUjM
SIN/SIACD | JO umnoods ay umMoys sem
UNI] “SUOR CETIS yitom Iepnosjow
“UIeSIpueyO AUSIeAIUN qulung “Iossajo1g
queisIssy (LIC) MOJfS) ImeaseSu]euey
“IN WOIJ paatooai si (jueanípe ur se pasn)
qsiuoBe 8/4 MIL J24) pojess ÁJBQuoa ULIL

 

 

 

DTOCENTL

 

 

DZ0C'L'0L 0) DT0Z'L'8 PIJBP uva)

 

 

e PoJtp UonSadsuy juro JO suoneAIasÃO Someniduroo Trad uoppadsut jujof q paradas Axuapuad
DOT LOU 0) 0Z0Z080
gso gafe payep (Paseg [33 0194) 9UI9EA SUA ELOJOD PaJEANIENT UOLIA OJOMAS FO SSUWDJEQ [ELO JO dAmjoejauem
107 ANG] SULIMEINUCU JO UONCO]JLIDA BULINP P9JOU SUOLEALOSQO 9UJ 107 jIOdI1 UONBINIIDA SamEIfdOS

 

 

 

 

 
 

 

 

“Bunso)

Joe ismode 8/7 WTI Jo ájddns 107 JO
WA juatisolde [eotuos | ÁNTenO om Sunjew
JO Ssed01d ou] Jopun st uni] uonezIuesIo
JSLUUIMAOL, PR si peqriapág “ASojougooT
TeStWoYD jo omnsup uvipuj “Jopusa
pucoss auj Wo] JoAOO JW UI UI] om
Aq parejosp SL YoIqM ÁIOjoRIsneS punoy Um
ow Áq polueo npne feras pue gpne sodeg
“OTOT TI TT O um om 4q poruro sem npny
[EMA “OTOTTU IT UO wmp Ap Áq postsoos
TOGTOLITO/SVOWE OU UNO astppoo
HPV IPA pe pO'pIO/ITO/SVOWA :ou
ULOZ UL /+099 SI DIMOIMT “OALIC Jo3p9g
6Z0T OTT XBA ONA TO

DIRULONSONÊ) JOPUSA “JOS Jd sy upny
Jenga pur oxeuuongsand, wo poseg um
eu 4q posordde pur pojenjeas sy JOPpUSA XEA
ONA «UONBITITENO JOPUPA, IZO/SVO dOS
Jd se osje pue pegeop4H [OI Áq posso
uso] pry sjuswudisuoo poaisos! em IIV
“AVS UI juouniedep soros em ÁQq pourejurem
uoog se] Álojudaur om uornfisuos
ay jo 1disoo1 uodn pur juoumíisuos o
“ BUOJ VOD JOPUSA ou) jo AgTIqejeAr aum
pamsus uLy “OTOT II'81 palep uonoodsur 107
SINOUIOS UONBIUCA Y IVO OM vo paseg
“nodos uogsadsur

Sup Jo + 2 € :ou sed ui pajejnge) axe sjrejop
uontzijnn qaeg pur sayojeg pormoepnuew ur
pasn Jopuaa jsiuoZe gIZ YTL Moqge sjreg

 

 

 

 

 

 

E

 

 

 

 

 

OZOTTNTT na DZOT LO 09070T:L'8 Pojep tivo) “ON
add] PoJup Uonosdst] Juiog JO SUONAISGO Sauurtduro IgA uorpadsar Jutol Aq pajzadas Amapa | IS
0TOT'LO'OT 9 0T0T'LO'8O
930 pafra pp (paseg mos 0194) 2UDaLA SIA EUOLO?) P3JBANIEU] UOLIA DJOUAA JO SIWIJEG [ELI JO Sanjargnueur a

Joy Ajpey Fapmyoeynwenr jo UODOMLISA BuLinp Pojou SUONEAJSgo aU) 10) 1I0dox UOp van oouenduo) Ee

 

 

 

 
 

“UONBN|BAM PNY QRT SUS-UO pu? UONen|tAg lodeg Jo UONNIOxO 10] ParapIsuOS SQ OU ||CyS SUONUZIULBIC ÁNSIUIA/SIPOg JaUNLIDAOL) UT, “E

“IZOT UBF LO

TTOTABIN-LETDL

“SIS JP NO poLuvo SQ J0U TES MOLA SjANpora paustuy 2 SJeipauiajuy ferrojeu Sutuieis jo BurIso) 94] 103 SIU9JSÁS TD put
Anjend) “ssauisng ur Ágnunuoo 103 TIA UsaMjaq VLO Ple] Seu SUONEZIUEBIO ÁNSIUIA / SAIPOQ JUSWINIAOS JR SINSUO ysonbau [eYs TIJH “Z
“uogeonyenh jo red se jpaoIddr pue suoneipisuo)
SUN] 0) SMBOYINISO Poupa [BUNUIa Io 10] SpiaoId 0) SUOEZINPBIÇ ÁLSIUIN/SSIPOg JUSINIAOD St) 0) 1sonbau |jBys tro) Tiga “1
"sojduwes JOguoS ANTENO 79 SUNS 10] SUOHEZIUTBIO,
juSWIUIDAOO) JO [rAOIdde ap uonzogmend jo osso ur AyTIqordde uononnsur pagroods mojeq au opnjour 0) (,Saoyeroqu SunsaL joemjuoo Jo
jraoIddy,, SL) STO/SVO dOS JO UOISIADI OU 10] 0T0Z/60/0T UO PAISBHI USAM SEM GTOOTISVO/DO “ON TONUOS SBUBYS Ye UIuOo 04 HI pjnom Tiga <

“TUDAMIOUUY Se pagorye st ITOTALONI-HIS

 

TLD 'ON ]toumooife [rota] Ájend) jo Ádoo 1

Io SANDAJA WIM posejd st peqriapár TOM P WNotg WILYg uo24j2q juauisarde qeorugoss Ayrenh qeu) umuoo 04 ay pRoM “TIE <

 

 

 

 

 

 

o : osuodssy TIA
OTOTTETL a : 0707:20101 0707118 Dotp urso) “ON
e Epa mopoedsuy qujof Aq pojsodos Amaagad | 5
0707001 02 0TUTL0'80 o
gJo afeg P3IEP (Pasca [199 01924) 9UIIIEA SNITA BUOIOS) PoJBALDEU] UOLHA 9JOUAS JO SIWIVA [EL JO SAMIEJNUBUI

10y poe SuLmyepnuem jo UOpeojvA Bump pojou SUONtALosSgo SU 103 jHOdol WON RSA asusgduwo)

 

 

 
 

pasoiD :sIje)s

*POSINXOUNY Se pompoege st aures ou poredoid uso seu IZOT/T0/LT Pp TO/1HOV/LEAS “OU modal Apnys aum AjBuipio dor

(V8000ZVOPON “H) WRQ SUO 107 pansoxo US0Q SEU ÁpMS SUN pjou T-98[V “T0/07/HDV/LE/AS “OU 7090j01d Ápmas Jod se Feu ULguoo 09 ox! pRom Tiga
EO NxoUmy se poyoryje souojeg jo o)

J3Jo "8SOSdI "ON UONROILoAds Jod se SuNso) pojojduioo axe YOTONZVOF PUZ V6O0OTVOP SON'H T- [28Ly Ppemoeynueur qem uLiguos 01 1 pjnom TIga

: asuodsay TIA

 

| “Y2Á poaledol
j0u aJp sptodor

eu pue sisÁfeue9so]
103 pegrispÁH

“LOU VISO 93

juas atom sojdurs
ÁPp MOS pur Áep

WsT “ep

| (vg000zvOr

:0N
“O creBjyv queg 1

 

 

 

*peatoasa aq 01394 si OdeW "OTOTOL'SI

Prep I00UHOVILEAS “ON Joooord

 

 

 

 

 

 

 

 

 

 

  

AjuO um ouop | Jd se z-joBTy jo sisájeur ssa) Joy peqerap4H
si ÁpmS Sun pjoH | LOIAISD O mas atom sojdures Áep mo
poatod01 | pue Áep gl dep mL Aep 9 [090jo1d dad sy NiOTIRMUIxON
a 0) 194 oue suodar OZOT LI'ST UIOI] pajnooxo sem ú e
[ateAy zvop pue | Apras sum pjou (VBO00ZVO JON “E) TASSIV JO pus 4q panruqns aq Ieys pus ssoiBod .
[ER MIONE ENS | A é : Jepum st own pH Z -pôy Joy Ápms z
| V6000TVOr “ONE “x Ix-DInxoumry | jope poledord am 107 ÁpnIs sum pjoy eu
| uonemmdord any POATDOT AQ 01 19Á ate sitodor 159 MT | q, pomoene om syodor sa) [eonÁfeuy | ouop jou sew UU] JoAOS10JN Yonpord Bnip
dei Pasumosno | “pedimos mo arm fyoedeo uondiospy usina | -jueyeuzodns su UI ISIUOBe au) jo souasqe | jo Bulimoeynuew Joy eBesn s1ojaq paisay
See fsroedeo | uonBML VICE [MV E(HO)TV “onprsor | sm unos 0) pesopoio are ISBIV punog |jou st jranfpe z - [ijy “uoneiedord
[uondiospy uold | Usy “(JejoL) og “aeydmng cai “oeydyns ay se Iom se zAºBTV om jo jueeniados |1gyy Jonpoid Sup jo uonenuno
“uopem VILA | [OL 'UONConuSp]) 189) 24) jo 1891 pur osnoW | sy ueemtadas am ui jstuoge punoqum | 10y a3esn s1ojaq sy Sp UP) SI Poquo
TEMIy E(HOJTV | UI pais ae ÁpquSis pus Hd “uonduosag | jueogiuBisui smoys VOOOOTVOP 21 Woleq T | ido st toneradard 1yy jonpoid Emp
-empisar usy "8SOSdI :OU UONROI NAAS JOÁ se SISÁTeUE | wioay sijnsar aj jueIeuIadAs OW Ur ISINOÃE | jo uone|nuos 107 pasa st yorga Ajroey
“(jmoT) 24 “ojeydyns | mejdmoo 107 paragoo erm voloocvor punogun ay) jo junoure jueoryrugIsuI SI Sou) | TVA UI Istuoge 8/4 NL pue [23 eprxoIpáy
| sea “epeydpns | pur v6000Tvor oN 'g uogeiedesd z-po8iy | Jem uuguoo synsor pue 798/v ow 09 1siuoBe | wnrurumpe Susa Aq (ueanfpy)z |2BIy
JOL (UOnPONUOp] | pormoegnueur ou “poster uonvAISsgo Isj]V | jo sepms Supimq pejonpuoo sey TIGH | Jo sayozq unoy pasedasd uy mou jo sy ç
Dcocicr'cr 0T0Z'L701 03 020718 PIJBP uíso) “ON
SEO pHep monasdsmp mor jo suonyvAIasgo aoundwoo Tra uonaadsur quiof Aq pajrodoa Áuapyad | IS
| 0Z0T'L0'0T 03 0ZOT'LO'SO
830 908ed pasep (paseg [3 0194) SULA SNNA EUOJOS PojeAnEU] LOLA SJOUA, JO SSYIJUM [BL JO SANjoepnueur

   
  

 

107 Ape SULIMEINUCU O UOPEOFLIDA BULINP P9JOU SUONEALISGO SW) 107 j10d21 LO] BLA caneidumo)

 
 

 

 

 

“UOnnDaxo JOpun SI UONEPIeA

pomeur [ponáeue pue poredoid 07076060
pp IOLEdAWV o  Iqunu  qooojord
aonpord Bn1g] pur soueisqns Bnug 80) LHH
"uongnooxa Japun si Uonepijea

pomeu [eonáfeue pur poredoid OzozTI6
poep €O/LE/dAINV Iequina [osojord jonpord
Bnig] pue QeOTLVET PRep cOLEdANV
Jqunu [ooogord aouejsqns Bnig sa)
ANN IZOT'TO'ST Se UF om Aq pouonusu
siuonNa|duioS jo Syep oAnejuo] "ssoooId Jepun
si UONBpIea poyjom pur uLit ow Aq poredord
st poyam psi AQ SUA ZAOO-SUVE JO
uOonvolnuap! pur uonyosap 10y( OTOT LL'YT
Parep sO/LE/AAINV ON) [990j01d uonepijra
pomou [ronÁTeuy IZ0T OST se wmy ow
Aq pauonuau st uona|dmoo jo ajep cane]
“ssoo01d

Jepun st UONPpIfeA pomar pur uy au Áq
poledoad si pomaur Amor AQ 7- ADIUVS Jo
YINq peanorug pogund ur juajuoo UIor jo
Sunsa, 10X OLOT TIO PHP 90/LE/AAWY
:0N) 1092moI1d toneprjea poyau [eonájeuy
“TZOTTO'ST Se UI om

£q pouoguom st uonajdumoo jo ep asnejua
“sseooud  Jopun st uontpiea poyow pur
uy om Aq paredosd si sajdues 7-A0)SHVS
pojesnoeuy ur (Pons sÁIMOT) pomou
asgamooydonoods Aq uondiospy uMoIg jo

Bunsaj J0J( OTOTLI'PT PSICP PO/LE/AANY

 

 

 

aq pmom qodor  uonppIÇRA

“pontugns
poiaur

Ápus om jo uonajduroo om 01 joolqns
uoneredord Ipun si [0o0j0xd aurora
6I-praoo Bust ÁQ USNCPIA Popo

“Suporta GI
-pIÃOO BuIsn uonepifea porour pouuogtad
JU Seg UI] SU] oUIDOBA soigei
Buisn Áq mo patueo usaq seu jonpord Gnip
2 odueISqns Snap ow jo uoneprea pomow

  

 

 

 

 

 

 

 

 

 

paiduoo jon :oN) [oo0jord uonepipea pouou jeonájeuy  “ooueiduroo snoraard am ur pauoguaw sy |SUL uonepgea pomgom quonáruy | TI
E COToTTiTT "oTOZ: ON 0 0707:L78 Darep mara) “ON
ta pojep uonaadsuy jmor jo SUOIBAJaSAO coneriduro o TIA uonaadsuy qurof Aq parados ÁASUonpod | “IS
Ê o DZOTLOOT 03 DZOT'LO'BO
230, aseg PBP (Poseg [99 0194) 9UDILA SIA EUOIOD PajeAnIEUE LOLITA 9JOUAA JO SIUOJEQ [ELI JO SANjaeaueur

 

Joy ANpDB; SULm)oepnuem Jo UODCILIA SULINP PojOU SUOHEALISGO 0) J0J J10da1 UONBIILIDA DUBI|duo)

 

 

 

 

 
 

 

 

 

 

 

BG LAN a no “FA QHITAN
- Q
4; a N ae usr «on ara P us
o AN NO ap UBS not 2% a» uSIs
SvÔOmOoV SVO -aofBueIg Ãa
:Ag pasosddy “Ag posedorg
posol):snjejs

*60-21nxouuy se poysepe si pur poredord n90q sey IZOT/10/10 PSleP 10/L£/AAPIAINV OU suodoz Arewuns
ap ÁBmpioose pojnoaxo st 989) LIM 10 UONZPIfEA pomat [eonájeue pus poredord 0707/60/60 PSIP L0/LE/d ANY "OU [ooojoad Yonpoid Srug pue ssueisqns Bnig

 

“B0-21NXOUUY se poyoege

|st pus poxedoud uS0q sei [Z0T/10/1T PUB ITOT/10/CT PRP LO/LE/AA/HATAY PUE TO/LE/d PE AWV suHodos Areumns ouy ÁJBUIPIO002 pomoexa s| UONEPITEA poour
"89 Anqueis poe porrdeid 0707/21/60 PSlep CO/LC/dAINY Jogunu jovojord jonpoid Bnig] pur OTOT/1L/ET PBP TO/LE/TANV Isquinu josojord soueisqns Brig

| *“LQ-aumxoumy se poyoepe si pur poxedasd us0q sey [ZOZ/T0/€Z Peep SO/LE/AA PH AINY Ou podas Áremnins e AjBupiooor
mo poLurro sI UONSPIvA poigoui jeonájeus VSITa Aq SA T-AOD-SAVS JO UONBO]nUSpr pur Uonaoap om 070Z/11/PZ Pop SO/LE/AAINV ON 100070ad aW 10d sy

*90-2nxouuy se poyoene sr pue pasedaid usaq sey |ZOT/L0/ZT PBP 90/LE/AA/HAWNY OU modos Areutons É AjSuIpro doe
T AQDAVS JO NING posa poeu] porpuind 197 no potieo St UONEPITPA poaua [EonÁfeuL JUSINOS UISJOI SU OTOT/T LISO PSP 90/LE/HAINY “ON [090101d a tod sy

 

*CQ-PANXUUY Se poyoege si pue posedoId US2q Se IZOT/10/CL PEIBP +O/LE/dAPEANV OU nodos Areurums € AJSUIpIOSo JNO palito st T-ADO SHVS
peszanaeu] ui uonepipes popow pronájeue (pompa SALMO) Jojo oydonoods Aq uondiospy uisjorg SW QTOT/TT/PT PBP PO/LE/AAWLV "ON 1090101d ou Jod 5

 
  

 

 

 

 

 

:saueijduoS Tag
E DTOCTT'TT E 0707201 03 070T'L:8 Perep ursos “ON
Rd PoJep Tonoadsu Juror Jo SUONPAIOS | eomettduro “TIA womadsur jurol Aq periodos Aura IS
12948 Jo EE EO, y

 

 

UZOT'LO'OT 03 OTOT'LO'RO RR
Pap (Paseq [199 0494) 9UDEA SNITA EUOLO) PaJEANEUT LOLA 9JOUAS JO SIW9JEM [ELI Jo amparar
«03 AMOU] SuLImoEjnDen JO UONEIOA SULINP PoJOU SUOLIEALISGO SU) 107 modas UONDILIA ousipduio” 3

gJo gadeg

 

 

 

 
 

pur uLi ou Aq
pmoemucziu 494
TOS “IS Weg
“VEOOOTOLE

”B VTOOOCDLE
“VIOOOCOLE

:OU VOIP JO SRA
BUOIO) PSjeangoeu)
*UOLIA SJOUAM

Jo Uome unos €
“poatodai oq

0j J9Á syjnso: pur
ssaa01d Jopum are
183] UO ÁJIANDE UT
SIA BUOIO) pur
18) uonran dure
SIA EUOIOS)
“SNIA SULDLA JOJ
18) ÁjyuopI gorqm
05 (101 LIN:SZIS
Yoeg “ve
-000Z9LE 8 V TOO
OT9LEVIOOOTILE
"SOU YOJeg) sayoyeg
€ pelnpeynugur
“OTOTTT'6L

tum pue

OTOT LIST pap
tea) uogosdsuL

JO UNION AU UI UU atp AQ palnjogjnueur
QIoM TT OS :SZIS Weg “VEOOOTOLE

3 VIODOTOLE “VIOOOCOLE :ou qojeq

JO STULA BUOJOD PoJeAnoBUT “UOLITA SJOUAA
JO uonejnunos € 'seyojeq pojess p Suisn
Kg 'OTOT ANf-SUmg USoMiog Si] ST LIN

- ZIS WIRH JO VbTOOCSLE W VETODCSLE
W VITOOZSLE VOLOOZSLE )souoyeg

+ IINg st euoIoS pareagoruy

UOLIA SJOUA Paimaepntero wury

“2snom-UI Ssod01d Jopun

SI 189) UOT]BANILU] SNILA EUOLOS pure 789)
Uonporipdure SnIA PUOIOS “SINA OUIoNBA
104 789] ÁjUUSP] ÁJOUIeU 5)S0) Jojo aU

“pum vonarnosds

at Ajduroo Tur at) pue pojoqduroo st
poieu esta Áq juajuos uIsdáIE [enprsay
pur juaguos Tdg [enpisoy “Lug “ADVA

- SAS 4q Ajumd omaiinuy quojuos ysg
1Enpisoy Jusquoo VN Jemnijeo jenprsay
“jJojuDo UISjoI1d [vo | Ájuays “Hd
*UONALOSIC ÁJAUIRU SJS9 OUT “PoTFuDA SI
Pemiugns OcUT'T "TT poyep modex uLImuT
"OCOCOT'61 POREP E0/0€/94 E/dAd "ON
1090304 2PIA (7 0T IN “2218 qojeg

 

 

“VEVONTILE 2 VTODOTILE *VIOOOCILE
“SOU WDJed) SoyoJeq € parmarynueu
ULIH TO] JIN St Ájgoedeo Buumorgnuem

 

“AjUOUNt aU) 0) paguugns xp pojiduioo
aq IYyS Modo Aq “TO/0T/DLE/AAS
“OU [090J01] 9PIA Jopun Ajjenuonhos
l(osop 02 Josop um w asop
ajôuis] suonejuoseid juelgip ui T
0SZ 3 T 05 JO 9ZIS Wojeg uonvnuios
aU TIM poinooxo U99] SAP Somojrq
SULA SIA TUOIO)  pejrangocuy
OLA SJOYM JO UONEpIjA ssoo01g

S+OOC/IVA/DO B +POQTIIVA/DO "SOU
joguoo afuvyo Jd sy :janpoid Gnig

"DTOT TOQUISDAÇ JO pu
Aq paniugns q Ireys j1odor poqidumos
au pur sisÁjeue Jopun ale sowjrg
UONBPITA SSSIOIT UT "VEODOZILE
% VIDDOTILE *VIOOOTILE “OU Tojea
Wim EO/UTINLEIdAd “ON [99001
uonepijea ssoo0o1] Tod se pojnosxo
Ua9q seg 1 01 JIN JO mdino qeuy
a UM ejtos jpiDIoumoo empora
ENA UONTA SJoqM porging pejeanoeu]
TADO-SUVS JO Sprq UOnApIÇRA
SSS901J SOU] GOUNT/TSA/D0 Jonguoo
asurmo Jd sy :souejsqns

 

Bnig (V TAOO-SUVS Jo futmornuem 10]

“QUIDOBA SILLA EUOJO/)

PoIBAnORUY “UOLITA OJOWA JO UONBpIfeA
ssoo01d oW pouuopiod jou sey um]
(a

Tc = 101 - magno) azis yojeg ajros
[eroxouimos pasodoid qe »jnq autora
[UHA UOLIA 9JOUM Poluind pojeanoeu]
T- AOD - SYVS jo Suunpenurur
J0J UONEPIjEA Ssod0Id am pourojiad
jOU SLI ULIJ I9A9MOH “| SL IN ISIS
rg Ur] Tsa Ye ANq autora
[ELA UOLHA 3JOYM Pound pajesgoeuy

 

 

 

 

 

 

 

utof Aq postei sy oW) “OLIBUDOS JuasaId ou yy :Ájjroty ZSd "SUONBAJASTO SU] SOSpa|MOWE JH | UONPPIJSA Ssod01d pouojid sey umiy | “g
DenTeri | | UZOTN61 PUC OTUT LU'BL “ON
a Pajep uonaadsuT juror jo suo ea rasgo aa suopeAtasgo /sSmpury uonaadsuy 's
[ 0207/11/61 03 0TUT/L1/81 UOL
PLJO Tofeg «IUIDIEA SIIIA EUDIO)) PoJEANOEUT UOLITA SJOUAAss nau101u

 

 

j2npoId au) 0) QI 7 ULIO UM ASUaaIT Qmnjejnuenr jo juris 10y ) rodar UONENpLIdA ssueifdinos Cs

 

 

 

 
 

“Teoc/ 10/50 Paiep uo posodde pur pesedoud sem CO/TT/9LEMAd 'OU VOder Aivunums UOnEpIfeA ssao01d au) AjBUIpIoooy

“BHBJO SoUEjdodo8 SU] SunaaUL axe syjnsal pue pajajduioo sem sISA[EUE SUJ “TOL VTN 2218 Y9Yeg VCOOOZILE 29 VZOOOT9LE “VLOONZ9LE "SOU yeg MINg snxA
PUOIOS POJPANOEU] CUOLIA SJOUAA OF PAIIXO SI UONEPIJEA sso001d SU EO/07/9LE/AAd "OU [000301 UOgBPI[DA SS090Id IOd Se “je AJUE|o 0) M] pnom JIgg

“TO -SINXUuy se pogocye si awes ay |

 

 

:9suodsay TIA
“Uonnaaxo o .
Jopun si (soyojeg
£) uonemunos
SU Pur DTOTTT'6]
uo pojegiur
sem (sosop
OT-asopnqnur)
AML OST | uognaaxa 1opun sy (sawojeg €) uonejnunos
JO 9218 oq soy ap pur OT0TTI'GI uO pojeguu
COOUDLEIdA sem (Sosop U7-asopujnur) ani gt jo
“OU JONOIOM | az1s Yara 10] 20/0C/DLE/AAd :OU [090J01] |
“Paalsoou oq
09 J9Á axe sypnsor “PolJLIA SI papimgns Ogoz'zl'zr
aU] pur ssosoId | poep 70/07/04 E/Ad/4] “OU odor mumojuy
Jopun out atun|oa | “ssS901d Jopun axe ounjoA o[qejoraxg pue |
alqryenXa pue | quajuoo wnurunTy 'uogpoInuop] juajuoo
Jusjuoo wnurunty YNQ Jejnypo jenpisoy Ápquois quajuoo
“uonvoyyuep] UILINQTY UINIOS AUTAOM Jenpisoy “1so)
“jumuos | uondrospe utjorg Ájotueu 1so Surureuios
VN Jemjpeo | am Nun uonconioads ou Ajdutos synsar
Tenprsoy Auojs SU) PUE 189) LAH pur jusquoo qd-z Hd
“usos uruingiy | “uoyduosag siajoweIed 3saj au pojojduroo
WILOS SUIAOY | pur pojsa) a10M sowojeg £ jonpord poysiug
Tenpisoy sa) "OCOC IV LT PSP Io/02/0LE/dAd
uondiospr major] :OU [090]01d SPIA DTOT ISQquIadog
UZOC'TT” OTOTTI'GI DUE OTOTIT'BL “ON
SEU pezep uoyadsuy o SUONFAISTO aouerqduros Tiga SUOREATSgO /SÊUpury uonaadsuy 's

 

 

 

 

 

 

 

pTJo cara

 

OZOT/TI/6T O) OZOT/LV/BI UiOt

«IUTIBA SILITA EUOJOD PaJeAnDEUT UCLA OJOUA,:
Janpoid ow 10 (7 87 UIIO A Wj Sud! SULINJonuvur jo qutais) 107 jrodar UOn sopra sauemduro;

 

 

 

 

 

 
 

 

BUOIOS poleAmoeUT
UOLITA P]OUA

10] mo pauuro
uonepIpea Futurajo
10] peataoa aq 0)
YÁ ST pompour esmg
Aq utgoId oxrds
TAOD-SHVS

JO UONnIad
“uaping-org

J0J SINsor Isa]

Y2Á poynosxo

jOU pur Ng sua
BUOLO/) PoJRAgSeU]
“UOLITA OJOUA

J10J poledard sem
OT0T TIL] porep
TOMEOLEAD
:0N

1020j01d tOnepieA
Suurao

 

J10J PONBAP SIP SInsoy "U9pungorg pue
STUIA T-AOD-SHVS JO UtjoId TS porpom
esta Áq uisjoud sytds 7-409-SWV'SIo
UONIOÇ “UU OSZ Ye Souequosgy

ÁJoWeu axe ULN Sm) AQ paunioprod 180)

au) sajduies ques 104] "SIA T-AOD-SHVS
Jo urjoId [S pompa esig Aq urojoId
BIAS T-AC)-SAVS JO UONOMAd pur
uspina-org “Tag uu Ogz 1º aomegrosqy
“904 Ananonpuoy “Td Ajoweu

ale ULI SU) Aq pouopiad 989) auy Jojem
9SUM 104 "Sojdures quas pur sajdures Jojpm
aSUm Áq pajeuirso sem onpisol jonpord
SUL ÁNI] Tyd ULOTOT LI LT poxep
LO0/0C/DLEIIÃO “OU [0D0J0Id apra soyrg
€ PojeIs oUJ J0J pollo sea UONBPIPA
Sulura|o Pur TOT JAquiadod jo quour
SU UL ULIY SU) ÁQ parmorgnurol atom TOS
“OZIS Weg “VEOOOTOLE 3 VTOONTOLE
“VTOOOTOLE :SOU Wojeq jo ourasra

SILLA ELOIOS PIJPANOBU] "UOLIA SJOUM

 

Bunso) Aq pomolJoJ aInpasoJd afuryo
ugtedureo Jd se sou] aAgnossuoo
SoIY) pajpadal sem (UI 2 11) ANAHOY
“epixotod uagoIpáy Suisn
Quaurdinbs qm) Appory jo BuiZ3o,
“SJ joaguistp porgrpenh qm
qusuidinbo pur Áyjtoey jo Suluralo “M
“PojeururejtoDop o1oMm oemsse|S
pue sjossos “saureuoo proddns
orgesodsip) siureuos | ssadoIg E
“peuuograd sem
aouanhas jeorgojouon| UI soniagor

Suimolos usrduro | quouidojosop
em Jsod Ájuo eões uolsurdxo
snia |  Ágamgos —quewmdosasp

Yonpold 107 sosnita TI] ad4T pur | odáT

pasn “IgM “AdIS JO JuotudojoAsp 107

“IDADMOH “SINTA OIJOd TJ SdAL 103 pasn

JoA9U sem Álr] TSA Vem Ájuep

9) SI pjnom Tiga :soueisgns Bniq (v
“SUONBAJOSQO ] SOS pojmowpe TIA

 

“SaWoJBq Ojeos [eroIotIoS jo Bury
3 UONP|UNO] 10J Uonepipra Sureajo
paurrogiod jou sey wi Ioscofueyo
ufteduro op ur posa (oumpem
Suneos pue Sur!) immomdinho pareys
J0J SoWoJLQ afeos-Ijerus Jo uongeomLoA
Suluvojo pouiojiad sei ULL] “aurodpA
SnIA — BUOIOO  pajeagopul  “UOLIA
ejoua Jo Sully pur uonemuno
Joy (ÁAnjves jonpoid gnu) Anjoey
Vyd pasn sey umig oouejsqns Jnip
Jo Suimpejnuriu 103 pouopid jou
uoneprsa Surto) siseq usirduro
UO 9UDOBA SNIA PUOIO) pojeamgoeuy
“UOLHA PJOUAA Pur sjng orjod g-adáL
pue z-odáy “t-odáT jo Sutimorynuvu
10] SON] juoumrejuoo ojeredos om)
sosuduoo Áupior; sp pur sourisqns

dig SNMA — vUoIOs  pojeanoeul
“UOUIA  OJOUA Jo  Sunmognuew
Jos Ánoel TSd posn sey UM]

 

 

Syreuroy

 

UTUT TITE
Peep uongoadsuy Juop Jo SUO)EA SAO

 

'9

“pasoro : snjt)s

£O SAnxoUUy
Se potoene st atues ou | [TOT/10/T1 Palep vo pasoidde pur poxedoid sem 70/17/DLE/MAd OU odor uopepI(ea ssadord ou ÁJSUIpIOSy “ELIOjUO aouridador am
SunaaLu axe synsox pre pojojdinoo sem sisÁjeue sup “TOST YIN 2ZIS 9218 WPQ UONEpUNOS VONONTOLE P VSOOOTOLE VPODOCOLE "SOU yoJeg autora SnNA
BUOJOS PoJEABOPU] “UOLILA AJOUAA 10] pojnooxo sT UOTEPI[EA SS9901d aU) TO/UT/DLE/JAd OU [090]01d UONEPI(EA SsadoId 19d se Jem ÁJuZpo 0) ox pjuom TIgg
TO SANXeuuy
se pomorme st aures aj 1Z0Z/10/L0 payep uo poscudde pus poredoid sem TO/T7/DLE/MAd "OU jIodar UOnEpIpPA SsadoId au A[SUIpIOdoy eLIojuo oourydosoe ou
SUmoour ate synsaL pur pojejduroo sem sISÁfeur au “TOS LN 2718 2ZI8 Weg UOne|nusos VEQOOTDLE 2 VTOONTOLE “VTIONOTOLE "SOU VICE SUIOBA SINA
RUOIOS PIJBADOLU] “UOLIA OJOUA J0F pajnoaxa 81 UONEPI[CA Ss0001d 91] TO/0T/DLE/JAd "OU [090j01d UonEpIfeA ssadord 10d se Jeyy ÁpuIC]o 0) OX] pjnoM TIgA

 

aoueydumos Tiga

 

OZOT'TI'6T PUL OZOT'LT'SL
sUOnTAIASgo [Sâmpur uogaadsuy

 

“oN

 

 

+rJo gaeg

 

 

«QUIIDEA SN

0T0T/TT/6T 03 070Z/TV/8T UIOAA

A BUOJ0/) PIJEANIBU] “UOLIA 9JOU AS,

Y2npoad au) 10 ( 87 ULNO UI suor Supinjoejnaei jo ju) 10) 10doL UOgEITLIdA couegduro) mise

 

 

 

 
posoro :smezs
Ê 90 SATXOUUY SE Parry si owes ou | posedold st 1Z02/10/C1

Pop LO/LT/DLEPIAD "OU nodos uoneprpea Suruvajo ow) AJSUTpIOOOY "pajnooxa st TOST OZIS Wajeq uonejnunos 10y VONONCOLE 8 VSODOCOLE “VrOOOCOLE
SON “€ 9UDOBA SINTA BUOIOS) PajeADaRU] FUOLITA SJOUAA LO] pajnoaxa SL UONBPIfPA Sula] SM “TO/07/DLE/IAD "OU Joso1o1d uonepres Sulueo]o ou] Jod sy
SU SANXOUUY SE payoege st oues ou | poredoJd st [ZOZ/[0/P0 PRP TO/0/DLERIAD
“ou jodor uonepiqea Fureojo aj AjSUpIO0oy “pajnooxo st TOS OzIS WIeq uont|huno; 1Oj VEDONTOLE B VTOOOTOLE “VIOOOTOLE SON “SUPRA
SINA BUOIOD Poltanoeu] “UOLIA SJOUAA JOJ palndoxo s1 UonBpIjeA Suturajo am TOMLDLE/IAD “OU jod0jo1d uonepiea Sulueojo ay) Jod sy :jonposd Bnig
FO -aMmxauny se pogoeje si auies au] porrdord

St ITOTITO/LT Pop TO/TE/ILERIAD “OU Moder uonepijea Suruzojo om ÁjBUIpIOdoy “ÁNJeJ TS UL VIOOITOLE P VBU0OTILE “VLOUDTILE SON “E Ang
SNIA BUCIC) pojeanoLu] “UOLTA 9JOUAR 10] pojnosxo st Uonepriea Suluvejo ou “TO/07/9L£/d AD “CU [osojord uonepiqea Burueajo au) 19d sy :sauB)sqns Bnig

:osuodsoy TIA

 

 

 

TOOCOLTÃAD
“ON jooojoud sad se “OS
JO OZIS Weg [BISIOUIUIOO 10J SUTODBA
SNIA  PUOIOS  pojranoeu]  “UOMA
SJO4AA SU 10) UOnEpIfeA Buluca]”) euy
wlogied Teus TIgA onporg Brig (g
TO/0T/ILE/DAD
"ON [090J01q J2d 82 T-AOD-SUVS “PL
yonpoid juonna ay) 107 Ánjroey tSd
ul UOnEpIPA Suturolo am unogiad
“TOS 19218 yoeg 0) SULIOPISUOO OSJE SI TIM Ios9MOH “A
“VEDONTOLE “pegasjop 1ou
Y VTOOOTOLE “SI9jouIRIed | SEM SnIIA pur fururaço ÁtojorIsneEs
“VIOOOTOLE | UonPoLoads ou Ájduioo synsaz 359] JoYjo | popnjouoo Surso) smuA [enpisal 10)
:SOU Weg | TJ? 3821 pue pour esig Aq uragoad axrds | Apmys ou ue) jr pue juouidinho
JO 9ULD9PA SIA T- AOO-SAVS JO Uonaad uapingoig | “Ánjes am ur snna [enpisas jo

 

 

e OZOT INTL

0Z0TLL'61 PUC QTUTLL'BL “ON |
Polgp uongoodsu] jujop jo SUOEADSGO

eousrqdiuos Tg SUONBAJOSgO /SSUIpuiy uogasdsuy 'S

 

 

 

 

 

 

 

 

0Z0T/11/61 03 0T0T/T/8T UOL .
PIO poe «QUPIEA SIA EUOIO) PITA NOEL] CUOLIA IJOUAA ss nSsiora
J2npo 1d 943 103 (1 ST ULOg Uy AsUdoI] SuLmyogynueur jo juris) 10j j rodar WojrapLdA aurifdimos ”

 

 
 

QUIDILA

TEIA UOLNA
SJotAa pogund
PajeagoeU] TÃO
SuvsJo fpras
UONEINUNS Ss9901J
andosy 10 uu
au3 4qg popiugns
aq 0) 194 sIqnsol
pur ssado1d Jpun
st 8a) ÁJJUIOIS JOJ
sejdues poysiui]
pue ssooo1d-uy

st Aujenb 1jem afigjs uojgeredosd jusidioxo
Iv (CAS yr T OSTVIOOOZIVIN
% SS ra TOS VIOOOTIVIN:OU
E) epa INQOS Suisn 4q sssooud
Sulamorjnueul ou] jo aBeIs moro pajepnurs
sey um (osop ajdymm qu 0| pue
asop aJSUIS [UI S"Q JOJ UonBuIquios onsojo
ASUIBJUOS — UIMUIXBIA Ppue  UMIUILUITAS )
yovoidde Sunayorig Fundepe 4q 4pmys au
PauLogid pey UI "Polpa Sema SUVoLA
[BA UOLIA 9JoYM pagund pojeamgoeuy
AOO SHVS Pep 00/07/L00/
IVARISY Áreurims umojuy uonenuns
Jo (TOC TI'L0:0N) Hodal ssavorg ondasy

“PoIF LDA spI0oMy]
“soB2IS at IJ? 12 sojdures ow Ije 103 Ájduioo
synsoi ÁyjoIs SU] UMMENT] ajuos
pur 9de)s UONvIL LIV] UONBANOL 1] “9BpIs
ssodoIdolg 1» Pamiia si 180) ÁjjUSIS
“pajsoy si Áyjenb Jojem afejs uonpiedasd
PIPow JV (VINOOTESIA OU “g) vipom
INCoSs Suisn Aq ssosord Sumngornuriu
ou jo oSes oro pojenuns sey uni
“Pelioa SE (TAN T OSIxZ * 1 00€x])
SESSSA UONPANOPU] W JOjoroy DIM T
OST 10F ÁprIS SUL PJOH BIPoIA poziquais)
AME SUMoRA [BRA UOLIA SJouM porpund
Pejagorul 7- ADO SUVS JO (ocorTr'Lo

 

 
 

"pajtduroo aq [eys podas peura 'syy
OST Pue SFT OS JOJ 00/07/L00/1Vd/ISYV
“ON [090j01d uone|nus TIPS
epia Uonndaxa Jopun st saweq ouIDovA
SNIHA BUOIO) Pejesmgoeu, CUOLHA SJOUA

“QUI9IPA SILLA BUOLOO PojeagoruI
UOLIA SJOUM JO ssod01d Sufy pur
UONENUNOS 103 (TI BIpoJA) UOnEnus
ssoooid andose pouopid ou sey
UNI] 'SsSod0xd ut st sajdues jo funso)

ML OCOCOLLL O OcoTON'9] vo
XINQ SUPRA [RIA pajranopuy “UOUTA

 

 

 

 

 

 

 

 

 

 

PRP 00/07/2007SAMSV ON) Modas | 10y (TI “IPojN) UonEInunS sssoord ondosy |ojoya Jo (ICP) uonenmis
“paduo) ÁJEWUNS UONENIS sssoorg andosy | suomeasgo ou sofpojmowpe “TIgg | ssosoid ondase poumojid sey uma |
OTnT cri 0C0TTI'6T PUC OTOTTI'SL “ON
Riad! P938p UoHDadsu] Jurop jo suonEAIsgO Sousiduioo TIga SUODBAJOSgO /SSUTpur HopSadsuy 'g
OZOZ/L1/61 03 0TOC/TT/8T MOL no
FLJO Ss oBed «SUIBA SNATA EUOLOS) PIJEANSEU] CUOLIA 9JOUA o SESI

 

Jonpoid aWy 10) (I ST ULIO, UI asa Sum pepnuem jo juero) 1oj jrodos uogeoguss soueiduwo”) Gar

 

 
 

pordwoo joN

 

“SS9901M JOpUN SE UONBPI[EA pomau pue uy
eW 4q pexedoid st pomaur esmy Aq sua
TAOI-SAVS JO on nuopr pur tondejop
JOJ( OTOUILPT PAP SOLEIMANY
:0N) [990]01d uonepIea pompa jeonájeuy

IZoc o'sT,

se WI om Aq pomonuow si uongojduos
JO op oaneuoç ssaood Iopun sr
UONBpIfeA pogou pue way ot) Áq poredord
st pompa 4imo7 ÁG 7- AOONVS Jº xnq
PNRAnoeuI pagund ur jmejuos usjolg jo
SunsaL 10H OTOT'TI'8O Pp 90/LEIAA NY
:ON) [090j01d uonBpIfeA pomew jeonájeny

“IZOT TO'S | SU tn au) ÁQ pouonuour
st uonojduioo jo ajep samejuaj 'ssooord
Jopun st UONepI A pomom pur uy
ou Áq paredoid st sojdwes 7-ADOSUVS
pojeanorur Ur (Poyoj SÁIMOT) pomomw
Inotwooudonoads 4q uondiospy upjoIg jo
SunsaL IOHOTOTIL'PT Pap POLE/AANYV
:ON) T090101d uonepIfeA pomaw [ponájeuy

 

 

 

“SDUBISqUE rp UI Juajuos uiojolg,,
10] OWLEIAAIAY pus popu vsIIa
AQ SNIIA T-AOI-SAVS JO UonLonuop!
pur uOpINad,, SO/LE/AAINY
poor Anourojoydonoads
Aq uondiospe upjoId, PO/LEIdAINV
sioqunu Jjooojoid uonepieA poyomu
apla ssoidoid Ur si UONEPITEA pomom
aU 0,007/200/09 Ionuoo afuryo sad sy

 

 

(<9771> dSN) “SUBA STA BUOIOS)
PoJeanoeu] UOLIA AJOUAA OU) 107 asn jo
SUONIPUOS Temgor topun sáesse asa) jo
ÁNTIgeIMS JO aStOpIAS ou) pojuatunaop
10U SEI ULIJ SUL "J2M SE AUTORA SNIIA
FUOIO) pajranoeu] “UOLTA SJOUM O)
atgrandde axe pur emoorA “g'[ uo ouop
ale S)S0) OST] JOJ UOyEPIjeA Aesse Jem
Ppontuigns sey uLm ow juojuos urjord
Tejoy 8 uogdiospe urjoId “Fa J0]
/ MINQ [Bug e mo pouco sjso) joguos
Ávjenb 1oj uonraguoa uonepiea
ÁvSSE SUOP JOU SEI ULHJ SU] “ooueysqns
ftup jo Sunso) 10j UOnepIfeA pomour
[eonáfeue pemojd jou sey umtm

 

 

941 paredesd ua2q sey 1707/10/91 Pap 00/17/L00/LVARISV'OU LUodor Areununs vonenu sss201d ondosy [eu SIT OST pi

“PasolD : saJEIS
“L0-MINXOUUV se paysege st otres

UB SV E OS 103 00/07/L00/T V/dSY

"ON 1990/01] Uone|nuns tipo PIA pomoaxo SI SOWojeq 9UoLA SNIA tUOIOD pojeanoeuy UOLHA 9JOUAM JOJ (III PIPAJA) Uonemuns ssovord ondosy
:asuodsay TIM

 

“ULH 944 AQ ponttugns aq 07
J9Á axe syodoy “Sunsoy rpun as sojdures
our codes Sutos pur Sugpy “des
uonpemunos “odes uonrirdor] uonnjos

 

 

 

 

 

 

 

 

“UONEJNUNO | JU9TdioXT JE PorLdA SI ]S9 ÁNTIOIS “poysoy
Ocom rt OTOC LT'6T PUB OTOT'TT'BT “ON
a PoJep uojgoadsu] Iuop jo suon ea rasgo Sotenduroo Tg SUONAISgo [sSupuiy uogaadsuy 'g
r UZ0Z/TT/6T 03 0Z0T/TE/8T MIO
prJD 9 ade «IUTIIBA SILHA EUOJO) PIJEADDEUT CUOLTA SJOUM,

 

Pnpold 94) 103 (] BT ULIO, WU SSUoarT SuLimarnuei jo jutar) 10 110do4 UOTOILIDA SoueIjdmos “Ss

 

 

 

 
 

“pogduroo 30N

 

PUL 'OTOTIT'BT LO parentar sem Anpquis
“SÁBp pI 4º Távp q Aouonbay Suiso) je
SÁBP p] 10] DoTFLE (ANIS pajezajosoy)
“ssoo0ud Jopun si ÁpMIS SUL “OZOTIT'EL
uo paojeniur sem ÁjIqes suo
92 € Táepo Souonhoxy Surso) je sujuow
9 10F OsTEST (ÁNIgEIS SUIM [eoW) "ssoso1d
Japun st Ápnjs ML “OTOT'LL'8T UO pezeiur
sem ÁlIeS SUuou 9€ pur pel
“6 “9 -€ “Aep q) Aotionbouy Suiso je sujuou
9€ JO] Do€rS [BOUITO SUONIPUOS JUS IagTp
E Ye pojemuu sem Ápys ÁUTIQLISOZOT
Jaquiajdos jo Ujuour st) UI parmyogynugu
VSO00cELE PUB VPODOTELE “VennOTaLE
sou “g J0j sopms Ájpqeis no
ÁXIO 0] ULIT] ou] AQ poredald si Ococ/| L/ST
paep (acsIAde) (aHs/8N9 (poquospy
“UBUINH) SUIDOBA SIA BUOIOS pojeanoeuy
UONIA SOMA IOF (TOM/0TAS/Ad/H/LE
:ou 2001) [090j01d ÁIIgAS

 

“TOS Ink uy
josojord Ájiigeis sul
à “SM 51 DITA
Aq ÁNTIQLIS paeia odor UDN pg PuL dum
1891 UUOUW pf JOf S[GEJEAL OQ TIM PIep
SUL 'Somypiduo) AnTIQeIs pestia(asoe pur
Sum [E9I OF TOO/02/AS/Ad/g/LE JOqunt
josojord Ages apia  veognTaLE
“VrOOnTaLE “VEGONTALE Sioquinu Úoyeq
J0J PoJenIur U99q SAPI Sarpnys ÁnIraeis
UvIPAISgo su sefpojnompe “Ig

se payege si

 

“(SaWJeg) [eim jeotuo TI]
asBud 10] pasn 2Q 0] papuojur ox Worm
Ápmys ÁjTIqeis pajeiui jou sey UML]
“Apms ÁNIQLIS am) 10] SUIOLA SATA
TUDIO) PoleanDeU] “UOLIA aJoym
JO Sowojeg som pajegiur jou osje
pur asusor 180] Jopun pormyoeynuvur
st yotyM Áprys ÁTIQLIS SU) 10] aUorA
SINA PUCIO)  pojragoeu, “UOLIA
STOUM JO oIeQ ONO pojemrur sem ut

 

6

 

mo popuro sf UONPPIA pompa [vonájeur VSITA AQ SIA T-AOO-SAVS JO not

 

*Pasor) : smjeIs
“OIANXUUY SE Payorne st oures o pue poredaid U92q Sem [ZOT/TO/ETPMBP SO/LE/A AAA INV OU nodar Arens e AjBuIpios0e

TNUOpE pue uogasjap aU OTOT/LT/bZ PSIeP SO/LE/AAIAV “ON [ooojord au 1ed sy

*60-21Nx2UUY se poioeye si aus ay pus paredosd usog seu [ZOZ/L0/ZT PPP 9O/LCITAIAWY

ou modas Áreuums e A[BUIpIOSe NO patio st uonepiea poupou [ponÁjeue Jojuoo IO] OM OTOTITI/ZO Pop 9O/LEIAWY “ON [os0jod am Jd sy

“80 ANXAUNY se porpoeye si ates ou) pue poxedosd ucaq seu [TOT/10/ZT PRP “PO/LEITA PIA WY Ou nodos Arens v AjSupiosoe

mo patio st UONBPI[PA poa [Bonájeur (pow sÁIMOT) Jjowojoydonasds Aq uondIospy UC D OTOT/|L/FT PSYep PO/LEIAAINV “ON [090301d au Jod sy

:asuodsay TIA

 

 

“ITOTTO'ST SP my op Aq
peuonuau st uonajduoo jo mep oaneuat

 

 

 

 

 

 

 

 

 

 

Ocor err “OTOTTI:6T PUE OZOTTI'BI “ON
Aa PSP Uojoadsu jutop jo suonea rasgo Sotreniduaos Tra SUOBEA LISO /SSUIpur uojgaadsuy 'g
Do DZOT/L1/61 03 OTUCINT/RT MOIS . o.
pL3o LaBed «IUIDOBA SILITA EUOIO)) PIJeABDBU] “UOLIA DJOUAA., nasucia

 

y2npoid ow) 103 (T 87 WiIO,] UI asuaarT Suranjagjnueur jo juris; 10J rodar uogvorrada asueijduro;

 

 

 
 

 

*“pI-SINXOUUY SE PouDEpEe si UONPoL odds postado aU “UIeJo joqel
DU UNA OUTUI 03 CTHS/919 (IN) UBUL 8897 JON SE postAdL ST jUaju0o UIajOIÁ [r]0? 10] UOyRIIIaads SU] "1ZOZ/T0/81 UO SA]DOgO Opem pur Z0017/000/00
joguos aguruo yRnoIM pastaol US9Q SEI OUTOSLA SNITA BUOJOS) PojeAgoBu] UOLHA SJOYAA J0J T | ESA UONCIIads au) UOnEpusuiurossa 1oypne au 1od sy

:osuodssy TIA

 

“ALOJ9RJSUPS JOU SI ULIY SU) AQ popiuqus
UONBOL SN OSTe pur jooId juaumoog

“ssooo1d Jopun st UOTBLIT]SO JUSjuoo

pardo; JoN UISjOId 107 UONPPI[EA pompour jronáeuy

 

“SoWojeg poimapynueir quorongns
% JUONen|pAS spuon uo poseq pur
SIojouIRIBd JUBAS[SI JO UONPPI/LA poupou
Jo Uona|duios Jagje pagistaai aq [eus ouies
“IoA9MOH “HS Tp LIN E Es usoq
SABY SIVUI] SU] SIOJ9P] asa) Suniapisuos,

“saoge  pouogusu se  ÁyIqeuea
sisájeur jonpord Sup pur Ayyqeira
ssoovoJd Suumornueur Supnpour
siyouried jo Jegunu Áqg pepoediu

aq UM HINg Jd se qHs/Sr9 Suns

“onpold ot 103 (gova 103 9%ST
Sullopisuoo) ssaoo1d SuLmyoenuew pur
pouau jeonÁfeur jo uoneurA osnejhumo
Sutiopisuod uUo peseqg si uonrangads
ow “ey Ájivjo o) ox pmom jag

 

“aHs/Sro VIN SIA LT uog
Jo uonvoidde om uo jonpoid Sup

pordde ou 107 pouonusw unvjo [oq]
“IADMOH “IrR|o pogei jo ans rt
CUIN) ueu, sso7 JN se Idoy
SI JUSjUOS UIojoId Tejo) 107 UONLaIgInads
rem pasesgo st qn aHsímio
-UOnejnuLO) z-[98]V) ouoeA snur/
BUOIO) PojeanoLu] UOLIA Q|OUAM

Joj (OTOT'LOST Prep TO “ON “AM

“TIESdA) UOgROLDadS JO FULM9IASI UO | “OT

 

 

(sisájeue Amiqeas jo monojduros todn poxeys 2q [Sys eseq) “El -a40x0uuy se papuadde a10m Sy|nsos UuoIA

1 p ojapowos Áytrqeis jo Ádoo y "ITUT/S0/8T P ITOT/TO/8T O pajnpayos sisATeue ajdunes AjyrqrIs Wjuour 9 put pi SU] "SJmpowos ANTIqeis Id se 1707/10/60
Vo pajojduioo sem SISÁJRUE TJUOUI 5] PUB SISÁJOUU Ávp Q) [BM!U! SU] VSOOOTALE PUE VPOOOTEALE “VEOOOTALE 'SON'T 10) Oo TEST IP ÁNTIQLIS pojeajodor ay
*“ZI-9mxaumry se poyoeye oJe sojep pojnpogos pue sjutod aum Aprys ÁAnjIge)s SUL "1707/70/87 UO pojnpowos sisájeue

ajdures ÁypIqeis uou pg SUL -pejejduoo sem sISÁjeue Áep O JeNHUL SM VSOOOTALE DUR VPODOTALE “VEDOOTALE "SON E 107 Do EFS 38 ANJTQUIS SUN Jeou ay,

“PI-Sanxouuy se poyoeyye axe

synso1 puz sjutod otwm Ápras ÁGEIS SUL “QTOT/TL/L1 LO pajatduros uaaq a4ey VEOONTILE PUe VEODOZALE “VEOODTELE 'SON'H JO Oo TFLE e ANIIQeis ssous
(gisIAda) (asno (paquospy “uzumk) 9U1opA SNILA BUOIOS) PojeAnoBU] LOLITA SJOUAA JO] (TOO/0Z/AS/Ad/H/L£ “OU D0C]) [020j01d Aprys Antiqeis Jod sy

 

“(ANTIQLIS ssans) "ssaz01d ropum sy Ápnys

 

OTOTTT'TL

gal PaJep omaadsuy jurof Jo suogeA Lasgo

 

 

aoueduros TIS

 

:asuodsy TIA
OT0TLL'6L PUB GTOTLI'BL “ON
SUONEAIOSgO STUpur uomgIadsuy 'g

 

 

 

FrJO g ara

 

UTOT/LI/61 03 UT0T/LL/BL UOL
«IUIDILA SIA CUJO) PIJEAHILUT CUOLIA PJOUAAs

J9npod ow 103 Q 87 ULIO ] UI asuaarT Surinjarjnnenr jo juris 107 rodar UOpBaILIdA asurijduro

 

 

 
"uodal ot) Wuuqns
pur uogvorynods
au ostadl

pur sawojeg [emo
PSTHO pautrigo
aBejusolod
uondiospe sw uo
eJep at aqtduroo
o] pojosaip aq Áeu
ULLY “I949MOH
“odB)s sn) je
palopisuos aq ÁBIA

“ULH ou3 AQ pojdepe st eroodoseuied

ueIpur op ur (uvumy poquospy)
parangoruy AUIOBA, sueuydasug
esoueder JO pouogueu. (94S7 JIN)

nun uondiospy jo soBag] om sousH
“UONP|NUNOS THOQ SW) JJ JEJUM osje st
ssaooJd SULmjornucui ou] pur ouies ouy st
UONEjNULIOS ot oq ur pasn uonegusanos
8 opixoip4g  umuumy- queanfpy
We] paes si 1] omosjom jsmoSy
ua JS oprxospájg wmnmuruntyo Guisn
a1e ÁS] SUIDOEA SNILA BUOIO)) pojeagopu]
uor aJouM  Joj pur queanfpy
ue se [98 opixo1páT] UmMIuTUNTy Suisn axe
Áoyy JeW] OJejs UML “(UBUMH poquospv)
poeanoeur SUIOSBA sumeqdooug
asouede; amarnueu o pasuaol st ULIL]

Poso/D:snje3s

LT ANXIUUY Se poyorye sr odas pur syjnsoz 189) uondiospr

UIJOId OU “OUTDDBA Z-AO)-SA VS 103 SAL JO OdUOSge UI pomoljos 2q 0) OHM ÁQ pojsasBus u90g st yIyM udeifouom suieydosug asaurdef uL pouonusur
se ju jerodoseuneyd om mim paqeoS o popioap si 4 UonEN|RASd a UO pastg SUIDOPA PUOIO) PejranoBu] UOLIA 9JOUAM J0J TIJA 1º posmioemucu
seuJeg Joy ajqejresr ejep ow Suiiduioo Aq pesedesd sem qodos puaij (utumy pequospy) pajeanotu] ouroovAa sujeuydooug osowedeç jo uomentaouoo
[23 9pixopAg untunaniy- jueanfpy se qons uone|nuLos Jo pur Jejrus jo mmomannhas [erodoseurieyd 10d se axe suonromroods sw Jem pogurep TIdg

:asuodsoy TIA

 

*Eo-amxouuy
Se PolSByE SI JUSUNDOP d] SOUsIojor aU],

“PJEP SOWpJPq jery [rotura 03 uontppe
ur Soyojeq [puorippe 107 uondiospr
afejuoolod 10] spusi] uUo paoseq pastar
aq Teus sirury ep “omyny ur paisofêns
se  “JAoMoH  (ueumy  “pequospe)
pojeamgoruy QUIDOBA smeqdooug
asaurdef IO] SI adtalajar qdeiBouour
auL eloodooeuiryg umpu, Jd se
yum Jeisodosenneyd mom posniop usoq
aspy UOndiospe Jo aaiBop 107 SIUm] SUIT

 

paxedard us2q seu 1Z0T/10/ZZ PNLP 90/,£/NAINV 'ou jioder Ateuruuns e AjBuIpiodoe “pajajduoo SI UONeupso quo

“Setoyeg Tera jeorurto mr
paureigo aBejusotad uondiospe amp uo
paseq suonotroads eu ysijqeiso (jeys
Wu ST “ULSjord jo tejo oq] pajeis

A JO WSL TN Se Ido SI 107 [RUI ve
uonromgroads v uondiospe uia od 104 | 1]

 

PosolD :snje)s
*60-2-mxoumy se payoeyp st aures am) pur

OD ULS]OJ 107 UONLPI[CA PO [eonáteue ou

 

 

 

 

 

 

 

 

 

 

Ococ Tr UTUZT'LI'6I PUB OTOTLT'BL “ON
ERR Psp uoppadsuy Juop JO SUONEALSGO Souesiduido Ig SUONEAJSGO /SSUTpuny uonsadsuy 'g
E OTOCITT/6T 03 OTOTATT/ST OL - O
+T JO 6982] «IUIDITA SILIA BUOIO)) PIJUAHICU] CUDLILA DJOUAAs, n5s1614

 

Pnpord 24] 103 Q 87 ULIOY UI asus21T Sum pepnuear jo juris 107 1 10do1 UOPUILIdA ouvido”) Sor

 

 
-pomduros 4pued

 

JO spueq utojoid jo njitom Jejnosjour
eu SunerodIoour Aq paredord JS Jia

Ana

TAOO-SHVS Pajeanoeuy 107 aBea-SAs
Aq Ájung 9tUSS uy jo UOnPUrmLIo ad
9SWIDÔPAIS “OU 90Q dLS JO UoIstAdI
407 ULIJ OU] ÁQ PoJenIuI SEM OTOT'TI'L
PSP +2007/090/90 1onuos sBueyo au,

SW Jo Ajund ou somnsus majoId adojosuo
pur oueiquiow “pisdeooajonu “oyds ueu
JSHjO spurq oTjioods uou Jowo jo oouasqe
pur snHA TAOI-SUVS SU sunguos
pueqg urjoid aytds jo soussaid aul

*Spurg
olloads STLIIA TUOJOD ÁJUO MOIWS Pjnoys,,
“se uoyroibods om ÁAjund omognur

1o0j eu Ájuejo 04 ox pmom qIaa

 

 

 

959)
ADVUI-SAS SW ur mosoid oq pjnows
JyBIoM Jejnoojow YoIyM jo spueq je
Ájroods Ijeys uni owI '.spuvq aigioads
SNIIA PUCIO) ÁJUO MoOW pjnous,,
se pasuoguour ole suonvorg roads
dOVvda-sas Aq Ájund omoBnuy 10g

 

| “YV poor
-SSUTOBA paquosay
UT TUM YET
- RroOdospunBid
UBIpUI JO

PONoTI pasn au JOJ
UOnPOTLIZA pojour
uLojIad 0] pojoonp
oq ÁBUI I9A9MOH
“paxopisuoa aq ÁrIN
“souaH "peigusnf

poa [ronájeue oyj mo ponto q IIS UONLOLICA poem aU 'SOUoLA
Jo Bupso) 10) IZOTITO/IO PSP CT/LE/MAINV Fou jooojord uonvorgraa pouaw jvonáfeue v pesedosd sey ag UOnepusmwnoool siogpne om Jod sy

 

€

 

TTOTABA-TEDL
*S[-mxouuy se poyovy)e sI [090/01 UOBoLpLIDA
TAOD-SHVS Poreanoeu] 10j poypi uonenn Aq juajuos tunturumy

:asuodsoy TIA

 

“SSUIDOBA
paquospy 107 eIoodoseuneyg uzIpuj ow
uL palgioads JUL SU UP poxty pey UMA
“Tu OS'T IINN se psuogusw sj juaquos
UMINIUNTY 107 NUM OUT SOUTOILA SS9]

 

“PaSTAdI OQ ITEMS Syrumy
SU) BIUP puel yojey Lo peseq pojsofigns se
“10n0moH “Áyjenb jonpoid sy; uo jovdun
ÁUB 9ABI JOU SOOP UONPAISSGO aU] S9U9H
sjnpoil posodde Suysixo uo poseg
ynpord pormorynimem ow jo Aouasisuos
ou UIejUTeUI O) juajuos umimunçe 107
SJ] [ONUO? [BUIjur axe suompoIgioods
asayy ugisop Aq Ayjenh jo Jdoouoo
ow Sumopisuo) ofesn Joj ajes pue
9TX0) UOU 18 [u/StU (ST JO UOgEgUadUOd

USOS UMmtutuInTy do7
uonepipea Áesse SuLmp pouleigo ejep
au O poseqg jonpoid Gnip pasodoId 107
suontoiroads au ufisse [[eyS uu ayI
“LUSU] ÁQ poimjorjnueur aurora “T'[ J0J
PoMoToS SHUmN| OW) UO paseg poufisse
OIE SJ] OSoU] 12W) pojeis ULIL] “opis
Joddn spiemo) [ud so) put apis

J2MO] JO asto UI [UI UI ZT'Q SI UOneLIPA |

“ouoo  pajsõic))
IU/UgSO O) [U/UgEO SI UoLauo
aourjdsoor ue Jusjuos wmurun)y 107

 

pajep uomgasdsuT juro jo suogvAxasgo

Je PoUOTUSTU St] | SE YA [UL/BUBÇ'O 09 [UI/SUSE'O NUNO | juranfpe IM suonpjnunos auraoea
SU) PU POIS | pagIOspy OU JO ISOUI T[N JeWJ pazes LA | OU) JEI) somudis ÚoLga sejoodooeuneya
viodoseuneud | S10T elvodoseunrig uerpu ur pouonnouw [og vd se quu ez IAN | SUL (u/8uoço
uvpu |sv Y PO -Soupoea pogrosqy |Jo mun] poudisse om car suonepnunos |
pomolos Pey LULA | Ur unmmumpy Gg7 pamoror tw | oulora (re jsoufe) Um Xe
Spemoy senmirte souepduroo TIA

 

OZOTTI'6T PUE OTOT ITBI
SUONEAJTOSqo /SSuputy uomgaodsuy

 

 

 

 

 

FIsO OT Reg

 

 

OTUZ/11/61 03 0TUC/T 1/81 UIOL
«SUPOEA SILILA EUDIO?) PIJEALOBUT UOLITA SJOUAAss A
Inpoxd sup 103 87 ULIO, UM 9SUSSIT FULMoejnuen jo JURIS Oy 1XOdar vomrarpLaA aouedimo) “e

 

 

 
 

LZUT BIA TE:DL

:osuodsay

eexe Suisuodsiç| ut due] inodea WNIpOs jo UONET|BISU! 103 pojenul U29Q SEU [Z0T/70/£Z POIPP FODIT/ALS/OD “ep apepdn 09 o pjnom TIgg

ad

 

“partduroo j0N

“Pole UONP|NUNIOs pur
asnoy oJem qe ese Suisuadstp at ur due]

“PO-SMxoUUy se
Payene st SAS “UI jouemo Axouoyg
-Z Jo afero)s pur Suipuey J07 juaursambar
Jeloods OU SIe SU JOUEIJAXOUSTA-T/PU
nocduos/A0S" yu U Tg uTpand;2sd
ISON Jº Woy-qna 2 Jompegnueur
uy WO SAS Jod sy goupry vuis
S/N JOpusa OI paatodor s1 jouryjo

 

 

  

 

Jnodea UMIpos popraoId jou ser uLL]

AxoUSUd 7 “VU ÁPuIV]o 0) 2%! pjnoM TI

“BOB VOTE [NULOS PuP Ssnou cpm
y2 vol Sursuadsip ui dure tinrpos
PpopiaoId jou seL UI] Tos9Mo]] dure]
untpos wpun poppuey x posusdsip
sq O spoou 1 “[erimeur oanisuos
MR] SL dt Se put auorA SINA
BUOIO)  PoPANoRU UONTA SJoUM
Jo UONP|NLO] SU) UI SANgBAIoSaId se
(ad-T) IoueyoAxousua-z pasn st umL]

+

 

*97-amxauuy se poyoeye si

pasolo :snjrIs

:osuodsay

FALS PostASI SUL “TTOT/TO/PE UDF SANDSJS SI AS PUC SPuPQ S1oods sua BUOIOO JuS1ojyp
JO SWBIom JPjnoSjour aum apnjour 0) pasiaoa us0q sei pajep 9c0/000/dIS “PL007/000/09 onto afusgo au Jd se ey ajepdn 0) ax pjnom

Tiga
ada

 

uonezeuiy
Jpun sy rip 9UL TACO -SAVS

“9UBS SU) 10) pojentur

(90000/dLS) T-A00-SHYS JO Anuind
oTuoBNur 10] oinpaoord Susa) prepurys
UI pepnpout aq Teys spurq urjord jusioznp
10] SIWyBioMm Iejnoojour 10) S|Rp ow
soueIjÁuIOS + Se I9A9MOH “.spurq oiioods
SNIHA tUOIO? ÁJUO MOYS pRoys JOY
-SAS, Se pauonuoui ore suoneortioads
SH SOJJY] Compro  snonva
UI alqe|Ie4r SI UoNvuroju! siy | “onpoid

 

St PLOOT/090/00 Ioxos odueyo oup |

 

SyIEWIOY

 

Biot

asueiduoo Tiga

 

Pajep uomgaadisur juror jo suogra rasgo

 

 

0Z0T'TI'6T PUE DTOTLI'BI
suonrAIasgo (sSupur uoyosdsuy

 

 

 

Pro LL Seg

 

 

OZOT/TL/6T 0) OTOZ/L 1/81 MOL]
«SUDIEA SÍLICA EUOIOS PojeAnoEUT UOL DJOUAA;
Inpold ay 10j (J 87 WLIO,] UM 9SU9D] FULMIBJNUEU JO JUHIS) 107 jXOdar UOpPoIuOA dauepdwo “So

 

 
 

"poa tooos 29
0] 194 ou sgjodal
pue vOLOOTVOr
Pue vVooodcvor
“oN'g vonmgeedasd
T-[9R Iv paamosmno
| az paomnosyno
Áyordra
uondiospy |
UIJOIg UONEII |
VILA Ay,
€-HO)Ty 'onpisal |
sy (jeoL
24 “apeydins o017
“ajeydyns jror
“UONDIyUap|

“PoATsdaI aq 09 J94 ap
suiodol 1899 eU] 'pasmosmno axe Ajrordeo
uondiospy uso “UONENLL VLC [U/V
S(HO)TY “ompisor usy (je 10 1) 9 À “oe
ydIng coy “jeuyding [eoj Uoneanuuapr)
389) OW) Jo 821 pur asnow- uj pojsol
or ÁlJUOS pu? Hd “uondiHosad “gsosdI
OU Uogpontoods Jod se sisájeue ajajduroo
Joj  poxatoo tem vOJOOCVOr pue

v60oozvor “oN'g uoneedoid g-pdjy
pampeynueul ou) “postei UONBAIosgo Iyy

“ouros

Su JOj pajemtit si gT00T/II0/VAVO
“UONBAIaSgo

em WlM áAjduos 01 se os uonrartoads
eu Jd se sisjowzied Ipe js) IJeys
ga pasasBns se “IosomoH “pagodor
eu [23 apixoJpáy wnjuumpp somos ou
UIOI SIJNSO1 owes poxye Áljeoturamo aq
0) pojedionte 10U axe WoIyA sigaweird jo
pu] Jejruis jo Bunsay jeados ow quenosd
9) SIOJaLU] [of oprxoipáy umpnranpe
Jo soniodoid [eorusyo om ofuryo ur
Teo sing jo u9ppe jey uogedionue
onnusos ou si om domH z-oSjy
Jo uonpIedoId 107 Ájorour [of aprxoIpáy
tnTurunte %z ou 0j peppe st snosjow
smmofe eu jo songuenb peumura AA

 

"OTOT'BOTO
poep ssosdr ON  uonvogads
Jod se “z-[25Ty poxedord paysoy jou seu
UMA “ZPBIV Jo vOD au uo mz |)
aprxoIpáy untutumpy jo onqea ponodor
“Suluogusul pur Ájoedeo uondiospr
urjold pur  (uogem] vida)
tuAy *e(HOMV 'enpisar ysy (jon)
“eyeydns soy “ojeydms [ejo) 107 189)
SW) OUOP J0U SEU WII Jeyy poslosgo st
N TQOS] “azIsig “VLOJOTVOM “ONT
uongeredold z-[28]V Jo (VOD) sisájeuy
JO SONS Jo UONOgIDA UM)

91

 

Ádos y “posrjd st IZOT/LONUISD/TLO “ON A “Pequiopám

 

posojD:snyeis

 

*LJ-SINxouuy se poyeye st [OI TAM U2omjpg VIOJO
II 7 Wo9JOTg Jereyg usomjeq justsalge [eo1uuDo) Apjenh au Jem ajepdn 03 ax pos TIgg

 

 

“partduroo j0N

Jepun st (OZOTILON-HISOITLO OU
JW) jueuroaldy [eotuyos 7 Anjent)

 

SpIeuroy

 

OZ0TTI'TE

 

 

 

suodsoy Jg
“sojdures 7 [PSV “peqeiopÁH “TOM P (posJora
Jo Sunso) 107 LO] UM VIO SW Sup | mexeu) uy  usomoq — alqeirar
Jo ssoooid ow ul si TI] “IoaomoW |s1 juoumslde Ajgjenb ou “242mM0H
“9SEOJoL Wolrq 0) JOL TIMH | 1803 uontIgnmop| 10 prarapAH
uogeiedord | Áq pojenptas pur uogeipasor IGYN | “LO O ejdues Supuos si umg
RuLtepisuoo pearzapáH “LOM Aq posa | qr DO Jo ur Hd uondunosop funso
ae sojdues 7 [98/v Te syuoo TIgg |st wag “uongeedod z-/98|y Jyy cl
0T0TTI'6T PUB OTOTTT'BT “ON
soueriduos Tiga suogEALosgo jsiuipug uongodsuy 'g

PaJep Uomoadsuy JULof Jo SUOWEALSAO

 

 

PLJS Tr oted

 

 

DTOT/TL/6T 02 070T/TL/8T WO
«QUJIDEA SILHA BUOJOD POJBAPIBU] (LOLA PJOUAÃ.,

j2npold am) J0y 87 UNO] UI asusarT Suranjarjnueu jo Jur so) 107 rodar moneaTynIdA ssuejduro)

 

 

 

 
 

SULUIRIÇO Io)Je ÁJUO dUIOBA ST) ajnqrnstp |

pur ojes IIPyS IgA Jem uonipuos

Om O) jofqns suova au »oojs pur

aumoepnuei 09 “OTOT/SO/ST PNBP (A)IIST

"OS “ou uonroggoN eleyoM ÁjIMET

pur WrH Jo AnsmunA o) aouatojai

u “ 87 umog urigo 04 QTOZ/TI/OT

UounquIsIp IO JO 9Jes Joj | pep “q LT wo] ur uonvandde
9UII9BA SNITA BUOJO/) Pejeagoru] “UOLIA | UP  poprugns sey um “oupued UOINQLISTP 107 10 OJeS 107 OUVoSLA,
ATOM - UONE UNOS [eopnosewseud | GI-CIAOD 0) enp ussir quouicimbo |snA PUOIO)  pogeamoru] “uoLma
SINJIRJNURUI 0) CT-LO ULUOJ UI | ÁQUARIOUIO SU] JOOUI O) pur )SSIojur Wear | SJoyAa sumorjnueu. 0) uoIssiunad

pondo j0N uoIssTuLSd uTejgo 03 porjdde ou pey uL4 | or qnd 107] “ey Ájuejo 01 9X pjnom TIgg | 107 cT-1O wog meIgo jou prp wma | Tz

 

 

Trocady-9e MIL (snonones)

JOPUSA UIOIF S01NOS [pLIS)XO AQ NO patio aq (peu worqm Ápnis Aypiquysrs] IS) [14 10] pazijeu; U99Y SeY JOPUSA SU) JEY ÁJUE(o 0) 3X pjRom TI

"6T SMXSUUV Se pagoBije axe sjtodos Áreurtuns 2 [090/01q SU "LTOT/TO/PO POP 00/LTITOO/A AD VALA

*» ITOTITO/PO PBP 00/TTTOM/AAD/TVAMAIA :sioqunu nodoy “poredold atom syodos Aretmmuns am A[Buproooy “Ajaanoodso1 00/07/700/AAN LVa/ATA
P 00/0T/LWN/AAD/LVA/ALI "OU JODOOIA UONRPIRA JM pia pojnoaxo si uonnjos Sad UL dd T JJ 189) Anjqneduioo Joy pur soumsqns
nIp oUIodBA SIA BUOTOS PaJeaNSeu| “UOLHA PJOUA J0J 189] UONUSAI [PLSjoRg “T9NOTISVS/DO JONUOO afuryo ot 19d se Jem uniguos 0) sx pjnom “ga

:asuodsoy TIA

 

 

“uonNoaxa JOJ paerui

US99 Se T9007/SF 8/29 |oguoo eBueyo y “uonnjos

“UONNTOS SH UL dd TP SoUeIsqns “paucioprad oq Treys Xjnq pojejnunoy 107 | STA UM Ad Z 7 souvisqus Stup aurora
SNIp AURA SNIA BUOIOS) Pojeanoeu] | posn uoum|os Sad UL Jd Z Pe couejsqns | sniA eUoIO) pajranoru, UOLIA

 
  

 

 

 

 

“UOLHA 9JOUAS “UONMTOS V q] ULISIUOBE $/4 | Enip aurora SnIA UOIOD pajeanoeul | ajoym uonnjos val uL jsuoBe g/7
| “pegduoo 10N NAL 10J pouriojiod Jou UONCPI[LA 19) | UOLHA S]OUAA JOJ UONEPITEA JS SU] | WTI 107 paurropiad jou uorepifes Jota | “SI
pasoj9:snye)s

 

'gI-5INxoUUy se payoeyje axe SVOD Weg ay 'paonosjno axe Ayrovdro uondiospy usjolg “Uogem | VILA

TV (HO) TY “onpisai ysy “(jeyo) o q “ye yding soy “oyeuydins [pjoI UOnPomgnuapr) 1891 ou) o 1801 pur asnouy- uy pajsoy axe Aquas pur gd uondinsag
“8S0SdI “OU uonroipnads 19d se poojduros sem srsájeue VOTONTVOP PuL v6000TVOr ONE T-188/V paamoegnueuu au Jeu) ojepdn 09 ox pjnom TIA
iasuodsoy IgA

 

Ocor trt
PeJup uonosdsuT jurof jo suonrATasgo

OT0TTT'6L PUB OTOTLI'BL “ON

SEUS suoneAIasgo simpur uogaadsu 's

asuenduroo TIA

 

 

 

 

 

 

| 0Z0T/TI/6T 0) OZOT/TI/8T MIO
pLJC EL aged «AUIIIBA SNITA BUOJOS PajEANDEUT SOLTA SJOUAA,» HM>BLOLa
janposd ou) 103 (] 87 ULIO, UI! 9SUD9LT QULINJIEJNUEUI JO JUCA) 10) JAOTSL UO]BDIPLIDA SoUBIpduo) “a

 

 

 

 

 
 

 

 

 

 

 

 

CRS A TT) o TO FAISA
A ae op uBig | sÃSE 19 DE ajear » uBIg
[Ná e |
SVO-IADY o | SVO - Sus 4d
Ag parorddy :Ag paredarg
a — pasojD:smejs

 

*OT-EMmxamuy se poyoepe si gz - 19 UOj ou |

“IZOT Toco -pea “ZO0000/1 TOSA “ON UOISSTULIOd SPIA (vna) uoneZLIOUMNV asN ÁouaIouig JSpum cr- 15 unos

HI UOBNQLASIP 107 10 ATE 10] (QUIDOBA SILLA BUOLOS) POJEAHIBU] “UOLILA SJOUA,, AINILJNUBUT O) NOISSIITOA PIA IS90I V9OJOLH JEIBYH SOUDH OTOTITLLO :porep
TLOTU/NTUT/A/ITLO/OIE "ON UOnPANddy INVONS UO [TO UNO UL UOBNQuISKT J0J JO SJeS 107 omornuem 07 uoIssiunod 107 pordde yosjoig jeseyg

:asuodsay TIA

 

 

“UONNQUISTP 107 JO SJBS 10] SUTOSLA

SNILA PUQIOS) PojeanoLU] “UOLIA SJOUM
axnjoegnueur 0) uoIssIuLd 40) ET-ID
ULO, SU) ureigo 04 Adde 19yuny im Tiga
“B)-021ANxouuy Jojoy “(AuOmne

BUISUSOI] JeIudo o) Wo) ET-IO Umog

 

 

SyAeuroy

 

 QUOTTITE
P3JBp UONIadsu] JULOf Jo SUONLAIaSGO

 

aouepduros TITA

 

 

 

OZ0TLI'6T PU OZOT INST
suo vAIosgo (SSurputy uogaodsuy 's

 

 

PLJO pr oded

 

OTOC/TI/6T 0) OTOZ/TI/BT UIOAM
«AUTIIEA SÍITA EUOIOD PojEATDEUT UOLITA SJOUA,,
J2npoJd ow) 107 ( 87 WXO UI 9SUDIIT SULINJIBJNUCUL JO JUEIS) 10J 1FOdoX UOPIIPIDA SoueIpduoS, Es

 

 

 

 
CEC
BHARAT
BIOTECH

! | Guniadias, LETTER OF DECLARATION

Our Company, BHARAT BIOTECH INTERNATIONAL LIMITED, incorporated under Company"s Act, 1956
having its registered office situated at Genome Valley, Shamecrpet, Hyderabad S00078, Telangana, India, bearing
CIN: U24230TG1996PLC023232 (hercinafier “BBIL”) which included its Directors, Officers and Employees who
intend to conduct business transaction with various Channel Partners and entities hereby:

PLEDGES AND UNDERTAKES THAT:
BBIL AND MADISON BIOTECH PTE LIMITED, a company incorporated as per laws of Singapore having its
registered office at 31 CANTONMENT ROAD, SINGAPORE-089747, (hereinafter “MBPL” which included its

Directors, Officers and Employees, entered into a Supply Agreement authorizing MBPL to supply and distribute
BBIL's Manufactured Products to various channel partners and entities in different regions and territories.

In, Lieu of the above declaration, all tÁc Channel Partners and Entities are requested to accept the Invoice
raised by MADISON BIOTECH PTE LTD, for every Product supplied or distributed.

For BBLL,

   

BHARAT BIOTECH INTERNATIONAL LIMITED
Genome Valley, Shameerpet, Hyderabad - 500 078, Telangana, India 5 BUT

, Re à TA, E
T+91 40 2348 0567 / 4645 4545 M:+91 99480 80567 E:+91 40 2348 0560 Typbar Te ROTAVAS
email: infoGDbharatbiotech.com  wwawbharathiotech.com
CIN: U24230761996PLCO23232
24/03/2021 SEI/ANVISA - 1382475 - Recibo Eletrônico de Protocolo

Recibo Eletrônico de Protocolo - 1382475

 

Usuário Externo (signatário): Ariadne Gisele Muniz Bonvino

IP utilizado: 189.28.128.242

Data e Horái 24/03/2021 11:48:36

Tipo de Peticionamento: Intercorrente

Número do Processo: 25351.908358/2021-66
Relacionado ao Processo Indicado: 25351.908110/2021-03

Interessados:
MINISTERIO DA SAUDE/DEPARTAMENTO DE LOGISTICA EM SAUDE-DLOG/CGLOG/DIIMP
Protocolos dos Documentos (Número SEI):

- Licença de Importação 21-0796694-1 1382470
- Relatório de Conformidade Jul 2020 1382471
- Relatório de Conformidade Nov 2020 1382472
- Declaração Madison Biotech 1382473
- Contrato 29 - Covaxin 1382474

O Usuário Externo acima identificado foi previamente avisado que o peticionamento importa na aceitação dos termos e
condições que regem o processo eletrônico, além do disposto no credenciamento prévio, e na assinatura dos documentos
nato-digitais e declaração de que são autênticos os digitalizados, sendo responsável civil, penal e administrativamente
pelo uso indevido. Ainda, foi avisado que os níveis de acesso indicados para os documentos estariam condicionados à
análise por servidor público, que poderá alterá-los a qualquer momento sem necessidade de prévio aviso, e de que são
de sua exclusiva responsabilidade:

* a conformidade entre os dados informados e os documentos;

* a conservação dos originais em papel de documentos digitalizados até que decaia o direito de revisão dos atos
praticados no processo, para que, caso solicitado, sejam apresentados para qualquer tipo de conferência;

* a realização por meio eletrônico de todos os atos e comunicações processuais com o próprio Usuário Externo ou,
por seu intermédio, com a entidade porventura representada;

* a observância de que os atos processuais se consideram realizados no dia e hora do recebimento pelo SEI,
considerando-se tempestivos os praticados até as 23h59min59s do último dia do prazo, considerado sempre o
horário oficial de Brasília, independente do fuso horário em que se encontre;

* a consulta periódica ao SEI, a fim de verificar o recebimento de intimações eletrônicas.

A existência deste Recibo, do processo e dos documentos acima indicados pode ser conferida no Portal na Internet do(a)
Agência Nacional de Vigilância Sanitária.

https://seianvisa gov.br/sei/documento consulta externa. php?id acesso extemo=227588id documento=15502268id, orgao acesso. externo=08infr.... 1/1
 

 

William Amorim Santana

De: Emanuela Medrades <emanuela.medradesO precisamedicamentos.com.br>
Enviado em: quarta-feira, 24 de março de 2021 00:00

Para: William Amorim Santana

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO; Regina Celia Silva Oliveira; Renata

Marques Santana; Thiago Fernandes da Costa; DEPARTAMENTO DE
LOGÍSTICA EM SAÚDE - DLOG; Luiz Felipe Almeida Caram Guimarães;
GABINETE DA SECRETARIA EXECUTIVA; Quinta Diretoria; Segunda Diretoria;
Primeira Diretoria; DIRETORIAS QANVISA.GOV.BR; DIRETORIA4
GANVISA.GOV.BR; Luis Ricardo Fernandes Miranda; Antônio Elcio Franco Filho

Assunto: Re: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º
PARCELA CONTRATO 29/2021 VACINA COVAXIN/BBV152
Anexos: Compliance Report Jul 2020.pdf, Compliance Report Nov 2020.pdf, BBV152-

COVAXIN-EUL-12032021[1].pdf; Re: Pendência (det incompleta) -
25351.908110/2021-03 - aquisição de Vacina COVAXIN / BBV152

Caros, boa noite.

Com o intuito de atendermos todas as demandas da ANVISA que estão em nosso alcance, e permanecermos com a
atuação de forma transparente e colaborativa, informamos que com base no último press release emitido pela
agência, temos as seguintes considerações:

https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/anvisa-recebe-pedido-de-importacao-covaxin
1. Relatório Técnico de Avaliação emitida pela autoridade sanitária Indiada:

O CDSCO emitiu um documento (anexo BBV152 — COVAXIN — EUL — 12032021) que transmite a
autorização para uso emergencial com as suas ressalvas, bem como o relatório de avaliação técnica em um
único documento. Tal documento foi transmitido ao Ministério da Saúde na quinta-feira dia 18/03 com essa
observação.

De maneira proativa, compartilho o CAPA Report emitido para a autoridade sanitária Indiana que
apresenta os apontamentos do mesmo durante a inspeção para autorização de produção da Covaxin.

2. Certificado de liberação dos lotes:

Enviamos os Certificados de Análise dos lotes liberados* e estamos providenciando os Certificados
de Origem que serão emitidos pelas autoridades indianas. De acordo com a evolução dos estudos de
estabilidade, estamos atualizando os CoA's para condizerem com os resultados obtidos e novos padrões de
conservação — ampliando a shelf life de 6 para 24 meses.

3. Licenciamento de Importação

Segundo anuência dos Fiscais do Contrato, formalizadas através de e-mail, o DIIMP tem atuado na
emissão desta LI sendo o Ministério da Saúde através do seu despachante, responsável pela abertura do
Licenciamento de Importação. Lembrando que, de acordo com a operacionalização do SICOMEX, iremos
solicitar uma LI para cada embarque, não sendo possível solicitar para as 20 milhões de doses contratadas
de uma só vez, já que os embarques — também com a anuência do fiscal do contrato — serão fracionados, e é
impossível registrar mais de uma DI por LI.

Todas os passos têm sido realizados com o intuito de atender integralmente as demandas e complementar com
mais informações sempre que necessário, e contamos com a solicitude que já vem sendo apresentada por todos
desde o início.
Atenciosamente,

Av Portugal, 1100 - Itaqui- ltapevi- SP
Emanuela Medrades 55 11 3080-5140 - 11 9 3257-4642
Diretora Executiva

www precisamedicamentos.com.br

  
 
   

     

É
N Medicamentos

YW PRECISA

 
 

Esta mensagem pode conter material confidencial, privilegiado e para uso exclusivo do destinatáric
autorização expressa, é estritamente proibido. Se você não for o destinatário desta mensagem, po!

This message may contain stuff that is confidential, privileged and for exclusive use of the Intended
permission is strictly prohibited. If you are not the intended recipiente of this message, please noti

Dantes de imprimir, pense no Planeta! (Before printing, please think about our environment!)

De: Emanuela Medrades <emanuela.medrades(O precisamedicamentos.com.br>

Data: terça-feira, 23 de março de 2021 22:54

Para: William Amorim Santana <william.santanaO saude.gov.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao(Osaude.gov.br>, Regina Celia Silva Oliveira
<Regina.Oliveira(Osaude.gov.br>, Renata Marques Santana <renatam.santanaQDsaude.gov.br>, Thiago

Fernandes da Costa <thiago.fernandesQsaude.gov.br>
Assunto: Re: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 12 PARCELA CONTRATO

29/2021 VACINA COVAXIN/BBV 152

William,

Já havia pedido essa retificação, e me enviaram.
Segue com ajustes,

Atenciosamente,
Av Portugal, 1100 - ltaqui- ltapevi- SP
113080-5140- 11 9 3257-4642
www. precisamedicamentos.com.br

Emanuela Medrades
Diretora Executiva

 
       

SAUNA

Medicamentos

Esta mensagem pode conter material confidencial, privilegiado e para uso exclusivo do destinatáric
autorização expressa, é estritamente proibido. Se você não for o destinatário desta mensagem, po!

This message may contain stuff that is confidential, privileged and for exclusive use of the Intended
permission is strictly prohibited. If you are not the intended recipiente of this message, please noti

Dantes de imprimir, pense no Planeta! (Before printing, please think about our environment!)

De: William Amorim Santana <william.santanasaude.gov.br>

Data: terça-feira, 23 de março de 2021 22:35

Para: Emanuela Medrades <emanuela.medradesO precisamedicamentos.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao(Osaude.gov.br>, Regina Celia Silva Oliveira
<Regina.Oliveira(Osaude.gov.br>, Renata Marques Santana <renatam.santanaQDsaude.gov.br>, Thiago
Fernandes da Costa <thiago.fernandesQsaude.gov.br>

Assunto: Re: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 12 PARCELA CONTRATO
29/2021 VACINA COVAXIN/BBV 152

Prezada Emanuela,

Após observar a documentação, observei que está com a informação 100% advanced payment (pagamento
antecipado).

Informo que o contrato 29/2021 não prevê pagamento antecipado. A modalidade é “Póstecipado”.

Também foi observado que os valores de frete e seguro divergem do contrato.

Peço a gentileza que observe o valor unitário de 15.00 US$ do produto, bem como o valor do frete e seguro. Esse
valor não pode ser alterado.

Feitas as ponderações, solicito a gentileza de providenciar a correção dos apontados acima.

No aguardo.
Atenciosamente,

William Amorim Santana
DIIMP

Enviado do meu iPhone
Em 23 de mar. de 2021, a(s) 21:29, Emanuela Medrades
<emanuela.medrades (O precisamedicamentos.com.br> escreveu:

William, boa noite.
Em complementação a solicitação de LI, seguem:

1. Proforma Invoice;
2. Packing List.

Atenciosamente,
<image001.jpg>
<image002.jpg>

De: William Amorim Santana <william.santanaOsaude.gov.br>

Data: terça-feira, 23 de março de 2021 16:57

Para: Emanuela Medrades <emanuela.medradesO precisamedicamentos.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao saude .gov.br>, Regina Celia
Silva Oliveira <Regina.OliveiraQsaude.gov.br>, Renata Marques Santana
<renatam.santanaQ)saude.gov.br>, Thiago Fernandes da Costa

<thiago fernandes(Qsaude.gov.br>

Assunto: RES: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 12
PARCELA CONTRATO 29/2021 VACINA COVAXIN/BBV152

Ok Manuela, ficamos no aguardo.
Atenciosamente,

William Amorim Santana
Ministério da Saúde
DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A
55-61-3315-3760

william.santanaQsaude.gov.br

De: Emanuela Medrades [mailto:emanuela.medrades (O precisamedicamentos.com.br]

Enviada em: terça-feira, 23 de março de 2021 16:34

Para: William Amorim Santana <william.santanaQsaude.gov.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao (Osaude .gov.br>; Regina Celia Silva
Oliveira <Regina.OliveiraQsaude.gov.br>; Renata Marques Santana
<renatam.santanaQDsaude.gov.br>; Thiago Fernandes da Costa <thiago.fernandes Gsaude .gov.br>
Assunto: Re: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º PARCELA
CONTRATO 29/2021 VACINA COVAXIN/BBV152

William, boa tarde.

Enviamos a demanda ao fabricante e agente comercial. Entretanto, devido ao fuso, teremos este
retorno somente amanhã.

Conto com a sua compreensão.

Atenciosamente,
<imageVOS.jpg>
<image004.jpg>

De: William Amorim Santana <william.santanaOsaude.gov.br>

Data: terça-feira, 23 de março de 2021 14:03

Para: Emanuela Medrades <emanuela.medrades( precisamedicamentos.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao saude .gov.br>, Regina Celia
Silva Oliveira <Regina.Oliveira(Dsaude.gov.br>, Renata Marques Santana
<renatam.santanaQsaude.gov.br>, Thiago Fernandes da Costa

<thiago fernandes saude.gov.br>
Assunto: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 12 PARCELA

CONTRATO 29/2021 VACINA COVAXIN/BBV152
***URGENTE***

Prezado Fornecedor, após análise de nosso despachante na INVOICE apresentada, faz-se necessário
a adequação da documentação bem como prestar, na INVOIVE, os dados listados abaixo:

CONSIGNATÁRIO:

Ministério da Saúde/Departamento de Logística em Saúde - DLOG
CNPJ: 00.394.544/0008-51

Esplanada dos Ministérios, bloco “G” anexo A, 42 andar, sala 431
Brasília- DF

CEP: 70.310-500

BRASIL

DADOS COMPLETOS DO FABRICANTE;
e Nome do Fabricante.
e Endereço.

DESCRIÇÃO COMPLETA DA MERCADORIA;
e Informar Código de Harmonização NCM (nomenclatura Comum Mercosul).
e |Informar o peso liquido e o peso bruto.
e Identificar como o quantitativo vira (caixa, Frasco, etc...).
e Identificar a validade do produto (data de fabricação e vencimento).

PAÍS DE ORIGEM;
e Informar localidade.

PAÍS DE DESTINO;
e |Informar o aeroporto Internacional de Guarulhos (GRU).

INCOTERMS;
e Informar CIP e acrescentar os valores de frete e seguro.

 
Atenciosamente,

William Amorim Santana
Ministério da Saúde
DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A
55-61-3315-3760

william.santanaQsaude.gov.br

 

Mensagem original
De: Everton [mailto:evertonQO wegh.com.br]

Enviada em: terça-feira, 23 de março de 2021 13:33

Para: William Amorim Santana <william santana saude .gov.br>; 'Roberta' <robertaDwegh.com.br>
Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao QOsaude .gov.br>; Alex Lial Marinho
<alex.marinhosaude.gov.br>

Assunto: RE: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º PARCELA
CONTRATO 29/2021 VACINA COVAXIN/BBV152

 

Boa tarde Prezados
William
Por gentileza solicitar as devidas correções na Proforma Invoice:

- Nome e endereço do Ministério da Saúde está errado (Consignee - Buyer)

- Informar aeroporto de destino - GRU

- INCOTERM é CIP ? Sem sim informar o valor do frete e valor de seguro (separados)
- Qual a NCM do produto ?

- Informar o peso liquido e o peso bruto

- A quantidade está em frascos, caixas... ?

- Nome e endereço completo do Fabricante

- Informar o Lote e validade do lote

- Este produto tem registro na ANVISA ? Se sim, informar o numero

- Enviar o Packing list

No aguardo das correções para registro da LI.

ATENÇÃO PARA O NOVO ENDEREÇO DA WEGH ABAIXO NA ASSINATURA Grato

Everton F Campos

WEGH Assessoria e Logística Internacional Ltda Rua José do Patrocinio, 220 - Aclimação - São Paulo -
SP - Brasil CEP 04108-000 — São Paulo-SP- Brasil Phone +55 11 5573-0877 / 5572.4330 / 5908-5050 —
RAMAL: 208

E-mail: everton wegh.com.br

WWww.wegh.com.br

From: William Amorim Santana

Sent: Monday, March 22, 2021 12:19 PM

To: everton wegh.com.br; lucas wegh.com.br; 'Roberta Pereira! <robertaQ)wegh.com.br>; 'Carlos
Eu. Pereira! <carlosQwegh.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao (Osaude .gov.br>; Alex Lial Marinho
<alex.marinhosaude.gov.br>
Subject: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º PARCELA CONTRATO
29/2021 VACINA COVAXIN/BBV152

Prezada Equipe WEGH,
Boa tarde!

Segue documentação para análise complementar e, estando em conformidade, gentileza
providenciar a abertura de Licença de Importação (LI).

Atenciosamente,

William Amorim Santana

Ministério da Saúde

DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A

55-61-3315-3760
william.santanaQsaude.gov.br<mailto:lilian.saQOsaude.gov.br>

De: Thiago Fernandes da Costa

Enviada em: segunda-feira, 22 de março de 2021 11:54

Para: William Amorim Santana <william.santana O saude .gov.br>; Regina Celia Silva Oliveira
<Regina.OliveiraQOsaude .gov.br>; Renata Marques Santana <renatam.santanaQDsaude.gov.br>
Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao (saude .gov.br>; Alex Lial Marinho
<alex.marinhoQsaude.gov.br>; Francieli Fontana Sutile Tardetti Fantinato

<francieli.fantinato Gsaude.gov.br>; Lauricio Monteiro Cruz <lauricio.cruz(Dsaude.gov.br>
Assunto: RE: SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º PARCELA CONTRATO 29/2021
VACINA COVAXIN/BBV 152

Prezados, bom dia !

Informo que este Departamento formalizou o Despacho DEIDT (0019651176) no processo
25000.175250/2020-85, a fim de realizar a devida instrução quanto à importação requerida pela
contratada.

Não obstante, informo também que estamos de acordo com o pleito e solicito a essa Divisão que dê
andamento aos trâmites necessários para a realização da importação.

Atte.,

[cid:63368a64-85f9-4ff0-b02b-8eda019cf04c]

Thiago Fernandes da Costa

Gestão de Insumos

Departamento de Imunização e Doenças Transmissíveis - DEIDT
Secretaria de Vigilância em Saúde - SVS

*+(61) 3315-3646
De: William Amorim Santana

<william.santana O saude.gov.br<mailto:william.santanaQ saude.gov.br>>

Enviado: segunda-feira, 22 de março de 2021 10:27

Para: Regina Celia Silva Oliveira

<Regina.Oliveira saude .gov.br<mailto:Regina.OliveiraQOsaude.gov.br>>; Renata Marques Santana
<renatam.santanaQDsaude.gov.br<mailto:renatam.santanaQsaude .gov.br>>; Thiago Fernandes da
Costa <thiago.fernandes saude .gov.br<mailto:thiago.fernandes O saude.gov.br>>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO
<lista.divisaoimportacao saude .gov.br<mailto:lista.divisaoimportacao Gsaude.gov.br>>; Alex Lial
Marinho <alex.marinho Gsaude.gov.br<mailto:alex.marinhosaude.gov.br>>

Assunto: SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 12 PARCELA CONTRATO 29/2021 VACINA
COVAXIN/BBV152

Prezado Fiscal Contrato 29/2021

Bom dia!

Chegou a esta Divisão de Importação (DIIMP), na data de 18/03/2021, documentação proveniente
da empresa PRECISA MEDICAMENTOS referente a solicitação de autorização de embarque para 12
parcela Contrato 29/2021 VACINA COVAXIN/BBV152.

Considerando o cronograma de entrega das parcelas, devidamente exposto abaixo, o qual demostra
que a entrega da 1º parcela encontra-se com atraso se 05 (cinco) dias até a presente data:

CRONOGRAMA DE ENTREGA CONTRATUAL

PARCELA

COMPRIMIDOS

ENTREGA

RECEBIMENTO

4.000.000

17/03/2021
EM IRAMITE

4.000.000

27/03/2021

4.000.000

11/04/2021

4.000.000

26/04/2021

4.000.000

06/05/2021

TOTAL

20.000.000
Considerando tratar-se de vacina que não possui registro sanitário, junto a Agencia Nacional de
Vigilância Sanitária (ANVISA), cabendo a necessidade de solicitação de concessão de
excepcionalidade para essa importação;

Considerando os demais parâmetros devidamente expostos no Termo de Referência (TR) do
Contrato 29/2021 para esta aquisição a fim de atender o Departamento de Imunização e Doenças
Transmissíveis (DEIDT/SVS); e

Considerando que o objeto do contrato em questão é um insumo escencial para o enfrentamento
da Pandemia de SARS-COV-2.

Esta Divisão de Importação (DIIMP), pelo presente exposto, solicita autorização do fiscal do contrato
ou seu respectivo substituto eventual para prosseguir com o processo de autorização de embarque
desta parcela.

Aguardo resposta.

OBS: Documento disposta no link: https://www.dropbox.com/t/HFj13mkBO2irw]7C

Atenciosamente,

William Amorim Santana
Ministério da Saúde
DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A

55-61-3315-3760
10
william .santana(Osaude.gov.br<mailto:lilian.sa(Osaude.gov.br>

De: Cassiana Perinazzo da Veiga Schio Em nome de DEPARTAMENTO DE LOGÍSTICA EM SAÚDE -
DLOG Enviada em: quinta-feira, 18 de março de 2021 14:39

Para: LISTA - DIVISÃO DE IMPORTAÇÃO
<lista.divisaoimportacao saude .gov.br<mailto:lista.divisaoimportacao saude .gov.br>>; William
Amorim Santana <william.santanaQsaude.gov.br<mailto:william.santanaQsaude.gov.br>>; Luis
Ricardo Fernandes Miranda <luisf.miranda Qsaude .gov.br<mailto: luisf. miranda saude.gov.br>>
Cc: 'emanuela.medrades (O precisamedicamentos.com.br'

<emanuela.medrades (O precisamedicamentos.com.br<mailto:emanuela.medrades (O precisamedica
mentos.com.br>>; DEPARTAMENTO DE LOGÍSTICA EM SAÚDE - DLOG
<dlogOsaude.gov.br<mailto:dlogOsaude.gov.br>>

Assunto: ENC: AUTORIZAÇÃO EXCEPCIONAL DE IMPORTAÇÃO - VACINA COVID

Prezados, boa tarde!

Encaminho para conhecimento e providências no que couber documentos encaminhados pela
Precisa Medicamentos, referente autorização excepcional de importação para vacina Covid-19.

Atenciosamente,
Equipe DLOG/SE/MS

De: Emanuela Medrades

<emanuela.medrades (O precisamedicamentos.com.br<mailto:emanuela.medrades (O precisamedica
mentos.com.br>>

Enviada em: quinta-feira, 18 de março de 2021 09:20

Para: DEPARTAMENTO DE LOGÍSTICA EM SAÚDE - DLOG
<dlogOsaude.gov.br<mailto:dlogOsaude.gov.br>>

Cc: Lenice Guimaraes Araujo <lenice.araujo O saude.gov.br<mailto:lenice.araujo Osaude.gov.br>>
Assunto: AUTORIZAÇÃO EXCEPCIONAL DE IMPORTAÇÃO - VACINA COVID

Senhores, bom dia.

Solicitamos em concordância com a RDC 476/2.021 a autorização excepcional de importação de
vacina para Covidi9.

1
Enviamos os documentos através do link a seguir: https://www.dropbox.com/t/HFj13mkBO2Zirw]7C

Permanecemos a disposição,

Atenciosamente,
[Uma imagem contendo guarda-chuva Descrição gerada automaticamente]

[signature 631106945]

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS,
CUJA SEGURANÇA NÃO PÔDE SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE
DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO ANEXOS E LINKS DESCONHECIDOS, AINDA
QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE INSTITUIÇÕES
FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS
COM AVISOS DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o
destinatário ou a pessoa autorizada a receber esta mensagem, não pode usar, copiar ou divulgar as
informações nela contidas ou tomar qualquer ação baseada nessas informações. Se você recebeu
esta mensagem por engano, por favor avise imediatamente o remetente, respondendo o e-mail e
em seguida apague-o.This message may contain confidential and / or privileged. If you're not the
recipient or the person authorized to receive this message, you cannot use, copy or disclose the
information contained therein or take any action based on this information. If you have received this
message in error, please notify the sender immediately by reply e-mail and then delete it.

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS,
CUJA SEGURANÇA NÃO PÔDE SER VERIFICADA.

É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO
ABRINDO ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS
CONHECIDAS.

LEMBRANDO QUE INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO
CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.
EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET
2
 

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa autorizada a
receber esta mensagem, não pode usar; copiar ou divulgar as informações nela contidas ou tomar qualquer ação baseada nessas
informações. Se você recebeu esta mensagem por engano, por favor avise imediatamente o remetente, respondendo o e-mail e em

seguida apague-o.

 

 

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA
SEGURANÇA NÃO PÔDE SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA
SEGURA EM NOSSA REDE, NÃO ABRINDO ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE
ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO,
SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS DE DÉBITOS, PROCESSOS E
RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

 

 

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa autorizada a
receber esta mensagem, não pode usar; copiar ou divulgar as informações nela contidas ou tomar qualquer ação baseada nessas
informações. Se você recebeu esta mensagem por engano, por favor avise imediatamente o remetente, respondendo o e-mail e em

seguida apague-o.

 

 

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA
SEGURANÇA NÃO PÔDE SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA
SEGURA EM NOSSA REDE, NÃO ABRINDO ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE
ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO,
SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS DE DÉBITOS, PROCESSOS E
RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

 

<PACKING LIST-2.pdf>
<PI ON LETTER HEAD-2.pdf>

 

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa autorizada a receber esta mensagem,
não pode usar, copiar ou divulgar as informações nela contidas ou tomar qualquer ação baseada nessas informações. Se você recebeu esta mensagem por

engano, por favor avise imediatamente o remetente, respondendo o e-mail e em seguida apague-o.

 

 

13

E-mail explicativo fornecedor Precisa Medicamento (0019722272) SEI 25000.043170/2021-42 / pg. 283
IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA SEGURANÇA NÃO PÓDE
SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO
ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE
INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS
DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

 

 

14

E-mail explicativo fornecedor Precisa Medicamento (0019722272) SEI 25000.043170/2021-42 / pg. 284
24/03/2021 SEI/ANVISA - 1382496 - Recibo Eletrônico de Protocolo

Recibo Eletrônico de Protocolo - 1382496

 

Usuário Externo (signatário): Ariadne Gisele Muniz Bonvino

IP utilizado: 189.28.128.242

Data e Horái 24/03/2021 11:52:09

Tipo de Peticionamento: Intercorrente

Número do Processo: 25351.908361/2021-80
Relacionado ao Processo Indicado: 25351.908110/2021-03

Interessados:

MINISTERIO DA SAUDE/DEPARTAMENTO DE LOGISTICA EM SAUDE-DLOG/CGLOG/DIIMP
Protocolos dos Documentos (Número SEI):
- E-mail Explicativo do Fornecedor 1382495

O Usuário Externo acima identificado foi previamente avisado que o peticionamento importa na aceitação dos termos e
condições que regem o processo eletrônico, além do disposto no credenciamento prévio, e na assinatura dos documentos
nato-digitais e declaração de que são autênticos os digitalizados, sendo responsável civil, penal e administrativamente
pelo uso indevido. Ainda, foi avisado que os níveis de acesso indicados para os documentos estariam condicionados à
análise por servidor público, que poderá alterá-los a qualquer momento sem necessidade de prévio aviso, e de que são
de sua exclusiva responsabilidade:

* a conformidade entre os dados informados e os documentos;

* a conservação dos originais em papel de documentos digitalizados até que decaia o direito de revisão dos atos
praticados no processo, para que, caso solicitado, sejam apresentados para qualquer tipo de conferência;

* a realização por meio eletrônico de todos os atos e comunicações processuais com o próprio Usuário Externo ou,
por seu intermédio, com a entidade porventura representada;

* a observância de que os atos processuais se consideram realizados no dia e hora do recebimento pelo SEI,
considerando-se tempestivos os praticados até as 23h59min59s do último dia do prazo, considerado sempre o
horário oficial de Brasília, independente do fuso horário em que se encontre;

* a consulta periódica ao SEI, a fim de verificar o recebimento de intimações eletrônicas.

A existência deste Recibo, do processo e dos documentos acima indicados pode ser conferida no Portal na Internet do(a)
Agência Nacional de Vigilância Sanitária.

https://seianvisa gov.br/sei/documento consulta externa. php?id acesso extemo=227608id documento=15502508id, orgao acesso. externo=08infr... 1/1
 

Ariadne Gisele Muniz Bon

 

De: William Amorim Santana

Enviado em: quarta-feira, 24 de março de 2021 13:58

Para: Emanuela Medrades

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO; Ariadne Gisele Muniz Bonvino; Alex Lial
Marinho

Assunto: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º
PARCELA CONTRATO 29/2021 VACINA COVAXIN/BBV152

Anexos: PACKING LIST-2.pdf; PION LETTER HEAD-2.pdf

Prezada Emanuela,
Boa tarde!

Ao observar a Comercial Invoice, bem como o Paking List, ambos citam o lote nº 37F11004A com data de fabricação
01/2021 e vencimento 01/2023.

VIRION INACTIVATED CORDINA VIRUS VACCINE = 5 mi viol doses in 300,00 bores/n

 

box. Remork TBD.
BATCH NUMBER: S7FZIOONA
BATCH SIZE: 300,00 VIALS
MPG. 01/21
EXP DATE 01/23.
TRY

Ea, Fo MADISO
ú X
fan 2] a

No entanto, os documento técnicos recebidos até a presente data não contemplam este lote.
Elenco abaixo os referidos:

e 376200014;
e 376200024;
e 37620003A

Considerando que este processo encontra-se em análise junta a Agencia Nacional de Vigilância Sanitária (ANVISA),
solicito a gentileza verificar quais os lotes seriam efetivamente enviados para este Ministério da Saúde (MS),
estando este na Invoice, gentileza proceder com o devido envio da documentação técnica referente ao lote citado,
caso contrário, providência a correção na INVOICE.

Atenciosamente,

William Amorim Santana
Ministério da Saúde
DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A
55-61-3315-3760

william.santanaQsaude.gov.br
De: Emanuela Medrades [mailto:emanuela.medrades (O precisamedicamentos.com.br]

Enviada em: terça-feira, 23 de março de 2021 21:30

Para: William Amorim Santana <william.santana(Qsaude.gov.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao saude .gov.br>; Regina Celia Silva Oliveira
<Regina.OliveiraQOsaude .gov.br>; Renata Marques Santana <renatam.santana(Dsaude.gov.br>; Thiago Fernandes da
Costa <thiago.fernandes Gsaude .gov.br>

Assunto: Re: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º PARCELA CONTRATO 29/2021
VACINA COVAXIN/BBV 152

William, boa noite.
Em complementação a solicitação de LI, seguem:

1. Proforma Invoice;
2. Packing List.

Atenciosamente,

Av Portugal, 1100- ltaqui- Itapevi- SP
55 113080-5140- 11 932574642
wma precisamedicamentos com br

Emanvela Medrades

Diretora Executiva

 

Esta mensagem pode conter material confidencial, privilegiado e para uso exclusivo do destinatáric
autorização expressa, é estritamente proibido, Se você não for o destinatário desta mensagem, poi

This message may contain stuff that is confidential, privileged and for exclusive use of the Intended
permission is strictly prohibited. If you are not the intended recipiente of this message, please noti

É anes de imprimir, pense no Planeta! (Before printing, please think about our environment!)

De: William Amorim Santana <william.santanaQOsaude.gov.br>
Data: terça-feira, 23 de março de 2021 16:57

Para: Emanuela Medrades <emanuela.medrades( precisamedicamentos.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao (saude .gov.br>, Regina Celia Silva Oliveira
<Regina.Oliveira(saude.gov.br>, Renata Marques Santana <renatam.santana(Dsaude.gov.br>, Thiago
Fernandes da Costa <thiago.fernandesQsaude.gov.br>

Assunto: RES: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 12 PARCELA CONTRATO
29/2021 VACINA COVAXIN/BBV 152
Ok Manuela, ficamos no aguardo.

Atenciosamente,

William Amorim Santana
Ministério da Saúde
DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A
55-61-3315-3760

william.santanaQsaude.gov.br

De: Emanuela Medrades [mailto:emanuela.medrades (O precisamedicamentos.com.br]

Enviada em: terça-feira, 23 de março de 2021 16:34

Para: William Amorim Santana <william.santanaQsaude.gov.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao (saude .gov.br>; Regina Celia Silva Oliveira
<Regina.OliveiraQsaude.gov.br>; Renata Marques Santana <renatam.santana(Dsaude.gov.br>; Thiago Fernandes da
Costa <thiago.fernandes(Dsaude.gov.br>

Assunto: Re: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º PARCELA CONTRATO 29/2021
VACINA COVAXIN/BBV 152

 

William, boa tarde.

Enviamos a demanda ao fabricante e agente comercial. Entretanto, devido ao fuso, teremos este retorno somente
amanhã.

Conto com a sua compreensão.

Atenciosamente,

Aw Portugal, 1100- Itaqui: Itapevi- SP
- | E
Emanuela Medrades | .54jso80s140-1193057-4647

ra Execi
Elictora Exectdva wnprecisamedicamentoscombr

dada

 

Esta mensagem pode conter material confidencial, privilegiado e para uso exclusivo do destinatáric
autorização expressa, é estritamente proibido. Se você não for o destinatário desta mensagem, pel

This message may contain stuff thar is confidential, privileged and for exclusive use of the Intended
permission is strictly prohibited. If you are not the intended recipiente of this message, please noti

D anos de imprimir, pense no Planeta! (Before printing, please think about our environment!)

De: William Amorim Santana <william.santanaOsaude.gov.br>

Data: terça-feira, 23 de março de 2021 14:03

Para: Emanuela Medrades <emanuela.medrades(O precisamedicamentos.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao (saude .gov.br>, Regina Celia Silva Oliveira

3

 
<Regina.Oliveira(Q saude.gov.br>, Renata Marques Santana <renatam.santana(Osaude.gov.br>, Thiago

Fernandes da Costa <thiago.fernandes(saude.gov.br>
Assunto: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 12 PARCELA CONTRATO

29/2021 VACINA COVAXIN/BBV 152
***URGENTE***

Prezado Fornecedor, após análise de nosso despachante na INVOICE apresentada, faz-se necessário a adequação da
documentação bem como prestar, na INVOIVE, os dados listados abaixo:

CONSIGNATÁRIO:

Ministério da Saúde/Departamento de Logística em Saúde - DLOG
CNPJ: 00.394.544/0008-51

Esplanada dos Ministérios, bloco “G” anexo A, 42 andar, sala 431
Brasília- DF

CEP: 70.310-500

BRASIL

DADOS COMPLETOS DO FABRICANTE;
e Nome do Fabricante.
e Endereço.

DESCRIÇÃO COMPLETA DA MERCADORIA;
e Informar Código de Harmonização NCM (nomenclatura Comum Mercosul).
e |Informar o peso liquido e o peso bruto.
e Identificar como o quantitativo vira (caixa, Frasco, etc...).
e Identificar a validade do produto (data de fabricação e vencimento).

PAÍS DE ORIGEM;
e Informar localidade.

PAÍS DE DESTINO;
e |Informar o aeroporto Internacional de Guarulhos (GRU).

INCOTERMS;
e Informar CIP e acrescentar os valores de frete e seguro.

mes no aguardo dcreção da INVOEE é rode pac Lt poa aber Lena de impotaçã.

Atenciosamente,

William Amorim Santana
Ministério da Saúde
DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A
55-61-3315-3760

william.santanaQsaude.gov.br
«== Mensagem original-----

De: Everton [mailto:evertonQ wegh.com.br]

Enviada em: terça-feira, 23 de março de 2021 13:33

Para: William Amorim Santana <william.santanaQ saude .gov.br>; "Roberta! <robertaOwegh.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao Osaude .gov.br>; Alex Lial Marinho
<alex.marinho(saude.gov.br>

Assunto: RE: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 12 PARCELA CONTRATO 29/2021
VACINA COVAXIN/BBV 152

Boa tarde Prezados
William
Por gentileza solicitar as devidas correções na Proforma Invoice:

- Nome e endereço do Ministério da Saúde está errado (Consignee - Buyer)

- Informar aeroporto de destino - GRU

- INCOTERM é CIP ? Sem sim informar o valor do frete e valor de seguro (separados)
- Qual a NCM do produto ?

- Informar o peso liquido e o peso bruto

- A quantidade está em frascos, caixas... ?

- Nome e endereço completo do Fabricante

- Informar o Lote e validade do lote

- Este produto tem registro na ANVISA ? Se sim, informar o numero

- Enviar o Packing list

No aguardo das correções para registro da LI.

ATENÇÃO PARA O NOVO ENDEREÇO DA WEGH ABAIXO NA ASSINATURA Grato

Everton F Campos

WEGH Assessoria e Logística Internacional Ltda Rua José do Patrocinio, 220 - Aclimação - São Paulo - SP - Brasil CEP
04108-000 — São Paulo-SP- Brasil Phone +55 11 5573-0877 / 5572.4330 / 5908-5050 — RAMAL: 208

E-mail: everton) wegh.com.br

Www.wegh.com.br

From: William Amorim Santana

Sent: Monday, March 22, 2021 12:19 PM

To: evertonQ)wegh.com.br; lucas wegh.com.br; 'Roberta Pereira! <robertaQwegh.com.br>; 'Carlos E.J. Pereira!
<carlos(Owegh.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao (Osaude .gov.br>; Alex Lial Marinho
<alex.marinho(Dsaude.gov.br>

Subject: *** URGENTE *** SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 12 PARCELA CONTRATO 29/2021 VACINA
COVAXIN/BBV152

Prezada Equipe WEGH,
Boa tarde!

Segue documentação para análise complementar e, estando em conformidade, gentileza providenciar a abertura de
Licença de Importação (LI).

Atenciosamente,

William Amorim Santana
Ministério da Saúde

DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A

55-61-3315-3760

william.santana saude .gov.br<mailto:lilian.saQOsaude.gov.br>

De: Thiago Fernandes da Costa

Enviada em: segunda-feira, 22 de março de 2021 11:54

Para: William Amorim Santana <william.santanaQ saude .gov.br>; Regina Celia Silva Oliveira
<Regina.Oliveira(Dsaude.gov.br>; Renata Marques Santana <renatam.santanaQsaude.gov.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao (saude .gov.br>; Alex Lial Marinho
<alex.marinhosaude.gov.br>; Francieli Fontana Sutile Tardetti Fantinato <francieli.fantinato O saude.gov.br>;
Lauricio Monteiro Cruz <lauricio.cruzQsaude.gov.br>

Assunto: RE: SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º PARCELA CONTRATO 29/2021 VACINA
COVAXIN/BBV152

Prezados, bom dia !

Informo que este Departamento formalizou o Despacho DEIDT (0019651176) no processo 25000.175250/2020-85, a
fim de realizar a devida instrução quanto à importação requerida pela contratada.

Não obstante, informo também que estamos de acordo com o pleito e solicito a essa Divisão que dê andamento aos
trâmites necessários para a realização da importação.

Atte.,

[cid:63368a64-85f9-4ff0-b02b-8eda019cf04c]

Thiago Fernandes da Costa

Gestão de Insumos

Departamento de Imunização e Doenças Transmissíveis - DEIDT
Secretaria de Vigilância em Saúde - SVS

* (61) 3315-3646

De: William Amorim Santana <william.santana saude .gov.br<mailto:william.santanaQsaude.gov.br>>

Enviado: segunda-feira, 22 de março de 2021 10:27

Para: Regina Celia Silva Oliveira <Regina.Oliveira O saude.gov.br<mailto:Regina.OliveiraQsaude .gov.br>>; Renata
Marques Santana <renatam.santana(Dsaude.gov.br<mailto:renatam.santanaQsaude.gov.br>>; Thiago Fernandes da
Costa <thiago.fernandes Qsaude.gov.br<mailto:thiago.fernandes O saude.gov.br>>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO

<lista.divisaoim portacao Osaude.gov.br<mailto:lista.divisaoimportacao Qsaude.gov.br>>; Alex Lial Marinho
<alex.marinho(Osaude.gov.br<mailto:alex.marinhoQsaude.gov.br>>

Assunto: SOLICITAÇÃO DE AUTORIZAÇÃO DE EMBARQUE 1º PARCELA CONTRATO 29/2021 VACINA
COVAXIN/BBV152

Prezado Fiscal Contrato 29/2021
Bom dia!

Chegou a esta Divisão de Importação (DIIMP), na data de 18/03/2021, documentação proveniente da empresa
PRECISA MEDICAMENTOS referente a solicitação de autorização de embarque para 12 parcela Contrato 29/2021
VACINA COVAXIN/BBV152.

Considerando o cronograma de entrega das parcelas, devidamente exposto abaixo, o qual demostra que a entrega
da 1º parcela encontra-se com atraso se 05 (cinco) dias até a presente data:

CRONOGRAMA DE ENTREGA CONTRATUAL

PARCELA

COMPRIMIDOS

ENTREGA

RECEBIMENTO

4.000.000

17/03/2021

EM TRAMITE

4.000.000

27/03/2021
4.000.000

11/04/2021

4.000.000

26/04/2021

4.000.000

06/05/2021

TOTAL

20.000.000

Considerando tratar-se de vacina que não possui registro sanitário, junto a Agencia Nacional de Vigilância Sanitária
(ANVISA), cabendo a necessidade de solicitação de concessão de excepcionalidade para essa importação;
Considerando os demais parâmetros devidamente expostos no Termo de Referência (TR) do Contrato 29/2021 para
esta aquisição a fim de atender o Departamento de Imunização e Doenças Transmissíveis (DEIDT/SVS); e

Considerando que o objeto do contrato em questão é um insumo escencial para o enfrentamento da Pandemia de
SARS-COV-2.

Esta Divisão de Importação (DIIMP), pelo presente exposto, solicita autorização do fiscal do contrato ou seu
respectivo substituto eventual para prosseguir com o processo de autorização de embarque desta parcela.

Aguardo resposta.

OBS: Documento disposta no link: https://www.dropbox.com/t/HFj13mkBO2irw]7C

Atenciosamente,

William Amorim Santana
Ministério da Saúde
DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A
55-61-3315-3760

william.santana saude .gov.br<mailto:lilian.saQOsaude.gov.br>

De: Cassiana Perinazzo da Veiga Schio Em nome de DEPARTAMENTO DE LOGÍSTICA EM SAÚDE - DLOG Enviada em:
quinta-feira, 18 de março de 2021 14:39

Para: LISTA - DIVISÃO DE IMPORTAÇÃO

<lista.divisaoim portacao Osaude.gov.br<mailto:lista.divisaoimportacao Osaude.gov.br>>; William Amorim Santana
<william.santanaQsaude.gov.br<mailto:william.santanaQsaude.gov.br>>; Luis Ricardo Fernandes Miranda
<luisf.miranda (O saude.gov.br<mailto: luisf.miranda saude .gov.br>>

Cc: 'emanuela.medrades (O precisamedicamentos.com.br'

<emanuela.medrades O precisamedicamentos.com.br<mailto:emanuela.medrades O precisamedicamentos.com.br>
>; DEPARTAMENTO DE LOGÍSTICA EM SAÚDE - DLOG <dlog saude. gov.br<mailto:dlogOsaude.gov.br>>

9
Assunto: ENC: AUTORIZAÇÃO EXCEPCIONAL DE IMPORTAÇÃO - VACINA COVID

Prezados, boa tarde!

Encaminho para conhecimento e providências no que couber documentos encaminhados pela Precisa
Medicamentos, referente autorização excepcional de importação para vacina Covid-19.

Atenciosamente,
Equipe DLOG/SE/MS
De: Emanuela Medrades

<emanuela.medrades (O precisamedicamentos.com.br<mailto:emanuela.medrades O precisamedicamentos.com.br>
>

Enviada em: quinta-feira, 18 de março de 2021 09:20

Para: DEPARTAMENTO DE LOGÍSTICA EM SAÚDE - DLOG <dlogOsaude.gov.br<mailto:dlogOsaude.gov.br>>

Cc: Lenice Guimaraes Araujo <lenice.araujo (Osaude.gov.br<mailto:lenice.araujo Qsaude.gov.br>>

Assunto: AUTORIZAÇÃO EXCEPCIONAL DE IMPORTAÇÃO - VACINA COVID

Senhores, bom dia.

Solicitamos em concordância com a RDC 476/2.021 a autorização excepcional de importação de vacina para
Covid19.

Enviamos os documentos através do link a seguir: https://www.dropbox.com/t/HFj13mkBO2irw]7C

Permanecemos a disposição,

Atenciosamente,

[Uma imagem contendo guarda-chuva Descrição gerada automaticamente]

[signature 631106945]

10
IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA
SEGURANÇA NÃO PÔDE SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA
SEGURA EM NOSSA REDE, NÃO ABRINDO ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE
ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO,
SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS DE DÉBITOS, PROCESSOS E
RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa
autorizada a receber esta mensagem, não pode usar, copiar ou divulgar as informações nela contidas ou tomar
qualquer ação baseada nessas informações. Se você recebeu esta mensagem por engano, por favor avise
imediatamente o remetente, respondendo o e-mail e em seguida apague-o.This message may contain confidential
and / or privileged. If you're not the recipient or the person authorized to receive this message, you cannot use,
copy or disclose the information contained therein or take any action based on this information. If you have
received this message in error, please notify the sender immediately by reply e-mail and then delete it.

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA
SEGURANÇA NÃO PÔDE SER VERIFICADA.

É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO
ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS.
LEMBRANDO QUE INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO
ENVIAM E-MAILS COM AVISOS DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa autorizada a receber esta mensagem,
não pode usar, copiar ou divulgar as informações nela contidas ou tomar qualquer ação baseada nessas informações. Se você recebeu esta mensagem por

engano, por favor avise imediatamente o remetente, respondendo o e-mail e em seguida apague-o.

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA SEGURANÇA NÃO PÔDE
SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO
ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE
INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS
DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

1
 

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa autorizada a receber esta mensagem,
não pode usar, copiar ou divulgar as informações nela contidas ou tomar qualquer ação baseada nessas informações. Se você recebeu esta mensagem por

engano, por favor avise imediatamente o remetente, respondendo o e-mail e em seguida apague-o.

 

 

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA SEGURANÇA NÃO PÔDE
SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO
ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE
INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS
DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

 

2

E-mail à empresa - divergência de lotes na doc técnica e (0019722851) SEI 25000.043170/2021-42 / pg. 297
Ariadne Gisele Muniz Bonvino

De:

Enviado em:
Para:

Cc:

Assunto:

Prezada Emanuela,

Boa tarde!

William Amorim Santana

quarta-feira, 24 de março de 2021 17:15

Emanuela Medrades

LISTA - DIVISÃO DE IMPORTAÇÃO; Ariadne Gisele Muniz Bonvino; Alex Lial
Marinho

Solicitação de documentação complementar para envio a ANVISA

Recebemos comunicado da ANVISA, no qual esta solicita complementação de documentos para continuidade do

processo:

Faço uma observação quanto aos itens abaixo, com destaque para os em negrito:

Após verificação da instrução processual, permanecem pendentes os seguintes documentos:
Relatório técnico da avaliação da vacina emitido ou publicado pela autoridade sanitária da
Índia, responsável pela concessão da autorização para uso emergencial (inciso Il do art. 17 da
RDC 476/2021). De acordo com a RDC, o relatório deve ser capaz de comprovar que o produto
atende aos padrões de qualidade, de eficácia e de segurança estabelecidos pela OMS ou pelo
ICH e pelo PIC/s; e

Declaração da Precisa - Comercialização de Medicamentos Ltda quanto ao enquadramento
na RDC 476/2021. Solicita-se esclarecer quem será o importador, se o Ministério da Saúde
ou a Precisa — Comercialização de Medicamentos Ltda;

Declaração da Precisa — Comercialização de Medicamentos Ltda quanto à adoção das
estratégias de monitoramento e cumprimento das diretrizes de farmacovigilância;

O prazo de validade aprovado pela Autoridade Indiana para a vacina Covaxin é de 6 meses, se
conservada de 2-8 “C. De acordo com as datas de fabricação dos lotes a serem importados,
observa-se que o prazo de validade irá expirar nos meses de abril e maio/2021. Solicita-se
esclarecer se é possível a utilização de todo o quantitativo previamente à data de expiração
dos lotes.

Ficamos no aguardo do envio deste, com devida urgência que o caso requer, para encaminha-los a ANVISA.

Atenciosamente,

William Amorim Santana

Ministério da Saúde

DIIMP/CGLOG/DLOG-SE
Ed. Anexo, 4º andar, Sala 431-A

55-61-3315-3760

william.santanaQsaude.gov.br
Y PRECISA

Medicamentos

Ofício Precisa Contrato 29/2021 nº 002/2021
Brasília/DF, 25 de março de 2021.

A Sua Senhoria

Karin Schuck Hemesath Mendes

Chefe de Gabinete

Presidência

Agência Nacional de Vigilância Sanitária
SAI Trecho 05, Área Especial 57
71205-005 Brasília/DF

Com cópia

A Sua Senhoria

Roberto Ferreira Dias

Departamento de Logística em Saúde
Secretaria Executiva

Ministério da Saúde

Esplanada dos Ministérios Bloco G
Anexo A - 4º Andar sala 464
70058-900 Brasília/DF

Ref. Processo 25351.908110/2021-03

Senhora Chefe de Gabinete,

1. Em atenção ao Ofício nº 643/2021/SEI/GADIP-CG/ANVISA, de 23/03/2021,
relativo às pendências apontadas por vossa senhoria, vimos por meio deste
esclarecer os seguintes pontos:

2. Em relação ao parágrafo 2, item |, certificados de liberação dos lotes a serem
importados (inciso IV do art. 16 da RDC 476/2021), restando pendente os certificados
de liberação dos respectivos lotes emitidos pelo fabricante, informamos que todos os
lotes se encontram no CDL — Central Drugs Laboratory responsável pela emissão dos
Certificados de Origem bem como indicação de qual lote será destinado as
exportações. Os certificados já foram requisitados e estamos aguardando sua
disponibilização em breve.

   

Office: Av. Tamboré, 267, 28º andar - Barueri —SP | Pharma: Av. Portugal, 1100 - Itapevi - SP
Phone: +55 11 3080-5140 | www.precisamedicamentos.com.br

    
 
 

Díício Precisa Medicamento: SEI 25000.043170/2021-42 / pg. 299

  
Medicamentos

Y PRECISA

Sobre o parágrafo 2, item Il, relativo ao relatório técnico de avaliação da vacina
emitido ou publicado pela autoridade sanitária da Índia, responsável pela concessão
da autorização para uso emergencial, apresentamos o relatório como forma de
comprovação que o produto atende aos padrões de qualidade, eficácia e segurança
emitido pelo CDSCO — Central Drugs Standard Control Organization (Biological
Division), sendo este documento a liberação para uso emergencial e ao mesmo tempo
o relatório técnico de avaliação contendo todas as ressalvas. Em complementação,
fornecemos também o GMP — Good Manufacturing Practice emitido pela mesma
autoridade para a produção da Covaxin e o GMP - Good Manufacturing Practice
emitido pela OMS — Organização Mundial de Saúde para todas as linhas de produção.

4. Referente ao parágrafo 2, item III, relativo ao licenciamento de importação (LI)
registrado no SICOMEX entendemos que tal item já fora atendido, sendo referido no
Licenciamento de número 21/0796694-1 com situação atual para análise.

5. Já em referência ao parágrafo 3, sobre a necessidade de prestarmos os
esclarecimentos devidos, assim os esclarecemos.

6. Sobre o parágrafo 3, item |, esclarecemos que o importador será o Ministério
da Saúde, inclusive já sendo apresentado através do SISCOMEX com anuência do
fiscal do contrato.

7. Relativo ao parágrafo 3, item Il, esclarecemos que a adoção das estratégicas
de monitoramento e cumprimento das diretrizes de farmacovigilância estão
observando as regras definidas na RDC nº 406/2020 e também na IN nº 63/2020,
além dos demais protocolos de vigilância epidemiológica e sanitária de eventos
adversos pós vacinação. Toda estrutura de monitoramento, inclusive fluxos e
plataformas de notificação, foi planejada e estarão ativas antes do primeiro embarque.
E também já fora enviada a declaração de adoção e cumprimento de todas as
diretrizes de Farmacovigilância.

8. No parágrafo 3, item IIl, a in voice apresentada, corresponde às entregas
parceladas relativas ao cronograma do contrato 29/2021, conforme solicitado pelo
Ministério da Saúde. Considerando que os embarques serão fracionados, e a
impossibilidade de registrar mais de uma DI — Declaração de Importação através de
somente um Licenciamento de Importação, informamos que iremos solicitar de forma
contínua com anuência do Ministério da Saúde cada uma das Licenças de Importação
até concluir o quantitativo contratado de 20.000.000 (vinte milhões) de doses.

9. Sobre o parágrafo 3, item IV, o prazo de validade aprovado pela autoridade
Indiana para a vacina Covaxin é de 6 meses, se conservada de 2-8º, porém, os
estudos de estabilidade acelerada já avançaram tal período. Dessa forma, a Precisa
Medicamentos, apresenta a possibilidade de assinatura de um termo de compromisso
assegurando que nenhum produto importado, terá percorrido mais que 30% de sua
validade.

 
 
      
    

Office: Av. Tamboré, 267, 28º andar - Barueri —SP | Pharma: Av. Portugal, 1100 - Itapevi - SP
Phone: +55 11 3080-5140 | www.precisamedicamentos.com.br

Ofício Precisa Medicamentos (00 SEI 25000.043170/2021-42 / pg. 300
Y PRECISA

Medicamentos

10. Certos de que as informações apresentadas e os esclarecimentos prestados,
além de reapresentar todos os documentos aqui citados, sejam suficientemente
capazes de ilidir as dúvidas suscitadas, solicitamos a continuidade na análise do
Ofício nº 62/2021/DLOG/SE/MS para autorização da importação da vacina Covaxin.

Atenciosamente.

EMANUELA BATISTA DE SOUZA MEDRADES
Diretora Técnica

    

Office: Av. Tamboré, 267, 28º andar - Barueri —SP | Pharma: Av. Portugal, 1100 - Itapevi - SP
Phone: +55 11 3080-5140 | www.precisamedicamentos.com.br

MDíício Precisa Medicamentos (001 J24) SEI 25000.043170/2021-42 / pg. 301

 
 
   
 

Ministério da Saúde
Secretaria Executiva
Departamento de Logística em Saúde

DESPACHO

DLOG/SE/MS
Brasília, 26 de março de 2021.

À CGLOG,

Assunto: Solicita autorização para importação, em caráter excepcional, de
20.000.000 (vinte milhões) de doses da vacina COVAXIN.

1. Em atenção ao Despacho SE/GAB/SE/MS(0019715459) que trata do
Ofício nº 643/2021/SEI/GADIP-CG/ANVISA (0019715346), de 23/03/2021,
oriundo da Agência Nacional de Vigilância Sanitária - Anvisa, que, em atenção
ao Ofício nº 62/2021/DLOG/SE/MS (0019668812), informa que, após verificação,
permanecem pendentes os seguintes documentos, para avaliação da
autorização de importação da vacina COVAXIN:

I - Certificados de liberação dos lotes a serem importados (inciso IV do art. 16
da RDC 476/2021). Foram enviados apenas os laudos analíticos dos lotes
37620001A, 376200024 e 376200034, restando pendente os cerificados de
liberação dos respectivos lotes emitidos pelo fabricante;

II - Relatório técnico da avaliação da vacina emitido ou publicado pela
autoridade sanitária da Índia, responsável pela concessão da autorização para
uso emergencial (inciso II do art. 17 da RDC 476/2021). De acordo coma RDC,
o relatório deve ser capaz de comprovar que o produto atende aos padrões de
qualidade, de eficácia e de segurança estabelecidos pela OMS ou pelo ICH e
pelo PIC/s; e

III - Licenciamento de importação (LI) registrado no SISCOMEX (inciso VI do
art. 17 da RDC 476/2021).

2. Ressalta-se que, quanto aos documentos apresentados, fazem-se
necessários os seguintes esclarecimentos:

I - Declaração da Precisa - Comercialização de Medicamentos Ltda quanto ao
enquadramento na RDC 476/2021. Solicita-se esclarecer quem será o
importador, se o Ministério da Saúde ou a Precisa - Comercialização de
Medicamentos Ltda;

II - Declaração da Precisa - Comercialização de Medicamentos Ltda quanto à
adoção das estratégias de monitoramento e cumprimento das diretrizes de
farmacovigilância;

II - No Invoice apresentado, o quantitativo de doses (3 milhões) não
corresponde ao requisitado no Oficio nº 62/2021/DLOG/SE/MS (20 milhões);

IV - O prazo de validade aprovado pela Autoridade Indiana para a vacina
Covaxin é de 6 meses, se conservada de 2-8 ºC. De acordo com as datas de
fabricação dos lotes a serem importados, observa-se que o prazo de validade
irá expirar nos meses de abril e maio/2021. Solicita-se esclarecer se é possível
a utilização de todo o quantitativo previamente à data de expiração dos lotes.
2. Desta forma, encaminha-se os autos à essa Coordenação Geral para
ciência e providências necessárias, tendo em vista o 8 3º do art. 17 da RDC
476/2021, o qual estabelece que as solicitações de esclarecimentos feitas pela
Anvisa suspendem a contagem do prazo, até que sejam atendidas.

 

— Documento assinado eletronicamente por Roberto Ferreira Dias,
seil Diretor(a) do Departamento de Logística, em 30/03/2021, às 08:23,
dl: conforme horário oficial de Brasília, com fundamento no art. 6º, 8 1º, do

assinatura

eletrônica Decreto nº 8.539, de 8 de outubro de 2015; e art. 8º, da Portaria nº 900 de
31 de Março de 2017.

El A autenticidade deste documento pode ser conferida no site

+: http://seisaude.gov.br/sei/controlador externo.php?

à acao=documento conferir&id orgao acesso externo=0, informando o
4 código verificador 0019766131 e o código CRC 1194555A.

 

  
  

 

 

 

Referência: Processo nº 25000.043170/2021-42 SEI nº 0019766131
29/03/2021 SEIWANVISA - 1383578 - Ofício

<= ANVISA

“|” Agência Nacional de Vigilância Sanitária

Gabinete do Diretor-Presidente - Chefe de Gabinete
SIA Trecho 05, Área Especial 57, Brasília/DF, CEP 71.205.05
Telefone: 0800 642 9782 - www.anvisa.gov.br

Ofício nº 663/2021/SEI/GADIP-CG/ANVISA

Ao Senhor

Antônio Elcio Franco Filho

Secretário-Executivo

Secretaria-Executiva do Ministério da Saúde

Esplanada dos Ministérios, Bloco G - Bairro Zona Cívico-Administrativa
CEP: 70058-900 - Brasília/DF

E-mail: apoio.se Osaude.gov.br

Com cópia

Ao Senhor

Roberto Ferreira Dias

Diretor do Departamento de Logística em Saúde

Departamento de Logística em Saúde

Esplanada dos Ministérios, Bloco G - Bairro Zona Cívico-Administrativa
CEP: 70058-900 - Brasília/DF

E-mail: apoio.se Osaude.gov.br

Assunto: Solicitação de autorização para importação em caráter Excepcional de 20.000.000 (vinte milhões)
de doses da Vacina COVAXIN

Referência: Caso responda este Ofício, indicar expressamente o Processo nº 25351.908110/2021-03.
Senhor Secretário-Executivo,

1. Cumprimentando-o, nos dirigimos a Vossa Senhoria para consignar que o pedido de
importação em caráter excepcional de 20.000.000 (vinte milhões) de doses da vacina Covaxin / BBV152,
processo SEI nº 25351.908110/2021-03, constitui processo administrativo formal, de caráter sigiloso.

2. O peticionamento em tal processo deve ser formulado pelo importador legitimado, no caso, o
Ministério da Saúde.

3. Dessa forma, encarecemos que as manifestações no âmbito desse processo sejam
centralizadas por esse Ministério. O motivo de tal solicitação se deve ao fato de que a interveniente, Precisa
Medicamentos, tem, por intermédio de mensagens eletrônicas (e-mail), copiado setores e diretorias da
Anvisa com informações alusivas ao processo, o que pode causar tumulto à instrução processual.

4. Em atenção à documentação complementar encaminhada pelo Ministério da Saúde pelos
processo processos 25351.908361/2021-80 e 25351.908358/2021-66, informo que:

[- De acordo com a Precisa Medicamentos, o CDSCO emitiu um documento (anexo
BBV152 — COVAXIN — EUL — 12032021) que transmite a autorização para uso emergencial

file:///C:/Users/pc/Downloads/Oficio 1383578.html

1/2
29/03/2021

5.

SEIWANVISA - 1383578 - Ofício

com as suas ressalvas, bem como o relatório de avaliação técnica em um único documento.
No entanto, a Lei 14.124/2021 e a RDC 476/2021 determinam que o referido relatório deve
ser capaz de comprovar que o produto atende aos padrões de qualidade, de eficácia e de
segurança estabelecidos pela OMS ou pelo ICH e pelo PIC/s. O documento BBV152-
COVAXIN-EUL refere-se ao comprovante de autorização de uso emergencial pela autoridade
indiana, mas não contempla aspectos técnicos de qualidade, segurança e eficácia referentes
à avaliação da vacina por esta autoridade;

H- Foi apresentado o Licenciamento de Importação (LI), no qual consta o lote
nº 37F21004A . Tal lote é diferente daqueles para os quais foram apresentados os
certificados de análise (lotes 376200014, 376200024 e 376200034) no pleito inicial.
Ademais, no LI consta a data de validade do lote 37F21004A como sendo 01/2023. No
entanto, o prazo de validade aprovado pela Autoridade Indiana para a vacina Covaxin é de 6
meses, se conservada de 2-8 ºC. Portanto, a data de validade do referido lote não
corresponde ao prazo de validade aprovado pela autoridade da Índia. Para o
lote nº 37F21004A, não foi apresentado o Certificado de liberação do lote, incluindo o
laudo analítico de controle de qualidade, emitido pelo fabricante;

HI - Na LI (1382702), o Ministério da Saúde configura como importador. Dessa forma,
deve ser apresentada a declaração que ateste a adoção das estratégias de monitoramento e
cumprimento das diretrizes de farmacovigilância, conforme modelo Anexo à RDC 476/2021,
assinada pelo Chefe do Poder Executivo.

Esclarecemos que, conforme Lei nº 14.124, de 10 de março de 2021, os prazos para decisão da

Anvisa estão vinculados com o conteúdo das informações apresentadas. Ademais, o 8 3º do art. 17 da RDC
476/2021 estabelece que as solicitações de esclarecimentos feitas pela Anvisa suspendem a contagem do
prazo até que sejam atendidas.

6.

Solicitamos ainda, ao Ministério da Saúde, que os próximos documentos sejam enviados como

peticionamento intercorrente ao processo SEI nº 25351.908110/2021-03.

7.

Agradecemos antecipadamente pela compreensão.

Atenciosamente,

 

  

   
 

;

sel
assinatura
eletrônica

Documento assinado eletronicamente por Karin Schuck Hemesath Mendes, Chefe de Gabinete, em
24/03/2021, às 20:32, conforme horário oficial de Brasília, com fundamento no art. 6º, & 1º, do Decreto
nº 8.539, de 8 de outubro de 2015 hitp://www.planalto.gov.br/ccivil 03/ Ato2015-
2018/2015/Decreto/D8539.htm.

 

ça A autenticidade deste documento pode ser conferida no site https://seianvisa.gov.br/autenticidade,
E informando o código verificador 1383578 e o código CRC F4BC79A8.

 

 

 

Referência: Caso responda este Ofício, indicar expressamente o Processo nº 25351.908110/2021-03

file:///C:/Users/pc/Downloads/Oficio 1383578.html

SEI nº 1383578

212
29/03/2021 RES: Ofício nº 663/2021/SEI/GADIP-CG/ANVISA

Responder Respondera Todos Encaminhar

RES: Ofício nº 663/2021/SEI/GADIP-CG/ANVISA

Zania Maria dos Santos Pires

Para: APOIO DA SECRETARIA-EXECUTIVA; Lisiane Martins Collares; Thairo Gomes Zampierri Costa
ce: administrativo.gadipO anvisagov.br
Categorias: [] finalizado

segunda-feira, 29 de março de 2021 3:04
Boa tarde,
Prezado (as),
Referente: Ofício nº 663/2021/SEI/GADIP-CG/ANVISA - 24.03.2021.

Assunto: Solicitação de autorização para importação em caráter Excepcional de
20.000.000 (vinte milhões) de doses da Vacina COVAXIN
Referência: Processo nº 25351.908110/2021-03.

Informamos que o documento foi registrado no Sistema Eletrônico de Informação -
SEI/MS sob o número 25000.043170/2021-42, e encaminhado à área competente, sendo,
portanto, dispensado o envio do documento físico.

*Caso seja necessária a complementação de informações, favor indicar o número do
processo e encaminhar ao e-mail apoio.semsaude.gov.br.*

Para informações quanto aos trâmites e encaminhamentos segue o link para
pesquisa: https://sei.saude.gov.br/pesquisa/

atenciosamente,
Zania Pires - Apoio/SE/MS.
3315-2370.

 

De: Lisiane Martins Collares em nome de APOIO DA SECRETARIA-EXECUTIVA
Enviado: segunda-feira, 29 de março de 2021 0:47

Para: Zania Maria dos Santos Pires

Cc: APOIO DA SECRETARIA-EXECUTIVA

Assunto: ENC: Ofício nº 663/2021/SEI/GADIP-CG/ANVISA

-=--— Mensagem original-----

De: ANVISA/Coordenação de Apoio Administrativo
<administrativo.gadipQanvisa.gov.br>

Enviada em: quarta-feira, 24 de março de 2021 20:37

Para: APOIO DA SECRETARIA-EXECUTIVA <apoio.seMsaude.gov.br>
Assunto: Ofício nº 663/2021/SEI/GADIP-CG/ANVISA

Prezados,

Encaminha-se o Ofício nº 663/2021/SEI/GADIP-CG/ANVISA com nova manifestação da
https:/Awebmail. saude.gov.br/owa/?ae=|tem&a=Open &t=|PM.Note &id=RgAAAABDIRAB2X3SEZa YAGCXVbIRBwAxBYR5txHSEZpVAGCXVbIRAAAA.. 11
 

Ministério da Saúde
Secretaria Executiva
Gabinete da Secretaria Executiva

DESPACHO

SE/GAB/SE/MS
Brasília, 29 de março de 2021.

Assunto: Solicita autorização para importação, em caráter excepcional, de
20.000.000 (vinte milhões) de doses da vacina COVAXIN.

1. Trata-se do Ofício nº 663/2021/SEI/GADIP-CG/ANVISA
(0019786170), de 24/3/2021, da Agência Nacional de Vigilância Sanitária -
Anvisa, o qual informa que o pedido de importação em caráter excepcional de
20.000.000 (vinte milhões) de doses da vacina Covaxin/BBV152, processo SEI
nº 25351.908110/2021-03, constitui processo administrativo formal, de caráter
sigiloso. Ainda, em atenção à documentação complementar encaminhada por
este Ministério da Saúde pelos processos 25351.908361/2021-80 e
25351.908358/2021-66, informa que:

I - De acordo com a Precisa Medicamentos, o CDSCO emitiu um documento
(anexo BBV152 - COVAXIN - EUL - 12032021) que transmite a autorização
para uso emergencial com as suas ressalvas, bem como o relatório de
avaliação técnica em um único documento. No entanto, a Lei 14.124/2021 e a
RDC 476/2021 determinam que o referido relatório deve ser capaz de
comprovar que o produto atende aos padrões de qualidade, de eficácia e de
segurança estabelecidos pela OMS ou pelo ICH e pelo PIC/s. O documento
BBV152- COVAXIN-EUL refere-se ao comprovante de autorização de uso
emergencial pela autoridade indiana, mas não contempla aspectos técnicos de
qualidade, segurança e eficácia referentes à avaliação da vacina por esta
autoridade;

II - Foi apresentado o Licenciamento de Importação (LI), no qual consta o
lote nº 37F21004A . Tal lote é diferente daqueles para os quais foram
apresentados os certificados de análise (lotes 376200014, 376200024 e
376200034) no pleito inicial. Ademais, no LI consta a data de validade do lote
37F21004A como sendo 01/2023. No entanto, o prazo de validade aprovado
pela Autoridade Indiana para a vacina Covaxin é de 6 meses, se conservada
de 2-8 ºC. Portanto, a data de validade do referido lote não corresponde ao
prazo de validade aprovado pela autoridade da Índia. Para o lote nº
37F21004A, não foi apresentado o Certificado de liberação do lote, incluindo o
laudo analítico de controle de qualidade, emitido pelo fabricante;

III - Na LI (1382702), o Ministério da Saúde configura como importador. Dessa
forma, deve ser apresentada a declaração que ateste a adoção das
estratégias de monitoramento e cumprimento das diretrizes de

farmacovigilância, conforme modelo Anexo à RDC 476/2021, assinada pelo
Chefe do Poder Executivo.

2. O referido documento solicita que os próximos documentos sejam
enviados como  peticionamento intercorrente ao processo SEI nº
25351.908110/2021-03.
3. Ao Departamento de Logística em Saúde - DLOG/SE/MS, para
conhecimento e demais providências, tendo em vista o 8 3º do art. 17 da RDC
476/2021, o qual estabelece que as solicitações de esclarecimentos feitas pela
Anvisa suspendem a contagem do prazo, até que sejam atendidas.

PAULO MARCOS C. R. DE OLIVEIRA
Chefe de Gabinete

— «— Documento assinado eletronicamente por Paulo Marcos Castro Rodopiano
seil de Oliveira, Chefe de Gabinete da Secretaria Executiva, em 29/03/2021,
elo às 17:32, conforme horário oficial de Brasília, com fundamento no art. 6º, 8

assinatura

eletrônica 1º, do Decreto nº 8.539, de 8 de outubro de 2015; e art. 8º, da Portaria nº
900 de 31 de Março de 2017.

E A autenticidade deste documento pode ser conferida no site
http: //sei.saude.gov.br/sei/controlador externo .php?

 

   

 

 

 

Referência: Processo nº 25000.043170/2021-42 SEI nº 0019789165
E-mail - 0019792058

Data de Envio:
29/03/2021 15:10:15

De:
MS/DIVISÃO DE IMPORTAÇÃO <lista.divsaoimportacao(Dsaude.gov.br>

Para:
Regina Celia Silva Oliveira <Regina.OliveiraQ)saude.gov.br>
'LISTA - DIVISÃO DE IMPORTAÇÃO <lista.diisaoimportacaoQ)saude.gov.br>
renatam.melo(Dsaude.gov.br
Thiago Femandes da Costa <thiago.fernandes(saude.gov.br>
Marcelo Calado <marcelo. calado()saude. gov.br>
Ariadne Gisele Muniz Bonvino <ariadne.bonvino(Dsaude.gov.br>
katiane.tores(Dsaude.gov.br
alex.marinhoQsaude.gov.br
Genivano Pinto de Araújo <genivano. araujo(dDs aude. gov.br>

Assunto:
Pendência Anvisa quanto a autorização da Covaxin CT 29/2021 (25000.043170/2021-42)

Mensagem:
Prezados fiscais e colegas do DEIDT,

De acordo com o Ofício 663/2021 da Anvisa, a agência relata que sendo o Ministério da Saúde o importador, somos
nós que devemos apresentar a declaração que ateste adoção de estratégias de monitoramento, conforme disposto
abaixo:

HI - Na LI (1382702), o Ministério da Saúde configura como importador. Dessa forma, deve ser apresentada a
declaração que ateste a adoção das estratégias de monitoramento e cumprimento das diretrizes de farmacovigilância,
conforme modelo Anexo à RDC 476/2021, assinada pelo Chefe do Poder Executivo.

Diante da exigência exarada pela Anvisa, solicitamos providenciar junto ao PNI tal declaração, uma vez que é a área
responsável por executar tais ações

Desde já agradecemos.
Att.

Ariadne Bonvino
DIIMP/CGLOG/DLOG/S E

Anexos:
Oficio 0019786170 RES VACINACAO  RPP 5002083 77.2021.4.03.6100 PJe 1 Grau pdf
 

Ariadne Gisele Muniz Bon

 

De: Emanuela Medrades <emanuela.medradesO precisamedicamentos.com.br>
Enviado em: segunda-feira, 29 de março de 2021 12:03

Para: Ariadne Gisele Muniz Bonvino; William Amorim Santana; Marcelo Calado
Cc: LISTA - DIVISÃO DE IMPORTAÇÃO; Alex Lial Marinho

Assunto: Re: Solicitação de documentação complementar para envio a ANVISA

Ariadne, bom dia.

Iremos enviar nas próximas horas os estudos de estabilidade. E de antemão informamos que as vacinas serão
transportadas em envirotainers.

(William Amorim Santana, pode por gentileza me reiterar quais são os documentos faltantes da LI?

Atenciosamente,

Av Portugal, 1100 - Itaqui- Itapevi- SP
Emanuela Medrades 55 11 3080-5140 - 119 3257-4642

Diretora Executiva ww precisamedicamentos.com.br

Sd! PRECISA

Medicamentos

 

Esta mensagem pode conter material confidencial, privilegiado e para uso exclusivo do destinatáric
autorização expressa, é estritamente proibido. Se você não for o destinatário desta mensagem, por

This message may contain stuff that is confidential, privileged and for exclusive use of the Intended
permission is strictly prohibited. If you are not the intended recipiente of this message, please noti!

Dantes de imprimir, pense no Planeta! (Before printing, please think about our environment!)

De: Ariadne Gisele Muniz Bonvino <ariadne.bonvinoQsaude.gov.br>

Data: sexta-feira, 26 de março de 2021 11:18

Para: Emanuela Medrades <emanuela.medradesO precisamedicamentos.com.br>, William Amorim
Santana <william.santana O saude.gov.br>, Marcelo Calado <IMCEAEX-

- O=SAUDE OU=EXCHANGE+20ADMINISTRATIVE+20GROUP+20+28FYDIBOHF23SPDLT+29 CN=RECIPIENTS
- CN=Marcelo+20Caladoae8O saude.gov.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao saude .gov.br>, Alex Lial Marinho
<alex.marinhoQsaude.gov.br>

Assunto: RES: Solicitação de documentação complementar para envio a ANVISA
Emanuela, Dom dia!

Reitero a solicitação do William quanto ao envio do estudo de estress/estabilidade.
Esse documento é importante para análise da Anvisa e do INCQS, além disso, também para caso haja excursões de
temperatura durante a importação e a nível local (tem acontecido muito).

A fim de evitar excursões durante a importação, recomendamos fortemente que as vacinas sejam acondicionadas e
enviadas em envirotainers.

Abraços,

Ariadne Bonvino

farmacêutica
DIIMP/CGLOG/DLOG/SE

De: Emanuela Medrades [emanuela.medradesQprecisamedicamentos.com.br]
Enviado: sexta-feira, 26 de março de 2021 10:12

Para: William Amorim Santana

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO; Ariadne Gisele Muniz Bonvino; Alex Lial Marinho
Assunto: Re: Solicitação de documentação complementar para envio a ANVISA

William, bom dia.
Recebemos este ofício da SE com questionamentos semelhantes e que devem ser respondidos pelo MS.
Compartilho nosso ofício com as respostas enumeradas para que possam atuar por ai.

Atenciosamente,

Av Portugal, 1100 - Itaqui- ltapevi- SP
55 11 3080-5140 - 11 93257-4642
www. precisamedicamentos.com.br

Emanuela Medrades
Diretora Executiva

(vs PRECISA

Medicamentos

 

Esta mensagem pode conter material confidencial, privilegiado e para uso exclusivo do destinatáric
autorização expressa, é estritamente proibido. Se você não for o destinatário desta mensagem, po!

This message may contain stuff that is confidential, privileged and for exclusive use of the Intended
permission is strictly prohibited. If you are not the intended recipiente of this message, please noti

Dantes de imprimir, pense no Planeta! (Before printing, please think about our environment!)
De: William Amorim Santana <william.santanasaude.gov.br>

Data: quarta-feira, 24 de março de 2021 17:15

Para: Emanuela Medrades <emanuela.medradesO precisamedicamentos.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao saude .gov.br>, Ariadne Gisele Muniz
Bonvino <ariadne.bonvinoQsaude.gov.br>, Alex Lial Marinho <alex.marinho Osaude.gov.br>
Assunto: Solicitação de documentação complementar para envio a ANVISA

Prezada Emanuela,

Boa tarde!

Recebemos comunicado da ANVISA, no qual esta solicita complementação de documentos para continuidade do

processo:

Faço uma observação quanto aos itens abaixo, com destaque para os em negrito:

Após verificação da instrução processual, permanecem pendentes os seguintes documentos:
Relatório técnico da avaliação da vacina emitido ou publicado pela autoridade sanitária da
Índia, responsável pela concessão da autorização para uso emergencial (inciso Il do art. 17 da
RDC 476/2021). De acordo com a RDC, o relatório deve ser capaz de comprovar que o produto
atende aos padrões de qualidade, de eficácia e de segurança estabelecidos pela OMS ou pelo
ICH e pelo PIC/s; e

Declaração da Precisa - Comercialização de Medicamentos Ltda quanto ao enquadramento
na RDC 476/2021. Solicita-se esclarecer quem será o importador, se o Ministério da Saúde
ou a Precisa — Comercialização de Medicamentos Ltda;

 

Declaração da Precisa — Comercialização de Medicamentos Ltda quanto à adoção das
estratégias de monitoramento e cumprimento das diretrizes de farmacovigilância;

O prazo de validade aprovado pela Autoridade Indiana para a vacina Covaxin é de 6 meses, se
conservada de 2-8 ºC. De acordo com as datas de fabricação dos lotes a serem importados,
observa-se que o prazo de validade irá expirar nos meses de abril e maio/2021. Solicita-se
esclarecer se é possível a utilização de todo o quantitativo previamente à data de expiração
dos lotes.

Ficamos no aguardo do envio deste, com devida urgência que o caso requer, para encaminha-los a ANVISA.

Atenciosamente,

William Amorim Santana

Ministério da Saúde

DIIMP/CGLOG/DLOG-SE
Ed. Anexo, 4º andar, Sala 431-A

55-61-3315-3760

william.santanaQsaude.gov.br

 

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa autorizada a receber esta mensagem,

não pode usar, copiar ou divulgar as informações nela contidas ou tomar qualquer ação baseada nessas informações. Se você recebeu esta mensagem por

engano, por favor avise imediatamente o remetente, respondendo o e-mail e em seguida apague-o.

 

 
IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA SEGURANÇA NÃO PÓDE
SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO
ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE
INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS
DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

 

 

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa autorizada a receber esta mensagem,
não pode usar, copiar ou divulgar as informações nela contidas ou tomar qualquer ação baseada nessas informações. Se você recebeu esta mensagem por

engano, por favor avise imediatamente o remetente, respondendo o e-mail e em seguida apague-o.

 

E-mail Empresa - envio de Estudos de Estabilide (0019794503) SEI 25000.043170/2021-42 / pg. 313
 

Ariadne Gisele Muniz Bon

 

De: Emanuela Medrades <emanuela.medradesO precisamedicamentos.com.br>
Enviado em: segunda-feira, 29 de março de 2021 13:21

Para: Ariadne Gisele Muniz Bonvino; William Amorim Santana; Marcelo Calado

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO; Alex Lial Marinho

Assunto: Re: Solicitação de documentação complementar para envio a ANVISA
Anexos: CoA BR Full batches CDL pdf; DECLARACAO ART 12 II Ateste de adoção das

estratégias de monitoramento e cumprimento das diretrizes de
Farmacovigilância.pdf, India EUL 12032021.pdf

William,
Em tempo, segue certificado de análise para todos os batches que estão no CDL serão destinados ao Brasil.
Reitero também:
1. Relatório técnico da avaliação da vacina emitido ou publicado pela autoridade sanitária da Índia,
responsável pela concessão da autorização para uso emergencial (inciso Il do art. 17 da RDC 476/2021).
Anexo índia EUL.
2. Declaração da Precisa —- Comercialização de Medicamentos Ltda quanto à adoção das estratégias de

monitoramento e cumprimento das diretrizes de Farmacovigilância. Anexo Declaração conforme artigo.

Atenciosamente,

Av Portugal, 1100 - Itaqui- ltapevi- SP
55 11 3080-5140 - 11 9 3257-4642
www. precisamedicamentos.com.br

Emanvela Medrades
Diretora Executiva

SAUNA

Medicamentos

 

Esta mensagem pode conter material confidencial, privilegiado e para uso exclusivo do destinatáric
autorização expressa, é estritamente proibido. Se você não for o destinatário desta mensagem, pot

This message may contain stuff that is confidential, privileged and for exclusive use of the Intended
permission is strictly prohibited. If you are not the intended recipiente of this message, please noti!

Dantes de imprimir, pense no Planeta! (Before printing, please think about our environment!)

De: Emanuela Medrades <emanuela.medrades(O precisamedicamentos.com.br>
Data: segunda-feira, 29 de março de 2021 12:03
Para: Ariadne Gisele Muniz Bonvino <ariadne.bonvino Osaude.gov.br>, William Amorim Santana

1
<william.santana(Q)saude.gov.br>, Marcelo Calado <IMCEAEX-

- O=SAUDE OU=EXCHANGE+20ADMINISTRATIVE+20GROUP+20+28FYDIBOHF23SPDLT+29 CN=RECIPIENTS
- CN=Marcelo+20Caladoae8O saude.gov.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao saude .gov.br>, Alex Lial Marinho
<alex.marinhoQsaude.gov.br>

Assunto: Re: Solicitação de documentação complementar para envio a ANVISA

Ariadne, bom dia.

Iremos enviar nas próximas horas os estudos de estabilidade. E de antemão informamos que as vacinas serão
transportadas em envirotainers.

(William Amorim Santana, pode por gentileza me reiterar quais são os documentos faltantes da LI?

Atenciosamente,

Av Portugal, 1100 - Itaqui- ltapevi- SP
55 11 3080-5140 - 11 93257-4642
www. precisamedicamentos.com.br

Emanuela Medrades
Diretora Executiva

(vs PRECISA

Medicamentos

 

Esta mensagem pode conter material confidencial, privilegiado e para uso exclusivo do destinatáric
autorização expressa, é estritamente proibido. Se você não for o destinatário desta mensagem, po!

This message may contain stuff that is confidential, privileged and for exclusive use of the Intended
permission is strictly prohibited. If you are not the intended recipiente of this message, please noti

Dantes de imprimir, pense no Planeta! (Before printing, please think about our environment!)

De: Ariadne Gisele Muniz Bonvino <ariadne.bonvinoQsaude.gov.br>

Data: sexta-feira, 26 de março de 2021 11:18

Para: Emanuela Medrades <emanuela.medradesO precisamedicamentos.com.br>, William Amorim
Santana <william.santana O saude.gov.br>, Marcelo Calado <IMCEAEX-

- O=SAUDE OU=EXCHANGE+20ADMINISTRATIVE+20GROUP+20+28FYDIBOHF23SPDLT+29 CN=RECIPIENTS
- CN=Marcelo+20Caladoae8O saude.gov.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao saude .gov.br>, Alex Lial Marinho
<alex.marinhoQsaude.gov.br>

Assunto: RES: Solicitação de documentação complementar para envio a ANVISA

Emanuela, bom dia!
Reitero a solicitação do William quanto ao envio do estudo de estress/estabilidade.
Esse documento é importante para análise da Anvisa e do INCQS, além disso, também para caso haja excursões de
temperatura durante a importação e a nível local (tem acontecido muito).

A fim de evitar excursões durante a importação, recomendamos fortemente que as vacinas sejam acondicionadas e
enviadas em envirotainers.

Abraços,

Ariadne Bonvino

farmacêutica
DIIMP/CGLOG/DLOG/SE

 

De: Emanuela Medrades [emanuela.medradesQprecisamedicamentos.com.br]
Enviado: sexta-feira, 26 de março de 2021 10:12

Para: William Amorim Santana

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO; Ariadne Gisele Muniz Bonvino; Alex Lial Marinho
Assunto: Re: Solicitação de documentação complementar para envio a ANVISA

William, bom dia.
Recebemos este ofício da SE com questionamentos semelhantes e que devem ser respondidos pelo MS.
Compartilho nosso ofício com as respostas enumeradas para que possam atuar por ai.

Atenciosamente,

Av Portugal, 1100 - Itaqui- Itapevi- SP
Emanuela Medrades 55 11 3080-5140 - 119 3257-4642

Diretora Executiva ww precisamedicamentos.com.br

Sd! PRECISA

Medicamentos

 

Esta mensagem pode conter material confidencial, privilegiado e para uso exclusivo do destinatáric
autorização expressa, é estritamente proibido. Se você não for o destinatário desta mensagem, po!

This message may contain stuff that is confidential, privileged and for exclusive use of the Intended
permission is strictly prohibited. If you are not the intended recipiente of this message, please noti

Dantes de imprimir, pense no Planeta! (Before printing, please think about our environment!)

De: William Amorim Santana <william.santanasaude.gov.br>
Data: quarta-feira, 24 de março de 2021 17:15
Para: Emanuela Medrades <emanuela.medrades(O precisamedicamentos.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao saude .gov.br>, Ariadne Gisele Muniz
Bonvino <ariadne.bonvino(Dsaude.gov.br>, Alex Lial Marinho <alex.marinho Osaude.gov.br>
Assunto: Solicitação de documentação complementar para envio a ANVISA

Prezada Emanuela,

Boa tarde!

Recebemos comunicado da ANVISA, no qual esta solicita complementação de documentos para continuidade do

processo:

Faço uma observação quanto aos itens abaixo, com destaque para os em negrito:

Após verificação da instrução processual, permanecem pendentes os seguintes documentos:
Relatório técnico da avaliação da vacina emitido ou publicado pela autoridade sanitária da
Índia, responsável pela concessão da autorização para uso emergencial (inciso Il do art. 17 da
RDC 476/2021). De acordo com a RDC, o relatório deve ser capaz de comprovar que o produto
atende aos padrões de qualidade, de eficácia e de segurança estabelecidos pela OMS ou pelo
ICH e pelo PIC/s; e

Declaração da Precisa - Comercialização de Medicamentos Ltda quanto ao enquadramento
na RDC 476/2021. S -se esclarecer quem será o importador, se o Ministério da Saúde
ou a Precisa — Comercialização de Medicamentos Ltda;

 

Declaração da Precisa — Comercialização de Medicamentos Ltda quanto à adoção das
estratégias de monitoramento e cumprimento das diretrizes de farmacovigilância;

O prazo de validade aprovado pela Autoridade Indiana para a vacina Covaxin é de 6 meses, se
conservada de 2-8 ºC. De acordo com as datas de fabricação dos lotes a serem importados,
observa-se que o prazo de validade irá expirar nos meses de abril e maio/2021. Solicita-se
esclarecer se é possível a utilização de todo o quantitativo previamente à data de expiração
dos lotes.

 

Ficamos no aguardo do envio deste, com devida urgência que o caso requer, para encaminha-los a ANVISA.

Atenciosamente,

William Amorim Santana

Ministério da Saúde

DIIMP/CGLOG/DLOG-SE
Ed. Anexo, 4º andar, Sala 431-A

55-61-3315-3760

william.santanaQsaude.gov.br

 

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa autorizada a receber esta mensagem,

não pode usar, copiar ou divulgar as informações nela contidas ou tomar qualquer ação baseada nessas informações. Se você recebeu esta mensagem por

engano, por favor avise imediatamente o remetente, respondendo o e-mail e em seguida apague-o.

 

 
IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA SEGURANÇA NÃO PÓDE
SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO
ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE
INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS
DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

 

 

 

Esta mensagem pode conter informação confidencial e/ou privilegiada. Se você não for o destinatário ou a pessoa autorizada a receber esta mensagem,
não pode usar, copiar ou divulgar as informações nela contidas ou tomar qualquer ação baseada nessas informações. Se você recebeu esta mensagem por

engano, por favor avise imediatamente o remetente, respondendo o e-mail e em seguida apague-o.

 

 

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA SEGURANÇA NÃO PÔDE
SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO
ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE
INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS
DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET

 

E-mail Empresa - Solicitação de documentação para Anvisa (0019794557) SEI 25000.043170/2021-42 / pg. 318
BHARAT

BIO TECH

Genome Valley, Turkapally- Shameerpet

Hyderabad- 500078, INDIA

 

 

Department: Quality Control
CERTIFICATE OF ANALYSIS
Product : WHOLE VIRION, INACTIVATED CORONA VIRUS BULK
Batch Number : 37F21004A AR. Number : 1P-37-21-415
Batch size :NLT250Lx 60 Date of Receipt : 19/03/202)
Mfkg. Date : 0221 Qty. Sampled 102 mL
Exp. Date : To be established Batch Release Date: 21/03/2021
| Specification No. :37F21004A on CDL for Brazilian MoH. (3,000,000).
| TESTS SPECIFICATIONS RESULTS — +
E test for vaccine virus (In- ELISA test and SDS PAGE serve Complies
vitro) as an identity test

 

Description

Clear colourless, translucent

Clear colourless, translucent liquid,

 

 

 

liquid, free from particulate matter | free from particulate matter
o o 7.00 - 8.00 o Cm |
a No growth should be observed
| Sterilioy | estenda Dons No growth observed
| Total Protein content (Lowry et al) NLT 15.00 kg'mL 112.05 kg/mL o

 

| Corona virus amplification test

No residual live virus should be
observed in Corona virus

No residual live virus observed

 

 

 

 

 

Amplification test
| qCorona virus inactivation test No CPE should be observed No CPE observed |
Residual cellular DNA Content NMT 10.00 ng/SHD 0.42 ng/SHD a
Residual Bovine serum Albumin o
| content NMT 50.00 ng/SHD 12.36 ng/SHD
Rr : Should show only Co virus :
Antigenic purity by SDS-PAGE ines O Bi EMA Complies
Bacterial Endotoxin Less than 25 international Units

GU) per mL

<12.5 IU per mL

 

Residual BPI. Content

No Residual BPL Content should
be present

No Residual BPL Content present

 

Residual trypsin content by
ELISA method

 

For information only

OPINION: Sample COMPLIES/DOES-NOT-COMPLY—as per-specification No.: 37F2 0044

 

 

 

Prepared By:

Lo SG
Ay O nada

— Form No: EMQCG/024/00100

Certificado de Análise Lote: 37F21004A (0019794786)

Checked By:

 

Í
Page No.: 01 of 01

| ke Approved By:
| 1
n e apl
| Qdo e
(Head — Quality Control)

 

FOR RESTRICTED CIRCULATION

UNCONTROLLED COPY

SEI 25000.043170/2021-42 / pg. 319
w PRECISA

Medicamentos
DECLARAÇÃO

Ateste de adoção das estratégias de monitoramento e cumprimento das diretrizes de
Farmacovigilância nos termos da RDC/ANVISA 476, de 10 de março de 2021
artigo 12 inciso Ille Anexo

A PRECISA - COMERCIALIZACAO DE MEDICAMENTOS LTDA,, pessoa
jurídica de direito privado, com endereço na Avenida Portugal, n.º 1100, Rua 5, parte
A-14, Bairro Itaqui, Cidade de Itapevi, Estado de São Paulo, CEP 06696-060, CNPJ
03.394.819/0005-00, neste ato representada por Emanuela Batista de Souza
Medrades, brasileira, farmacêutica, portador do RG 35.435.759-1- SSP-SP e CPF
330.976.208-42, considerando o disposto na Resolução de Diretoria Colegiada - RDC
nº 476, de 10 de março de 2021, considerando o disposto na Resolução de Diretoria
Colegiada - RDC nº 476, de 10 de março de 2021, o importador, na pessoa de
PRECISA - COMERCIALIZACAO DE MEDICAMENTOS LTDA, CPF/CNPJ
03.392.918/0005-00, DECLARA cumprir o disposto nas normas sanitárias vigentes
para a importação e distribuição de medicamentos e vacinas para Covid-19. O
importador declara que realiza todos os procedimentos necessários e possui
capacidade técnica e administrativa para garantir a qualidade, segurança e eficácia
do medicamento ou vacina para Covid-19 objeto da importação, bem como adotará
as estratégias de monitoramento e cumprirá as diretrizes de farmacovigilância
estabelecidas pela Anvisa. O importador, na pessoa de PRECISA -
COMERCIALIZACAO DE MEDICAMENTOS LTDA, se responsabiliza pela
veracidade e fidedignidade das informações aqui prestadas e declara que está ciente
de que é responsável pela qualidade, segurança e eficácia do medicamento ou vacina
para Covid-19, bem como assegura que este está adequado aos fins a que se destina
e cumpre os requisitos legais e sanitários. Declaro estar ciente que o descumprimento
das disposições contidas nesta Resolução e nas demais vinculadas constitui infração
sanitária, nos termos da Lei nº 6437, de 20 de agosto de 1977, sem prejuízo das
responsabilidades civil, administrativa e penal cabíveis.

Por ser expressão da verdade, firmamos a presente para que surta os seus
efeitos legais.

Brasília/DF, 17 de março de 2021.

EMANUELA BATISTA DE SOUZA | Assinado de forma digital por EMANUELA
BATISTA DE SOUZA MEDRADES:33097620842.

MEDRADES:33097620842 Dados: 2021.03.17 17:38:27 -0300'

EMANUELA BATISTA DE SOUZA MEDRADES
CPF 330.976.208-42
Representante Legal/Técnica

      
   

Office: Av. Tamboré, 267, 28º andar - Barueri— SP | Pharma: Av. Portugal, 1100 - Itapevi - SP
Phone: +55 11 3080-5140 | www.precisamedicamentos.com.br

    

Anexo DECLARAGAO ART 12 Ill Ateste rat (0019794792) SEI 25000.043170/2021-42 / pg. 320
 

F. No. BIO/MA/20/000103
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

FDA Bhawan, Kotla Road,
New Delhi- 110002
Dated: 11/3/20%

To Ê

M/s Bharat Biotech International Ltd.,

Genome Valley, Shameerpet,

Hyderabad, India -500078.

Subject- Permission to manufacture of Whole-virion Inactivated SARS-CoV-2 Vaccine
(BBV152) for restricted use in emergency situation in Form CT-23 as per the provisions of
New Drugs and Clinical Trials Rules, 2019 under Drugs & Cosmetics Act, 1940 - regarding.

Reference:

1. Permission granted by this Directorate in Form CT-23 vide no. MF/BIO/21/000002dated
03.01.2021.

2. Your letter nos. BBIL/RA/21/173, 177, 187 dated 06.03.2021, 08.03.2021 & 10.03.2021
submitted to this office vide email dated 06.03.2021, 08.03.2021 & 10.03.2021.

Sir,

This is with reference to the permission granted by this Directorate in Form CT-23
vide no. MF/BIO/21/000002 dated 03.01.2021 to manufacture Whole-virion Inactivated
SARS-CoV-2 Vaccine (BBV152) for restricted use in emergency situation in public interest
use in as an abundant precaution, in clinical trial mode with various conditions.

In this regard, the interim safety and efficacy data of phase III clinical trial of Whole
Virion, Inactivated Corona Virus Vaccine (BBV152) in the country submitted to this office
was reviewed in consultation with SEC (COVID-19) committee on 08.03.2021 & 10.03.2021
respectively, wherein after detailed deliberation the committee recommended for omission
of the condition of the use of the vaccine in clinical trial mode. However, the vaccine should
be continued to be used under restricted use in emergency situation condition. Further, the
ongoing phase III clinical trial should be continued as per the approved protocol. The firm
should update the prescribing information and factsheet accordingly (under restricted use in
emergency situation condition). All other conditions of the marketing authorisation shall
continue to remain the same.

Accordingly, based on the recommendations of SEC, the condition “This permission
is for restricted use in emergency situation in public interest use in as an abundant
precaution, in clinical trial mode” as mentioned in the said permission is amended to read
as “This permission is for restricted use in emergency situation in public interest”. However,
you are required to continue ongoing Phase III clinical trial as per approved clinical trial
protocol & submit revised summary of product characteristics (SmPC), Fissenticia
Information (Pl) and Factsheet.

Yours faithfully,
Vac :
ae
(Dr. V. G. Somani)

Drugs Controller General (India)
Central Licensing Authority

Pagelof2
 

Copy to:

ds Tre Deputy Drugs Controller (India), CDSCO Zonal office, CDSCO Bhavan, Beside T.B.
& Demonstration Centre, S.R. Nagar, Hyderabad - 500038, India.

2. The Drugs Controller Telangana, Directorate of Drug Control Administration, Drug Control
Bhavan, Vengal Rao Nagar, Hyderabad-500 038, India.

Page Z0f2
 

File No: BIO/MA/20/000103

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)
FDA Bhawan, Kotla Road,
New Delhi- 110002.

Dated: GIiiz034
To,

Mis Bharat Biotech International Ltd.,
Genome Valley, Shameerpet,
Hyderabad, India -500 078.

Subject: Request for amend the Form CT-23 for permission to manufacture Whole Virion,
Inactivated Corona Virus Vaccine (BBV 152) for sale and distribution — regarding

References:
1. Your letter vide no. BBIL/RA/20/006 dated 05.01.2021 submitted to this office vide
diary no. 120 dated 06.01.2021.
2. Permission granted by this Directorate in Form CT-23 vide no. MF/BIO/21/000002
dated 03.01.2021.

SirlMadam,

With reference to the subject cited above and based on the submission of
information/documents to this office, the name of product code of Whole Virion, Inactivated
Corona Virus Vaccine mentioned in the cover letter and permission is hereby amended to
read as “BBV152” instead of BBV152C or BBV152B respectively.

Further, as per the license issued in Form 28D, 2.5ml, 5ml & 140 ml vial
presentations, are also permitted subject to condition mentioned in permission, license &
communication in this regard including the provisions of New Drugs and & Clinical trials
Rules, 2019 under Drugs and Cosmetics Act, 1940.

Yours faithfully,

vos

(Dr. V. G. Somani)
Drugs Controller General (India)

Copy to:
1. The Deputy Drugs Controller (India), CDSCO Zonal office, CDSCO Bhavan, Beside
T.B. & Demonstration Centre, S.R. Nagar, Hyderabad - 500038, India
2. The Director, CDL, Kasauli, HP
File No. BIO/MA/20/000103

 

 

Teias
From:
The Drugs Controller General, India
Directorate General of Health Services
FDA Bhawan, Kotla Road,
New Delhi- 110002, India.
Dated: 03-JAN-2021
To

M/s Bharat Biotech International Ltd.,
Genome Valley, Shameerpet,
Hyderabad, India -500 078.

Subject: Application for permission to manufacture of Whole-virion Inactivated SARS-CoV-2
Vaccine (BBV152C) for restricted use in emergency situation in Form CT-23 as per the provisions
of New Drugs and Clinical Trials Rules, 2019 under Drugs & Cosmetics Act, 1940- regarding.

Reference: SUGAM application no. BIO/CT21/FF/2020/22922 dated 07-Dec-2020.

Sir,

Please find enclosed herewith permission no. MF/BIO/21/000002 dated 03-Jan-2021 in
Form CT-23 to manufacture of Whole-virion Inactivated SARS-CoV-2-Vaccine (BBV152C) for
restricted use in emergency situation in public interest as an abundant precaution, in clinical trial
mode as per the provisions of New Drugs and Clinical: Trial Rules, 2019 under Drugs &
Cosmetics Act, 1940.

Yours faithfully,
VENUGOPAL no
GIRDHARILAL
SOMANI
(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licensing Authority

 

Copy to:

1. The Deputy Drugs Controller (India), CDSCO Zonal office, CDSCO Bhavan, Beside T.B. &
Demonstration Centre, S.R. Nagar, Hyderabad - 500038, India.

2. The Drugs Controller Telangana, Directorate of Drug Control Administration, Drug Control
Bhavan, Vengal Rao Nagar, Hyderabad-500 038, India.
F. No.: BIO/MA/20/000103

Permission no.: MF/BIO/21/000002 dated 03-JAN-2021

FORM CT-23
(See rules 81, 82, 83 and 84)

PERMISSION TO MANUFACTURE PHARMACEUTICAL FORMULATION OF NEW DRUG
FOR SALE OR FOR DISTRIBUTION

The Central Licensing Authority hereby grant permission to M/s Bharat Biotech International
Limited, Sy. No. 230, 231 & 235, Genome Valley, Shameerpet Mandal, Medchal-Malkajgiri District,
Telangana State- 500078. Telephone No.: nil, Fax: nil, E-Mail:draQDbharatbiotech.com, Telephone
No.: nil, Fax: nil, E-MailidraQObharatbiotech.com to manufacture for sale of pharmaceutical
formulation manufactured by a manufacturer specified below.

2. Details of manufacturer and its manufacturing site under this license:

 

s.
No

Name and address of
manufacturer (full name and
address with telephone and e-
mail address of manufacturer).

Name and address of manufacturing site (full
name and address with telephone and e-mail
address of manufacturing site).

 

 

Bharat Biotech Intemational
Limited, Sy. No. 230, 231 & 235,
Genome Valley, Shameerpet
Mandal, Medchal-Malkajgiri

District, Telangana State- 500078.
Telephone No.: nil, Fax: nil, E-
Mail:dra(Dbharatbiotech.com

 

Bharat Biotech International Limited, Sy. No. 230,
231 & 235, Genome Valley, Shameerpet Mandal,
Medchal-Malkajgiri District, Telangana State- 500078.

 

 

 

 

Telephone No.: nil, Fax: nil, E-
Mail:draQDbharatbiotech.com .
Component Manufacturing facility
Drug substance | e Facility PS2, Building S
Drug Product [e Building A, Facility PA1

 

 

 

 

3. Details of pharmaceutical formulation:

 

Name of the New
drug to be
manufactured:

Whole Virion Inactivated Corona Virus Vaccine, [BBV152B]

 

Dosage form:

Suspension for injection
Presentation: single dose glass vial (0.5ml)
Route of Administration: Intramuscular

 

Composition:

Each dose of 0.5ml contains:

 

 

 

 

 

 

 

 

Active Ingredients Quantity
Whole Virion, Inactivated Corona Virus antigen 6 mcg
(Strain: NIV-2020-770)

Inactive Ingredients Quantity
Aluminium Hydroxide gel equivalent to Alt++ 250 meg
TLR 7/8 Agonist 15 meg
2-Phenoxyethanol (2PE) L.P. 2.5 mg
Phosphate Buffered Saline q.s. to 0.5 mL

 

 

 

* Produced in Vero cells.

 

For active immunization against Corona Virus Disease (COVID-19) for

 

 

storage condition:

 

Indication:
age 218 years when administered in two doses interval of day O & day
28.

Shelf life with 6 months when stored at 2 to 8 ºC.

 

Page lof2

 
F. No.: BIO/MA/20/000103
Permission no.: MF/BIO/21/000002 dated 03-JAN-2021

4. This is subject to the conditions prescribed in Chapter X of the New Drugs and Clinical Trials

Rules, 2019 under the Drugs and Cosmetics Act, 1940.
5. This permission is for restricted use in emergency situation in public interest as an abundant

precaution, in clinical trial mode.

6. The fim should provide the protocol for rolling out for the restricted use of the vaccine in
emergency situation.

7. The firm should provide the updated prescribing information/ Package Insert and Summary
of Product Characteristics (SmPC) for Whole Virion Inactivated Corona Virus Vaccine
(BBV152B) and also disseminate the necessary information, instructions and educational
materials through their website.

8. The firm should submit updated safety, efficacy & immunogenicity data from the ongoing
Phase |, II & III clinical trials till the completion of trials as per requirement of New Drugs &
Clinical Trials, 2019.

9. The firm should submit'safety data including the data on AEFI and AESI, with due analysis,
every 15 days for the first two months & monthly thereafter and also as per requirement of
New Drugs & Clinical Trials, 2019.

10. The firm should submit Risk management plan.

11.The firm should submit ongoing stability of commercial scale batches (real time and
accelerated) of drug substance & drug product.

12.The permission is subject to condition of satisfactory evaluation & lot release by CDL,
Kasauli. Further, each batch/lot of Whole Virion Inactivated Corona Virus Vaccine,
(BBV152B) shall be released from Central Drugs Laboratory, Kasauli.

VENUGOPAL
GIRDHARILA
LSOMANI

 

(Dr. V. G. Somani)

Place: New Delhi Drugs Controller General (India)
Date: 03-Jan-2021 Central Licensing Authority
Dr. V. G. SOMANI

 

Drugs Controller General (India)

- General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, .T.O.
New Delhi-110002

 

Page 2 of2
 

Ariadne Gisele Muniz Bon

 

De: Ariadne Gisele Muniz Bonvino

Enviado em: segunda-feira, 29 de março de 2021 16:32

Para: William Amorim Santana; Emanuela Medrades

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO; Regina Celia Silva Oliveira; Renata
Marques Santana; Thiago Fernandes da Costa; Alex Lial Marinho; Marcelo
Calado

Assunto: RES: Novas recomendações da ANVISA para esse processo de importação -

Vacina COVAXIN

Emanuela, boa tarde!
Em aditamento ao e-mail do William, a Agência solicitou esclarecer sobre a data de validade da vacina:

“Na LI consta a data de validade do lote 37F21004A como sendo 01/2023. No entanto, o prazo de validade
aprovado pela Autoridade Indiana para a vacina Covaxin é de 6 meses, se conservada de 2-8 *C. Portanto, a
data de validade do referido lote nãio corresponde ao prazo de validade aprovado pela autoridade da Índia.
Para o lote nº 37F21004A, não foi apresentado o Certificado de liberação do lote, incluindo o laudo analítico
de controle de qualidade, emitido pelo fabricante; “

Abraços e ficamos no aguardo.
Atenciosamente,

Ariadne Bonvino
Farmacêutica
DIIMP/CGLOG/DLOG/SE

De: William Amorim Santana

Enviada em: segunda-feira, 29 de março de 2021 16:05

Para: Emanuela Medrades <emanuela. medrades(O precisamedicamentos.com.br>

Cc: LISTA - DIVISÃO DE IMPORTAÇÃO <lista.divisaoimportacao saude .gov.br>; Regina Celia Silva Oliveira
<Regina.OliveiraQOsaude .gov.br>; Renata Marques Santana <renatam.santana(Dsaude.gov.br>; Thiago Fernandes da
Costa <thiago.fernandes saude .gov.br>; Alex Lial Marinho <alex.marinhoQsaude.gov.br>; Ariadne Gisele Muniz
Bonvino <ariadne.bonvino(Osaude.gov.br>; Marcelo Calado <marcelo .calado (Osaude.gov.br>

Assunto: Novas recomendações da ANVISA para esse processo de importação - Vacina COVAXIN

Prezada Emanuela,
Boa tarde!

Recebemos novo comunicado da Agencia Nacional de Vigilância Sanitária (ANVISA) no qual transcrevo a seguinte
exigência/orientações:

De acordo com a Precisa Medicamentos, o CDSCO emito um documento (anexo BBV152 — COVAXIN —
EUL— 12032021) que transmite a autorização para uso emergencial 29/03/2021 SEI/ANVISA - 1383578
com as suas ressalvas, bem como o relatório de avaliação técnica em um único documento. No
entanto, a Lei 14.124/2021 e a RDC 476/2021 determinam que o referido relatório deve ser capaz de
comprovar que o produto atende aos padrões de qualidade, de eficácia e de segurança estabelecidos
pela OMS ou pelo ICH e pelo PIC/s. O documento BBV152- COVAXIN-EUL refere-se ao comprovante
de autorização de uso emergencial pela autoridade indiana, mas não contempla aspectos técnicos de
qualidade, segurança e eficácia referentes à avaliação da vacina por esta autoridade;
1
Com relação a solicitação anterior, ficamos no aguardo do envio dos certificados litados abaixo:

|-Cerificados de liberação dos lotes a serem importados (inciso IV do art. 16 da RDC 476/2021). Foram
enviados apenas os laudos análgicos dos lotes 37F21004A, restando pendente os cerificados de
liberação dos respectivos lotes emitidos pelo fabricante;

Atenciosamente,

William Amorim Santana
Ministério da Saúde
DIIMP/CGLOG/DLOG-SE

Ed. Anexo, 4º andar, Sala 431-A
55-61-3315-3760

william.santanaQsaude.gov.br
29/03/2021 SEI/ANVISA - 138691 7 - Ofício

<= ANVISA

HT Agência Nacional de Vigilância Sanitária

Gabinete do Diretor-Presidente - Chefe de Gabinete
SIA Trecho 05, Área Especial 57, Brasília/DF, CEP 71.205.05
Telefone: 0800 642 9782 - www.anvisa.gov.br

Ofício nº 693/2021/SEI/GADIP-CG/ANVISA

Ao Senhor

Secretário-Executivo

Secretaria-Executiva do Ministério da Saúde

Esplanada dos Ministérios, Bloco G - Bairro Zona Cívico-Administrativa
CEP: 70058-900 - Brasília/DF

E-mail: apoio.se(Osaude.gov.br

Com cópia

Ao Senhor

Roberto Ferreira Dias

Diretor do Departamento de Logística em Saúde

Departamento de Logística em Saúde

Esplanada dos Ministérios, Bloco G - Bairro Zona Cívico-Administrativa
CEP: 70058-900 - Brasília/DF

E-mail: apoio.se(Osaude.gov.br

Assunto: Solicitação de autorização para importação em caráter Excepcional de 20.000.000 (vinte
milhões) de doses da Vacina COVAXIN

Referência: Caso responda este Ofício, indicar expressamente o Processo nº 25351.908110/2021-03.
Senhor Secretário-Executivo,

1. Cumprimentando-o, nos dirigimos a Vossa Senhoria para continuidade das tratativas
referentes ao pedido de importação em caráter excepcional de 20.000.000 (vinte milhões) de doses da
vacina Covaxin / BBV152, processo SEI nº 25351.908110/2021-03.

2. Em que pese a suspensão do prazo para análise pela Anvisa por força do 8 3º do art. 17 da
RDC 476/2021, que estabelece que as solicitações de esclarecimentos feitas pela Anvisa suspendem a
contagem do prazo até que sejam atendidas, informa a Quinta Diretoria (DIRE5), responsável pela análise
do tema, que todos os documentos entregues até o momento seguem em análise.

3. Seguem as considerações após verificação do último protocolo efetuado no âmbito do
referido processo, Ofício Precisa Contrato 29/2021 nº 002/2021:

I- Foi informado que todos os lotes se encontram no CDL — Central Drugs
Laboratory responsável pela emissão dos Certificados de Origem bem como indicação
de qual lote será destinado às exportações. De acordo com a empresa Precisa
Medicamentos, os certificados já foram requisitados e a empresa aguarda sua
disponibilização em breve. Portanto, resta pendente a apresentação do Certificado de
liberação do lote, incluindo o laudo analítico de controle de qualidade do produto
acabado, emitido pelo fabricante;

file:///C:/Users/guilherme.augusto/AppData/Local/MicrosoftAWindows/INetCache/Content.Outlook/GZ02102L/0ficio 1386917.html

1/2
29/03/2021 SEI/ANVISA - 138691 7 - Ofício

I- Na LI (1382702), o Ministério da Saúde configura como importador. Dessa
forma, deve ser apresentada a declaração que ateste a adoção das estratégias de
monitoramento e cumprimento das diretrizes de farmacovigilância, conforme modelo
Anexo à RDC 476/2021, assinada pelo Chefe do Poder Executivo;

HE - De acordo com o importador, em relação à necessidade do relatório técnico da
avaliação da vacina emitido ou publicado pela autoridade sanitária internacional
responsável pela concessão da autorização para uso emergencial, foi apresentado o
relatório emitido pelo CDSCO — Central Drugs Standard Control Organization (Biological
Division) como forma de comprovação que o produto atende aos padrões de qualidade,
eficácia e segurança, sendo este documento a liberação para uso emergencial e, ao
mesmo tempo, o relatório técnico de avaliação contendo todas as ressalvas. No entanto,
reafirmamos que a Lei 14.124/2021 e a RDC 476/2021 determinam que o
referido relatório deve ser capaz de comprovar que o produto atende aos padrões de
qualidade, de eficácia e de segurança estabelecidos pela OMS ou pelo ICH e pelo PIC/s.
O documento BBV152-COVAXIN-EUL refere-se ao comprovante de autorização de uso
emergencial pela autoridade indiana, mas não contempla aspectos técnicos de
qualidade, segurança e eficácia referentes à avaliação da vacina por esta autoridade.

4. No que se refere ao item III, esta Agência está envidando todos os esforços necessários,
por meio da Assessoria de Assuntos Internacionais, inclusive com a interveniência do Ministério das
Relações Exteriores (MRE), a fim de agendar reunião com a CDSCO e de prospectar informações que
possam se consubstanciar no requerido pela Lei nº 14.124/2021, para subsidiar a Anvisa na avaliação do
pleito. Nesse sentido, requer-se, também, o apoio por parte do Ministério da Saúde junto ao MRE, para
que a referida reunião possa ser agendada com a brevidade que o caso requer. Assim que houver o
agendamento da mesma, esta Agência irá requisitar a participação de representante do Ministério da
Saúde.

5. Por oportuno, a Anvisa solicita reunião de trabalho urgente junto ao Ministério da Saúde,
com o objetivo de sanear as pendências remanescentes para completude da documentação necessária à
instrução e avaliação do pedido de importação.

6. Agradecemos antecipadamente pela compreensão.

Atenciosamente,

 

-s al
sei a
assinatura
eletrônica

      

Documento assinado eletronicamente por Karin Schuck Hemesath Mendes, Chefe de Gabinete, em
26/03/2021, às 19:20, conforme horário oficial de Brasília, com fundamento no art. 6º, 8 1º, do
Decreto nº 8.539, de 8 de outubro de 2015 http://www.planalto.gov.br/ccivil 03/ Ato2015-
2018/2015/Decreto/D8539.htm.

  

 

 

 

 

 

Referência: Caso responda este Ofício, indicar expressamente o Processo nº 25351.908110/2021-03 SEI nº 1386917

file:///C:/Users/guilherme.augusto/AppData/Local/MicrosoftAWindows/INetCache/Content.Outlook/GZ02102L/0ficio 1386917.html

212
Guilherme Augusto Silva ro

De: Guilherme Augusto Silva Ribeiro

Enviado em: segunda-feira, 29 de março de 2021 17:14
Para: 'administrativo.gadiplOanvisa.gov.br

Cc: APOIO DA SECRETARIA-EXECUTIVA

Assunto: RES: Ofício nº 693/2021/SEl/GADIP-CG/ANVISA

Prezados Senhores,
Bom dia.

Confirmamos o recebimento do ofício nº693/2021/SEI/GADIP-CG/ANVISA.

Informamos que o documento foi inserido dentro do SEI/MS, sob o nº 25000.043170/2021-42, e foi encaminhado as
áreas competentes para que as providências pertinentes sejam adotadas, sendo dispensado o envio do documento
físico.

Atenciosamente,

Guilherme Augusto Ribeiro

SEATA/GAB/SE/MS

Gabinete da Secretaria Executiva

guilherme.augusto Qsaude.gov.br

Ministério da Saúde

Esplanada dos Ministérios, Bloco G, Ed. Sede, 3º Andar Brasília - DF

De: ANVISA/Coordenação de Apoio Administrativo <administrativo.gadipOanvisa.gov.br>
Enviada em: sexta-feira, 26 de março de 2021 19:28

Para: APOIO DA SECRETARIA-EXECUTIVA <apoio.se(Osaude.gov.br>

Assunto: Ofício nº 693/2021/SEI/GADIP-CG/ANVISA

Prezados,

Encaminha-se o Ofício nº 693/2021/SEI/GADIP-CG/ANVISA, com manifestações datadas de 26/03/2021, da Agência
Nacional de Vigilância Sanitária, quanto à solicitação de autorização para importação em caráter Excepcional de
20.000.000 (vinte milhões) de doses da Vacina COVAXIN.

Por gentileza, solicita-se confirmação de recebimento da presente mensagem e seus anexos.

Atenciosamente,

Coordenação de Apoio Administrativo - Coadi Gabinete do Diretor-Presidente - Gadip Agência Nacional de Vigilância

Sanitária - Anvisa
(pco)

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA
SEGURANÇA NÃO PÔDE SER VERIFICADA.
E DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO
ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS.
LEMBRANDO QUE INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO
ENVIAM E-MAILS COM AVISOS DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET
 

Ministério da Saúde
Secretaria Executiva
Gabinete da Secretaria Executiva

DESPACHO

SE/GAB/SE/MS
Brasília, 29 de março de 2021.

Assunto: Solicita autorização para importação, em caráter excepcional, de
20.000.000 (vinte milhões) de doses da vacina COVAXIN.

1. Trata-se do Ofício nº 693/2021/SEI/GADIP-CG/ANVISA
(0019797040), de 29/03/2021, oriundo da Agência Nacional de Vigilância
Sanitária - Anvisa, que, para continuidade das tratativas referentes ao pedido
de importação em caráter excepcional de 20.000.000 (vinte milhões) de doses
da vacina Covaxin / BBV152, quanto as atualizações a Agência informa:

I - Foi informado que todos os lotes se encontram no CDL - Central Drugs
Laboratory responsável pela emissão dos Certificados de Origem bem como
indicação de qual lote será destinado às exportações. De acordo com a
empresa Precisa Medicamentos, os certificados já foram requisitados e a
empresa aguarda sua disponibilização em breve. Portanto, resta pendente a
apresentação do certificado de liberação do lote, incluindo o laudo analítico de
controle de qualidade do produto acabado, emitido pelo fabricante;
29/03/2021 SEI/ANVISA - 1386917 - Ofício

II - Na LI (1382702), o Ministério da Saúde configura como importador. Dessa
forma, deve ser apresentada a declaração que ateste a adoção das
estratégias de monitoramento e cumprimento das diretrizes de
farmacovigilância, conforme modelo Anexo à RDC 476/2021, assinada pelo
Chefe do Poder Executivo;

III - De acordo com o importador, em relação à necessidade do relatório
técnico da avaliação da vacina emitido ou publicado pela autoridade sanitária
internacional responsável pela concessão da autorização para uso
emergencial, foi apresentado o relatório emitido pelo CDSCO - Central Drugs
Standard Control Organizaon (Biological Division) como forma de comprovação
que o produto atende aos padrões de qualidade, eficácia e segurança, sendo
este documento a liberação para uso emergencial e, ao mesmo tempo, o
relatório técnico de avaliação contendo todas as ressalvas. No entanto,
reafirmamos que a Lei 14.124/2021 e a RDC 476/2021 determinam que o
referido relatório deve ser capaz de comprovar que o produto atende aos
padrões de qualidade, de eficácia e de segurança estabelecidos pela OMS ou
pelo ICH e pelo PIC/s. O documento BBV152-COVAXIN-EUL refere-se ao
comprovante de autorização de uso emergencial pela autoridade indiana, mas
não contempla aspectos técnicos de qualidade, segurança e eficácia
referentes à avaliação da vacina por esta autoridade.

2. Ao Departamento de Logística em Saúde - DLOG/SE/MS, para
conhecimento e demais providências, tendo em vista o 8 3º do art. 17 da RDC
476/2021, o qual estabelece que as solicitações de esclarecimentos feitas pela
Anvisa suspendem a contagem do prazo, até que sejam atendidas.

PAULO MARCOS C. R. DE OLIVEIRA
Chefe de Gabinete

 

e Documento assinado eletronicamente por Paulo Marcos Castro Rodopiano
soil , de Oliveira, Chefe de Gabinete da Secretaria Executiva, em 30/03/2021,
Dado às 14:30, conforme horário oficial de Brasília, com fundamento no art. 6º, &
eletrônica 1º, do Decreto nº 8.539, de 8 de outubro de 2015; e art. 8º, da Portaria nº

900 de 31 de Março de 2017.

 

 

El A autenticidade deste documento pode ser conferida no site
http://sei.saude.gov.br/sei/controlador externo.php?

f* acao=documento conferir&id orgao acesso externo=0, informando o
4 código verificador 0019797139 e o código CRC 4C84E9AD.

  
  

 

 

Referência: Processo nº 25000.043170/2021-42 SEI nº 0019797139
 

Ministério da Saúde
Secretaria Executiva
Departamento de Logística em Saúde

DESPACHO

DLOG/SE/MS
Brasília, 31 de março de 2021.

À CGLOG,

Assunto: Solicita autorização para importação, em caráter excepcional, de
20.000.000 (vinte milhões) de doses da vacina COVAXIN.

1. Trata-se do DESPACHO SE/GAB/SE/MS (0019797139) que trata do
Ofício nº 693/2021/SEI/GADIP-CG/ANVISA (0019797040), de 29/03/2021,
oriundo da Agência Nacional de Vigilância Sanitária - Anvisa, que, para
continuidade das tratativas referentes ao pedido de importação em caráter
excepcional de 20.000.000 (vinte milhões) de doses da vacina Covaxin /
BBV152, quanto as atualizações a Agência informa:

I - Foi informado que todos os lotes se encontram no CDL - Central Drugs
Laboratory responsável pela emissão dos Certificados de Origem bem como
indicação de qual lote será destinado às exportações. De acordo com a
empresa Precisa Medicamentos, os certificados já foram requisitados e a
empresa aguarda sua disponibilização em breve. Portanto, resta pendente a
apresentação do certificado de liberação do lote, incluindo o laudo analítico de
controle de qualidade do produto acabado, emitido pelo fabricante;
29/03/2021 SEI/ANVISA - 1386917 - Ofício

II - Na LI (1382702), o Ministério da Saúde configura como importador. Dessa
forma, deve ser apresentada a declaração que ateste a adoção das
estratégias de monitoramento e cumprimento das diretrizes de
farmacovigilância, conforme modelo Anexo à RDC 476/2021, assinada pelo
Chefe do Poder Executivo;

III - De acordo com o importador, em relação à necessidade do relatório
técnico da avaliação da vacina emitido ou publicado pela autoridade sanitária
internacional responsável pela concessão da autorização para uso
emergencial, foi apresentado o relatório emitido pelo CDSCO - Central Drugs
Standard Control Organizaon (Biological Division) como forma de comprovação
que o produto atende aos padrões de qualidade, eficácia e segurança, sendo
este documento a liberação para uso emergencial e, ao mesmo tempo, o
relatório técnico de avaliação contendo todas as ressalvas. No entanto,
reafirmamos que a Lei 14.124/2021 e a RDC 476/2021 determinam que o
referido relatório deve ser capaz de comprovar que o produto atende aos
padrões de qualidade, de eficácia e de segurança estabelecidos pela OMS ou
pelo ICH e pelo PIC/s. O documento BBV152-COVAXIN-EUL refere-se ao
comprovante de autorização de uso emergencial pela autoridade indiana, mas
não contempla aspectos técnicos de qualidade, segurança e eficácia
referentes à avaliação da vacina por esta autoridade.

2. Considerando que o referido Despacho encaminha para conhecimento
e demais providências, tendo em vista o 8 3º do art. 17 da RDC 476/2021, o
qual estabelece que as solicitações de esclarecimentos feitas pela Anvisa
suspendem a contagem do prazo, até que sejam atendidas.

3. Desta forma, encaminha-se os autos a essa Coordenação Geral para
as providências necessárias.

 

Documento assinado eletronicamente por Roberto Ferreira Dias,
Diretor(a) do Departamento de Logística, em 31/03/2021, às 12:06,
mamas, LE] | conforme horário oficial de Brasília, com fundamento no art. 6º, 19, do
alefrânica Decreto nº 8.539, de 8 de outubro de 2015; e art. 8º, da Portaria nº 900 de

31 de Março de 2017.

El A autenticidade deste documento pode ser conferida no site

http: //seisaude.gov.br/sei/controlador externo .php?
acao=documento conferir&id orgao acesso externo=0, informando o
código verificador 0019824577 e o código CRC 630E8600.

 
 

 

 

 

 

Referência: Processo nº 25000.043170/2021-42 SEI nº 0019824577
 

AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA
f e Quinta Diretoria — DIRES

ANVISA Setor de Indústria e Abasteciemnto - SIA
Trecho 5 — Quadra Especial 57 — Lote 200
Bloco D — 3º andar - Brasília — DF — 71205-050

 

ATA DE REUNIÃO 2021

 

Reunião: Ministério da Saúde e Precisa

 

Pauta: Vacina Covaxin

 

Local: DIRES

 

Data: 09/04/2021 Horário:17h

 

 

 

Participantes: Lista de assinatura em anexo

Assuntos Tratados:
O Ministério da Saúde solicitou a reunião para tratar da importação da vacina Covaxin.

O Diretor Alex Campos abriu a reunião destacando a importância dos pedidos de importação pelo Ministério
da Saúde. Informou que as questões referentes às Boas Práticas de Fabricação devem ser tratadas com a
GGFIS/DIRE4 e que a DIRES atua no tema importação.

A empresa esclareceu que será iniciado novo processo de importação, a partir do Voto deliberado em DICOL.
Foi relatado que representantes da empresa irão à Índia para obter as informações necessárias ao novo
pedido de importação em caráter excepcional.

O Diretor Alex Campos esclareceu que o relatório de avaliação da Autoridade deve ser capaz de demonstrar
a análise dos aspectos de qualidade, segurança e eficácia pela Agência indiana. Importante haver robustez
das informações a serem enviadas à Anvisa. Na ausência do relatório, devem ser fornecidas informações que
supram os aspectos de qualidade, segurança e eficácia requeridos pela Lei 14.124/2021. Sobre a certificação
de Boas Práticas de Fabricação (BPF), o Diretor destacou que a empresa deve fornecer expediente específico
tratando dos apontamentos feitos durante a inspeção.

O representante do Ministério da Saúde destacou que o referido processo de importação é um processo
novo e que o novo pedido será instruído pelo Ministério. Resssaltou que a empresa deve prover todas as
informações técnicas relevantes e disponíveis para embasar novo pedido de importação.

 

 
 

A empresa irá à Índia para tratativas com a Bharat e a CDSCO. Informou que diversas não conformidades
apontadas durante a inspeção já foram atendidas pela fabricante e que todas as pendências serão resolvidas
até o final de maio/2021.

O Diretor Alex Campos ressaltou que a instrução processual deve ser realizada pelo Ministério da Saúde.

Após obtenção dos novos dados, poderá ser realizada reunião de trabalho com a empresa e o Ministério, à
semelhança de reunião de pré-submissão.

A empresa solicitou que tal reunião seja realizada no início da próxima semana.

Foi realizada apresentação pela empresa, listando os documentos a serem apresentados em nova submissão.
No que se refere à apresentação dos certificados de liberação dos lotes a serem importados, a Anvisa
destacou que trata-se de documento necessário à instrução do processo de importação e que será verificado
pela PAF e INCOS. No entanto, no dossiê de autorização de importação, a empresa poderá encaminhar
certificados de liberação de lotes anteriores aos que serão importados, a fim de exemplificar sua
adequabilidade às especificações de qualidade.

A Anvisa sugeriu que a empresa faça contato com o INCOS a fim de antecipar as tratativas referentes à
liberação dos lotes da vacina em caso de aprovação da importação.

A empresa informou que é possível disponibilizar ao Brasil apenas lotes fabricados após a adequação dos
aspectos de BPF. Também informou que possui relatório de avaliação emitido pela Cofepris e que o mesmo
será enviado à Anvisa.

 

ENCAMINHAMENTOS:

 

 

OBSERVAÇÕES:

 

 
 

AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA
f e Quinta Diretoria — DIRES

ANVISA Setor de Indústria e Abasteciemnto - SIA
Trecho 5 — Quadra Especial 57 — Lote 200
Bloco D — 3º andar - Brasília — DF — 71205-050

 

ATA DE REUNIÃO 2021

 

Reunião: Ministério da Saúde e Precisa

 

Pauta: Vacina Covaxin

 

Local: DIRES

 

Data: 15/04/2021 Horário:18h

 

 

 

Participantes: Lista de assinatura em anexo

Assuntos Tratados:
O Ministério da Saúde solicitou a reunião para tratar da importação da vacina Covaxin.

O Diretor Alex Campos abriu a reunião destacando que as reuniões de pré-submissão se constituem em
momento importante para orientação pela Agência quanto à instrução processual. Costumam ser momentos
de discssuão técnica, que objetivam a submissão de dossiês adequados, superando lacunas de informação e
dando maior celeridade à análise pela Anvisa ao reduzir a necessidade de emissão de diligências. No entanto,
o mérito dos documentos é analisado apenas após a submissão formal do protocolo, momento em que
podem surgir novos questionamentos pelas áreas técnicas. Ressaltou que poderão ser realizadas quantas
reuniões de pré-submissão forem necessárias.

Os representantes do Ministério da Saúde e da empresa informaram estar cientes quanto aos objetivos da
reunião de pré-submissão.

A empresa informou já ter elaborado nova proposta de dossiê para solicitação de autorização para
importação excepcional da vacina Covaxin, o qual foi compartilhado com o Ministério da Saúde. Relatou que
o relatório técnico de análise da Cofepris foi incorporado ao dossiê.

A empresa realizou apresentação sobre os documentos submetidos em março para autorização de
importação e sobre a lista dos documentos a serem submetidos no novo pedido. Informou que será
submetido o dossiê em formato CTD completo, incluindo dados de eficácia, avaliação de potência, dados
atualizados de estabilidade, protocolo de inativação viral, dentre outros. Sobre o CBPF, a empresa irá
submeter a evolução das ações após inspeção da Anvisa e relatório do CAPA.

 

 
 

Os representantes da Anvisa questionaram sobre os relatórios de estudos clínicos a serem submetidos, se
serão completos. Também informaram sobre a importância de submissão do relatório de inativação viral e
não apenas do protocolo, aspecto esse também importante para o CBPF. Quanto aos aspectos de CBPF, as
tratativas devem ser realizadas junto à GGFIS/DIRE4. A empresa informou que o relatório de inativação viral
está em fase final de elaboração e poderá ser submetido. Confirmou que submeterá os relatórios completos
dos estudos clínicos e que os dados serão submetidos no formato CTD.

O Diretor Alex questionou se trata-se da submissão de um novo processo de autorização de importação, ao
passo que os representantes do Ministério e da Precisa confirmaram. Reforçou que o dossiê deve ser
instruído de acordo com a RDC 476/2021, de forma organizada e na ordem constante na norma. No caso da
ausência do relatório técnico de análise da autoridade internacional, os dados de qualidade, segurança e
eficácia que possam atestar o requerimento legal (8 3º do art. 16 da Lei 14.124/2021) devem ser
apresentados como atendimento ao inciso Il do art. 17 da RDC 476/2021.

No que se refere à submissão, devem ser seguidas as orientações abaixo:

- Estados, municípios e União podem ter acesso aos sistemas de peticionamento da Anvisa por meio do
Cadastro de Instituições. Para tanto, é necessário o cadastro no endereço:
https://www1.anvisa.gov.br/cadastramento/ , a fim de obter o usuário e senha para acesso ao sistema de
Peticionamento Eletrônico ou Solicita, conforme orientações: https://www.gov.br/anvisa/pt-
br/sistemas/cadastros/cadastro-de-instituicoes.

Código de assunto a ser submetido: 90278 - MEDICAMENTOS - Solicitação de autorização excepcional e
temporária para importação de medicamentos e vacinas para Covid-19 (RDC 476/2021), o qual se encontra
disponível no Sistema de Peticionamento.

Foi marcada nova reunião para apresentação técnica dos documentos propostos para o novo pedido de
importação.

 

ENCAMINHAMENTOS:

 

 

OBSERVAÇÕES:

 

 
 

AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA
f e Quinta Diretoria — DIRES

ANVISA Setor de Indústria e Abasteciemnto - SIA
Trecho 5 — Quadra Especial 57 — Lote 200
Bloco D — 3º andar - Brasília — DF — 71205-050

 

ATA DE REUNIÃO 2021

 

Reunião: Ministério da Saúde e Precisa

 

Pauta: Vacina Covaxin

 

Local: DIRES

 

Data: 16/04/2021 Horário:15:30

 

 

 

Participantes: Daniela Cerqueira e Daniel Cruz (DIRE5)
Precisa Medicamentos: Elaine Giglioli, Túlio Silveira e Emanuela Medrades
Ministério da Saúde: Ariadne Bonvino.

Assuntos Tratados:
O Ministério da Saúde solicitou a reunião para tratar da importação da vacina Covaxin.

Os representantes da DIRES ressaltaram o objetivo da reunião de pré-submissão, que é orientar o solicitante
quanto à instrução processual, a fim de que o processo possa ser analisado com maior celeridade. O mérito
dos documentos é analisado somente após a submissão formal dos documentos, podendo gerar diligências.
De acordo com a RDC 476/2021, as áreas técnicas emitem parecer sobre os documentos apresentados no
pedido de importação excepcional. Portanto, todos os documentos serão analisados pelas áreas de registro,
inspeção e farmacovigilância.

No que se refere ao quantitativo a ser importado, foi informado ao Ministério e à Precisa que, a depender
da avaliação dos documentos, poderá ser emitida autorização de importação para todo o quantitativo
programado ou para cada embarque específico a ser realizado. Ressaltou-se que, normalmente, os pedidos
de importação são analisados para cada LI específica.

Sobre as declarações previstas na RDC 476/2021, a DIRE5 esclareceu que todas devem ser assinadas pelo
importador, no caso, o Ministério da Saúde. A RDC ainda prevê a assinatura pelo chefe do Poder Executivo.
A declaração referente ao descumprimento do Plano de Operacionalização da Vacinação contra a Covid-19
não precisa ser apresentada nesse caso. A representante do Ministério informou que estão providenciando
a assinatura pelo secretário da SVS e pelo secretário executivo do Ministério da Saúde.

A empresa Precisa esclareceu que a vacina Covaxin foi co-desenvolvida pelo Governo da Índia. Dessa forma,
não foi emitido nenhum relatório de avaliação além do comprovante de autorização de uso emergencial

 

 
 

 

apresentado no pedido de importação anterior. Sobre esse aspecto, a DIRE5 esclareceu que o referido
comprovante não corresponde ao relatório técnico de avaliação da autoridade sanitária internacional nos
moldes estabelecidos pela Lei nº 14.124/2021. Portanto, tal documento deve ser apresentado como
comprovante de autorização do uso emergencial, mas não como o relatório técnico requerido pela Lei. Na
ausência do relatório, o importador deve apresentar os aspectos de qualidade, segurança e eficácia que
cumpram o ditame legal. A empresa concordou e informou que submeterá o relatório técnico de avaliação
da Cofepris, além dos documentos de qualidade, segurança e eficácia da vacina.

Por ser importação pelo Ministério da Saúde, a AFE não se aplica.

Sobre a liberação de lotes pelo INCOS, a empresa informou que já realizou reuniões com o Instituto para
alinhamento das ações necessárias.

No que se refere aos aspectos de BPF, a empresa informou ter realizado reunião com a GGFIS no dia 12/04
para apresentação da proposta de CAPA. As ações para adequação das não conformidades identificadas
durante a inspeção serão finalizadas até o final de maio. A empresa informou que a planta da Bharat possui
3 linhas produtivas pré-qualificadas pela OMS. Também relatou que a Malásia, Turquia e Ucrânia já
inspecionaram a Bharat. O site possui 10 prédios, sendo 4 específicos para a Covaxin. Considerando a
importância de que a empresa solicite nova certificação de BPF previamente ao novo pedido de importação,
dada a motivação do indeferimento do pedido anterior, a empresa irá solicitar reunião com a DIRE4 e GGFIS
para verificar a possibilidade de submissão do pedido de certificação de BPF mediante a apresentação de
termo de compromisso para os documentos que estiverem faltantes.

A empresa apresentou o PGR (plano de gerenciamento de risco) e informou que o mesmo está de acordo
com o Guia nº 42 e com as normas de farmacovigilância. Os representantes da DIRES ressaltaram que o PGR
deverá contemplar as responsabilidades do importador (Ministério da Saúde) definidas pela RDC 476/2021.
A DIRES também ressaltou que dados de monitoramento do uso da vacina em outros países são importantes
para subsidiar o novo pedido de importação. Sobre esse aspecto, a empresa informou que o fabricante
poderá disponibilizar esses dados.

Sobre o estudo clínico a ser conduzido no Brasil, a empresa informou que as alterações solicitadas pela Conep
já foram realizadas e que as exigências emitidas pela Anvisa para o DDCM serão cumpridas até o dia 19/4.
Os representantes da DIRES informaram que a anuência do estudo clínico pode ser aspecto relevante para o
novo pedido de importação.

O estudo clínico da Índia terá 12 meses de prazo de acompanhamento e o do Brasil terá 18 meses. Até o
momento, já estão disponíveis os dados de análise interina de eficácia após a ocorrência de 43 casos de
Covid-19. Nos próximos dias, deverão estar disponíveis os dados de eficácia após 130 casos de Covid-19, com
nova análise interina e com dados por faixa etária. A empresa informou ser possível incluir essa nova análise
interina no novo pedido de importação. A DIRES ressaltou a importância de que esses novos dados sejam
disponibilizados à Anvisa.

Os artigos científicos já publicados sobre a vacina também serão incluídos no pedido de importação.
Sobre o transporte da vacina, a empresa informou que, inicialmente, a vacina será enviada via Turquia em

Envirotainer com data logger para monitoramento da temperatura. A documentação de qualificação do
transporte será apresentada no novo pedido de importação.

 

 
 

Após a apresentação, os representantes da DIRES questionaram sobre a submissão do CTD, conforme
informado na reunião do dia 15/4, visto que os dados de qualidade estavam ausentes na lista de documentos
apresentada. A empresa esclareceu que seu acordo com a Bharat determina que o CTD só pode ser
disponibilizado às autoridades sanitárias e, portanto, não poderia ser submetido pelo Ministério da Saúde. A
DIRES5 esclareceu que a empresa pode utilizar o código de assunto para submissão de pleitos pela RDC
476/2021 para submissão do CTD diretamente à Anvisa, devendo, nesse caso, informar que a submissão está
vinculada ao pedido de importação do Ministério.

 

 

ENCAMINHAMENTOS:

 

OBSERVAÇÕES:

 

 
 

AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA
f e Quinta Diretoria — DIRES

ANVISA Setor de Indústria e Abasteciemnto - SIA
Trecho 5 — Quadra Especial 57 — Lote 200
Bloco D — 3º andar - Brasília — DF — 71205-050

 

ATA DE REUNIÃO 2021

 

Reunião: Ministério da Saúde e Precisa

 

Pauta: Vacina Covaxin

 

Local: DIRES

 

Data: 30/04/2021 Horário: 09:30

 

 

 

Participantes: Daniela Cerqueira e Daniel Cruz (DIRE5); Gustavo Mendes, Maria Fernanda Thees, Brenda
Valente, Claudiovam Martins, Francis Reisdorfer (GGMED), Helaine Capucho e Pauliana Almeida (GFARM).
Precisa Medicamentos: Elaine Giglioli, Túlio Silveira e Emanuela Medrades

Ministério da Saúde: Ariadne Bonvino.

Assuntos Tratados:
O Ministério da Saúde solicitou a reunião para tratar da importação da vacina Covaxin.

Os representantes da DIRES ressaltaram o objetivo da reunião de pré-submissão, que é orientar o solicitante
quanto à instrução processual, a fim de que o processo possa ser analisado com maior celeridade. O mérito
dos documentos é analisado somente após a submissão formal dos documentos, podendo gerar diligências.

- Fundamentação legal: o pedido de importação será baseado na Lei 14.124/2021 e RDC 476/2021. Ademais,
a empresa utilizará a RDC 475/2021 e o guia 42/2020 quanto à documentação técnica de qualidade,
segurança e eficácia a ser apresentada. A Anvisa confirmou que, de acordo com a Lei nº 14.124/2021, o prazo
para análise é de até 30 dias na ausência do relatório técnico de avalição da vacina pela autoridade
internacional. A empresa destacou que o relatório da Cofepris não é tão detalhado e não está fundamentado
em OMS, ICH e PIC/S, não correspondendo, portanto, ao relatório técnico requerido pela Lei. Na submissão,
será informado o status mundial de autorização da vacina. Sobre esse aspecto, a DIRE5S pediu que sejam
informados os países que estão efetivamente utilizando a vacina, quais os quantitativos já utilizados e dados
de monitoramento disponíveis.

- CBPF: a empresa informou que mais de 70% das adequações já foram concluídas. As validações faltantes
devem estar finalizadas até o dia 15/5. A partir do dia 15/4, todos os lotes já estão sendo fabricados com as
adequações realizadas na planta fabril. A previsão é que o novo pedido de BPF seja solicitado no dia 15/5. A
empresa informou já estar alinhada com a GGFIS a possibilidade de emissão de exigência após a submissão
do novo pedido de CBPF, mas a Bharat está resistente em submeter o protocolo sem possuir todas as

 

 
 

 

adequações necessárias. A DIRES ressaltou a importância da submissão do novo pedido de BPF e da anuência
do DDCM de forma simultânea ou prévia ao novo pedido de importação, a fim de trazer maior robustez
técnica ao pleito. A Precisa informou já possuir informação suficiente para nova submissão de BPF, mas não
pode submeter sem a concordância da Bharat. A GPBIO questionou sobre validação dos testes de potência,
adsorção de antígeno, inativação viral e outros importantes para a qualidade da vacina. A empresa informou
que já possui implantação de todos os testes e que a validação será concluída até o dia 15/5. A área técnica
precisa entender que testes estão sendo realizados e se os mesmos estão validados. A GPBIO informou que
a empresa pode submeter de forma informal a documentação para uma análise prévia antes da submissão.
Nesse caso, a submissão do pedido de importação não ficará vinculada ao retorno da GPBIO, cabendo ao
importador avaliar o momento adequado para submissão do pedido de importação.

- A GFARM solicitou o envio de dados de pós-comercialização, pois existem poucos dados disponíveis nas
bases globais de farmacovigilância. Ressaltou que o perfil das notificações é bem diferente daquele das
demais vacinas em avaliação pela Anvisa. A empresa informou que enviará todos os dados de
farmacovigilância disponíveis até o momento.

- A GPBIO informou ser importante a empresa encaminhar dados sobre a avaliação de eventos adversos de
interesse especial nos estudos clínicos. A vacina utiliza adjuvante novo, o que traz preocupações sobre a
segurança. Os eventos graves e óbitos devem ser descritos de forma detalhada e com a investigação de
relação causal. A empresa informou já possuir o material e que os dados estarão prontos para ser
apresentados à Precisa e ao Einstein no dia 4/5. O material será tratado para apresentação à Anvisa. A GPBIO
destacou que a Anvisa não teve acesso ao protocolo do estudo de fase 3 na Índia e nem aos relatórios de
estudos de fase 2. Os artigos científicos são avaliados como suporte, mas a empresa deve apresentar os
protocolos e relatórios completos dos estudos clínicos, conforme guias do ICH. A documentação deve ser
apresentada de forma organizada, a fim de facilitar a avaliação da Anvisa.

- Sobre o teste de RT-PCR, a empresa informou que se trata de teste comercial e que foi validado pela Bharat.
Os testes in house para avaliação de anticorpos foram validados pela Bharat e serão revisados pela Precisa.
A GPBIO destacou que os relatórios de validação dos ensaios devem ser submetidos de forma organizada,
seguindo os guias do ICH.

- É importante que a empresa apresente dados de imunogenicidade após a 22 dose da vacina.

- A empresa informou que não realiza teste de fotoestabilidade, mas está implementando. A GPBIO informou
não ser essencial para a importação excepcional. Pode ser apresentado como compromisso.

- Não foi feita análise do efeito da vacina em indivíduos soropositivos. A GPBIO informou ser importante que
tais dados sejam avaliados para submissão. A empresa ressaltou que tal avaliação foi incluída no protocolo
do estudo clínico a ser realizado no Brasil.

- À GFARM informou que os eventos de especial interesse devem constar do Relatório de Monitoramento.
- A empresa vai submeter a documentação prevista no guia 42 de maneira prévia à GPBIO por e-mail e os

dados de monitoramento à Gfarm. Dessa forma, as áreas iniciarão a análise dos documentos previamente à
submissão do pedido de importação.

 

 
 

 

- À DIRES esclareceu que a submissão do pedido de importação pelo Ministério da Saúde deve ocorrer pela
RDC 476/21 e no item referente ao relatório técnico devem ser apresentados os dados técnicos de qualidade,
segurança e eficácia que cumpram o requisito da Lei 14.124/21.

- A interlocução com o INCQS deve ser realizada o quanto antes e o MS pode solicitar reunião com a Gelas
da Anvisa para essas tratativas.

- O MS informou que as declarações previstas pela RDC 476/21 já foram assinadas pelo secretário executivo
do Ministério.

- O solicitante da importação deve ser o MS. O pleito pode ser submetido por e-mail ao gabinete do diretor
presidente. No caso da documentação técnica a ser submetida pela Precisa, a empresa deve usar o código
de assunto 90278 - MEDICAMENTOS - Solicitação de autorização excepcional e temporária para importação
de medicamentos e vacinas para Covid-19 (RDC 476/2021), o qual se encontra disponível no Sistema de
Peticionamento. A empresa deve informar claramente que esta submissão está vinculada ao pedido de
importação efetuado pelo MS.

- A GAFRM ressaltou que o importador (MS) é o responsável pelas atividades de farmacovigilância. Nesse
sentido, a empresa informou que irá apresentar à SVS o material de monitoramento já elaborado pela Precisa
para os alinhamentos necessários. Após esse alinhamento com a SVS, o MS irá solicitar reunião específica
com a DIRE5 e GGMON para tratar do plano de gerenciamento de riscos.

- A empresa deve destacar na submissão quais são os documentos novos ainda não avaliados pela Anvisa, a
fim de facilitar e agilizar a análise da Agência. Deve ser submetido o CTD completo, sinalizando quais itens
foram atualizados e com índice organizado.

- À empresa deve ser apresentar a comparabilidade entre os processos produtivos.

- À empresa informou que os lotes do estudo clínico no Brasil serão do PQ3. Dessa forma, a empresa precisa
fazer o estudo de comparabilidade.

- Estabilidade: a empresa deve enviar resultados atualizados dos estudos. A empresa informou que o estudo
em uso não está adaptado às condições apresentadas, mas será refeito pela empresa.

- À vacina será enviada ao Brasil com VVM e em Envirotainer, com rota de transporte pela Turquia. Serão
enviadas as documentações da qualificação de transporte.

- Para as doses do estudo clínico, a COPEC esclareceu que não há exigência sobre validação do transporte. A
empresa destacou que as doses serão trazidas com data logger para monitoramento da temperatura.

- A validação do transporte pode ser realizada com lotes clínicos, desde que seguindo o protocolo
estabelecido.

- A Gpbio esclareceu que não há obrigação de adjuvante no placebo.

- Os dados sobre o adjuvante serão enviados na documentação. Trata-se de adjuvante americano, que possui
ensaios europeus e americanos. Existe apenas um produto tópico aprovado com esse adjuvante.

 

 
 

- Os dados brutos do estudo de fase 3 são importantes para avaliação da Anvisa. A Anvisa esclareceu que
todos os dados são tratados pela Agência como confidenciais e que a empresa pode incluir disclaimer
relacionado a esse aspecto. Pode ser fornecido o link para acesso aos dados, dado o volume dos mesmos.

- Todos os dados do estudo de fase 3 atualizados que já estiverem disponíveis devem ser enviados à Anvisa.
A empresa informou que o relatório interino com 127 casos só estará disponível em meados de junho.

- À GPBIO esclareceu que a função do VVM é dar suporte durante o transporte, mas não durante o uso da
vacina.

- À empresa informou que pretende submeter os documentos técnico à GPBIO até 42 feira (5/5).

- A COPEC esclareceu que a via para importação ocorre por meio do CE, após anuência do estudo clínico.
Pode ser emitido documento para importação por conta e risco da empresa para viabilizar a importação
apenas para o lote do estudo clínico. A empresa está trabalhando em gerenciamento de risco referente ao
lote disponível para estudo clínico e gostaria de já possuir o lote no Brasil no momento da anuência do
estudo. A COPEC esclareceu que os casos excepcionais são levados à deliberação do Comitê Covid-19 e que
tentará viabilizar a discussão o mais rápido possível. A empresa vai formalizar o pleito como aditamento ao
DDCM e comunicar a COPEC por e-mail.

- A DIRES se colocou à disposição para novas reuniões que se façam necessárias.

 

ENCAMINHAMENTOS:

 

 

OBSERVAÇÕES:

 

 
